PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	PICKWORTH, WB				PICKWORTH, WB			CAFFEINE DEPENDENCE	LANCET			English	Editorial Material							DISCRIMINATION				PICKWORTH, WB (corresponding author), NIDA,ADDICT RES CTR,CLIN PHARMACOL BRANCH,POB 5180,BALTIMORE,MD 21224, USA.							GLASS RM, 1994, JAMA-J AM MED ASSOC, V272, P1065, DOI 10.1001/jama.272.13.1065; GRIFFITHS RR, 1990, J PHARMACOL EXP THER, V252, P970; HUGHES JR, J SUB ABUSE, V1, P67; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; SILVERMAN K, 1992, NEW ENGL J MED, V327, P1109, DOI 10.1056/NEJM199210153271601; SILVERMAN K, 1992, J EXP ANAL BEHAV, V57, P91, DOI 10.1901/jeab.1992.57-91; Spitzer R., 1985, STRUCTURED CLIN INTE; STRAIN EC, 1994, JAMA-J AM MED ASSOC, V272, P1043, DOI 10.1001/jama.272.13.1043; 1994, BASIS DRUG DEPENDENC; 1994, DIAGNOSTIC STATISTIC	10	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1066	1066		10.1016/S0140-6736(95)90814-5	http://dx.doi.org/10.1016/S0140-6736(95)90814-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715336				2022-12-01	WOS:A1995QV41100006
J	THOMPSON, NP; MONTGOMERY, SM; POUNDER, RE; WAKEFIELD, AJ				THOMPSON, NP; MONTGOMERY, SM; POUNDER, RE; WAKEFIELD, AJ			IS MEASLES VACCINATION A RISK FACTOR FOR INFLAMMATORY BOWEL-DISEASE	LANCET			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; VIRUS-INFECTION; EPIDEMIOLOGY	Measles virus may persist in intestinal tissue, particularly that affected by Crohn's disease, and early exposure to measles may be a risk factor for the development of Crohn's disease. Crohn's disease and ulcerative colitis occur in the same families and may share a common aetiology. in view of the rising incidence of inflammatory bowel disease (Crohn's disease and ulcerative colitis), we examined the impact of measles vaccination upon these conditions. Prevalences of Crohn's disease, ulcerative colitis, coeliac disease, and peptic ulceration were determined in 3545 people who had received live measles Vaccine in 1964 as part of a measles vaccine trial. A longitudinal birth cohort of 11 407 subjects was one unvaccinated comparison cohort, and 2541 partners of those vaccinated was another. Compared with the birth cohort, the relative risk of developing Crohn's disease in the vaccinated group was 3.01 (95% CI 1.45-6.23) end of developing ulcerative colitis was 2.53 (1.15-5.58). There was no significant difference between these two groups in coeliac disease prevalence. Increased prevalence of inflammatory bowel disease, but not coeliac disease or peptic ulceration, was found in the vaccinated cohort compared with their partners. These findings suggest that measles virus may play a part in the development not only of Crohn's disease but also of ulcerative colitis.	CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON,ENGLAND	City University London	THOMPSON, NP (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT MED,INFLAMMATORY BOWEL DIS STUDY GRP,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.							BARTON JR, 1989, GUT, V30, P618, DOI 10.1136/gut.30.5.618; Butler N.R., 1963, PERINATAL MORTALITY; EKBOM A, 1994, LANCET, V334, P508; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; HALL AJ, 1993, BRIT MED J, V307, P1294, DOI 10.1136/bmj.307.6915.1294; LEWIN J, 1995, GUT, V36, P564, DOI 10.1136/gut.36.4.564; MILLER C, 1992, INT J EPIDEMIOL, V21, P998, DOI 10.1093/ije/21.5.998; RAMSAY MEB, 1994, EPIDEMIOL INFECT, V112, P409, DOI 10.1017/S0950268800057824; RIIS P, 1990, INFLAMMATORY BOWEL D; SANDLER RS, 1994, EPIDEMIOLOGY INFLAMM, P10; STEVENS CE, 1992, PEDIATRICS, V90, P170; THOMPSON NP, IN PRESS EUR J GASTR; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WHELAN G, 1990, MED CLIN N AM, V74, P1; WURZELMANN JI, 1994, DIGEST DIS SCI, V39, P555, DOI 10.1007/BF02088342; 1966, BRIT MED J, V1, P441; 1975, OPCS SERIES MB2, V2	18	162	164	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1071	1074		10.1016/S0140-6736(95)90816-1	http://dx.doi.org/10.1016/S0140-6736(95)90816-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715338				2022-12-01	WOS:A1995QV41100008
J	VONKRIES, R; HACHMEISTER, A; GOBEL, U				VONKRIES, R; HACHMEISTER, A; GOBEL, U			REPEATED ORAL VITAMIN-K PROPHYLAXIS IN WEST-GERMANY - ACCEPTANCE AND EFFICACY	BMJ-BRITISH MEDICAL JOURNAL			English	Article											VONKRIES, R (corresponding author), UNIV DUSSELDORF, KINDERKLIN, D-40225 DUSSELDORF, GERMANY.							GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; Schmidt E, 1993, MONATSSCHR KINDERH, V141, P758; VONKRIES R, 1993, THROMB HAEMOSTASIS, V69, P293; 1993, DTSCH ARZTEBLAN, V90, P53; 1992, VITAMIN K PROPHYLAXI	5	24	24	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	1995	310	6987					1097	1098		10.1136/bmj.310.6987.1097	http://dx.doi.org/10.1136/bmj.310.6987.1097			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742675	Green Published			2022-12-01	WOS:A1995QW61800014
J	WIJNEN, RMH; BOOSTER, MH; STUBENITSKY, BM; DEBOER, J; HEINEMAN, E; KOOTSTRA, G				WIJNEN, RMH; BOOSTER, MH; STUBENITSKY, BM; DEBOER, J; HEINEMAN, E; KOOTSTRA, G			OUTCOME OF TRANSPLANTATION OF NON-HEART-BEATING DONOR KIDNEYS	LANCET			English	Article							MACHINE PERFUSION; CANINE PANCREAS; PRESERVATION; GRAFTS; PROCUREMENT; REJECTION; ISCHEMIA; TISSUE	To reduce the shortage of kidneys for transplantation, we started a non-heart-beating (NHB) donor programme, and compared the short-term and long-term outcomes of kidneys from NHB donors with those of a matched group of kidneys from heart-beating (HB) donors. 57 NHB kidneys were procured at the University Hospital in Msaastricht and at three regional hospitals in the Netherlands, and were transplanted in 21 transplant centres within the Eurotransplant exchange organisation. 114 matched controls from HB donors were selected from Eurotransplant files. Mean follow-up was 85 months. At 5 years, graft survival was 54% for NHB kidneys and 55% for HB kidneys; patient survival was 75% and 77%. Kidneys from NHB donors had a significantly higher rate of delayed graft function (60% vs 35%), resulting in a longer hospital stay. Primary non-function of the graft was seen as frequently in the NHB donor-kidney group as in the HB group (14% vs 8%, p=0.3). We conclude that NHB donors are a valuable source of kidneys for transplantation.	UNIV LIMBURG HOSP,DEPT SURG,6202 AZ MAASTRICHT,NETHERLANDS; EUROTRANSPLANT FDN,LEIDEN,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC)			Heineman, Erik/ABG-9592-2021; Wijnen, R.M.H./L-4758-2015					ARIAS J, 1991, TRANSPLANT P, V23, P2581; BELZER FO, 1967, LANCET, V2, P536; BOOSTER MH, 1993, TRANSPLANT P, V25, P3012; BOOSTER MH, 1993, TRANSPLANT P, V25, P3006; BOOSTER MH, 1992, TRANSPLANTATION, V56, P613; BROCKMEYER C, 1993, TRANSPLANTATION, V55, P610; CANAFAX DM, 1986, TRANSPLANTATION, V41, P177, DOI 10.1097/00007890-198602000-00009; CASTELAO AM, 1991, TRANSPLANT P, V23, P2584; COHEN B, 1993, 1992 EUR ANN REP, P31; FUJINO Y, 1993, TRANSPLANTATION, V56, P1083, DOI 10.1097/00007890-199311000-00006; GARVIN PJ, 1980, ARCH SURG-CHICAGO, V115, P180; GORE SM, 1991, BRIT MED J, V302, P149, DOI 10.1136/bmj.302.6769.149; GROENEWOUD AF, 1992, TRANSPLANT INT, V5, pS429; HOFFMANN RM, 1989, TRANSPLANTATION, V47, P32, DOI 10.1097/00007890-198901000-00008; KALLERHOFF M, 1987, UROL RES, V15, P5; KOOTSTRA G, 1991, TRANSPLANT P, V23, P912; KOZAKI M, 1991, TRANSPLANT P, V23, P2575; LAND W, 1994, TRANSPLANTATION, V57, P211, DOI 10.1097/00007890-199401001-00010; MATSUNO N, 1994, TRANSPLANTATION, V57, P293; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; PHILLIPS AO, 1994, BRIT MED J, V308, P575, DOI 10.1136/bmj.308.6928.575a; PLOEG RJ, 1992, LANCET, V340, P129, DOI 10.1016/0140-6736(92)93212-6; PREUSCHOF L, 1991, TRANSPLANT P, V23, P1300; RIJKSEN JFW, 1972, EUROTRANSPLANT MANUA, P30; SCHLUMPF R, 1992, TRANSPLANT INT, V5, pS424; SCHWEIZER RT, 1981, TRANSPLANTATION, V32, P482, DOI 10.1097/00007890-198112000-00005; VARTY K, 1994, BRIT MED J, V308, P575, DOI 10.1136/bmj.308.6928.575; VERDUYN W, 1993, HUM IMMUNOL, V37, P59, DOI 10.1016/0198-8859(93)90143-O; VROEMEN JPA, 1983, NETH J SURG, V35, P50; WAHLBERG JA, 1987, TRANSPLANTATION, V43, P5, DOI 10.1097/00007890-198701000-00002	30	243	247	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1067	1070		10.1016/S0140-6736(95)90815-3	http://dx.doi.org/10.1016/S0140-6736(95)90815-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715337				2022-12-01	WOS:A1995QV41100007
J	WILKINSON, P; HANSELL, DM; JANSSENS, J; RUBENS, M; RUDD, RM; TAYLOR, AN; MCDONALD, C				WILKINSON, P; HANSELL, DM; JANSSENS, J; RUBENS, M; RUDD, RM; TAYLOR, AN; MCDONALD, C			IS LUNG-CANCER ASSOCIATED WITH ASBESTOS EXPOSURE WHEN THERE ARE NO SMALL OPACITIES ON THE CHEST RADIOGRAPH	LANCET			English	Article							WORKERS; MORTALITY	This study was designed to test the hypothesis that the risk of lung cancer from asbestos exposure is confined to persons with radiographic evidence of pulmonary fibrosis. Occupational and smoking histories were obtained from 271 patients with a confirmed diagnosis of primary lung cancer and 678 referents (279 with other respiratory disease and 399 with cardiac disease). Histories were reviewed blind to assess the timing, duration, and probability of exposure to asbestos. To allow for a lag between asbestos exposure and the development of lung cancer, subjects were classified by the time they had spent in an occupation entailing definite or probable exposure more than 15 years before diagnosis. The presence and extent of fibrosis was assessed blindly from chest radiographs by three readers and scored for small opacities with the ILO 1989 International Classification of Radiographs of the Pneumoconioses. 93 (34.3%) cases had worked in an occupation with definite or probable asbestos exposure compared with 176 (25. 8%) referents (crude odds ratio for lung cancer 1.49, 95% CI 1.09-2.04). After adjustment for age, sex, smoking history, and area of referral, the odds ratio (95% CI) was 2.03 (1.00-4.13) in the subgroup of 211 with a median ILO score for small parenchymal opacities of 1/0 or more, and 1.56 (1.02-2.39) in the 738 with a score of 0/1 or less (ie, those without radiological evidence of pulmonary fibrosis). These results suggest that asbestos is associated with lung cancer even in the absence of radiologically apparent pulmonary fibrosis.	ROYAL BROMPTON HOSP,LONDON SW3 6LY,ENGLAND; NATL HEART & LUNG INST,LONDON SW3 6LY,ENGLAND; LONDON CHEST HOSP,LONDON E2 9JX,ENGLAND	Royal Brompton Hospital; Imperial College London; University of London; Queen Mary University London				Wilkinson, Paul/0000-0001-7456-259X				DOLL R, 1981, CAUSES CANC, P1238; HUGHES JM, 1991, BRIT J IND MED, V48, P229; IRVINE HD, 1993, BMJ-BRIT MED J, V306, P1503, DOI 10.1136/bmj.306.6891.1503; KIPEN HM, 1987, BRIT J IND MED, V44, P96; LIDDELL FDK, 1980, BRIT J IND MED, V37, P257; LIDDELL FDK, 1977, BRIT J IND MED, V34, P85; MARTISCHNIG M, 1977, BMJ-BRIT MED J, V1, P756; MCDONALD AD, 1980, CANCER, V46, P1650, DOI 10.1002/1097-0142(19801001)46:7<1650::AID-CNCR2820460726>3.0.CO;2-Y; MCDONALD JC, 1981, QUANTIFICATION OCCUP, P73; MCLEOD TC, 1983, RADIOLOGY, V149, P353; MEREDITH SK, 1994, OCCUP MED-OXFORD, V44, P183, DOI 10.1093/occmed/44.4.183; RECKLAKE MR, 1991, MINERAL FIBERS HLTH, P105; SLUISCREMER GK, 1989, BRIT J IND MED, V46, P537; STAPLES CA, 1989, AM REV RESPIR DIS, V139, P1502, DOI 10.1164/ajrccm/139.6.1502; 1980, OCCUPATIONAL SAFETY, V22; CANCER STATISTIC MB1, V20	16	72	73	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1074	1078		10.1016/S0140-6736(95)90817-X	http://dx.doi.org/10.1016/S0140-6736(95)90817-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715339				2022-12-01	WOS:A1995QV41100009
J	ENDRIZZI, JA; CRONK, JD; WANG, WD; CRABTREE, GR; ALBER, T				ENDRIZZI, JA; CRONK, JD; WANG, WD; CRABTREE, GR; ALBER, T			CRYSTAL-STRUCTURE OF DCOH, A BIFUNCTIONAL, PROTEIN-BINDING TRANSCRIPTIONAL COACTIVATOR	SCIENCE			English	Article							NUCLEAR FACTOR-I; DIMERIZATION DOMAIN; 4A-CARBINOLAMINE DEHYDRATASE; DNA-BINDING; ACTIVATION DOMAINS; RAT-LIVER; HOMEODOMAIN; HYDROXYLASE; PROMOTERS; RECOGNITION	DCoH, the dimerization cofactor of hepatocyte nuclear factor-1, stimulates gene expression by associating with specific DNA binding proteins and also catalyzes the dehydration of the biopterin cofactor of phenylalanine hydroxylase. The x-ray crystal structure determined at 3 angstrom resolution reveals that DCoH forms a tetramer containing two saddle-shaped grooves that comprise likely macromolecule binding sites. Two equivalent enzyme active sites flank each saddle, suggesting that there is a spatial connection between the catalytic and binding activities. Structural similarities between the DCoH fold and nucleic acid-binding proteins argue that the saddle motif has evolved to bind diverse ligands or that DCoH unexpectedly may bind nucleic acids.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,MOLEC & GENET MED UNIT,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University	ENDRIZZI, JA (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928				BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; CITRON BA, 1993, AM J HUM GENET, V53, P768; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CRONK JD, UNPUB; DAVIS MD, 1992, FEBS LETT, V302, P73, DOI 10.1016/0014-5793(92)80288-R; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HANSEN LP, 1994, THESIS STANFORD U ST; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HUANG CY, 1973, J BIOL CHEM, V248, P4235; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAUFMAN S, 1970, J BIOL CHEM, V245, P4751; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V360, P520; KIM Y, 1993, NATURE, V360, P512; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P921; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LAZARUS RA, 1983, J BIOL CHEM, V258, P960; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; LUNDQVIST T, 1994, STRUCTURE, V2, P937, DOI 10.1016/S0969-2126(94)00095-6; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NAGAI K, 1991, NATURE, V348, P515; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PASTORE A, 1992, PROTEIN ENG, V5, P749, DOI 10.1093/protein/5.8.749; PASTORE A, 1991, BIOCHEMISTRY-US, V30, P148, DOI 10.1021/bi00215a022; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STEIGEMANN W, 1991, PROTEIN VERSION 3 1; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VONSTRANDMANN EP, IN PRESS DEVELOPMENT; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZENG WL, 1993, DEVELOPMENT, V118, P339; ZHAO GS, 1994, P NATL ACAD SCI USA, V91, P1366, DOI 10.1073/pnas.91.4.1366; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	53	56	56	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					556	559		10.1126/science.7725101	http://dx.doi.org/10.1126/science.7725101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725101				2022-12-01	WOS:A1995QV40700034
J	HSIEH, JJD; HAYWARD, SD				HSIEH, JJD; HAYWARD, SD			MASKING OF THE CBF1/RBPJ(KAPPA) TRANSCRIPTIONAL REPRESSION DOMAIN BY EPSTEIN-BARR-VIRUS EBNA2	SCIENCE			English	Article							BINDING-PROTEIN GENE; DROSOPHILA HOMOLOG; NUCLEAR ANTIGEN-2; INFECTION; PROMOTER; MOTIF	Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) is a transcriptional activator that is essential for EBV-driven B cell immortalization. EBNA2 is targeted to responsive promoters through interaction with a cellular DNA binding protein, C promoter binding factor 1 (CBF1). A transcriptional repression domain has been identified within CBF1. This domain also interacts with EBNA2, and repression is masked by EBNA2 binding. Thus, EBNA2 acts by countering transcriptional repression. Mutation at amino acid 233 of CBF1 abolishes repression and correlates with a loss-of-function mutation in the Drosophila homolog Su(H).	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,MOLEC VIROL LABS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA042245, R37CA042245] Funding Source: NIH RePORTER; NCI NIH HHS [CA42245] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAKAWA R, 1993, GENOMICS, V17, P306, DOI 10.1006/geno.1993.1326; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HSIEH JM, UNPUB; Liebowitz David, 1993, P107; LING PD, 1993, J VIROL, V67, P2990, DOI 10.1128/JVI.67.6.2990-3003.1993; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WOISETSCHLAEGER M, 1991, P NATL ACAD SCI USA, V88, P3942, DOI 10.1073/pnas.88.9.3942; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	25	262	269	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					560	563		10.1126/science.7725102	http://dx.doi.org/10.1126/science.7725102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725102				2022-12-01	WOS:A1995QV40700035
J	KARLOVICH, CA; BONFINI, L; MCCOLLAM, L; ROGGE, RD; DAGA, A; CZECH, MP; BANERJEE, U				KARLOVICH, CA; BONFINI, L; MCCOLLAM, L; ROGGE, RD; DAGA, A; CZECH, MP; BANERJEE, U			IN-VIVO FUNCTIONAL-ANALYSIS OF THE RAS EXCHANGE FACTOR SON OF SEVENLESS	SCIENCE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; DROSOPHILA-RETINA; ADAPTER PROTEIN; GENE-PRODUCT; SH3 DOMAINS; PATHWAY; ACTIVATION; LIGAND; CELLS	The Son of sevenless (Sos) protein functions as a guanine nucleotide transfer factor for Ras and interacts with the receptor tyrosine kinase Sevenless through the protein Drk, a homolog of mammalian Grb2. In vivo structure-function analysis revealed that the amino terminus of Sos was essential for its function in flies. A molecule lacking the amino terminus was a potent dominant negative. In contrast, a Sos fragment lacking the Drk binding sites was functional and its activity was dependent on the presence of the Sevenless receptor. Furthermore, membrane localization of Sos was independent of Drk. A possible role for Drk as an activator of Sos is discussed and a Drk-independent interaction between Sos and Sevenless is proposed that is likely mediated by the pleckstrin homology domain within the amino terminus.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			daga, andrea/J-1865-2018	daga, andrea/0000-0001-8935-5489; Rogge, Ronald/0000-0002-1875-3938	NEI NIH HHS [R01EY08152-06] Funding Source: Medline; NIGMS NIH HHS [GM-08375, GM-07104] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KARLOVICH CA, UNPUB; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, UNPUB; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; ROGGE R, 1992, P NATL ACAD SCI USA, V89, P5271, DOI 10.1073/pnas.89.12.5271; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	25	77	79	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					576	579		10.1126/science.7725106	http://dx.doi.org/10.1126/science.7725106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725106				2022-12-01	WOS:A1995QV40700040
J	KOH, JY; GWAG, BJ; LOBNER, D; CHOI, DW				KOH, JY; GWAG, BJ; LOBNER, D; CHOI, DW			POTENTIATED NECROSIS OF CULTURED CORTICAL-NEURONS BY NEUROTROPHINS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PROGRAMMED CELL-DEATH; CHOLINERGIC NEURONS; GLUTAMATE NEUROTOXICITY; FACTOR DEPRIVATION; PROTEIN-SYNTHESIS; TRK FAMILY; RAT-BRAIN; DEGENERATION; RECEPTOR	The effects of neurotrophins on several forms of neuronal degeneration in murine cortical cell cultures were examined. Consistent with other studies, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 all attenuated the apoptotic death induced by serum deprivation or exposure lo the calcium channel antagonist nimodipine, Unexpectedly, however, 24-hour pretreatment with these same neurotrophins markedly potentiated the necrotic death induced by exposure to oxygen-glucose deprivation or N-methyl-D-aspartate. Thus, certain neurotrophins may have opposing effects on different types of death in the same neurons.	WASHINGTON UNIV, SCH MED, CTR STUDY NERVOUS SYST INJURY, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030337] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30337] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; BEHERENS MI, UNPUB; BERINGER B, 1993, NEUROREPORT, V4, P1303; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, NEURODEGENERATIVE D, P233; CSERNANSKY CA, 1994, J NEUROSCI RES, V38, P101, DOI 10.1002/jnr.490380113; DAVIES SW, 1992, NEUROSCI LETT, V140, P161, DOI 10.1016/0304-3940(92)90092-L; FERNANDEZSANCHEZ MT, 1993, FEBS LETT, V335, P124, DOI 10.1016/0014-5793(93)80453-2; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Gwag B. J., 1994, Society for Neuroscience Abstracts, V20, P248; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HEFTI F, 1986, J NEUROSCI, V6, P2155; HENNEBERRY RC, 1989, ANN NY ACAD SCI, V568, P225; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVINE ES, IN PRESS J NEUROSCI; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORELLI A, 1986, J NEUROCHEM, V47, P375; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SHIGENO T, 1990, NEUROSCI LETT, V120, P117, DOI 10.1016/0304-3940(90)90182-9; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; WIDMER HR, 1993, NEUROREPORT, V4, P363, DOI 10.1097/00001756-199304000-00005; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YIP NY, 1993, NEURON, V10, P137	42	333	343	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					573	575		10.1126/science.7725105	http://dx.doi.org/10.1126/science.7725105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725105				2022-12-01	WOS:A1995QV40700039
J	LIPTON, RJ				LIPTON, RJ			DNA SOLUTION OF HARD COMPUTATIONAL PROBLEMS	SCIENCE			English	Article								DNA experiments are proposed to solve the famous ''SAT'' problem of computer science. This is a special case of a more general method that can solve NP-complete problems. The advantage of these results is the huge parallelism inherent in DNA-based computing. It has the potential to yield vast speedups over conventional electronic-based computers for such search problems.			LIPTON, RJ (corresponding author), PRINCETON UNIV, PRINCETON, NJ 08540 USA.							ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Garey M.R., 1979, COMPUTERS INTRACTABI; LIPTON RJ, 1994, UNPUB SPEEDING COMPU; SHANNON CE, 1949, BELL SYST TECH J, V28, P59, DOI 10.1002/j.1538-7305.1949.tb03624.x; Sinden R.R., 1994, DNA STRUCTURE FUNCTI	5	715	848	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					542	545		10.1126/science.7725098	http://dx.doi.org/10.1126/science.7725098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725098				2022-12-01	WOS:A1995QV40700030
J	LOWE, J; STOCK, D; JAP, R; ZWICKL, P; BAUMEISTER, W; HUBER, R				LOWE, J; STOCK, D; JAP, R; ZWICKL, P; BAUMEISTER, W; HUBER, R			CRYSTAL-STRUCTURE OF THE 20S PROTEASOME FROM THE ARCHAEON T-ACIDOPHILUM AT 3.4-ANGSTROM RESOLUTION	SCIENCE			English	Article							MULTICATALYTIC PROTEINASE COMPLEXES; ATP-DEPENDENT PROTEASES; THERMOPLASMA-ACIDOPHILUM; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; MECHANISM; GENE; REFINEMENT; PEPTIDASE; FEATURES	The three-dimensional structure of the proteasome from the archaebacterium Thermoplasma acidophilum has been elucidated by x-ray crystallographic analysis by means of isomorphous replacement and cyclic averaging. The atomic model was built and refined to a crystallographic R factor of 22.1 percent. The 673-kilodalton protease complex consists of 14 copies of two different subunits, alpha and beta, forming a barrel-shaped structure of four stacked rings. The two inner rings consist of seven beta subunits each, and the two outer rings consist of seven alpha subunits each. A narrow channel controls access to the three inner compartments. The alpha(7) beta(7) beta(7) alpha(7) subunit assembly has 72-point group symmetry. The structures of the alpha and beta subunits are similar, consisting of a core of two antiparallel beta sheets that is flanked by alpha helices on both sides. The binding of a peptide aldehyde inhibitor marks the active site in the central cavity at the amino termini of the beta subunits and suggests a novel proteolytic mechanism.	MAX PLANCK INST BIOCHEM,STRUKT FORSCH ABT,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST BIOCHEM,STRUKT BIOL ABT,D-82152 MARTINSRIED,GERMANY	Max Planck Society; Max Planck Society			Löwe, Jan/B-3882-2011; Löwe, Jan/X-6998-2019	Lowe, Jan/0000-0002-5218-6615				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BROTHERS HM, 1990, BIOCHEMISTRY-US, V29, P7468, DOI 10.1021/bi00484a016; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BRUENGER AT, 1992, XPLOR VERSION 3 1 SY; CHEN CCH, 1993, J MOL BIOL, V234, P165, DOI 10.1006/jmbi.1993.1571; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAHLMANN B, 1992, EUR J BIOCHEM, V208, P789, DOI 10.1111/j.1432-1033.1992.tb17249.x; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DAUTER Z, 1990, ACTA CRYSTALLOGR B, V46, P833, DOI 10.1107/S0108768190008059; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20887; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; DJABALLAH H, 1992, BIOCHEMISTRY-US, V31, P4133, DOI 10.1021/bi00131a033; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAGAN JM, 1992, J BIOL CHEM, V267, P23015; FINKE RG, 1986, J AM CHEM SOC, V108, P2947, DOI 10.1021/ja00271a025; GHUYSEN JM, 1981, TOP MOL PHARM, V1, P63; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JAP B, 1983, J MOL BIOL, V234, P881; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KELLY JA, 1989, J MOL BIOL, V209, P281, DOI 10.1016/0022-2836(89)90277-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN PJ, 1965, INORG CHEM, V4, P1482, DOI 10.1021/ic50032a028; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; LUPAS A, 1994, FEBS LETT, V354, P45, DOI 10.1016/0014-5793(94)01082-X; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2579; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Puehler Gabriela, 1994, Systematic and Applied Microbiology, V16, P734; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RECHSTEINER M, 1993, J BIOL CHEM, V268, P60; RICHTERRUOFF B, 1993, FEBS LETT, V336, P34, DOI 10.1016/0014-5793(93)81603-W; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SEEMULLER E, 1995, FEBS LETT, V359, P173, DOI 10.1016/0014-5793(95)00036-9; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; STEIGEMANN W, 1991, CRYSTALLOGRAPHIC COM, V5; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1992, NEW BIOL, V4, P173; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; TURK D, 1992, THESIS TU MUNCHEN; WENZEL T, 1993, FEBS LETT, V326, P215, DOI 10.1016/0014-5793(93)81793-Y; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; ZWICKL P, 1990, J STRUCT BIOL, V103, P197, DOI 10.1016/1047-8477(90)90037-D; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004; 1979, CCP4 SERC4 DAR LAB S	68	1329	1355	1	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					533	539		10.1126/science.7725097	http://dx.doi.org/10.1126/science.7725097			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725097				2022-12-01	WOS:A1995QV40700028
J	MOUGNEAU, E; ALTARE, F; WAKIL, AE; ZHENG, SC; COPPOLA, T; WANG, ZE; WALDMANN, R; LOCKSLEY, RM; GLAICHENHAUS, N				MOUGNEAU, E; ALTARE, F; WAKIL, AE; ZHENG, SC; COPPOLA, T; WANG, ZE; WALDMANN, R; LOCKSLEY, RM; GLAICHENHAUS, N			EXPRESSION CLONING OF A PROTECTIVE LEISHMANIA ANTIGEN	SCIENCE			English	Article							MAJOR SURFACE-ANTIGEN; T-CELL LINES; CUTANEOUS LEISHMANIASIS; MURINE LEISHMANIASIS; INTERFERON-GAMMA; MICE; MACROPHAGES; INFECTION; PROMASTIGOTES; RECEPTORS	Parasite-specific CD4(+) T cells have been shown to transfer protection against Leishmania major in susceptible BALB/c mice. An epitope-tagged expression library was used to identify the antigen recognized by a protective CD4(+) T cell clone, The expression library allowed recombinant proteins made in bacteria to be captured by macrophages for presentation to T cells restricted to major histocompatibility complex class II. A conserved 36-kilodalton member of the tryptophan-aspartic acid repeat family of proteins was identified that was expressed in both stages of the parasite life Cycle. A 24-kilodalton portion of this antigen protected susceptible mice when administered as a vaccine with interleukin-12 before infection.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; CNRS, UPR 411, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California San Francisco			Coppola, Thierry/I-5036-2016; Waldmann, Rainer/Q-2108-2016; altare, frederic/K-8664-2015	Coppola, Thierry/0000-0003-1018-722X; Waldmann, Rainer/0000-0002-4599-2926; altare, frederic/0000-0002-5077-4616	NIAID NIH HHS [AI26918] Funding Source: Medline; NIDDK NIH HHS [T32 DK07007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI026918, R01AI026918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007007] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; ANTOINE JC, 1991, INFECT IMMUN, V59, P764, DOI 10.1128/IAI.59.3.764-775.1991; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; BRAKE DA, 1988, J IMMUNOL, V140, P1989; BRAKE DA, 1986, J IMMUNOL, V137, P345; BUTTON LL, 1990, J EXP MED, V171, P589; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; COLOMERGOULD V, 1985, J EXP MED, V162, P902, DOI 10.1084/jem.162.3.902; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73; LANG T, 1994, J CELL SCI, V107, P2137; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MORRIS L, 1992, J IMMUNOL, V149, P2715; MOUGNEAU E, UNPUB; MULLER I, 1989, IMMUNOL REV, V112, P95, DOI 10.1111/j.1600-065X.1989.tb00554.x; MULLER I, 1988, IMMUNOL LETT, V19, P251, DOI 10.1016/0165-2478(88)90151-4; MULLER I, 1989, EUR J IMMUNOL, V19, P865, DOI 10.1002/eji.1830190513; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NICKELL SP, 1987, J IMMUNOL, V138, P914; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RUSSELL DG, 1992, J CELL SCI, V103, P1193; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCOTT P, 1990, J IMMUNOL, V144, P1075; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1989, IMMUNOL REV, V112, P161, DOI 10.1111/j.1600-065X.1989.tb00557.x; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; WANG Z, UNPUB; WANG ZE, 1994, P NATL ACAD SCI USA, V91, P12932, DOI 10.1073/pnas.91.26.12932; WANG ZE, 1993, J IMMUNOL, V151, P2077; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WHITE J, 1989, J IMMUNOL, V143, P1822	36	320	345	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					563	566		10.1126/science.7725103	http://dx.doi.org/10.1126/science.7725103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725103				2022-12-01	WOS:A1995QV40700036
J	PANDEY, A; SHAO, HN; MARKS, RM; POLVERINI, PJ; DIXIT, VM				PANDEY, A; SHAO, HN; MARKS, RM; POLVERINI, PJ; DIXIT, VM			ROLE OF B61, THE LIGAND FOR THE ECK RECEPTOR TYROSINE KINASE, IN TNF-ALPHA-INDUCED ANGIOGENESIS	SCIENCE			English	Article							NECROSIS-FACTOR-ALPHA; RESPONSE GENE; PROTEIN; CLONING	B61, a cytokine-inducible endothelial gene product, is the ligand for the Eck receptor protein tyrosine kinase (RPTK), Expression of a B61-immunoglobulin chimera showed that B61 could act as an angiogenic factor in vivo and a chemoattractant for endothelial cells in vitro, The Eck RPTK was activated by tumor necrosis factor-alpha (TNF-alpha) through induction of B61, and an antibody to B61 attenuated angiogenesis induced by TNF-alpha but not by basic fibroblast growth factor, This finding suggests the existence of an autocrine or paracrine loop involving activation of the Eck RPTK by its inducible ligand B61 after an inflammatory stimulus, the net effect of which would be to promote angiogenesis, a hallmark of chronic inflammation,	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH DENT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012; Polverini, Peter/AAJ-8392-2020; Pandey, Akhilesh/B-4127-2009	dixit, vishva m/0000-0001-6983-0326; Pandey, Akhilesh/0000-0001-9943-6127	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39926] Funding Source: Medline; NIAID NIH HHS [P0 1AI331890004] Funding Source: Medline; NIDDK NIH HHS [DK 39255] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BAGLIONI C, 1992, TUMOR NECROSIS FACTO, P425; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, UNPUB; SARMA V, 1992, J IMMUNOL, V148, P3302; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; STREITER RM, 1992, AM J PATHOL, V141, P1279	17	343	374	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					567	569		10.1126/science.7536959	http://dx.doi.org/10.1126/science.7536959			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7536959				2022-12-01	WOS:A1995QV40700037
J	CASTIELLO, U; SCARPA, M; BENNETT, K				CASTIELLO, U; SCARPA, M; BENNETT, K			A BRAIN-DAMAGED PATIENT WITH AN UNUSUAL PERCEPTUOMOTOR DEFICIT	NATURE			English	Article							CORTEX; PERCEPTION	WHEN interacting,vith objects, the pattern of movements is influenced by such object characteristics as size and position(1-4). Little is known about the effect of higher level categorical encoding of objects upon movements. Here we present evidence for an approval-for-action process which takes into account such encoding. For the brain-damaged subject L.P., the ability to complete actions involving two objects in central vision is influenced by the semantic or functional relationship between the objects. Even though she perceives only one object, she can integrate two related objects into a coordinated action. If the objects are not related she is unable to integrate them into a single motor act, We propose that selection-for-action systems(5) include processes which gate conceptually the behavioural disposition to action.	UNIV MODENA,NEUROL CLIN,I-41100 MODENA,ITALY; EUROPEAN MED CTR,BOLOGNA,ITALY; UNIV BOLOGNA,DIPARTIMENTO PSICOL,I-40127 BOLOGNA,ITALY	Universita di Modena e Reggio Emilia; University of Bologna				Castiello, Umberto/0000-0003-0629-1286				Allport D. A., 1987, PERSPECTIVES PERCEPT, V15, P395; ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; [Anonymous], 1982, BOSTON NAMING TEST; Arbib M. A., 2011, HDB PHYSL NERVOUS SY, P1449, DOI [10.1002/cphy.cp010233, DOI 10.1016/J.JPHYSPARIS.2008.03.001]; CASTIELLO U, 1993, EXP BRAIN RES, V94, P165; COSLETT HB, 1991, BRAIN, V114, P1523, DOI 10.1093/brain/114.4.1523; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; FERRIGNO G, 1985, IEEE T BIO-MED ENG, V32, P943, DOI 10.1109/TBME.1985.325627; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.ne.11.030188.001033; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Goodglass H., 2001, ASSESSMENT APHASIA R; HUMPHREYS GW, 1994, COGNITIVE NEUROPSYCH, V11, P393, DOI 10.1080/02643299408251980; JAKOBSON LS, 1991, EXP BRAIN RES, V86, P199; JEANNEROD M, 1994, NEUROPSYCHOLOGIA, V32, P369, DOI 10.1016/0028-3932(94)90084-1; JEANNEROD M, 1988, OXFORD SCI PUBLICATI, V15; Jeannerod M., 1981, ATTENTION PERFORM, P153; KINSBOURNE M, 1963, BRAIN, V86, P697, DOI 10.1093/brain/86.4.697; KINSBOURNE M, 1962, BRAIN, V85, P461, DOI 10.1093/brain/85.3.461; Kugler P.N., 1980, TUTORIALS MOTOR BEHA, P49, DOI DOI 10.1016/S0166-4115(08)61937-8; LAIACONA M, 1993, CORTEX, V29, P727, DOI 10.1016/S0010-9452(13)80293-6; MILNER AD, 1991, BRAIN, V114, P405, DOI 10.1093/brain/114.1.405; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; Roy E. A., 1985, NEUROPSYCHOLOGICAL S, P45; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; WARRINGTON EK, 1978, PERCEPTION, V7, P695, DOI 10.1068/p070695; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; Weir PL, 1994, ADV PSYCHOL, V105, P129, DOI [10.1016/S0166-4115(08)61276-5, DOI 10.1016/S0166-4115(08)61276-5]	27	13	13	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					805	808		10.1038/374805a0	http://dx.doi.org/10.1038/374805a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QV315	7723824				2022-12-01	WOS:A1995QV31500045
J	CHATTERJEE, S; STRUHL, K				CHATTERJEE, S; STRUHL, K			CONNECTING A PROMOTER-BOUND PROTEIN TO TBP BYPASSES THE NEED FOR A TRANSCRIPTIONAL ACTIVATION DOMAIN	NATURE			English	Article							CRYSTAL-STRUCTURE; TATA ELEMENTS; YEAST; BINDING; INVITRO; SPECIFICITY; MECHANISM; MUTANTS; COMPLEX; CLONING	BIOCHEMICAL analyses have suggested potential targets for transcriptional activation domains, which include several components of the RNA polymerase II machinery(1-7), as well as the chromatin template(8-12). Here we examine the mechanism of transcriptional activation in yeast cells by connecting a heterologous DNA-binding domain (LexA) to the TATA-binding protein (TBP), LexA-TBP efficiently activates transcription from a promoter containing a LexA operator upstream of a TATA element, Activation is promoter-specific and is sensitive to mutations on the DNA-binding surface of TBP; hence it is not due to a fortuitous activation domain on TBP, Thus a promoter-bound protein lacking an activation domain can stimulate transcription if it is directly connected to TBP. This suggests that recruitment of TBP to the promoter can be a rate-limiting step for transcription in vivo, and that interactions between activation domains and factors that function after TBP recruitment can be bypassed for activation.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CORMACK BP, 1994, GENE DEV, V8, P1335, DOI 10.1101/gad.8.11.1335; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	31	174	176	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					820	822		10.1038/374820a0	http://dx.doi.org/10.1038/374820a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723828				2022-12-01	WOS:A1995QV31500050
J	FRASER, AM; BROCKERT, JE; WARD, RH				FRASER, AM; BROCKERT, JE; WARD, RH			ASSOCIATION OF YOUNG MATERNAL AGE WITH ADVERSE REPRODUCTIVE OUTCOMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BIRTH-WEIGHT; TEENAGE PREGNANCY; PRENATAL-CARE; ADOLESCENT PREGNANCY; PRETERM DELIVERY; ADULT WOMEN; RISK; POPULATION; HEALTH; GROWTH	Background. Pregnancy in adolescence is associated with an excess risk of poor outcomes, including low birth weight and prematurity, Whether this association simply reflects the deleterious sociodemographic environment of most pregnant teenagers or whether biologic immaturity is also causally implicated is not known, Methods. To determine whether a young age confers an intrinsic risk of adverse outcomes of pregnancy, we performed stratified analyses of 134,088 white girls and women, 13 to 24 years old, in Utah who delivered singleton, first-born children between 1970 and 1990. Relative risk for subgroups of this study population was examined to eliminate the confounding influence of marital status, educational level, and the adequacy of prenatal care, The adjusted relative risk for the entire study group was calculated as the weighted average of the stratum-specific risks. Results. Among white married mothers with educational levels appropriate for their ages who received adequate prenatal care, younger teenage mothers (13 to 17 years of age) had a significantly higher risk (P<0.001) than mothers who were 20 to 24 years of age of delivering an infant who had low birth weight (relative risk, 1.7; 95 percent confidence interval, 1.5 to 2.0), who was delivered prematurely (relative risk, 1.9; 95 percent confidence interval, 1.7 to 2.1), or who was small for gestational age (relative risk, 1.3; 95 percent confidence interval, 1.2 to 1.4). Older teenage mothers (18 or 19 years of age) also had a significant increase in these risks, Even though sociodemographic variables associated with teenage pregnancy increase the risk of adverse outcomes, the relative risk remained significantly elevated for both younger and older teenage mothers after adjustment for marital status, level of education, and adequacy of prenatal care. Conclusions. In a study of mothers 13 to 24 years old who had the characteristics of most white, middle-class Americans, a younger age conferred an increased risk of adverse pregnancy outcomes that was independent of important confounding sociodemographic factors.	UNIV UTAH,ECCLES INST HUMAN GENET 2100,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UTAH DEPT HLTH,BUR VITAL RECORDS,SALT LAKE CITY,UT	Utah System of Higher Education; University of Utah					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023492] Funding Source: NIH RePORTER; NICHD NIH HHS [1R01 HD23492] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahmed F, 1990, J Community Health, V15, P35, DOI 10.1007/BF01350184; ANNIE E, 1992, KIDS COUNT DATA BOOK, P110; BROWN HL, 1991, SOUTHERN MED J, V84, P46, DOI 10.1097/00007611-199101000-00012; BUCHI KF, 1993, OBSTET GYNECOL, V81, P239; DAVID RJ, 1983, SOUTHERN MED J, V76, P1401, DOI 10.1097/00007611-198311000-00020; DIXON WJ, 1990, BMDP STATISTICAL SOF, V1, P231; DUNN PM, 1985, ACTA PAEDIATR SC   S, V319, P7; EISNER V, 1979, AM J PUBLIC HEALTH, V69, P887, DOI 10.2105/AJPH.69.9.887; ELSTER AB, 1984, AM J OBSTET GYNECOL, V149, P845, DOI 10.1016/0002-9378(84)90602-1; FRIEDE A, 1987, PUBLIC HEALTH REP, V102, P192; GALE R, 1989, J ADOLESCENT HEALTH, V10, P404, DOI 10.1016/0197-0070(89)90219-2; HAIEK L, 1989, J ADOLESCENT HEALTH, V10, P16, DOI 10.1016/0197-0070(89)90041-7; HEDIGER ML, 1989, OBSTET GYNECOL, V74, P6; HORON IL, 1983, AM J OBSTET GYNECOL, V146, P444, DOI 10.1016/0002-9378(83)90826-8; KETTERLINUS RD, 1990, J ADOLESCENT HEALTH, V11, P423, DOI 10.1016/0197-0070(90)90090-O; LEE KS, 1988, AM J OBSTET GYNECOL, V158, P84, DOI 10.1016/0002-9378(88)90783-1; MAKINSON C, 1985, FAM PLANN PERSPECT, V17, P132, DOI 10.2307/2135024; MCANARNEY ER, 1987, AM J DIS CHILD, V141, P1053, DOI 10.1001/archpedi.1987.04460100031017; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; Scholl T O, 1989, Paediatr Perinat Epidemiol, V3, P357, DOI 10.1111/j.1365-3016.1989.tb00524.x; SCHOLL TO, 1988, LANCET, V1, P701, DOI 10.1016/S0140-6736(88)91494-8; SCHOLL TO, 1987, OBSTET GYNECOL, V69, P312; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; TRUSSELL J, 1988, FAM PLANN PERSPECT, V20, P262, DOI 10.2307/2135482; TURNER RJ, 1990, J HEALTH SOC BEHAV, V31, P43, DOI 10.2307/2137044; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; 1993, EXECUTIVE SUMMARY MA; 1993, MMWR-MORBID MORTAL W, V42, P230; 1992, 162 UT STAT U DEP SO; 1993, MMWR-MORBID MORTAL W, V42, P255; [No title captured]; 1993, 167 UT STAT U DEP SO; 1993, MON VITAL STAT REP S, V42; 1991, STATISTICAL ABSTRACT, P63	34	608	641	0	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1113	1117		10.1056/NEJM199504273321701	http://dx.doi.org/10.1056/NEJM199504273321701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QU302	7700283				2022-12-01	WOS:A1995QU30200001
J	HARRIS, JM; PARKER, AJ				HARRIS, JM; PARKER, AJ			INDEPENDENT NEURAL MECHANISMS FOR BRIGHT AND DARK INFORMATION IN BINOCULAR STEREOPSIS	NATURE			English	Article							SPATIAL-INTERVAL DISCRIMINATION; VISUAL-SYSTEM; EFFICIENCY; SEGREGATION; AFFERENTS; DISPARITY; CHANNELS; VISION; CORTEX	EARLY visual processing is organized into a number of independent channels. In the retina, increments and decrements of brightness are processed independently by different groups of neurons', For psychophysical measurements of human vision, independence can be tested statistically, Using this criterion in a depth judgement task, we show here that, for binocular stereo vision, increments and decrements are treated independently, at least as far as the level at which information from the left and right eyes is first combined, At later stages of stereo processing, the information from the two channels is no longer independent, Because the signals for stereo vision are first combined at the visual cortex, these results suggest that the neural 'on' and 'off' channels remain independent right up to early cortical stages, Theoretical studies of stereo vision have proposed that visual features in the views of the two eyes are matched on the basis of 'similarity'(2). Our results show that stereo matching treats features as statistically independent (and therefore dissimilar) if they appear perceptually bright and dark relative to the background, If features differ perceptually but only in the degree of brightness or darkness, human stereo vision treats them as similar.	SMITH KETTLEWELL EYE RES INST,SAN FRANCISCO,CA 94115	The Smith-Kettlewell Eye Research Institute	HARRIS, JM (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Parker, Andrew J/I-7867-2013	Parker, Andrew J/0000-0001-5800-0407; Harris, Julie/0000-0002-3497-4503	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HH, 1981, 7TH P INT JOINT C AR, P631; BARLOW HB, 1979, VISION RES, V19, P783, DOI 10.1016/0042-6989(79)90154-8; BARLOW HB, 1978, VISION RES, V18, P637, DOI 10.1016/0042-6989(78)90143-8; BJORKLUND RA, 1981, PERCEPTION, V10, P511, DOI 10.1068/p100511; BURGESS A, 1983, VISION RES, V23, P811, DOI 10.1016/0042-6989(83)90204-3; BURTON GJ, 1977, BIOL CYBERN, V27, P189, DOI 10.1007/BF00344140; DEVALOIS KK, 1977, VISION RES, V17, P209, DOI 10.1016/0042-6989(77)90084-0; DOLAN RP, 1994, VISUAL NEUROSCI, V11, P23, DOI 10.1017/S095252380001107X; EDWARDS M, 1994, VISION RES, V34, P2849, DOI 10.1016/0042-6989(94)90054-X; HANLY M, 1979, EXP BRAIN RES, V35, P37; HARRIS JM, 1994, VISION RES, V34, P2761, DOI 10.1016/0042-6989(94)90231-3; HARRIS JM, 1992, J OPT SOC AM A, V1, P14; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KAUFMAN L, 1969, PERCEPT PSYCHOPHYS, V6, P10, DOI 10.3758/BF03210666; LEVI DM, 1987, J OPT SOC AM A, V4, P1304, DOI 10.1364/JOSAA.4.001304; LEVI DM, 1990, VISION RES, V30, P1735, DOI 10.1016/0042-6989(90)90156-F; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; MARR D, 1976, SCIENCE, V194, P283, DOI 10.1126/science.968482; MCCONNELL SK, 1984, P NATL ACAD SCI-BIOL, V81, P1590, DOI 10.1073/pnas.81.5.1590; MORGAN MJ, 1991, VISION RES, V31, P2075, DOI 10.1016/0042-6989(91)90165-2; POLLARD SB, 1985, PERCEPTION, V14, P449, DOI 10.1068/p140449; SCHILLER PH, 1986, NATURE, V322, P824, DOI 10.1038/322824a0; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; WATT RJ, 1985, VISION RES, V25, P1661, DOI 10.1016/0042-6989(85)90138-5; ZAHS KR, 1988, J NEUROPHYSIOL, V59, P1410, DOI 10.1152/jn.1988.59.5.1410	25	36	36	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					808	811		10.1038/374808a0	http://dx.doi.org/10.1038/374808a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723825				2022-12-01	WOS:A1995QV31500046
J	JACOBSON, MD; RAFF, MC				JACOBSON, MD; RAFF, MC			PROGRAMMED CELL-DEATH AND BCL-2 PROTECTION IN VERY-LOW OXYGEN	NATURE			English	Article							APOPTOSIS; INDUCTION	PROGRAMMED cell death (PCD) is a fundamental feature of animal cells', but the mechanism remains unknown, Similarly, the Bcl-2 oncoprotein can suppress PCD in a variety of cell types and circumstances(2), but it is not known how it does so, It has been suggested that PCD involves the generation of reactive oxygen species (ROS) and that Bcl-2 protects against PCD by inhibiting the generation or action of ROS(3-6). To determine whether ROS are required for PCD, we cultured cells in a near-anaerobic atmosphere where the generation of ROS would be expected not to occur, or at least to be greatly reduced, We find that these conditions inhibit PCD induced by ROS-generating agents but do not inhibit PCD induced by other means, Furthermore, we show that Bcl-2 can protect cells from PCD in these anaerobic conditions. These results suggest that ROS are not required for PCD, and that Bcl-2 protects against PCD in ways that do not depend on the inhibition of ROS production or activity.	UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London	JACOBSON, MD (corresponding author), UNIV LONDON UNIV COLL,MRC,DEV NEUROBIOL PROGRAMME,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.							ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ABRAMS JS, 1988, J IMMUNOL, V140, P131; BAUDRY M, 1993, BIOCHEM BIOPH RES CO, V192, P964, DOI 10.1006/bbrc.1993.1509; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; DEXTER TM, 1994, PHIL T R SOC B, V345, P231; Franklin J. L., 1994, Society for Neuroscience Abstracts, V20, P432; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; MARVEL J, 1994, ONCOGENE, V9, P1117; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RATAN RR, 1994, J NEUROCHEM, V62, P376; RATAN RR, 1994, J NEUROSCI, V14, P4385; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	29	628	647	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					814	816		10.1038/374814a0	http://dx.doi.org/10.1038/374814a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7536895				2022-12-01	WOS:A1995QV31500048
J	KLAGES, N; STRUBIN, M				KLAGES, N; STRUBIN, M			STIMULATION OF RNA-POLYMERASE-II TRANSCRIPTION INITIATION BY RECRUITMENT OF TBP IN-VIVO	NATURE			English	Article							TATA-BINDING PROTEIN; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAIN; YEAST; PROMOTER; DNA; ELEMENTS; COMPLEX; REGION	EUKARYOTIC transcriptional activators may stimulate RNA polymerase II activity by promoting assembly of preinitiation complexes on promoters through their interactions with one or more components of the basal machinery(1,2). On the basis of its central role in initiating transcription-complex formation upon binding to the TATA box, the general transcription factor TFIID, which includes the TATA-binding protein (TBP) and several TBP-associated factors(3-5), has been implicated as a target for activators. Consistent with this idea, an increasing number of activators have been reported to bind directly to TBP6-9. To assess the functional importance of these in vitro interactions for transcriptional regulation in vivo, we made use of a novel strategy in yeast to show that a physical interaction with TBP is sufficient for a sequence-specific DNA-binding protein to increase initiation of transcription by RNA polymerase II. These results imply that binding of TFIID to promoter elements is a limiting step in transcription complex assembly in vivo.			KLAGES, N (corresponding author), UNIV GENEVA,CTR MED,DEPT GENET & MICROBIOL,9 AVE CHAMPEL,CH-1211 GENEVA 4,SWITZERLAND.							AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CORMACK BP, 1994, GENE DEV, V8, P1335, DOI 10.1101/gad.8.11.1335; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; SIKORSKI RS, 1989, GENETICS, V122, P19; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	25	162	162	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					822	823		10.1038/374822a0	http://dx.doi.org/10.1038/374822a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723829				2022-12-01	WOS:A1995QV31500051
J	MURAKAMI, H; OKAYAMA, H				MURAKAMI, H; OKAYAMA, H			A KINASE FROM FISSION YEAST RESPONSIBLE FOR BLOCKING MITOSIS IN S-PHASE	NATURE			English	Article							DNA-POLYMERASE-ALPHA; SCHIZOSACCHAROMYCES-POMBE; GENE; REPAIR; REPLICATION; DIVISION; MUTANTS; CLONING; RAD1	IN virtually all eukaryotes, mitosis starts after the completion of DNA synthesis, This orderly process is ensured by the checkpoint mechanism that blocks:the onset of mitosis while DNA is being Synthesized or is damaged, In the fission yeast Schizosaccharomyces pombe, this mechanism involves some rad(+) and hus(+) genes(1-4). However, it is not known how the checkpoint system monitors these events, Recently a multicopy suppressor of a temperature-sensitive DNA polymerase-alpha mutant was isolated, This gene, named cds1(+) (checking DNA synthesis), encodes a typical protein kinase, Here we report that this protein kinase is a key component of the DNA replication-monitoring S/G2 checkpoint system, Our data suggest that its primary role is to monitor DNA synthesis by interacting: with DNA polymerase alpha and send a signal to block the onset of mitosis while DNA synthesis is in progress.	JRDC,ERATO,OKAYAMA CELL SWITCHING PROJECT,SAKYO KU,KYOTO,JAPAN		MURAKAMI, H (corresponding author), UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN.							ALKHODAIRY, 1994, MOL BIOL CELL, V5, P147; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Allen JB, 1994, GENE DEV, V8, P2416; DAMAGNEZ V, 1991, MOL GEN GENET, V226, P182, DOI 10.1007/BF00273602; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; NASMYTH KA, 1977, CELL, V12, P101; PECK VM, 1993, BIOCHEM BIOPH RES CO, V190, P325, DOI 10.1006/bbrc.1993.1051; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SINGH J, 1993, NATURE, V361, P271, DOI 10.1038/361271a0; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SUNNERHAGEN P, 1990, MOL CELL BIOL, V10, P3750, DOI 10.1128/MCB.10.7.3750; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG P, 1993, MOL CELL BIOL, V9, P5829	22	254	260	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					817	819		10.1038/374817a0	http://dx.doi.org/10.1038/374817a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723827				2022-12-01	WOS:A1995QV31500049
J	SERVICE, FJ				SERVICE, FJ			MEDICAL PROGRESS - HYPOGLYCEMIC DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INSULIN-INDUCED HYPOGLYCEMIA; PLASMA-GLUCOSE CONCENTRATION; CHRONIC-RENAL-FAILURE; GROWTH-HORMONE; REACTIVE HYPOGLYCEMIA; POSTPRANDIAL HYPOGLYCEMIA; GLYCEMIC THRESHOLDS; ADRENERGIC-BLOCKADE; AUTOIMMUNE SYNDROME; DIABETES-MELLITUS				SERVICE, FJ (corresponding author), MAYO CLIN & MAYO FDN,DIV ENDOCRINOL & METAB,200 1ST ST SW,ROCHESTER,MN 55905, USA.							AHLQUIST DA, 1980, ANN INTERN MED, V93, P281, DOI 10.7326/0003-4819-93-2-281; ALMIRALL J, 1989, NEPHRON, V53, P273, DOI 10.1159/000185757; ANDREANI D, 1987, HYPOGLYCEMIA, V38, P312; [Anonymous], 1987, DIABETES CARE, V10, P95; ARCHAMBEAUDMOUV.F, 1989, BIOMED PHARMACOTHER, V43, P581; AREM R, 1983, ARCH INTERN MED, V143, P827, DOI 10.1001/archinte.143.4.827; BARRETT CT, 1968, NEW ENGL J MED, V278, P1260, DOI 10.1056/NEJM196806062782304; BEARD CM, 1983, MAYO CLIN PROC, V58, P802; BENZING G, 1969, CIRCULATION, V40, P209, DOI 10.1161/01.CIR.40.2.209; BLOCK MB, 1977, MIL MED, V142, P32; BLOCK MB, 1972, LANCET, V2, P736; BOUCHARD P, 1982, DIABETES, V31, P40, DOI 10.2337/diabetes.31.1.40; BOYLE PJ, 1991, AM J PHYSIOL, V260, pE395, DOI 10.1152/ajpendo.1991.260.3.E395; BOYLE PJ, 1989, AM J PHYSIOL, V256, pE651, DOI 10.1152/ajpendo.1989.256.5.E651; BRESSLER R, 1969, PHARMACOL REV, V21, P105; CHALEW SA, 1984, JAMA-J AM MED ASSOC, V251, P612, DOI 10.1001/jama.251.5.612; CHEN YT, 1984, NEW ENGL J MED, V310, P171, DOI 10.1056/NEJM198401193100306; CLARKE WL, 1979, AM J PHYSIOL, V236, pE147, DOI 10.1152/ajpendo.1979.236.2.E147; COHEN MM, 1971, AM J DIS CHILD, V122, P515, DOI 10.1001/archpedi.1971.02110060085015; COLLINS JE, 1990, ARCH DIS CHILD, V65, P1118, DOI 10.1136/adc.65.10.1118; CONNOR H, 1979, POSTGRAD MED J, V55, P735, DOI 10.1136/pgmj.55.648.735; COX DJ, 1993, DIABETES CARE, V16, P519, DOI 10.2337/diacare.16.2.519; Cryer PE, 1993, HYPOGLYCAEMIA DIABET, P34; DAUGHADAY WH, 1989, ENDOCRIN METAB CLIN, V18, P91, DOI 10.1016/S0889-8529(18)30390-6; DAVIS MR, 1991, J CLIN ENDOCR METAB, V72, P788, DOI 10.1210/jcem-72-4-788; DEFEO P, 1989, AM J PHYSIOL, V256, pE835, DOI 10.1152/ajpendo.1989.256.6.E835; DEFEO P, 1989, AM J PHYSIOL, V257, pE35, DOI 10.1152/ajpendo.1989.257.1.E35; DEFRONZO RA, 1972, DIABETES, V26, P445; DEVIVO DC, 1991, NEW ENGL J MED, V325, P703, DOI 10.1056/NEJM199109053251006; DOHERTY GM, 1991, SURGERY, V110, P989; DOPPMAN JL, 1991, RADIOLOGY, V178, P237, DOI 10.1148/radiology.178.1.1984311; DOPPMAN JL, 1993, RADIOLOGY, V187, P880; FELIG P, 1982, NEW ENGL J MED, V306, P895, DOI 10.1056/NEJM198204153061503; FELIG P, 1970, NEW ENGL J MED, V283, P1436, DOI 10.1056/NEJM197012242832604; FISCHER KF, 1986, NEW ENGL J MED, V315, P1245, DOI 10.1056/NEJM198611133152002; FUSHIMI H, 1980, ENDOCRINOL JAPON, V27, P679; GALIBER AK, 1988, RADIOLOGY, V166, P405, DOI 10.1148/radiology.166.2.2827232; GARBER AJ, 1974, DIABETES, V23, P982, DOI 10.2337/diab.23.12.982; GERICH J, 1979, AM J PHYSIOL, V236, pE380, DOI 10.1152/ajpendo.1979.236.4.E380; GLASGOW AM, 1973, AM J DIS CHILD, V125, P809, DOI 10.1001/archpedi.1973.04160060021004; GOLDMAN J, 1979, J CLIN INVEST, V63, P1050, DOI 10.1172/JCI109374; GOODENOW TJ, 1977, JAMA-J AM MED ASSOC, V237, P1961, DOI 10.1001/jama.237.18.1961; GRANT CS, 1988, WIEN KLIN WOCHENSCHR, V100, P376; Heard C R, 1978, World Rev Nutr Diet, V30, P107; HECHT A, 1959, METABOLISM, V8, P418; HEINIG RE, 1979, ARCH INTERN MED, V139, P1229, DOI 10.1001/archinte.139.11.1229; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1991, DIABETES CARE, V14, P949, DOI 10.2337/diacare.14.11.949; Hepburn DA, 1993, HYPOGLYCAEMIA DIABET, P93; HIRATA Y, 1983, LANCET, V2, P1037; HOFELDT FD, 1972, AM J CLIN NUTR, V25, P1193; HOGAN MJ, 1983, MAYO CLIN PROC, V58, P491; JOHANSSON C, 1978, ACTA MED SCAND, V204, P509; JOHNSON DD, 1980, JAMA-J AM MED ASSOC, V243, P1151, DOI 10.1001/jama.243.11.1151; KANE LA, 1993, DIABETES CARE, V16, P1298, DOI 10.2337/diacare.16.9.1298; KAO PC, 1994, J CLIN ENDOCR METAB, V78, P1048, DOI 10.1210/jc.78.5.1048; KOGUT MD, 1969, J PEDIATR-US, V74, P853, DOI 10.1016/S0022-3476(69)80220-9; KOJAK G, 1969, AM J PSYCHIAT, V126, P573, DOI 10.1176/ajp.126.4.573; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; LEVIN H, 1990, CAN J ANAESTH, V37, P477, DOI 10.1007/BF03005631; LEVRAN A, 1981, DIABETES, V30, P996, DOI 10.2337/diabetes.30.12.996; LIMBURG PJ, 1993, ANN INTERN MED, V119, P218, DOI 10.7326/0003-4819-119-3-199308010-00007; LIU D, 1992, DIABETOLOGIA, V35, P287, DOI 10.1007/BF00400932; LUYCKX AS, 1971, DIABETES, V20, P435, DOI 10.2337/diab.20.6.435; MACARON CI, 1981, DIABETES CARE, V4, P113, DOI 10.2337/diacare.4.1.113; Madison L L, 1968, Adv Metab Disord, V3, P85; MCCALL AL, 1993, HYPOGLYCAEMIA DIABET, P56; MCMAHON MM, 1989, MAYO CLIN PROC, V64, P1481, DOI 10.1016/S0025-6196(12)65703-6; MERIMEE TJ, 1973, J CLIN ENDOCR METAB, V37, P698, DOI 10.1210/jcem-37-5-698; MERIMEE TJ, 1971, J CLIN INVEST, V50, P574, DOI 10.1172/JCI106527; MILLER DR, 1977, NEW ENGL J MED, V297, P339; MILLER SI, 1980, AM J MED, V68, P649, DOI 10.1016/0002-9343(80)90250-8; MITRAKOU A, 1991, AM J PHYSIOL, V260, pE67, DOI 10.1152/ajpendo.1991.260.1.E67; MITRAKOU A, 1993, NEW ENGL J MED, V329, P834, DOI 10.1056/NEJM199309163291203; NAPPI JM, 1983, WESTERN J MED, V138, P95; NELSON RL, 1983, HYPOGLYCEMIC DISORDE, P97; NORTON JA, 1990, ANN SURG, V212, P615, DOI 10.1097/00000658-199011000-00009; OBRIEN T, 1993, J CLIN ENDOCR METAB, V77, P448, DOI 10.1210/jc.77.2.448; OOI TC, 1980, J ENDOCRINOL INVEST, V3, P45, DOI 10.1007/BF03348216; PALARDY J, 1989, NEW ENGL J MED, V321, P1421, DOI 10.1056/NEJM198911233212101; PEDERSEN J, 1954, ACTA ENDOCRINOL-COP, V15, P33, DOI 10.1530/acta.0.0150033; PHILLIPS RE, 1986, BRIT MED J, V292, P1319, DOI 10.1136/bmj.292.6531.1319; RASCHKE R, 1991, ARCH INTERN MED, V151, P591, DOI 10.1001/archinte.151.3.591; RICH LM, 1990, ARCH INTERN MED, V150, P894, DOI 10.1001/archinte.150.4.894; RIZZA RA, 1979, J CLIN INVEST, V64, P62, DOI 10.1172/JCI109464; ROSCH T, 1992, NEW ENGL J MED, V326, P1721, DOI 10.1056/NEJM199206253262601; ROSEN SG, 1984, J CLIN INVEST, V73, P405, DOI 10.1172/JCI111226; SANTIAGO JV, 1980, J CLIN ENDOCR METAB, V51, P877, DOI 10.1210/jcem-51-4-877; SCHWARTZ NS, 1987, J CLIN INVEST, V79, P777, DOI 10.1172/JCI112884; SERVICE FJ, 1992, J CLIN ENDOCR METAB, V74, P204, DOI 10.1210/jc.74.1.204; SERVICE FJ, 1989, NEW ENGL J MED, V321, P1472, DOI 10.1056/NEJM198911233212109; SERVICE FJ, 1974, ARCH INTERN MED, V134, P336, DOI 10.1001/archinte.134.2.336; SERVICE FJ, 1991, MAYO CLIN PROC, V66, P711, DOI 10.1016/S0025-6196(12)62083-7; SERVICE FJ, 1976, MAYO CLIN PROC, V51, P417; SERVICE FJ, 1993, J CLIN ENDOCR METAB, V76, P655, DOI 10.1210/jc.76.3.655; Service FJ., 1995, ENDOCRINOLOGY, P1605; SERVICE FJ, 1978, AM J MED, V64, P698; Service FJ, 1992, ENDOCRINOLOGIST, V2, P173; SERVICE FJ, 1987, HYPOGLYCEMIA, V38, P45; SKETRIS I, 1984, DRUG INTEL CLIN PHAR, V18, P142, DOI 10.1177/106002808401800210; SNORGAARD O, 1990, BRIT MED J, V300, P16, DOI 10.1136/bmj.300.6716.16; SOVIK O, 1989, ACTA PAEDIATR SCAND, V78, P161, DOI 10.1111/j.1651-2227.1989.tb11052.x; STARKE AAR, 1983, DIABETOLOGIA, V25, P336; Takei M, 1980, J TOKYO WOMENS MED C, V50, P54; TALENTE GM, 1994, ANN INTERN MED, V120, P218, DOI 10.7326/0003-4819-120-3-199402010-00008; TOWLER DA, 1993, DIABETES, V42, P1791, DOI 10.2337/diabetes.42.12.1791; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; TSALIKIAN E, 1983, HYPOGLYCEMIC DISORDE, P35; TSE TF, 1983, J CLIN INVEST, V72, P278, DOI 10.1172/JCI110967; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233; VINIK AI, 1991, SURGERY, V109, P1; Whipple AO., 1938, J INT CHIR, V3, P237; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; ZIMMERMAN BR, 1983, HYPOGLYCERMIA PATHOG	114	340	349	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1144	1152		10.1056/NEJM199504273321707	http://dx.doi.org/10.1056/NEJM199504273321707			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU302	7700289				2022-12-01	WOS:A1995QU30200007
J	SHIMIZU, S; EGUCHI, Y; KOSAKA, H; KAMIIKE, W; MATSUDA, H; TSUJIMOTO, Y				SHIMIZU, S; EGUCHI, Y; KOSAKA, H; KAMIIKE, W; MATSUDA, H; TSUJIMOTO, Y			PREVENTION OF HYPOXIA-INDUCED CELL-DEATH BY BCL-2 AND BCL-XL	NATURE			English	Article							PRE-B-CELLS; CHROMOSOMAL BREAKPOINT; FOLLICULAR LYMPHOMA; GROWTH-FACTOR; C-ELEGANS; GENE; SURVIVAL; PROTEIN; INVOLVEMENT; EXPRESSION	THE proto-oncogene bcl-2, isolated from the t(14;18) chromosomal breakpoint in follicular B-lymphoma(1-3), and a bcl-2related gene bcl-x (ref. 4) prevent apoptotic cell death induced by various treatments(5-8). Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS)(910) expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. Furthermore, neither ROS scavenger nor inhibitor of ROS scavenger affects cell death, regardless of the expression of Bcl-2 or Bcl-xL. Thus our data suggest that Bcl-2 and Bcl-xL exert an anti-fell death function by a mechanism other than regulation of ROS activity.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MED GENET,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORZILLO GV, 1992, ONCOGENE, V7, P869; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIROTA K, 1987, CANCER RES, V47, P3742; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; ITOH N, 1993, J IMMUNOL, V151, P621; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KHALBUSS WE, 1991, HEPATOLOGY, V13, P962, DOI 10.1016/0270-9139(91)90271-V; KU RH, 1986, ARCH BIOCHEM BIOPHYS, V247, P183, DOI 10.1016/0003-9861(86)90547-3; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAKEUCHI T, 1993, BIOCHEM BIOPH RES CO, V194, P57, DOI 10.1006/bbrc.1993.1784; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	28	606	625	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					811	813		10.1038/374811a0	http://dx.doi.org/10.1038/374811a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723826				2022-12-01	WOS:A1995QV31500047
J	WILSON, C; SZOSTAK, JW				WILSON, C; SZOSTAK, JW			IN-VITRO EVOLUTION OF A SELF-ALKYLATING RIBOZYME	NATURE			English	Article							RNA	RNA enzymes are postulated to have catalysed all chemical reactions in the earliest living cells. This idea is now investigated in a search for alkyl transferases from a pool of random sequence RNAs. Selection for self-biotinylation yields a transfer RNA-like ribozyme that efficiently catalyses carbon-nitrogen bond formation. Ribozymes can thus promote reactions other than those involving the RNA sugar-phosphate backbone, suggesting that RNA may be capable of a broad range of catalytic activities.	MASSACHUSETTS GEN HOSP,DEPT BIOL MOLEC,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital								ALHAKIM AH, 1988, BIOCHEM J, V251, P935, DOI 10.1042/bj2510935; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; FERSHT A, 1985, ENZYME STRUCTURE MEC, P57; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PRUDENTJR, 1994, SCIENCE, V264, P1924; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; WILSON C, 1992, CURR OPIN STRUC BIOL, V2, P749	19	194	208	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					777	782		10.1038/374777a0	http://dx.doi.org/10.1038/374777a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723823				2022-12-01	WOS:A1995QV31500035
J	PETERSEN, RC; SMITH, GE; IVNIK, RJ; TANGALOS, EG; SCHAID, DJ; THIBODEAU, SN; KOKMEN, E; WARING, SC; KURLAND, LT				PETERSEN, RC; SMITH, GE; IVNIK, RJ; TANGALOS, EG; SCHAID, DJ; THIBODEAU, SN; KOKMEN, E; WARING, SC; KURLAND, LT			APOLIPOPROTEIN-E STATUS AS A PREDICTOR OF THE DEVELOPMENT OF ALZHEIMERS-DISEASE IN MEMORY-IMPAIRED INDIVIDUALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TYPE-4 ALLELE; MENTAL STATUS; DEMENTIA; DIAGNOSIS	Objective.-The outcome of patients with mild cognitive impairment is not known, yet these patients present a difficult dilemma for the clinician. This study was designed to characterize the outcome of a group of patients with mild cognitive impairment and to determine whether the presence of the epsilon 4 allele on the apolipoprotein E gene (APOE) is a predictor of that outcome. Design.-A prospective, longitudinal inception cohort. Setting.-General community clinic. Participants.-A consecutive sample of 66 patients who met criteria for a diagnosis of a mild cognitive impairment and who had at least one clinical reevaluation was identified from the Mayo Clinic Alzheimer's Disease Center/Alzheimer's Disease Patient Registry. Interventions.-We evaluated patients initially and at 12- to 18-month intervals up to 54 months using standard neurological and neuropsychological measures such as the Mini-Mental State Examination, the Dementia Rating Scale, the Wechsler Adult Intelligence Scale-Revised, the Wechsler Memory Scale-Revised, and the Free and Cued Selective Reminding Test. The APOE status of study patients was determined. Main Outcome Measure.-The development of dementia as determined by the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition and the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria. Results.-Sixty-six individuals had been reevaluated once (mean of 18 months), 36 individuals twice (mean of 36 months), and 22 individuals on three occasions (mean of 54 months), with conversion rates to dementia at these intervals of 24%, 44%, and 55%, respectively. A multivariate Cox regression model demonstrated that possession of an APOE epsilon 4 allele was the strongest predictor of clinical outcome. Conclusions.-These data suggest the following: (1) patients with mild cognitive impairment can be clinically defined, (2) many members of this group progress to Alzheimer's disease, and (3) APOE epsilon 4 allele status appears to be a strong predictor of clinical progression.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PSYCHIAT & PSYCHOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV COMMUNITY INTERNAL MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PATHOL & LAB MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	PETERSEN, RC (corresponding author), MAYO CLIN & MAYO FDN, DEPT NEUROL, ROCHESTER, MN 55905 USA.		Waring, Stephen/AAR-6870-2021	Waring, Stephen/0000-0002-9674-0083; Smith, Glenn/0000-0003-1506-9484	NATIONAL INSTITUTE ON AGING [P30AG008031, U01AG006786] Funding Source: NIH RePORTER; NIA NIH HHS [AG06786, AG08031] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; ARRIAGADA PV, 1992, NEUROLOGY, V42, P1681, DOI 10.1212/WNL.42.9.1681; Benton AL, 1989, MULTILINGUAL APHASIA; BENTON AL, 1988, CONTRIBUTIONS NEUROP; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUSCHKE H, 1984, J CLIN NEUROPSYCHOL, V6, P433, DOI 10.1080/01688638408401233; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GROBER E, 1988, NEUROLOGY, V38, P900, DOI 10.1212/WNL.38.6.900; HIXSON JE, 1990, J LIPID RES, V31, P545; Ivnik RJ., 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; IVNIK RJ, 1990, PSYCHOL ASSESSMENT, V2, P804; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; Jastak S, 1984, WIDE RANGE ACHIEVEME; Kaplan E, 1978, BOSTON NAMING TEST; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOKMEN E, 1987, MAYO CLIN PROC, V62, P281, DOI 10.1016/S0025-6196(12)61905-3; KOKMEN E, 1991, ARCH NEUROL-CHICAGO, V48, P725, DOI 10.1001/archneur.1991.00530190071018; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; MALEC JF, 1991, PSYCHOL ASSESSMENT J, V3, P82; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mattis S., 1976, GERIATRIC PSYCHIAT, P77; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Petersen R C, 1990, Aging (Milano), V2, P408; PETERSEN RC, 1992, NEUROLOGY, V42, P396, DOI 10.1212/WNL.42.2.396; PETERSEN RC, 1994, NEUROLOGY, V44, P867, DOI 10.1212/WNL.44.5.867; PETERSEN RC, 1993, ANN NEUROL, V34, P292; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; Rey A., 1964, LEXAMEN CLINIQUE PSY; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; TSAI MS, 1994, AM J HUM GENET, V54, P643; Wechsler D., 1987, WMS R WECHSLER MEMOR; Wechsler D, 1981, ADULT INTELLIGENCE S; Weintraub S, 1982, ALZHEIMERS DIS REPOR, P189; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555; 1987, DIAGNOSTIC STATISTIC	45	632	656	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1274	1278		10.1001/jama.273.16.1274	http://dx.doi.org/10.1001/jama.273.16.1274			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7646655				2022-12-01	WOS:A1995QU57100030
J	RIDKER, PM; STAMPFER, MJ; HENNEKENS, CH				RIDKER, PM; STAMPFER, MJ; HENNEKENS, CH			PLASMA-CONCENTRATION OF LIPOPROTEIN(A) AND THE RISK OF FUTURE STROKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; APOLIPOPROTEIN-A-I; MYOCARDIAL-INFARCTION; CEREBROVASCULAR-DISEASE; SERUM LIPOPROTEIN(A); CEREBRAL INFARCTION; LP(A) LIPOPROTEIN; ARTERY DISEASE; ATHEROSCLEROSIS; MEN	Objective.-To assess prospectively the risk of future stroke associated with baseline concentration of lipoprotein(a), abbreviated Lp(a). Design.-Nested case-control study using baseline plasma samples. Setting.-Men in the Physicians' Health Study. Participants.-A cohort of 14 916 male physicians with no prior history of stroke, transient ischemic attack, or myocardial infarction provided plasma samples at baseline and were followed prospectively for 7.5 years. Samples from 198 physicians who subsequently developed stroke (155 thromboembolic, 35 hemorrhagic, eight indeterminate) were analyzed for Lp(a) concentration together with paired controls, matched for age and smoking habit. Main Outcome Measure.-Fatal and nonfatal stroke. Results.-Median Lp(a) concentration (8.88 mg/dL [0.23 mmol/L] vs 8.55 mg/dL [0.22 mmol/L]), P=.69) and overall distributions of Lp(a) (P=.54) were similar at baseline in men who did and did not develop future stroke. In analyses controlling for age, smoking status, blood pressure, obesity, and the presence of diabetes, the relative risks (RRs) associated with baseline Lp(a) concentration exceeding the 25th, 50th, 75th, 90th, and 95th percentiles of the control distribution were 1.26, 0.99, 1.06, 0.90, and 1.03 (all P values nonsignificant). There was likewise no association in analyses limited to thromboembolic events. For example, among subjects with baseline Lp(a) values exceeding the 95th percentile of the control distribution, the RR of future thromboembolic stroke was 1.01 (P=.9). No evidence of association between Lp(a) and stroke risk was found in analyses limited to individuals with hypercholesterolemia. Conclusions.-Among nearly 15 000 predominantly white, healthy, middle-aged men followed in the Physicians' Health Study for a period of 7.5 years, we found no evidence of association between baseline plasma concentration of Lp(a) and future risk of total or thromboembolic stroke.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV CARDIOVASC DIS, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, 900 COMMONWEALTH AVE, BOSTON, MA 02115 USA.				NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BERG K, 1974, CLIN GENET, V6, P230; BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HOLLANDERS FD, 1975, POSTGRAD MED J, V51, P386, DOI 10.1136/pgmj.51.596.386; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JOVICIC A, 1993, ATHEROSCLEROSIS, V98, P59, DOI 10.1016/0021-9150(93)90223-H; JURGENS G, 1987, NEUROLOGY, V37, P513, DOI 10.1212/WNL.37.3.513; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KOLTRINGER P, 1985, ATHEROSCLEROSIS, V58, P187, DOI 10.1016/0021-9150(85)90065-6; KOSTNER GM, 1986, EUR NEUROL, V25, P346, DOI 10.1159/000116033; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KOSTNER GM, 1991, ARCH DIS CHILD, V66, P1054, DOI 10.1136/adc.66.9.1054; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; NAGAYAMA M, 1994, STROKE, V25, P74, DOI 10.1161/01.STR.25.1.74; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SCHEINER PJ, 1994, ANN EPIDEMIOL, V4, P351; SCHREINER PJ, 1993, ARTERIOSCLER THROMB, V13, P826, DOI 10.1161/01.ATV.13.6.826; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SLUNGA L, 1992, SCAND J CLIN LAB INV, V52, P95, DOI 10.3109/00365519209088771; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOO J, 1990, STROKE, V21, P1407, DOI 10.1161/01.STR.21.10.1407; WOO J, 1991, STROKE, V22, P203, DOI 10.1161/01.STR.22.2.203; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942; ZHUANG YY, 1993, CHINESE MED J-PEKING, V106, P597	39	108	117	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1269	1273		10.1001/jama.273.16.1269	http://dx.doi.org/10.1001/jama.273.16.1269			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7715039				2022-12-01	WOS:A1995QU57100029
J	AIDOO, M; LALVANI, A; ALLSOPP, CEM; PLEBANSKI, M; MEISNER, SJ; KRAUSA, P; BROWNING, M; MORRISJONES, S; GOTCH, F; FIDOCK, DA; TAKIGUCHI, M; ROBSON, KJH; GREENWOOD, BM; DRUILHE, P; WHITTLE, HC; HILL, AVS				AIDOO, M; LALVANI, A; ALLSOPP, CEM; PLEBANSKI, M; MEISNER, SJ; KRAUSA, P; BROWNING, M; MORRISJONES, S; GOTCH, F; FIDOCK, DA; TAKIGUCHI, M; ROBSON, KJH; GREENWOOD, BM; DRUILHE, P; WHITTLE, HC; HILL, AVS			IDENTIFICATION OF CONSERVED ANTIGENIC COMPONENTS FOR A CYTOTOXIC T-LYMPHOCYTE-INDUCING VACCINE AGAINST MALARIA	LANCET			English	Article							FALCIPARUM CIRCUMSPOROZOITE PROTEIN; PARASITE PLASMODIUM-FALCIPARUM; CELL RESPONSE; SPOROZOITES; SURFACE; PROTECTION; EXPRESSION; SEQUENCE; PEPTIDES; THROMBOSPONDIN	Several cellular and humoral mechanisms probably play a role in natural immunity to Plasmodium falciparum malaria, but the development of an effective vaccine has been impeded by uncertainty as to which antigens are targeted by protective immune responses. Experimental models of malaria have shown that cytotoxic T lymphocytes (CTL) which kill parasite-infected hepatocytes can provide complete protective immunity against certain species of Plasmodium in mice, and studies in The Gambia have provided indirect evidence that CTL play a protective role against P falciparum in humans. By using an HLA-based approach, termed reverse immunogenetics, we have previously identified peptide epitopes for CTL in liver-stage antigen-1 and the circumsporozoite protein of P falciparum, We have extended this work to identify CTL epitopes for HLA class I antigens that are found in most individuals from Caucasian and African populations. Most of these epitopes are in conserved regions of P falciparum. CTL peptide epitopes were found in a further two antigens, thrombospondin-related anonymous protein and sporozoite threonine and asparagine rich protein, indicating that a subunit vaccine designed to induce a protective CTL response may need to include parts of several parasite antigens. However, CTL levels in both children with malaria and in semi-immune adults from an endemic area were low suggesting that boosting these low levels by immunisation might provide substantial or even complete protection against infection and disease.	UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND; MRC LABS, Fajara, SENEGAL; INST PASTEUR, PARIS, FRANCE; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	University of Oxford; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Tokyo			HILL, Adrian V>S>/C-1306-2008; Takiguchi, Masafumi/E-7468-2013; Plebanski, Magdalena/AAU-3144-2021	Lalvani, Ajit/0000-0002-2396-246X; , Magdalena/0000-0001-6889-3667; Fidock, David/0000-0001-6753-8938	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411; ANDO K, 1994, J IMMUNOL, V153, P482; BOURGAULT I, 1994, J IMMUNOL, V152, P2530; BROWN F, 1994, DEV BIOL STAND BASEL, V82, P1; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; BROWNING MJ, 1995, TISSUE ANTIGENS, V45, P177, DOI 10.1111/j.1399-0039.1995.tb02437.x; COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2; COX WI, 1993, VIROLOGY, V195, P845, DOI 10.1006/viro.1993.1442; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DOOLAN DL, 1993, INT IMMUNOL, V5, P37, DOI 10.1093/intimm/5.1.37; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V64, P219, DOI 10.1016/0166-6851(94)00012-3; FIDOCK DA, 1994, J IMMUNOL, V153, P190; FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V67, P255, DOI 10.1016/0166-6851(94)00138-3; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; GOOD MF, 1988, ANNU REV IMMUNOL, V6, P663, DOI 10.1146/annurev.iy.06.040188.003311; HILL AVS, 1994, PHILOS T R SOC B, V346, P379, DOI 10.1098/rstb.1994.0155; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; KHUSMITH S, 1994, INFECT IMMUN, V62, P2979, DOI 10.1128/IAI.62.7.2979-2983.1994; LALVANI A, 1994, RES IMMUNOL, V145, P461, DOI 10.1016/S0923-2494(94)80177-0; LAYTON GT, 1993, J IMMUNOL, V151, P1097; Marsh K., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P91; MCADAM S, IN PRESS J IMMUNOL; MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V45, P193, DOI 10.1016/0166-6851(91)90086-L; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NUSSENZWEIG RS, 1969, NATURE, V222, P488, DOI 10.1038/222488a0; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RODRIGUES M, 1992, J EXP MED, V175, P895, DOI 10.1084/jem.175.4.895; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SEDEGAH M, 1992, J IMMUNOL, V149, P966; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; YASUTOMI Y, 1993, J IMMUNOL, V150, P3101; ZHU JD, 1991, MOL BIOCHEM PARASIT, V48, P223, DOI 10.1016/0166-6851(91)90117-O	46	134	140	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	1995	345	8956					1003	1007		10.1016/S0140-6736(95)90754-8	http://dx.doi.org/10.1016/S0140-6736(95)90754-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7536870				2022-12-01	WOS:A1995QU57300006
J	GILBERT, RE; STANFORD, MR; JACKSON, H; HOLLIMAN, RE; SANDERS, MD				GILBERT, RE; STANFORD, MR; JACKSON, H; HOLLIMAN, RE; SANDERS, MD			INCIDENCE OF ACUTE SYMPTOMATIC TOXOPLASMA RETINOCHOROIDITIS IN SOUTH LONDON ACCORDING TO COUNTRY OF BIRTH	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL TOXOPLASMOSIS; OCULAR TOXOPLASMOSIS; INFECTION; PREGNANCY; SEROPREVALENCE; PREVALENCE; WEST	Objective-To determine the incidence of acute symptomatic toxoplasma retinochoroiditis presenting to ophthalmologists for patients born in Britain and elsewhere. Design-Population based, cross sectional study. Setting-11 districts in south Greater London. Subjects-All patients presenting ophthalmologists with symptoms due toxoplasma retinochoroiditis in 1992-3. Main outcome measure-Intraocular inflammation in association with a retinochoroidal scar, active adjoining retinitis, and IgG serum antibodies to toxoplasma. Results-The estimated incidence of acute symptomatic retinochoroiditis for all people born in Britain was 0.4/100 000/year and for black people born in west Africa 57/100 000/year. If a mean of two symptomatic episodes per lifetime is assumed, 100 people born in Britain may be affected each year, about a fifth of the estimated 500-600 congenitally infected people born each year. Conclusions-A substantial proportion of people with acute symptomatic toxoplasma retinochoroiditis were born outside the country, and the number born in Britain was smaller than the number previously estimated to develop retinochoroidal lesions due to congenital toxoplasmosis. These findings suggest that prenatal screening for toxoplasmosis in Britain may be of limited benefit.	ST THOMAS HOSP,MED EYE UNIT,LONDON SE1 7EH,ENGLAND; ST GEORGE HOSP,DEPT OPHTHALMOL,LONDON SW17 0QT,ENGLAND; ST GEORGE HOSP,PUBL HLTH LAB SERV,TOXOPLASMA REFERENCE UNIT,LONDON SW17 0QT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; St Georges University London; Public Health England; St Georges University London	GILBERT, RE (corresponding author), INST CHILD HLTH,DEPT BIOSTAT & EPIDEMIOL,LONDON WC1N 1EH,ENGLAND.			Gilbert, Ruth/0000-0001-9347-2709	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADES AE, 1992, EPIDEMIOL INFECT, V108, P367, DOI 10.1017/S0950268800049839; ADES AE, 1993, AM J EPIDEMIOL, V137, P1022, DOI 10.1093/oxfordjournals.aje.a116758; ADES AE, IN PRESS EPIDEMIC MO; BERREBI A, 1994, LANCET, V344, P36, DOI 10.1016/S0140-6736(94)91054-5; Chatterton JMW., 1992, HUMAN TOXOPLASMOSIS, P144; CHESTERTON JR, 1967, BRIT J OPHTHALMOL, V51, P617, DOI 10.1136/bjo.51.9.617; CONYNVANSPAENDO.MA, 1989, INT OPHTHALMOL, V13, P403; Couvreur J., 1988, Handbook of Clinical Neurology. Vol 52, Revised Series 8. Microbial Disease., P351; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; DESMONTS G, 1990, LANCET, V336, P1017, DOI 10.1016/0140-6736(90)92485-Z; FATHY VC, 1993, PUBLIC HEALTH, V107, P19, DOI 10.1016/S0033-3506(05)80488-3; FRIEDMAN.CT, 1969, ARCH OPHTHALMOL-CHIC, V81, P481; GILBERT RE, 1993, BRIT MED J, V306, P185, DOI 10.1136/bmj.306.6871.185; GLASNER PD, 1992, AM J OPHTHALMOL, V114, P136, DOI 10.1016/S0002-9394(14)73976-5; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; HALL SM, 1992, BMJ-BRIT MED J, V305, P291, DOI 10.1136/bmj.305.6848.291; HARTUP C, 1992, LANCET, V340, P118, DOI 10.1016/0140-6736(92)90444-8; HOLLIMAN RE, 1990, SERODIAG IMMUN INF D, V4, P83, DOI 10.1016/0888-0786(90)90031-I; HOYEN DO, 1992, HUMAN TOXOPLASMOSIS, P56; JOSS AWL, 1988, PUBLIC HEALTH, V102, P409, DOI 10.1016/S0033-3506(88)80078-7; JOSS AWL, 1990, PUBLIC HEALTH, V104, P9, DOI 10.1016/S0033-3506(05)80340-3; JOYNSON DHM, 1988, LANCET, V2, P795; KOPPE JG, 1989, INT OPHTHALMOL, V13, P387, DOI 10.1007/BF02306486; LAKHANPAL V, 1983, AM J OPHTHALMOL, V95, P605, DOI 10.1016/0002-9394(83)90378-1; NOKES DJ, 1993, PARASITOLOGY, V107, P33, DOI 10.1017/S0031182000079373; PERKINS ES, 1973, BRIT J OPHTHALMOL, V57, P1, DOI 10.1136/bjo.57.1.1; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; ROTHOVA A, 1993, BRIT J OPHTHALMOL, V77, P371, DOI 10.1136/bjo.77.6.371; SILVEIRA C, 1988, AM J OPHTHALMOL, V106, P362, DOI 10.1016/0002-9394(88)90382-0; STAGNO S, 1980, PEDIATRICS, V65, P706; Thalhammer O., 1979, PERINATAL MED, P51; THORP JM, 1988, NEW ENGL J MED, V319, P372, DOI 10.1056/NEJM198808113190615; THOUMSIN H, 1992, SCAND J INFECT DIS S, V84, P84; WILLIAMS KAB, 1981, J INFECTION, V3, P219, DOI 10.1016/S0163-4453(81)90773-8; WILSON CB, 1980, PEDIATRICS, V66, P767; 1994, ETHNIC GROUP COUNTRY, V1, P214; 1992, PRENATAL SCREENING T	37	38	41	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1037	1040		10.1136/bmj.310.6986.1037	http://dx.doi.org/10.1136/bmj.310.6986.1037			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728057	Green Published			2022-12-01	WOS:A1995QV31300016
J	GOOD, MF				GOOD, MF			HARNESSING CYTOTOXIC T-LYMPHOCYTES FOR VACCINE DESIGN	LANCET			English	Editorial Material							FALCIPARUM CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-FALCIPARUM; MALARIA SPOROZOITES; CELLS				GOOD, MF (corresponding author), ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA.							AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; NUSSENZWEIG RS, 1984, PHILOS T ROY SOC B, V307, P117, DOI 10.1098/rstb.1984.0113; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; QUAKYI IA, 1994, J IMMUNOL, V153, P2082; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SEDEGAH M, 1992, J IMMUNOL, V149, P966; UDHAYAKUMAR V, 1994, INFECT IMMUN, V62, P1410, DOI 10.1128/IAI.62.4.1410-1413.1994; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573	14	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					999	1000		10.1016/S0140-6736(95)90750-5	http://dx.doi.org/10.1016/S0140-6736(95)90750-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7536872				2022-12-01	WOS:A1995QU57300002
J	INGAMELLS, S; SAUNDERS, NJ; BURGE, D				INGAMELLS, S; SAUNDERS, NJ; BURGE, D			GASTROSCHISIS AND REDUCED FETAL HEART-RATE-VARIABILITY	LANCET			English	Note								Most liveborn babies with gastroschisis do well after surgical repair, although about one-eighth of affected cases die late in utero. Our practice is to use weekly computerised cardiotocograph (CTG) analysis after week 34 of gestation in cases of gastroschisis. In a look-back at the records in 18 such singleton pregnancies, CTG showed 7 to be highly abnormal or preterminal. All but 1 of these 7 had a normal fetal heart rate. In all 7 cases, delivery was expedited. Only 1 infant had neurological sequelae, and in all the abdominal defect was successfully repaired. Monitoring of these high-risk pregnancies with serial computerised CTG may be helpful in timing delivery.	PRINCESS ANNE HOSP,SOUTHAMPTON SO16 5YA,HANTS,ENGLAND									COHEN WR, 1986, CLIN OBSTET GYNECOL, V29, P73, DOI 10.1097/00003081-198603000-00011; CRAWFORD RAF, 1992, BRIT J OBSTET GYNAEC, V99, P899, DOI 10.1111/j.1471-0528.1992.tb14438.x; DAWES GS, 1991, J PERINAT MED, V19, P39, DOI 10.1515/jpme.1991.19.1-2.39; DEVRIES PA, 1980, J PEDIATR SURG, V15, P245, DOI 10.1016/S0022-3468(80)80130-8; FRIES MH, 1993, J ULTRAS MED, V12, P583; LINDHAM S, 1981, ACTA PAEDIATR SCAND, V70, P55, DOI 10.1111/j.1651-2227.1981.tb07173.x; SMITH JH, 1988, BRIT J OBSTET GYNAEC, V95, P980, DOI 10.1111/j.1471-0528.1988.tb06501.x; STREET P, 1991, AM J OBSTET GYNECOL, V165, P515, DOI 10.1016/0002-9378(91)90277-X; TORFS C, 1990, J PEDIATR-US, V116, P1, DOI 10.1016/S0022-3476(05)81637-3; VISSER GHA, 1990, AM J OBSTET GYNECOL, V162, P698, DOI 10.1016/0002-9378(90)90989-K	10	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1024	1025		10.1016/S0140-6736(95)90760-2	http://dx.doi.org/10.1016/S0140-6736(95)90760-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723500				2022-12-01	WOS:A1995QU57300012
J	KHUROO, MS; KAMILI, S; JAMEEL, S				KHUROO, MS; KAMILI, S; JAMEEL, S			VERTICAL TRANSMISSION OF HEPATITIS-E VIRUS	LANCET			English	Note							NON-B HEPATITIS; NON-A	Little is known about vertical transmission of hepatitis E virus from infected mothers to their infants. We studied eight babies born to mothers infected with hepatitis fin third trimester. One baby was icteric at birth with elevated transaminases and four babies had anicteric hepatitis. Two babies were born with hypothermia and hypoglycaemia and died within 24 h; one had massive hepatic necrosis. Hepatitis E virus RNA was detected by PCR in cord or birth blood samples of five infants. Six infants had evidence of hepatitis E infection. We conclude that hepatitis E virus is commonly transmitted from infected mothers to their babies with significant perinatal morbidity and mortality.	INT CTR GENET ENGN & BIOTECHNOL,NEW DELHI,INDIA	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	KHUROO, MS (corresponding author), SHERIKASHMIR INST MED SCI,DEPT GASTROENTEROL,POST BOX 27,SRINAGAR 190001,JAMMU & KASHMIR,INDIA.		Khuroo, Mohammad Sultan/N-3571-2014	Khuroo, Mohammad Sultan/0000-0003-2823-8814				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; JAMEEL S, 1992, J MED VIROL, V37, P263, DOI 10.1002/jmv.1890370405; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4	4	218	228	2	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1025	1026		10.1016/S0140-6736(95)90761-0	http://dx.doi.org/10.1016/S0140-6736(95)90761-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723501				2022-12-01	WOS:A1995QU57300013
J	OAKLEY, A; BENDELOW, G; BARNES, J; BUCHANAN, M; HUSAIN, OAN				OAKLEY, A; BENDELOW, G; BARNES, J; BUCHANAN, M; HUSAIN, OAN			HEALTH AND CANCER PREVENTION - KNOWLEDGE AND BELIEFS OF CHILDREN AND YOUNG-PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To collect information from children and young people about their knowledge of and attitudes towards cancer and their understanding of health and health related behaviours to inform future health promotion work. Design-Questionnaire survey of 15-16 year olds, and interviews with play materials with 9-10 year old children. Setting-Six inner city, suburban, and rural schools. Subjects-226 children aged 15-16 years and 100 aged 9-10 years. Main outcome measures-Knowledge about different types of cancer; beliefs about health; sources of information; quality of research data obtainable from young children about cancer and health. Results-Both samples knew most about lung cancer, but there was also some knowledge of breast and skin cancer and leukaemia. Smoking, together with pollution and other environmental factors, were seen as the dominant causes of cancer. Environmental factors were mentioned more often by the inner city samples. Television and the media were the most important sources of information. Young people were more worried about unemployment than about ill health. More than half the young people did not describe their health as good, and most said they did not have a healthy lifestyle. Children were able to provide detailed information about their knowledge and understanding by using drawings as well as interviews. Conclusions-Children and young people possess considerable knowledge about cancer, especially about lung cancer and smoking, and show considerable awareness of predominant health education messages. Despite this knowledge, many lead less than healthy lifestyles. Health is not seen as the most important goal in life by many young people; the circumstances in which many children and young people live are not experienced as health promoting.	WOMENS NATIONWIDE CANC CONTROL CAMPAIGN,MED ADVISORY COMM,LONDON EC2A 3AR,ENGLAND		OAKLEY, A (corresponding author), UNIV LONDON,INST EDUC,SOCIAL SCI RES UNIT,LONDON WC1H 0NS,ENGLAND.		Bendelow, Gillian A/B-2943-2018	Bendelow, Gillian A/0000-0002-9293-5297				Backett K., 1991, HEALTH EDUC J, V50, P34, DOI [10.1177/001789699105000110, DOI 10.1177/001789699105000110]; BLAXTER M, 1983, SOC SCI MED, V17, P59, DOI 10.1016/0277-9536(83)90356-8; BRANNEN J, 1993, YOUNG PEOPLE HLTH FA; Calnan M., 1987, HLTH ILLNESS LAY PER; Cornwell J., 1985, HARD EARNED LIVES AC; HARDING G, 1989, 9 T COR RES UN OCC P; IVERSON DC, 1983, J SCHOOL HEALTH, V53, P294, DOI 10.1111/j.1746-1561.1983.tb05347.x; KALNINS I, 1992, HEALTH PROMOT INT, V7, P55; MAYALL B, 1993, SOCIOL HEALTH ILL, V15, P464; OAKLEY A, 1989, SOCIOL HEALTH ILL, V11, P311, DOI 10.1111/1467-9566.ep11372513; Qvortrup Jens, 1993, CHILDHOOD SOCIAL PHE; Qvortrup Jens, 1994, CHILDHOOD MATTERS SO, P1; SONTAG Susan, 1977, ILLNESS METAPHOR; TONES K, 1990, HLTH ED J, V49, P2; 1990, INCIDENCE UK MALES F	15	73	74	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1029	1033		10.1136/bmj.310.6986.1029	http://dx.doi.org/10.1136/bmj.310.6986.1029			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV313	7728055	Green Accepted, Green Published			2022-12-01	WOS:A1995QV31300014
J	TILZEY, AJ				TILZEY, AJ			HEPATITIS-B VACCINE BOOSTING - THE DEBATE CONTINUES	LANCET			English	Editorial Material							IMMUNOGENICITY; EFFICACY				TILZEY, AJ (corresponding author), ST THOMAS HOSP,GUYS & ST THOMAS HOSP TRUST,DEPT VIROL,LONDON,ENGLAND.							GESEMANN M, 1995, LANCET, V345, P395, DOI 10.1016/S0140-6736(95)90387-9; GILKS WR, 1995, LANCET, V345, P395; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; MARGOLIS HS, 1993, J INFECT DIS, V168, P9, DOI 10.1093/infdis/168.1.9; TILZEY AJ, 1994, LANCET, V344, P1438, DOI 10.1016/S0140-6736(94)90609-2; VANHATTUM J, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P774; VENTO S, 1989, LANCET, V1, P332; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; 1992, IMMUNISATION INFECTI; 1991, MMWR-MORBID MORTAL W, V40, P1; 1993, PROTECTING HLTH CARE	11	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1000	1001		10.1016/S0140-6736(95)90751-3	http://dx.doi.org/10.1016/S0140-6736(95)90751-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723493				2022-12-01	WOS:A1995QU57300003
J	AGUILARBRYAN, L; NICHOLS, CG; WECHSLER, SW; CLEMENT, JP; BOYD, AE; GONZALEZ, G; HERRERASOSA, H; NGUY, K; BRYAN, J; NELSON, DA				AGUILARBRYAN, L; NICHOLS, CG; WECHSLER, SW; CLEMENT, JP; BOYD, AE; GONZALEZ, G; HERRERASOSA, H; NGUY, K; BRYAN, J; NELSON, DA			CLONING OF THE BETA-CELL HIGH-AFFINITY SULFONYLUREA RECEPTOR - A REGULATOR OF INSULIN-SECRETION	SCIENCE			English	Article							SENSITIVE K+ CHANNELS; PANCREATIC B-CELLS; PROTEIN-PHOSPHORYLATION; POTASSIUM CHANNELS; GLYBURIDE ANALOG; STRUCTURAL MODEL; BINDING-SITES; HIT CELLS; ATP; MEMBRANE	Sulfonylureas are a class of drugs widely used to promote insulin secretion in the treatment of non-insulin-dependent diabetes mellitus. These drugs interact with the sulfonylurea receptor of pancreatic beta cells and inhibit the conductance of adenosine triphosphate (ATP)-dependent potassium (K-ATP) channels. Cloning of complementary DNAs for the high-affinity sulfonylurea receptor indicates that it is a member of the ATP-binding cassette or traffic ATPase superfamily with multiple membrane-spanning domains and two nucleotide binding folds. The results suggest that the sulfonylurea receptor may sense changes in ATP and ADP concentration, affect K-ATP channel activity, and thereby modulate insulin release.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110	Baylor College of Medicine; Washington University (WUSTL); Washington University (WUSTL)	AGUILARBRYAN, L (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Nichols, Colin/D-6336-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041898, R01DK044311] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45742] Funding Source: Medline; NIDDK NIH HHS [DK41898, DK44311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Ashford M. L. J, 1990, POTASSIUM CHANNELS S, P300; BERNARDI H, 1992, BIOCHEMISTRY-US, V31, P6328, DOI 10.1021/bi00142a023; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; DEWEILLE JR, 1992, J BIOL CHEM, V267, P4557; DUNNE MJ, 1989, FEBS LETT, V250, P262, DOI 10.1016/0014-5793(89)80734-3; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GILON P, 1993, J BIOL CHEM, V268, P22265; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KHAN RN, 1993, P ROY SOC B-BIOL SCI, V253, P225, DOI 10.1098/rspb.1993.0107; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1983, MICROBIOL REV, V47, P1; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NELSON DA, 1992, J BIOL CHEM, V267, P14928; NICHOLS CG, 1991, BIOPHYS J, V60, P1164, DOI 10.1016/S0006-3495(91)82152-X; NIKI I, 1991, BIOCHIM BIOPHYS ACTA, V1133, P95, DOI 10.1016/0167-4889(91)90246-T; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PANTEN U, 1992, HORM METAB RES, V24, P549, DOI 10.1055/s-2007-1003387; QSHFORD ML, 1994, NATURE, V370, P456; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RAJAN AS, 1993, J BIOL CHEM, V268, P15221; RONNER P, 1993, DIABETES, V42, P1760, DOI 10.2337/diabetes.42.12.1760; SCHWANSTECHER C, 1992, MOL PHARMACOL, V41, P480; SCHWANSTECHER M, 1991, N-S ARCH PHARMACOL, V343, P83; SKEER JM, 1994, FEBS LETT, V338, P98, DOI 10.1016/0014-5793(94)80124-X; STURGESS NC, 1985, LANCET, V31, P474; TERZIC A, 1994, CARDIOVASC RES, V28, P746, DOI 10.1093/cvr/28.6.746; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; 1991, PROGRAM MANUAL GCG P	42	1182	1218	1	31	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					423	426		10.1126/science.7716547	http://dx.doi.org/10.1126/science.7716547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716547				2022-12-01	WOS:A1995QU57200042
J	CHEN, CY; SARNOW, P				CHEN, CY; SARNOW, P			INITIATION OF PROTEIN-SYNTHESIS BY THE EUKARYOTIC TRANSLATIONAL APPARATUS ON CIRCULAR RNAS	SCIENCE			English	Article							5' NONTRANSLATED REGION; INTERNAL RIBOSOMAL ENTRY; MESSENGER-RNA; VIRUS-RNA; POLIOVIRUS RNA; PICORNAVIRUS RNA; BINDING-PROTEIN; SITE; SEQUENCE; ELEMENTS	The ribosome scanning model predicts that eukaryotic ribosomal 40S subunits enter all messenger RNAs at their 5' ends. Here, it is reported that eukaryotic ribosomes can initiate translation on circular RNAs, but only if the RNAs contain internal ribosome entry site elements, Long-repeating polypeptide chains were synthesized from RNA circles with continuous open reading frames. These results indicate that ribosomes can translate such RNA circles for multiple consecutive rounds and that the free 5' end of a messenger RNA is not necessarily the entry point for 40S subunits.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DYDE LAB,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Sarnow, Peter/0000-0002-2043-2770				CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; COOPER G, 1994, J BIOTECHNOL, V33, P123, DOI 10.1016/0168-1656(94)90105-8; DUKE GM, 1992, J VIROL, V66, P1602, DOI 10.1128/JVI.66.3.1602-1609.1992; EDERY I, 1983, J BIOL CHEM, V258, P1398; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; GRABOWSKI PJ, 1981, CELL, V23, P467, DOI 10.1016/0092-8674(81)90142-2; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HAMBIDGE SJ, 1991, J VIROL, V65, P6312, DOI 10.1128/JVI.65.11.6312-6315.1991; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KONARSKA M, 1981, EUR J BIOCHEM, V114, P221, DOI 10.1111/j.1432-1033.1981.tb05139.x; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1979, NATURE, V280, P82, DOI 10.1038/280082a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LUZ N, 1990, FEBS LETT, V169, P311; MACEJAK DG, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P152; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MEEROVITCH K, 1991, J VIROL, V65, P5895, DOI 10.1128/JVI.65.11.5895-5901.1991; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOLLA A, 1992, NATURE, V356, P255, DOI 10.1038/356255a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PESTOVA TV, 1991, J VIROL, V65, P6194, DOI 10.1128/JVI.65.11.6194-6204.1991; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; ROBERTSON HD, 1992, CURR TOP MICROBIOL, V176, P213; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992	33	491	547	5	71	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					415	417		10.1126/science.7536344	http://dx.doi.org/10.1126/science.7536344			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7536344				2022-12-01	WOS:A1995QU57200039
J	COLONNA, M; SAMARIDIS, J				COLONNA, M; SAMARIDIS, J			CLONING OF IMMUNOGLOBULIN-SUPERFAMILY MEMBERS ASSOCIATED WITH HLA-C AND HLA-B RECOGNITION BY HUMAN NATURAL-KILLER-CELLS	SCIENCE			English	Article							NK CLONES; ALLOANTIGEN RECOGNITION; ANTIGEN RECOGNITION; EXPRESSION; MOLECULES; SPECIFICITY; RECEPTORS; LYSIS; GENE; HETEROGENEITY	Cytotoxicity by natural killer (NK) cells is inhibited by major histocompatibility complex (MHC) class I molecules on target cells. This inhibition may be mediated by NK receptors with different MHC specificities. A family of four NK-specific complementary DNAs (cDNAs), designated NKATs (NK-associated transcripts), was identified that encoded related transmembrane proteins, characterized by an extracellular region with two or three immunoglobulin-superfamily domains and by a cytoplasmic domain with an unusual antigen receptor activation motif (ARAM). The distribution of these cDNAs was clonotypic and correlated with NK cell inhibition by particular class I alleles. Thus, NKAT cDNAs may encode receptors for class I molecules on NK cells.			COLONNA, M (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.			Colonna, Marco/0000-0001-5222-4987				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ARM JP, 1991, J BIOL CHEM, V266, P15966; BARCLAY AN, 1993, LEUKOCYTE ANTIGEN FA, P64; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P7983, DOI 10.1073/pnas.89.17.7983; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KORNBLUTH J, 1982, J IMMUNOL, V129, P2831; LANIER LL, 1983, J IMMUNOL, V131, P1789; LARSEN CJ, 1988, LEUKEMIA, V2, P247; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MALNATI MS, 1995, SCIENCE, V267, P1016, DOI 10.1126/science.7863326; MELERO I, 1994, J IMMUNOL, V152, P1662; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	33	689	725	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					405	408		10.1126/science.7716543	http://dx.doi.org/10.1126/science.7716543			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716543				2022-12-01	WOS:A1995QU57200036
J	GALITSKI, T; ROTH, JR				GALITSKI, T; ROTH, JR			EVIDENCE THAT F-PLASMID TRANSFER REPLICATION UNDERLIES APPARENT ADAPTIVE MUTATION	SCIENCE			English	Article							DIRECTED MUTATION; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; MUTAGENESIS; SELECTION; HYPOTHESIS; REVERSION; UNICORNS	Escherichia coli K12 strain, FC40, has been used extensively in the analysis of adaptive mutability. This strain carries a revertible mutant lac allele on an F plasmid and accumulates Lac(+) (lactose utilizing) revertants, but not unselected mutants, when placed on selective medium. These adaptive mutations are a subset of spontaneous types and their formation depends on the RecABC functions. Data presented here suggest that this phenomenon depends on transfer functions of the F factor. Fertility inhibition eliminates RecA-dependent adaptive reversion. Thus, ''adaptive'' revertants may form during replication from the transfer origin, whereas loci in the nonreplicating chromosome show little mutation.			GALITSKI, T (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027068] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07464-15, GM27068] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; BRIDGES BA, 1994, MUTAT RES, V307, P149, DOI 10.1016/0027-5107(94)90287-9; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CHEAH KC, 1986, J GEN MICROBIOL, V132, P3269; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DEMPSEY WB, 1993, BACTERIAL CONJUGATIO, P53; FISHER KW, 1957, J GEN MICROBIOL, V16, P136, DOI 10.1099/00221287-16-1-136; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FOSTER PL, 1994, GENETICS, V138, P253; FOSTER PL, 1992, J BACTERIOL, V174, P1711, DOI 10.1128/jb.174.6.1711-1716.1992; FOSTER PL, 1994, EMBO J, V13, P5240, DOI 10.1002/j.1460-2075.1994.tb06855.x; FOSTER PL, 1991, BOST STUD PHILOS SCI, V129, P213; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; GALITSKI T, UNPUB; GASSON MJ, 1975, J BACTERIOL, V122, P518, DOI 10.1128/JB.122.2.518-525.1975; Hall BG, 1992, CURR OPIN GENET DEV, V2, P943, DOI 10.1016/S0959-437X(05)80120-0; HALL BG, 1992, P NATL ACAD SCI USA, V89, P4300, DOI 10.1073/pnas.89.10.4300; HALL BG, 1993, J BACTERIOL, V175, P6411, DOI 10.1128/jb.175.20.6411-6414.1993; HALL BG, 1994, MOL BIOL EVOL, V11, P159; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; KOCH WH, 1992, J BACTERIOL, V174, P2809, DOI 10.1128/JB.174.9.2809-2815.1992; LEDERBERG J, 1952, J BACTERIOL, V63, P399, DOI 10.1128/JB.63.3.399-406.1952; LENSKI RE, 1993, SCIENCE, V259, P188, DOI 10.1126/science.7678468; LENSKI RE, 1989, P NATL ACAD SCI USA, V86, P2775, DOI 10.1073/pnas.86.8.2775; Luria SE, 1943, GENETICS, V28, P491; MACPHEE DG, 1993, MUTAT RES, V285, P109, DOI 10.1016/0027-5107(93)90058-N; MAENHAUTMICHEL G, 1994, EMBO J, V13, P5229, DOI 10.1002/j.1460-2075.1994.tb06854.x; MCINTIRE SA, 1987, NUCLEIC ACIDS RES, V15, P2029, DOI 10.1093/nar/15.5.2029; Miller JH., 1972, EXPT MOL GENETICS; MITTLER JE, 1990, NATURE, V344, P173, DOI 10.1038/344173a0; MITTLER JE, 1992, NATURE, V356, P446, DOI 10.1038/356446a0; OVERBYE KM, 1981, J BACTERIOL, V146, P170, DOI 10.1128/JB.146.1.170-178.1981; PETERS JE, 1995, J BACTERIOL, V177, P847, DOI 10.1128/jb.177.3.847-850.1995; RADICELLA JP, 1995, SCIENCE, V268, P418, DOI 10.1126/science.7716545; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; SANDERSON KE, 1983, CAN J MICROBIOL, V29, P1205, DOI 10.1139/m83-184; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; STAHL FW, 1992, GENETICS, V132, P865; STEELE DF, 1992, GENETICS, V132, P9; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; WILLETTS N, 1987, CELLULAR MOL BIOL, P1110; WING JP, 1968, J BACTERIOL, V95, P1828, DOI 10.1128/JB.95.5.1828-1834.1968	46	118	120	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					421	423		10.1126/science.7716546	http://dx.doi.org/10.1126/science.7716546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716546	Green Submitted			2022-12-01	WOS:A1995QU57200041
J	GLUCKSMANNKUIS, MA; TAYBER, O; WOOLF, EA; BOUGUELERET, L; DENG, NH; ALPERIN, GD; IRIS, F; HAWKINS, F; MUNRO, C; LAKEY, N; DUYK, G; SCHNEIDER, MC; GENG, L; ZHANG, F; ZHAO, ZH; TOROSIAN, S; ZHOU, J; REEDERS, ST; BORK, P; POHLSCHMIDT, M; LOHNING, C; KRAUS, B; NOWICKA, U; LEUNG, ALS; FRISCHAUF, AM				GLUCKSMANNKUIS, MA; TAYBER, O; WOOLF, EA; BOUGUELERET, L; DENG, NH; ALPERIN, GD; IRIS, F; HAWKINS, F; MUNRO, C; LAKEY, N; DUYK, G; SCHNEIDER, MC; GENG, L; ZHANG, F; ZHAO, ZH; TOROSIAN, S; ZHOU, J; REEDERS, ST; BORK, P; POHLSCHMIDT, M; LOHNING, C; KRAUS, B; NOWICKA, U; LEUNG, ALS; FRISCHAUF, AM			POLYCYSTIC KIDNEY-DISEASE - THE COMPLETE STRUCTURE OF THE PKD1 GENE AND ITS PROTEIN	CELL			English	Article							CELL-ADHESION; CARBOHYDRATE-RECOGNITION; SEQUENCE; GLYCOPROTEINS; DOMAINS; LOCALIZATION; INTEGRINS; MEMBRANES; EPITHELIA; POLARITY	Mutations in the PKD1 gene sire the most common cause of autosomal dominant polycystic kidney disease (ADPKD). Other PKD1-like loci on chromosome 16 are approximately 97% identical to PKD1. To determine the authentic PKD1 sequence, we obtained the genomic sequence of the PKD1 locus and assembled a PKD1 transcript from the sequence of 46 exons. The 14.5 kb PKD1 transcript encodes a 4304 amino acid protein that has a novel domain architecture. The amino-terminal half of the protein consists of a mosaic of previously described domains, including leucine-rich repeats flanked by characteristic cysteine-rich structures, LDL-A and C-type lectin domains, and 14 units of a novel 80 amino acid domain. The presence of these domains suggests that the PKD1 protein is involved in adhesive protein-protein and protein-carbohydrate interactions in the extracellular compartment. We propose a hypothesis that links the predicted properties of the protein with the diverse phenotypic features of ADPKD.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; EUROPEAN MOLEC BIOL LAB,PROT DESIGN GRP,D-69117 HEIDELBERG,GERMANY; MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Cancer Research UK	GLUCKSMANNKUIS, MA (corresponding author), MILLENNIUM PHARMACEUT INC,CAMBRIDGE,MA 02139, USA.		Bork, Peer/F-1813-2013	Bork, Peer/0000-0002-2627-833X				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; [Anonymous], 1994, CELL, V77, P881; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BEZOUSKA K, 1991, J BIOL CHEM, V226, P11604; BORK P, 1994, CURR OPIN STRUC BIOL, V4, P393, DOI 10.1016/S0959-440X(94)90109-0; BORK P, 1995, TRENDS BIOCH SCI, V20; BROCKL G, 1991, EUR J BIOCHEM, V199, P147, DOI 10.1111/j.1432-1033.1991.tb16102.x; BUTOWSKI RJ, 1985, KIDNEY INT, V28, P744; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; CALVET JP, 1994, CURR OPIN NEPHROL HY, V3, P330; CARONE FA, 1994, LAB INVEST, V70, P437; CARONE FA, 1989, KIDNEY INT, V35, P1034, DOI 10.1038/ki.1989.87; CARONE FA, 1993, LAB INVEST, V70, P648; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DVERGSTEN J, 1994, KIDNEY INT, V45, P828, DOI 10.1038/ki.1994.109; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; EVAN AP, 1979, KIDNEY INT, V16, P743, DOI 10.1038/ki.1979.191; FOSSDAL R, 1993, HUM GENET, V91, P609; GABOW PA, 1990, AM J KIDNEY DIS, V16, P403, DOI 10.1016/S0272-6386(12)80051-5; GERMINO GG, 1992, GENOMICS, V13, P144, DOI 10.1016/0888-7543(92)90214-D; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HAVERTY TP, 1988, LAB INVEST, V58, P245; HENIKOFF S, 1993, PROTEINS, V17, P97; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P325; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P1017; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KLINGEL R, 1993, NEPHRON, V65, P111, DOI 10.1159/000187451; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONTUSAARI S, 1990, J CLIN INVEST, V86, P1465, DOI 10.1172/JCI114863; KOONIN EV, 1994, EMBO J, V13, P493, DOI 10.1002/j.1460-2075.1994.tb06287.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KWON BS, 1993, J INVEST DERMATOL, V100, P134; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; MYERS KA, 1994, J BIOL CHEM, V269, P9319; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; REEDERS ST, 1992, NAT GENET, V1, P235, DOI 10.1038/ng0792-235; RODRIGUEZBOULAN E, 1989, SCIENCE, V247, P718; ROHDE K, 1993, COMPUT APPL BIOSCI, V9, P183; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROTH GJ, 1991, BLOOD, V77, P5; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SNAREY A, 1994, AM J HUM GENET, V55, P365; SOMLO S, 1992, GENOMICS, V13, P152, DOI 10.1016/0888-7543(92)90215-E; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIS WI, 1992, COLD SPRING HARB SYM, V57, P281, DOI 10.1101/SQB.1992.057.01.033; WELLING LW, 1972, J CLIN INVEST, V51, P1063, DOI 10.1172/JCI106898; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAO R, 1994, BBA-GENE STRUCT EXPR, V1219, P697, DOI 10.1016/0167-4781(94)90230-5; YOSHIHARA K, 1994, J BACTERIOL, V176, P6489, DOI 10.1128/JB.176.21.6489-6496.1994	68	524	532	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					289	298						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736581	Bronze			2022-12-01	WOS:A1995QV41000018
J	GUO, LF; DEGENSTEIN, L; DOWLING, J; YU, QC; WOLLMANN, R; PERMAN, B; FUCHS, E				GUO, LF; DEGENSTEIN, L; DOWLING, J; YU, QC; WOLLMANN, R; PERMAN, B; FUCHS, E			GENE TARGETING OF BPAG1 - ABNORMALITIES IN MECHANICAL STRENGTH AND CELL-MIGRATION IN STRATIFIED EPITHELIA AND NEUROLOGIC DEGENERATION	CELL			English	Article							BULLOUS PEMPHIGOID ANTIGEN; BASEMENT-MEMBRANE ADHESION; CDNA CLONING; HEMIDESMOSOMES; INTEGRIN; ALPHA-6-BETA-4; IDENTIFICATION; EXPRESSION; COMPONENT; PROTEIN	BPAG1 is the major antigenic determinant of autoimmune sera of bullous pemphigoid (BP) patients. It is made by stratified squamous epithelia, where it localizes to the inner surface of specialized integrin-mediated adherens junctions (hemidesmosomes). To explore the function of BPAG1 iind its relation to BP, we targeted the removal of the BPAG1 gene in mice. Hemidesmosomes are otherwise normal, but they lack the inner plate and have no cytoskeleton attached. Though not affecting cell growth or substratum adhesion, this compromises mechanical integrity and influences migration. Unexpectedly, the mice also develop severe dystonia and sensory nerve degeneration typical of dystonia musculorum (dt/dt) mice. We show that in at least one other strain of dt/dt mice, BPAG1 gene is defective.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago	GUO, LF (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.		Fuchs, Elaine/G-1565-2016					ANTON-LAMPBRECHT I, 1983, J INVEST DERMATOL S, V81, P149; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BROWN A, 1994, GENOMICS, V20, P371, DOI 10.1006/geno.1994.1190; CAMPBELL RM, 1992, NEURON, V9, P693, DOI 10.1016/0896-6273(92)90032-9; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHAN YM, 1994, GENE DEV, V8, P2574, DOI 10.1101/gad.8.21.2574; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1993, GENOMICS, V15, P180, DOI 10.1006/geno.1993.1027; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DIAZ LA, 1977, J IMMUNOL, V118, P455; Duchen L W, 1976, Adv Neurol, V14, P353; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; Hogan B., 2014, MANIPULATING MOUSE E; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; KLATTE DH, 1989, J CELL BIOL, V109, P3377, DOI 10.1083/jcb.109.6.3377; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LABIB RS, 1986, J IMMUNOL, V136, P1231; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MESSER A, 1980, NEUROSCIENCE, V5, P543, DOI 10.1016/0306-4522(80)90051-2; MUELLER S, 1989, J INVEST DERMATOL, V92, P33, DOI 10.1111/1523-1747.ep13070476; OWARIBE K, 1990, DIFFERENTIATION, V45, P207, DOI 10.1111/j.1432-0436.1990.tb00475.x; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1994, J INVEST DERMATOL, V103, P651, DOI 10.1111/1523-1747.ep12398405; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SUGI T, 1989, J CLIN INVEST, V84, P1050, DOI 10.1172/JCI114266; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; WESTGATE GE, 1985, J INVEST DERMATOL, V84, P218, DOI 10.1111/1523-1747.ep12265229	41	390	395	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					233	243		10.1016/0092-8674(95)90333-X	http://dx.doi.org/10.1016/0092-8674(95)90333-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736575	Bronze			2022-12-01	WOS:A1995QV41000012
J	IRNIGER, S; PIATTI, S; MICHAELIS, C; NASMYTH, K				IRNIGER, S; PIATTI, S; MICHAELIS, C; NASMYTH, K			GENES INVOLVED IN SISTER-CHROMATID SEPARATION ARE NEEDED FOR B-TYPE CYCLIN PROTEOLYSIS IN BUDDING YEAST	CELL			English	Article							MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; INTERPHASE EXTRACTS; ESCHERICHIA-COLI; DNA-REPLICATION; AMPHIBIAN EGGS; M-PHASE; TRANSCRIPTION	B-type cyclin destruction is necessary for exit from mitosis and the initiation of a new cell cycle. Through the isolation of mutants, we have identified three essential yeast genes, CDC16, CDC23, and CSE1, which are required for proteolysis of the B-type cyclin CLBS but not of other unstable proteins. cdc23-1 mutants are defective in both entering and exiting anaphase. Their failure to exit anaphase can be explained by defective cyclin proteolysis. CDC23 is required at the metaphase/anaphase transition to separate sister chromatids, and we speculate that it might promote proteolysis of proteins that hold sister chromatids together. Proteolysis of CLB2 is initiated in early anaphase, but a fraction of CLB2 remains stable until anaphase is complete.			IRNIGER, S (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403; Piatti, Simonetta/0000-0003-1958-8919				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KOSHLAND D, 1994, CELL, V77, P951, DOI 10.1016/0092-8674(94)90432-4; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LORCA T, 1992, J CELL SCI, V102, P55; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Maniatis T., 1982, MOL CLONING; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ROSE MD, 1990, LABORATORY COURSE MA; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; TUGENDREICH S, 1995, CELL, V81; WAN J, 1992, J BIOL CHEM, V267, P11274; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880	43	377	384	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					269	278		10.1016/0092-8674(95)90337-2	http://dx.doi.org/10.1016/0092-8674(95)90337-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736579	Bronze			2022-12-01	WOS:A1995QV41000016
J	KASHIWABUCHI, N; IKEDA, K; ARAKI, K; HIRANO, T; SHIBUKI, K; TAKAYAMA, C; INOUE, Y; KUTSUWADA, T; YAGI, T; KANG, Y; AIZAWA, S; MISHINA, M				KASHIWABUCHI, N; IKEDA, K; ARAKI, K; HIRANO, T; SHIBUKI, K; TAKAYAMA, C; INOUE, Y; KUTSUWADA, T; YAGI, T; KANG, Y; AIZAWA, S; MISHINA, M			IMPAIRMENT OF MOTOR COORDINATION, PURKINJE-CELL SYNAPSE FORMATION, AND CEREBELLAR LONG-TERM DEPRESSION IN GLUR-DELTA-2 MUTANT MICE	CELL			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; GLUTAMATE-RECEPTOR; NMDA RECEPTOR; FAMILY; POTENTIATION; HIPPOCAMPUS; INDUCTION; CURRENTS; CALCIUM	Of the six glutamate receptor (GluR) channel subunit families identified by molecular cloning, five have been shown to constitute either the AMPA, kainate, or NMDA receptor channel, whereas the function of the delta subunit family remains unknown. The selective localization of the delta 2 subunit or the GluR delta subfamily in cerebellar Purkinje Cells prompted us to examine its possible physiological roles by the gene targeting technique. Analyses of the GluR delta 2 mutant mice reveal that the delta 2 subunit plays important roles in motor coordination, formation of parallel fiber-Purkinje cell synapses and climbing fiber-Purkinje cell synapses, and long-term depression of parallel fiber-Purkinje cell synaptic transmission. These! results suggest a close relationship between synaptic plasticity and synapse formation in the cerebellum.	NIIGATA UNIV,BRAIN RES INST,DEPT PHYSIOL,NIIGATA 951,JAPAN; KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 606,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 060,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,IBARAKI,OSAKA 305,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL,TOKYO 113,JAPAN	Niigata University; Kyoto University; Hokkaido University; RIKEN; University of Tokyo	KASHIWABUCHI, N (corresponding author), NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPHARMACOL,NIIGATA 951,JAPAN.		Ikeda, Kazutaka/I-4694-2013	Ikeda, Kazutaka/0000-0001-8342-0278				ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; DUDEK SM, 1993, J NEUROSCI, V13, P2910; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Goldowitz Dan, 1992, V8, P271; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; HIRANO T, 1994, NEUROSCI LETT, V182, P172, DOI 10.1016/0304-3940(94)90790-0; Hogan B., 1986, MANIPULATING MOUSE E; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MISHINA M, 1993, ANN NY ACAD SCI, V707, P136, DOI 10.1111/j.1749-6632.1993.tb38049.x; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHIBUKI K, 1992, NEUROREPORT, V3, P231, DOI 10.1097/00001756-199203000-00003; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMAKUNI T, 1984, NEUROSCI LETT, V45, P235, DOI 10.1016/0304-3940(84)90232-5; YAMAZAKI M, 1992, BIOCHEM BIOPH RES CO, V183, P886, DOI 10.1016/0006-291X(92)90566-4	36	482	485	1	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					245	252		10.1016/0092-8674(95)90334-8	http://dx.doi.org/10.1016/0092-8674(95)90334-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736576	Bronze			2022-12-01	WOS:A1995QV41000013
J	KING, RW; PETERS, JM; TUGENDREICH, S; ROLFE, M; HIETER, P; KIRSCHNER, MW				KING, RW; PETERS, JM; TUGENDREICH, S; ROLFE, M; HIETER, P; KIRSCHNER, MW			A 20S COMPLEX CONTAINING CDC27 AND CDC16 CATALYZES THE MITOSIS-SPECIFIC CONJUGATION OF UBIQUITIN TO CYCLIN-B	CELL			English	Article							MATURATION-PROMOTING FACTOR; CELL-CYCLE; ASPERGILLUS-NIDULANS; CLAM EMBRYO; DEGRADATION; PROTEIN; EXTRACTS; ANAPHASE; DESTRUCTION; KINASE	Cyclin B is degraded at the onset of anaphase by a ubiquitin-dependent proteolytic system. We have fractionated mitotic Xenopus egg extracts to identify components required for this process. We find that UBC4 and at least one other ubiquitin-conjugating enzyme can support cyclin B ubiquitination. The mitotic specificity of cyclin ubiquitination is determined by a 20S complex that contains homologs of budding yeast CDC16 and CDC27. Because these proteins are required for anaphase in yeast and mammalian cells, we refer to this complex as the anaphase-promoting complex (APC). CDC27 antibodies deplete APC activity, while immunopurified CDC27 complexes are sufficient to complement either interphase extracts or a mixture of recombinant UBC4 and the ubiquitin-activating enzyme E1. These results suggest that APC functions as a regulated ubiquitin-protein ligase that targets cyclin B far destruction in mitosis.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; MITOTIX INC, CAMBRIDGE, MA 02139 USA	Johns Hopkins University	KING, RW (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026875, R37GM026875, R01GM039023] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26875-17, GM39023-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BAILLY E, 1992, J CELL SCI, V101, P529; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIROD PA, 1993, J BIOL CHEM, V268, P955; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUANG J, 1991, P NATL ACAD SCI USA, V88, P11530, DOI 10.1073/pnas.88.24.11530; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MALDONADOCODINA G, 1992, J CELL BIOL, V116, P967, DOI 10.1083/jcb.116.4.967; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; ODONNELL KL, 1991, J CELL SCI, V99, P711; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SUAKIN V, 1995, MOL BIOL CELL, V6, P185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72	45	823	835	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					279	288		10.1016/0092-8674(95)90338-0	http://dx.doi.org/10.1016/0092-8674(95)90338-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736580	hybrid			2022-12-01	WOS:A1995QV41000017
J	LAIRD, PW; JACKSONGRUSBY, L; FAZELI, A; DICKINSON, SL; JUNG, WE; LI, E; WEINBERG, RA; JAENISCH, R				LAIRD, PW; JACKSONGRUSBY, L; FAZELI, A; DICKINSON, SL; JUNG, WE; LI, E; WEINBERG, RA; JAENISCH, R			SUPPRESSION OF INTESTINAL NEOPLASIA BY DNA HYPOMETHYLATION	CELL			English	Article							CYTOSINE METHYLTRANSFERASES; 5-METHYLCYTOSINE CONTENT; INDUCED DEAMINATION; RAS ONCOGENES; HUMAN CANCERS; COLON-CANCER; CPG ISLANDS; METHYLATION; MOUSE; GENE	We have used a combination of genetics and pharmacology to assess the effects of reduced DNA methyltransferase activity on Apc(Min)-induced intestinal neoplasia in mice. A reduction in the DNA methyltransferase activity in Min mice due to heterozygosity of the DNA methyltransferase gene, in conjunction with a weekly dose of the DNA methyltransferase inhibitor 5-azadeoxycytidine, reduced the average number of intestinal adenomas from 113 in the control mice to only 2 polyps in the treated heterozygotes. Hence, DNA methyltransferase activity contributes substantially to tumor development in this mouse model of intestinal neoplasia. Our results argue against an oncogenic effect of DNA hypomethylation. Moreover, they are consistent with a role for DNA methyltransferase in the generation of the C to T transitions seen at high frequency in human colorectal tumors.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,BOSTON,MA 02129	Massachusetts Institute of Technology (MIT)	LAIRD, PW (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.		Laird, Peter W/G-8683-2012	Laird, Peter W/0000-0001-9117-3641	NATIONAL CANCER INSTITUTE [F32CA009097, R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44339, F32 CA 09097] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS RLP, 1982, CRC CR REV BIOCH MOL, V13, P349, DOI 10.3109/10409238209108714; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; BROWN TC, 1989, MUTAT RES, V227, P233, DOI 10.1016/0165-7992(89)90102-4; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1988, CANCER RES, V48, P1159; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HANADA M, 1993, BLOOD, V82, P1820; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Leonhardt H., 1993, DNA methylation: molecular biology and biological significance., P109; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MONK M, 1990, DEVELOPMENT S, P66; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NAKAMURA Y, 1993, ADV CANCER RES, V62, P65, DOI 10.1016/S0065-230X(08)60315-2; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RAO PM, 1989, CARCINOGENESIS, V10, P933, DOI 10.1093/carcin/10.5.933; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SHENOY S, 1987, J MOL BIOL, V197, P617, DOI 10.1016/0022-2836(87)90468-2; SHIVAPURKAR N, 1986, J NATL CANCER I, V77, P213; SILVERMAN AL, 1989, CANCER RES, V49, P3468; Singer-Sam J., 1993, DNA methylation: molecular biology and biological significance., P358; SPRUCK CH, 1993, DNA METHYLATION MOL, P487; SU LK, 1992, SCIENCE, V256, P1114, DOI 10.1126/science.256.5060.1114-c; TAMURA G, 1994, CANCER RES, V54, P1149; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; VORCE RL, 1991, J TOXICOL ENV HEALTH, V34, P367, DOI 10.1080/15287399109531574; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yeivin A, 1993, EXS, V64, P523	74	636	653	0	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					197	205		10.1016/0092-8674(95)90329-1	http://dx.doi.org/10.1016/0092-8674(95)90329-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7537636	Bronze			2022-12-01	WOS:A1995QV41000008
J	LI, CJ; FRIEDMAN, DJ; WANG, CL; METELEV, V; PARDEE, AB				LI, CJ; FRIEDMAN, DJ; WANG, CL; METELEV, V; PARDEE, AB			INDUCTION OF APOPTOSIS IN UNINFECTED LYMPHOCYTES BY HIV-1 TAT PROTEIN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRAMMED CELL-DEATH; T-CELLS; PERIPHERAL-BLOOD; ACTIVATION; AIDS; INDIVIDUALS; EXPRESSION; INFECTION; CD4	Infection by human immunodeficiency virus-type 1 (HIV-1) is typified by the progressive depletion of CD4 T lymphocytes and deterioration of immune function in most patients. A central unresolved issue in acquired immunodeficiency syndrome (AIDS) pathogenesis is the mechanism underlying this T cell depletion. HIV-1 Tat protein was shown to induce cell death by apoptosis in a T cell line and in cultured peripheral blood mononuclear cells from uninfected donors, This Tat-induced apoptosis was inhibitable by growth factors and was associated with enhanced activation of cyclin-dependent kinases.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; WORCESTER FDN EXPTL BIOL INC, SHREWSBURY, MA 01545 USA	Harvard University; Harvard Medical School; Worcester Foundation for Biomedical Research	LI, CJ (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT, 44 BINNEY ST, BOSTON, MA 02115 USA.		Metelev, Valeri/I-3238-2012	Friedman, David/0000-0002-0301-9298	NIAID NIH HHS [AI-35511] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMEISEN JC, 1992, IMMUNOL TODAY, V13, P388, DOI 10.1016/0167-5699(92)90086-M; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V6, P778; CARBONARI M, 1994, BLOOD, V83, P1268; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOU QP, 1993, CANCER RES, V53, P1493; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ESTAQUIER J, 1994, P NATL ACAD SCI USA, V91, P9431, DOI 10.1073/pnas.91.20.9431; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FINKEL TH, 1994, CURR OPIN IMMUNOL, V6, P605, DOI 10.1016/0952-7915(94)90149-X; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GOUGEON ML, 1993, SCIENCE, V262, P1356, DOI 10.1126/science.262.5138.1356; Green D R, 1992, Semin Immunol, V4, P379; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; LEDERMAN MM, COMMUNICATION; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li C, UNPUB; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; LI CJ, 1994, J BIOL CHEM, V269, P7051; MARTIN SJ, 1994, J IMMUNOL, V152, P330; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PANTALEO G, 1994, CURR OPIN IMMUNOL, V6, P600, DOI 10.1016/0952-7915(94)90148-1; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; ROSEN CA, 1986, J VIROL, V57, P379, DOI 10.1128/JVI.57.1.379-384.1986; ROSSI AD, 1994, VIROLOGY, V198, P234; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; ZAULI G, 1993, CANCER RES, V53, P4481	47	532	553	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	1995	268	5209					429	431		10.1126/science.7716549	http://dx.doi.org/10.1126/science.7716549			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716549				2022-12-01	WOS:A1995QU57200044
J	LUMB, KJ; KIM, PS				LUMB, KJ; KIM, PS			MEASUREMENT OF INTERHELICAL ELECTROSTATIC INTERACTIONS IN THE GCN4 LEUCINE-ZIPPER	SCIENCE			English	Article							X-RAY STRUCTURE; COILED-COIL; PROTEINS; STABILITY; DIMERIZATION; REGION; DNA; SPECTROSCOPY; TROPOMYOSIN; CONTRIBUTE	The dimerization specificity of the bZIP transcription factors resides in the leucine zipper region. It is commonly assumed that electrostatic interactions between oppositely charged amino acid residues on different helices of the leucine zipper contribute favorably to dimerization specificity. Crystal structures of the GCN4 leucine zipper contain interhelical salt bridges between Glu(20) and Lys(15') and between Glu(22) and Lys(27'). C-13-nuclear magnetic resonance measurements of the glutamic acid pK(a) values at physiological ionic strength indicate that the salt bridge involving Glu(22) does not contribute to stability and that the salt bridge involving Glu(20) is unfavorable, relative to the corresponding situation with a neutral (protonated) Glu residue, Moreover, the substitution of Glu(20) by glutamine is stabilizing. Thus, salt bridges will not necessarily contribute favorably to bZIP dimerization specificity and may indeed be unfavorable, relative to alternative neutral-charge interactions.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute				Lumb, Kevin/0000-0003-2778-9956	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BERGER B, IN PRESS P NATL ACAD; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN JS, 1970, NATURE, V228, P642, DOI 10.1038/228642a0; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; Fersht A R, 1972, Cold Spring Harb Symp Quant Biol, V36, P71; GOODMAN EM, 1991, BIOCHEMISTRY-US, V30, P11615, DOI 10.1021/bi00114a002; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; Honig B., 1992, CURR OPIN STRUC BIOL, V2, P40; JOHN M, 1994, J BIOL CHEM, V269, P16247; Kirkwood JG, 1938, J CHEM PHYS, V6, P506, DOI 10.1063/1.1750302; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LETAI A, 1995, P NATL ACAD SCI USA, V92, P92, DOI 10.1073/pnas.92.1.92; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; LUMB KJ, UNPUB; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; NILGES M, 1991, PROTEIN ENG, V4, P649, DOI 10.1093/protein/4.6.649; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; OSHEA EK, 1992, CELL, V66, P699; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SHAKA AJ, 1983, J MAGN RESON, V53, P313, DOI 10.1016/0022-2364(83)90035-5; STONE D, 1975, PROTEINS CONTRACTILE, P125; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	49	180	184	2	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					436	439		10.1126/science.7716550	http://dx.doi.org/10.1126/science.7716550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716550				2022-12-01	WOS:A1995QU57200046
J	MARTOGLIO, B; HOFMANN, MW; BRUNNER, J; DOBBERSTEIN, B				MARTOGLIO, B; HOFMANN, MW; BRUNNER, J; DOBBERSTEIN, B			THE PROTEIN-CONDUCTING CHANNEL IN THE MEMBRANE OF THE ENDOPLASMIC-RETICULUM IS OPEN LATERALLY TOWARD THE LIPID BILAYER	CELL			English	Article							SIGNAL-RECOGNITION PARTICLE; MICROSOMAL-MEMBRANES; SECRETORY PROTEIN; BIOSYNTHETIC INCORPORATION; DOCKING PROTEIN; MESSENGER-RNA; TRANSLOCATION; SEQUENCE; ELONGATION; CHAIN	Lipids and proteins were found to contact a nascent type II membrane protein, as well as a nascent secretory protein, during their insertion into the membrane of the endoplasmic reticulum. This suggests that the protein-conducting channel is open laterally toward the lipid bilayer during an early stage of protein insertion. Contact to lipids was confined to the hydrophobic core region of the respective signal or signal anchor sequence. Thus, the nascent polypeptide is positioned in the translocation complex such that the signal or signal anchor sequence faces the lipid bilayer, whereas the hydrophilic, translocating portion is in proteinaceous environment.	ETH ZURICH, BIOCHEM LAB, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	MARTOGLIO, B (corresponding author), UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, D-69052 HEIDELBERG, GERMANY.			Hofmann, Michael Werner/0000-0002-2729-6062				ALBERTS B, 1988, MOL BIOL CELL; BAIN JD, 1991, J ORG CHEM, V56, P4615, DOI 10.1021/jo00015a011; BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; BRUNNER J, 1993, CHEM SOC REV, V22, P183, DOI 10.1039/cs9932200183; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; ENGELMANN DM, 1991, CELL, V23, P411; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GLASER KB, 1986, BIOCHEM PHARMACOL, V35, P449, DOI 10.1016/0006-2952(86)90218-2; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1993, J BIOL CHEM, V268, P26745; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP J, 1987, J BIOL CHEM, V262, P1680; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1985, CURRENT TOPICS MEMBR, V24; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323	41	239	239	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					207	214		10.1016/0092-8674(95)90330-5	http://dx.doi.org/10.1016/0092-8674(95)90330-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736572	Bronze, Green Published			2022-12-01	WOS:A1995QV41000009
J	MIYAZAKI, T; LIU, ZJ; KAWAHARA, A; MINAMI, Y; YAMADA, K; TSUJIMOTO, Y; BARSOUMIAN, EL; PERLMUTTER, RM; TANIGUCHI, T				MIYAZAKI, T; LIU, ZJ; KAWAHARA, A; MINAMI, Y; YAMADA, K; TSUJIMOTO, Y; BARSOUMIAN, EL; PERLMUTTER, RM; TANIGUCHI, T			3 DISTINCT IL-2 SIGNALING PATHWAYS MEDIATED BY BCL-2, C-MYC, AND LCK COOPERATE IN HEMATOPOIETIC-CELL PROLIFERATION	CELL			English	Article							RECEPTOR-BETA-CHAIN; PROTEIN-TYROSINE KINASE; INTERLEUKIN-2 RECEPTOR; FOLLICULAR LYMPHOMA; LIGAND-BINDING; TRANSDUCTION; APOPTOSIS; DEATH; ACTIVATION; LINE	Two interleukin-2 receptor-dependent signaling pathways have thus far been identified: the c-fos/c-jun induction pathway mediated by src family protein-tyrosine kinases and the c-myo induction pathway. Here, we provide evidence for the existence of a third, rapamycin-sensitive pathway, which results in the induction of another proto-oncogene, bcl-2. In the hematopoietic cell line BAF-B03, the expression of any two of lckF505 (an active form of p56(lck)), Bcl-2, or c-Myc is sufficient to promote transit of the cell cycle, regardless of the activation state of the third pathway. We also provide evidence that epidermal growth factor receptor signaling may act through the same pathway that involves p56(lck). These studies demonstrate a novel approach to dissecting signaling pathways regulating cellular proliferation.	NIPPON BOEHRINGER INGELHEIM CO LTD,INST MOLEC & CELLULAR BIOL,KAWANISHI,HYOGO 66601,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,SUITA,OSAKA 565,JAPAN; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Boehringer Ingelheim; Osaka University; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Tokyo	MIYAZAKI, T (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Miyazaki, Tadaaki/D-9368-2012					ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COLLINS MKL, 1993, TRENDS BIOCHEM SCI, V18, P307, DOI 10.1016/0968-0004(93)90042-L; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DOI T, 1989, EUR J IMMUNOL, V19, P2375, DOI 10.1002/eji.1830191229; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTANI H, 1993, J BIOL CHEM, V268, P22733; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SATOH T, 1992, J BIOL CHEM, V267, P25423; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	46	349	361	2	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					223	231		10.1016/0092-8674(95)90332-1	http://dx.doi.org/10.1016/0092-8674(95)90332-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736574	Bronze			2022-12-01	WOS:A1995QV41000011
J	NOWAK, MW; KEARNEY, PC; SAMPSON, JR; SAKS, ME; LABARCA, CG; SILVERMAN, SK; ZHONG, W; THORSON, JS; ABELSON, JN; DAVIDSON, N; SCHULTZ, PG; DOUGHERTY, DA; LESTER, HA				NOWAK, MW; KEARNEY, PC; SAMPSON, JR; SAKS, ME; LABARCA, CG; SILVERMAN, SK; ZHONG, W; THORSON, JS; ABELSON, JN; DAVIDSON, N; SCHULTZ, PG; DOUGHERTY, DA; LESTER, HA			NICOTINIC RECEPTOR-BINDING SITE PROBED WITH UNNATURAL AMINO-ACID-INCORPORATION IN INTACT-CELLS	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASE; ACETYLCHOLINE-RECEPTOR; ALPHA-SUBUNIT; RECOGNITION; PHENYLALANINE; CONSTRUCTION; SUPPRESSION; NUCLEOTIDES; MUTATIONS; ANTICODON	The nonsense codon suppression method for unnatural amino acid incorporation has been applied to intact Cells and combined with electrophysiological analysis to probe structure-function relations in the nicotinic acetylcholine receptor, Functional receptors were expressed in Xenopus oocytes when tyrosine and phenylalanine derivatives were incorporated at positions 93, 190, and 198 in the binding site of the a subunit, Subtle changes in the structure of an individual side chain produced readily detectable changes in the function of this large channel protein, At each position, distinct features of side chain structure dominated the dose-response relation, probably by governing the agonist-receptor binding.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT CHEM, BERKELEY, CA 94720 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Berkeley	NOWAK, MW (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.		Thorson, Jon S/L-3696-2013	Thorson, Jon S/0000-0002-7148-0721; Nowak, Mark/0000-0001-5097-2682; Silverman, Scott/0000-0001-8166-3460				ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ADAMS PR, 1981, J MEMBRANE BIOL, V58, P161, DOI 10.1007/BF01870902; AYLWIN ML, 1994, MOL PHARMACOL, V46, P1149; BAIN JD, 1989, J AM CHEM SOC, V111, P8013, DOI 10.1021/ja00202a052; BIENZ M, 1980, NUCLEIC ACIDS RES, V8, P5169, DOI 10.1093/nar/8.22.5169; CACCHI S, 1992, TETRAHEDRON LETT, V33, P3939, DOI 10.1016/S0040-4039(00)74824-6; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; ELLMAN JA, 1992, METHOD ENZYMOL, V202, P301; England T E, 1980, Methods Enzymol, V65, P65; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Hammett LP, 1937, J AM CHEM SOC, V59, P96, DOI 10.1021/ja01280a022; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LEVITT LS, 1976, PROG PHYS ORG CHEM, V12, P119; LIN SX, 1984, BIOCHEMISTRY-US, V23, P4109, DOI 10.1021/bi00313a015; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; NAZARENKO IA, 1992, NUCLEIC ACIDS RES, V20, P475, DOI 10.1093/nar/20.3.475; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAMPSON JR, 1992, BIOCHEMISTRY-US, V31, P4161, DOI 10.1021/bi00132a002; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SINE SM, 1994, J BIOL CHEM, V269, P8808; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THORSON JS, IN PRESS J AM CHEM S; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; Topsom, 1976, PROG PHYS ORG CHEM, V12, P1, DOI DOI 10.1002/9780470171912.CHL; Unger S.H., 1976, PROG PHYS ORG CHEM, V12, P91, DOI 10.1002/9780470171912.ch4; URRY DW, 1993, J AM CHEM SOC, V115, P7509, DOI 10.1021/ja00069a063; YARUS M, 1982, SCIENCE, V218, P646, DOI 10.1126/science.6753149; YOSHII K, 1987, J GEN PHYSIOL, V90, P553, DOI 10.1085/jgp.90.4.553	42	209	276	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					439	442		10.1126/science.7716551	http://dx.doi.org/10.1126/science.7716551			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716551				2022-12-01	WOS:A1995QU57200047
J	ORNITZ, DM; HERR, AB; NILSSON, M; WESTMAN, J; SVAHN, CM; WAKSMAN, G				ORNITZ, DM; HERR, AB; NILSSON, M; WESTMAN, J; SVAHN, CM; WAKSMAN, G			FGF BINDING AND FGF RECEPTOR ACTIVATION BY SYNTHETIC HEPARAN-DERIVED DISACCHARIDES AND TRISACCHARIDES	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; 3-DIMENSIONAL STRUCTURE; SULFATE; REFINEMENT; DOMAINS; CELLS	Fibroblast growth factors (FGFs) require a polysaccharide cofactor, heparin or heparan sulfate (HS), for receptor binding and activation. To probe the molecular mechanism by which heparin or HS (heparin/HS) activates FGF, small nonsulfated oligosaccharides found within heparin/HS were assayed for activity, These synthetic and isomerically pure compounds can activate the FGF signaling pathway. The crystal structures of complexes between FGF and these heparin/HS oligosaccharides reveal several binding sites on FGF and constrain possible mechanisms by which heparin/HS can activate the FGF receptor. These studies establish a framework for the molecular design of compounds capable of modulating FGF activity.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; PHARMACIA AB, DEPT ORGAN CHEM, S-11287 STOCKHOLM, SWEDEN	Washington University (WUSTL); Pfizer; Pharmacia Corporation	ORNITZ, DM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA.		Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399; Ornitz, David/0000-0003-1592-7629	NCI NIH HHS [CA60673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIEZER D, 1994, J BIOL CHEM, V269, P114; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CASU B, 1989, ANN NY ACAD SCI, V556, P1; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; GLABE CG, 1983, ANAL BIOCHEM, V130, P287, DOI 10.1016/0003-2697(83)90590-0; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HEATH WF, 1991, BIOCHEMISTRY-US, V30, P5608, DOI 10.1021/bi00236a039; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSSMANN MG, 1972, INT SCI REV SERIES, V13; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SVAHN C, UNPUB; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WESTMAN J, 1995, J CARBOHYD CHEM, V14, P95, DOI 10.1080/07328309508006439; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	37	269	288	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	1995	268	5209					432	436		10.1126/science.7536345	http://dx.doi.org/10.1126/science.7536345			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7536345				2022-12-01	WOS:A1995QU57200045
J	PAPAVASILIOU, F; MISULOVIN, Z; SUH, HK; NUSSENZWEIG, MC				PAPAVASILIOU, F; MISULOVIN, Z; SUH, HK; NUSSENZWEIG, MC			THE ROLE OF IG-BETA IN PRECURSOR B-CELL TRANSITION AND ALLELIC EXCLUSION	SCIENCE			English	Article							ANTIGEN RECEPTOR COMPLEX; T-CELL; TRANSGENIC MICE; LYMPHOCYTE-B; LIGHT-CHAIN; PRE-B; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; GENE REARRANGEMENT; IMMUNOGLOBULIN-MU	Lymphocytes express multicomponent receptor complexes that mediate diverse antigen-dependent and antigen-independent responses. Despite the central role of antigen-independent events in B cell development, little is known about the mechanisms by which they are initiated. The association between the membrane immunoglobulin (Ig) M heavy chain (m mu) and the Ig alpha-Ig beta heterodimer is now shown to be essential in inducing both the transition from progenitor to precursor B cells and subsequent allelic exclusion in transgenic mice. The cytoplasmic domain of Ig beta is sufficient to induce these early antigen-independent events by a mechanism that requires conserved tyrosine residues in this protein.	ROCKEFELLER UNIV,MOLEC IMMUNOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University			Nussenzweig, Michel/AAE-7292-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037526, R29AI033890, R01AI033890, R01AI037526] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37526, AI33890] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; IGLESIAS A, 1993, EUR J IMMUNOL, V23, P2622, DOI 10.1002/eji.1830231036; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; LOVE PJ, 1994, J EXP MED, V180, P1485; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MATSUO T, 1993, J IMMUNOL, V150, P3766; METZGER H, 1992, J IMMUNOL, V149, P1477; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MITCHELL RN, 1991, J BIOL CHEM, V266, P8856; MOMBAERTS P, 1992, CELL, V66, P869; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PFEFFER K, 1994, ANNU REV IMMUNOL, V12, P367, DOI 10.1146/annurev.immunol.12.1.367; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1994, CURR OPIN IMMUNOL, V12, P196; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; SHINKAI Y, 1992, CELL, V66, P855; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WEGNER AMK, 1992, CELL, V68, P83; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	52	123	124	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					408	411		10.1126/science.7716544	http://dx.doi.org/10.1126/science.7716544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716544				2022-12-01	WOS:A1995QU57200037
J	PHILLIPS, JH; GUMPERZ, JE; PARHAM, P; LANIER, LL				PHILLIPS, JH; GUMPERZ, JE; PARHAM, P; LANIER, LL			SUPERANTIGEN-DEPENDENT, CELL-MEDIATED CYTOTOXICITY INHIBITED BY MHC CLASS-I RECEPTORS ON T-LYMPHOCYTES	SCIENCE			English	Article							NATURAL-KILLER-CELLS; ENTEROTOXIN-B; NK CLONES; SPECIFICITY; EXPRESSION; SUSCEPTIBILITY; STIMULATION; PROTECTION; COMPLEX; ALLELES	Bacterial superantigens bind with high affinity to major histocompatibility complex (MHC) class II antigens on antigen-presenting cells and with T cell antigen receptor (TCR) beta chains on T lymphocytes,which results in the T cell activation responsible for toxic shock syndrome and food poisoning, Many cytotoxic T lymphocyte (CTL) clones were shown to have receptors for human leukocyte antigen (HLA) class I molecules that inhibited superantigen-induced cytotoxicity against appropriate class I-bearing target cells. One type of inhibitory receptor, NKB1, was present on CD4(+) and CD8(+)TCR alpha beta(+) CTL clones and blocked the killing of staphylococcal enterotoxin B (SEB)-coated targets bearing certain polymorphic HLA-B molecules. Expression of HLA-A, -B, and -C molecules on the SEE-coated targets also protected against cytolysis mediated by many NKB1-negative T cell clones, suggesting the presence of additional inhibitory MHC class I receptors. These HLA class I receptors may limit tissue destruction and possibly autoimmunity caused by activated T lymphocytes.	STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University; Stanford University	PHILLIPS, JH (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT HUMAN IMMUNOL,901 CALIF AVE,PALO ALTO,CA 94304, USA.		Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952	NIAID NIH HHS [AI22039] Funding Source: Medline; NIGMS NIH HHS [GM07276] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022039] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; HEWITT CRA, 1992, J EXP MED, V175, P1493, DOI 10.1084/jem.175.6.1493; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; LANIER LL, 1983, J IMMUNOL, V131, P1789; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; MINASI LAE, 1993, J EXP MED, V177, P1451, DOI 10.1084/jem.177.5.1451; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; Phillips J. A., UNPUB; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SHIMIZU Y, 1989, EUR J IMMUNOL, V19, P447, DOI 10.1002/eji.1830190306; STORKUS WJ, 1989, P NATL ACAD SCI USA, V86, P2361, DOI 10.1073/pnas.86.7.2361; SUNDSTEDT A, 1994, IMMUNOLOGY, V82, P117; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	27	310	314	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					403	405		10.1126/science.7716542	http://dx.doi.org/10.1126/science.7716542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716542				2022-12-01	WOS:A1995QU57200035
J	RADICELLA, JP; PARK, PU; FOX, MS				RADICELLA, JP; PARK, PU; FOX, MS			ADAPTIVE MUTATION IN ESCHERICHIA-COLI - A ROLE FOR CONJUGATION	SCIENCE			English	Article							DIRECTED MUTATION; MUTANTS; ORIGIN	When subjected to selective conditions that impose starvation, a bacterial population can accumulate mutations, called adaptive, that allow colony formation. Here, the reversion of a lac allele under selective conditions, in a model system using Escherichia coli with the lac mutation on an F' plasmid, was shown to require the conjugational capacity of the plasmid. Reversion associated with transfer was shown, and when the same lac allele was chromosomal, reversion to Lac(+) was 25 to 50 times less frequent. Postplating reversion was 25 times less when mating was inhibited by the presence of detergent. Mutability associated with conjugation provides new ways of thinking about the origin of adaptive mutations.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Radicella, J. Pablo/AAU-3178-2020	Radicella, J. Pablo/0000-0002-8807-7226; Park, Peter U./0000-0002-6892-3018	PHS HHS [A105388] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHTMAN M, 1978, J BACTERIOL, V135, P1053, DOI 10.1128/JB.135.3.1053-1061.1978; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CHARLESWORTH D, 1988, NATURE, V336, P525, DOI 10.1038/336525a0; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FOSTER PL, 1994, GENETICS, V138, P253; FOSTER PL, IN PRESS P NATL ACAD; FOX M, 1993, MOL GEN GENET, V240, P355, DOI 10.1007/BF00280386; GALITSKI T, 1995, SCIENCE, V268, P421, DOI 10.1126/science.7716546; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HAYES W, 1952, NATURE, V169, P118, DOI 10.1038/169118b0; LEDERBERG J, 1952, GENETICS, V37, P720; LEDERBERG J, 1952, J BACTERIOL, V63, P399, DOI 10.1128/JB.63.3.399-406.1952; LENSKI RE, 1993, SCIENCE, V259, P188, DOI 10.1126/science.7678468; LENSKI RE, 1993, SCIENCE, V260, P1222, DOI 10.1126/science.260.5112.1222; LENSKI RE, 1988, NATURE, V336, P123; LICHTEN M, 1983, GENETICS, V103, P5; Luria SE, 1943, GENETICS, V28, P491; Miller J. H., 1972, EXPT MOL GENETICS, P431; NOVICK A, 1950, P NATL ACAD SCI USA, V36, P708, DOI 10.1073/pnas.36.12.708; PARTRIDGE L, 1988, NATURE, V336, P22, DOI 10.1038/336022a0; PETERS JE, 1995, J BACTERIOL, V177, P847, DOI 10.1128/jb.177.3.847-850.1995; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; RYAN FJ, 1959, J GEN MICROBIOL, V21, P530, DOI 10.1099/00221287-21-3-530; RYAN FJ, 1961, Z VEREBUNGSL, V92, P38, DOI 10.1007/BF01854099; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; SINGER M, 1989, MICROBIOL REV, V53, P1; STAHL FW, 1992, GENETICS, V132, P865; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEWART FM, 1990, GENETICS, V124, P175; SYMONDS N, 1989, NATURE, V337, P119, DOI 10.1038/337119a0; TESSMAN I, 1988, NATURE, V336, P527, DOI 10.1038/336527b0	34	102	105	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					418	420		10.1126/science.7716545	http://dx.doi.org/10.1126/science.7716545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716545				2022-12-01	WOS:A1995QU57200040
J	SANGUINETTI, MC; JIANG, CG; CURRAN, ME; KEATING, MT				SANGUINETTI, MC; JIANG, CG; CURRAN, ME; KEATING, MT			A MECHANISTIC LINK BETWEEN AN INHERITED AND AN ACQUIRED CARDIAC-ARRHYTHMIA - HERG ENCODES THE I-KR POTASSIUM CHANNEL	CELL			English	Article							PIG VENTRICULAR MYOCYTES; III ANTIARRHYTHMIC AGENT; RECTIFIER K+-CURRENT; DELAYED RECTIFIER; CELLS; KINETICS; BLOCK; PROLONGATION; MODULATION; DOFETILIDE	Mutations in HERG cause an inherited cardiac arrhythmia, long QT syndrome (LQT), To define the function of HERG, we expressed the protein in Xenopus oocytes. The biophysical properties of expressed HERG are nearly identical to the rapidly activating delayed rectifier K+ current (I-Kr) in cardiac myocytes. HERG current is K+ selective, declines with depolarizations above 0 mV, is activated by extracellular K+, and is blocked by lanthanum. Interestingly, HERG current is not blocked by drugs that specifically block I-Kr in cardiac myocytes, These data indicate that HERG proteins form I-Kr channels, but that an additional subunit may be required for drug sensitivity. Since block of I-Kr is a known mechanism for drug-induced cardiac;arrhythmias, the finding that HERG encodes I-Kr channels provides a mechanistic link between certain forms of inherited and acquired LQT.	UNIV UTAH,HLTH SCI CTR,DIV CARDIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	SANGUINETTI, MC (corresponding author), UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112, USA.		Sanguinetti, Michael/AAN-2615-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052338] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL48074, P50-HL 52338-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BALSER JR, 1990, J GEN PHYSIOL, V96, P835, DOI 10.1085/jgp.96.4.835; BLUMENTHAL EM, 1992, J NEUROSCI, V12, P290; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; CHINN K, 1993, J PHARMACOL EXP THER, V264, P553; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; CURRY P, 1976, LANCET, V2, P231; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FOLLMER CH, 1992, AM J PHYSIOL, V262, pC75, DOI 10.1152/ajpcell.1992.262.1.C75; GINTANT GA, 1992, HEART CARDIOVASCULAR, P1121; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; LYNCH JJ, 1994, J PHARMACOL EXP THER, V269, P541; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; ROSEN DM, 1988, CONTROL CARDIAC ARRH, P559; SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77; SANGUINETTI MC, 1992, PFLUG ARCH EUR J PHY, V420, P180, DOI 10.1007/BF00374988; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; SANGUINETTI MC, 1990, AM J PHYSIOL, V259, pH1881, DOI 10.1152/ajpheart.1990.259.6.H1881; SCAMPS F, 1989, AM J PHYSIOL, V257, pC1086, DOI 10.1152/ajpcell.1989.257.6.C1086; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; SURAWICZ B, 1989, J AM COLL CARDIOL, V14, P172, DOI 10.1016/0735-1097(89)90069-7; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870	32	2000	2088	3	114	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					299	307		10.1016/0092-8674(95)90340-2	http://dx.doi.org/10.1016/0092-8674(95)90340-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736582	Bronze			2022-12-01	WOS:A1995QV41000019
J	SATO, T; IRIE, S; KITADA, S; REED, JC				SATO, T; IRIE, S; KITADA, S; REED, JC			FAP-1 - A PROTEIN-TYROSINE-PHOSPHATASE THAT ASSOCIATES WITH FAS	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; APOPTOSIS; ANTIGEN; EXPRESSION; INTERACTS; BCL-2; CELLS	Fas is a cell surface receptor that controls a poorly understood signal transduction pathway that leads to cell death by means of apoptosis. A protein tyrosine phosphatase, FAP-1, capable of interacting with the cytosolic domain of Fas, was identified. The carboxyl terminal 15 amino acids of Fas are necessary and sufficient for interaction with FAP-1. FAP-1 expression is highest in tissues and cell lines that are relatively resistant to Fas-mediated cytotoxicity. Gene transfer-mediated elevations in FAP-1 partially abolished Fas-induced apoptosis in a T cell line. These findings are consistent with an inhibitory effect of FAP-1 on Fas signal transduction.	LA JOLLA CANC RES FDN,ONCOGENE & TUMOR SUPPRESSOR GENE PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; GORCZYCA W, 1993, CANCER RES, V53, P1945; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO TJ, UNPUB; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	25	684	724	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					411	415		10.1126/science.7536343	http://dx.doi.org/10.1126/science.7536343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7536343				2022-12-01	WOS:A1995QU57200038
J	STJOHNSTON, D				STJOHNSTON, D			THE INTRACELLULAR-LOCALIZATION OF MESSENGER-RNAS	CELL			English	Review							XENOPUS-OOCYTES; DROSOPHILA OOGENESIS; BICOID RNA; POSTERIOR DETERMINANT; INSITU HYBRIDIZATION; BINDING PROTEIN; VEGETAL CORTEX; ANTERIOR POLE; GERM PLASM; TGF-BETA		UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE CB2 1QR, ENGLAND	University of Cambridge	STJOHNSTON, D (corresponding author), UNIV CAMBRIDGE, INST CANC RES CAMPAIGN, WELLCOME TRUST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		St Johnston, Daniel/C-9568-2009	St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Ainger K., 1993, Molecular Biology of the Cell, V4, p421A; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; BASSELL GJ, 1994, NEURON, V12, P571, DOI 10.1016/0896-6273(94)90213-5; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BRUCKENSTEIN DA, 1990, NEURON, V5, P809, DOI 10.1016/0896-6273(90)90340-L; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DAVIS I, 1993, COLD SPRING HARB SYM, V58, P793, DOI 10.1101/SQB.1993.058.01.086; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; DING D, 1993, MOL CELL BIOL, V13, P3773, DOI 10.1128/MCB.13.6.3773; DING D, 1993, BIOESSAYS, V15, P651, DOI 10.1002/bies.950151004; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; Driever Wolfgang, 1993, P301; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; ELINSON RP, 1993, DEV BIOL, V160, P554, DOI 10.1006/dbio.1993.1329; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GERGEN JP, 1988, GENE DEV, V2, P1179, DOI 10.1101/gad.2.9.1179; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JEFFERY WR, 1983, DEV BIOL, V99, P408, DOI 10.1016/0012-1606(83)90290-7; JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E; JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; KU M, 1993, DEVELOPMENT, V119, P1161; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LITMAN P, 1994, NEURON, V13, P1463, DOI 10.1016/0896-6273(94)90432-4; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MORRIS EJ, 1994, J CELL SCI, V107, P377; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; RAFF JW, 1990, DEVELOPMENT, V110, P1249; RAN B, 1994, DEVELOPMENT, V120, P1233; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHWARTZ SP, 1992, P NATL ACAD SCI USA, V89, P11895, DOI 10.1073/pnas.89.24.11895; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TORRE ER, 1992, J NEUROSCI, V12, P762; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WILSON IA, 1995, IN PRESS BIOCH J; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	88	467	473	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					161	170		10.1016/0092-8674(95)90324-0	http://dx.doi.org/10.1016/0092-8674(95)90324-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736568	Bronze			2022-12-01	WOS:A1995QV41000003
J	THOMAS, PM; COTE, GJ; WOHLLK, N; HADDAD, B; MATHEW, PM; RABL, W; AGUILARBRYAN, L; GAGEL, RF; BRYAN, J				THOMAS, PM; COTE, GJ; WOHLLK, N; HADDAD, B; MATHEW, PM; RABL, W; AGUILARBRYAN, L; GAGEL, RF; BRYAN, J			MUTATIONS IN THE SULFONYLUREA RECEPTOR GENE IN FAMILIAL PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY	SCIENCE			English	Article							CYSTIC-FIBROSIS; POLYMORPHISM; CHANNELS; LINKAGE; MAP; DNA	Familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI), an autosomal recessive disorder characterized by unregulated insulin secretion, is linked to chromosome 11p14-15.1. The newly cloned high-affinity sulfonylurea receptor (SUR) gene, a regulator of insulin secretion, was mapped to 11p15.1 by means of fluorescence in situ hybridization, Two separate SUR gene splice site mutations, which segregated with disease phenotype, were identified in affected individuals from nine different families, Both mutations resulted in aberrant processing of the RNA sequence and disruption of the putative second nucleotide binding domain of the SUR protein. Abnormal insulin secretion in PHHI appears to be caused by mutations in the SUR gene.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; ARAMCO,DHAHRAN HLTH CTR,DIV SPECIALTY PEDIAT,DHAHRAN 31311,SAUDI ARABIA; TECH UNIV MUNICH,KINDERKLIN,D-80804 MUNICH,GERMANY; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Saudi Aramco; Technical University of Munich; Baylor College of Medicine; Baylor College of Medicine	THOMAS, PM (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED SPECIALTIES,ENDOCRINOL SECT,BOX 15,HOUSTON,TX 77030, USA.			Wohllk, Nelson/0000-0002-7354-6894	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038146, R01DK044311] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38146, DK44311] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, pCH6; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; GRANDCHAMP B, 1989, NUCLEIC ACIDS RES, V17, P6637, DOI 10.1093/nar/17.16.6637; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAISER N, 1990, DIABETOLOGIA, V33, P482, DOI 10.1007/BF00405110; KHAN RN, 1993, P ROY SOC B-BIOL SCI, V253, P225, DOI 10.1098/rspb.1993.0107; KHORANA S, 1994, NUCLEIC ACIDS RES, V22, P3425, DOI 10.1093/nar/22.16.3425; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LOU H, 1994, MOL ENDOCRINOL, V8, P1618, DOI 10.1210/me.8.12.1618; MATHEW PM, 1988, CLIN PEDIATR, V27, P148, DOI 10.1177/000992288802700307; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MATSUTANI A, 1992, GENOMICS, V13, P495, DOI 10.1016/0888-7543(92)90116-A; PANTEN U, 1992, HORM METAB RES, V24, P549, DOI 10.1055/s-2007-1003387; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; STOFFEL M, 1993, DIABETES, V42, P1215, DOI 10.2337/diabetes.42.8.1215; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; THOMAS P, UNPUB; THOMAS PM, 1995, AM J HUM GENET, V56, P416; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WEIL D, 1989, J BIOL CHEM, V264, P16804	28	651	676	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					426	429		10.1126/science.7716548	http://dx.doi.org/10.1126/science.7716548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716548				2022-12-01	WOS:A1995QU57200043
J	TUGENDREICH, S; TOMKIEL, J; EARNSHAW, W; HIETER, P				TUGENDREICH, S; TOMKIEL, J; EARNSHAW, W; HIETER, P			CDC27HS COLOCALIZES WITH CDC16HS TO THE CENTROSOME AND MITOTIC SPINDLE AND IS ESSENTIAL FOR THE METAPHASE TO ANAPHASE TRANSITION	CELL			English	Article							EXPRESSED SEQUENCE TAGS; ASPERGILLUS-NIDULANS; SNAP HELIX; MITOSIS; FAMILY; IDENTIFICATION; PROTEINS; ENCODES; GENES; MOTIF	have isolated cDNAs and raised antibodies corresponding to the human homologs of the S. cerevisiae CDC27 and CDC16 proteins, which are tetratrico peptide repeat (TPR)-containing proteins essential for mitosis in budding yeast. We find that the CDC27Hs and CDC16Hs proteins colocalize to the centrosome at all stages of the mammalian cell circle, and to the mitotic spindle. Injection of affinity-purified anti-CDC27Hs antibodies into logarithmically growing HeLa cells causes a highly reproducible cell cycle arrest in metaphase with apparently normal spindle structure. We conclude that CDC27 and CDC16 are evolutionarily conserved components of the centrosome and mitotic spindle that control the onset of postmetaphase events during mitosis.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Johns Hopkins University	TUGENDREICH, S (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1974, SCIENCE, V183, P48; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; IRNIGER S, 1995, CELL, V81; JORDAN MA, 1992, J CELL SCI, V102, P401; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; ODONNELL KL, 1991, J CELL SCI, V99, P711; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; WEINERT TA, 1993, GENETICS, V134, P63; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X	30	316	322	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					261	268		10.1016/0092-8674(95)90336-4	http://dx.doi.org/10.1016/0092-8674(95)90336-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736578	Bronze			2022-12-01	WOS:A1995QV41000015
J	UTSCHIG, LM; BRYSON, JW; OHALLORAN, TV				UTSCHIG, LM; BRYSON, JW; OHALLORAN, TV			HG-199 NMR OF THE METAL RECEPTOR-SITE IN MERR AND ITS PROTEIN-DNA COMPLEX	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SOLID-STATE HG-199; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; METALLOREGULATORY PROTEIN; POPLAR PLASTOCYANIN; BIOSENSOR MERR; BINDING DOMAIN; THIOLATE; SPECTROSCOPY	Structural insights have been provided by mercury-199 nuclear magnetic resonance (NMR) into the metal receptor site of the MerR metalloregulatory protein alone and in a complex with the regulatory target, DNA, The one- and two-dimensional NMR data are consistent with a trigonal planar Hg-thiolate coordination environment consisting only of Cys side chains and resolve structural aspects of both metal ion recognition and the allosteric mechanism. These studies establish Hg-199 NMR techniques as useful probes of the metal coordination environment of regulatory proteins, copper enzymes, and zinc transcription factor complexes as large as 50 kilodaltons.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELLULAR BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA	Northwestern University; Northwestern University			O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NIGMS NIH HHS [GM-08061, GM-38784, R01 GM038784, GM-45972] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784, R37GM038784, R01GM045972, R29GM038784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1995, NATURE, V374, P371; ARMITAGE IM, 1976, J AM CHEM SOC, V98, P5710, DOI 10.1021/ja00434a058; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BERTINI I, 1994, BIOINORG CHEM, P43; BLAKE PR, 1994, NEW J CHEM, V18, P387; BRYSON JW, UNPUB; CARSON GK, 1982, INORG CHIM A-BIOINOR, V66, P157, DOI 10.1016/S0020-1693(00)85806-5; CHURCH WB, 1986, J BIOL CHEM, V261, P234; COLEMAN JE, 1993, METHOD ENZYMOL, V227, P16; ELLIS PD, 1983, SCIENCE, V221, P1141, DOI 10.1126/science.221.4616.1141; FALCHUK KH, 1977, CHEM MERCURY, P260; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; FREY MH, 1985, J AM CHEM SOC, V107, P6847, DOI 10.1021/ja00310a017; GARRETT TPJ, 1984, J BIOL CHEM, V259, P2822; GOVINDASWAMY N, 1992, INORG CHEM, V31, P5343, DOI 10.1021/ic00052a001; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KUBICKI MM, 1981, J ORGANOMET CHEM, V219, P329, DOI 10.1016/S0022-328X(00)90018-4; Lippard S. J., 1994, PRINCIPLES BIOINORGA; LIVE DH, 1985, J AM CHEM SOC, V107, P3043, DOI 10.1021/ja00297a008; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MOORE JM, 1991, J MOL BIOL, V221, P533, DOI 10.1016/0022-2836(91)80071-2; NATAN MJ, 1990, J AM CHEM SOC, V112, P3255, DOI 10.1021/ja00164a080; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; OTVOS JD, 1985, J MAGN RESON, V61, P579, DOI 10.1016/0022-2364(85)90202-1; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; RALSTON DM, 1990, P NATL ACAD SCI USA, V87, P3846, DOI 10.1073/pnas.87.10.3846; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SANTOS RA, 1991, J AM CHEM SOC, V113, P469, DOI 10.1021/ja00002a014; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SUDMEIER JL, 1977, J AM CHEM SOC, V99, P7732, DOI 10.1021/ja00465a067; SUMMERS MF, 1988, COORDIN CHEM REV, V86, P43, DOI 10.1016/0010-8545(88)85012-4; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; UTSCHIG LM, 1993, METHOD ENZYMOL, V226, P71, DOI 10.1016/0076-6879(93)26006-U; UTSCHIG LM, UNPUB; UTSCHIG LM, IN PRESS INORG CHEM; WATTON SP, 1990, J AM CHEM SOC, V112, P2824, DOI 10.1021/ja00163a067; Wrackmeyer B., 1992, ANNU REP NMR SPECTRO, V24, P267, DOI [10.1016/S0066-4103(08)60200-8., DOI 10.1016/S0066-4103(08)60200-8]; WRIGHT JG, 1990, PROG INORG CHEM, V38, P323; WRIGHT JG, 1990, J AM CHEM SOC, V112, P2434, DOI 10.1021/ja00162a062	43	147	149	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	1995	268	5209					380	385		10.1126/science.7716541	http://dx.doi.org/10.1126/science.7716541			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716541				2022-12-01	WOS:A1995QU57200028
J	WATT, PM; LOUIS, EJ; BORTS, RH; HICKSON, ID				WATT, PM; LOUIS, EJ; BORTS, RH; HICKSON, ID			SGS1 - A EUKARYOTIC HOMOLOG OF ESCHERICHIA-COLI RECQ THAT INTERACTS WITH TOPOISOMERASE-II IN-VIVO AND IS REQUIRED FOR FAITHFUL CHROMOSOME SEGREGATION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; PROTEIN; MITOSIS; MEIOSIS; YEAST; MUTANTS; NONDISJUNCTION; RECOMBINATION; TRANSMISSION	Topoisomerase II (topo II) catalyzes the decatenation of interlinked DNA molecules and is essential for chromosome segregation. To test the hypothesis that the noncatalytic C-terminal domain of topo II is necessary for mediating interactions with other proteins required for chromosome segregation, we used a two-hybrid cloning strategy to identify proteins that interact with S. cerevisiae topo II in vivo. One protein identified (Sgs1p) is structurally related to E. coli RecQ protein and contains helicase signature! motifs. Strains lacking Sgs1p exhibit elevated levels of chromosome missegregation during both mitotic and meiotic division. We propose a model to account for the interaction of a topoisomerase and a helicase in the faithful segregation of newly replicated eukaryotic chromosomes.	UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, YEAST GENET GRP, OXFORD OX3 9DU, ENGLAND	University of Oxford	WATT, PM (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND.		Hickson, Ian/AAJ-7548-2020; Louis, Edward/B-7920-2008	Louis, Edward/0000-0003-1157-3608; Hickson, Ian/0000-0002-0583-566X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTWELL LH, 1985, GENETICS, V110, P381; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; KAMIGUCHI Y, 1993, HUM GENET, V90, P533; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LOUIS EJ, 1989, GENETICS, V123, P81; LUISIDELUCA C, 1989, GENETICS, V122, P269; Luria SE, 1943, GENETICS, V28, P491; MCCUSKER JH, 1988, GENETICS, V119, P303; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cb.01.110185.001445; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROSE D, 1993, MOL CELL BIOL, V13, P3445, DOI 10.1128/MCB.13.6.3445; SAMEJIMA I, 1993, J CELL SCI, V105, P135; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPENCER F, 1990, GENETICS, V124, P237; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WANG JC, 1991, J BIOL CHEM, V266, P6659; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	38	375	379	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					253	260		10.1016/0092-8674(95)90335-6	http://dx.doi.org/10.1016/0092-8674(95)90335-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736577	Bronze			2022-12-01	WOS:A1995QV41000014
J	ALKEMA, MJ; VANDERLUGT, NMT; BOBELDIJK, RC; BERNS, A; VANLOHUIZEN, M				ALKEMA, MJ; VANDERLUGT, NMT; BOBELDIJK, RC; BERNS, A; VANLOHUIZEN, M			TRANSFORMATION OF AXIAL SKELETON DUE TO OVEREXPRESSION OF BMI-1 IN TRANSGENIC MICE	NATURE			English	Article							POSITION-EFFECT VARIEGATION; POSTERIOR SEX COMBS; NULL MUTATION; RETINOIC ACID; DROSOPHILA; GENE; CHROMATIN; MOUSE; MYC; LYMPHOMAGENESIS	THE oncogene bmi-1, which was originally found to be involved in B- and T-cell lymphoma formation(1-3) encodes a protein with a domain of homology to the Drosophila protein Posterior sex combs (Psc) and its relative Suppressor 2 of Zeste (Su(z)2) (refs 4 and 5), Psc is a member of the Polycomb-group gene family, which is required to maintain the repression of homeotic genes that regulate the identities of Drosophila segments(6). The possibility that bmi-1 may play a similar role in vertebrates was suggested by our previous finding(7) that mice lacking the bmi-1 gene show posterior transformations of the axial skeleton. Here we report that transgenic mice overexpressing Bmi-1 protein show the opposite phenotype, namely a dose-dependent anterior transformation of vertebral identity, The anterior expression boundary of the Hoxc-5 gene is shifted in the posterior direction, indicating that Bmi-1 is involved in the repression of Hox genes. We propose that Bmi-1 is a member of a vertebrate Polycomb complex that regulates segmental identity by repressing Hox genes throughout development.	NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,DEPT BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; University of Amsterdam								ADLER PN, 1991, DEV GENET, V12, P349, DOI 10.1002/dvg.1020120504; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FRANKE A, 1993, EMBO J, V12, P1513; GAUNT SJ, 1990, DEVELOPMENT, V109, P329; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRESS C, 1990, DEVELOPMENT, V109, P775; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVY LS, 1993, ONCOGENE, V8, P1833; LOCKE J, 1988, GENETICS, V120, P181; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MARTIN EC, 1993, DEVELOPMENT, V117, P641; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PELLEGRI F, 1994, GENETICS, V136, P1341; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RASTELLI L, 1992, EMBO J, V11, P2941; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SHARP EJ, 1994, DEV BIOL, V161, P379, DOI 10.1006/dbio.1994.1039; SIMON J, 1992, DEVELOPMENT, V114, P493; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0	28	148	152	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					724	727		10.1038/374724a0	http://dx.doi.org/10.1038/374724a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715727				2022-12-01	WOS:A1995QU30400050
J	ANTSON, AA; OTRIDGE, J; BRZOZOWSKI, AM; DODSON, EJ; DODSON, GG; WILSON, KS; SMITH, TM; YANG, M; KURECKI, T; GOLLNICK, P				ANTSON, AA; OTRIDGE, J; BRZOZOWSKI, AM; DODSON, EJ; DODSON, GG; WILSON, KS; SMITH, TM; YANG, M; KURECKI, T; GOLLNICK, P			THE STRUCTURE OF TRP RNA-BINDING ATTENUATION PROTEIN	NATURE			English	Article							BACILLUS-SUBTILIS; TRANSCRIPTION ATTENUATION; ESCHERICHIA-COLI; OPERON; EXPRESSION; GENE; ANTITERMINATION; PROGRAM	The crystal structure of the trp RNA-binding attenuation protein of Bacillus subtilis solved at 1.8 Angstrom resolution reveals a novel structural arrangement in which the eleven subunits are stabilized through eleven intersubunit beta-sheets to form a beta-wheel with a large central hole. The nature of the binding of L-tryptophan in clefts between adjacent beta-sheets in the beta-wheel suggests that this binding induces conformational changes in the flexible residues 25-33 and 49-52. It is argued that upon binding, the messenger RNA target forms a matching circle in which eleven U/GAG repeats are bound to the surface of the protein ondecamer modified by the binding of L-tryptophan.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260; DESY,EUROPEAN MOLEC BIOL LAB,D-22603 HAMBURG,GERMANY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	ANTSON, AA (corresponding author), UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Antson, Alfred/N-2551-2016	Antson, Alfred/0000-0002-4533-3816; Wilson, Keith/0000-0002-3581-2194				AMZEL LM, 1979, JA REV BIOCH, V48, P967; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ANTSON AA, 1994, J MOL BIOL, V243, P1; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; HOFFMAN RJ, 1995, J BACTERIOL, V177, P839, DOI 10.1128/jb.177.3.839-842.1995; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JOZWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053, DOI 10.1073/pnas.89.11.5053; KLEYWEGT GJ, 1994, FIRST MAP FINAL MODE, P59; KONG XP, 1993, CELL, V69, P425; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUODA MI, 1988, J BACTERIOL, V170, P3080; KURODA MI, 1986, J BACTERIOL, V167, P792, DOI 10.1128/jb.167.3.792-798.1986; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OLDFIELD TJ, 1992, J MOL GRAPHICS, V10, P247, DOI 10.1016/0263-7855(92)80077-Q; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SHEVITZ RW, 1985, NATURE, V317, P782; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; TURNER RJ, 1994, J BACTERIOL, V176, P7211; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; [No title captured]	38	177	184	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					693	700		10.1038/374693a0	http://dx.doi.org/10.1038/374693a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715723				2022-12-01	WOS:A1995QU30400041
J	CHITTENDEN, T; HARRINGTON, EA; OCONNOR, R; FLEMINGTON, C; LUTZ, RJ; EVAN, GI; GUILD, BC				CHITTENDEN, T; HARRINGTON, EA; OCONNOR, R; FLEMINGTON, C; LUTZ, RJ; EVAN, GI; GUILD, BC			INDUCTION OF APOPTOSIS BY THE BCL-2 HOMOLOG BAK	NATURE			English	Article							PROGRAMMED CELL-DEATH; SEQUENCE SIMILARITY; GENE; PROTEINS	CELLS are eliminated in a variety of physiological settings by apoptosis, a genetically encoded process of cellular suicide(1,2). Apoptosis comprises an intrinsic cellular defence against tumorigenesis, which, when suppressed, may contribute to the development of malignancies(3). The bcl-2 oncogene, which is activated in follicular lymphomas, functions as a potent suppressor of apoptosis under diverse conditions(4). Here we describe the complementary DNA cloning and functional analysis of a new Bcl-2 homologue, Bak, which promotes cell death and counteracts the protection from apoptosis provided by Bcl-2. Moreover, enforced expression of Bak induces rapid and extensive apoptosis of serum-deprived fibroblasts. This raises the possibility that Bak is directly involved in activating the cell death machinery.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	CHITTENDEN, T (corresponding author), APOPTOSIS TECHNOL INC, 148 SIDNEY ST, CAMBRIDGE, MA 02139 USA.		O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; ELLIS RE, 1991, REV CELL BIOL, V7, P663; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	22	679	727	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					733	736		10.1038/374733a0	http://dx.doi.org/10.1038/374733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715730				2022-12-01	WOS:A1995QU30400053
J	DARCANGELO, G; MIAO, GG; CHEN, SC; SOARES, HD; MORGAN, JI; CURRAN, T				DARCANGELO, G; MIAO, GG; CHEN, SC; SOARES, HD; MORGAN, JI; CURRAN, T			A PROTEIN RELATED TO EXTRACELLULAR-MATRIX PROTEINS DELETED IN THE MOUSE MUTANT REELER	NATURE			English	Article							NEURAL CELL-ADHESION; GENE; MICE; CEREBELLUM; MUTATIONS; MOLECULES; ENCODES; BRAIN	THE autosomal recessive mouse mutation reeler(1-3) leads to impaired motor coordination, tremors and ataxia(4). Neurons in affected mice fail to reach their correct locations in the developing brain, disrupting the organization of the cerebellar and cerebral cortices and other laminated regions(5-8). Here we use a previously characterized reeler allele (rl(tg))(9) to clone a gene, reelin, deleted in two reeler alleles. Normal but not mutant mice express reelin in embryonic and postnatal neurons during periods of neuronal migration. The encoded protein resembles extracellular matrix proteins involved in cell adhesion. The reeler phenotype thus seems to reflect a failure of early events associated with brain lamination which are normally controlled by reelin.	HOFFMANN LA ROCHE INC, NEUROGENET PROGRAM, NUTLEY, NJ 07110 USA	Roche Holding	DARCANGELO, G (corresponding author), HOFFMANN LA ROCHE INC, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA.		Curran, Tom/C-1164-2008; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Morgan, James/N-8104-2018; Curran, Tom/F-5234-2018; Morgan, James/GRO-2905-2022	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Morgan, James/0000-0002-8920-1065; D'Arcangelo, Gabriella/0000-0003-1575-1010				BAR I, IN P0RESS GENOMICS; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; DERER P, 1983, J HIRNFORSCH, V24, P209; DERNONCOURT C, 1991, GENOMICS, V11, P1167, DOI 10.1016/0888-7543(91)90049-K; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FLAHERTY L, 1992, P NATL ACAD SCI USA, V89, P2859, DOI 10.1073/pnas.89.7.2859; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GODFRAIND C, 1988, DEV BRAIN RES, V42, P99, DOI 10.1016/0165-3806(88)90205-2; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1992, INT J DEV BIOL, V36, P101; GUENET JL, 1981, MOUSE NEWS LETT, V41; HAMBURGH M, 1963, DEV BIOL, V8, P165, DOI 10.1016/0012-1606(63)90040-X; HEIJNE GV, 1984, J MOL BIOL, V173, P243; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MARIANI J, 1977, PHILOS T R SOC B, V281, P1, DOI 10.1098/rstb.1977.0121; MIAO GG, 1994, P NATL ACAD SCI USA, V91, P11050, DOI 10.1073/pnas.91.23.11050; MISCHEL PS, 1995, J NEUROPATH EXP NEUR, V54, P137, DOI 10.1097/00005072-199503000-00001; MONTGOMERY JC, IN PRESS MAMM GENOME; OGAWA, IN PRESS NEURONS; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; STANFIELD BB, 1979, J COMP NEUROL, V185, P461, DOI 10.1002/cne.901850304; TERASHIMA T, 1986, J COMP NEUROL, V252, P264, DOI 10.1002/cne.902520209; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	30	1410	1437	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					719	723		10.1038/374719a0	http://dx.doi.org/10.1038/374719a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715726				2022-12-01	WOS:A1995QU30400049
J	FARROW, SN; WHITE, JHM; MARTINOU, I; RAVEN, T; PUN, KT; GRINHAM, CJ; MARTINOU, JC; BROWN, R				FARROW, SN; WHITE, JHM; MARTINOU, I; RAVEN, T; PUN, KT; GRINHAM, CJ; MARTINOU, JC; BROWN, R			CLONING OF A BCL-2 HOMOLOG BY INTERACTION WITH ADENOVIRUS E1B 19K	NATURE			English	Article							PROGRAMMED CELL-DEATH; HUMAN B-CELLS; APOPTOSIS; PROTEIN; 19-KDA; GENE	NUMBER Of DNA viruses carry apoptosis-inhibiting genes which enable the virus to escape from the host reponse(1-5). The adenovirus E1B 19K protein can inhibit apoptosis induced by E1A, tumour-necrosis factor-alpha, FAS antigen and nerve growth factor deprivation(6-9). The molecular basis of this inhibition remains poorly understood, but the fact that protection is seen in the absence of other viral proteins suggests that E1B 19K targets cellular proteins. We report here the identification of three cellular proteins that bind E1B 19K, One of these is a new member of the bcl-2 family(10-16), which we have called bak (for bcl-2 homologous antagonist/killer). This protein, which is expressed in a wide variety of cell types, binds to E1B 19K and to the Bcl-2 homologue Bcl-x(L) (ref, 17) in yeast, In addition, overexpression of bak in sympathetic neurons deprived of nerve growth factor accelerates apoptosis and blocks the protective effect of co-injected E1B 19K.	GLAXO RES & DEV LTD,DEPT MOLEC VIROL,GREENFORD UB6 0HE,MIDDX,ENGLAND; GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline; GlaxoSmithKline				martinou, Jean-claude/0000-0002-9847-2051; Pun, Tao/0000-0001-5241-2187				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HASHIMOTO S, 1991, INT IMMUN, V343, P343; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	27	464	492	2	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					731	733		10.1038/374731a0	http://dx.doi.org/10.1038/374731a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715729				2022-12-01	WOS:A1995QU30400052
J	FIELDS, BA; GOLDBAUM, FA; YSERN, X; POLJAK, RJ; MARIUZZA, RA				FIELDS, BA; GOLDBAUM, FA; YSERN, X; POLJAK, RJ; MARIUZZA, RA			MOLECULAR-BASIS OF ANTIGEN MIMICRY BY AN ANTI-IDIOTOPE	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; IDIOTYPIC ANTIBODIES; COMPLEX; LYSOZYME; D1.3	IDIOTOPES are antigenic determinants, unique to an antibody or group of antibodies, defined by the reaction of anti-idiotopic antibodies with the antibodies bearing the idiotopes. The ensemble of idiotopes of an antibody constitutes its idiotype. Idiotypes are useful as markers to follow specific antibodies and clones of cells in immune responses and the inheritance of immunoglobulin genes. As external antigens and anti-idiotypic antibodies can competitively bind the combining site of specific antibodies, some antiidiotypic antibodies may resemble the external antigen, thus mimicking its structure. It has been proposed(1-5) that an anti-idiotypic antibody, anti-anti-X, may resemble the external antigen X and thus carry its 'internal image', but this idea is not unequivocally supported by the three-dimensional structures of anti-idiotopic antibodies(6-9), either because the structures of the external antigen(8) or of the anti-idiotopic antibody(7) were unknown, or because the anti-idiotopic antibodies showed no resemblance to the external antigens(6,9) (reviewed in ref. 10). Functional mimicry of ligands of biological receptors by anti-idiotypic antibodies has been described in several systems (reviewed in ref. 11). But how closely can antibodies mimic antigens at the molecular level? Here we present the crystal structure of an idiotope-anti-idiotope complex between the Fv fragments of the anti-lysozyme antibody D1.3 and the anti-D1.3 antibody E5.2. D1.3 contacts the antigen, lysozyme and the anti-idiotopic E5.2 through essentially the same combining-site residues, In addition, E5.2 interacts with D1.3, making contacts similar to those between lysozyme and D1.3. Thus, the anti-idiotopic antibody E5.2 mimics lysozyme in its binding interactions with D1.3. Validating these observations, E5.2, used as an immunogen, induces an anti-lysozyme response.	US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)	FIELDS, BA (corresponding author), UNIV MARYLAND,CTR ADV RES BIOTECHNOL,INST BIOTECHNOL,9600 GUDELSKY DR,ROCKVILLE,MD 20850, USA.			Goldbaum, Fernando/0000-0001-6235-3002; Fields, Barry/0000-0003-0628-1328				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BAN N, 1994, P NATL ACAD SCI USA, V91, P1604, DOI 10.1073/pnas.91.5.1604; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOULOT G, 1987, J MOL BIOL, V194, P577, DOI 10.1016/0022-2836(87)90685-1; BOULOT G, 1990, J MOL BIOL, V213, P617, DOI 10.1016/S0022-2836(05)80248-7; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; EVANS SV, 1994, J MOL BIOL, V241, P691, DOI 10.1006/jmbi.1994.1544; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GOLDBAUM FA, 1994, J MOL BIOL, V241, P739, DOI 10.1006/jmbi.1994.1549; HARPER M, 1987, MOL IMMUNOL, V2, P97; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KABAT EA, 1991, NIH913242 US DEP HLT; LEU JG, 1994, P NATL ACAD SCI USA, V91, P10690, DOI 10.1073/pnas.91.22.10690; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; POLJAK RJ, 1994, P NATL ACAD SCI USA, V91, P1599, DOI 10.1073/pnas.91.5.1599; ROITT IM, 1981, LANCET, V1, P1041; SACKS DL, 1983, SPRINGER SEMIN IMMUN, V6, P79, DOI 10.1007/BF01857368; Tello Diana, 1994, Journal of Molecular Recognition, V7, P57, DOI 10.1002/jmr.300070108	21	152	160	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					739	742		10.1038/374739a0	http://dx.doi.org/10.1038/374739a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7536303				2022-12-01	WOS:A1995QU30400055
J	INGERSOLL, AP; KANAMORI, H				INGERSOLL, AP; KANAMORI, H			WAVES FROM THE COLLISIONS OF COMET SHOEMAKER-LEVY-9 WITH JUPITER	NATURE			English	Article							VOYAGER	OBSERVATIONS Of the collisions of the fragments of comet Shoemaker-levy 9 with Jupiter provided an unprecedented opportunity to probe the depths of the planet's atmosphere, Images taken by the Hubble Space Telescope revealed circular rings surrounding five of the impact sites(1). The rings were observed for up to 2.5 hours after the impacts and spread at a constant velocity of 450 m s(-1). There are three types of disturbance that might explain these observations: acoustic waves trapped at the tropopause temperature minimum(2), gravity waves propagating vertically and horizontally in the stratosphere(3), and gravity waves trapped in a stable layer which acts as a horizontal waveguide and is located within the hypothesized tropospheric water cloud(4). Here we show that only the last of these phenomena fan match the speed and relative amplitude of the observed waves, with the requirement that the impacts were deep and the stability of the trapping layer is large. The origin of the stable layer is still uncertain, but if it is produced by moist convection in the water cloud, then the ratio of oxygen to hydrogen on Jupiter must be surprisingly large-approximately ten times that on the Sun.			INGERSOLL, AP (corresponding author), CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125, USA.							ACHTERBERG RK, 1989, J ATMOS SCI, V46, P2448, DOI 10.1175/1520-0469(1989)046<2448:ANMATJ>2.0.CO;2; BJORAKER GL, 1986, ICARUS, V66, P579, DOI 10.1016/0019-1035(86)90093-X; CARLSON BE, 1992, ASTROPHYS J, V388, P648, DOI 10.1086/171182; CARLSON RW, IN P0RESS GEOPHYS RE; GOLDREICH P, 1990, ASTROPHYS J, V363, P694, DOI 10.1086/169376; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; HARRINGTON J, 1994, NATURE, V368, P525, DOI 10.1038/368525a0; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; INGERSOLL AP, 1994, GEOPHYS RES LETT, V21, P1083, DOI 10.1029/94GL01057; KANAMORI H, 1993, GEOPHYS RES LETT, V20, P2921, DOI 10.1029/93GL03187; LINDAL GF, 1981, J GEOPHYS RES-SPACE, V86, P8721, DOI 10.1029/JA086iA10p08721; LINDZEN RS, 1968, MON WEATHER REV, V96, P133, DOI 10.1175/1520-0493(1968)096<0133:OIAWT>2.0.CO;2; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; [No title captured]	15	60	62	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					706	708		10.1038/374706a0	http://dx.doi.org/10.1038/374706a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715724				2022-12-01	WOS:A1995QU30400044
J	KIEFER, MC; BRAUER, MJ; POWERS, VC; WU, JJ; UMANSKY, SR; TOMEI, LD; BARR, PJ				KIEFER, MC; BRAUER, MJ; POWERS, VC; WU, JJ; UMANSKY, SR; TOMEI, LD; BARR, PJ			MODULATION OF APOPTOSIS BY THE WIDELY DISTRIBUTED BCL-2 HOMOLOG BAK	NATURE			English	Article							PROGRAMMED CELL-DEATH; MOLECULAR-CLONING; GENE; PROTEIN; RNA	MEMBERS Of the Bcl-2 family of proteins are characterized by their ability to modulate cell death, Bcl-2 and some of its homologues inhibit apoptosis(1-4), whereas other family members, such as Bax, will accelerate apoptosis under certain conditions(5). Here we describe the identification and characterization of a complementary DNA that encodes a previously unknown Bcl-2 homologue designated Bak. Like Bax, the bak gene product primarily enhances apoptotic cell death following an appropriate stimulus. Unlike Bax, however, Bak can inhibit cell death in an Epstein-Barr-virus-transformed cell line. The widespread tissue distribution of Bak messenger RNA, including those containing long-lived, terminally differentiated cell types, suggests that cell-death-inducing activity is broadly distributed, and that tissue-specific modulation of apoptosis is controlled primarily by regulation of molecules that inhibit apoptosis.			KIEFER, MC (corresponding author), LXR BIOTECHNOL INC, 1401 MARINA WAY S, RICHMOND, CA 94804 USA.							BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J., 1989, MOL CLONING LAB MANU; STRIKE LE, 1984, J IMMUNOL, V132, P1798; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; WILDE CD, 1982, NATURE, V297, P83, DOI 10.1038/297083a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAPF J, 1990, J BIOL CHEM, V265, P14892	19	483	507	2	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					736	739		10.1038/374736a0	http://dx.doi.org/10.1038/374736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715731				2022-12-01	WOS:A1995QU30400054
J	KING, GN; HEALY, CM; GLOVER, MT; KWAN, JTC; WILLIAMS, DM; LEIGH, IM; WORTHINGTON, HV; THORNHILL, MH				KING, GN; HEALY, CM; GLOVER, MT; KWAN, JTC; WILLIAMS, DM; LEIGH, IM; WORTHINGTON, HV; THORNHILL, MH			INCREASED PREVALENCE OF DYSPLASTIC AND MALIGNANT LIP LESIONS IN RENAL-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALLOGRAFT RECIPIENTS; SKIN-CANCER; CARCINOMA; TUMORS	Background. Renal-transplant recipients are known to have increased rates of skin cancer associated with exposure to the sun. Little is known, however, about the prevalence and histologic features of lesions of the lips in these patients, or about risk factors for such lesions. Methods. We examined the lips of 160 renal-transplant recipients (105 men and 55 women; mean [+/-SD] age, 48+/-13 years) and 160 normal subjects matched with the transplant recipients for age, sex, and skin type. The mean length of time between transplantation and the examination was 69+/-52 months; 58 percent of the recipients had received their grafts more than 60 months earlier. Results. Among the 160 renal-transplant recipients, 21 (13 percent) had leukoplakia; in 2 (1.2 percent) the leukoplakia contained squamous-cell carcinoma. In contrast, only one normal subject (0.6 percent) had leukoplakia. Histologically, 13 of the 21 leukoplakias (62 percent) in the renal-transplant recipients who underwent biopsy were dysplastic, and 2 (10 percent) contained squamous-cell carcinoma. Actinic change was evident in 91 percent of the dysplastic lesions but not in the nondysplastic lesions (P<0.001). Exposure to the sun and smoking were risk factors for dysplastic and malignant lip lesions in the renal-transplant recipients (P<0.001 and P=0.003, respectively). Among these recipients, only men had dysplastic or malignant lip lesions (P=0.006); lipstick was used frequently by 73 percent of the women. The clinical appearance of lip lesions did not predict the presence of dysplasia or cancer. Conclusions. Renal-transplant recipients have an increased prevalence of leukoplakia, dysplasia, and cancer of the lip.	UNIV LONDON LONDON HOSP,COLL MED,DEPT DERMATOL,LONDON E1 2AD,ENGLAND; UNIV LONDON LONDON HOSP,COLL MED,DEPT NEPHROL,LONDON E1 2AD,ENGLAND; UNIV LONDON LONDON HOSP,COLL MED,INST DENT SURG,JOINT DEPT ORAL PATHOL,LONDON E1 2AD,ENGLAND; UNIV MANCHESTER,DEPT ORAL HLTH,MANCHESTER,LANCS,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; University of Manchester	KING, GN (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,DEPT ORAL MED & PERIODONTOL,LONDON E1 2AD,ENGLAND.		Healy, Claire M/AGL-9755-2022; Worthington, Helen/U-8971-2019	Healy, Claire M/0000-0003-0583-6360; Worthington, Helen/0000-0002-4851-7469; Healy, Claire M/0000-0001-7940-4611; Thornhill, Martin/0000-0003-0681-4083				BARR BBB, 1989, LANCET, V1, P124; BLESSING K, 1989, HISTOPATHOLOGY, V14, P129, DOI 10.1111/j.1365-2559.1989.tb02123.x; BLOHME I, 1985, TRANSPLANTATION, V39, P23; BLOHME I, 1984, TRANSPLANTATION, V37, P165, DOI 10.1097/00007890-198402000-00010; Bouquot J E, 1987, Quintessence Int, V18, P277; BOYLE J, 1984, LANCET, V1, P702; BUNNEY MH, 1987, LANCET, V2, P151; DOUGLASS CW, 1984, ORAL SURG ORAL MED O, V57, P631, DOI 10.1016/0030-4220(84)90286-X; HARDIE IR, 1980, SURGERY, V87, P177; HOXTELL EO, 1977, ARCH DERMATOL, V113, P436, DOI 10.1001/archderm.113.4.436; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KRAMER I R H, 1978, Oral Surgery Oral Medicine Oral Pathology, V46, P518; LINDQVIST C, 1981, COMMUNITY DENT ORAL, V9, P247, DOI 10.1111/j.1600-0528.1981.tb00339.x; LUTZNER M, 1980, J INVEST DERMATOL, V75, P353, DOI 10.1111/1523-1747.ep12531131; MARSHALL V, 1974, TRANSPLANTATION, V17, P272, DOI 10.1097/00007890-197403000-00006; PATHAK MA, 1987, DERMATOLOGY GENERAL, V1, P1507; PENN I, 1980, CLIN PLAST SURG, V7, P361; PENN I, 1993, HEMATOL ONCOL CLIN N, V7, P431, DOI 10.1016/S0889-8588(18)30250-8; ROGERS GS, 1988, J AM ACAD DERMATOL, V18, P1039, DOI 10.1016/S0190-9622(88)70101-2	19	94	96	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1052	1057		10.1056/NEJM199504203321602	http://dx.doi.org/10.1056/NEJM199504203321602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898522				2022-12-01	WOS:A1995QT18700002
J	MCKENNA, MT; MCCRAY, E; ONORATO, I				MCKENNA, MT; MCCRAY, E; ONORATO, I			THE EPIDEMIOLOGY OF TUBERCULOSIS AMONG FOREIGN-BORN PERSONS IN THE UNITED-STATES, 1986 TO 1993	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDOCHINESE REFUGEES; BRITISH-COLUMBIA; IMMIGRANTS; CONVERSIONS; COUNTRIES; INFECTION; CHILDREN; HEALTH	Background. One third of the world's population is infected with Mycobacterium tuberculosis, and in the developed countries immigration is a major force that sustains the incidence of tuberculosis. We studied the effects of immigration on the epidemiology of tuberculosis and its recent resurgence in the United States. Methods. We analyzed data from the national tuberculosis reporting system of the Centers for Disease Control and Prevention. Since 1986 reports of tuberculosis have included the patient's country of origin. Population estimates for foreign-born persons were derived from special samples from the 1980 and 1990 censuses. Results. The proportion of persons reported to have tuberculosis who were foreign-born increased from 21.6 percent (4925 cases) in 1986 to 29.6 percent (7346 cases) in 1993. For the entire eight-year period, most foreign-born patients with tuberculosis were from Latin America (43.9 percent; 21,115 cases) and Southeast Asia (34.6 percent; 16,643 cases). Among foreign-born persons the incidence rate was almost quadruple the rate for native residents of the United States (30.6 vs. 8.1 per 100,000 person-years), and 55 percent of immigrants with tuberculosis had the condition diagnosed in their first five years in the United States. Conclusions. Immigration has had an increasingly important effect on the epidemiology of tuberculosis in the United States. It will be difficult to eliminate tuberculosis without better efforts to prevent and control it among immigrants and greater efforts to control it in the countries from which they come.			MCKENNA, MT (corresponding author), CTR DIS CONTROL & PREVENT,DIV TUBERCULOSIS ELIMINAT,1600 CLIFTON RD E-10,ATLANTA,GA 30333, USA.							AICKIN M, 1991, AM J PUBLIC HEALTH, V81, P918, DOI 10.2105/AJPH.81.7.918; ASCH S, 1994, WESTERN J MED, V161, P373; BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670; BROEKMANS JF, 1993, TUBERCULOSIS COMPREH, P641; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; CLAYTON D, 1993, STATISTICAL MODELS E; ENARSON DA, 1989, AM J EPIDEMIOL, V129, P1268, DOI 10.1093/oxfordjournals.aje.a115246; FEIN DJ, 1990, DEMOGRAPHY, V27, P285, DOI 10.2307/2061454; JACOBSON ML, 1987, AM J PUBLIC HEALTH, V77, P29, DOI 10.2105/AJPH.77.1.29; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MORSE DL, 1985, AM REV RESPIR DIS, V132, P516; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NOLAN CM, 1988, AM REV RESPIR DIS, V137, P805, DOI 10.1164/ajrccm/137.4.805; NOLAN CM, 1989, AM REV RESPIR DIS, V140, P996, DOI 10.1164/ajrccm/140.4.996; ONORATO IM, 1992, J INFECT DIS, V165, P87, DOI 10.1093/infdis/165.1.87; ORMEROD LP, 1990, RESP MED, V84, P269, DOI 10.1016/S0954-6111(08)80051-0; ORR P, 1993, TUBERCULOSIS COMPREH, P531; ORR PH, 1990, CAN MED ASSOC J, V142, P453; PEREZSTABLE EJ, 1985, PEDIATR INFECT DIS J, V4, P476, DOI 10.1097/00006454-198509000-00007; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; POWELL KE, 1983, JAMA-J AM MED ASSOC, V249, P1455, DOI 10.1001/jama.249.11.1455; POWELL KE, 1981, AM J PUBLIC HEALTH, V71, P1223, DOI 10.2105/AJPH.71.11.1223; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STEHRGREEN JK, 1992, NEW ZEAL MED J, V105, P301; STYBLO K, 1989, REV INFECT DIS, V11, pS339; SUTTER RW, 1990, AM REV RESPIR DIS, V141, P1483, DOI 10.1164/ajrccm/141.6.1483; WANG JS, 1991, TUBERCLE, V72, P277, DOI 10.1016/0041-3879(91)90054-V; WANG JS, 1989, TUBERCLE, V70, P179, DOI 10.1016/0041-3879(89)90048-2; 1990, MMWR-MORBID MORTAL W, V39, P1; 1992, AM REV RESPIR DIS, V146, P1623; 1991, DHHS PHS911101; 1977, PROCEDURAL GUIDE REC; 1993, 1993 WORLD BANK WORL; 1992, 1990 CENSUS POPULATI; 1993, 1990 CENSUS POPULATI; 1994, STATISTICAL YB IMMIG; 1994, MMWR-MORBID MORTAL W, V43, P361; 1994, LANCET, V344, P277; 1991, TECHNICAL INSTRUCTIO; 1992, THORAX, V47, P770; 1989, MMWR MORB MORTAL SS3, V38, P1; 1993, MMWR-MORBID MORTAL W, V42, P1	49	320	324	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1071	1076		10.1056/NEJM199504203321606	http://dx.doi.org/10.1056/NEJM199504203321606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT187	7898526	Bronze			2022-12-01	WOS:A1995QT18700006
J	MULLER, KJ; ROMANO, N; GERSTNER, O; GARCIAMAROTO, F; POZZI, C; SALAMINI, F; ROHDE, W				MULLER, KJ; ROMANO, N; GERSTNER, O; GARCIAMAROTO, F; POZZI, C; SALAMINI, F; ROHDE, W			THE BARLEY HOODED MUTATION CAUSED BY A DUPLICATION IN A HOMEOBOX GENE INTRON	NATURE			English	Article							EXPRESSION; KNOTTED-1; ANTIRRHINUM; VECTORS; FAMILY; FATES; LOCUS	IN barley (Hordeum vulgare L.) the unit of inflorescence is the spikelet, which bears a fertile bract, the lemma, and the floret consisting of palea, two lodicules, three stamens and the pistil(1). The Hooded mutation causes the appearance of an extra flower of inverse polarity on the lemma(2). This phenotype is governed by the single dominant genetic locus K-3 Here we show that the homeobox gene Knox3 represents this locus, Ectopic Knox3 gene expression in the primordium of the extra floret is caused by a 305-base pair duplication in inh on 4, and phenocopies of the mutation are obtained in the heterologous tobacco system by Knox3 overexpression. It is concluded that homeotic genes of the Knox gene family are involved in floral evocation. Furthermore, the study of polarity of reproductive organs in K and related mutants can now focus on homeobox genes.	UNIV POLITECN MADRID,ETS INGN AGRON,DEPT BIOQUIM & BIOL MOLEC,E-28040 MADRID,SPAIN	Universidad Politecnica de Madrid	MULLER, KJ (corresponding author), MAX PLANCK INST ZUCHTUNGSFORSCH,CARL VON LINNE WEG 10,D-50829 COLOGNE,GERMANY.		Maroto, Federico Garcia/G-8616-2013	Maroto, Federico Garcia/0000-0002-0565-6995; Pozzi, Carlo Massimo/0000-0002-2899-177X				[Anonymous], 1985, FAMILIES MONOCOTYLED, DOI DOI 10.1007/978-3-642-61663-1; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bossinger G., 1992, Barley: genetics, biochemistry, molecular biology and biotechnology., P231; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CLANCY M, 1994, PLANT SCI, V98, P151, DOI 10.1016/0168-9452(94)90005-1; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DECANDOLLE C, 1891, MEM SOC PHYS HIST S, V6, P1; DICKINSON TA, 1978, BOT REV, V44, P181, DOI 10.1007/BF02919079; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HAKE S, 1992, TRENDS GENET, V8, P109, DOI 10.1016/0168-9525(92)90065-C; HALFORD NG, 1992, PLANT J, V2, P791, DOI 10.1046/j.1365-313X.1992.t01-16-00999.x; HARLAN HARRY V., 1931, JOUR HEREDITY, V22, P264; JACKSON D, 1994, DEVELOPMENT, V120, P405; Nilan R.A., 1964, CYTOLOGY GENETICS BA; Sambrook J., 1989, MOL CLONING; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1992, DEVELOPMENT, V116, P21; Stebbins G.L., 1974, FLOWERING PLANTS EVO; STEBBINS GL, 1966, GENETICS, V54, P727; TAKAHASHI R, 1953, OHARA I LANDW FORSCH, V10, P29; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0; Weberling F., 1989, MORPHOLOGY FLOWERS I; WOLF N, 1992, MOL GEN GENET, V234, P33, DOI 10.1007/BF00272342; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	26	163	176	2	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					727	730		10.1038/374727a0	http://dx.doi.org/10.1038/374727a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715728				2022-12-01	WOS:A1995QU30400051
J	VANMEERVELT, L; VLIEGHE, D; DAUTANT, A; GALLOIS, B; PRECIGOUX, G; KENNARD, O				VANMEERVELT, L; VLIEGHE, D; DAUTANT, A; GALLOIS, B; PRECIGOUX, G; KENNARD, O			HIGH-RESOLUTION STRUCTURE OF A DNA HELIX-FORMING (C-CENTER-DOT-G)ASTERISK-G BASE TRIPLETS	NATURE			English	Article								TRIPLE helices result from interaction between single- and double-stranded nucleic acids. Their formation is a possible mechanism for recombination of homologous gene sequences in nature and provides, inter alia, a basis for artificial control of gene activity, Triple-helix motifs have been extensively studied by a variety of techniques, but few high-resolution structural data are available, The only triplet structures characterized so far by X-ray diffraction were in protein-DNA complexes(1,2) studied at about 3 Angstrom resolution, We report here the X-ray analysis of a DNA nonamer, d(GCGAATTCG), to a resolution of 2.05 Angstrom, in which the extended crystal structure contains (C . G)*G triplets as a fragment of triple helix. The guanosine-containing chains are in a parallel orientation, This arrangement is a necessary feature of models for homologous recombination which results ultimately in replacement of one length of DNA by another of similar sequence, The present-structure agrees with many published predictions of tripler organization, and provides an accurate representation of an element that allows sequence-specific association between single- and double-stranded nucleic acids.	UNIV BORDEAUX 1, CRISTALLOG LAB, CNRS, ERS 133, F-33405 TALENCE, FRANCE; CAMBRIDGE CRYSTALLOG DATA CTR, CAMBRIDGE CB2 1EZ, ENGLAND	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Cambridge	VANMEERVELT, L (corresponding author), KATHOLIEKE UNIV LEUVEN, DEPT CHEM, CELESTIJNENLAAN 200F, B-3001 HEVERLEE, BELGIUM.		Van Meervelt, Luc/AAD-2878-2022	Van Meervelt, Luc/0000-0003-2186-5209				ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; [Anonymous], 1989, EMBO J, V8, P1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHENG YK, 1992, J AM CHEM SOC, V114, P4465, DOI 10.1021/ja00038a004; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OUALI M, 1993, J AM CHEM SOC, V115, P4264, DOI 10.1021/ja00063a049; PIRIOU JM, 1994, BIOPHYS CHEM, V50, P323, DOI 10.1016/0301-4622(93)E0103-C; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	12	63	64	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					742	744		10.1038/374742a0	http://dx.doi.org/10.1038/374742a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715732				2022-12-01	WOS:A1995QU30400056
J	WATKINS, H; MCKENNA, WJ; THIERFELDER, L; SUK, HJ; ANAN, R; ODONOGHUE, A; SPIRITO, P; MATSUMORI, A; MORAVEC, CS; SEIDMAN, JG; SEIDMAN, CE				WATKINS, H; MCKENNA, WJ; THIERFELDER, L; SUK, HJ; ANAN, R; ODONOGHUE, A; SPIRITO, P; MATSUMORI, A; MORAVEC, CS; SEIDMAN, JG; SEIDMAN, CE			MUTATIONS IN THE GENES FOR CARDIAC TROPONIN-T AND ALPHA-TROPOMYOSIN IN HYPERTROPHIC CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; CLINICAL MANIFESTATIONS; MISSENSE MUTATION; PATHO-PHYSIOLOGY; EXPRESSION; INTERRELATIONS; SEQUENCE; THERAPY; DISEASE; LOCUS	Background. Familial hypertrophic cardiomyopathy can be caused by mutations in the genes for beta cardiac myosin heavy chain, alpha-tropomyosin, or cardiac troponin T. It is not known how often the disease is caused by mutations in the tropomyosin and troponin genes, and the associated clinical phenotypes have not been carefully studied. Methods. Linkage between polymorphisms of the alpha-tropomyosin gene or the cardiac troponin T gene and hypertrophic cardiomyopathy was assessed in 27 families. In addition, 100 probands were screened for mutations in the alpha-tropomyosin gene, and 26 were screened for mutations in the cardiac troponin T gene. Life expectancy, the incidence of sudden death, and the extent of left ventricular hypertrophy were compared in patients with different mutations. Results. Genetic analyses identified only one alpha-tropomyosin mutation, identical to one previously described. Five novel mutations in cardiac troponin were identified, as well as a further example of a previously described mutation. The clinical phenotype of four troponin T mutations in seven unrelated families was similar and was characterized by a poor prognosis (life expectancy, approximately 35 years) and a high incidence of sudden death. The mean (+/-SD) maximal thickness of the left ventricular wall in subjects with cardiac troponin T mutations (16.7+/-5.5 mm) was significantly less than that in subjects with beta cardiac myosin heavy-chain mutations (23.7+/-7.7 mm, P<0.001). Conclusions. Mutations in alpha-tropomyosin are a rare cause of familial hypertrophic cardiomyopathy, accounting for approximately 3 percent of cases. Mutations in cardiac troponin T account for approximately 15 percent of cases of familial hypertrophic cardiomyopathy in this referral-center population. These mutations are characterized by relatively mild and sometimes subclinical hypertrophy but a high incidence of sudden death. Genetic testing may therefore be especially important in this group.	HOWARD HUGHES MED INST,BOSTON,MA; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; FRANZ VOLHARD KLIN,BERLIN,GERMANY; MAX DELBRUCK CTR,BERLIN,GERMANY; OSPED GALLIERA,DIV CARDIOL,GENOA,ITALY; KYOTO UNIV,DEPT INTERNAL MED,KYOTO,JAPAN; CLEVELAND CLIN FDN,CTR ANESTHESIOL RES,CLEVELAND,OH	Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; St Georges University London; Harvard University; Harvard Medical School; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ente Ospedaliero Ospedali Galliera; Kyoto University; Cleveland Clinic Foundation			McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016	Telethon [600] Funding Source: Medline	Telethon(Fondazione Telethon)		ANAN R, 1994, J CLIN INVEST, V93, P280, DOI 10.1172/JCI116957; CARRIER L, 1993, NAT GENET, V4, P311, DOI 10.1038/ng0793-311; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Cox DR., 1984, ANAL SURVIVAL DATA; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; GEISTERFERLOWRA.AA, 1990, CELL, V62, P999; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P277; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P276; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P3, DOI 10.1006/jmcc.1994.1002; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE ET, 1980, STATISTICAL METHODS; MACRAE CA, 1994, CIRCULATION, V89, P33, DOI 10.1161/01.CIR.89.1.33; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MCKENNA WJ, 1989, DISEASES HEART, P933; MCKENNA WJ, 1995, METABOLIC MOL BASES, V3, P4253; MESNARD L, 1993, FEBS LETT, V328, P139, DOI 10.1016/0014-5793(93)80981-Y; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; PERRYMAN MB, 1992, J CLIN INVEST, V90, P271, DOI 10.1172/JCI115848; Solomon SD, 1993, J AM COLL CARDIOL, V22, P498, DOI 10.1016/0735-1097(93)90055-6; THIERFELDER L, 1993, P NATL ACAD SCI USA, V90, P6270, DOI 10.1073/pnas.90.13.6270; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOWNSEND PJ, 1994, GENOMICS, V21, P311, DOI 10.1006/geno.1994.1271; WATKINS H, 1993, NAT GENET, V3, P333, DOI 10.1038/ng0493-333; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WATKINS H, 1994, HUM MOL GENET, V3, P2267, DOI 10.1093/hmg/3.12.2267; WATKINS H, 1994, CURRENT PROTOCOLS HU; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	31	696	722	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1058	1064		10.1056/NEJM199504203321603	http://dx.doi.org/10.1056/NEJM199504203321603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898523				2022-12-01	WOS:A1995QT18700003
J	WONG, ROL; CHERNJAVSKY, A; SMITH, SJ; SHATZ, CJ				WONG, ROL; CHERNJAVSKY, A; SMITH, SJ; SHATZ, CJ			EARLY FUNCTIONAL NEURAL NETWORKS IN THE DEVELOPING RETINA	NATURE			English	Article							IMMEDIATE EARLY GENES; CALCIUM WAVES; MAMMALIAN RETINA; GANGLION-CELLS; FERRET RETINA; GLUTAMATE; ASTROCYTES; EXPRESSION; PATTERNS; NEURONS	IN the adult mammalian retina, the principal direction of information flow is along a vertical pathway from photoreceptors to retinal interneurons to ganglion cells, the output neurons of the retina. We report here, however, that initially in development, at a time when the photoreceptors are not yet even present, there are already functionally defined networks within the retina. These networks are spontaneously active rather than visually driven, and they involve horizontal rather than vertical pathways. By means of optical recording using the calcium-sensitive dye Fura-2, we have found that sets of retinal ganglion cells and amacrine cells, a type of retinal interneuron, undergo synchronized oscillations in intracellular calcium concentration, These oscillations are highly correlated among subgroups of neighbouring cells, and spread in a wave-like fashion tangentially across the retina, Thus, in development of retinal circuitry, the initial patterning of neuronal function occurs in the horizontal domain before the adult pattern of vertical information transfer emerges.	STANFORD UNIV, BECKMAN CTR, DEPT PHYSIOL, STANFORD, CA 94305 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; STANFORD UNIV, SCH MED, DEPT NEUROBIOL, STANFORD, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Stanford University								BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; COOK JE, 1991, TRENDS NEUROSCI, V14, P397, DOI 10.1016/0166-2236(91)90028-S; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GREINER JV, 1981, EXP EYE RES, V33, P315, DOI 10.1016/S0014-4835(81)80055-3; HENDERSON Z, 1988, J NEUROSCI, V8, P1194; Katz L C, 1993, Curr Opin Neurobiol, V3, P93, DOI 10.1016/0959-4388(93)90041-V; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; PENN AA, 1994, J NEUROSCI, V14, P3805; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; POW DV, 1994, VISUAL NEUROSCI, V11, P1115, DOI 10.1017/S0952523800006933; RAMOA AS, 1988, J NEUROSCI, V8, P4239; REDBURN DA, 1992, NEUROCHEM RES, V17, P61, DOI 10.1007/BF00966865; ROBINSON SR, 1991, VISION VISUAL DYSFUN, V3, P69; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SPITZER NC, 1994, TRENDS NEUROSCI, V17, P115, DOI 10.1016/0166-2236(94)90120-1; Vaney D.I., 1990, PROGR RETINAL RES, V9, P49, DOI [10.1016/0278-4327(90)90004-2, DOI 10.1016/0278-4327(90)90004-2]; Wong R O, 1993, Curr Opin Neurobiol, V3, P595, DOI 10.1016/0959-4388(93)90061-3; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S; ZORUMSKI CF, 1992, PROG NEUROBIOL, V39, P295, DOI 10.1016/0301-0082(92)90020-F	29	237	239	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					716	718		10.1038/374716a0	http://dx.doi.org/10.1038/374716a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715725				2022-12-01	WOS:A1995QU30400048
J	HENKIN, RI				HENKIN, RI			BODY ODOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HENKIN, RI (corresponding author), TASTE & SMELL CLIN,WASHINGTON,DC, USA.							GOLDBERG RL, 1985, PSYCHOSOMATICS, V26, P326; HENKIN RI, 1993, OTOLARYNGOLOGY, V2, P1; HENKIN RI, 1994, OLFACTION TASTE, V11, P568; Jackson JH., 1871, LANCET, V1, P376; MUNRO A, 1982, CAN J PSYCHIAT, V27, P374, DOI 10.1177/070674378202700504; PERRY TL, 1970, CLIN CHIM ACTA, V30, P721, DOI 10.1016/0009-8981(70)90266-4; PHILLIPS M, 1994, CLIN RES, V42, pA260; POTOLICCHIO SJ, 1986, CLIN RES, V34, P635; PRYSEPHILLIPS W, 1991, ACTA PSYCHIAT SCAND, V47, P484; RUBERT SL, 1961, ARCH GEN PSYCHIAT, V5, P313; SMITH K, 1969, SCIENCE, V166, P398, DOI 10.1126/science.166.3903.398; Taylor RB, 1992, DIFFICULT DIAGNOSIS, P348	12	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1171	1172						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT100	7707616				2022-12-01	WOS:A1995QT10000011
J	LEE, IM; HSIEH, CC; PAFFENBARGER, RS				LEE, IM; HSIEH, CC; PAFFENBARGER, RS			EXERCISE INTENSITY AND LONGEVITY IN MEN - THE HARVARD ALUMNI HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; TOTAL ENERGY-INTAKE; TIME PHYSICAL-ACTIVITY; LEISURE-TIME; EPIDEMIOLOGIC ANALYSES; COLLEGE ALUMNI; FINNISH MEN; RISK FACTOR; FOLLOW-UP; MORTALITY	Objective.-To examine the independent associations of vigorous (greater than or equal to 6 resting metabolic rate [MET] score) and nonvigorous (<6 MET score) physical activity with longevity. Design.-Prospective cohort study, following up men from 1962 or 1966 through 1988. Setting/Participants.-Subjects were Harvard University alumni, without self-reported, physician-diagnosed cardiovascular disease, cancer, or chronic obstructive pulmonary disease (n=17 321). Men with a mean age of 46 years reported their physical activities on questionnaires at baseline. Main Outcome Measure.-All-cause mortality (3728 deaths). Results.-Total energy expenditure and energy expenditure from vigorous activities, but not energy expenditure from nonvigorous activities, related inversely to mortality. After adjustment for potential confounders, the relative risks of dying associated with increasing quintiles of total energy expenditure were 1.00 (referent), 0.94, 0.95, 0.91 and 0.91, respectively (P [trend]<.05). The relative risks of dying associated with less than 630, 630 to less than 1680, 1680 to less than 3150, 3150 to less than 6300, and 6300 or more kJ/wk expended on vigorous activities were 1.00 (referent), 0.88, 0.92, 0.87, and 0.87, respectively (P[trend]=.007). Corresponding relative risks for energy expended on nonvigorous activities were 1.00 (referent), 0.89, 1.00, 0.98, and 0.92, respectively (P[trend]=.36). Analyses of vigorous and nonvigorous activities were mutually adjusted. Among men who reported only vigorous activities (259 deaths), we observed decreasing age-standardized mortality rates with increasing activity (P=.05); among men who reported only nonvigorous activities (380 deaths), no trend was apparent (P=.99). Conclusions.-These data demonstrate a graded inverse relationship between total physical activity and mortality. Furthermore, vigorous activities but not nonvigorous activities were associated with longevity. These findings pertain only to all cause mortality; nonvigorous exercise has been shown to benefit other aspects of health.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; STANFORD UNIV, SCH MED, DIV EPIDEMIOL, STANFORD, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Stanford University	LEE, IM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Lee, I-Min/ABD-5409-2021		NCI NIH HHS [CA 09001, CA 44854] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044854] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, J CLIN EPIDEMIOL, V46, P1403, DOI 10.1016/0895-4356(93)90140-V; AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Albanes D, 1990, Epidemiology, V1, P65, DOI 10.1097/00001648-199001000-00014; ALESSIO HM, 1993, MED SCI SPORT EXER, V25, P218, DOI 10.1249/00005768-199302000-00010; ARMITAGE P, 1987, STATISTICAL METHODS, P91; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CAULEY JA, 1987, AM J CLIN NUTR, V45, P14, DOI 10.1093/ajcn/45.1.14; COX DR, 1972, J R STAT SOC B, V34, P187; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FROELICHER VF, 1990, EXERCISE, FITNESS, AND HEALTH, P429; HAGBERG JM, 1990, EXERCISE, FITNESS, AND HEALTH, P455; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HORTON E S, 1986, Diabetes Metabolism Reviews, V2, P1; HOWE GR, 1986, AM J EPIDEMIOL, V124, P157, DOI 10.1093/oxfordjournals.aje.a114365; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; LAPORTE RE, 1982, J CHRON DIS, V35, P787, DOI 10.1016/0021-9681(82)90090-X; LEE IM, 1992, AM J EPIDEMIOL, V135, P169, DOI 10.1093/oxfordjournals.aje.a116269; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; MAGNUS K, 1979, AM J EPIDEMIOL, V110, P724, DOI 10.1093/oxfordjournals.aje.a112853; MORRIS JN, 1980, LANCET, V2, P1207; MORRIS JN, 1990, BRIT HEART J, V63, P325; NEWSHOLME EA, 1990, EXERCISE, FITNESS, AND HEALTH, P293; OBERMAN A, 1988, HEART DISEASE TXB CA, P1395; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PEKKANEN J, 1987, LANCET, V1, P1473, DOI 10.1016/S0140-6736(87)92218-5; PIKE MC, 1989, AM J EPIDEMIOL, V129, P1312, DOI 10.1093/oxfordjournals.aje.a115254; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHEKELLE RB, 1987, AM J EPIDEMIOL, V126, P980, DOI 10.1093/oxfordjournals.aje.a114736; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; Siegel P Z, 1991, MMWR CDC Surveill Summ, V40, P1; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; SMITH GD, 1992, LANCET, V340, P709; Stefanovic-Racic M., 1994, P417; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P848, DOI 10.1093/oxfordjournals.aje.a117333; WASHBURN RA, 1991, J CLIN EPIDEMIOL, V44, P1319, DOI 10.1016/0895-4356(91)90093-O; Willet W, 1990, NUTR EPIDEMIOLOGY, P245; WOOD PD, 1990, EXERCISE, FITNESS, AND HEALTH, P409; 1992, ALLIED DUNBAR NATION; 1985, GUIDELINES GRADED EX; [No title captured]	50	437	453	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1179	1184		10.1001/jama.273.15.1179	http://dx.doi.org/10.1001/jama.273.15.1179			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707624				2022-12-01	WOS:A1995QT10000025
J	MOON, RE				MOON, RE			FASTING BEFORE SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							GASTRIC FLUID VOLUME; GUIDELINES; CHILDREN; PH; INGESTION; LIQUIDS				MOON, RE (corresponding author), DUKE UNIV,MED CTR,DURHAM,NC, USA.		Moon, Richard/AAF-2170-2019	Moon, Richard/0000-0003-4432-0332				COTE CJ, 1990, ANESTHESIOLOGY, V72, P589, DOI 10.1097/00000542-199004000-00001; GOODWIN APL, 1991, ANAESTHESIA, V46, P1066, DOI 10.1111/j.1365-2044.1991.tb09926.x; GORESKY GV, 1990, CAN J ANAESTH, V37, P493, DOI 10.1007/BF03006313; KALLAR SK, 1993, ANESTH ANALG, V77, P171; MALTBY JR, 1991, CAN J ANAESTH, V38, P425, DOI 10.1007/BF03007577; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; MINAMI H, 1984, GASTROENTEROLOGY, V86, P1592; MOORE JG, 1981, DIGEST DIS SCI, V26, P16, DOI 10.1007/BF01307971; PHILLIPS S, 1993, BRIT J ANAESTH, V70, P6, DOI 10.1093/bja/70.1.6; SANDHAR BK, 1989, ANESTHESIOLOGY, V71, P327, DOI 10.1097/00000542-198909000-00001; SCARR M, 1989, CAN MED ASSOC J, V141, P1151; SCHREINER MS, 1990, ANESTHESIOLOGY, V72, P593, DOI 10.1097/00000542-199004000-00002; SNOW J, 1847, INHALATION VAPOUR ET, P43; SPLINTER WM, 1990, CAN J ANAESTH, V37, P36, DOI 10.1007/BF03007481; STRUNIN L, 1993, BRIT J ANAESTH, V70, P1, DOI 10.1093/bja/70.1.1	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1171	1171						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707615				2022-12-01	WOS:A1995QT10000010
J	NEASE, RF; KNEELAND, T; OCONNOR, GT; SUMNER, W; LUMPKINS, C; SHAW, L; PRYOR, D; SOX, HC				NEASE, RF; KNEELAND, T; OCONNOR, GT; SUMNER, W; LUMPKINS, C; SHAW, L; PRYOR, D; SOX, HC			VARIATION IN PATIENT UTILITIES FOR OUTCOMES OF THE MANAGEMENT OF CHRONIC STABLE ANGINA - IMPLICATIONS FOR CLINICAL-PRACTICE GUIDELINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREFERENCES	Objective.-Although practice guidelines sometimes make recommendations based on symptom severity, they rarely account for how patients feel about their symptoms. To investigate the possible importance of patient preferences in treatment of ischemic heart disease, we assessed attitudes toward symptoms in patients with angina pectoris. Design.-Case series. Setting.-Ambulatory cardiology clinics at two tertiary care medical centers. Patients.-A total of 220 subjects were selected from 589 patients with chronic stable angina referred from cardiologists to achieve patient samples balanced for sex, race, and angina severity. Main Outcome Measures.-We measured patients' attitudes toward their angina using the rating scale, time trade-off, and standard gamble utility metrics. Reliability of measurements was evaluated by repeating the assessments 2 weeks later on 50 willing patients. Results.-While the mean responses followed the expected patterns (those with more severe Canadian Cardiovascular Society scores chose lower utilities), attitudes toward symptoms varied substantially among patients with similarly severe angina. For example, there was a 33% chance that a patient with class II angina had a time trade-off utility that was lower (ie, more bothered by symptoms) than a patient with more severe angina (class III/IV). This variation in utilities was not due to random error in the assessments. Conclusions.-Angina patients with similar functional limitation vary considerably in their tolerance for their symptoms, as measured by utilities. Our findings suggest that guidelines for the management of ischemic heart disease should be based on the preferences of the individual patient rather than on symptom severity alone.	DARTMOUTH COLL, SCH MED, DEPT COMMUNITY & FAMILY MED, CTR EVALUAT CLIN SCI, HANOVER, NH 03755 USA; DARTMOUTH COLL, SCH MED, DEPT MED, HANOVER, NH 03755 USA; UNIV KENTUCKY, DEPT FAMILY PRACTICE, LEXINGTON, KY USA; DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27710 USA	Dartmouth College; Dartmouth College; University of Kentucky; Duke University			Sumner, Walton/H-5045-2019		AHRQ HHS [HS06503-04] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Conover WJ, 1999, PRACTICAL NONPARAMET, V3; COX J, 1992, ANN INTERN MED, V117, P677, DOI 10.7326/0003-4819-117-8-677; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; GRADY D, 1992, ANN INTERN MED, V117, P1038; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; NEASE R, 1993, CLIN RES, V41, pA181; NEASE RF, 1994, MED DECIS MAKING, V11, P382; OCONNOR AMC, 1987, J CHRON DIS, V40, P811, DOI 10.1016/0021-9681(87)90133-0; Owens D K, 1993, Jt Comm J Qual Improv, V19, P248; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; Sox HC, 1988, MED DECISION MAKING; SUMNER W, 1991, 15TH P ANN S COMP AP, P701; Weinstein MC, 1980, CLIN DECISION ANAL	16	254	256	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1185	1190		10.1001/jama.273.15.1185	http://dx.doi.org/10.1001/jama.273.15.1185			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707625				2022-12-01	WOS:A1995QT10000026
J	AONO, S; ADACHI, Y; UYAMA, E; YAMADA, Y; KEINO, H; NANNO, T; KOIWAI, O; SATO, H				AONO, S; ADACHI, Y; UYAMA, E; YAMADA, Y; KEINO, H; NANNO, T; KOIWAI, O; SATO, H			ANALYSIS OF GENES FOR BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE IN GILBERTS-SYNDROME	LANCET			English	Note							CRIGLER-NAJJAR SYNDROME; IDENTIFICATION; COMPLEX; MUTATION; PATIENT	Gilbert's and Crigler-Najjar syndromes are characterised by unconjugated hyperbilirubinaemia due to complete and partial absence of bilirubin UDP-glucuronosyltransferase (UGT). Nucleotide sequences of the genes for bilirubin UGT were analysed in six patients with Gilbert's syndrome. All patients had a missense mutation caused by a single nucleotide substitution and the mutations were heterozygous. In addition, relatives of patients with Crigler-Najjar syndrome types I and II, and of those with Gilbert's syndrome were analysed. All ten relatives with mild hyperbilirubinaemia were heterozygotes with respect to each defective allele. These results suggest that Gilbert's syndrome is inherited as a dominant trait.	SHIGA UNIV MED SCI,DEPT BIOL,OTSU,SHIGA 52021,JAPAN; KINKI UNIV,SCH MED,DEPT PERINATOL,OSAKA,JAPAN; KINKI UNIV,SCH MED,INST DEV RES,DEPT GENET,OSAKA,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 1,KUMAMOTO,JAPAN; AICHI CANC CTR,RES INST,DEPT BIOCHEM,AICHI,JAPAN	Shiga University of Medical Science; Kindai University (Kinki University); Kindai University (Kinki University); Kumamoto University; Aichi Cancer Center								AONO S, 1993, BIOCHEM BIOPH RES CO, V197, P1239, DOI 10.1006/bbrc.1993.2610; AONO S, 1994, PEDIATR RES, V35, P629, DOI 10.1203/00006450-199406000-00002; BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; HERIWEGH KP, 1972, BIOCHEM J, V129, P605; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; PETERS WHM, 1984, J BIOL CHEM, V259, P1701; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RITTER JK, 1992, J BIOL CHEM, V26, P3257; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89	10	150	159	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					958	959		10.1016/S0140-6736(95)90702-5	http://dx.doi.org/10.1016/S0140-6736(95)90702-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715297				2022-12-01	WOS:A1995QT91900012
J	BAILEY, TC; FRASER, VJ; SPITZNAGEL, EL; DUNAGAN, WC				BAILEY, TC; FRASER, VJ; SPITZNAGEL, EL; DUNAGAN, WC			RISK-FACTORS FOR A POSITIVE TUBERCULIN SKIN-TEST AMONG EMPLOYEES OF AN URBAN, MIDWESTERN TEACHING HOSPITAL	ANNALS OF INTERNAL MEDICINE			English	Article						TUBERCULIN TEST; AGE FACTORS; RACIAL STOCKS; SOCIOECONOMIC FACTORS; TUBERCULOSIS	HEALTH-CARE WORKERS; MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL TRANSMISSION; INFECTION; OUTBREAK; PROGRAM	Objective: To determine the prevalence and incidence of and the relative risks for positive tuberculin skin tests among employees of a large, urban teaching hospital. Design: Retrospective cohort study. Setting: Barnes Hospital, St, Louis, Missouri. Participants: Hospital personnel employed at any time between January 1989 and July 1991. Results: 684 of 6070 employees screened (11.3% [95% CI, 10.4% to 12.1%]) had positive tuberculin skin tests. Factors associated with a positive result were age (odds ratio, 2.02 per decade [CI, 1.87 to 2.18]; P < 0.0001); black race (odds ratio, 1.58 [CI, 1.26 to 2.00]; P < 0.0001); Asian race (odds ratio, 16.7 [CI, 9.33 to 29.9]; P < 0.0001); Hispanic ethnicity (odds ratio, 9.45 [CI, 3.58 to 25.0]; P < 0.0001); and percentage of low-income persons within the employee's residential postal zone (odds ratio, 1.14 per 10% [CI, 1.05 to 1.23]; P = 0.001). Twenty-nine of 3106 employees who had at least two tests had skin-test conversions (0.93% [CI, 0.60% to 1.3%]); 15 of these conversions (52%) occurred among employees who had no direct contact with patients. Only the percentage of low-income persons within the employee's residential postal zone (odds ratio 1.39 [CI, 1.09 to 1.78]; P = 0.0075) was independently associated with conversion. Conclusions: The most important associations with a positive tuberculin skin test were older age, minority group status, and the proportion of low-income persons within the employee's residential postal zone. Skin-test conversion was independently associated only with the percentage of low-income persons in the employee's postal zone. Stratifying employees according to degree of contact with patients or according to departmental group was not useful in determining risk for a positive tuberculin skin test or for skin-test conversion. For certain groups of employees, an exposure to tuberculosis in the community probably poses a greater risk than exposure in the hospital setting.			BAILEY, TC (corresponding author), WASHINGTON UNIV, SCH MED, BOX 8217, 660 S EUCLID, ST LOUIS, MO 63110 USA.			Fraser, Victoria/0000-0001-6251-0733				ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306; AITKEN ML, 1987, AM REV RESPIR DIS, V136, P805, DOI 10.1164/ajrccm/136.4.805; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; BERMAN J, 1981, AM J PUBLIC HEALTH, V71, P1217, DOI 10.2105/AJPH.71.11.1217; Dowdle W R, 1989, MMWR Suppl, V38, P1; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECKER MD, 1993, INFECT CONT HOSP EP, V14, P689, DOI 10.1086/646671; DIPERRI G, 1992, LANCET, V340, P682; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRASER VJ, 1994, INFECT CONT HOSP EP, V15, P95; FRASER VJ, 1993, INFECT CONT HOSP EP, V14, P623; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; HOGE CW, 1994, AM J EPIDEMIOL, V139, P520, DOI 10.1093/oxfordjournals.aje.a117035; JARVIS WR, 1995, ANN INTERN MED, V122, P142, DOI 10.7326/0003-4819-122-2-199501150-00011; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; LIFSON AR, 1993, J INFECT DIS, V168, P1048, DOI 10.1093/infdis/168.4.1048; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAAD I, 1989, INFECT CONT HOSP EP, V10, P465, DOI 10.1086/645922; RILEY RL, 1962, AM REV RESPIR DIS, V85, P511; SNIDER DE, 1984, AM J INFECT CONTROL, V12, P305, DOI 10.1016/0196-6553(84)90001-4; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STROUD L, 1993, INTERSCIENCE C ANTIM; 1990, MMWR-MORBID MORTAL W, V39, P9; 1994, FED REGISTER, V59, P54242	33	61	63	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					580	585		10.7326/0003-4819-122-8-199504150-00004	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887551				2022-12-01	WOS:A1995QR52500004
J	BHATTI, N; LAW, MR; MORRIS, JK; HALLIDAY, R; MOOREGILLON, J				BHATTI, N; LAW, MR; MORRIS, JK; HALLIDAY, R; MOOREGILLON, J			INCREASING INCIDENCE OF TUBERCULOSIS IN ENGLAND AND WALES - A STUDY OF THE LIKELY CAUSES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine factors responsible for the recent increase in tuberculosis in England and Wales. Design-Study of the incidence of tuberculosis (a) in the 403 local authority districts in England and Wales, ranked according to Jarman score, and (b) in one deprived inner city district, according to ethnic origin and other factors. Setting-(a) England and Wales 1980-92, and (b) the London borough of Hackney 1986-93. Main outcome measure-Age and sex adjusted rate of tuberculosis. Results-In England and Wales notifications of tuberculosis increased by 12% between 1988 and 1992. The increase was 35% in the poorest 10th of the population and 13% in the next two; and in the remaining 70% there was no increase. In Hackney the increase affected traditionally high risk and low risk ethnic groups to a similar extent. In the ''low risk'' white and West Indian communities the incidence increased by 58% from 1986-8 (78 cases) to 1991-3 (123), whereas in residents of Indian subcontinent origin the increase was 41% (from 51 cases to 72). Tuberculosis in recently arrived immigrants-refugees (11% of the Hackney population) and Africans (6%)-accounted for less than half of the overall increase, and the proportion of such residents was much higher than in most socioeconomically deprived districts. The local increase was not due to an increase in the proportion of cases notified, to HIV infection, nor to an increase in homeless people. Conclusions-The national rise in tuberculosis affects only the poorest areas. Within one such area all residents (white and established ethnic minorities) were affected to a similar extent. The evidence indicates a major role for socioeconomic factors in the increase in tuberculosis and only a minor role for recent immigration from endemic areas.	ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND; E LONDON & CITY DIST HLTH AUTHOR,DEPT PUBL HLTH,LONDON E3 2AN,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT RESP MED,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London				Morris, Joan/0000-0002-7164-612X				AWAIH J, 1992, HLTH CITY HACKNEY AN, P24; JACOBSON B, 1992, BRIT MED J, V305, P1344, DOI 10.1136/bmj.305.6865.1344; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JENKINS SP, 1994, DISCUSSION PAPER SER, V9407; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221; WATSON JM, 1991, COMMUN DIS REP CDR R, V1, P13; 1994, HLTH STATISTICS 1992; 1994, COMMUNICABLE DISEASE	9	119	119	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					967	969		10.1136/bmj.310.6985.967	http://dx.doi.org/10.1136/bmj.310.6985.967			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728031	Green Published			2022-12-01	WOS:A1995QT90400018
J	BROWN, JS; WELLS, F; DUCKWORTH, G; PAUL, EA; BARNES, NC				BROWN, JS; WELLS, F; DUCKWORTH, G; PAUL, EA; BARNES, NC			IMPROVING NOTIFICATION RATES FOR TUBERCULOSIS	BRITISH MEDICAL JOURNAL			English	Article									LONDON CHEST HOSP,E LONDON TB CTR,LONDON E2 9JX,ENGLAND; ROYAL LONDON HOSP,COMMUNICABLE DIS CONTROL E LONDON & CITY HLTH AUT,LONDON E1 1BB,ENGLAND; ROYAL LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital; Barts Health NHS Trust; Royal London Hospital								[Anonymous], 1978, Tubercle, V59, P245; CAPEWELL S, 1984, BRIT J DIS CHEST, V78, P317; HICKMAN M, 1992, BRIT MED J, V304, P1567, DOI 10.1136/bmj.304.6841.1567-c; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015	4	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					974	974		10.1136/bmj.310.6985.974	http://dx.doi.org/10.1136/bmj.310.6985.974			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728034	Green Published			2022-12-01	WOS:A1995QT90400021
J	CLARK, AL; COATS, AJS				CLARK, AL; COATS, AJS			SEVERITY OF HEART-FAILURE AND DOSAGE OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS	BRITISH MEDICAL JOURNAL			English	Article											CLARK, AL (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				Acute Infarction Ramipril Efficacy (AIRE) Study Inves- tigators, 1993, LANCET, V342, P821; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; KLEBER FX, 1992, BRIT HEART J, V67, P289; MCMURRAY J, 1993, BR J MED EC, V6, P99; 1991, NEW ENGL J MED, V352, P293	5	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					973	974		10.1136/bmj.310.6985.973	http://dx.doi.org/10.1136/bmj.310.6985.973			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728033	Green Published			2022-12-01	WOS:A1995QT90400020
J	GLANCY, JM; GARRATT, CJ; WOODS, KL; DEBONE, DP				GLANCY, JM; GARRATT, CJ; WOODS, KL; DEBONE, DP			QT DISPERSION AND MORTALITY AFTER MYOCARDIAL-INFARCTION	LANCET			English	Article							2-YEAR FOLLOW-UP; SUDDEN-DEATH; INTERVAL PROLONGATION; DISCHARGE; MAGNESIUM; RISK	QT dispersion may serve as a measure of variability in ventricular recovery time and may be a means of identifying patients at risk of arrhythmias and sudden death after acute myocardial infarction. We investigated this possibility on electrocardiograms (ECGs) recorded 2 or 3 days after infarction (early) and at least 4 weeks later (late). 163 patients who died between 1 day and 5 years after infarct were compared with an equal number of survivors matched for age and sex. 53 of the patients who died and 82 survivors also had late ECGs. There was no difference in early QT dispersion between the patients who died and the survivors (mean QT(c) dispersion 112.1 [SD 44.4] vs 109.9 [42.7] ms(1/2)). QT(c) dispersion fell significantly from early to late ECGs in survivors (110.9 [48.5] to 76.5 [28.8] ms(1/2)), but not in patients who died during follow-up (108.0 [51.0] to 98.9 [43.1] ms(1/2)). The difference between the groups in the mean change was significant (34.4 [55.2] vs 9.1 [60.8] ms(1/2), p=0.016). QT dispersion measured on an ECG recorded 2 or 3 days after acute myocardial infarction does not predict mortality during the next 5 years. Increased QT dispersion on ECGs recorded at least 4 weeks after infarct may be associated with subsequent mortality, but this finding must be confirmed in a prospective trial.	UNIV LEICESTER,DIV CARDIOL,LEICESTER,LEICS,ENGLAND; UNIV LEICESTER,DEPT MED & THERAPEUT,DIV CLIN PHARMACOL,LEICESTER,LEICS,ENGLAND	University of Leicester; University of Leicester								AHNVE S, 1984, AM HEART J, V108, P395, DOI 10.1016/0002-8703(84)90631-8; BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; BHULLAR HK, 1993, J ELECTROCARDIOL, V26, P321, DOI 10.1016/0022-0736(93)90053-G; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; BUTROUS GS, 1989, CLIN ASPECTS VENTRIC, P379; DAVEY P, 1994, BRIT HEART J, V71, P268; DAY CP, 1990, BRIT HEART J, V63, P342; DOROGHAZI RM, 1977, AM J CARDIOL, V41, P684; ELDAR M, 1990, BRIT HEART J, V63, P273; GLANCY JM, 1994, CLIN SCI S30, V86, P18; HIGHAM P, 1994, BRIT HEART J, V71, P508; HIGHAM PD, 1991, CIRCULATION S2, V13, P61; LAUNBJERG J, 1994, BRIT MED J, V308, P1196, DOI 10.1136/bmj.308.6938.1196; LEPESCHKIN E, 1952, CIRCULATION, V6, P378, DOI 10.1161/01.CIR.6.3.378; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; POHJOLASINTONEN S, 1986, AM J CARDIOL, V57, P1066, DOI 10.1016/0002-9149(86)90675-2; POTRATZ J, 1993, EUR HEART J S, V114, P254; PYE M, 1993, BRIT HEART J, V71, P511; SCHWARTZ PJ, 1978, CIRCULATION, V57, P1074, DOI 10.1161/01.CIR.57.6.1074; SHEN AC, 1972, AM J PATHOL, V67, P417; WARD D E, 1988, European Heart Journal, V9, P139; WHEELAN K, 1986, AM J CARDIOL, V57, P745, DOI 10.1016/0002-9149(86)90606-5; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; ZARDINI P, 1993, AM J CARDIOL, V72, pG98, DOI 10.1016/0002-9149(93)90114-R; 1983, NEW ENGL J MED, V309, P331	25	256	258	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					945	948		10.1016/S0140-6736(95)90697-5	http://dx.doi.org/10.1016/S0140-6736(95)90697-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715292				2022-12-01	WOS:A1995QT91900007
J	GROVER, SA; LOWENSTEYN, I; ESREY, KL; STEINERT, Y; JOSEPH, L; ABRAHAMOWICZ, M				GROVER, SA; LOWENSTEYN, I; ESREY, KL; STEINERT, Y; JOSEPH, L; ABRAHAMOWICZ, M			DO DOCTORS ACCURATELY ASSESS CORONARY RISK IN THEIR PATIENTS - PRELIMINARY-RESULTS OF THE CORONARY HEALTH ASSESSMENT STUDY	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; COST-EFFECTIVENESS; LIFE EXPECTANCY; CHOLESTEROL; HYPERCHOLESTEROLEMIA; PHYSICIANS; PREVENTION; FRAMINGHAM; HYPERLIPIDEMIA; INTERNISTS	Objective-To evaluate the ability of doctors in primary care to assess risk patients) risk of coronary heart disease. Design-Questionnaire survey. Setting-Continuing medical education meetings, Ontario and Quebec, Canada. Subjects-Community based doctors who agreed to enrol in the coronary health assessment study. Main outcome measure-Ratings of coronary risk factors and estimates by doctors of relative and absolute coronary risk of two hypothetical patients and the ''average'' 40 year old Canadian man and 70 year old Canadian woman. Results-253 doctors answered the questionnaire. For 30 year olds the doctors rated cigarette smoking as the most important risk factor and raised serum triglyceride concentrations as the least important; for 70 year old patients they rated diabetes as the most important risk factor and raised serum triglyceride concentrations as the least important. They rated each individual risk factor as significantly less important for 70 year olds than for 30 year olds (all risk factors, P < 0.001). They showed a strong understanding of the relative importance of specific risk factors, and most were confident in their ability to estimate coronary risk. While doctors accurately estimated the relative risk of a specific patient (compared with the average adult) they systematically overestimated the absolute baseline risk of developing coronary disease and the risk reductions associated with specific interventions. Conclusions-Despite guidelines on targeting patients at high risk of coronary disease accurate assessment of coronary risk remains difficult for many doctors. Additional strategies must be developed to help doctors to assess better their patients' coronary risk.	SIR MORTIMER B DAVIS JEWISH HOSP,DEPT FAMILY MED,MONTREAL,PQ H3T 1E2,CANADA	McGill University	GROVER, SA (corresponding author), MONTREAL GEN HOSP,CTR ANAL COST EFFECT CARE,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3G 1A4,CANADA.			Abrahamowicz, Michal/0000-0002-3172-3952				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; DEFRIESE GH, 1990, PREVENTING DISEASE R, P460; DUNNIGAN MG, 1993, BRIT MED J, V306, P1355, DOI 10.1136/bmj.306.6889.1355; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1991, CAN MED ASSOC J, V144, P161; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; GROVER SA, 1994, ARCH INTERN MED, V154, P1697, DOI 10.1001/archinte.154.15.1697; GROVER SA, 1993, CARDIOVASC DRUG THER, V7, P761, DOI 10.1007/BF00878927; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LANGNER NR, 1989, CAN MED ASSOC J, V141, P33; LAUPACIS A, 1990, CAN MED ASSOC J, V142, P329; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; MANN KV, 1989, PREV MED, V18, P45, DOI 10.1016/0091-7435(89)90053-4; MCBRIDE PE, 1992, AM HEART J, V123, P817, DOI 10.1016/0002-8703(92)90535-4; NAYLOR CD, 1990, J CLIN EPIDEMIOL, V43, P1021; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OLIVER MF, 1993, CARDIOVASC DRUG THER, V7, P785, DOI 10.1007/BF00878931; OPIE LH, 1993, CARDIOVASC DRUG THER, V7, P779, DOI 10.1007/BF00878930; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; TANNENBAUM TN, 1990, CAN MED ASSOC J, V143, P875; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; [No title captured]; 1981, 82538 HLTH WELF CAN; 1993, CAN MED ASSOC J, V148, P521; 1987, LANCET, V1, P377; 1993, JAMA-J AM MED ASSOC, V269, P3015; [No title captured]	34	130	131	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					975	978		10.1136/bmj.310.6985.975	http://dx.doi.org/10.1136/bmj.310.6985.975			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728035	Green Published, Green Submitted			2022-12-01	WOS:A1995QT90400022
J	KOLETZKO, S; HAISCH, M; SEEBOTH, I; BRADEN, B; HENGELS, K; KOLETZKO, B; HERING, P				KOLETZKO, S; HAISCH, M; SEEBOTH, I; BRADEN, B; HENGELS, K; KOLETZKO, B; HERING, P			ISOTOPE-SELECTIVE NONDISPERSIVE INFRARED SPECTROMETRY FOR DETECTION OF HELICOBACTER-PYLORI INFECTION WITH C-13-UREA BREATH TEST	LANCET			English	Note								C-13-urea breath tests were sampled in 51 subjects with an isotope-selective non-dispersive infrared spectrometer (NDIRS) and compared with the results of conventional isotope-ratio mass-spectrometry (IRMS). Delta-over-baseline values oi both methods correlated well (r=0.976 at 15 min and 0.985 at 30 min, both p<0.0005). With a cut-off for delta-over-baseline values of 5 parts per thousand (ie, 5 per thousand), both methods correctly classified all 36 Helicobacter-pylori-negative and all 15 H-pylori-positive subjects. All infected subjects had values over 11 parts per thousand in all samples with both methods. NDIRS is of equal value as IRMS for the diagnosis of H pylori infection. Because NDIRS gives on-line results and is easier and cheaper, we consider NDIRS useful for clinical practice.	UNIV DUSSELDORF,INST LASER MED,DUSSELDORF,GERMANY; UNIV DUSSELDORF,MED KLIN,DUSSELDORF,GERMANY; UNIV FRANKFURT,MED KLIN,FRANKFURT,GERMANY; MAX PLANCK INST QUANTUM OPT,GARCHING,GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Goethe University Frankfurt; Max Planck Society	KOLETZKO, S (corresponding author), UNIV MUNICH,KINDERPOLIKLIN,PETTENKOFERSTR 8A,D-80336 MUNICH,GERMANY.		Braden, Barbara/AAH-8693-2021; Braden, Barbara/AAI-7869-2020	Braden, Barbara/0000-0002-8534-6873				BRADEN B, 1994, Z GASTROENTEROL, V32, P198; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; DEMMELMAIR H, IN PRESS J PEDIATR G; DILL S, 1990, GUT, V31, P1237, DOI 10.1136/gut.31.11.1237; EGGERS RH, 1990, EUR J GASTROEN HEPAT, V2, P437; GHOOS YF, 1993, GASTROENTEROLOGY, V104, P1640, DOI 10.1016/0016-5085(93)90640-X; HAISCH M, IN PRESS ISOTOPENPRA; LOTTERER E, 1991, Z GASTROENTEROL, V29, P590; VANDENPLAS Y, 1992, PEDIATRICS, V90, P608	9	156	160	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					961	962		10.1016/S0140-6736(95)90704-1	http://dx.doi.org/10.1016/S0140-6736(95)90704-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715299				2022-12-01	WOS:A1995QT91900014
J	MANGTANI, P; JOLLEY, DJ; WATSON, JM; RODRIGUES, LC				MANGTANI, P; JOLLEY, DJ; WATSON, JM; RODRIGUES, LC			SOCIOECONOMIC DEPRIVATION AND NOTIFICATION RATES FOR TUBERCULOSIS IN LONDON DURING 1982-91	BRITISH MEDICAL JOURNAL			English	Article							NEW-YORK-CITY; OUTBREAK; HOMELESS; SHELTER	Objectives-To investigate the association between four sociodemographic measures (unemployment, overcrowding, low social class, and the proportion of migrants from areas of high prevalence of tuberculosis) and average level and rate of change of notification rates for tuberculosis. Design-Ecological analysis of both the average and the rate of change of standardised annual notification rates for tuberculosis from 1982-91 and sociodemographic measures from the 1981 and 1991 censuses. Setting-32 London boroughs. Subjects and data-Sociodemographic measures from the 1981 and 1991 censuses and tuberculosis notification rates for 1982-91. Main outcome measures-A measure of the association between average levels and rate of change in tuberculosis notification rates and four sociodemographic measures in 1981 and between the rate of change in tuberculosis notification rates between 1981 and 1991 and changes in sociodemographic measures between 1981 and 1991. Results-The average level of notifications was correlated with overcrowding and the proportion of migrants but not with unemployment or social class. No significant association was found between the rate of change in notification rates and sociodemographic measures in 1981. An association was found between increases in unemployment and the Fate of change in notification rates, but the effect was small. Changes in the levels of unemployment explained 23% of the variation between boroughs in the rate of change in their notification rates. Conclusion-The average tuberculosis notification rates were related to overcrowding and the proportion of migrants in 1981. Only increases in unemployment from 1981 to 1991, however, were significantly associated with the rate of change in notifications over the same period.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Public Health England	MANGTANI, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		RODRIGUES, LAURA CUNHA/AAO-4130-2021	Mangtani, Punam/0000-0001-7074-2999				BRADLEY BL, 1988, BMJ-BRIT MED J, V297, P595, DOI 10.1136/bmj.297.6648.595; BRESLOW NE, 1980, STATISTICAL METHODS, V2; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CARSTAIRS V, 1989, COMMUNITY MED, V11, P210, DOI 10.1093/oxfordjournals.pubmed.a042469; DRUCKER E, 1994, LANCET, V343, P1482, DOI 10.1016/S0140-6736(94)92588-7; GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PATEL KR, 1985, BRIT J DIS CHEST, V79, P60, DOI 10.1016/0007-0971(85)90008-7; RAMSDEN SS, 1988, J ROY COLL PHYS LOND, V22, P16; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; TEALE C, 1991, J INFECTION, V23, P327, DOI 10.1016/0163-4453(91)93224-Z; Townsend P, 1988, HLTH DEPRIVATION INE; WATSON JM, 1993, THORAX, V48, P199, DOI 10.1136/thx.48.3.199; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221; WATSON JM, 1991, COMMUN DIS REP CDR R, V1, P13; 1988, MMWR-MORBID MORTAL W, V36, P817; 1979, TUBERCLE, V191, P194; 1982, BRIT MED J, V284, P1454; 1985, BRIT MED J, V291, P658; 1992, THORAX, V47, P770	24	81	85	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					963	966		10.1136/bmj.310.6985.963	http://dx.doi.org/10.1136/bmj.310.6985.963			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728030	Green Published			2022-12-01	WOS:A1995QT90400017
J	MAPLE, PA; EFSTRATIOU, A; GEORGE, RC; ANDREWS, NJ; SESARDIC, D				MAPLE, PA; EFSTRATIOU, A; GEORGE, RC; ANDREWS, NJ; SESARDIC, D			DIPHTHERIA IMMUNITY IN UK BLOOD-DONORS	LANCET			English	Article							TETANUS; ADULTS; POPULATION; ANTITOXIN; TOXIN	Immunity to diphtheria was determined in serum samples from 1000 UK-born blood donors at the North London Blood Transfusion Centre during a three-month period in 1993; 125 women and 125 men were stratified in 10-year age groups, from 20 to 59. A tissue (vero cell)-culture toxin-neutralisation assay was used to measure serum diphtheria antitoxin concentrations. According to internationally accepted definitions (antitoxin <0.01 IU/mL=susceptibility, 0.01-0.09 IU/mL=basic protection, and greater than or equal to 0.1 IU/mL=full protection), 37.6% of donors were susceptible to diphtheria, 31.5% had basic protection, and 30.9% were fully protected. Log-linear modeling of the influence of age and sex on population immunity showed a significant trend (p<0.001) of decreasing immunity with increasing age: 25.2% of donors aged 20-29 were susceptible compared with 52.8% of those aged 50-59. There was a small sex effect (p=0.052); similar proportions of men and women were susceptible, but fewer women had full protection. There was no age-sex interaction on immunity (p=0.454). Our results suggest that booster immunisation of adults is necessary to increase herd immunity of the adult population.	PUBL HLTH LAB SERV,STAT UNIT,LONDON,ENGLAND; NATL INST BIOL STAND & CONTROLS,DIV BACTERIOL,POTTERS BAR,HERTS,ENGLAND	Public Health England; National Institute for Biological Standards & Control	MAPLE, PA (corresponding author), CENT PUBL HLTH LAB,RESP & SYSTEM INFECT LAB,LONDON NW9 5HT,ENGLAND.			Maple, Peter/0000-0002-5534-5191				AJELLO F, 1991, VACCINE, V9, P502, DOI 10.1016/0264-410X(91)90036-6; CELLESI C, 1989, VACCINE, V7, P417, DOI 10.1016/0264-410X(89)90155-2; CROSSLEY K, 1979, JAMA-J AM MED ASSOC, V242, P2298, DOI 10.1001/jama.242.21.2298; GALAZKA A, 1989, EPIDEMIOL INFECT, V103, P587, DOI 10.1017/S0950268800030983; GALAZKA AM, 1993, WHOEPIGEN9312; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; KWANTES W, 1984, J HYG-CAMBRIDGE, V93, P433, DOI 10.1017/S0022172400065025; MASTERTON RG, 1987, J INFECTION, V15, P27, DOI 10.1016/S0163-4453(87)91351-X; MELVILLESMITH M, 1988, J MED MICROBIOL, V25, P279, DOI 10.1099/00222615-25-4-279; MILLER E, 1994, BRIT MED J, V308, P598, DOI 10.1136/bmj.308.6928.598b; PALMER SR, 1983, BRIT MED J, V286, P624, DOI 10.1136/bmj.286.6365.624; PARISH HJ, 1955, BRIT MED J, V2, P631, DOI 10.1136/bmj.2.4940.631; SESARDIC D, 1992, LANCET, V340, P737, DOI 10.1016/0140-6736(92)92284-M; SIMONSEN O, 1989, DAN MED BULL, V36, P24; WEISS BP, 1983, AM J PUBLIC HEALTH, V73, P802, DOI 10.2105/AJPH.73.7.802; 1989, 2ND WHO M NAT PROGR; 1956, LANCET, V2, P1223; 1978, LANCET, V1, P428; 1961, BRIT MED J, V2, P763; 1953, STATISTICAL REV ENGL; 1944, NEW ANN SERIES 1, V19; 1945, 19445 UK MIN HLTH CI; 1993, JUL WHO M DIPHTH EP; 1957, BRIT MED J, V2, P167; 1994, COMMUNICAB DIS REP, V4, P47; 1955, 555 UK MIN HLTH CIRC; 1990, APR WHO M CONTR DIPH; 1962, BRIT MED J, V2, P149; 1993, SERIES MB2, V18	29	84	86	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					963	965		10.1016/S0140-6736(95)90705-X	http://dx.doi.org/10.1016/S0140-6736(95)90705-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715300				2022-12-01	WOS:A1995QT91900015
J	OTT, A; BRETELER, MMB; VANHARSKAMP, F; CLAUS, JJ; VANDERCAMMEN, TJM; GROBBEE, DE; HOFMAN, A				OTT, A; BRETELER, MMB; VANHARSKAMP, F; CLAUS, JJ; VANDERCAMMEN, TJM; GROBBEE, DE; HOFMAN, A			PREVALENCE OF ALZHEIMERS-DISEASE AND VASCULAR DEMENTIA - ASSOCIATION WITH EDUCATION - THE ROTTERDAM STUDY	BRITISH MEDICAL JOURNAL			English	Article							MENTAL STATE; HEALTH; EPIDEMIOLOGY; DIAGNOSIS; IMPACT	Objective-To estimate the prevalence of dementia and its subtypes in the general population and examine the relation of the disease to education. Design-Population based cross sectional study. Setting-Ommoord, a suburb of Rotterdam. Subjects-7528 participants of the Rotterdam study aged 55-106 years. Results-474 cases of dementia were detected, giving an overall prevalence of 6.3%, Prevalence ranged from 0.4% (5/1181 subjects) at age 55-59 years to 43.2% (19/44) at 95 years and over. Alzheimer's disease was the main subdiagnosis (339 cases; 72%); it was also the main cause of the pronounced increase in dementia with age. The relative proportion of vascular dementia (76 cases; 16%), Parkinson's disease dementia (30; 6%), and other dementias (24; 5%) decreased with age. A substantially higher prevalence of dementia was found in subjects with a low level of education. The association with education was not due to confounding by cardiovascular disease. Conclusions-The prevalence of dementia increases exponentially with age. About one third of the population aged 85 and over has dementia. Three quarters of all dementia is due to Alzheimer's disease. In this study an inverse dose-response relation was found between education and dementia -in particular, Alzheimer's disease.			OTT, A (corresponding author), ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		Grobbee, Diederick/C-7651-2014; Breteler, Monique M.B./J-5058-2014	Grobbee, Diederick/0000-0003-4472-4468; Breteler, Monique M.B./0000-0002-0626-9305				BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; BRETELER MMB, 1992, NEUROEPIDEMIOLOGY, V11, P23, DOI 10.1159/000110957; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; DARTIGUES JF, 1991, REV NEUROL-FRANCE, V147, P225; DEWEY ME, 1990, CASE FINDING DEMENTI; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIEDLAND RP, 1993, NEUROLOGY, V43, P246, DOI 10.1212/WNL.43.2.246; HASHINSKI V, 1983, NEUROL CLIN, V1, P27; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HOFMAN A, 1991, INT J EPIDEMIOL, V20, P735; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; ROCCA WA, 1991, ANN NEUROL, V30, P381, DOI 10.1002/ana.410300310; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; 1987, DIAGNOSTIC STATISTIC; 1987, SOI1978 NETH CENTR B; 1974, STATISTISCH JB	25	596	603	1	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					970	973		10.1136/bmj.310.6985.970	http://dx.doi.org/10.1136/bmj.310.6985.970			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT904	7728032	Green Published			2022-12-01	WOS:A1995QT90400019
J	SACKS, DL; KENNEY, RT; KREUTZER, RD; JAFFE, CL; GUPTA, AK; SHARMA, MC; SINHA, SP; NEVA, FA; SARAN, R				SACKS, DL; KENNEY, RT; KREUTZER, RD; JAFFE, CL; GUPTA, AK; SHARMA, MC; SINHA, SP; NEVA, FA; SARAN, R			INDIAN KALA-AZAR CAUSED BY LEISHMANIA-TROPICA	LANCET			English	Note							OPERATION DESERT-STORM	Kala-azar, or visceral leishmaniasis, in India is generally assumed to be a result of infection with Leishmania donovani. 15 parasite isolates collected over the past 10 years from patients with classical disease were typed by monoclonal antibodies, isoenzymes, and kDNA analysis. 4 were shown to be L tropica, a species historically associated with cutaneous disease and more recently a mild ''visceralising'' disease from the Desert Storm experience. The results confirm that L tropica is a co-endemic agent of visceral leishmaniasis in India, and may shed light on the rising frequency of therapeutic unresponsiveness to sodium antimony gluconate, which complicates treatment of this lethal disease.	YOUNGSTOWN STATE UNIV,DEPT BIOL,YOUNGSTOWN,OH; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PARASITOL,JERUSALEM,ISRAEL; INDIAN COUNCIL MED RES,RAJENDRA MEM RES INST,PATNA,BIHAR,INDIA	University System of Ohio; Youngstown State University; Hebrew University of Jerusalem; Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI)	SACKS, DL (corresponding author), NIAID,PARASIT DIS LAB,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA.		Jaffe, Charles/AAU-8686-2020	Jaffe, Charles/0000-0002-2042-9993				JAFFE CL, 1987, J IMMUNOL, V138, P1310; KREUTZER RD, 1993, AM J TROP MED HYG, V49, P357, DOI 10.4269/ajtmh.1993.49.357; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MEBRAHTU Y, 1989, AM J TROP MED HYG, V41, P289, DOI 10.4269/ajtmh.1989.41.289; SCHNUR LF, 1989, NATO ADV SCI I SERIE, P939; SMYTH AJ, 1992, PARASITOLOGY, V105, P183, DOI 10.1017/S0031182000074096; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8	7	95	100	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					959	961		10.1016/S0140-6736(95)90703-3	http://dx.doi.org/10.1016/S0140-6736(95)90703-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715298				2022-12-01	WOS:A1995QT91900013
J	SHINDO, M; ARAI, K; SOKAWA, Y; OKUNO, T				SHINDO, M; ARAI, K; SOKAWA, Y; OKUNO, T			HEPATIC HEPATITIS-C VIRUS-RNA AS A PREDICTOR OF A LONG-TERM RESPONSE TO INTERFERON-ALPHA THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C VIRUSES; HEPATITIS C; RNA, VIRAL; INTERFERON-ALPHA; HEPATITIS, CHRONIC ACTIVE	POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; CONTROLLED TRIAL; VIRAL SEQUENCES; ALFA THERAPY; NON-A; SERUM; LIVER; GENOTYPES; PLACEBO	Objective: To identify predictors of a long-term response to interferon-alpha therapy in chronic hepatitis C and to determine whether hepatitis C virus (HCV) was eradicated in patients with chronic hepatitis C who had a long-term response to therapy. Design: A retrospective analysis. Setting: In- and outpatient liver clinic of a municipal hospital in Japan. Patients: 47 patients with chronic hepatitis C who responded to interferon-alpha were divided into two groups: 22 patients with a long-term response (serum aminotransferase levels remained normal for > 1 year after therapy) and 25 patients with a short-term response (serum aminotransferase levels increased again after therapy). Measurements: Genotyping of HCV, titers of HCV RNA in liver and serum samples (using the reverse transcriptase-polymerase chain reaction), histologic activity index, and liver histologic tests during and 1 year after therapy. Results: Among the 22 long-term responders, HCV RNA was no longer detectable in liver and serum samples of 21 (95%) at the end of therapy and remained undetectable in the serum of 20 (98%) and in the liver of 19 (86%) 1 year after therapy. Liver histologic tests improved substantially immediately after therapy and 1 year after therapy in the long-term responders; however, 18 (82%) of these patients still had mild, chronic hepatitis. Among the 25 short-term responders, HCV RNA was still detected in the liver of 19 (76%) and in the serum of 9 (36%) at the end of therapy. Multivariate logistic regression analysis showed that the persistent presence of hepatic HCV RNA at the end of therapy was the strongest predictor of relapse. Conclusion: These findings suggest that HCV infection was eradicated in most of the long-term responders to interferon-alpha therapy because HCV RNA could no longer be detected in their serum and liver samples and because a significant improvement gradually occurred in their liver histologic results. The persistent presence of hepatic HCV RNA at the end of therapy was the most important predictor of relapse.	KYOTO INST TECHNOL, KYOTO, JAPAN	Kyoto Institute of Technology	SHINDO, M (corresponding author), AKASHI MUNICIPAL HOSP, DEPT INTERNAL MED, 1-33 TAKASHOMACHI, AKASHI, HYOGO 673, JAPAN.							BALART LA, 1993, GASTROENTEROLOGY, V104, P1472, DOI 10.1016/0016-5085(93)90358-J; CAMPS J, 1994, J HEPATOL, V21, P4, DOI 10.1016/S0168-8278(94)80129-0; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS GL, 1994, J HEPATOL, V21, P1, DOI 10.1016/S0168-8278(94)80128-2; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DAVIS GL, 1990, HEPATOLOGY, V12, P905; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIBISCEGLIE AM, 1993, GASTROENTEROLOGY, V105, P858, DOI 10.1016/0016-5085(93)90905-R; FONG TL, 1991, J CLIN INVEST, V88, P1058, DOI 10.1172/JCI115368; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; HAGIWARA H, 1993, GASTROENTEROLOGY, V104, P877, DOI 10.1016/0016-5085(93)91025-D; KANAI K, 1992, LANCET, V339, P1543, DOI 10.1016/0140-6736(92)91311-U; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SERFATY L, 1994, J HEPATOL, V21, P12, DOI 10.1016/S0168-8278(94)80130-4; SHINDO M, 1992, J INFECT DIS, V166, P424, DOI 10.1093/infdis/166.2.424; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	24	103	103	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					586	591		10.7326/0003-4819-122-8-199504150-00005	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887552				2022-12-01	WOS:A1995QR52500005
J	STEEL, M				STEEL, M			TELOMERASE THAT SHAPES OUR ENDS	LANCET			English	Editorial Material							HUMAN FIBROBLASTS; CELLS				STEEL, M (corresponding author), UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS,FIFE,SCOTLAND.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENIS H, 1993, TRENDS GENET, V9, P7, DOI 10.1016/0168-9525(93)90065-P; GILSON E, 1993, TRENDS CELL BIOL, V33, P128; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; STEEL CM, 1994, BRIT MED BULL, V50, P536, DOI 10.1093/oxfordjournals.bmb.a072909	11	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					935	936		10.1016/S0140-6736(95)90692-4	http://dx.doi.org/10.1016/S0140-6736(95)90692-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715287				2022-12-01	WOS:A1995QT91900002
J	TEMMERMAN, M; NDINYAACHOLA, J; AMBANI, J; PLOT, P				TEMMERMAN, M; NDINYAACHOLA, J; AMBANI, J; PLOT, P			THE RIGHT NOT TO KNOW HIV-TEST RESULTS	LANCET			English	Article							WOMEN; ZAIRE	Large numbers of pregnant women in Africa have been invited to participate in studies on HIV infection. Study protocols adhere to guidelines on voluntary participation after pre-test and post-test counselling and informed consent; nevertheless, women may consent because they have been asked to do so without fully understanding the implications of being tested for HIV. Our studies in Nairobi, Kenya, show that most women informed consent did not actively results, less than one third informed their partner, and violence against women because of a positive HIV-antibody test was common. It is important to have carefully designed protocols weighing the benefits against the potential harms for women participating in a study. Even after having consented to HIV testing, women should have the right not to be told their result.	UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; INST TROP MED,DEPT MED MICROBIOL,ANTWERP,BELGIUM	University of Nairobi; Institute of Tropical Medicine (ITM)								ALLEN S, 1993, AM J PUBLIC HEALTH, V83, P705, DOI 10.2105/AJPH.83.5.705; HEYWARD WL, 1993, AIDS, V7, P1633, DOI 10.1097/00002030-199312000-00014; RYDER RW, 1991, AIDS, V5, P1521, DOI 10.1097/00002030-199112000-00016; TEMMERMAN M, 1992, AIDS, V6, P1181, DOI 10.1097/00002030-199210000-00019; TEMMERMAN M, 1990, AIDS Care, V2, P247, DOI 10.1080/09540129008257737; TEMMERMAN M, 1994, OBSTET GYNECOL, V83, P495, DOI 10.1097/00006250-199404000-00002; TEMMERMAN M, IN PRESS AM J OBSTET; 1989, WHOGPAESR892; 1990, WHO AIDS SERIES, V8	9	164	167	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					969	970						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT919	7619122				2022-12-01	WOS:A1995QT91900017
J	TOWNEND, JN; LITTLER, WA				TOWNEND, JN; LITTLER, WA			CARDIAC VAGAL ACTIVITY - A TARGET FOR INTERVENTION IN HEART-DISEASE	LANCET			English	Editorial Material							CONVERTING ENZYME-INHIBITION; ACUTE MYOCARDIAL-INFARCTION; FAILURE; HYDRALAZINE; MORTALITY; TRIAL; TONE				TOWNEND, JN (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT CARDIOVASC MED,BIRMINGHAM,W MIDLANDS,ENGLAND.			Townend, Jonathan/0000-0002-5881-5806				ABLAD B, 1991, J AM COLL CARDIOL, V17, pA1545; BINKLEY PF, 1993, J AM COLL CARDIOL, V21, P655, DOI 10.1016/0735-1097(93)90098-L; BONADUCE D, 1994, CIRCULATION, V90, P108, DOI 10.1161/01.CIR.90.1.108; CASADEI B, 1993, CIRCULATION, V88, P353, DOI 10.1161/01.CIR.88.2.353; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; ECKBERG DL, 1971, NEW ENGL J MED, V285, P877, DOI 10.1056/NEJM197110142851602; FARRELL TG, 1992, BRIT HEART J, V67, P129; FONAROW GC, 1992, J AM COLL CARDIOL, V19, P842, DOI 10.1016/0735-1097(92)90529-V; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LAROVERE MT, 1994, CIRCULATION, V90, P838, DOI 10.1161/01.CIR.90.2.838; LUMBERS ER, 1979, J PHYSIOL-LONDON, V294, P69, DOI 10.1113/jphysiol.1979.sp012915; MALLIANI A, 1994, BRIT HEART J, V71, P1; TOWNEND JN, IN PRESS HYPERTENSIO; WILKSTRAND J, 1992, EUR HEART J SD, V113, P111; ZUANETTI G, 1987, CIRC RES, V61, P429, DOI 10.1161/01.RES.61.3.429	16	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					937	938		10.1016/S0140-6736(95)90694-0	http://dx.doi.org/10.1016/S0140-6736(95)90694-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715289				2022-12-01	WOS:A1995QT91900004
J	WISNIEWSKI, T; LALOWSKI, M; GOLABEK, A; VOGEL, T; FRANGIONE, B				WISNIEWSKI, T; LALOWSKI, M; GOLABEK, A; VOGEL, T; FRANGIONE, B			IS ALZHEIMERS-DISEASE AN APOLIPOPROTEIN-E AMYLOIDOSIS	LANCET			English	Note							BINDING; PEPTIDE; ALLELE	The presence of the apolipoprotein E4 allele has been identified as a major risk factor for late-onset Alzheimer's disease. Apolipoprotein E has also been found immunohistochemically in Alzheimer's disease lesions. We biochemically isolated amyloid beta from senile plaques and found that a carboxyl-terminal fragment (residues 216-299) of apolipoprotein E co-purified. In vitro this fragment from recombinant apolipoprotein E could form amyloid-like fibrils, which were Congo-red positive. Thus senile plaques may contain both amyloid beta and apolipoprotein E amyloid fibrils.	NYU,MED CTR,DEPT NEUROL,NEW YORK,NY 10016; BIOTECHNOL GEN LTD,REHOVOT,ISRAEL	New York University	WISNIEWSKI, T (corresponding author), NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016, USA.		Wisniewski, Thomas/Q-6525-2019; Lalowski, Maciej/AAB-4151-2019	Wisniewski, Thomas/0000-0002-3379-8966; Lalowski, Maciej/0000-0002-3683-4096	NATIONAL INSTITUTE ON AGING [R01AG008721, R01AG005891, R35AG010953, R37AG005891] Funding Source: NIH RePORTER; NIA NIH HHS [AG05891, AG08721, AG10953] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; PEPYS MB, 1995, IMMUNOLOGICAL DISEAS, P637; Prelli F., 1994, Society for Neuroscience Abstracts, V20, P1642; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	10	147	151	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					956	958		10.1016/S0140-6736(95)90701-7	http://dx.doi.org/10.1016/S0140-6736(95)90701-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715296	hybrid			2022-12-01	WOS:A1995QT91900011
J	DAMBROSIO, D; HIPPEN, KL; MINSKOFF, SA; MELLMAN, I; PANI, G; SIMINOVITCH, KA; CAMBIER, JC				DAMBROSIO, D; HIPPEN, KL; MINSKOFF, SA; MELLMAN, I; PANI, G; SIMINOVITCH, KA; CAMBIER, JC			RECRUITMENT AND ACTIVATION OF PTP1C IN NEGATIVE REGULATION OF ANTIGEN RECEPTOR SIGNALING BY FC-GAMMA-RIIB1	SCIENCE			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASES; FC-GAMMA RECEPTOR; LYMPHOCYTES-B; CROSS-LINKING; MOTH-EATEN; PHOSPHOTYROSINE PHOSPHATASE; IMMUNODEFICIENT MUTANT; MOTHEATEN LOCUS; SH2 DOMAINS	Coligation of the Fc receptor on B cells, Fc gamma RIIB1, with the B cell antigen receptor (BCR) leads to abortive BCR signaling. Here it was shown that the Fc gamma RIIB1 recruits the phosphotyrosine phosphatase PTP1C after BCR coligation. This association is mediated by the binding of a 13-amino acid tyrosine-phosphorylated sequence to the carboxyl terminal Src homology 2 domain of PTP1C and activates PTP1C. Inhibitory signaling and PTP1C recruitment are dependent on the presence of the tyrosine within the 13-amino acid sequence. Inhibitory signaling mediated by Fc gamma RIIB1 is deficient in motheaten mice which do not express functional PTP1C. Thus, PTP1C is an effector of BCR-Fc gamma RIIB1 negative signal cooperativity.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Yale University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Mellman, Ira/ABG-5896-2020; Siminovitch, Katherine/K-1475-2013; Pani, Giovambattista/AAB-1446-2019	Pani, Giovambattista/0000-0001-7133-8728; Cambier, John/0000-0002-7803-242X				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN PL, 1971, IMMUNOLOGY, V21, P967; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; DAMBROSIO D, UNPUB; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FRIDMAN WH, 1992, IMMUNOL REV, V125, P49, DOI 10.1111/j.1600-065X.1992.tb00625.x; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JONES B, 1986, J IMMUNOL, V136, P348; JUSTEMENT LB, 1989, J IMMUNOL, V143, P881; KIM KJ, 1979, J IMMUNOL, V122, P549; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHLER H, 1977, J IMMUNOL, V119, P1979; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1976, J IMMUNOL, V116, P936; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SHULTZ LD, 1988, CURR TOP MICROBIOL, V137, P216; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WILSON HA, 1987, J IMMUNOL, V138, P1712; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	42	526	529	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					293	297		10.1126/science.7716523	http://dx.doi.org/10.1126/science.7716523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716523				2022-12-01	WOS:A1995QT18500040
J	HIDALGO, P; MACKINNON, R				HIDALGO, P; MACKINNON, R			REVEALING THE ARCHITECTURE OF A K+ CHANNEL PORE THROUGH MUTANT CYCLES WITH A PEPTIDE INHIBITOR	SCIENCE			English	Article							POTASSIUM CHANNEL; TEA BLOCKADE; BINDING-SITE; CHARYBDOTOXIN; ION; TETRAETHYLAMMONIUM; SELECTIVITY; REGION	Thermodynamic mutant cycles provide a formalism for studying energetic coupling between amino acids on the interaction surface in a protein-protein complex. This approach was applied to the Shaker potassium channel and to a high-affinity peptide inhibitor (scorpion toxin) that binds to its pore entryway. The assignment of pairwise interactions defined the spatial arrangement of channel amino acids with respect to the known inhibitor structure. A strong constraint was placed on the Shaker channel pore-forming region by requiring its amino-terminal border to be 12 to 15 angstroms from the central axis. This method is directly applicable to sodium, calcium, and other ion channels where inhibitor or modulatory proteins bind with high affinity.			HIDALGO, P (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.		Hidalgo, Patricia/I-7506-2013	Hidalgo, Patricia/0000-0002-4162-6590	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; DEBIASI M, 1993, BIOPHYS J, V64, pA341; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GROSS AF, UNPUB; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HILLE B, 1975, IONIC SELECTIVITY NA, P255; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KREZEL AM, UNPUB; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	23	417	424	1	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					307	310		10.1126/science.7716527	http://dx.doi.org/10.1126/science.7716527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716527				2022-12-01	WOS:A1995QT18500044
J	LIN, AN; MINDEN, A; MARTINETTO, H; CLARET, FX; LANGECARTER, C; MERCURIO, F; JOHNSON, GL; KARIN, M				LIN, AN; MINDEN, A; MARTINETTO, H; CLARET, FX; LANGECARTER, C; MERCURIO, F; JOHNSON, GL; KARIN, M			IDENTIFICATION OF A DUAL-SPECIFICITY KINASE THAT ACTIVATES THE JUN KINASES AND P38-MPK2	SCIENCE			English	Article							PROTEIN-KINASE; C-JUN; PHOSPHORYLATION; SERINE-63; PATHWAY; FAMILY; YEAST; RAF; MEK	One Ras-dependent protein kinase cascade leading from growth factor receptors to the ERK (extracellular signal-regulated kinases) subgroup of mitogen-activated protein kinases (MAPKs) is dependent on the protein kinase Raf-1, which activates the MEK(MAPK or ERK kinase) dual specificity kinases. A second protein kinase cascade leading to activation of the Jun kinases (JNKs) is dependent on MEKK (MEK kinase). A dual-specificity kinase that activates JNK, named JNKK, was identified that functions between MEKK and JNK. JNKK activated the JNKs but did not activate the ERKs and was unresponsive to Raf-1 in transfected Hela cells. JNKK also activated another MAPK, p38 (Mpk2; the mammalian homolog of HOG1 from yeast), whose activity is regulated similarly to that of the JNKs.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, DENVER, CO 80206 USA; SIGNAL PHARMACEUT, SAN DIEGO, CA 92110 USA	University of California System; University of California San Diego; National Jewish Health			Claret, Francois X/R-2104-2016	Claret, Francois X/0000-0003-4629-6495; Lange, Carol/0000-0003-2751-3976				AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHOI KY, 1994, CELL, V78, P499; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RE, UNPUB; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER C, UNPUB; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AL, UNPUB; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, UNPUB; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SU B, UNPUB; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	37	715	745	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	1995	268	5208					286	290		10.1126/science.7716521	http://dx.doi.org/10.1126/science.7716521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716521				2022-12-01	WOS:A1995QT18500038
J	LU, Q; MILLER, C				LU, Q; MILLER, C			SILVER AS A PROBE OF PORE-FORMING RESIDUES IN A POTASSIUM CHANNEL	SCIENCE			English	Article							K+ CHANNELS; CYSTEINE-SUBSTITUTION; RECEPTOR-SITE; TEA BLOCKADE; AMINO-ACIDS; ION; SELECTIVITY; STOICHIOMETRY; INACTIVATION; PERMEATION	In voltage-dependent potassium channels, the molecular determinants of ion selectivity are found in the P (pore) region, a stretch of 21 contiguous residues. Cysteine was introduced at each P region position in a Shaker potassium channel. Residues projecting side chains into the pore were identified by means of channel inhibition by a sulfhydryl-reactive potassium ion analog, silver ion. The pattern of silver ion reactivity contradicts a beta barrel architecture of potassium channel pores.	BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Howard Hughes Medical Institute; Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031768, R37GM031768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANDERSEN OS, COMMUNICATION; BOGUSZ S, 1992, PROTEIN ENG, V5, P295; BOLAND LM, 1994, BIOPHYS J, V66, P694, DOI 10.1016/S0006-3495(94)80843-4; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; DANCE IG, 1986, POLYHEDRON, V5, P1037, DOI 10.1016/S0277-5387(00)84307-7; DEBIASI M, 1993, BIOPHYS J, V65, P1235, DOI 10.1016/S0006-3495(93)81154-8; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEIGENBOTHAM L, 1993, THESIS HARVARD U; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LIESEGANG GW, 1977, J AM CHEM SOC, V99, P3240, DOI 10.1021/ja00452a006; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1993, SCIENCE, V261, P1692, DOI 10.1126/science.8397443; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; NYHOLM RS, 1961, P CHEM SOC LONDON, P273; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; TAGLIALATELA M, 1993, PFLUG ARCH EUR J PHY, V423, P104, DOI 10.1007/BF00374967; XU M, 1993, J BIOL CHEM, V268, P21505; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; ZHULKE RD, 1994, SOC NEUR ABSTR, V20, P864	38	174	176	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					304	307		10.1126/science.7716526	http://dx.doi.org/10.1126/science.7716526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716526				2022-12-01	WOS:A1995QT18500043
J	MAGEE, JC; JOHNSTON, D				MAGEE, JC; JOHNSTON, D			SYNAPTIC ACTIVATION OF VOLTAGE-GATED CHANNELS IN THE DENDRITES OF HIPPOCAMPAL PYRAMIDAL NEURONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; CA2+ CHANNELS; CALCIUM CHANNELS; GUINEA-PIG; P-TYPE; CELLS; RAT; SODIUM; CA1; DETERMINES	Activation of dendritic voltage-gated ion channels by local synaptic input was tested by simultaneous dendrite-attached patch-clamp recordings and whole-cell somatic voltage recordings made from CA1 pyramidal neurons in hippocampal slices. Schaffer collateral stimulation elicited subthreshold excitatory postsynaptic potentials (EPSPs) that opened voltage-gated sodium and calcium channels in the apical dendrites. The EPSP-activated sodium channels opened near the peak of the EPSP, whereas low voltage-activated calcium channels opened near the EPSP peak and during the decay phase. Dendritic high voltage-activated channels required somatic action potential generation or suprathreshold synaptic trains for activation. Dendritic voltage-gated channels are, therefore, likely to participate in dendritic integration of synaptic events.			MAGEE, JC (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030, USA.				NIMH NIH HHS [MH44754] Funding Source: Medline; NINDS NIH HHS [NS09482, NS11535] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH044754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011535, P01NS011535] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALZHEIMER C, 1993, J NEUROSCI, V13, P660; ANDERSEN P, 1990, COLD SH Q B, V55, P81; CHRISTIE BR, IN PRESS J NEUROPHYS; DEISZ RA, 1991, J NEUROPHYSIOL, V65, P371, DOI 10.1152/jn.1991.65.2.371; ELLINOR PT, 1993, NATURE, V32, P455; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hille B., 1992, IONIC CHANNELS EXCIT; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JAFFE DB, 1993, J NEUROPHYSIOL, V71, P1065; JASLOVE SW, 1992, NEUROSCIENCE, V47, P495, DOI 10.1016/0306-4522(92)90161-T; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MAGEE JC, IN PRESS J PHYSL LON; MARKRAM H, 1994, P NATL ACAD SCI USA, V91, P5207, DOI 10.1073/pnas.91.11.5207; MIYAKAWA H, 1992, NEURON, V9, P1163, DOI 10.1016/0896-6273(92)90074-N; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; ODELL TJ, 1991, J PHYSIOL-LONDON, V436, P739, DOI 10.1113/jphysiol.1991.sp018577; OGATA N, 1990, PFLUG ARCH EUR J PHY, V416, P594, DOI 10.1007/BF00382695; SAH P, 1988, J GEN PHYSIOL, V91, P373, DOI 10.1085/jgp.91.3.373; SCHNEIDER T, 1994, BIOPHYS J, V66, pA423; SPRUSTON N, 1994, TRENDS NEUROSCI, V17, P161, DOI 10.1016/0166-2236(94)90094-9; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; THIBAULT O, 1993, P NATL ACAD SCI USA, V90, P11792, DOI 10.1073/pnas.90.24.11792; TRAUB RD, 1979, J NEUROPHYSIOL, V42, P476, DOI 10.1152/jn.1979.42.2.476; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WHITE G, 1990, J NEUROPHYSIOL, V64, P1186, DOI 10.1152/jn.1990.64.4.1186; ZHANG JF, 1993, NEUROPHARMACOLOGY, V363, P1075	34	358	363	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					301	304		10.1126/science.7716525	http://dx.doi.org/10.1126/science.7716525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716525				2022-12-01	WOS:A1995QT18500042
J	MAIGNAN, S; GUILLOTEAU, JP; FROMAGE, N; ARNOUX, B; BECQUART, J; DUCRUIX, A				MAIGNAN, S; GUILLOTEAU, JP; FROMAGE, N; ARNOUX, B; BECQUART, J; DUCRUIX, A			CRYSTAL-STRUCTURE OF THE MAMMALIAN GRB2 ADAPTER	SCIENCE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SH3 DOMAINS; TYROSINE KINASES; PROTEIN; RAS	The mammalian growth factor receptor- binding protein Grb2 is an adaptor that mediates activation of guanine nucleotide exchange on Ras. Grb2 binds to the receptor through its SH2 domain and to the carboxyl-terminal domain of Son of sevenless through its two SH3 domains. It is thus a key element in the signal transduction pathway. The crystal structure of Grb2 was determined to 3.1 angstrom resolution. The asymmetric unit is composed of an embedded dimer. The interlaced junctions between the SH2 and SH3 domains bring the two adjacent faces of the SH3 domains in van der Waals contact but leave room for the binding of proline-rich peptides.	UNIV PARIS SUD, STRUCT BIOL LAB, CNRS, UNITE MIXTE RECH, F-91198 GIF SUR YVETTE, FRANCE; RHONE POULENC RORER, SERV BIOCHIM, F-94403 Vitry Sur Seine, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis								BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKOL V, 1995, J MOL BIOL, V246, P344, DOI 10.1006/jmbi.1994.0089; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	181	194	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	1995	268	5208					291	293		10.1126/science.7716522	http://dx.doi.org/10.1126/science.7716522			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716522				2022-12-01	WOS:A1995QT18500039
J	SHI, YG; BERG, JM				SHI, YG; BERG, JM			SPECIFIC DNA-RNA HYBRID BINDING BY ZINC-FINGER PROTEINS	SCIENCE			English	Article							CRYSTAL-STRUCTURE; 5S RNA; RECOGNITION; RULES	Zinc finger proteins of the Cys(2)His(2) type represent a large class of proteins that have been assumed to function by means of specific interactions with DNA. Experiments motivated by structural characteristics of zinc finger protein-DNA complexes revealed that certain zinc finger proteins bound DNA-RNA hybrids with affinities comparable to or greater than those for DNA duplexes. The interactions between the zinc finger proteins and the DNA-RNA hybrids were dependent on which strand was RNA and were sequence-specific. Thus, interactions with DNA-RNA hybrids should be considered with regard to the biological roles of zinc finger proteins.			SHI, YG (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205, USA.		Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Shi, Yigong/0000-0003-2030-168X; Berg, Jeremy/0000-0003-3022-0963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046257] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46257] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN A, 1989, CURRENT PROTOCOLS MO, V2; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Shi Y. G., UNPUB	15	82	124	3	43	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					282	284		10.1126/science.7536342	http://dx.doi.org/10.1126/science.7536342			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7536342				2022-12-01	WOS:A1995QT18500036
J	SMITH, AB; ESKO, JD; HAJDUK, SL				SMITH, AB; ESKO, JD; HAJDUK, SL			KILLING OF TRYPANOSOMES BY THE HUMAN HAPTOGLOBIN-RELATED PROTEIN	SCIENCE			English	Article							GENE; IDENTIFICATION; BRUCEI; LIVER	African trypanosomes cause disease in humans and animals. Trypanosoma brucei brucei affects cattle but not humans because of its sensitivity to a subclass of human high density lipoproteins (HDLs) called trypanosome lytic factor (TLF). TLF contains two apolipoproteins that are sufficient to cause lysis of T. b. brucei in vitro. These proteins were identified as the human haptoglobin-related protein and paraoxonase-arylesterase. An antibody to haptoglobin inhibited TLF activity. TLF was shown to exhibit peroxidase activity and to be inhibited by catalase. These results suggest that TLF kills trypanosomes by oxidative damage initiated by its peroxidase activity.	UNIV ALABAMA,SCH MED & DENT,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI273316] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAERNSTEIN HD, 1963, J PARASITOL, V49, P12, DOI 10.2307/3275663; BENSI G, 1985, EMBO J, V4, P119, DOI 10.1002/j.1460-2075.1985.tb02325.x; BONKOVSKY HL, 1991, AM J MED SCI, V301, P32, DOI 10.1097/00000441-199101000-00006; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONNELL GE, 1959, BIOCHEM J, V72, P115, DOI 10.1042/bj0720115; FAWCETT HAC, 1990, BIOCHIM BIOPHYS ACTA, V1048, P187, DOI 10.1016/0167-4781(90)90055-7; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; KINO K, 1980, J BIOL CHEM, V255, P9616; MAEDA N, 1985, J BIOL CHEM, V260, P6698; MCEVOY SM, 1988, J BIOL CHEM, V263, P15740; MESHNICK SR, 1977, BIOCHEM PHARMACOL, V26, P1923, DOI 10.1016/0006-2952(77)90167-8; MESHNICK SR, 1978, J EXP MED, V148, P569, DOI 10.1084/jem.148.2.569; MOLINA HA, 1989, IMMUNOLOGY, V66, P289; OSHIRO S, 1988, J BIOL CHEM, V263, P16032; RIFKIN MR, 1978, EXP PARASITOL, V46, P189, DOI 10.1016/0014-4894(78)90131-5; SEED JR, 1990, J PROTOZOOL, V37, P393, DOI 10.1111/j.1550-7408.1990.tb01163.x; TYTLER EM, 1995, MOL BIOCHEM PARASIT, V69, P9, DOI 10.1016/0166-6851(94)00172-J; YANG FM, 1983, P NATL ACAD SCI-BIOL, V80, P5875, DOI 10.1073/pnas.80.19.5875; ZECH R, 1993, CHEM-BIOL INTERACT, V87, P85, DOI 10.1016/0009-2797(93)90028-W; [No title captured]	21	146	151	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					284	286		10.1126/science.7716520	http://dx.doi.org/10.1126/science.7716520			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716520				2022-12-01	WOS:A1995QT18500037
J	SPRUSTON, N; SCHILLER, Y; STUART, G; SAKMANN, B				SPRUSTON, N; SCHILLER, Y; STUART, G; SAKMANN, B			ACTIVITY-DEPENDENT ACTION-POTENTIAL INVASION AND CALCIUM INFLUX INTO HIPPOCAMPAL CA1 DENDRITES	SCIENCE			English	Article							LONG-TERM POTENTIATION; SOURCE-DENSITY ANALYSIS; PYRAMIDAL CELLS; CA2+ ENTRY; SYNAPTIC TRANSMISSION; NEURONS; RECORDINGS; ACTIVATION; DISCHARGE	The temporal and spatial profile of activity-evoked changes in membrane potential and intracellular calcium concentration in the dendrites of hippocampal CA1 pyramidal neurons was examined with simultaneous somatic and dendritic patch-pipette recording and calcium imaging experiments. Action potentials are initiated close to the soma of these neurons and backpropagate into the dendrites in an activity-dependent manner; those occurring early in a train propagate actively, whereas those occurring later fail to actively invade the distal dendrites. Consistent with this finding, dendritic calcium transients evoked by single action potentials do not significantly attenuate with distance from the soma, whereas those evoked by trains attenuate substantially. Failure of action potential propagation into the distal dendrites often occurs at branch points. Consequently, neighboring regions of the dendritic tree can experience different voltage and calcium signals during repetitive action potential firing. The influence of backpropagating action potentials on synaptic integration and plasticity will therefore depend on both the extent of dendritic branching and the pattern of neuronal activity.			SPRUSTON, N (corresponding author), MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,JAHNSTR 29,D-69120 HEIDELBERG,GERMANY.		stuart, greg j/F-7328-2011; Hausser, Michael/AAW-6827-2020	Hausser, Michael/0000-0002-2673-8957; Spruston, Nelson/0000-0003-3118-1636; stuart, greg/0000-0001-9395-2219				ANDERSEN P, 1966, EXP BRAIN RES, V2, P247; ANDERSEN P, 1966, ACTA PHYSIOL SCAND, V66, P461, DOI 10.1111/j.1748-1716.1966.tb03224.x; ANDERSEN P, 1960, ACTA PHYSIOL SCAND, V48, P178, DOI 10.1111/j.1748-1716.1960.tb01856.x; BLAND BH, 1993, PROG NEUROBIOL, V41, P157, DOI 10.1016/0301-0082(93)90007-F; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLLING SB, 1994, NEUROSCI LETT, V172, P73, DOI 10.1016/0304-3940(94)90665-3; CRAGG BG, 1955, J PHYSIOL-LONDON, V129, P608, DOI 10.1113/jphysiol.1955.sp005382; Eccles, 2013, PHYSL SYNAPSES; FUJITA Y, 1962, J NEUROPHYSIOL, V25, P209, DOI 10.1152/jn.1962.25.2.209; GOLDSTEIN SS, 1974, BIOPHYS J, V14, P731, DOI 10.1016/S0006-3495(74)85947-3; GROVER LM, 1990, NATURE, V347, P447; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HERRERAS O, 1990, J NEUROPHYSIOL, V64, P1429, DOI 10.1152/jn.1990.64.5.1429; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JEFFERYS JGR, 1979, J PHYSIOL-LONDON, V289, P375, DOI 10.1113/jphysiol.1979.sp012742; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LUSCHER C, 1994, J NEUROPHYSIOL, V72, P634, DOI 10.1152/jn.1994.72.2.634; LUSCHER G, 1994, J NEUROPHYSIOL, V72, P622; MAGEE JC, IN PRESS J PHYSL LON; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MIYAKAWA H, 1986, BRAIN RES, V399, P303, DOI 10.1016/0006-8993(86)91520-9; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; POOLOS NP, 1990, BRAIN RES, V524, P342, DOI 10.1016/0006-8993(90)90714-M; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; REGEHR WG, 1992, J NEUROSCI, V12, P4202; RICHARDSON TL, 1987, J NEUROPHYSIOL, V58, P981, DOI 10.1152/jn.1987.58.5.981; SCHILLER J, IN PRESS J PHYSL LON; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STUART G, 1994, NEURON, V13, P703, DOI 10.1016/0896-6273(94)90037-X; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TURNER RW, 1989, J NEUROPHYSIOL, V62, P1375, DOI 10.1152/jn.1989.62.6.1375; TURNER RW, 1991, J NEUROSCI, V11, P2270; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986	36	660	667	0	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					297	300		10.1126/science.7716524	http://dx.doi.org/10.1126/science.7716524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716524				2022-12-01	WOS:A1995QT18500041
J	YOUVAN, DC				YOUVAN, DC			GREEN FLUORESCENT PETS	SCIENCE			English	Editorial Material											YOUVAN, DC (corresponding author), PALO ALTO INST MOLEC MED,MT VIEW,CA 94043, USA.							CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305	2	4	4	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					264	264		10.1126/science.7716519	http://dx.doi.org/10.1126/science.7716519			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716519				2022-12-01	WOS:A1995QT18500028
J	ASCHERIO, A; RIMM, EB; STAMPFER, MJ; GIOVANNUCCI, EL; WILLETT, WC				ASCHERIO, A; RIMM, EB; STAMPFER, MJ; GIOVANNUCCI, EL; WILLETT, WC			DIETARY-INTAKE OF MARINE N-3 FATTY-ACIDS, FISH INTAKE, AND THE RISK OF CORONARY-DISEASE AMONG MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; HEART-DISEASE; MYOCARDIAL-INFARCTION; ADIPOSE-TISSUE; CONSUMPTION; MORTALITY; GREENLAND	Background. It has been hypothesized that a diet containing n-3 fatty acids from fish reduces the risk of coronary heart disease, but few large epidemiologic studies have examined this question. Methods. In 1986, 44,895 male health professionals, 40 to 75 years of age, who were free of known cardiovascular disease completed detailed and validated dietary questionnaires as part of the Health Professionals Followup Study. During six years of follow-up, we documented 1543 coronary events in this group: 264 deaths from coronary disease, 547 nonfatal myocardial infarctions, and 732 coronary-artery bypass or angioplasty procedures. Results. After controlling for age and several coronary risk factors, we observed no significant associations between dietary intake of n-3 fatty acids or fish intake and the risk of coronary disease, For men in the top fifth of the group in terms of intake of n-3 fatty acids (median, 0.58 g per day), the multivariate relative risk of coronary heart disease was 1.12 (95 percent confidence interval, 0.96 to 1.31), as compared with the men in the bottom fifth (median, 0.07 g per day). For men who consumed six or more servings of fish per week, as compared with those who consumed one serving per month or less, the multivariate relative risk of coronary disease was 1.14 (95 percent confidence interval, 0.86 to 1.51). The risk of death due to coronary disease among men who ate any amount of fish, as compared with those who ate no fish, was 0.74 (95 percent confidence interval, 0.44 to 1.23), but the risk did not decrease as fish consumption increased. Conclusions, Although the possibility of residual confounding by unmeasured factors cannot be entirely excluded, these data suggest that increasing fish intake from one to two servings per week to five to six servings per week does not substantially reduce the risk of coronary heart disease among men who are initially free of cardiovascular disease.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	ASCHERIO, A (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANG HO, 1980, AM J CLIN NUTR, V33, P2657, DOI 10.1093/ajcn/33.12.2657; BRR ML, 1989, LANCET, V2, P757; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; CURB JD, 1985, NEW ENGL J MED, V313, P821; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6; HIRAI A, 1980, LANCET, V2, P1132; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; KROMANN N, 1980, ACTA MED SCAND, V208, P401; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MIETTINEN TA, 1982, BRIT MED J, V285, P993, DOI 10.1136/bmj.285.6347.993; MORRIS MC, 1992, CIRCULATION, V86, P463; NORELL SE, 1986, BRIT MED J, V293, P426, DOI 10.1136/bmj.293.6544.426; RAPER NR, 1992, 50 DEP AGR HOM EC RE; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1992, AM J EPIDEMIOL, V135, P114; RIMM EB, 1993, NEW ENGL J MED, V328, P450; Rose GA., 1982, WHO MONOGRAPH SERIES, V58; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SCHMIDT EB, 1994, DRUGS, V47, P405, DOI 10.2165/00003495-199447030-00003; SCHRADE W, 1961, J ATHEROSCLER RES, V1, P47, DOI 10.1016/S0368-1319(61)80053-7; SEIDELIN KN, 1992, AM J CLIN NUTR, V55, P1117, DOI 10.1093/ajcn/55.6.1117; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WOOD DA, 1984, LANCET, V2, P117, DOI 10.1016/S0140-6736(84)91044-4; WOOD DA, 1987, LANCET, V1, P117; 1963, AGR HDB DEP AGR, V8	32	427	429	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					977	982		10.1056/NEJM199504133321501	http://dx.doi.org/10.1056/NEJM199504133321501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885425				2022-12-01	WOS:A1995QT73700001
J	DAS, G; HINKLEY, CS; HERR, W				DAS, G; HINKLEY, CS; HERR, W			BASAL PROMOTER ELEMENTS AS A SELECTIVE DETERMINANT OF TRANSCRIPTIONAL ACTIVATOR FUNCTION	NATURE			English	Article							RNA POLYMERASE-II; TRANS-ACTIVATOR; SNRNA PROMOTER; BINDING; DOMAINS; OCT-1; SPECIFICITY; EXPRESSION; ENHANCER; DISTINCT	IN eukaryotes, activation of transcription involves an interplay between activators bound to cis-regulatory elements and factors bound to basal elements near the start site of transcription. The basal elements, for example the TATA box or proximal sequence element (PSE) of small nuclear RNA (snRNA) promoters, nucleate the assembly of basal transcription complexes, components of which interact with activators(1,2). Although one basal transcription complex can interact with many activators, it is unclear whether different basal transcription complexes can direct different responses to particular activators. We show here that changing the arrangement of basal elements can alter the response to transcriptional activation domains. Indeed, in the human U6 snRNA promoter, point mutation of either a TATA box or PSE results in diametrically opposed responses to VP16- and Sp1-derived activation domains. These basal elements can even discriminate small changes in an activation domain. Thus the arrangement of basal promoter elements provides a mechanism for differential regulation of transcription.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546				BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAS G, 1993, J BIOL CHEM, V268, P25026; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TANAKA M, 1994, MOL CELL BIOL, V16, P6046; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3	30	105	111	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					657	660		10.1038/374657a0	http://dx.doi.org/10.1038/374657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715708				2022-12-01	WOS:A1995QT18900064
J	GERBER, HP; HAGMANN, M; SEIPEL, K; GEORGIEV, O; WEST, MAL; LITINGTUNG, Y; SCHAFFNER, W; CORDEN, JL				GERBER, HP; HAGMANN, M; SEIPEL, K; GEORGIEV, O; WEST, MAL; LITINGTUNG, Y; SCHAFFNER, W; CORDEN, JL			RNA-POLYMERASE-II C-TERMINAL DOMAIN REQUIRED FOR ENHANCER-DRIVEN TRANSCRIPTION	NATURE			English	Article							LARGEST SUBUNIT; STIMULATES TRANSCRIPTION; PROMOTER; ACTIVATION; EXPRESSION; REPEAT; CELLS; GENE; PROTEIN; INVITRO	THE RNA polymerase II carboxy-terminal domain (CTD) consists of tandem repeats of the sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser(1-3). The CTD may participate in activated transcription through interaction with a high-molecular-weight mediator complex(4-6). Such a role would be consistent with observations that some genes are preferentially sensitive to CTD mutations(7,8). Here we investigate the function of the mouse RNA polymerase CTD in enhancer-driven transcription. Transcription by alpha-amanitin-resistant CTD-deletion mutants was tested by transient transfection of tissue culture cells in the presence of alpha-amanitin in order to inhibit endogenous RNA polymerase II. Removal of most of the CTD abolishes transcriptional activation by all enhancers tested, whereas transcription from promoters driven by Sp1, a factor that typically activates housekeeping genes from positions proximal to the initiation sites, is not affected. These findings show that the CTD is essential in mediating 'enhancer'-type activation of mammalian transcription.	UNIV CALIF DAVIS,DIV BIOL SCI,PLANT BIOL SECT,DAVIS,CA 95616; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University of California System; University of California Davis; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	GERBER, HP (corresponding author), UNIV ZURICH,INST MOLEK BIOL 2,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Seipel, Katja/0000-0003-3128-1573				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, P81; GERBER HP, 1992, NUCLEIC ACIDS RES, V20, P5855, DOI 10.1093/nar/20.21.5855; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GUARENTE L, 1984, CELL, V36, P799, DOI 10.1016/0092-8674(84)90028-X; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WIELAND S, 1990, ACTIVATION HORMONE G, P215; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351	28	142	144	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					660	662		10.1038/374660a0	http://dx.doi.org/10.1038/374660a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715709				2022-12-01	WOS:A1995QT18900065
J	HE, X; SAINTJEANNET, JP; WOODGETT, JR; VARMUS, HE; DAWID, IB				HE, X; SAINTJEANNET, JP; WOODGETT, JR; VARMUS, HE; DAWID, IB			GLYCOGEN-SYNTHASE KINASE-3 AND DORSOVENTRAL PATTERNING IN XENOPUS EMBRYOS	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; MESODERM INDUCTION; SPEMANN ORGANIZER; VENTRALIZING FACTOR; AXIAL MESODERM; BODY AXIS; EXPRESSION; DROSOPHILA; WINGLESS; XWNT-8	Glycogen synthase kinase 3 (GSK-3) is homologous to the product of the Drosophila gene shaggy (zeste-white 3), which is required for signalling by wingless during Drosophila development. To test whether GSK-3 is also involved in vertebrate pattern formation, its role was investigated during early Xenopus development. It was found that dominant-negative GSK-3 mutants induced dorsal differentiation, whereas wild-type GSK-3 induced ventralization. These results indicate that GSK-3 is required for ventral differentiation, and suggest that dorsal differentiation may involve the suppression of GSK-3 activity by a wingless/wnt-related signal.	NICHHD,GENET MOLEC LAB,BETHESDA,MD 20892; ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Toronto; University Toronto Affiliates; University Health Network Toronto	HE, X (corresponding author), NCI,VARMUS LAB,BLDG 49,ROOM 4A56,BETHESDA,MD 20892, USA.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BOHN H, 1992, J EMBRYOL EXP MORPH, V28, P185; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V289, P6259; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; GERHART J, 1989, DEVELOPMENT, V107, P37; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OGURA K, 1994, GENE DEV, V8, P2389, DOI 10.1101/gad.8.20.2389; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SATO SM, 1991, DEVELOPMENT, V112, P747; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STANBOLIC V, 1994, BIOCHEM J, V303, P701; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269	50	440	449	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					617	622		10.1038/374617a0	http://dx.doi.org/10.1038/374617a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715701				2022-12-01	WOS:A1995QT18900051
J	HENRY, RW; SADOWSKI, CL; KOBAYASHI, R; HERNANDEZ, N				HENRY, RW; SADOWSKI, CL; KOBAYASHI, R; HERNANDEZ, N			A TBP-TAF COMPLEX REQUIRED FOR TRANSCRIPTION OF HUMAN SNRNA GENES BY RNA-POLYMERASE-II AND RNA-POLYMERASE-III	NATURE			English	Article							TATA-BINDING PROTEIN; FACTOR-TFIIIB	THE TATA-box-binding protein TBP exists in the cell complexed with different sets of TBP-associated factors (TAFs)(1). In general, each of these TBP-TAP complexes is dedicated to transcription by a single RNA polymerase. Thus, SL1, TFIID and TFIIIB are required for transcription by polymerases I, II and III, respectively(2-10). Here we characterize a fourth TBP-TAF complex called SNAPc(11). Unlike the other TBP-TAF complexes, SNAPc is implicated in transcription by two types of polymerases; it is required for transcription of both the RNA polymerase II and III small-nuclear RNA genes and binds specifically to the proximal sequence element PSE, a non-TATA-box basal promoter element common to these two types of genes(11-13). In addition to TBP, SNAPc is composed of at least three TAFs, SNAP43, SNAP45 and SNAP50. The predicted amino-acid sequence of SNAP43 reveals that it corresponds to a new protein.	SUNY STONY BROOK, DEPT PHARMACOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	HENRY, RW (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Hernandez, Nouria/0000-0003-1465-4585				COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	16	125	126	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	1995	374	6523					653	656		10.1038/374653a0	http://dx.doi.org/10.1038/374653a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715707				2022-12-01	WOS:A1995QT18900063
J	KHAMASHTA, MA; CUADRADO, MJ; MUJIC, F; TAUB, NA; HUNT, BJ; HUGHES, GRV				KHAMASHTA, MA; CUADRADO, MJ; MUJIC, F; TAUB, NA; HUNT, BJ; HUGHES, GRV			THE MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTICARDIOLIPIN ANTIBODIES; DIFFERENT INTENSITIES; VENOUS THROMBOSIS; ANTICOAGULANT; WARFARIN; FEATURES; TRIAL	Background. The anti phospholipid-anti body syndrome is a thrombophilic disorder in which venous or arterial thrombosis, or both, may occur in patients with antiphospholipid antibodies. The optimal treatment of these patients is unclear. We assessed the efficacy of warfarin, low-dose aspirin, or both in the secondary prevention of thrombosis in patients with the syndrome. Methods. One hundred forty-seven patients (124 [84 percent] of whom were female) with the antiphospholipid-antibody syndrome and a history of thrombosis were studied retrospectively. The syndrome was primary in 62 patients and was associated with systemic lupus erythematosus in 66 patients and lupus-like disease in 19. Each patient's history was reviewed. Results. One hundred one patients (69 percent) had a total of 186 recurrences of thrombosis. The median time between the initial thrombosis and the first recurrence was 12 months (range, 0.5 to 144 months). Treatment with high-intensity warfarin (producing an international normalized ratio of greater than or equal to 3) with or without law-dose aspirin (75 mg per day) was significantly more effective (P<0.001 by the log-rank test) than treatment with low-intensity warfarin (producing an international normalized ratio of <3) with or without low-dose aspirin or treatment with aspirin alone in preventing further thrombotic events (recurrence rates per patient-year, 0.013, 0.23, and 0.18, respectively). The rate of recurrence of thrombosis was highest (1.30 per patient-year) during the first six months after the cessation of warfarin therapy. Complications involving bleeding occurred in 29 patients during warfarin therapy and were severe in 7 (0.071 and 0.017 occurrence per patient-year, respectively). Conclusions. The risk of recurrent thrombosis in patients with the antiphospholipid-antibody syndrome is high. Long-term anticoagulation therapy in which the international normalized ratio is maintained at or above 3 is advisable in these patients.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, RAYNE INST, LUPUS & ARTHRITIS RES UNIT, LONDON SE1 7EH, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, DEPT PUBL HLTH MED, LONDON SE1 7EH, ENGLAND; ST THOMAS HOSP, CTR HEMOPHILIA, LONDON, ENGLAND	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust								ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P1014; ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P482; ARMITAGE P, 1994, STATISTICAL METHODS, P144; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; ASHERSON RA, 1991, ANN RHEUM DIS, V50, P805, DOI 10.1136/ard.50.11.805; ASHERSON RA, 1985, ANN RHEUM DIS, V44, P823, DOI 10.1136/ard.44.12.823; BARBUI T, 1994, LUPUS, V3, P303, DOI 10.1177/096120339400300419; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; COX DR, 1972, J R STAT SOC B, V34, P187; DERKSEN RHWM, 1993, ANN RHEUM DIS, V52, P689, DOI 10.1136/ard.52.9.689; EXNER T, 1975, PATHOLOGY, V7, P319, DOI 10.3109/00313027509081688; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; HARRIS E N, 1987, British Journal of Rheumatology, V26, P19; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HIRSH J, 1994, CIRCULATION, V89, P1469, DOI 10.1161/01.CIR.89.3.1469; HUGHES GRV, 1983, BRIT MED J, V287, P1088, DOI 10.1136/bmj.287.6399.1088; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016/S0140-6736(94)90008-6; LEVINE SR, 1992, STROKE S1, V23, P29; LIE JT, 1989, J RHEUMATOL, V16, P713; LOCKSHIN MD, 1993, RHEUM DIS CLIN N AM, V19, P235; MACHIN SJ, 1991, J CLIN PATHOL, V44, P885; MACKWORTHYOUNG CG, 1989, ANN RHEUM DIS, V48, P362, DOI 10.1136/ard.48.5.362; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; RIVIER G, 1994, LUPUS, V3, P85, DOI 10.1177/096120339400300205; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VIANNA JL, 1994, AM J MED, V96, P3, DOI 10.1016/0002-9343(94)90108-2; VLACHOYIANNOPOULOS PG, 1994, LUPUS, V3, P91, DOI 10.1177/096120339400300206; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707	33	1130	1153	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					993	997		10.1056/NEJM199504133321504	http://dx.doi.org/10.1056/NEJM199504133321504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885428	Bronze			2022-12-01	WOS:A1995QT73700004
J	LUBITZ, J; BEEBE, J; BAKER, C				LUBITZ, J; BEEBE, J; BAKER, C			LONGEVITY AND MEDICARE EXPENDITURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; CARE; COMPRESSION; MORBIDITY; PAYMENTS; DEATH	Background. In the United States, the elderly account for over one third of health care spending. The total population over the age of 65 is projected to increase, as is life expectancy beyond the age of 65. We studied current patterns of Medicare expenses according to age at death and the possible effect of future demographic changes on Medicare spending. Methods. We used data from the Medicare program to estimate lifetime Medicare expenses for a sample of 129, 166 beneficiaries, 65 or older, who died in 1989 and 1990, according to age at death. Spending for nursing home care not covered by Medicare was excluded. (Nursing home costs represent about 20 percent of total health care spending for the elderly and increase with age.) Through simulation, we assessed the lifetime payments by Medicare for enrollees who turned 65 in 1990 and those who will do so in 2020. Results. Estimated lifetime Medicare payments (in 1990 dollars) ranged from $13,044 for persons who died at 65 years of age, to $56,094 for those who died at 80, to $65,633 for those who died at 101 or older. The payments associated with an additional year of life and the average annual payments over an enrollee's lifetime both decreased as the age at death increased. The estimated 7.9 percent increase in life expectancy beyond 65 years that will have taken place between 1990 and 2020 (19.1 years past the age of 65 in 2020, as compared with 17.7 years in 1990) was associated with an estimated increase of 2.0 percent in lifetime Medicare payments. Of the estimated $98 billion increase in total lifetime payments (in 1990 dollars) from the 1990 group to the 2020 group, 74.3 percent was due to the larger size of the original birth cohort who will reach the age of 65 in 2020, 22.5 percent to an increase in the proportion of that birth cohort projected to survive to 65 years of age, and 3.2 percent to improved life expectancy beyond 65. Conclusions. The effect on Medicare spending of increased longevity beyond the age of 65 may not be great. Total Medicare payments will be more substantially affected by the expected increase in the absolute number of elderly people.	HLTH ECON RES,WALTHAM,MA		LUBITZ, J (corresponding author), US HLTH CARE FINANCING ADM,OFF RES & DEMONSTRAT,ROOM 2504,OAK MEADOWS BLDG,6325 SECUR BLDG,BALTIMORE,MD 21207, USA.							FRIES JF, 1989, MILBANK Q, V67, P208, DOI 10.2307/3350138; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FUCHS VR, 1984, MILBANK FUND Q, V62, P143; GORNICK M, 1993, HEALTH AFFAIR, V12, P140, DOI 10.1377/hlthaff.12.2.140; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; Letsch S W, 1992, Health Care Financ Rev, V14, P1; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; MANTON KG, 1991, POPUL DEV REV, V7, P603; OLSHANSKY SJ, 1993, SCI AM, V268, P46, DOI 10.1038/scientificamerican0493-46; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; Peden E A, 1991, Health Care Financ Rev, V13, P75; RICE DP, 1983, VITAL HLTH STATIST 3, V23; ROOS NP, 1987, MILBANK Q, V65, P231, DOI 10.2307/3350021; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; Waldo D R, 1989, Health Care Financ Rev, V10, P111; 1993, 1993 BOARD TRUST ANN; 1993, CURRENT POPULATION R, V1104	17	152	153	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					999	1003		10.1056/NEJM199504133321506	http://dx.doi.org/10.1056/NEJM199504133321506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT737	7885430				2022-12-01	WOS:A1995QT73700006
J	MEDA, L; CASSATELLA, MA; SZENDREI, GI; OTVOS, L; BARON, P; VILLALBA, M; FERRARI, D; ROSSI, F				MEDA, L; CASSATELLA, MA; SZENDREI, GI; OTVOS, L; BARON, P; VILLALBA, M; FERRARI, D; ROSSI, F			ACTIVATION OF MICROGLIAL CELLS BY BETA-AMYLOID PROTEIN AND INTERFERON-GAMMA	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; NITRIC-OXIDE; NEURODEGENERATION; MACROPHAGES; CYTOKINES; INVITRO; RELEASE	ALZHEIMER'S disease is the most common cause of progressive intellectual failure(1). The lesions that develop, called senile plaques, are extracellular deposits principally composed of insoluble aggregates of beta-amyloid protein (A beta), infiltrated by reactive microglia and astrocytes(2,3). Although A beta, and a portion of it, the fragment 25-35 (A beta(25-35)), have been shown to exert a direct toxic effect on neurons(4-6), the role of microglia in such neuronal injury remains unclear(7). Here we report a synergistic effect between A beta and interferon-gamma (IFN-gamma) in triggering the production of reactive nitrogen intermediates and tumour-necrosis factor-alpha (TNF-alpha) from microglia. Furthermore, using co-culture experiments, we show that activation of microglia with IFN-gamma and A beta leads to neuronal cell injury in vitro. These findings suggest that A beta and IFN-gamma activate microglia to produce reactive nitrogen intermediates and TNF-alpha, and this may have a role in the pathogenesis of neuronal degeneration observed in ageing and Alzheimer's disease.	UNIV VERONA,INST GEN PATHOL,I-37134 VERONA,ITALY; UNIV MILAN,INST NEUROL,I-20122 MILAN,ITALY; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV FERRARA,INST GEN PATHOL,I-44100 FERRARA,ITALY	University of Verona; University of Milan; The Wistar Institute; University of Ferrara			villalba, martin/AAG-2604-2020; villalba, martin/N-7123-2017; Cassatella, M A/B-8037-2013; Ferrari, Davide/F-5644-2015	villalba, martin/0000-0002-4385-4888; villalba, martin/0000-0002-4385-4888; Cassatella, M A/0000-0001-7824-1806; Ferrari, Davide/0000-0002-5727-9204				AGRESTI C, 1991, DEV BIOL, V144, P16, DOI 10.1016/0012-1606(91)90474-H; ARANJO DM, 1992, BRAIN RES, V569, P141; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHAO CC, 1993, J IMMUNOL, V151, P1473; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DICKSON D, 1990, Society for Neuroscience Abstracts, V16, P1267; DING AH, 1988, J IMMUNOL, V141, P2407; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HERNANDEZCASELL.T, 1993, J IMMUNOL, V151, P3999; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PIKE CJ, 1993, J NEUROSCI, V13, P1676; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; SHER PK, 1990, BRAIN RES BULL, V25, P697, DOI 10.1016/0361-9230(90)90045-2; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; VILLALBA M, 1994, J BIOL CHEM, V269, P2468; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849	27	1192	1241	0	100	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					647	650		10.1038/374647a0	http://dx.doi.org/10.1038/374647a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715705				2022-12-01	WOS:A1995QT18900061
J	THOMAS, SA; MATSUMOTO, AM; PALMITER, RD				THOMAS, SA; MATSUMOTO, AM; PALMITER, RD			NORADRENALINE IS ESSENTIAL FOR MOUSE FETAL DEVELOPMENT	NATURE			English	Article								CATECHOLAMINES such as noradrenaline and adrenaline have been implicated in numerous physiological processes(1-4) but, although catecholamine synthesis begins at mid-gestation(5), previous studies have provided little evidence for any role in early development(6,7). Furthermore, there are several case reports of humans with noradrenaline deficiency(8). To investigate this, we used gene targeting(9) to produce mice lacking dopamine beta-hydroxylase and therefore unable to synthesize noradrenaline or adrenaline. We report here that in heterozygous mothers, most homozygous embryos died in utero, and only about 5% reached adulthood. Survival probably depends on catecholamine transfer across the placenta because, in homozygous mothers, all embryos die in utero. Mortality was due to lack of noradrenaline in utero because it could be prevented by treatment with dihydroxyphenylserine, a precursor that can be converted to noradrenaline in the absence of dopamine beta-hydroxylase. Mutant embryos had a histological phenotype similar to that of embryos deficient in tyrosine hydroxylase(10), suggesting that death might be due to cardiovascular failure.	UNIV WASHINGTON,SCH MED,VET ADM MED CTR,CTR GERENTOL RES EDUC & CLIN,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	THOMAS, SA (corresponding author), UNIV WASHINGTON,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM,SL-15,SEATTLE,WA 98195, USA.		Matsumoto, Alvin/AAH-6096-2020					ANGELETTI PU, 1970, P NATL ACAD SCI USA, V65, P114, DOI 10.1073/pnas.65.1.114; [Anonymous], 1989, SCIENCE; BERTI F, 1965, MED PHARMACOL EXP, V13, P227; KUDLACZ EM, 1990, J DEV PHYSIOL, V13, P243; LEVIMONT.R, 1966, PHARMACOL REV, V18, P619; ROBERTSON D, 1991, HYPERTENSION, V18, P1, DOI 10.1161/01.HYP.18.1.1; ROSEN TS, 1979, J PHARMACOL EXP THER, V208, P118; Rosenblueth A, 1937, AUTONOMIC NEUROEFFEC; Schlumpf M., 1980, BIOGENIC AMINES DEV, P567	9	443	450	2	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					643	646		10.1038/374643a0	http://dx.doi.org/10.1038/374643a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715704				2022-12-01	WOS:A1995QT18900060
J	TOHTONG, R; YAMASHITA, H; GRAHAM, M; HAEBERLE, J; SIMCOX, A; MAUGHAN, D				TOHTONG, R; YAMASHITA, H; GRAHAM, M; HAEBERLE, J; SIMCOX, A; MAUGHAN, D			IMPAIRMENT OF MUSCLE FUNCTION CAUSED BY MUTATIONS OF PHOSPHORYLATION SITES IN MYOSIN REGULATORY LIGHT-CHAIN	NATURE			English	Article							RABBIT SKELETAL-MUSCLE; INDIRECT FLIGHT-MUSCLE; DROSOPHILA-MELANOGASTER; STRETCH-ACTIVATION; STRIATED-MUSCLE; CROSS-BRIDGES; INSECT; KINETICS; FIBERS; MECHANISM	MYOSIN regulatory light chain is phosphorylated by myosin light chain kinase at conserved serine and threonine residues in a number of species(1). Phosphorylation of myosin regulatory light chain regulates smooth muscle contraction, but appears to have a modulatory role in striated muscle contraction(2). We assessed the in vivo role of myosin regulatory light chain phosphorylation in the striated muscles of Drosophila melanogaster by substituting alanine at each or both conserved myosin light chain kinase-dependent phosphorylation sites, serine 66 and serine 67. We report here that myosin light chain kinase-dependent phosphorylation is not required for myofibrillogenesis or for the development of maximal isometric force in Indirect flight muscles. However, mutants with substitutions at the major phosphorylation site (serine 66) or with the double substitutions had reduced power output in isolated flight muscle fibres and reduced flight ability, showing that myosin regulatory light chain phosphorylation is a key determinant of the stretch activation response in Drosophila.	OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH; UNIV VERMONT,DEPT MOLEC PHYSIOL & BIOPHYS,BURLINGTON,VT 05405	University System of Ohio; Ohio State University; University of Vermont								ABBOTT RH, 1984, J MUSCLE RES CELL M, V5, P387, DOI 10.1007/BF00818257; BERNSTEIN SI, 1993, INT REV CYTOL, V143, P63; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; GRANZIER HLM, 1993, J GEN PHYSIOL, V101, P235, DOI 10.1085/jgp.101.2.235; GUTH K, 1981, BIOPHYS STRUCT MECH, V7, P139, DOI 10.1007/BF00539176; HYATT CJ, 1994, BIOPHYS J, V67, P1149, DOI 10.1016/S0006-3495(94)80582-X; JEWELL BR, 1966, PROC R SOC SER B-BIO, V164, P428, DOI 10.1098/rspb.1966.0042; Kawai M, 1980, J Muscle Res Cell Motil, V1, P279, DOI 10.1007/BF00711932; LAURIEAHLBERG CC, 1985, GENETICS, V111, P845; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MOLLOY J, 1993, MECH MYOFILAMENT SLI, P165; PECKHAM M, 1992, J EXP BIOL, V168, P57; PECKHAM M, 1990, J MUSCLE RES CELL M, V11, P203, DOI 10.1007/BF01843574; PERSECHINI A, 1985, J BIOL CHEM, V260, P7951; PRINGLE JWS, 1978, PROC R SOC SER B-BIO, V201, P107, DOI 10.1098/rspb.1978.0035; REEDY MC, 1994, J MOL BIOL, V239, P52, DOI 10.1006/jmbi.1994.1350; SQUIRE JM, 1992, J MUSCLE RES CELL M, V13, P183, DOI 10.1007/BF01874155; Steiger G.J., 1977, P221; SWEENEY HL, 1986, AM J PHYSIOL, V250, pC657, DOI 10.1152/ajpcell.1986.250.4.C657; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TAKAHASHI S, 1987, ZOOL SCI, V4, P833; TAKAHASHI S, 1990, COMP BIOCHEM PHYS B, V95, P179, DOI 10.1016/0305-0491(90)90267-W; TAWADA K, 1990, BIOPHYS J, V57, P643, DOI 10.1016/S0006-3495(90)82582-0; THORSON J, 1983, J PHYSIOL-LONDON, V343, P59, DOI 10.1113/jphysiol.1983.sp014881; THORSON J, 1969, BIOPHYS J, V9, P360, DOI 10.1016/S0006-3495(69)86392-7; WARMKE J, 1992, J CELL BIOL, V119, P1523, DOI 10.1083/jcb.119.6.1523; WRAY JS, 1979, NATURE, V280, P325, DOI 10.1038/280325a0	30	112	114	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					650	653		10.1038/374650a0	http://dx.doi.org/10.1038/374650a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715706				2022-12-01	WOS:A1995QT18900062
J	ZHAO, JH; HOGAN, EM; BEVENSEE, MO; BORON, WF				ZHAO, JH; HOGAN, EM; BEVENSEE, MO; BORON, WF			OUT-OF-EQUILIBRIUM CO2/HCO3- SOLUTIONS AND THEIR USE IN CHARACTERIZING A NEW K/HCO3 COTRANSPORTER	NATURE			English	Article							SQUID GIANT-AXONS; INTRACELLULAR-PH; MECHANISM; CELL	IN typical physiological solutions, CO2 is in equilibrium with HCO3- and H+ (CO2 + H2O reversible arrow HCO3- + H+). Because one cannot independently alter CO2 and HCO3- concentrations and pH, it is impossible to distinguish between the effects of CO2 and HCO3- on physiological processes. Here we describe a continuous-flow, rapid-mixing approach for generating out-of-equilibrium CO2/HCO3- solutions with a physiological pH and CO2 (but little HCO3-), or pH and HCO3- (but little CO2). We have exploited these out-of-equilibrium solutions to introduce HCO3- exclusively to either the outside or inside of a squid giant axon, and verify the presence of a new K/HCO3 cotransporter. The out-of-equilibrium approach could be useful in a variety of applications for independently controlling CO2 and HCO3- concentrations and pH.			ZHAO, JH (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287				AICKIN CC, 1994, J PHYSIOL-LONDON, V479, P301, DOI 10.1113/jphysiol.1994.sp020297; BARO I, 1989, J PHYSIOL-LONDON, V417, pP161; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; BORON WF, 1983, J GEN PHYSIOL, V81, P373, DOI 10.1085/jgp.81.3.373; BRAZEAU P, 1953, AM J PHYSIOL, V175, P33, DOI 10.1152/ajplegacy.1953.175.1.33; BRINLEY FJ, 1967, J GEN PHYSIOL, V50, P2303, DOI 10.1085/jgp.50.10.2303; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; DALZIEL K, 1953, BIOCHEM J, V55, P79, DOI 10.1042/bj0550079; DORMAN PJ, 1954, J CLIN INVEST, V33, P82, DOI 10.1172/JCI102874; Eigen M., 1961, Z PHYS CHEM FRANKFUR, V30, P130; FRANKENHAEUSER B, 1956, J PHYSIOL-LONDON, V131, P341, DOI 10.1113/jphysiol.1956.sp005467; GIBBONS BH, 1963, J BIOL CHEM, V238, P3502; HINKE JAM, 1967, GLASS ELECTRODES HYD, P464; HO C, 1963, J BIOL CHEM, V238, P3499; HOGAN EM, IN PRESS J GEN PHYSL; NATTIE EE, 1995, LUNG BIOL HLTH DIS, V79, P473; POCOCK G, 1992, EUR J NEUROSCI, V4, P136, DOI 10.1111/j.1460-9568.1992.tb00860.x; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSSIBERNARDI L, 1968, J BIOL CHEM, V243, P1297; ROUGHTON FJW, 1941, J AM CHEM SOC, V63, P29; THOMAS RC, 1976, NATURE, V262, P54, DOI 10.1038/262054a0	22	55	55	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					636	639		10.1038/374636a0	http://dx.doi.org/10.1038/374636a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715702				2022-12-01	WOS:A1995QT18900058
J	ZHOU, QY; QUAIFE, CJ; PALMITER, RD				ZHOU, QY; QUAIFE, CJ; PALMITER, RD			TARGETED DISRUPTION OF THE TYROSINE-HYDROXYLASE GENE REVEALS THAT CATECHOLAMINES ARE REQUIRED FOR MOUSE FETAL DEVELOPMENT	NATURE			English	Article							SUPERIOR CERVICAL-GANGLION; MICE; RAT; CELLS; PHENOTYPE; PROTOONCOGENE; NEURONS; BRAIN	TYROSINE hydroxylase catalyses the initial, rate-limiting step in the catecholamine biosynthetic pathway. Catecholamines, which include dopamine, noradrenaline, and adrenaline, are important neurotransmitters and hormones that regulate visceral functions, motor coordination and arousal in adults(1). The gene encoding tyrosine hydroxylase becomes transcriptionally active in developing neuroblasts during mid-gestation of rodent embryos, before the onset of neurotransmission(2-6). Here we show that inactivation of both tyrosine hydroxylase alleles results in mid-gestational lethality: about 90% of mutant embryos die between embryonic days 11.5 and 15.5, apparently of cardiovascular failure. Administration of L-DOPA (dihydroxyphenylalanine), the product of the tyrosine hydroxylase reaction, to pregnant females results in complete rescue of mutant mice in utero. Without further treatment, however, they die before weaning. We conclude that catecholamines are essential for mouse fetal development and postnatal survival.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	ZHOU, QY (corresponding author), UNIV WASHINGTON, HOWARD HUGHES MED INST, SL-15, SEATTLE, WA 98195 USA.							BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; COCHARD P, 1978, P NATL ACAD SCI USA, V75, P2986, DOI 10.1073/pnas.75.6.2986; COOPER JR, 1991, BIOCH BASIS NEUROPHA, P221; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; GERSHON MD, 1984, J NEUROSCI, V4, P2269; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HALL AK, 1991, J NEUROSCI, V11, P472; IWATA N, 1992, BIOCHEM BIOPH RES CO, V182, P348, DOI 10.1016/S0006-291X(05)80151-2; JONAKAIT GM, 1989, J HISTOCHEM CYTOCHEM, V37, P1; KATO T, 1987, BIOCHEM PHARMACOL, V36, P3051, DOI 10.1016/0006-2952(87)90223-1; Kaufman M.H., 1992, ATLAS MOUSE DEV; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; OMALLEY KL, 1988, NUCLEIC ACIDS RES, V16, P4437; RUBIN E, 1985, J NEUROSCI, V5, P673; Sambrook J., 1989, MOL CLONING LAB MANU; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPECHT LA, 1981, J COMP NEUROL, V199, P233, DOI 10.1002/cne.901990207; TEITELMAN G, 1979, P NATL ACAD SCI USA, V76, P509, DOI 10.1073/pnas.76.1.509; TEITELMAN G, 1981, DEV BIOL, V86, P348, DOI 10.1016/0012-1606(81)90192-5; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	22	375	384	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 13	1995	374	6523					640	643		10.1038/374640a0	http://dx.doi.org/10.1038/374640a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715703				2022-12-01	WOS:A1995QT18900059
J	BLAIR, SN; KOHL, HW; BARLOW, CE; PAFFENBARGER, RS; GIBBONS, LW; MACERA, CA				BLAIR, SN; KOHL, HW; BARLOW, CE; PAFFENBARGER, RS; GIBBONS, LW; MACERA, CA			CHANGES IN PHYSICAL-FITNESS AND ALL-CAUSE MORTALITY - A PROSPECTIVE-STUDY OF HEALTHY AND UNHEALTHY MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOLLOW-UP; PREDICTOR	Objective.-To evaluate the relationship between changes in physical fitness and risk of mortality in men. Design.-Prospective study, with two clinical examinations (mean internal between examinations, 4.9 years) to assess change or lack of change in physical fitness as associated with risk of mortality during follow-up after the subsequent examination (mean follow-up from subsequent examination, 5.1 years). Setting.-Preventive medicine clinic. Study Participants.-Participants were 9777 men given two preventive medical examinations, each of which included assessment of physical fitness by maximal exercise tests and evaluation of health status. Main Outcome Measures.-All-cause (n=223) and cardiovascular disease (n=87) mortality. Results.-The highest age-adjusted all-cause death rate was observed in men who were unfit at both examinations (122.0/10000 man-years); the lowest death rate was in men who were physically fit at both examinations (39.6/10000 man-years). Men who improved from unfit to fit between the first and subsequent examinations had an age-adjusted death rate of 67.7/10 000 man-years. This is a reduction in mortality risk of 44% (95% confidence internal, 25% to 59%) relative to men who remained unfit at both examinations, Improvement in fitness was associated With lower death rates after adjusting for age, health status, and other risk factors of premature mortality, For each minute increase in maximal treadmill time between examinations, there was a corresponding 7.9% (P=.001) decrease in risk of mortality. Similar results were seen when the group was stratified by health status, and for cardiovascular disease mortality. Conclusions.-Men who maintained or improved adequate physical fitness were less likely to die from all causes and from cardiovascular disease during follow-up than persistently unfit men. Physicians should encourage unfit men to improve their fitness by starting a physical activity program.	COOPER CLIN,DALLAS,TX; STANFORD UNIV,SCH MED,STANFORD,CA 94305; UNIV S CAROLINA,SCH PUBL HLTH,COLUMBIA,SC 29208	Cooper Institute; Stanford University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	BLAIR, SN (corresponding author), COOPER INST AEROB RES,DIV EPIDEMIOL,12330 PRESTON RD,DALLAS,TX 75230, USA.		wright, beth/V-7496-2019		NATIONAL INSTITUTE ON AGING [R01AG006945, R37AG006945] Funding Source: NIH RePORTER; NIA NIH HHS [AG06945] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American College of Sports Medicine position stand, 1990, MED SCI SPORTS EXERC, V22, P265; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bond, 1989, AGING HLTH CARE SOCI, P27; Bouchard C., 1994, PHYS ACTIVITY FITNES, P106; BOUCHARD C, 1994, PHYSICAL ACTIVITY FI; BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; COX DR, 1972, J R STAT SOC B, V34, P187; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ERIKSSEN J, 1986, ACTA MED SCAND S, V711, P189; HEIN HO, 1992, J INTERN MED, V232, P471, DOI 10.1111/j.1365-2796.1992.tb00619.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES, P300; LIE H, 1985, EUR HEART J, V6, P147, DOI 10.1093/oxfordjournals.eurheartj.a061829; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SOBOLSKI J, 1987, AM J EPIDEMIOL, V125, P601, DOI 10.1093/oxfordjournals.aje.a114573; WILHELMSEN L, 1981, CARDIOLOGY, V68, P1, DOI 10.1159/000173310	23	1412	1453	0	103	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1093	1098		10.1001/jama.273.14.1093	http://dx.doi.org/10.1001/jama.273.14.1093			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707596				2022-12-01	WOS:A1995QR05900027
J	GILLMAN, MW; CUPPLES, LA; GAGNON, D; POSNER, BM; ELLISON, RC; CASTELLI, WP; WOLF, PA				GILLMAN, MW; CUPPLES, LA; GAGNON, D; POSNER, BM; ELLISON, RC; CASTELLI, WP; WOLF, PA			PROTECTIVE EFFECT OF FRUITS AND VEGETABLES ON DEVELOPMENT OF STROKE IN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SPONTANEOUSLY HYPERTENSIVE RATS; BLOOD-PRESSURE; PLASMA HOMOCYST(E)INE; JAPANESE MEN; CARDIOVASCULAR MORTALITY; RISK-FACTORS; DIETARY; CONSUMPTION; ALCOHOL	Objective.-To examine the effect of fruit and vegetable intake on risk of stroke among middle-aged men over 20 years of follow-up. Design.-Cohort. Setting.-The Framingham Study, a population-based longitudinal study. Participants.-All 832 men, aged 45 through 65 years, who were free of cardiovascular disease at baseline (1966 through 1969). Measurements and Data Analysis.-The diet of each subject was assessed at baseline by a single 24-hour recall. The estimated total number of servings per day of fruits and vegetables was the exposure variable for this analysis. Using Kaplan-Meier survival analysis, we examined age-adjusted cumulative incidence of stroke by quintile of servings per day. To adjust for multiple covariates, we used proportional hazards regression to calculate the relative risk (RR) of stroke for each increment of three servings per day. Main Outcome Measure.-Incidence of completed strokes and transient ischemic attacks. Results.-At baseline, the mean (+/-SD) number of fruit and vegetable servings per day was 5.1 (+/-2.8). During follow-up there were 97 incident strokes, including 73 completed strokes and 24 transient ischemic attacks. Age-adjusted risk of stroke decreased across increasing quintile of servings per day (log rank P for trend, .01). Age-adjusted RR for all stroke, including transient ischemic attack, was 0.78 (95% confidence interval [CI], 0.62 to 0.98) for each increase of three servings per day. For completed stroke the RR was 0.74 (95% CI, 0.57 to 0.96); for completed stroke of ischemic origin the RR was 0.76 (95% CI, 0.57 to 1.02); and for completed stroke of hemorrhagic origin, 0.49 (95% CI, 0.25 to 0.95). Adjustment for body mass index, cigarette smoking, glucose intolerance, physical activity, blood pressure, serum cholesterol, and intake of energy, ethanol, and fat did not materially change the results. Conclusion.Intake of fruits and vegetables may protect against development of stroke in men.	HARVARD UNIV,COMMUNITY HLTH PLAN,BOSTON,MA 02215; BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA; BOSTON UNIV,SCH MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,EVANS DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118; FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA	Harvard University; Boston University; Boston University; Boston University; Boston University; Framingham Heart Study	GILLMAN, MW (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,SUITE 200,BOSTON,MA 02215, USA.			Ellison, Robert Curtis/0000-0002-0582-7467; Gagnon, David/0000-0002-6367-3179; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL 48236, N01 HC 38038] Funding Source: Medline; NINDS NIH HHS [R01 NS 17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELL LL, 1952, J BIOL CHEM, V195, P357; ACHESON RM, 1983, LANCET, V1, P1191; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BRATTSTROM L, 1992, NEUROL RES, V14, P81, DOI 10.1080/01616412.1992.11740017; COULL BM, 1990, STROKE, V21, P572, DOI 10.1161/01.STR.21.4.572; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; IKEDA K, 1987, J NUTR SCI VITAMINOL, V33, P31, DOI 10.3177/jnsv.33.31; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; Klag M J, 1993, Ann Epidemiol, V3, P571; KLATSKY AL, 1987, J AM COLL CARDIOL, V9, P78; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LEE CN, 1988, NEW ENGL J MED, V318, P995; MANN GV, 1962, AM J CLIN NUTR, V11, P200, DOI 10.1093/ajcn/11.3.200; MANSON JE, 1993, J AM COLL NUTR, V12, P426, DOI 10.1080/07315724.1993.10718332; MANSON JE, 1994, CIRCULATION, V89, P932; MANSON JE, 1993, CIRCULATION, V87, P678; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; OMURA T, 1987, SOC SCI MED, V24, P401, DOI 10.1016/0277-9536(87)90212-7; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; ROUSE IL, 1983, LANCET, V1, P5; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SACKS FM, 1988, AM J CLIN NUTR, V48, P795, DOI 10.1093/ajcn/48.3.795; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; TOBIAN L, 1986, J HYPERTENS        S, V5, pS205; VERLANGIERI AJ, 1985, MED HYPOTHESES, V16, P7, DOI 10.1016/0306-9877(85)90035-0; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; WOLF PA, 1986, NEW ENGL J MED, V315, P1087, DOI 10.1056/NEJM198610233151709; YAMORI Y, 1984, HYPERTENSION, V6, P49, DOI 10.1161/01.HYP.6.1.49; 1994, HEART STROKE FACTS 1; 1991, HLTH PEOPLE 2000 NAT; 1989, RECOMMENDED DIETARY	47	367	375	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1113	1117		10.1001/jama.273.14.1113	http://dx.doi.org/10.1001/jama.273.14.1113			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707599				2022-12-01	WOS:A1995QR05900030
J	KEMP, KB				KEMP, KB			PUBLIC INFORMATION ON OSTEOPOROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KEMP, KB (corresponding author), US CONGRESS, OFF TECHNOL ASSESSMENT, WASHINGTON, DC 20510 USA.							1994, PUBLIC INFORMATION O, P70801	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1082	1082		10.1001/jama.273.14.1082	http://dx.doi.org/10.1001/jama.273.14.1082			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707584				2022-12-01	WOS:A1995QR05900006
J	KOTTKE, TE; TRAPP, MA; FORES, MM; KELLY, AW; JUNG, SH; NOVOTNY, PJ; PANSER, LA				KOTTKE, TE; TRAPP, MA; FORES, MM; KELLY, AW; JUNG, SH; NOVOTNY, PJ; PANSER, LA			CANCER SCREENING BEHAVIORS AND ATTITUDES OF WOMEN IN SOUTHEASTERN MINNESOTA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER WOMEN; MAMMOGRAPHY; PHYSICIANS; SMEAR	Objectives.-To determine the rates at which women received screening Papanicolaou tests, clinical breast examinations, and mammography and to determine the extent to which these women might be expected to respond to screening recommendations from their physicians. Design.-Random-digit-dial telephone interviews conducted in January 1993. Setting.-Fifteen counties in southeastern Minnesota. Subjects.-A sample of 1019 women who completed the telephone interview. Main Outcome Measures.-Self-reported Papanicolaou test, clinical breast examination, acid mammography screening rates, with verification from medical records for a randomly selected subsample of 200 respondents who reported having had a test within 1 year of the interview. Results.-For women aged 18 years and older, 60% (95% confidence interval, +/-3.4%) reported having had a Papanicolaou test within the preceding year. For women 40 years of age and older, 57% (95% confidence interval, +/-3,5%) reported having had a clinical breast examination in the past year, and 46% (95% confidence interval, +/-3,6%) reported having had a screening mammogram within 1 year. The verified 1-year Papanicolaou test and mammogram rates were 35% and 33%, respectively. More than 90% of the respondents expressed a willingness to have these tests if their physicians were to advise them that the tests were indicated. However, 53% and 54% of the respondents, respectively, said that they either did not care or did not want their physicians to remind them when they were due for a Papanicolaou test or a mammogram. Conclusions.-Although self-reported screening rates in this population meet Healthy People 2000 goals, verified rates were significantly below target levels. A substantial proportion of women in this population remain ambivalent about participating in cancer detection programs.			KOTTKE, TE (corresponding author), MAYO CLIN & MAYO FDN,NCI,DESIGNATED MAYO COMPREHENS CANC CTR,HARWICK 6,ROCHESTER,MN 55905, USA.				NATIONAL CANCER INSTITUTE [R25CA057825] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann S P, 1992, MMWR CDC Surveill Summ, V41, P17; Akaike H., 1973, 2 INT S INF THEOR, P267; BANDURA A, 1977, SOCIAL LEARNING THEO, P50; CUMMINGS KM, 1983, J FAM PRACTICE, V17, P1029; FREIDSON E, 1970, PROFESSION MED STUDY, P355; KAHNEMAN D, 1982, SCI AM, V246, P160, DOI 10.1038/scientificamerican0182-160; Kee F, 1992, Eur J Cancer Prev, V1, P311, DOI 10.1097/00008469-199206000-00006; KING ES, 1990, AM J PUBLIC HEALTH, V80, P1386, DOI 10.2105/AJPH.80.11.1386; KOTTKE T E, 1990, Journal of General Internal Medicine, V5, pS62, DOI 10.1007/BF02600845; KOTTKE TE, 1993, MAYO CLIN PROC, V68, P785, DOI 10.1016/S0025-6196(12)60638-7; KOTTKE TE, 1994, TOB CONTROL, V3, P46; LERMAN C, 1990, PREV MED, V19, P279, DOI 10.1016/0091-7435(90)90028-I; MOLLEMAN E, 1984, SOC SCI MED, V18, P475, DOI 10.1016/0277-9536(84)90003-0; MOODIE PJS, 1989, NEW ZEAL MED J, V102, P374; MOSELEY R, 1985, J MED PHILOS, V10, P163, DOI 10.1093/jmp/10.2.163; MURRAY M, 1993, J PUBLIC HEALTH MED, V15, P147; RATZAN RM, 1985, J MED PHILOS, V10, P147, DOI 10.1093/jmp/10.2.147; RESNIK MD, 1987, CHOICES INTRO DECISI, P8; Rimer B K, 1990, J Am Board Fam Pract, V3, P26; ROGERS EM, 1983, DIFFUSION INNOVATION, P250; SAWYER JA, 1989, AM J PUBLIC HEALTH, V79, P1036, DOI 10.2105/AJPH.79.8.1036; SKINNER BF, 1959, CUMULATIVE RECORD, P21; STEPTOE A, 1991, SOC SCI MED, V32, P627, DOI 10.1016/0277-9536(91)90141-X; WARNECKE RB, 1976, CANCER, V37, P2015, DOI 10.1002/1097-0142(197604)37:4<2015::AID-CNCR2820370453>3.0.CO;2-X; WEINBERGER M, 1991, J AM GERIATR SOC, V39, P22, DOI 10.1111/j.1532-5415.1991.tb05901.x; ZAPKA JG, 1992, J GERONTOL, V47, P93; 1989, GUIDE CLIN PREVENTIV, P39; 1990, SAS STAT USERS GUIDE, V2, P1071; 1991, PHS9150212 DEP HLTH; 1993, MMWR-MORBID MORTAL W, V42, P1	30	65	66	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1099	1105		10.1001/jama.273.14.1099	http://dx.doi.org/10.1001/jama.273.14.1099			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR059	7707597				2022-12-01	WOS:A1995QR05900028
J	STRYKER, J; COATES, TJ; DECARLO, P; HAYNESSANSTAD, K; SHRIVER, M; MAKADON, HJ				STRYKER, J; COATES, TJ; DECARLO, P; HAYNESSANSTAD, K; SHRIVER, M; MAKADON, HJ			PREVENTION OF HIV-INFECTION - LOOKING BACK, LOOKING AHEAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS; BEHAVIORS; IMPACT	For some, the occurrence of as many as 40 000 new human immunodeficiency virus (HIV) infections in the United States each year is evidence that HIV education and prevention efforts have failed. To the contrary, more than a decade of experience with HIV has demonstrated that lasting changes in behavior needed to avoid infection can occur as a result of carefully tailored, targeted, credible, and persistent HIV risk-reduction efforts. Given experience in other health behavior change endeavors, no interventions are likely to reduce the incidence of HIV infection to zero; indeed, insisting on too high a standard for HIV risk-reduction programs may actually undermine their effectiveness. A number of social, cultural, and attitudinal barriers continue to thwart the implementation of promising HIV risk-reduction programs. The remote prospects for a successful prophylactic vaccine for HIV and the difficulty in finding effective drug treatments have underscored the importance of sustained attention to HIV prevention and education. A series of ''correlates of immunity'' are identified-precedents that must exist to establish effective HIV prevention programs. These include sound policies promoting HIV risk reduction; access to health and social services, condoms, needles, and syringes; interventions shown to motivate behavioral change; organizations capable of reaching those at risk; and development and diffusion of technologies to interrupt the spread of the virus.	MOBILIZAT AGAINST AIDS,SAN FRANCISCO,CA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	STRYKER, J (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,CTR AIDS PREVENT STUDIES,74 NEW MONTGOMERY,SUITE 600,SAN FRANCISCO,CA 94105, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; BAYER R, 1994, AM J PUBLIC HEALTH, V84, P895, DOI 10.2105/AJPH.84.6.895; BURRIS S, 1993, AIDS LAW TODAY NEW G; CATANIA JA, 1993, SCIENCE, V258, P1101; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; CHOI KH, 1994, NEW ENGL J MED, V331, P406, DOI 10.1056/NEJM199408113310619; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; COHEN J, 1993, SCIENCE, V259, P1112, DOI 10.1126/science.8438161; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; FERREROS C, 1990, 6TH INT C AIDS SAN F; FIFE D, 1992, J ACQ IMMUN DEF SYND, V6, P1111; FISHBEIN M, 1993, J APPL SOC PSYCHOL, V23, P687, DOI 10.1111/j.1559-1816.1993.tb01110.x; GERBERT B, 1990, AM J PUBLIC HEALTH, V80, P467, DOI 10.2105/AJPH.80.4.467; Gorman M, 1989, Med Anthropol, V10, P159; HAHN RA, 1991, SOC SCI MED, V33, P1, DOI 10.1016/0277-9536(91)90444-H; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; JARLAIS DCD, 1992, ANN AM ACAD POLIT SS, V521, P42; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KAPLAN EH, 1989, EVALUATION REV, V13, P107, DOI 10.1177/0193841X8901300201; KEGELES SM, IN PRESS AM J PUBLIC; KELLY JA, 1993, AM PSYCHOL, V48, P1023, DOI 10.1037/0003-066X.48.10.1023; KIRBY D, 1994, PUBLIC HEALTH REP, V109, P339; LIFSON AR, 1994, LANCET, V343, P1306, DOI 10.1016/S0140-6736(94)92462-7; LURIE P, 1993, PUBLIC HLTH IMPACT N; MASCOLA JR, 1994, JAMA-J AM MED ASSOC, V272, P488, DOI 10.1001/jama.272.6.488; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MERSON M, 1994, 10TH INT C AIDS YOK; MOATTI JP, 1992, HEALTH POLICY, V21, P233, DOI 10.1016/0168-8510(92)90021-3; Perrow Charles, 1990, AIDS DISASTER FAILUR; PHILIPSON TJ, 1994, ISSUES SCI TECHNOL, V10, P33; RABIN SA, 1994, PUBLIC HLTH REP, V195, P42; RAMAH M, 1992, IDS PREVENTION ED WO; ROSENBERG PS, 1994, NEW ENGL J MED, V330, P789, DOI 10.1056/NEJM199403173301114; SHRIVER M, 1994, 5 CORRELATES IMMUNIT; STALL R, 1994, BRIT MED J, V309, P685, DOI 10.1136/bmj.309.6956.685; STEVENSON HC, 1994, AIDS EDUC PREV, V6, P126; STRYKER J, 1994, AM J PUBLIC HEALTH, V84, P1901, DOI 10.2105/AJPH.84.12.1901; WASSERFALLEN F, 1993, 9TH INT C AIDS BERL; WIEBEL W, 1993, 9 INT C AIDS BERL; 1990, MMWR-MORBID MORTAL W, V39, P1; 1995, MMWR-MORBID MORTAL W, V44, P64; 1994, NEW HLTH STRATEGY AI; 1993, MMWR-MORBID MORTAL W, V41, P1; 1992, EFFECTIVE APPROACHES; 1993, BEHAVIORAL SOCIAL SC; 1994, HIV PREVENTIVE VACCI; 1994, MMWR-MORBID MORTAL W, V42, P988; 1994, EFFECTIVENESS AIDS O; 1993, CHALLENGE HIV AID CO; 1992, HIV INCIDENCE PREVAL	50	54	54	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1143	1148		10.1001/jama.273.14.1143	http://dx.doi.org/10.1001/jama.273.14.1143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR059	7707604				2022-12-01	WOS:A1995QR05900035
J	TAPPERO, JW; SCHUCHAT, A; DEAVER, KA; MASCOLA, L; WENGER, JD				TAPPERO, JW; SCHUCHAT, A; DEAVER, KA; MASCOLA, L; WENGER, JD			REDUCTION IN THE INCIDENCE OF HUMAN LISTERIOSIS IN THE UNITED-STATES - EFFECTIVENESS OF PREVENTION EFFORTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPORADIC LISTERIOSIS; EPIDEMIC LISTERIOSIS; FOODS; MONOCYTOGENES; ASSOCIATION	Background.-Food-borne transmission is now recognized as a major cause of human listeriosis. Objective.-To assess the impact of prevention efforts, listeriosis rates before interventions were initiated in 1989 were compared with more recent rates (1990 through 1993). Design.-From 1989 through 1993, multistate, laboratory-based active surveillance was conducted to identify all cases in which Listeria monocytogenes was isolated from cultures or ordinarily sterile sites in an aggregate population of more than 19 million. Setting.-All laboratories serving acute care hospitals in up to nine surveillance areas in the United States. Interventions.-In 1989, a well-publicized case report of listeriosis linked to processed poultry led US regulatory agencies to enforce aggressive food monitoring policies and prompted industry to invest in cleanup efforts. In May 1992, consumer guidelines for listeriosis prevention were disseminated. Outcome Measures.-Cases of perinatal and nonperinatal listeriosis. Results.-The rate of listeriosis decreased in all surveillance areas. Projection of these rates to the US population suggests an estimated 1965 cases and 481 deaths occurred in 1989 compared with an estimated 1092 cases and 248 deaths in 1993, a 44% and 48% reduction in illness and death, respectively. Among adults 50 years of age and older, rates declined from 16.2 per 1 million in 1989 to 10.2 per 1 million in 1993 (P=.02). Perinatal disease decreased from 17.4 cases per 100 000 births in 1989 to 8.6 cases per 100 000 births in 1993 (P=.003). Three serotypes (1/2a, 1/2b, and 4b) of L monocytogenes accounted for more than 96% of cases during each year of the study (1989 through 1993). Conclusions. The incidence of listeriosis in study areas was substantially lower in 1993 than in 1989. The temporal association of this reduction with industry, regulatory, and educational efforts suggests these measures were effective.	LOS ANGELES CTY DEPT HLTH SERV, PUBL HLTH PROGRAMS & SERV, LOS ANGELES, CA USA		TAPPERO, JW (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, CHILDHOOD & RESP DIS BRANCH, ATLANTA, GA 30333 USA.				FDA HHS [FDA 224-88-2456] Funding Source: Medline	FDA HHS		ARCHER D L, 1988, Clinical Microbiology Reviews, V1, P377; Bernard D., 1994, Dairy, Food and Environmental Sanitation, V14, P140; BILLE J, 1990, T IND MICR, P71; Dowdle W R, 1989, MMWR Suppl, V38, P1; FARBER JM, 1991, MICROBIOL REV, V55, P476, DOI 10.1128/MMBR.55.3.476-511.1991; FARBER JM, 1989, J FOOD PROTECT, V52, P456, DOI 10.4315/0362-028X-52.7.456; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; GELLIN BG, 1991, AM J EPIDEMIOL, V133, P392, DOI 10.1093/oxfordjournals.aje.a115893; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; GILBERT RJ, 1989, LANCET, V1, P383; GOULET V, 1993, B EPIDEMIOL HEBDOM, V4, P13; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; MCLAUCHLIN J, 1991, BRIT MED J, V303, P773, DOI 10.1136/bmj.303.6805.773; McLauchlin J., 1990, PHLS Microbiology Digest, V7, P54; Newton L, 1992, Commun Dis Rep CDR Rev, V2, pR142; PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046; RYSER ET, 1991, LISTERIA LISTERIOSIS, P405; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHUCHAT A, 1991, CLIN MICROBIOL REV, V4, P169, DOI 10.1128/CMR.4.2.169-183.1991; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SCHWARTZ B, 1988, LANCET, V2, P779; Seeliger H.P.R., 1979, METHOD MICROBIOL, V13, P31, DOI [10.1016/S0580-9517(08)70372-6, DOI 10.1016/S0580-9517(08)70372-6]; SMITH JL, 1990, FOODBORNE LISTERIOSI, P137; THOMPSON P, 1990, LANCET, V336, P1557, DOI 10.1016/0140-6736(90)93320-O; TISLER JM, 1991, FOOD TECHNOL-CHICAGO, V45, P125; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WENGER JD, 1990, J FOOD PROTECT, V53, P1015, DOI 10.4315/0362-028X-53.12.1015; 1992, PREVENTING FOOD BORN; 1993, PUTTING CONSUMERS 1S; 1993, COMMUN DIS REP CDR W, V3, P136; 1992, MAKING CONNECTION US, P1; 1992, BACK GROUNDER LISTER; 1985, US PHS FDA229 US DEP; 1987, US PHS MI876 US DEP; 1992, JAMA-J AM MED ASSOC, V268, P180; 1992, PREVENTING FOODBORNE; 1986, MICROORGANISMS FOODS, P92; 1990, FSIS102401 FOOD SAF; 1987, FED REG         0311, V52, P7464; 1989, FED REG         0523, V54, P22345; 1992, MMWR-MORBID MORTAL W, V41, P251; 1988, MMWR-MORBID MORTAL W, V37, P764; 1992, MMWR-MORBID MORTAL W, V41, P257; 1992, FDA922232 PUBL; 1993, HIV AIDS SURVEILLANC, V5, P1; 1989, MMWR-MORBID MORTAL W, V38, P267	48	181	188	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1118	1122		10.1001/jama.273.14.1118	http://dx.doi.org/10.1001/jama.273.14.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707600				2022-12-01	WOS:A1995QR05900031
J	ATKISON, P; JOUBERT, G; BARRON, A; GRANT, D; PARADIS, K; SEIDMAN, E; WALL, W; ROSENBERG, H; HOWARD, J; WILLIAMS, S; STILLER, C				ATKISON, P; JOUBERT, G; BARRON, A; GRANT, D; PARADIS, K; SEIDMAN, E; WALL, W; ROSENBERG, H; HOWARD, J; WILLIAMS, S; STILLER, C			HYPERTROPHIC CARDIOMYOPATHY ASSOCIATED WITH TACROLIMUS IN PEDIATRIC TRANSPLANT PATIENTS	LANCET			English	Note							LIVER-TRANSPLANTATION; ALLOGRAFT RECIPIENTS; RENAL-FUNCTION; CYCLOSPORINE; FK-506	Reported side-effects of tacrolimus, a potent immunosuppressive agent, have not included cardiotoxicity. We describe 5 consecutive paediatric transplant recipients (3 small bowel with or without liver and 2 liver) who received tacrolimus. 2 developed congestive heart failure and hypertrophic obstructive cardiomyopathy which resolved after changing to cyclosporin. In the other 3 patients the cardiomyopathy regressed or improved with a lower dose of tacrolimus or after stopping the drug.	UNIV MONTREAL,HOP ST JUSTINE,MONTREAL,PQ H3T 1C5,CANADA	Universite de Montreal	ATKISON, P (corresponding author), UNIV WESTERN ONTARIO,CHILDRENS HOSP WESTERN ONTARIO,800 COMMISSIONERS RD E,LONDON,ON N6C 2V5,CANADA.							ABUELMAGD K, 1992, TRANSPLANT P, V24, P1243; DEMETRIS AJ, 1992, TRANSPLANTATION, V53, P1056, DOI 10.1097/00007890-199205000-00017; MCCAULEY J, 1990, TRANSPLANT P, V22, P17; MCDIARMID SV, 1993, TRANSPLANTATION, V56, P847, DOI 10.1097/00007890-199310000-00014; Noto S, 1994, TRANSPLANT P, V26, P855; TEXTOR SC, 1993, TRANSPLANTATION, V55, P855; THIRU S, 1987, TRANSPLANT P, V19, P98; WHITINGTON PF, 1994, SEMIN LIVER DIS, V14, P303, DOI 10.1055/s-2007-1007320; WIEDERRECHT G, 1994, ANN NY ACAD SCI, V696, P9; 1994, LANCET, V344, P423	10	166	170	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					894	896		10.1016/S0140-6736(95)90011-X	http://dx.doi.org/10.1016/S0140-6736(95)90011-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7535875				2022-12-01	WOS:A1995QR06700011
J	BARBER, N				BARBER, N			WHAT CONSTITUTES GOOD PRESCRIBING	BRITISH MEDICAL JOURNAL			English	Article							DRUG	Drugs are the mainstay of medical treatment, yet there are few reports on what constitutes ''good prescribing.'' What is more, the existing guidance tends to imply that right answers exist, rather than recognising the complex trade offs that have to be made between conflicting aims. This paper proposes four aims that a prescriber should try to achieve, both on first prescribing a drug and on subsequently monitoring it. They are: to maximise effectiveness, minimise risks, minimise costs, and respect the patient's choices. This model of good prescribing brings together the traditional balancing of risks and benefits with the need to reduce costs and the right of the patient to make choices in treatment. The four aims are shown as a diagram plotting their commonest conflicts, which may be used as an aid to discussion and decision making.			BARBER, N (corresponding author), UNIV LONDON,SCH PHARM,29-39 BRUNSWICK SQ,LONDON WC1N 1AX,ENGLAND.							Barber N., 1991, PHARM J, V246, P671; BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; FINNEY DJ, 1965, J CHRON DIS, V18, P77, DOI 10.1016/0021-9681(65)90054-8; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; PARISH PA, 1973, J ROY SOC HEALTH, V4, P213; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; 1992, RISK ANAL PERCEPTION, P2	7	78	81	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					923	925		10.1136/bmj.310.6984.923	http://dx.doi.org/10.1136/bmj.310.6984.923			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719188	Green Published			2022-12-01	WOS:A1995QR97200032
J	DENHEIJER, M; BLOM, HJ; GERRITS, WBJ; ROSENDAAL, FR; HAAK, HL; WIJERMANS, PW; BOS, GMJ				DENHEIJER, M; BLOM, HJ; GERRITS, WBJ; ROSENDAAL, FR; HAAK, HL; WIJERMANS, PW; BOS, GMJ			IS HYPERHOMOCYSTEINAEMIA A RISK FACTOR FOR RECURRENT VENOUS THROMBOSIS	LANCET			English	Article							PLASMA HOMOCYSTEINE; HOMOCYSTINURIA; DEFICIENCY; ARTERIAL; DISEASE	Several studies have shown a relation between hyperhomocysteinaemia and arterial Vascular disease. We looked at the association between hyperhomocysteinaemia and Venous thrombosis which could be clinically important as hyperhomocysteinaemia is easily corrected by Vitamin supplementation. We studied 185 patients with a history of recurrent venous thrombosis and 220 controls from the general population. Homocysteine concentrations were measured before and 6 h after oral methionine loading. We defined hyperhomocysteinaemia as the homocysteine concentration above the fasting or the postmethionine Value found for the 90th percentile of the controls. Of the 185 patients with recurrent thrombosis, 46 (25%) had fasting homocysteine concentrations above the 90th percentile or the controls (odds ratio is 3.1 [1.8-5.5]). After adjustment for age, sex, and menopausal status the odds ratio was 2.0 (1.5-2.7). Similar results were found for the post-methionine Value (unadjusted odds ratio 3.1 [1.7-5.5], adjusted 2.6 [1.9-3.5]). Hyperhomocysteinaemia is a common risk factor for recurrent Venous thrombosis and can lead to a two-fold or three-fold increase in risk.	UNIV NIJMEGEN HOSP,PAEDIAT & NEUROL LAB,6500 HB NIJMEGEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT HEMATOL,2333 AA LEIDEN,NETHERLANDS	Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	DENHEIJER, M (corresponding author), MUNICIPAL HOSP LEYENBURG,DEPT HEMATOL,THE HAGUE,NETHERLANDS.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496; Blom, Henk/0000-0001-5202-9241				ANDERSSON A, 1992, EUR J CLIN INVEST, V22, P79, DOI 10.1111/j.1365-2362.1992.tb01940.x; BIENVENU T, 1991, PRESSE MED, V20, P985; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; FRANKEN DG, 1994, ARTERIOSCLER THROMB, V14, P465, DOI 10.1161/01.ATV.14.3.465; HEIJEER M, 1994, FIBRINOLYSIS S2, V8, P91; MCCULLY KS, 1987, RES COMMUN CHEM PATH, V56, P349; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; Miettinen O.S., 1985, THEORETICAL EPIDEMIO; MIETTINEN OS, 1974, AM J EPIDEMIOL, V99, P352; MUDD SH, 1985, AM J HUM GENET, V37, P1; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1990, BLOOD, V75, P895; RODGERS GM, 1988, J CLIN INVEST, V81, P1911, DOI 10.1172/JCI113538; Schlesselman J.J., 1982, CASE CONTROL STUDIES; STAMPFER MJ, 1993, JAMA-J AM MED ASSOC, V270, P2726, DOI 10.1001/jama.270.22.2726; UBBINK JB, 1993, CLIN INVESTIGATOR, V71, P993, DOI 10.1007/BF00180030; UELAND PM, 1993, ATHEROSCLEROTIC CARD, P183	20	320	321	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					882	885		10.1016/S0140-6736(95)90008-X	http://dx.doi.org/10.1016/S0140-6736(95)90008-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707810	Green Submitted			2022-12-01	WOS:A1995QR06700008
J	EIDT, S; BAYERDORFFER, E; STOLTE, M				EIDT, S; BAYERDORFFER, E; STOLTE, M			TREAT THE INFECTION AND CURE THE CANCER	LANCET			English	Editorial Material							HELICOBACTER-PYLORI; LYMPHOID-TISSUE		UNIV MUNICH,DEPT MED 2,W-8000 MUNICH,GERMANY; CLIN BAYREUTH,INST PATHOL,BAYREUTH,GERMANY	University of Munich; Klinikum Bayreuth	EIDT, S (corresponding author), UNIV COLOGNE,INST PATHOL,W-5000 COLOGNE,GERMANY.							ALBRECHT S, 1991, J AM ACAD DERMATOL, V24, P621, DOI 10.1016/0190-9622(91)70095-J; BAYERDORFFER E, 1994, GASTROENTEROLOGY, V106, pA370; CALVERT R, 1995, LANCET, V345, P9; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; LOGAN RPH, 1994, LANCET, V344, P1078, DOI 10.1016/S0140-6736(94)91729-9; OROURKE EA, 1994, J PATHOL, V173, P166; ROONEY CM, 1995, LANCET, V345, P26; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; Young L S, 1992, Semin Cancer Biol, V3, P273	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					874	875		10.1016/S0140-6736(95)90004-7	http://dx.doi.org/10.1016/S0140-6736(95)90004-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707806				2022-12-01	WOS:A1995QR06700004
J	ESPINAL, MA; REINGOLD, AL; KOENIG, E; LAVANDERA, M; SANCHEZ, S				ESPINAL, MA; REINGOLD, AL; KOENIG, E; LAVANDERA, M; SANCHEZ, S			SCREENING FOR ACTIVE TUBERCULOSIS IN HIV TESTING CENTER	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS-DRUG-USERS; INFECTED PATIENTS; OUTBREAK	In industrialised nations HIV-seropositive individuals can be offered shin testing for tuberculosis (TB) and isoniazid prophylaxis, but this approach is neither practicable nor affordable in most developing countries. in Santo Domingo, Dominican Republic, we offered skin testing and a brief clinical examination for active TB to people requesting HIV testing at one centre. 200 newly detected HIV-positive individuals and 200 age and sex-matched HIV-negative ones were compared. 39 (9.7%) of the 400 individuals seeking HIV testing had active TB; 29 were HIV positive and 10 were HIV negative (adjusted odds ratio 3.3, 95% CI 1.3-8.7; p=0.01). In multivariate analysis, the strongest independent predictors of active TB were 10 mm or more of induration on skin testing, a history of chronic cough, lymphadenopathy, and HIV infection. Of the patients diagnosed with TB, 85% had one or more symptoms readily ascertainable in a brief screening questionnaire. Screening for TB at HIV-testing sites could be an effective approach to early detection of active TB among not just HIV-positive but also HIV-negative people. integrating screening for TB into HIV testing schemes could help to reduce the spread of TB and allow patients with TB to be diagnosed and treated earlier.	UNIV CALIF BERKELEY,SCH PUBL HLTH,DIV PUBL HLTH BIOL & EPIDEMIOL,BERKELEY,CA 94720; NATL LAB PUBL HLTH,SANTO DOMINGO,DOMINICAN REP; MINIST HLTH,NATL TB CONTROL PROGRAM,SANTO DOMINGO,DOMINICAN REP	University of California System; University of California Berkeley					FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00003-03] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BOUVET E, 1993, AIDS, V7, P1453, DOI 10.1097/00002030-199311000-00008; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DIPERRI G, 1989, LANCET, V2, P1502; DUCOS J, 1992, 7 INT C AIDS AMST; Espinal M, 1994, Bol Oficina Sanit Panam, V116, P452; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GARCIA V, 1993, NEUMOS, V8, P169; GARCIA V, 1992, NEUMOS, V7, P9; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; HARRIES AD, 1990, LANCET, V335, P390; JOHNSON MP, 1992, J INFECT DIS, V166, P194, DOI 10.1093/infdis/166.1.194; LONG R, 1991, AM REV RESPIR DIS, V143, P69, DOI 10.1164/ajrccm/143.1.69; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; SANCHEZ S, 1993, NEUMOS, V8, P55; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SNIDER DE, 1994, TUBERCULOSIS PATHOGE; Sutherland I, 1976, Adv Tuberc Res, V19, P1; 1994, TUBER LUNG DIS, V75, P96; 1989, MMWR-MORBID MORTAL W, V38, P243; 1989, MMWR-MORBID MORTAL W, V38, P236	21	23	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					890	893		10.1016/S0140-6736(95)90010-1	http://dx.doi.org/10.1016/S0140-6736(95)90010-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707812				2022-12-01	WOS:A1995QR06700010
J	GEISSLER, A; ANDUS, T; ROTH, M; KULLMANN, F; CAESAR, I; HELD, P; GROSS, V; FEUERBACH, S; SCHOLMERICH, J				GEISSLER, A; ANDUS, T; ROTH, M; KULLMANN, F; CAESAR, I; HELD, P; GROSS, V; FEUERBACH, S; SCHOLMERICH, J			FOCAL WHITE-MATTER LESIONS IN BRAIN OF PATIENTS WITH INFLAMMATORY BOWEL-DISEASE	LANCET			English	Note							CROHNS-DISEASE	Inflammatory bowel diseases are often associated with extra-intestinal manifestations, such as arthritis and iritis/uveitis. Using magnetic-resonance imaging we found hyperintense focal white-matter lesions in the brain in 20 of 48 (42%) patients with Crohn's disease, in 11 of 24 (46%) patients with ulcerative colitis, but in only 8 of 50 (16%) healthy age-matched controls (relative risk [95% CI] vs controls 2.6 [1.3-5.3] and 2.9 [1.3-6.2], respectively). These findings may represent another extra-intestinal manifestation of inflammatory bowel disease.	UNIV REGENSBURG,DEPT INTERNAL MED 1,D-93042 REGENSBURG,GERMANY; UNIV REGENSBURG,DEPT RADIOL,D-93042 REGENSBURG,GERMANY	University of Regensburg; University of Regensburg								ADAMEK RJ, 1993, LEBER MAGEN DARM, V23, P91; BELL CL, 1991, ARTHRITIS RHEUM, V34, P432, DOI 10.1002/art.1780340408; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; ERDEM E, 1993, NEURORADIOLOGY, V35, P142, DOI 10.1007/BF00593971; HORIKOSHI T, 1993, NEURORADIOLOGY, V35, P151, DOI 10.1007/BF00593975; ISHIKAWA O, 1994, J RHEUMATOL, V21, P87; MEGURO K, 1993, NEURORADIOLOGY, V35, P125, DOI 10.1007/BF00593968; MORRISSEY SP, 1993, BRAIN, V116, P135, DOI 10.1093/brain/116.1.135; RACHMILEWITZ D, 1989, BRIT MED J, V198, P82; WAKEFIELD AJ, 1989, LANCET, V2, P1057	10	96	99	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					897	898						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707814				2022-12-01	WOS:A1995QR06700013
J	GLYNN, JR; JENKINS, PA; FINE, PEM; PONNIGHAUS, JM; STERNE, JAC; MKANDWIRE, PK; NYASULU, S; BLISS, L; WARNDORFF, DK				GLYNN, JR; JENKINS, PA; FINE, PEM; PONNIGHAUS, JM; STERNE, JAC; MKANDWIRE, PK; NYASULU, S; BLISS, L; WARNDORFF, DK			PATTERNS OF INITIAL AND ACQUIRED ANTITUBERCULOSIS DRUG-RESISTANCE IN KARONGA DISTRICT, MALAWI	LANCET			English	Article							TUBERCULOSIS	There is concern that drug-resistant tuberculosis is increasing and may be concentrated among HIV-positive patients. Little information is available from developing countries, where surveillance studies are often unable to distinguish resistance in previously untreated patients (initial resistance) from resistance acquired following drug therapy, and where information on the HIV status of the patients is rare. Initial resistance patterns reflect the strains being transmitted in the community. We have studied patterns of resistance in northern Malawi, where the Lepra Evaluation Project has been collecting data on drug resistance since 1986. Initial drug sensitivity results were available for 373 new cases of tuberculosis. Initial resistance to at least one drug was found in 44 of these patients (11.8%, 95% CI 8.5-15.1): 13 were resistant to streptomycin alone, 13 to isoniazid alone, and 17 to more than one drug. Only 3 patients showed initial rifampicin resistance-1 in isolation, 1 in combination with streptomycin, and 1 with triple resistance. Drug resistance was not related to age, sex, or HIV status of the patient and there was no evidence of any increase over the period studied. There was no evidence of geographic clustering of the resistant strains, or of any increased risk of resistant strains in households with previous tuberculosis cases. Acquired resistance during follow-up was found in 5 of 329 patients with documented initially fully sensitive strains. 5 patients with initial resistance seemed to show reversion to sensitivity. The absence of an increase in drug resistance, despite an increase in tuberculosis cases over the period, is encouraging for the control programme. It emphasises the need to collect information from many areas before assuming that increases in antituberculosis drug resistance are occurring worldwide.	UNIV WALES HOSP,PHLS MYCOBACTERIUM REFERENCE UNIT,CARDIFF CF4 4XW,S GLAM,WALES; LEPRA,CHLLUMBA,MALAWI	Cardiff University	GLYNN, JR (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053				BOHMER PD, 1992, S AFR MED J, V81, P382; Boulahbal F, 1989, Bull Int Union Tuberc Lung Dis, V64, P23; BRAUN MM, 1992, AIDS, V6, P1327, DOI 10.1097/00002030-199211000-00014; COWIE RL, 1990, TUBERCLE, V71, P39, DOI 10.1016/0041-3879(90)90059-H; DECALUWE P, 1989, ANN SOC BELG MED TR, V69, P143; Freiden T.E., 1993, NEW ENGL J MED, V328, P521; GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z; Jenkins P. A., 1985, Isolation and identification of micro-organisms of medical and veterinary importance, P275; LEMMA E, 1984, ETHIOPIAN MED J, V22, P93; MITCHISON DA, 1984, BRIT MED BULL, V40, P84, DOI 10.1093/oxfordjournals.bmb.a071952; NKINDA S J, 1985, Tubercle, V66, P161; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P163, DOI 10.1016/0962-8479(94)90001-9; Nyangulu D S, 1991, Bull Int Union Tuberc Lung Dis, V66, P173; SHENNAN D H, 1964, Tubercle, V45, P1, DOI 10.1016/S0041-3879(64)80080-5; SWAI OB, 1989, TUBERCLE, V70, P5; VARELDZIS BP, 1994, TUBERCLE LUNG DIS, V75, P1, DOI 10.1016/0962-8479(94)90096-5; WEYER K, 1992, TUBERCLE LUNG DIS, V73, P106, DOI 10.1016/0962-8479(92)90064-Q; WOLDE K, 1986, ETHIOPIAN MED J, V24, P15	18	44	45	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					907	910		10.1016/S0140-6736(95)90016-0	http://dx.doi.org/10.1016/S0140-6736(95)90016-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707817				2022-12-01	WOS:A1995QR06700016
J	LITTLE, P; KEEFE, M; WHITE, J				LITTLE, P; KEEFE, M; WHITE, J			SELF SCREENING FOR RISK OF MELANOMA - VALIDITY OF SELF MOLE COUNTING BY PATIENTS IN A SINGLE GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							CUTANEOUS MALIGNANT-MELANOMA; DANISH CASE-CONTROL; MELANOCYTIC NEVI; SUNBURN; NAEVI; AUSTRALIA; EXPOSURE; WOMEN	Objective-To validate self screening by patients of high mole counts, assess the within family association of sun protection behaviour and mole counts, and estimate prevalence of risk factors for melanoma. Setting and subjects-Systematic sample of families from a single affluent general practice population in Wessex. Design-Subjects completed a questionnaire about risk factors for melanoma and counted their moles. Subsequently a mole count was done by a general practitioner trained at dermatology clinics. Main outcome measures-Validation of self counts by observer's count. Within family association of sun protection behaviour and mole counts; self reported risk factors. Results-199/237 subjects (84%) returned the questionnaire; 212/237 (89%) were examined, High counts by patients on the front of the trunk (>7 moles of greater than or equal to 2 mm) were reasonably sensitive (79%), predictive (75%), and specific (97%) of the observer's mole counts (kappa=0.74), unlike arm or total body counts. Sun protection behaviour correlated between individuals and other family members (Spearman's coefficient r=0.50, P<0.01), In the past three months 15/114 adults (13.2%, 95% confidence interval 7.0% to 19.1%) reported any change in a mole and 6/114 (5.3%, 2.0% to 11.1%) ''major'' changes; 6/109 adults (5.5%, 2.1% to 11.6%) had both high mole counts and freckling. Conclusions-Asking patients to count trunk moles could be a feasible way of identifying patients at high risk of melanoma. Concentrating on reported major changes in moles should avoid considerable workload in general practice. The generalisability of these findings and the adverse effects, net benefit in earlier diagnosis and prevention, and workload implications of such self screening need further research.	UNIV SOUTHAMPTON,DEPT DERMATOL,SOUTHAMPTON,HANTS,ENGLAND; HLTH CTR,THAME OX9 3JZ,OXON,ENGLAND	University of Southampton	LITTLE, P (corresponding author), UNIV SOUTHAMPTON,FAC MED,ALDERMOOR HLTH CTR,SOUTHAMPTON SO16 5ST,HANTS,ENGLAND.			Little, Paul/0000-0003-3664-1873				BAIN C, 1988, AM J EPIDEMIOL, V127, P703, DOI 10.1093/oxfordjournals.aje.a114851; BERAL V, 1983, BRIT J DERMATOL, V109, P165, DOI 10.1111/j.1365-2133.1983.tb07077.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BONETT A, 1986, MED J AUSTRALIA, V144, P680, DOI 10.5694/j.1326-5377.1986.tb113693.x; BYLES JE, 1944, BRIT J DERMATOL, V130, P51; CLARK WM, 1988, ARCH DERMATOL, V114, P732; COOKE KR, 1989, CANCER, V63, P1240, DOI 10.1002/1097-0142(19890315)63:6<1240::AID-CNCR2820630635>3.0.CO;2-9; COOKE KR, 1985, J EPIDEMIOL COMMUNIT, V39, P52; DARCY C, 1994, J NATL CANCER I, V72, P257; ELDER DE, 1989, J INVEST DERMATOL S, V92, P297; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; ELWOOD JM, 1985, BRIT J CANCER, V51, P543, DOI 10.1038/bjc.1985.77; ELWOOD JM, 1994, INT J CANCER, V35, P427; ELWOOD JM, 1994, BRIT MED J, V288, P99; ENGLISH DR, 1988, BRIT MED J, V296, P1285, DOI 10.1136/bmj.296.6632.1285; ENGLISH JSC, 1988, BRIT J DERMATOL, V118, P641, DOI 10.1111/j.1365-2133.1988.tb02564.x; GREEN A, 1985, BRIT J CANCER, V51, P393, DOI 10.1038/bjc.1985.53; GREEN A, 1985, INT J CANCER, V35, P297, DOI 10.1002/ijc.2910350303; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; JOHNSON N, 1994, BRIT J GEN PRACT, V44, P523; MACHIE R, 1985, BRIT J DERMATOL, V113, P167; MACKIE RM, 1982, BRIT J CANCER, V46, P955, DOI 10.1038/bjc.1982.307; MARKS R, 1994, BRIT MED J, V308, P75, DOI 10.1136/bmj.308.6921.75; MARTEAU T, 1991, BRIT MED J, V301, P26; NEWTON JA, 1994, BRIT MED BULL, V50, P677, DOI 10.1093/oxfordjournals.bmb.a072916; NEWTON JA, 1992, DIAGNOSIS MANAGEMENT, P53; NICHOLLS EM, 1973, CANCER, V32, P191, DOI 10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PACK GT, 1952, AMA ARCH SURG, V65, P862, DOI 10.1001/archsurg.1952.01260020856010; ROBERTS DL, 1990, CLIN EXP DERMATOL, V15, P406, DOI 10.1111/j.1365-2230.1990.tb02132.x; ROUSH GC, 1988, PREV MED, V17, P273, DOI 10.1016/0091-7435(88)90003-5; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555; WEINSTOCK MA, 1989, PEDIATRICS, V84, P199; ZANETTI R, 1992, EUR J CANCER, V28A, P1172, DOI 10.1016/0959-8049(92)90480-P	36	38	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					912	916		10.1136/bmj.310.6984.912	http://dx.doi.org/10.1136/bmj.310.6984.912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719184	Green Published			2022-12-01	WOS:A1995QR97200027
J	MALCOLM, PN; CHAN, TYK; LI, PL; RICHARDS, J; HATELY, W				MALCOLM, PN; CHAN, TYK; LI, PL; RICHARDS, J; HATELY, W			MANAGEMENT OF DYSPEPSIA AMONG ASIANS BY GENERAL-PRACTITIONERS IN EAST LONDON	BRITISH MEDICAL JOURNAL			English	Article							CONSULTATIONS		ROYAL LONDON TRUST,DEPT RADIOL,LONDON E1 1BB,ENGLAND; E LONDON & CITY HLTH AUTHOR,DEPT PUBL HLTH MED,LONDON E3 2AN,ENGLAND	St Georges University London								BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; CONRY BG, 1989, BMJ-BRIT MED J, V299, P1443, DOI 10.1136/bmj.299.6713.1443; MURRAY J, 1986, SOC PSYCH PSYCH EPID, V21, P139, DOI 10.1007/BF00582684; 1994, CENSUS USER GUIDE 58; 1993, CENSUS COUNTY REPO 1, V1	5	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					910	911		10.1136/bmj.310.6984.910	http://dx.doi.org/10.1136/bmj.310.6984.910			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719183	Green Published			2022-12-01	WOS:A1995QR97200024
J	STAMP, T				STAMP, T			GREY HAIRS, FALSE TEETH, AND BAD BONES	LANCET			English	Editorial Material							PHOTON-ABSORPTIOMETRY; RISK-FACTORS; OSTEOPOROSIS; WOMEN				STAMP, T (corresponding author), ROYAL NATL ORTHOPAED HOSP, STANMORE HA7 4LP, MIDDX, ENGLAND.							ARNOLD HL, 1990, ANDREWS DISEASES SKI, P891; COOPER C, 1991, OSTEOPOROSIS INT, V2, P48, DOI 10.1007/BF01627079; GLASSER M, 1991, MED HYPOTHESES, V36, P404, DOI 10.1016/0306-9877(91)90020-Y; HOUKI K, 1994, J BONE MINER RES  S1, V9, pS211; JEFFCOAT MK, 1993, J AM DENT ASSOC, V124, P49, DOI 10.14219/jada.archive.1993.0225; KEOGH EV, 1965, NATURE, V207, P877, DOI 10.1038/207877a0; KLEEREKOPER M, 1989, BONE MINER, V7, P171, DOI 10.1016/0169-6009(89)90074-3; ROSEN CJ, 1994, J CLIN ENDOCR METAB, V79, P854, DOI 10.1210/jc.79.3.854; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SPECTOR TD, 1992, CURRENT RES OSTEOPOR, V11, P86; 1993, J BONE MINER RES S2, V8, pS443; 1994, REPORT ADVISORY GROU, P76	12	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	1995	345	8954					876	876		10.1016/S0140-6736(95)90006-3	http://dx.doi.org/10.1016/S0140-6736(95)90006-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707808				2022-12-01	WOS:A1995QR06700006
J	TODD, CJ; FREEMAN, CJ; CAMILLERIFERRANTE, C; PALMER, CR; HYDER, A; LAXTON, CE; PARKER, MJ; PAYNE, BV; RUSHTON, N				TODD, CJ; FREEMAN, CJ; CAMILLERIFERRANTE, C; PALMER, CR; HYDER, A; LAXTON, CE; PARKER, MJ; PAYNE, BV; RUSHTON, N			DIFFERENCES IN MORTALITY AFTER FRACTURE OF HIP - THE EAST-ANGLIAN AUDIT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate differences between hospitals in clinical management of patients admitted With fractured hip and to relate these to mortality at 90 days. Design-A prospective audit of process and outcome of care based on interviews with patients, abstraction from records with standard proforma, and follow up at three months. Data were analysed with chi(2) test and forward stepwise regression modelling of mortality. Setting-All eight hospitals in East Anglia with trauma orthopaedic departments. Patients-580 consecutive patients admitted for fracture of neck of femur. Main outcome measure-Mortality at 90 days. Results-Patients admitted to each hospital were similar with respect to age, sex, pre-existing illnesses, and activities of daily living before fracture. In all, 560 (97%) were treated surgically, by a range of grades of surgeon. Two hundred and sixty one patients (45%; range between hospitals 10-91%) received pharmaceutical thromboembolic prophylaxis, 502 (93%; 81-99%) perioperative antibiotic prophylaxis. The incidence of fatal pulmonary emboli differed between patients who received and those who did not receive prophylaxis against deep vein thrombosis (P=0.001). Mortality at 90 days was 18%, differing significantly between hospitals (5-23%). One hospital had significantly better survival than the others (odds ratio 0 .14; 95% confidence interval 0.04-0.48; P=0.0016). Conclusions-No single factor or aspect of practice accounted for this protective effect. Lower mortality may be associated with the cumulative effects of several aspects of the organisation of treatment and the management of fracture of the hip, including thromboembolic pharmaceutical prophylaxis, antibiotic prophylaxis, and early mobilisation.	ANGLIA & OXFORD REG HLTH AUTHOR,DIRECTORATE PUBL HLTH MED,CAMBRIDGE,ENGLAND; PETERBOROUGH DIST GEN HOSP,DEPT ORTHOPAED,PETERBOROUGH PE3 6DA,ENGLAND; NORFOLK & NORWICH HEALTHCARE NHS TRUST,NORWICH,NORFOLK,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,ORTHOPAED RES UNIT,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	TODD, CJ (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,HLTH SERV RES GRP,CAMBRIDGE CB2 2SR,ENGLAND.		Todd, Chris/AAD-8661-2022; Todd, Chris/A-7904-2010; Hyder, Adnan/AAT-9503-2021	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Freeman, Carol/0000-0001-9751-0784				ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336; FREEMAN CJ, 1995, E ANGLIAN AUDIT FRAC; HOLLINGWORTH W, IN PRESS J PUBLIC HL; PARKER MJ, 1993, J BONE JOINT SURG BR, V75, P797, DOI 10.1302/0301-620X.75B5.8376443; Parker MJ., 1993, HIP FRACTURE MANAGEM; Pearse M, 1992, Health Trends, V24, P134; RUSSELL IT, 1992, QUALITY HLTH CARE, V1, P52; SAINSBURY R, 1991, REV CLIN GERONTOL, V1, P67; TODD C, 1993, TIJDSCHRIFT SOCIALE, V71, P72; 1989, FRACTURED NECK FEMUR; 1990, REPORT E ANGLIAN REG; 1994, HOSPITAL EPISODE STA, V1; 1992, BRIT MED J, V305, P567; 1989, CMND555; 1994, HOSPITAL AMBULANCE S	15	246	248	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					904	908		10.1136/bmj.310.6984.904	http://dx.doi.org/10.1136/bmj.310.6984.904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719180	Green Published			2022-12-01	WOS:A1995QR97200021
J	VARTIAINEN, E; SARTI, C; TUOMILEHTO, J; KUULASMAA, K				VARTIAINEN, E; SARTI, C; TUOMILEHTO, J; KUULASMAA, K			DO CHANGES IN CARDIOVASCULAR RISK-FACTORS EXPLAIN CHANGES IN MORTALITY FROM STROKE IN FINLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; COMMUNITY; TRENDS	Objectives-To estimate the extent to which the changes in the main cardiovascular risk factors (blood pressure, smoking, and serum cholesterol concentration) can explain the observed changes in mortality from stroke in Finland during the past 20 years. Design-Predicted changes in mortality from cerebrovascular disease mortality were calculated by a proportional hazards model from data obtained in cross sectional population surveys in 1972, 1977, 1982, 1987, and 1992. Predicted changes were compared with the observed changes in mortality statistics. Setting-North Karelia and Kuopio provinces, Finland. Subjects-16 741 men and 16 389 women aged 30-59 randomly selected from the national population register, of whom 14 054 men and 14 546 women participated. Main outcome measures-levels of risk factors and predicted and observed changes in mortality from cerebrovascular disease. Results-The observed changes in diastolic blood pressure, total serum cholesterol concentration, and smoking in the population from 1972 to 1992 predicted a 44% fall in mortality from stroke in men and changes in diastolic blood pressure and smoking predicted a 34% fall in women. The observed fall in mortality from stroke was 66% in men and 60% in women. Conclusions-Two thirds of the fall in mortality hom stroke in men and half in women can be explained by changes in the three main cardiovascular risk factors.			VARTIAINEN, E (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, MANNERHEIMINTIE 166, SF-00300 HELSINKI, FINLAND.			Kuulasmaa, Kari/0000-0003-2165-1411				BEEVERS DG, 1990, J HUM HYPERTENS, V4, P587; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DOBSON AJ, 1988, STAT MED, V7, P613, DOI 10.1002/sim.4780070508; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KAGAN A, 1980, STROKE, V11, P14, DOI 10.1161/01.STR.11.1.14; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAXWELL MH, 1982, LANCET, V2, P33; MENOTTI A, 1990, INT J EPIDEMIOL, V19, P309, DOI 10.1093/ije/19.2.309; PIETINEN P, 1990, INT CONGR SER, V953, P243; PUSKA P, 1985, PREV MED, V14, P573, DOI 10.1016/0091-7435(85)90078-7; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STOKES J, 1989, HYPERTENSION, V13, P113; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TUOMILEHTO J, 1992, AM J EPIDEMIOL, V135, P1259, DOI 10.1093/oxfordjournals.aje.a116232; TUOMILEHTO J, 1987, J HUM HYPERTENS, V1, P201; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; 1992, 1992 FAO WHO INT C N, P11; 1971, AUTOANALYZER II 26A	24	80	80	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	1995	310	6984					901	904		10.1136/bmj.310.6984.901	http://dx.doi.org/10.1136/bmj.310.6984.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719179	Green Published			2022-12-01	WOS:A1995QR97200020
J	AFSHAR, K; BARTON, NR; HAWLEY, RS; GOLDSTEIN, LSB				AFSHAR, K; BARTON, NR; HAWLEY, RS; GOLDSTEIN, LSB			DNA-BINDING AND MEIOTIC CHROMOSOMAL LOCALIZATION OF THE DROSOPHILA NOD KINESIN-LIKE PROTEIN	CELL			English	Article							DISTRIBUTIVE SEGREGATION; GENETIC-ANALYSIS; MELANOGASTER; SATELLITE; FEMALES; SPINDLE; DOMAIN	The Drosophila no distributive disjunction (nod) gene encodes a kinesin-like protein that has been proposed to push chromosomes toward the metaphase plate during female meiosis. We report that the nonmotor domain of the nod protein can mediate direct binding to DNA. Using an antiserum prepared against bacterially expressed nod protein, we show that during prometaphase nod protein is localized on oocyte chromosomes and is not restricted to either specific chromosomal regions or to the kinetochore. Thus, motor-based chromosome-microtubule interactions are not limited to the centromere, but extend along the chromosome arms, providing a molecular explanation for the polar ejection force.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	AFSHAR, K (corresponding author), UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616, USA.			Hawley, R. Scott/0000-0002-6478-0494				ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; ABERCROMBIE BD, 1978, EUR J BIOCHEM, V84, P173, DOI 10.1111/j.1432-1033.1978.tb12154.x; BAKER BS, 1972, GENETICS, V71, P255; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; CARPENTER AT, 1973, GENETICS, V73, P393; CARPENTER ATC, 1991, CELL, V64, P885, DOI 10.1016/0092-8674(91)90313-N; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; CHODOSH LA, 1991, CURRENT PROTOCOLS MO, V2; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; FUGE H, 1990, PROTOPLASMA, V158, P1, DOI 10.1007/BF01323267; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRELL RF, 1976, GENET BIOL DROSOPHIL, P435; HARLOW E, 1988, ANTIBODIES LABORATOR; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HAWLEY RS, 1993, ANNU REV GENET, V27, P281; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HAWLEY RS, 1993, DEV GENET, V13, P440; LE MH, 1995, IN PRESS GENETICS; LOHE AR, 1986, P NATL ACAD SCI USA, V83, P696, DOI 10.1073/pnas.83.3.696; MCKIM KS, 1993, NATURE, V362, P364, DOI 10.1038/362364a0; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RASOOLY RS, 1991, GENETICS, V129, P409; RASOOLY RS, 1994, MOL GEN GENET, V242, P145, DOI 10.1007/BF00391007; REEVES R, 1993, J BIOL CHEM, V268, P21137; Rhoades MM, 1942, GENETICS, V27, P0395; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; Sambrook J., 1989, MOL CLONING LAB MANU; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115	35	123	125	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					129	138		10.1016/0092-8674(95)90377-1	http://dx.doi.org/10.1016/0092-8674(95)90377-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720068	Bronze			2022-12-01	WOS:A1995QR97000014
J	CHRIST, WJ; ASANO, O; ROBIDOUX, ALC; PEREZ, M; WANG, YA; DUBUC, GR; GAVIN, WE; HAWKINS, LD; MCGUINNESS, PD; MULLARKEY, MA; LEWIS, MD; KISHI, Y; KAWATA, T; BRISTOL, JR; ROSE, JR; ROSSIGNOL, DP; KOBAYASHI, S; HISHINUMA, L; KIMURA, A; ASAKAWA, N; KATAYAMA, K; YAMATSU, I				CHRIST, WJ; ASANO, O; ROBIDOUX, ALC; PEREZ, M; WANG, YA; DUBUC, GR; GAVIN, WE; HAWKINS, LD; MCGUINNESS, PD; MULLARKEY, MA; LEWIS, MD; KISHI, Y; KAWATA, T; BRISTOL, JR; ROSE, JR; ROSSIGNOL, DP; KOBAYASHI, S; HISHINUMA, L; KIMURA, A; ASAKAWA, N; KATAYAMA, K; YAMATSU, I			E5531, A PURE ENDOTOXIN ANTAGONIST OF HIGH POTENCY	SCIENCE			English	Article							GRAM-NEGATIVE ENDOTOXIN; LIPID-A; ESCHERICHIA-COLI; SEPTIC SHOCK; INFLAMMATORY MEDIATORS; LIPOPOLYSACCHARIDE; SEPSIS; BIOSYNTHESIS; NEUTROPHILS; MACROPHAGES	Shock due to Gram-negative bacterial sepsis is a consequence of acute inflammatory response to lipopolysaccharide (LPS) or endotoxin released from bacteria. LPS is a major constituent of the outer membrane of Gram-negative bacteria, and its terminal disaccharide phospholipid (lipid A) portion contains the key structural features responsible for toxic activity. Based on the proposed structure of nontoxic Rhodobacter capsulatus lipid A, a fully stabilized endotoxin antagonist E5531 has been synthesized. In vitro, E5531 demonstrated potent antagonism of LPS-mediated cellular activation in a variety of systems. In vivo, E5531 protected mice from LPS-induced lethality and, in cooperation with an antibiotic, protected mice from a lethal infection of viable Escherichia coli.	EISAI RES INST,ANDOVER,MA 01810; EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN	Eisai Co Ltd; Eisai Co Ltd								BILLIAU A, 1991, EUR J CLIN INVEST, V21, P559, DOI 10.1111/j.1365-2362.1991.tb01410.x; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; BONE RC, 1991, CHEST, V100, P802, DOI 10.1378/chest.100.3.802; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; BUNNELL E, 1995, 24TH ED SCI S SOC CR; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; CHRIST WJ, 1836, Patent No. 935050; CHRIST WJ, UNPUB; CROSBY HA, 1994, J MED MICROBIOL, V40, P23, DOI 10.1099/00222615-40-1-23; DANNER RL, 1990, PHARMACEUT RES, V7, P260, DOI 10.1023/A:1015874012484; DANNER RL, 1987, J CLIN INVEST, V80, P605, DOI 10.1172/JCI113112; DOFFERHOFF ASM, 1991, SCAND J INFECT DIS, V23, P745, DOI 10.3109/00365549109024303; ENDO S, 1992, CIRC SHOCK, V38, P264; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GLAUSER MP, 1994, J CLIN INFECT DIS S2, V18, pS205; GOLENBOCK DT, 1987, INFECT IMMUN, V55, P2471, DOI 10.1128/IAI.55.10.2471-2476.1987; IMOTO M, 1985, TETRAHEDRON LETT, V26, P1545, DOI 10.1016/S0040-4039(00)98548-4; KAWATA T, 1992, 32ND INT C ANT AG CH, P1360; KRAUSS JH, 1989, EUR J BIOCHEM, V180, P519, DOI 10.1111/j.1432-1033.1989.tb14677.x; LOPPNOW H, 1990, INFECT IMMUN, V58, P3743, DOI 10.1128/IAI.58.11.3743-3750.1990; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PRINS JM, 1994, ANTIMICROB AGENTS CH, V38, P1211, DOI 10.1128/AAC.38.6.1211; PROCTOR RA, 1986, INFECT IMMUN, V52, P905, DOI 10.1128/IAI.52.3.905-907.1986; QURESHI N, 1988, J BIOL CHEM, V263, P5502; RAY BL, 1984, J BIOL CHEM, V259, P4852; Rokke O, 1988, Prog Clin Biol Res, V272, P247; ROSSIGNOL D, 1992, 3IND INT C ANT AG CH, P1361; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; VOGEL SN, 1980, J IMMUNOL, V124, P2004; WANG SC, 1994, SURGERY, V116, P339; WELBOURN CRB, 1992, BRIT J SURG, V79, P998, DOI 10.1002/bjs.1800791006	33	297	313	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					80	83		10.1126/science.7701344	http://dx.doi.org/10.1126/science.7701344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701344				2022-12-01	WOS:A1995QR45400028
J	DICKINSON, MH; LIGHTON, JRB				DICKINSON, MH; LIGHTON, JRB			MUSCLE EFFICIENCY AND ELASTIC STORAGE IN THE FLIGHT MOTOR OF DROSOPHILA	SCIENCE			English	Article							INSECT FLIGHT; POWER OUTPUT; MELANOGASTER; METABOLISM	Insects could minimize the high energetic costs of flight in two ways: by employing high-efficiency muscles and by using elastic elements within the thorax to recover energy expended accelerating the wings. However, because muscle efficiency and elastic storage have proven difficult variables to measure, it is not known which of these strategies is actually used. By comparison of mechanical power measurements based on gas exchange with simultaneously measured flight kinematics in Drosophila, a method was developed for determining both the mechanical efficiency and the minimum degree of elastic storage within the flight motor. Muscle efficiency values of 10 percent suggest that insects may minimize energy use in flight by employing an elastic flight motor rather than by using extraordinarily efficient muscles. Further, because of the trade-off between inertial and aerodynamic power throughout the wing stroke, an elastic storage capacity as low as 10 percent may be enough to minimize the energetic costs of flight.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	DICKINSON, MH (corresponding author), UNIV CHICAGO,DEPT ORGANISMAL BIOL & ANAT,CHICAGO,IL 60637, USA.		Lighton, John R B/A-9691-2009	Lighton, John/0000-0002-9264-924X				ALEXANDER RM, 1977, NATURE, V265, P114, DOI 10.1038/265114a0; CASEY T, 1988, INSECT FLIGHT, pCH11; CASEY TM, 1981, J EXP BIOL, V91, P117; DICKINSON MH, 1993, J EXP BIOL, V182, P173; ELLINGTON CP, 1985, J EXP BIOL, V115, P293; ELLINGTON CP, 1991, J EXP BIOL, V160, P71; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P145, DOI 10.1098/rstb.1984.0054; FREEMAN P, 1965, 12 INT C ENT LOND, P186; GOTZ K, COMMUNICATION; GOTZ KG, 1968, KYBERNETIK, V4, P199, DOI 10.1007/BF00272517; GOTZ KG, 1987, J EXP BIOL, V128, P35; HEISENBERG M, 1984, VISION DROSOPHILA; Kammer A.E., 1978, Advances in Insect Physiology, V13, P133, DOI 10.1016/S0065-2806(08)60266-0; LAURIEAHLBERG CC, 1985, GENETICS, V111, P845; LEHRMANN FO, 1994, THESIS EBERHARD KARL; LIGHTON JRB, 1991, CONCISE ENCY BIOL BI, P201; PENNYCUICK CJ, 1984, J EXP BIOL, V108, P377; WEISFOGH T, 1960, J EXP BIOL, V37, P889; WEISFOGH T, 1964, 12 INT C ENT; ZANKER JM, 1990, PHILOS T ROY SOC B, V327, P19, DOI 10.1098/rstb.1990.0041	20	170	172	1	27	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					87	90		10.1126/science.7701346	http://dx.doi.org/10.1126/science.7701346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701346				2022-12-01	WOS:A1995QR45400030
J	FRANCO, B; MERONI, G; PARENTI, G; LEVILLIERS, J; BERNARD, L; GEBBIA, M; COX, L; MAROTEAUX, P; SHEFFIELD, L; RAPPOLD, GA; ANDRIA, G; PETIT, C; BALLABIO, A				FRANCO, B; MERONI, G; PARENTI, G; LEVILLIERS, J; BERNARD, L; GEBBIA, M; COX, L; MAROTEAUX, P; SHEFFIELD, L; RAPPOLD, GA; ANDRIA, G; PETIT, C; BALLABIO, A			A CLUSTER OF SULFATASE GENES ON XP22.3 - MUTATIONS IN CHONDRODYSPLASIA PUNCTATA (CDPX) AND IMPLICATIONS FOR WARFARIN EMBRYOPATHY	CELL			English	Article							KALLMANN SYNDROME GENE; HUMAN ARYLSULFATASE-B; FULL-LENGTH CDNA; STEROID-SULFATASE; X-CHROMOSOME; NUCLEOTIDE-SEQUENCE; LINKED ICHTHYOSIS; Y-CHROMOSOME; SHORT ARM; EXPRESSION	X-linked recessive chondrodysplasia punctata (CDPX) is a congenital defect of bone and cartilage development characterized by aberrant bone mineralization, severe underdevelopment of nasal cartilage, and distal phalangeal hypoplasia. A virtually identical phenotype is observed in the warfarin embryopathy, which is due to the teratogenic effects of coumarin derivatives during pregnancy, We have cloned the genomic region within Xp22.3 where the CDPX gene has been assigned and isolated three adjacent genes showing highly significant homology to the sulfatase gene family. Point mutations in one of these genes were identified in five patients with CDPX, Expression of this gene in COS cells resulted in a heat-labile arylsulfatase activity that is inhibited by warfarin. A deficiency of a heat-labile arylsulfatase activity was demonstrated in patients with deletions spanning the CDPX region. These data indicate that CDPX is caused by an inherited deficiency of a navel sulfatase and suggest that warfarin embryopathy might involve drug-induced inhibition of the same enzyme.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; UNIV NAPLES,DEPT PEDIAT,I-80134 NAPLES,ITALY; INST PASTEUR,UNITE GENET MOLEC HUMAINE,CNRS,UNITE A1445,F-75724 PARIS 15,FRANCE; MURDOCH INST,ROYAL CHILDRENS HOSP,MELBOURNE,VIC 3050,AUSTRALIA; UNIV HEIDELBERG,INST HUMANGENET,D-69120 HEIDELBERG,GERMANY; UNIV SIENA,DEPT BIOL MOLEC,I-53100 SIENA,ITALY	Baylor College of Medicine; University of Naples Federico II; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Ruprecht Karls University Heidelberg; University of Siena			BALLABIO, Andrea/AAL-2672-2020; Bernard, Loris/K-5953-2014; andria, generoso/V-7172-2019; Melis, Daniela/AAD-3623-2019; FRANCO, Brunella/S-2882-2018	BALLABIO, Andrea/0000-0003-1381-4604; Melis, Daniela/0000-0002-9458-3926; parenti, giancarlo/0000-0002-6287-5748; Petit, Christine/0000-0002-9069-002X; FRANCO, Brunella/0000-0001-5588-4569	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031367] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31367-01] Funding Source: Medline; Telethon [TGM94000, TGM06S01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		BALL, 1995, METABOLIC MOL BASES, P2999; BALLABIO A, 1987, P NATL ACAD SCI USA, V84, P4519, DOI 10.1073/pnas.84.13.4519; BALLABIO A, 1985, HUM GENET, V70, P315, DOI 10.1007/BF00295367; Ballabio Andrea, 1992, Human Molecular Genetics, V1, P221, DOI 10.1093/hmg/1.4.221; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROWN CJ, 1990, NUCLEIC ACIDS RES, V18, P4191, DOI 10.1093/nar/18.14.4191; BURCH M, 1986, CLIN GENET, V30, P409; CHANG PL, 1985, ANAL BIOCHEM, V144, P362, DOI 10.1016/0003-2697(85)90129-0; CHANG PL, 1990, AM J HUM GENET, V46, P729; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CURRY CJR, 1984, NEW ENGL J MED, V311, P1010, DOI 10.1056/NEJM198410183111603; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DELCASTILLO I, 1992, NAT GENET, V2, P305, DOI 10.1038/ng1292-305; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HOWE AM, 1992, TERATOLOGY, V46, P379, DOI 10.1002/tera.1420460408; INCERTI B, 1992, NAT GENET, V2, P311, DOI 10.1038/ng1292-311; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; MAROTEAUX P, 1989, HUM GENET, V82, P167, DOI 10.1007/BF00284052; MUNROE DG, 1987, AM J HUM GENET, V40, P102; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; NEUFELD EF, 1995, METABOLIC MOL BASES, P2645; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAULI RM, 1987, AM J HUM GENET, V41, P566; PAULI RM, 1988, PATHOL IMMUNOPATH R, V7, P107, DOI 10.1159/000157104; PETERS C, 1990, J BIOL CHEM, V265, P3374; PRICE PA, 1985, VITAM HORM, V42, P65; ROBERTSON DA, 1988, BIOCHEM BIOPH RES CO, V157, P215; SASAKI H, 1988, EUR J BIOCHEM, V177, P9, DOI 10.1111/j.1432-1033.1988.tb14338.x; SCHAEFER L, 1993, NAT GENET, V4, P272, DOI 10.1038/ng0793-272; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; SHEFFIELD LJ, 1976, J PEDIATR-US, V89, P916, DOI 10.1016/S0022-3476(76)80596-3; SMITH MJ, 1994, HUM MOL GENET, V3, P1575, DOI 10.1093/hmg/3.9.1575; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SPRANGER JW, 1970, HUM GENET, V11, P190; STEIN C, 1989, J BIOL CHEM, V264, P13865; STEIN C, 1989, J BIOL CHEM, V264, P1252; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; WANG I, 1995, IN PRESS GENOMICS; WAPENAAR MC, 1994, HUM MOL GENET, V3, P1155, DOI 10.1093/hmg/3.7.1155; WICKER G, 1991, J BIOL CHEM, V266, P21386; WILSON PJ, 1990, P NATL ACAD SCI USA, V87, P8531, DOI 10.1073/pnas.87.21.8531; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; YEN PH, 1987, CELL, V49, P443, DOI 10.1016/0092-8674(87)90447-8	48	191	210	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					15	25		10.1016/0092-8674(95)90367-4	http://dx.doi.org/10.1016/0092-8674(95)90367-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720070	Bronze, Green Published			2022-12-01	WOS:A1995QR97000004
J	GIDER, S; AWSCHALOM, DD; DOUGLAS, T; MANN, S; CHAPARALA, M				GIDER, S; AWSCHALOM, DD; DOUGLAS, T; MANN, S; CHAPARALA, M			CLASSICAL AND QUANTUM MAGNETIC PHENOMENA IN NATURAL AND ARTIFICIAL FERRITIN PROTEINS	SCIENCE			English	Article							MAMMALIAN FERRITIN; ANTIFERROMAGNETS; ABSORPTION; PARTICLES	Artificial ferritin has been synthesized with control of both the magnetic state (antiferromagnetic or ferrimagnetic) and the particle size over an order of magnitude in the number of iron atoms. The magnetic properties of the artificial ferritin were compared with those of natural horse spleen ferritin in a range of temperatures (20 millikelvin to 300 kelvin) and fields (1 nanotesla to 27 tesla). In the classical regime, the blocking temperature was found to correlate with the average particle size. A correlation was also observed in the quantum regime between the resonance frequency of macroscopic quantum tunneling of the Neel vector and the particle size. At high magnetic fields (to 27 tesla), a spin flop transition with a strong dependence on orientation was seen in the natural ferritin, providing evidence of antiferromagnetism in this system.	UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106; UNIV BATH,SCH CHEM,BATH BA2 7AY,AVON,ENGLAND; NATL HIGH MAGNET FIELD LAB,TALLAHASSEE,FL 32306	University of California System; University of California Santa Barbara; University of Bath; State University System of Florida; Florida State University			Mann, Stephen/D-1332-2012; Douglas, Trevor/F-2748-2011; Douglas, Trevor/GRS-0012-2022	Mann, Stephen/0000-0003-3012-8964; Douglas, Trevor/0000-0002-7882-2704				AWSCHALOM DD, 1992, PHYS REV LETT, V68, P3092, DOI 10.1103/PhysRevLett.68.3092; AWSCHALOM DD, 1992, SCIENCE, V258, P414, DOI 10.1126/science.258.5081.414; AWSCHALOM DD, 1993, PHYS REV LETT, V71, P4276, DOI 10.1103/PhysRevLett.71.4276; BARBARA B, 1990, PHYS LETT A, V145, P205, DOI 10.1016/0375-9601(90)90682-E; BAUMINGER ER, 1989, HYPERFINE INTERACT, V50, P489, DOI 10.1007/BF02407681; BELL SH, 1984, BIOCHIM BIOPHYS ACTA, V787, P227, DOI 10.1016/0167-4838(84)90313-3; BLAISE A, 1973, INT C MAGNETISM, P280; BULTE JWM, 1994, INVEST RADIOL, V29, pS214, DOI 10.1097/00004424-199406001-00071; CERDAN S, 1989, MAGN RESON MED, V12, P151, DOI 10.1002/mrm.1910120202; CHANTRELL RW, 1991, IEEE T MAGN, V27, P3570, DOI 10.1109/20.102929; CHAPARALA M, 1992, AIP C P, V273; CHAPARALA M, 1992, SUPERCONDUCTIVITY IT, P407; CHARLES SW, 1990, J MAGN MAGN MATER, V85, P277, DOI 10.1016/0304-8853(90)90066-Y; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; FRANKEL RB, 1991, HYPERFINE INTERACT, V66, P71, DOI 10.1007/BF02395857; GIRARDET JL, 1970, J APPL PHYS, V41, P1002, DOI 10.1063/1.1658785; GITTLEMA.JI, 1974, PHYS REV B, V9, P3891, DOI 10.1103/PhysRevB.9.3891; HARRISON PM, 1973, INORGANIC BIOCHEMIST, V1, P253; HUNT C, 1994, HYPERFINE INTERACT, V91, P821, DOI 10.1007/BF02064613; KEFFER F, 1973, PHYS REV LETT, V31, P1061, DOI 10.1103/PhysRevLett.31.1061; KEFFER F, 1966, HDB PHYSIK FERROMAGN, V18, P134; KRIVE IV, 1990, J PHYS-CONDENS MAT, V2, P9457, DOI 10.1088/0953-8984/2/47/020; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; MACKLE P, 1993, J AM CHEM SOC, V115, P8471, DOI 10.1021/ja00071a076; MANN S, 1987, J MOL BIOL, V198, P405, DOI 10.1016/0022-2836(87)90290-7; MELDRUM FC, 1991, NATURE, V349, P684, DOI 10.1038/349684a0; MELDRUM FC, 1992, SCIENCE, V257, P522, DOI 10.1126/science.1636086; MILLS DL, 1968, PHYS REV LETT, V20, P18, DOI 10.1103/PhysRevLett.20.18; PANKHURST QA, 1993, J PHYS-CONDENS MAT, V5, P8487, DOI 10.1088/0953-8984/5/45/002; SERVICE RF, 1994, SCIENCE, V264, P510, DOI 10.1126/science.264.5158.510; STPIERRE TG, 1989, BIOMINERALIZATION CH, P295; TEJADA J, 1994, Z PHYS CONDENS MATTE, V6, P263; TREFFRY A, 1978, BIOCHEM J, V171, P313, DOI 10.1042/bj1710313	33	220	222	1	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					77	80		10.1126/science.7701343	http://dx.doi.org/10.1126/science.7701343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701343				2022-12-01	WOS:A1995QR45400027
J	GLOVER, DM; LEIBOWITZ, MH; MCLEAN, DA; PARRY, H				GLOVER, DM; LEIBOWITZ, MH; MCLEAN, DA; PARRY, H			MUTATIONS IN AURORA PREVENT CENTROSOME SEPARATION LEADING TO THE FORMATION OF MONOPOLAR SPINDLES	CELL			English	Article							MICROTUBULE-ORGANIZING CENTERS; DEPENDENT PROTEIN-KINASE; EARLY DROSOPHILA EMBRYOS; SEA-URCHIN EGGS; CELL-CYCLE; ABNORMAL SPINDLE; DNA-SYNTHESIS; MELANOGASTER; ANAPHASE; MITOSIS	We show that female sterile mutations of aurora (aur) are allelic to mutations in the lethal complementation group ck(10). This lies in a cytogenetic interval, 87A7-A9, that contains eight transcription units. A 250 bp region upstream of both a ur and a divergent transcription unit corresponds to the site of a specific chromatin structure (scs') previously proposed to be a barrier to insulate enhancers of the major hsp70 gene at 87A7. Syncytial embryos derived from aur mothers display closely paired centrosomes at inappropriate mitotic stages and develop interconnected spindles in which the poles are shared. Amorphic alleles result in pupal lethality and in mitotic arrest in which condensed chromosomes are arranged on circular monopolar spindles. The size of the single centrosomal body in these circular figures suggests that lass of function of the serine-threonine protein kinase encoded by aur leads to a failure of the centrosomes to separate and form a bipolar spindle.			GLOVER, DM (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT ANAT & PHYSIOL,CANC RES CAMPAIGN CELL CYCLE GENET GRP,DUNDEE DD1 4HN,SCOTLAND.			Glover, David/0000-0003-0956-0103				BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAGGESE C, 1979, P NATL ACAD SCI USA, V76, P2385, DOI 10.1073/pnas.76.5.2385; CALLAINI G, 1990, J CELL SCI, V97, P539; CASSIMERIS L, 1994, J CELL SCI, V107, P285; FARKAS G, 1992, NUCLEIC ACIDS RES, V20, P2604, DOI 10.1093/nar/20.10.2604; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FRASCH M, 1986, J CELL SCI, V82, P155; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GAUSZ J, 1981, GENETICS, V98, P775; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GONZALEZ C, 1990, J CELL SCI, V96, P605; GONZALEZ C, 1988, J CELL SCI, V89, P39; GONZALEZ C, 1993, CELL CYCLE PRACTICAL, P163; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HUETTNER ALFRED F., 1933, ZEITSCHR WISS BIOL ABT B ZEITSCHR ZELLFORSCH U MIKROSK ANAT, V19, P119, DOI 10.1007/BF00587553; ISHHOROWICZ D, 1980, J MOL BIOL, V142, P231, DOI 10.1016/0022-2836(80)90047-9; ISHHOROWICZ D, 1979, CELL, V17, P565, DOI 10.1016/0092-8674(79)90264-2; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KERYER G, 1990, J CELL SCI, V97, P553; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LEWIN B, 1994, GENES, V5; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MAZIA D, 1960, J BIOPHYS BIOCHEM CY, V7, P1, DOI 10.1083/jcb.7.1.1; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; NAGANO H, 1981, DEV BIOL, V85, P409, DOI 10.1016/0012-1606(81)90272-4; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RIPOLL P, 1985, CELL, V41, P907, DOI 10.1016/S0092-8674(85)80071-4; ROBERTSON HM, 1988, GENETICS, V118, P461; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1985, J CELL SCI, V76, P35; SLUDER G, 1985, J CELL BIOL, V100, P897, DOI 10.1083/jcb.100.3.897; SLUDER G, 1986, BIOL BULL, V170, P538; SPIERER P, 1983, J MOL BIOL, V168, P35, DOI 10.1016/S0022-2836(83)80321-0; SULLIVAN W, 1990, DEVELOPMENT, V110, P331; SUNKEL CE, 1988, J CELL SCI, V89, P25; SZABAD J, 1982, DEV BIOL, V93, P240, DOI 10.1016/0012-1606(82)90256-1; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VANDRE DD, 1989, J CELL SCI, V94, P245; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VESSEY KB, 1991, J CELL SCI, V98, P233; WANG RJ, 1983, J CELL BIOL, V96, P301, DOI 10.1083/jcb.96.1.301; WARN RM, 1985, EXP CELL RES, V163, P201; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361; WHITFIELD WGF, 1988, J CELL SCI, V89, P467	58	668	683	1	30	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					95	105		10.1016/0092-8674(95)90374-7	http://dx.doi.org/10.1016/0092-8674(95)90374-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720077	Bronze			2022-12-01	WOS:A1995QR97000011
J	HOU, XS; CHOU, TB; MELNICK, MB; PERRIMON, N				HOU, XS; CHOU, TB; MELNICK, MB; PERRIMON, N			THE TORSO RECEPTOR TYROSINE KINASE CAN ACTIVATE RAF IN A RAS-INDEPENDENT PATHWAY	CELL			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TERMINAL BODY PATTERN; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; DROSOPHILA-MELANOGASTER; EMBRYONIC TERMINI; GENE TAILLESS; SEVENLESS; TRANSFORMATION; EXPRESSION	Activation of the receptor tyrosine kinase (RTK) torso defines the spatial domains of expression of the transcription factors tailless and huckebein. Previous analyses have demonstrated that Ras1 (p21(ras)) operates upstream of the D-Raf (Raf1) serine/threonine kinase in this signaling pathway. By using a recently developed technique of germline mosaics, we find that D-Raf can be activated by torso in the complete absence of Ras1. This result is supported by analysis of D-Raf activation in the absence of either the exchange factor Son of sevenless (Sos) or the adaptor protein drk (Grb2), as well as by the phenotype of a D-Raf mutation that abolishes binding of Ras1 to D-Raf. Our study provides in vivo evidence that Raf can be activated by an RTK in a Ras-independent pathway.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	HOU, XS (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.		Chou, Tze-Bin/S-1188-2017	Chou, Tze-Bin/0000-0003-2453-0164; Perrimon, Norbert/0000-0001-7542-472X				AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRONNER G, 1994, NATURE, V369, P664, DOI 10.1038/369664a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAROLL MP, 1994, J BIOL CHEM, V269, P1249; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; CASANOVA J, 1994, MECH DEVELOP, V48, P59, DOI 10.1016/0925-4773(94)90006-X; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEV Z, 1993, RAS SUPERFAMILY GTPA, P187; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; NEUMANSILBERBER, 1984, CELL, V0037; OLIUVIER JP, 1993, SOS CELL, V73, P179; Perkins L A, 1991, In Vivo, V5, P521; PERRIMON N, 1994, TRENDS BIOCHEM SCI, V19, P509, DOI 10.1016/0968-0004(94)90140-6; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RONCHI E, 1993, CELL, V74, P347, DOI 10.1016/0092-8674(93)90425-P; ROSE MD, 1990, LABORATORY COURSE MA; Sambrook J., 1989, MOL CLONING LAB MANU; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SWANSON KD, 1992, GENE, V113, P183, DOI 10.1016/0378-1119(92)90394-5; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	64	110	110	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					63	71		10.1016/0092-8674(95)90371-2	http://dx.doi.org/10.1016/0092-8674(95)90371-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720074	Bronze			2022-12-01	WOS:A1995QR97000008
J	HU, QJ; KLIPPEL, A; MUSLIN, AJ; FANTL, WJ; WILLIAMS, LT				HU, QJ; KLIPPEL, A; MUSLIN, AJ; FANTL, WJ; WILLIAMS, LT			RAS-DEPENDENT INDUCTION OF CELLULAR-RESPONSES BY CONSTITUTIVELY ACTIVE PHOSPHATIDYLINOSITOL-3 KINASE	SCIENCE			English	Article							DIFFERENT SIGNALING PATHWAYS; PROTEIN; 3-KINASE; YEAST; DOWNSTREAM; RAPAMYCIN	Phosphatidylinositol (PI)-3 kinase is one of many enzymes stimulated by growth factors. A constitutively activated mutant, p110*, that functions independently of growth factor stimulation was constructed to determine the specific responses regulated by PI-3 kinase. The p110* protein exhibited high specific activity as a PI-3 kinase and as a protein kinase. Expression of p110* in NIH 3T3 cells induced transcription from the fos promoter. Coexpression of dominant negative Ras blocked this response. When expressed in Xenopus laevis oocytes, p110* increased the amount of guanosine 5'-triphosphate-bound Ras, caused activation of the Ras effector Raf-1, and induced Ras-dependent oocyte maturation. These findings show that PI-3 kinase can Stimulate diverse Ras-dependent cellular processes, including oocyte maturation and fos transcription.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL32898] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, UNPUB; FISH TM, 1987, MOL CELL BIOL, V7, P3490; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; Hu Q-L, UNPUB; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2685; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MULSIN AJ, UNPUB; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	33	514	528	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					100	102		10.1126/science.7701328	http://dx.doi.org/10.1126/science.7701328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701328				2022-12-01	WOS:A1995QR45400035
J	KAMPER, J; REICHMANN, M; ROMEIS, T; BOLKER, M; KAHMANN, R				KAMPER, J; REICHMANN, M; ROMEIS, T; BOLKER, M; KAHMANN, R			MULTIALLELIC RECOGNITION - NONSELF-DEPENDENT DIMERIZATION OF THE BE AND BW HOMEODOMAIN PROTEINS IN USTILAGO-MAYDIS	CELL			English	Article							AUTONOMOUS PLASMIDS; FILAMENTOUS GROWTH; SEXUAL DEVELOPMENT; 2-HYBRID SYSTEM; U-MAYDIS; A-ALPHA; LOCUS; ALLELES; GENES; YEAST	In the plant pathogenic fungus Ustilago maydis, sexual and pathogenic development are controlled by the multiallelic b mating-type locus. The b locus encodes a pair of unrelated homeodomain proteins termed bE and bW, with allelic differences clustering in the N-terminal domains of both polypeptides. Only combinations of bE and bW of different allelic origin are active. We have investigated the underlying molecular mechanism for this intracellular self/nonself recognition phenomenon. By using the two-hybrid system, we were able to show that bE and bW dimerize only if they are derived from different alleles. Dimerization involves the N-terminal variable domains. Different point mutants of bE2 were isolated that function in combination with bW2. The majority of such bE2 mutant polypeptides were also able to form heterodimers with bW2 in the two-hybrid system. Nonself-dependent dimerization of bE and bW was supported with a biochemical interaction assay with immobilized proteins. Our results suggest a model for self/nonself recognition in which variable cohesive contacts direct dimerization.			KAMPER, J (corresponding author), UNIV MUNICH,INST GENET & MIKROBIOL,MARIA WARD STR 1A,D-80638 MUNICH,GERMANY.			Bolker, Michael/0000-0002-7366-3855				BAKKEREN G, 1993, PLANT CELL, V5, P123, DOI 10.1105/tpc.5.1.123; BANUETT F, 1991, P NATL ACAD SCI USA, V88, P3922, DOI 10.1073/pnas.88.9.3922; BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BERGEMANN J, 1993, THESIS FREIE U BERLI; BOLKER M, 1992, CELL, V68, P441, DOI 10.1016/0092-8674(92)90182-C; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTENSEN JJ, 1963, AM PHYTOPATHOL SOC M, V2; DAHL M, 1991, ADV MOL GENETICS PLA, V1, P264; DAY PR, 1971, P NATL ACAD SCI USA, V68, P533, DOI 10.1073/pnas.68.3.533; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GILLISSEN B, 1992, CELL, V68, P647, DOI 10.1016/0092-8674(92)90141-X; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLIDAY R, 1961, GENET RES, V2, P204, DOI 10.1017/S0016672300000719; HURST HC, 1994, PROTEIN PROFILE, V1, P125; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P3; KUES U, 1992, TRENDS GENET, V8, P154, DOI 10.1016/0168-9525(92)90207-K; KUES U, 1992, GENE DEV, V6, P568, DOI 10.1101/gad.6.4.568; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; Miller, 1972, EXPT MOL GENETICS; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; PUHALLA JE, 1968, GENETICS, V60, P461; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; ROWELL JB, 1955, PHYTOPATHOLOGY, V45, P370; ROWELL JB, 1954, PHYTOPATHOLOGY, V44, P356; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; Sherman F., 1986, METHODS YEAST GENETI; SPECHT CA, 1992, P NATL ACAD SCI USA, V89, P7174, DOI 10.1073/pnas.89.15.7174; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; SPELLIG T, 1994, EMBO J, V13, P1620, DOI 10.1002/j.1460-2075.1994.tb06425.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; WONG GJ, 1985, T BRIT MYCOL SOC, V84, P95, DOI 10.1016/S0007-1536(85)80223-0; YEE AR, 1993, P NATL ACAD SCI USA, V90, P664, DOI 10.1073/pnas.90.2.664; [No title captured]	44	203	210	2	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					73	83		10.1016/0092-8674(95)90372-0	http://dx.doi.org/10.1016/0092-8674(95)90372-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720075	hybrid			2022-12-01	WOS:A1995QR97000009
J	LEMAIRE, P; GARRETT, N; GURDON, JB				LEMAIRE, P; GARRETT, N; GURDON, JB			EXPRESSION CLONING OF SIAMOIS, A XENOPUS HOMEOBOX GENE EXPRESSED IN DORSAL VEGETAL CELLS OF BLASTULAS AND ABLE TO INDUCE A COMPLETE SECONDARY AXIS	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; MESODERM INDUCTION; SPEMANN ORGANIZER; VENTRALIZING FACTOR; INJECTED XWNT-8; LAEVIS EMBRYOS; MESSENGER-RNAS; EARLY RESPONSE; GASTRULA; HOMOLOG	Using an expression cloning strategy that relies on a functional assay, we have cloned a novel Xenopus homeobox-containing gene, Siamois. Embryos injected in a ventral-vegetal blastomere with as little as 5 pg of Siamois mRNA develop a complete secondary axis, but the progeny of the injected cells do not participate in the secondary axis formation. In normal development, Siamois mRNA is first detected shortly after the midblastula transition, which is earlier than mRNAs for goosecoid or Xbrachyury, and is present most abundantly in the dorsal endoderm of early gastrulae. The activation of this gene can be obtained cell autonomously in dispersed embryo cells. These results indicate that Siamois may play an important role in the formation of the Nieuwkoop center.	CANC RES CAMPAIGN INST,WELLCOME TRUST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	CRUK Cambridge Institute; Wellcome Trust Sanger Institute; University of Cambridge			Lemaire, Patrick/D-4237-2009; Lemaire, Patrick/B-5560-2012; Lemaire, Patrick/P-8228-2019	Lemaire, Patrick/0000-0003-4925-2009; Lemaire, Patrick/0000-0003-4925-2009; GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DALE L, 1987, DEVELOPMENT, V99, P527; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEWITT JE, 1994, HUM MOL GENET, V3, P1287, DOI 10.1093/hmg/3.8.1287; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KATO K, 1992, P NATL ACAD SCI USA, V90, P1310; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KU M, 1993, DEVELOPMENT, V119, P1161; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; Vize P. D., 1991, METHOD CELL BIOL, V36, P368	30	468	476	0	14	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					85	94		10.1016/0092-8674(95)90373-9	http://dx.doi.org/10.1016/0092-8674(95)90373-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720076	Bronze			2022-12-01	WOS:A1995QR97000010
J	MCHEYZERWILLIAMS, MG; DAVIS, MM				MCHEYZERWILLIAMS, MG; DAVIS, MM			ANTIGEN-SPECIFIC DEVELOPMENT OF PRIMARY AND MEMORY T-CELLS IN-VIVO	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; POLYMERASE CHAIN-REACTION; PRIMARY IMMUNE-RESPONSE; B-CELLS; FINE SPECIFICITY; CELLULAR BASIS; CYTOCHROME-C; RECEPTOR; RECOGNITION; INVIVO	The expansion and contraction of specific helper T cells in the draining lymph nodes of normal mice after injection with antigen was followed. T cell receptors from purified primary and memory responder cells had highly restricted junctional regions, indicating antigen-driven selection. Selection for homogeneity in the length of the third complementarity-determining region (CDR3) occurs before selection for some of the characteristic amino acids, indicating the importance of this parameter in T cell receptor recognition. Ultimately, particular T cell receptor sequences come to predominate in the secondary response and others disappear, showing the selective presentation or expansion of specific T cell clones.	STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	MCHEYZERWILLIAMS, MG (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA.			Davis, Mark/0000-0001-6868-657X				Ahmed R, 1992, Semin Immunol, V4, P105; BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BEVERLEY PCL, 1990, CURR TOP MICROBIOL, V159, P111; BRADLEY LM, 1993, J IMMUNOL, V150, P3119; BRADLEY LM, 1991, J EXP MED, V174, P547, DOI 10.1084/jem.174.3.547; BUDD RC, 1987, J IMMUNOL, V138, P3120; Burnet FM, 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CELADA F, 1971, PROG ALLERGY, V15, P223; CEROTTINI JC, 1989, ANNU REV IMMUNOL, V7, P77, DOI 10.1146/annurev.iy.07.040189.000453; CHANG HL, 1989, J IMMUNOL, V143, P315; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; CORRADIN G, 1979, J EXP MED, V149, P436, DOI 10.1084/jem.149.2.436; DONG RP, 1992, TISSUE ANTIGENS, V39, P106, DOI 10.1111/j.1399-0039.1992.tb01918.x; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FORD JE, 1994, EUR J IMMUNOL, V24, P1816, DOI 10.1002/eji.1830240814; FORD JE, 1994, GENE, V142, P279, DOI 10.1016/0378-1119(94)90275-5; FULLER KA, 1993, J IMMUNOL, V151, P4505; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HAYAKAWA K, 1987, P NATL ACAD SCI USA, V84, P1379, DOI 10.1073/pnas.84.5.1379; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HOU S, 1993, J IMMUNOL, V150, P5494; HOU S, 1992, NATURE, V369, P651; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KELSO A, 1991, IMMUNOL REV, V123, P85, DOI 10.1111/j.1600-065X.1991.tb00607.x; KOOP BF, 1994, GENOMICS, V19, P478, DOI 10.1006/geno.1994.1097; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; MACDONALD HR, 1993, J EXP MED, V177, P1487, DOI 10.1084/jem.177.5.1487; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PADLAN EA, 1977, Q REV BIOPHYS, V10, P35, DOI 10.1017/S0033583500000135; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REAY PA, UNPUB; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; SPRENT J, 1976, CELL IMMUNOL, V21, P278, DOI 10.1016/0008-8749(76)90057-5; STRENT J, 1994, SCIENCE, V265, P1395; Swain S L, 1992, Semin Immunol, V4, P59; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WURZBURG U, 1973, EUR J IMMUNOL, V3, P762, DOI 10.1002/eji.1830031205; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0; ZINKERNAGEL RM, 1993, IMMUNOL REV, V133, P199, DOI 10.1111/j.1600-065X.1993.tb01517.x	64	389	396	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	1995	268	5207					106	111		10.1126/science.7535476	http://dx.doi.org/10.1126/science.7535476			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7535476				2022-12-01	WOS:A1995QR45400037
J	MURPHY, TD; KARPEN, GH				MURPHY, TD; KARPEN, GH			INTERACTIONS BETWEEN THE NOD(+) KINESIN-LIKE GENE AND EXTRACENTROMERIC SEQUENCES ARE REQUIRED FOR TRANSMISSION OF A DROSOPHILA MINICHROMOSOME	CELL			English	Article							DISTRIBUTIVE SEGREGATION; SATELLITE DNA; MELANOGASTER; CENTROMERE; PROTEIN; FEMALES; LOCUS; TRANSPOSITION; CHROMOSOMES; MUTATIONS	In this study, we demonstrate a role for extracentromeric sequences in chromosome inheritance. Genetic analyses indicate that transmission of the Drosophila minichromosome Dp1187 is sensitive to the dosage of nod(+), a kinesin-like gene required for the meiotic transmission of achiasmate chromosomes. Minichromosome deletions displayed increased loss rates in females heterozygous for a loss-of-function allele of nod (nod/+). We have analyzed the structures of nod-sensitive deletions and conclude that multiple regions of Dp1187 interact genetically with nod(+) to promote normal chromosome transmission. Most nod(+) interactions are observed with regions that are not essential for centromere function. We propose that normal chromosome transmission requires forces generated outside the kinetochore, perhaps to maintain tension on kinetochore microtubules and stabilize the attachment of achiasmate chromosomes to the metaphase spindle.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	MURPHY, TD (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037, USA.							AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; BRINKLEY BR, 1991, BIOESSAYS, V13, P675, DOI 10.1002/bies.950131210; CARPENTER AT, 1973, GENETICS, V73, P393; CARPENTER ATC, 1991, CELL, V64, P885, DOI 10.1016/0092-8674(91)90313-N; CARPENTER ATC, 1984, COLD SPRING HARB SYM, V49, P23, DOI 10.1101/SQB.1984.049.01.005; CASSIMERIS L, 1994, J CELL SCI, V107, P285; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; FULLER MT, 1995, CELL, V81, P5, DOI 10.1016/0092-8674(95)90364-X; HAWLEY RS, 1993, DEV GENET, V13, P440; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HSIEH T, 1979, J MOL BIOL, V135, P465, DOI 10.1016/0022-2836(79)90447-9; John B, 1988, HETEROCHROMATIN MOL, P1; KARPEN GH, 1992, GENETICS, V132, P737; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KARPEN GH, 1990, CELL, V63, P97; King RC., 1970, OVARIAN DEV DROSOPHI; KNOWLES BA, 1991, P NATL ACAD SCI USA, V88, P7165, DOI 10.1073/pnas.88.16.7165; LE MH, IN PRESS GENETICS; LICA LM, 1986, J CELL BIOL, V103, P1145, DOI 10.1083/jcb.103.4.1145; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; RASOOLY RS, 1991, GENETICS, V129, P409; REGAN CL, 1988, GENE DEV, V2, P82, DOI 10.1101/gad.2.1.82; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLEISTER HM, 1992, NUCLEIC ACIDS RES, V20, P3419, DOI 10.1093/nar/20.13.3419; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; THOMPSON SD, 1994, P NATL ACAD SCI USA, V91, P9042; TOWER J, 1993, GENETICS, V133, P347; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WRIGHT TRF, 1974, GENETICS, V76, P511; ZHANG P, 1993, GENETICS, V133, P361; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115	37	55	57	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					139	148		10.1016/0092-8674(95)90378-X	http://dx.doi.org/10.1016/0092-8674(95)90378-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720069	Bronze			2022-12-01	WOS:A1995QR97000015
J	MURRAY, K; SELLECK, P; HOOPER, P; HYATT, A; GOULD, A; GLEESON, L; WESTBURY, H; HILEY, L; SELVEY, L; RODWELL, B; KETTERER, P				MURRAY, K; SELLECK, P; HOOPER, P; HYATT, A; GOULD, A; GLEESON, L; WESTBURY, H; HILEY, L; SELVEY, L; RODWELL, B; KETTERER, P			A MORBILLIVIRUS THAT CAUSED FATAL DISEASE IN HORSES AND HUMANS	SCIENCE			English	Article							COMPARATIVE SEQUENCE-ANALYSIS; RESPIRATORY SYNCYTIAL VIRUS; PHOCINE DISTEMPER VIRUS; AMINO-ACID-SEQUENCES; NUCLEOTIDE-SEQUENCE; MATRIX PROTEIN; MOLECULAR-CLONING; RINDERPEST VIRUS; GENE; PARAMYXOVIRUSES	A morbillivirus has been isolated and added to an increasing list of emerging viral diseases. This virus caused an outbreak of fatal respiratory disease in horses and humans. Genetic analyses show it to be only distantly related to the classic morbilliviruses rinderpest, measles, and canine distemper. When seen by electron microscopy, viruses had 10- and 18-nanometer surface projections that gave them a ''double-fringed'' appearance. The virus induced syncytia that developed in the endothelium of blood vessels, particularly the lungs.	QUEENSLAND DEPT HLTH,CTR PUBL HLTH SCI,BRISBANE,QLD 4000,AUSTRALIA; QUEENSLAND DEPT PRIMARY IND,ANIM RES INST,YEERONGPILLY,QLD 4105,AUSTRALIA; QUEENSLAND HLTH,BRISBANE,QLD 4000,AUSTRALIA	Queensland Health; Queensland Department of Agriculture & Fisheries; Queensland Health	MURRAY, K (corresponding author), CSIRO,AUSTRALIAN ANIM HLTH LAB,RYRIE ST,GEELONG,VIC 3220,AUSTRALIA.		Selvey, Linda/B-8473-2017	Selvey, Linda/0000-0001-8493-0974				BARON MD, 1994, VIROLOGY, V200, P121, DOI 10.1006/viro.1994.1170; BARRETT T, 1993, VIROLOGY, V193, P1010, DOI 10.1006/viro.1993.1217; BEARD CW, 1983, DISEASES POULTRY, P452; BELLINI WJ, 1986, J VIROL, V58, P408, DOI 10.1128/JVI.58.2.408-416.1986; BLUMBERG BM, 1984, J VIROL, V52, P656, DOI 10.1128/JVI.52.2.656-663.1984; CATTANEO R, 1989, VIROLOGY, V173, P415, DOI 10.1016/0042-6822(89)90554-0; CURRAN MD, 1992, ARCH VIROL, V126, P159, DOI 10.1007/BF01309692; DIALLO A, COMMUNICATION; ENAMI M, 1989, J GEN VIROL, V70, P2191, DOI 10.1099/0022-1317-70-8-2191; Felsenstein J., 1989, PHYLIP 3 2 MANUAL; FINCH JT, 1970, J GEN VIROL, V6, P141, DOI 10.1099/0022-1317-6-1-141; GALINSKI MS, 1987, VIROLOGY, V157, P24, DOI 10.1016/0042-6822(87)90309-6; HSU D, 1988, VIROLOGY, V166, P149, DOI 10.1016/0042-6822(88)90156-0; HYATT AD, UNPUB; HYATT AD, 1991, ELECTRON MICROS, P59; JONES TC, 1983, VET PATHOL, P435; Lederberg J., 1992, EMERGING INFECT MICR; LIMO M, 1990, VIROLOGY, V175, P323, DOI 10.1016/0042-6822(90)90216-E; MIYAHARA K, 1992, ARCH VIROL, V124, P255, DOI 10.1007/BF01309807; MONATH TP, 1994, SEMIN VIROL, V5, P133, DOI 10.1006/smvy.1994.1014; MURPHY FA, 1994, SEMIN VIROL, V5, P85, DOI 10.1006/smvy.1994.1009; MURPHY FA, 1993, ADV VIRUS RES, V43, P1; NATHANSON N, 1993, VIRUS RES, V29, P3, DOI 10.1016/0168-1702(93)90122-4; NORRBY E, 1990, P1013; PALMER EL, 1988, ELECT MICROSCOPY VIR, P111; PRINGLE CR, 1991, CLASSIFICATION NOMEN, P242; SAMAL SK, 1991, J GEN VIROL, V72, P1715, DOI 10.1099/0022-1317-72-7-1715; SATAKE M, 1984, J VIROL, V50, P92, DOI 10.1128/JVI.50.1.92-99.1984; SCHEID A, 1987, ANIMAL VIRUS STRUCTU, P233; VANDEUSEN RA, 1983, AVIAN DIS, V27, P745, DOI 10.2307/1590317; VISSER IKG, 1993, J GEN VIROL, V74, P631, DOI 10.1099/0022-1317-74-4-631	31	528	571	1	45	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					94	97		10.1126/science.7701348	http://dx.doi.org/10.1126/science.7701348			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701348				2022-12-01	WOS:A1995QR45400033
J	NOBES, CD; HALL, A				NOBES, CD; HALL, A			RHO, RAC, AND CDC42 GTPASES REGULATE THE ASSEMBLY OF MULTIMOLECULAR FOCAL COMPLEXES ASSOCIATED WITH ACTIN STRESS FIBERS, LAMELLIPODIA, AND FILOPODIA	CELL			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; GROWTH CONE FILOPODIA; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; ADHESION PLAQUES; ANIMAL-CELLS; LEADING-EDGE; FIBROBLASTS; CONTACTS	Rho and rac, two members of the ras-related superfamily of small GTPases, regulate the polymerization of actin to produce stress fibers and lamellipodia, respectively. We report here that cdc42, another member of the rho family, triggers the formation of a third type of actin-based structure found at the cell periphery, filopodia. In addition to stress fibers, rho controls the assembly of focal adhesion complexes. We now show that rac and cdc42 also stimulate the assembly of multimolecular focal complexes at the plasma membrane. These complexes, which are associated with lamellipodia and filopodia, contain vinculin, paxillin, and focal adhesion kinase, but are distinct from and formed independently of rho-induced focal adhesions. Activation of cdc42 in Swiss 3T3 cells leads to the sequential activation of rac and then rho, suggesting a molecular model for the coordinated control of cell motility by members of the rho family of GTPases.	UNIV LONDON UNIV COLL,DEPT BIOCHEM,LONDON WC1E 6BT,ENGLAND	University of London; University College London	NOBES, CD (corresponding author), CANC RES CAMPAIGN,ONCOGENE & SIGNAL TRANSDUCT GRP,MRC,MOLEC CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ALBRECHTBUEHLER G, 1976, J CELL BIOL, V69, P275, DOI 10.1083/jcb.69.2.275; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CAO LG, 1990, J CELL BIOL, V110, P1089, DOI 10.1083/jcb.110.4.1089; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HEATH JP, 1978, J CELL SCI, V29, P197; IZZARD CS, 1988, CELL MOTIL CYTOSKEL, V10, P137, DOI 10.1002/cm.970100118; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lee Juliet, 1993, Trends in Cell Biology, V3, P366, DOI 10.1016/0962-8924(93)90084-E; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NOBES CD, 1995, J CELL SCI, V108, P225; OCONNOR TP, 1993, J CELL BIOL, V123, P935, DOI 10.1083/jcb.123.4.935; OKABE S, 1989, J CELL BIOL, V109, P1581, DOI 10.1083/jcb.109.4.1581; OSTER GF, 1987, J CELL SCI S, V8, P35; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHANNON M, 1993, NATURE, V365, P661; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Small JV, 1989, CURR OPIN CELL BIOL, V1, P75, DOI 10.1016/S0955-0674(89)80040-7; SMALL JV, 1995, TRENDS CELL BIOL, V5, P52, DOI 10.1016/S0962-8924(00)88939-4; SMALL JV, 1981, J CELL BIOL, V91, P695, DOI 10.1083/jcb.91.3.695; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; VUORI K, 1993, J BIOL CHEM, V268, P21459; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WOODS A, 1992, J CELL SCI, V101, P277; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zigmond SH, 1989, CURR OPIN CELL BIOL, V1, P80, DOI 10.1016/S0955-0674(89)80041-9	57	3649	3703	3	277	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					53	62		10.1016/0092-8674(95)90370-4	http://dx.doi.org/10.1016/0092-8674(95)90370-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7536630	Bronze			2022-12-01	WOS:A1995QR97000007
J	PERKINS, TT; SMITH, DE; LARSON, RG; CHU, S				PERKINS, TT; SMITH, DE; LARSON, RG; CHU, S			STRETCHING OF A SINGLE TETHERED POLYMER IN A UNIFORM-FLOW	SCIENCE			English	Article							PARTICLES; DNA	The stretching of single, tethered DNA molecules by a flow was directly visualized with fluorescence microscopy. Molecules ranging in length (L) from 22 to 84 micrometers were held stationary against the flow by the optical trapping of a latex microsphere attached to one end. The fractional extension x/L is a universal function of eta vL(0.54+/-0.05), where eta and v are the viscosity and velocity of the flow, respectively. This relation shows that the DNA is not ''free-draining'' (that is, hydrodynamic coupling within the chain is not negligible) even near full extension (similar to 80 percent). This function has the same form over a lone range as the fractional extension versus force applied at the ends of a worm-like chain. For small deformations (<30 percent of full extension), the extension increases with velocity as x similar to v(0.70+/-0.08). The relative size of fluctuations in extension decreases as sigma(x)/x congruent to 0.42 exp(-4.9 x/L). Video images of the fluctuating chain have a cone-like envelope and show as sharp increase in intensity at the free end.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305; AT&T BELL LABS,MURRAY HILL,NJ 07974	Stanford University; AT&T; Nokia Corporation; Nokia Bell Labs			Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632; Perkins, Thomas/0000-0003-4826-9490	PHS HHS [33289] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, UNPUB; BIRD RB, 1987, DYNAMICS POLYM LIQUI, V2, P19; BROCHARDWYART F, 1993, EUROPHYS LETT, V23, P105, DOI 10.1209/0295-5075/23/2/005; BROCHARDWYART F, 1994, EUROPHYS LETT, V23, P511; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; DEBYE P, 1948, J CHEM PHYS, V16, P573, DOI 10.1063/1.1746948; DEGENNES PG, 1974, J CHEM PHYS, V60, P5030, DOI 10.1063/1.1681018; Doi M., 1986, THEORY POLYM DYNAMIC; Ferry J. D., 1980, VISCOELASTIC PROPERT; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FIXMAN M, 1973, J CHEM PHYS, V58, P1564, DOI 10.1063/1.1679396; KIRKWOOD JG, 1954, J CHEM PHYS, V22, P1626, DOI 10.1063/1.1740494; KIRKWOOD JG, 1948, J CHEM PHYS, V16, P565, DOI 10.1063/1.1746947; KIRKWOOD JG, 1953, J POLYM SCI, V12, P1; Kuhn W, 1934, KOLLOID Z, V68, P2, DOI 10.1007/BF01451681; Larson R. G., 1988, CONSTITUTIVE EQUATIO; LARSON RG, 1989, MACROMOLECULES, V22, P3004, DOI 10.1021/ma00197a022; LARSON RG, UNPUB; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; SCHURR JM, 1990, BIOPOLYMERS, V29, P1161, DOI 10.1002/bip.360290806; SIMMONS RF, UNPUB; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; VOLOGODSKII A, 1994, MACROMOLECULES, V27, P5623, DOI 10.1021/ma00098a016; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462; ZIMM BH, 1992, Q REV BIOPHYS, V25, P171, DOI 10.1017/S0033583500004662; ZIMM BH, COMMUNICATION	30	512	524	1	96	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					83	87		10.1126/science.7701345	http://dx.doi.org/10.1126/science.7701345			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701345				2022-12-01	WOS:A1995QR45400029
J	RAUSCHECKER, JP; TIAN, B; HAUSER, M				RAUSCHECKER, JP; TIAN, B; HAUSER, M			PROCESSING OF COMPLEX SOUNDS IN THE MACAQUE NONPRIMARY AUDITORY-CORTEX	SCIENCE			English	Article							RHESUS-MONKEY; VISUAL PROPERTIES; SQUIRREL-MONKEY; MACACA-MULATTA; NEURONS; VOCALIZATIONS; ORGANIZATION; RESPONSES; ANATOMY; SPEECH	Neurons in the superior temporal gyrus of anesthetized rhesus monkeys were exposed to complex acoustic stimuli. Bandpassed noise bursts with defined center frequencies evoked responses that were greatly enhanced over those evoked by pure tons. This finding led to the discovery of at least one new cochleotopic area in the lateral belt of the nonprimary auditory cortex. The best center frequencies of neurons varied along a rostrocaudal axis, and the best bandwidths of the noise bursts varied along a mediolateral axis. When digitized monkey calls were used as stimuli, many neurons showed a preference for some calls over others. Manipulation of the calls' frequency structure and playback of separate components revealed different types of spectral integration. The lateral areas of the monkey auditory cortex appear to be part of a hierarchical sequence in which neurons prefer increasingly complex stimuli and may form an important stage in the preprocessing of communication sounds.	NIMH,NEUROPHYSIOL LAB,POOLESVILLE,MD 20837; HARVARD UNIV,DEPT ANTHROPOL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT PSYCHOL,PROGRAM NEUROSCI,CAMBRIDGE,MA 02138	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; Harvard University			Rauschecker, Josef P/A-4120-2013	Rauschecker, Josef P./0000-0003-4353-9084				BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; BOATMAN D, IN PRESS BRAIN LANGU; Brodmann K., 1908, J PSYCHOL NEUROL, V10, P231; BRUGGE JF, 1973, J NEUROPHYSIOL, V36, P1138, DOI 10.1152/jn.1973.36.6.1138; BURTON H, 1976, J COMP NEUROL, V168, P249, DOI 10.1002/cne.901680204; CREUTZFELDT O, 1989, EXP BRAIN RES, V77, P451, DOI 10.1007/BF00249600; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; DESIMONE R, 1986, J COMP NEUROL, V248, P164, DOI 10.1002/cne.902480203; DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; FENG AS, 1978, SCIENCE, V202, P645, DOI 10.1126/science.705350; GOUZOULES S, 1984, ANIM BEHAV, V32, P182, DOI 10.1016/S0003-3472(84)80336-X; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HAUSER MD, 1992, J ACOUST SOC AM, V91, P2175, DOI 10.1121/1.403676; HAUSER MD, 1993, BEHAV ECOL, V4, P194, DOI 10.1093/beheco/4.3.194; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; MERZENICH MM, 1973, BRAIN RES, V50, P275, DOI 10.1016/0006-8993(73)90731-2; MILLER JM, 1972, SCIENCE, V177, P449, DOI 10.1126/science.177.4047.449; MOREL A, 1993, J COMP NEUROL, V335, P437, DOI 10.1002/cne.903350312; PANDYA DN, 1994, J COMP NEUROL, V345, P447, DOI 10.1002/cne.903450311; PANDYA DN, 1972, Z ANAT ENTWICKLUNGS, V139, P127; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETERSEN SE, 1980, BRAIN RES, V197, P507, DOI 10.1016/0006-8993(80)91137-3; RAUSCHECKER JP, 1993, J NEUROSCI, V13, P4538; RAUSCHECKER JP, 1995, ARO ABSTR, V18, P103; SELDON HL, 1985, CEREB CORTEX, V4, P273; SUGA N, 1992, PHILOS T ROY SOC B, V336, P423, DOI 10.1098/rstb.1992.0078; SUGA N, 1978, SCIENCE, V200, P778, DOI 10.1126/science.644320; TIAN B, 1994, J NEUROPHYSIOL, V71, P1959, DOI 10.1152/jn.1994.71.5.1959; VANECONOMO C, 1925, CYTOARCHITEKTONIK HI; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4; WINTER P, 1973, EXP BRAIN RES, V18, P489; WINTER P, 1966, EXP BRAIN RES, V1, P359; WOLLBERG Z, 1972, SCIENCE, V175, P212, DOI 10.1126/science.175.4018.212; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	35	664	669	1	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					111	114		10.1126/science.7701330	http://dx.doi.org/10.1126/science.7701330			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701330				2022-12-01	WOS:A1995QR45400038
J	RICHARD, I; BROUX, O; ALLAMAND, V; FOUGEROUSSE, F; CHIANNILKULCHAI, N; BOURG, N; BRENGUIER, L; DEVAUD, C; PASTURAUD, P; ROUDAUT, C; HILLAIRE, D; PASSOSBUENO, MR; ZATZ, M; TISCHFIELD, JA; FARDEAU, M; JACKSON, CE; COHEN, D; BECKMANN, JS				RICHARD, I; BROUX, O; ALLAMAND, V; FOUGEROUSSE, F; CHIANNILKULCHAI, N; BOURG, N; BRENGUIER, L; DEVAUD, C; PASTURAUD, P; ROUDAUT, C; HILLAIRE, D; PASSOSBUENO, MR; ZATZ, M; TISCHFIELD, JA; FARDEAU, M; JACKSON, CE; COHEN, D; BECKMANN, JS			MUTATIONS IN THE PROTEOLYTIC-ENZYME CALPAIN-3 CAUSE LIMB-GIRDLE MUSCULAR-DYSTROPHY TYPE-2A	CELL			English	Article							ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; FUNCTIONAL IMPLICATIONS; BINDING PROTEINS; SEQUENCES; MUSCLE; GENE; TRANSCRIPTION; EXPRESSION; LINKAGE	Limb-girdle muscular dystrophies (LGMDs) are a group of inherited diseases whose genetic etiology has yet to be elucidated, The autosomal recessive forms (LGMD2) constitute a genetically heterogeneous group with LGMD2A mapping to chromosome 15q15.1-q21.1, The gene encoding the muscle-specific calcium-activated neutral protease 3 (CANP3) large subunit is located in this region. This cysteine protease belongs to the family of intracellular calpains, Fifteen nonsense, splice site, frameshift, or missense calpain mutations cosegregate with the disease in LGMD2A families, six of which were found within La Reunion island patients, A digenic inheritance model is proposed to account for the unexpected presence of multiple independent mutations in this small inbred population. Finally, these results demonstrate an enzymatic rather than a structural protein defect causing a muscular dystrophy, a defect that may have regulatory consequences, perhaps in signal transduction.	UNIV SAO PAULO, INST BIOCIENCIAS, DEPT BIOL, BR-05508900 SAO PAULO, BRAZIL; INDIANA UNIV, SCH MED, DEPT MED & MOLEC GENET, INDIANAPOLIS, IN 46202 USA; CNRS, UNITE A614, INSERM, F-75005 PARIS, FRANCE; HENRY FORD HOSP, DETROIT, MI 48202 USA; CTR ETUD POLYMORPHISME HUMAIN, FDN JEAN DAUSSET, F-75010 PARIS, FRANCE	Universidade de Sao Paulo; Indiana University System; Indiana University-Purdue University Indianapolis; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Henry Ford Health System; Henry Ford Hospital; Foundation Jean Dausset-CEPH	RICHARD, I (corresponding author), GENETHON, 1 RUE INT, F-91000 EVRY, FRANCE.		Allamand, Valerie/M-4333-2017; Richard, isabelle/J-8298-2013; Zatz, Mayana/M-5338-2015; Passos-Bueno, Maria Rita/I-6796-2016; Allamand, Valérie/AAH-6272-2021; Beckmann, Jacques Simon/A-9772-2008	Zatz, Mayana/0000-0003-3970-8025; Passos-Bueno, Maria Rita/0000-0002-9248-3008; Allamand, Valérie/0000-0001-8997-9742; Beckmann, Jacques Simon/0000-0002-9741-1900; Tischfield, Jay/0000-0003-3217-8287				ALLAMAND V, 1995, HUM MOL GENET, V4, P459, DOI 10.1093/hmg/4.3.459; ALLAMAND V, 1995, IN PRES AM J HUM GEN; BACH G, 1993, AM J HUM GENET, V53, P330; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Bushby K.M.D., 1994, DIAGNOSTIC CRITERIA, P25; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHIANNILKULCHAI N, 1995, IN PRESS HUM MOL GEN, V4; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; EMORI Y, 1986, FEBS LETT, V194, P249, DOI 10.1016/0014-5793(86)80094-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOUGEROUSSE F, 1994, HUM MOL GENET, V3, P285, DOI 10.1093/hmg/3.2.285; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HEINISCH U, 1995, AM J HUM GENET, V56, P51; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; JACKSON CE, 1961, PEDIATRICS, V28, P77; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KEEN J, 1991, TRENDS GENET, V7, P5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MATSUMURA K, 1993, LANCET, V341, P521, DOI 10.1016/0140-6736(93)90279-P; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIYAMOTO S, 1994, NATL ACAD SCI US, V94, P12740; MURACHI T, 1989, BIOCHEM INT, V18, P263; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; OHNO S, 1989, CYTOGENET CELL GENET, V51, P1054; OPPENHEIM A, 1990, HUM GENET, V86, P175; PASSOSBUENO MR, 1993, J MED GENET, V30, P385, DOI 10.1136/jmg.30.5.385; RICHARD I, 1994, GENOMICS, V23, P619, DOI 10.1006/geno.1994.1550; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; RODIUS F, 1994, AM J HUM GENET, V54, P1050; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sambrook J., 1989, MOL CLONING LAB MANU; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WALTON JN, 1954, BRAIN, V77, P169, DOI 10.1093/brain/77.2.169; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YOUNG K, 1992, GENOMICS, V13, P1370, DOI 10.1016/0888-7543(92)90074-3	54	793	821	1	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 7	1995	81	1					27	40		10.1016/0092-8674(95)90368-2	http://dx.doi.org/10.1016/0092-8674(95)90368-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720071	Bronze			2022-12-01	WOS:A1995QR97000005
J	SCHABERT, FA; HENN, C; ENGEL, A				SCHABERT, FA; HENN, C; ENGEL, A			NATIVE ESCHERICHIA-COLI OMPF PORIN SURFACES PROBED BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article							OUTER-MEMBRANE	Topographs of two-dimensional porin OmpF crystals reconstituted in the presence of lipids were recorded in solution by atomic force microscopy (AFM) to a lateral resolution of 10 angstroms and a vertical resolution of 1 angstrom. Protein-protein interactions were demonstrated on the basis of the AFM results and earlier crystallographic findings, To assess protein-lipid interactions, the bilayer was modeled with kinked lipids by fitting the head groups to contours determined with AFM. Finally, two conformations of the extracellular porin surface were detected at forces of 0.1 nanonewton, demonstrating the potential of AFM to monitor conformational changes with high resolution.	UNIV BASEL,BIOZENTRUM,INST MICROSCOP STRUCT BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel								BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUEHLER LK, 1991, J BIOL CHEM, V266, P2446; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; HOENGER A, 1993, J MOL BIOL, V233, P400, DOI 10.1006/jmbi.1993.1520; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; SAXTON WO, 1992, ULTRAMICROSCOPY, V46, P287, DOI 10.1016/0304-3991(92)90020-K; SCHABERT FA, 1994, BIOPHYS J, V67, P2394, DOI 10.1016/S0006-3495(94)80726-X; SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4893; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009	15	262	266	1	35	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					92	94		10.1126/science.7701347	http://dx.doi.org/10.1126/science.7701347			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701347				2022-12-01	WOS:A1995QR45400032
J	SCHIPANI, E; KRUSE, K; JUPPNER, H				SCHIPANI, E; KRUSE, K; JUPPNER, H			A CONSTITUTIVELY ACTIVE MUTANT PTH-PTHRP RECEPTOR IN JANSEN-TYPE METAPHYSEAL CHONDRODYSPLASIA	SCIENCE			English	Article							RHODOPSIN; MUTATIONS; GENE	A single heterozygous nucleotide exchange in exon M2 of the gene encoding the parathyroid hormone-parathyroid hormone-related peptide (PTH-PTHrP) receptor was identified in a patient with Jansen-type metaphyseal chondrodysplasia, which changes a strictly conserved histidine residue at position 223 in the receptor's first intracellular loop to arginine. Constitutive, ligand-independent adenosine 3',5'-monophosphate accumulation was observed in COS-7 cells expressing the mutant PTH-PTHrP receptor but not in cells expressing the wild-type receptor. This finding explains the severe ligand-independent hypercalcemia and hypophosphatemia, and most likely the abnormal formation of endochondral bone, in this rare form of short-limbed dwarfism.	MASSACHUSETTS GEN HOSP,DEPT MED,ENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CHILDRENS SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; UNIV LUBECK,PADIATRIE KLIN,D-23538 LUBECK,GERMANY	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Lubeck					PHS HHS [R01 46718] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Broadus Arthur E., 1994, P259; de Haas W H, 1969, J Bone Joint Surg Br, V51, P290; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Frame B, 1980, PEDIAT DIS RELATED C, P269; GRAM PB, 1959, J BONE JOINT SURG AM, V41, P951, DOI 10.2106/00004623-195941050-00015; HOLT JF, 1969, CLIN DELINEATION BIR, V5, P73; Jansen M, 1934, Z ORTHOP CHIR, V61, P253; Juppner H, 1994, Curr Opin Nephrol Hypertens, V3, P371; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KIKUCHI S, 1976, J BONE JOINT SURG BR, V58, P102, DOI 10.1302/0301-620X.58B1.1270485; KRONENBERG HM, 1993, HDB EXPT PHARM, P185; KRUSE K, 1993, EUR J PEDIATR, V152, P912, DOI 10.1007/BF01957529; LANSKE B, 1994, BONE MINER RES S1, V9, P121; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; Rao DS, 1979, VITAMIN D BASIC RES, P1173; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHIPANI E, 1992, P NATL ACAD SCI USA, V89, P2732; SCHIPANI E, IN PRESS J CLIN ENDO; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0	27	492	514	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					98	100		10.1126/science.7701349	http://dx.doi.org/10.1126/science.7701349			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701349				2022-12-01	WOS:A1995QR45400034
J	SCHNEEWIND, O; FOWLER, A; FAULL, KF				SCHNEEWIND, O; FOWLER, A; FAULL, KF			STRUCTURE OF THE CELL-WALL ANCHOR OF SURFACE-PROTEINS IN STAPHYLOCOCCUS-AUREUS	SCIENCE			English	Article							MALTOSE-BINDING-PROTEIN; GRAM-POSITIVE BACTERIA; SEQUENCE; GENE; RESISTANCE; REGION; LYSOSTAPHIN; ATTACHMENT; MEMBRANE	Many surface proteins are anchored to the cell wall of Gram-positive bacteria and are involved in the pathogenesis of these organisms. A hybrid molecule was designed that, when expressed in Staphylococcus aureus, was anchored to the cell wall and could be released by controlled enzymatic digestion. By a combination of molecular biology and mass spectrometry techniques, the structure of the cell wall anchor of surface proteins in S. aureus was revealed. After cleavage of surface proteins between threonine and glycine of the conserved LPXTG motif, the carboxyl of threonine is amide-linked to the free amino group of the pentaglycine crossbridge in the staphylococcal cell wall.	UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SCHNEEWIND, O (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024, USA.				NIAID NIH HHS [AI 33985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033985] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWDER HP, 1965, BIOCHEM BIOPH RES CO, V19, P383, DOI 10.1016/0006-291X(65)90473-0; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FORSGREN A, 1969, ACTA PATHOL MIC SC, V75, P481; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; GAREN A, 1955, VIROLOGY, V1, P347, DOI 10.1016/0042-6822(55)90030-1; GHUYSEN J. M., 1965, BIOCHEMISTRY, V4, P2245, DOI 10.1021/bi00886a043; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GUSS B, 1984, EUR J BIOCHEM, V138, P413, DOI 10.1111/j.1432-1033.1984.tb07931.x; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; KEHOE MA, 1994, BACTERIAL CELL WALL, P217; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MOKS T, 1986, EUR J BIOCHEM, V156, P3577; MUNOZ E, 1967, BIOCHEMISTRY-US, V6, P3659, DOI 10.1021/bi00864a007; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PANCHOLI V, 1989, J EXP MED, V170, P2119, DOI 10.1084/jem.170.6.2119; PANCHOLI V, 1988, J BACTERIOL, V170, P2618, DOI 10.1128/jb.170.6.2618-2624.1988; PATEL AH, 1987, INFECT IMMUN, V55, P3103, DOI 10.1128/IAI.55.12.3103-3110.1987; PETIT JF, 1966, BIOCHEMISTRY-US, V5, P2765; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RECSEI PA, 1987, P NATL ACAD SCI USA, V84, P1127, DOI 10.1073/pnas.84.5.1127; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SCHOCKMAN GD, 1983, ANNU REV MICROBIOL, V37, P501; SJOQUIST J, 1972, EUR J BIOCHEM, V29, P572, DOI 10.1111/j.1432-1033.1972.tb02023.x; SJOQUIST J, 1972, EUR J BIOCHEM, V30, P190, DOI 10.1111/j.1432-1033.1972.tb02086.x; SLOAN GL, 1977, BIOCHEM J, V167, P293, DOI 10.1042/bj1670293; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; STROMINGER JL, 1967, FED PROC, V26, P9; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; UHLEN M, 1984, J BIOL CHEM, V259, P1695; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156	38	372	408	0	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					103	106		10.1126/science.7701329	http://dx.doi.org/10.1126/science.7701329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701329				2022-12-01	WOS:A1995QR45400036
J	VERNOS, I; RAATS, J; HIRANO, T; HEASMAN, J; KARSENTI, E; WYLIE, C				VERNOS, I; RAATS, J; HIRANO, T; HEASMAN, J; KARSENTI, E; WYLIE, C			XKLP1, A CHROMOSOMAL XENOPUS KINESIN-LIKE PROTEIN ESSENTIAL FOR SPINDLE ORGANIZATION AND CHROMOSOME POSITIONING	CELL			English	Article							OOCYTES; SEQUENCE; INVITRO; MICROTUBULES; CYTOKERATIN; DROSOPHILA; INDUCTION; EXTRACTS; EMBRYOS; CYCLE	Xklp1 is a novel Xenopus kinesin-like protein with a motor domain at the amino terminus, nuclear localisation sequences in the stalk, and a putative zinc fingerlike sequence in the tail. It is nuclear during interphase and chromosomal during mitosis. During late anaphase, a fraction of the protein relocalizes to the spindle interzone and accumulates in the midbody during telophase. Depletion of Xklp1 protein by antisense oligo knockout in oocytes leads to defective mitosis during the first cell cycles following fertilization. The bipolarity of spindles assembled in vitro in the presence of anti-Xklp1 antibodies is unstable, and the chromosomes fail to congress on the metaphase plate.	EUROPEAN MOLEC BIOL LAB,CELL BIOPHYS PROGRAMME,D-69117 HEIDELBERG,GERMANY; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,ENGLAND	European Molecular Biology Laboratory (EMBL); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Francisco	VERNOS, I (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Hirano, Tatsuya/F-6008-2011; Vernos, Isabelle/C-1687-2015	Hirano, Tatsuya/0000-0002-4219-6473; Vernos, Isabelle/0000-0003-1469-9214	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; BLOOM GS, 1995, PROTEIN PROFILE, V1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEINBERG AP, 1983, ANAL BIOCHEM, V137, P266; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GORBSKY GJ, 1992, BIOESSAYS, V14, P73, DOI 10.1002/bies.950140202; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HARLOW E, 1988, ANTIBODIES LABORATOR; HEASMAN J, 1994, DEVELOPMENT, V120, P49; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; HEASMAN J, 1992, DEV S, V116, P119; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAZIA D, 1987, INT REV CYTOL, V100, P49; MILLER L, 1977, IN VITRO CELL DEV B, V13, P557; MURRAY AW, 1991, METHOD CELL BIOL, V36, P573; NICKLAS RB, 1985, J CELL BIOL, V100, P1, DOI 10.1083/jcb.100.1.1; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pereira Andrea, 1994, V13, P269; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; ROSENFELD R, 1993, J BIOMOL STRUCT DYN, V11, P557, DOI 10.1080/07391102.1993.10508015; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; STELZER EHK, 1989, P SOC PHOTOOPT INSTR, V1028, P146; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; TORPEY N, 1992, NATURE, V357, P413, DOI 10.1038/357413a0; TORPEY NP, 1990, DEVELOPMENT, V110, P1185; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VERNOS I, 1993, DEV BIOL, V157, P232, DOI 10.1006/dbio.1993.1127; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	42	209	212	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					117	127		10.1016/0092-8674(95)90376-3	http://dx.doi.org/10.1016/0092-8674(95)90376-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720067	Bronze			2022-12-01	WOS:A1995QR97000013
J	WITKE, W; SHARPE, AH; HARTWIG, JH; AZUMA, T; STOSSEL, TP; KWIATKOWSKI, DJ				WITKE, W; SHARPE, AH; HARTWIG, JH; AZUMA, T; STOSSEL, TP; KWIATKOWSKI, DJ			HEMOSTATIC, INFLAMMATORY, AND FIBROBLAST RESPONSES ARE BLUNTED IN MICE LACKING GELSOLIN	CELL			English	Article							ACTIN DEPOLYMERIZING FACTOR; FILAMENT-SEVERING PROTEIN; D-BINDING-PROTEIN; F-ACTIN; CAPPING PROTEIN; SKELETAL-MUSCLE; PLASMA GELSOLIN; CALCIUM-ION; STEM-CELLS; POLYMERIZATION	Gelsolin, an 82 kDa actin-binding protein, has potent actin filament-severing activity in vitro. To investigate the in vivo function of gelsolin, transgenic gelsolinnull (Osn(-)) mice were generated and found to have normal embryonic development and longevity. However, platelet shape changes are decreased in Gsn(-) mice, causing prolonged bleeding times. Neutrolphil migration in vivo into peritoneal exudates and in vitro is delayed. Gsn(-) dermal fibroblasts have excessive actin stress fibers and migrate more slowly than wildtype fibroblasts, but have increased contractility in vitro. These observations establish the requirement of gelsolin for rapid motile responses in cell types involved in stress responses such as hemostasis, inflammation, and wound healing. Neither gelsolin nor other proteins with similar actin filament-severing activity are expressed in early embryonic cells, indicating that this mechanism of actin filament dynamics is not essential for motility during early embryogenesis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	WITKE, W (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19429, HL 48743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbondanzo SJ, 1993, GUIDE TECHNIQUES MOU, P803; ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; ANKENBAUER T, 1988, J CELL BIOL, V107, P1489, DOI 10.1083/jcb.107.4.1489; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CONDELLIS J, 1994, ANN RV CELL BIOL, V9, P411; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DELCASTILLO AR, 1992, THROMB HAEMOSTASIS, V67, P248; DIFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; GRINNELL F, 1984, J CELL SCI, V66, P51; HARTMANN H, 1989, J BIOL CHEM, V264, P12639; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; ISENBERG G, 1980, NATURE, V288, P455, DOI 10.1038/288455a0; JANMEY PA, 1987, BLOOD, V70, P524; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KURTH M, 1984, J BIOL CHEM, V2598, P7473; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P8239; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMB JA, 1993, J BIOL CHEM, V268, P8999; LEE J, 1993, NATURE, V3622, P167; LEE WM, 1992, NEW ENGL J MED, V326, P1335; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIND SE, 1986, J CLIN INVEST, V78, P736, DOI 10.1172/JCI112634; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MARUYAMA K, 1965, BIOCHIM BIOPHYS ACTA, V94, P208, DOI 10.1016/0926-6585(65)90026-9; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHAFER DA, 1992, J CELL BIOL, V118, P335, DOI 10.1083/jcb.118.2.335; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1981, J BIOL CHEM, V256, P9693; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YOUNG WO, 1987, J LAB CLIN MED, V110, P83; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	59	370	387	1	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					41	51		10.1016/0092-8674(95)90369-0	http://dx.doi.org/10.1016/0092-8674(95)90369-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720072	Bronze			2022-12-01	WOS:A1995QR97000006
J	YIN, JCP; DELVECCHIO, M; ZHOU, H; TULLY, T				YIN, JCP; DELVECCHIO, M; ZHOU, H; TULLY, T			CREB AS A MEMORY MODULATOR - INDUCED EXPRESSION OF A DCREB2 ACTIVATOR ISOFORM ENHANCES LONG-TERM-MEMORY IN DROSOPHILA	CELL			English	Article							CAMP-RESPONSIVE-ELEMENT; APLYSIA SENSORY NEURONS; WITHDRAWAL REFLEX; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; PROTEIN-SYNTHESIS; GILL-WITHDRAWAL; BINDING; MELANOGASTER; PHOSPHORYLATION	Genetic studies of memory formation in Drosophila have revealed that the formation of a protein synthesis-dependent long-term memory (LTM) requires multiple training sessions. LTM is blocked specifically by induced expression of a repressor isoform of the cAMP-responsive element-binding protein (CREB). Here, we report an enhancement of LTM formation after induced expression of an activator isoform of dCREB2. Maximum LTM is achieved after one training session, and its formation depends on phosphorylation of the activator transgene. A model of LTM formation based on differential regulation of CREB isoforms is proposed.			YIN, JCP (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,COLD SPRING HARBOR,NY 11724, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32245] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ARMSTRONG RC, 1993, ANNU REV NEUROSCI, V16, P17, DOI 10.1146/annurev.ne.16.030193.000313; BACKSAI BJ, 1993, SCIENCE, V260, P222; BAILEY CH, 1994, SEMIN NEUROSCI, V6, P35; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; Byrne John H., 1993, V27, P47; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; Ebbinghaus H., 1885, GEDACHTNIS; ERBER J, 1976, J COMP PHYSIOL PSYCH, V90, P41, DOI 10.1037/h0077258; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GALL CM, 1991, MEMORY ORG LOCUS CHA, P301; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOELET P, 1986, TRENDS NEUROSCI, V9, P492, DOI 10.1016/0166-2236(86)90157-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENOUGH WT, 1984, TRENDS NEUROSCI, V7, P229, DOI 10.1016/S0166-2236(84)80211-8; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hintzman D. L., 1974, THEORIES COGNITIVE P, P77; Huang Y Y, 1994, Learn Mem, V1, P74; JAFFE K, 1980, PHYSIOL BEHAV, V25, P367, DOI 10.1016/0031-9384(80)90275-9; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LEWIS D, 1960, QUANTITATIVE METHODS; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; Menzel R., 1990, NEUROBIOLOGY COMP CO, P237; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; PALMERINO CC, 1980, SCIENCE, V208, P753, DOI 10.1126/science.7367891; PIROTTA V, 1988, SURVEY MOL CLONING V, P427; QIU YH, 1993, GENE DEV, V7, P1447, DOI 10.1101/gad.7.7b.1447; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Sokal R., 1981, BIOMETRY; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STEWART MG, 1991, NEURAL BEHAVIOURAL P, P305; SUN P, 1984, GENE DEV, V8, P2527; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1993, J NEUROGENET, V9, P55, DOI 10.3109/01677069309167275; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	67	544	569	2	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					107	115		10.1016/0092-8674(95)90375-5	http://dx.doi.org/10.1016/0092-8674(95)90375-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720066	Bronze			2022-12-01	WOS:A1995QR97000012
J	ALON, R; HAMMER, DA; SPRINGER, TA				ALON, R; HAMMER, DA; SPRINGER, TA			LIFETIME OF THE P-SELECTIN-CARBOHYDRATE BOND AND ITS RESPONSE TO TENSILE FORCE IN HYDRODYNAMIC FLOW	NATURE			English	Article							NEUTROPHIL ADHESION; GLYCOPROTEIN LIGAND; MYELOID CELLS; SHEAR-FLOW; BINDING; IDENTIFICATION; RECOGNITION; DETACHMENT; VENULES	SELECTINS tether to the blood vessel wall leukocytes that are flowing in the bloodstream and support subsequent labile rolling interactions as the leukocytes are subjected to hydrodynamic drag forces(1,2). To support this rolling, selectins have been proposed to have rapid bond association and dissociation rate constants, and special mechanical properties linking tensile forces and bond dissociation(3-6). We have visualized transient tethering and release of neutrophils in hydrodynamic flow on lipid bilayers containing densities of P-selectin below those required to support rolling. We report here that transient tethers had first-order kinetics and other characteristics suggesting a unimolecular interaction between P-selectin and its glycoprotein ligand (PSGL-1). The unstressed dissociation constant (off rate) was 1s(-1) Hydrodynamic shear stresses of up to 1.1 dyn cm(-2), corresponding to a force on the bond of up to 110 pN, increased the off rate only modestly, to 3.5 s(-1). The data was adequately matched by a proposed equation(7) relating off rate to the exponential of tensile force on the bond and the bond interaction distance, and gave a bond interaction distance of 0.5 Angstrom. This distance is compatible with hydrogen and metal coordination bonds between P-selectin and PSGL-1. Fast on and off rates, together with the high tensile strength of the selectin bond, appear necessary to support rolling at physiological shear stresses.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; CORNELL UNIV,SCH CHEM ENGN,ITHACA,NY 14853	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Cornell University								BELL GI, 1984, BIOPHYS J, V45, P1051, DOI 10.1016/S0006-3495(84)84252-6; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; DOWDY S, 1985, STATISTICS RES; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; Fersht A., 1985, ENZYME STRUCTURE MEC; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HAMMER DA, 1992, BIOPHYS J, V63, P35, DOI 10.1016/S0006-3495(92)81577-1; JANIN J, 1990, J BIOL CHEM, V265, P16027; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MASON DW, 1986, HDB EXPT IMMUNOLOG 1, V4; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V289, P23318; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Press W.H., 1986, NUMERICAL RECIPES AR; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEININGER CN, 1992, BIOCHEM BIOPH RES CO, V188, P760, DOI 10.1016/0006-291X(92)91121-6; TEMPELMAN LA, 1994, BIOPHYS J, V66, P1231, DOI 10.1016/S0006-3495(94)80907-5; TOZEREN A, 1992, BIOPHYS J, V63, P700, DOI 10.1016/S0006-3495(92)81660-0; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229	30	576	591	1	48	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					539	542		10.1038/374539a0	http://dx.doi.org/10.1038/374539a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7535385				2022-12-01	WOS:A1995QR06900051
J	BYSKOV, AG; ANDERSEN, CY; NORDHOLM, L; THOGERSEN, H; XIA, GL; WASSMANN, O; ANDERSEN, JV; GUDDAL, E; ROED, T				BYSKOV, AG; ANDERSEN, CY; NORDHOLM, L; THOGERSEN, H; XIA, GL; WASSMANN, O; ANDERSEN, JV; GUDDAL, E; ROED, T			CHEMICAL-STRUCTURE OF STEROLS THAT ACTIVATE OOCYTE MEIOSIS	NATURE			English	Article							FOLLICULAR-FLUID; GRANULOSA-CELLS; MATURATION; INVITRO; HYPOXANTHINE; ZYMOSTEROL; SUBSTANCE; REDUCTASE	GONADOTROPHINS and various growth factors, but not sex steroids, can induce resumption of meiosis in vitro, but only in oocytes enclosed by cumulus-granulosa cells(1). Follicular purines prevent resumption of meiosis(2,3). This process can be overcome, in vitro, by a transient elevation of cyclic AMP resulting in the production of a diffusible meiosis-inducing substance secreted by the cumulus cells(4). A meiosis-inducing activity has been detected in gonads of different species, for example, in preovulatory follicular fluid of women(5) and in mouse testes(6). We report here the isolation and characterization of meiosis-activating sterols from human follicular fluid and bull testes and the synthesis of two closely related C-29 sterols. All these sterols induce a resumption of meiosis in cultured cumulus-enclosed and naked mouse oocytes indicating their nonspecificity across species and sex. This family of sterols is for the first time considered crucial to meiosis.	NOVO NORDISK AS, DK-2760 MALOV, DENMARK	Novo Nordisk	BYSKOV, AG (corresponding author), UNIV COPENHAGEN HOSP, RIGSHOSP,DEPT OBSTET & GYNECOL,REPROD BIOL LAB, SECT 5712, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.			Andersen, Claus Yding/0000-0001-7681-253X				ABERNETHY D, 1976, STEROIDS, V27, P297, DOI 10.1016/0039-128X(76)90052-0; ANDERSEN CY, 1990, J CLIN ENDOCR METAB, V71, P1375, DOI 10.1210/jcem-71-5-1375; AOYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P659, DOI 10.1016/S0006-291X(86)80470-3; BYSKOV AG, 1976, DEV BIOL, V52, P193, DOI 10.1016/0012-1606(76)90239-6; BYSKOV AG, 1993, MOL REPROD DEV, V34, P47, DOI 10.1002/mrd.1080340108; COULON J, 1986, CAN J MICROBIOL, V32, P738, DOI 10.1139/m86-134; DOLLE RE, 1989, J AM CHEM SOC, V111, P278, DOI 10.1021/ja00183a042; DONAHOE PK, 1987, RECENT PROG HORM RES, V43, P431; DOWNS SM, 1985, P NATL ACAD SCI USA, V82, P454, DOI 10.1073/pnas.82.2.454; DOWNS SM, 1993, MOL REPROD DEV, V35, P82, DOI 10.1002/mrd.1080350114; DURHAM CR, 1985, MOL CELL ENDOCRINOL, V40, P211, DOI 10.1016/0303-7207(85)90177-7; EMMONS GT, 1989, MAGN RESON CHEM, V27, P1012, DOI 10.1002/mrc.1260271103; EPPIG JJ, 1978, J REPROD FERTIL, V53, P99, DOI 10.1530/jrf.0.0530099; JOSSO N, 1986, PHYSIOL REV, V66, P1038, DOI 10.1152/physrev.1986.66.4.1038; MAITRA U S, 1989, Steroids, V53, P597, DOI 10.1016/0039-128X(89)90034-2; MCNATTY KP, 1979, J CLIN ENDOCR METAB, V49, P687, DOI 10.1210/jcem-49-5-687; PONSINET G, 1965, B SOC CHIM FR, P3682; RICE C, 1981, J REPROD FERTIL, V62, P245, DOI 10.1530/jrf.0.0620245; SCHROEPFER GJ, 1988, CHEM PHYS LIPIDS, V47, P187, DOI 10.1016/0009-3084(88)90012-6; SMITH DM, 1980, J REPROD FERTIL, V60, P331, DOI 10.1530/jrf.0.0600331; TAYLOR UF, 1981, J LIPID RES, V22, P171; Wassarman Paul M., 1994, P79; WESTERGAARD L, 1985, FERTIL STERIL, V44, P663; XIA GL, 1994, MOL REPROD DEV, V39, P17, DOI 10.1002/mrd.1080390104	24	281	304	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 6	1995	374	6522					559	562		10.1038/374559a0	http://dx.doi.org/10.1038/374559a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	QR069	7700384				2022-12-01	WOS:A1995QR06900057
J	CONDRA, JH; SCHLEIF, WA; BLAHY, OM; GABRYELSKI, LJ; GRAHAM, DJ; QUINTERO, JC; RHODES, A; ROBBINS, HL; ROTH, E; SHIVAPRAKASH, M; TITUS, D; YANG, T; TEPPLER, H; SQUIRES, KE; DEUTSCH, PJ; EMINI, EA				CONDRA, JH; SCHLEIF, WA; BLAHY, OM; GABRYELSKI, LJ; GRAHAM, DJ; QUINTERO, JC; RHODES, A; ROBBINS, HL; ROTH, E; SHIVAPRAKASH, M; TITUS, D; YANG, T; TEPPLER, H; SQUIRES, KE; DEUTSCH, PJ; EMINI, EA			IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS	NATURE			English	Article							REVERSE-TRANSCRIPTASE; IMMUNODEFICIENCY	INHIBITORS Of the human immunodeficiency virus type 1 (HIV-1) protease have entered clinical study as potential therapeutic agents for HIV-1 infection. The clinical efficacy of HIV-1 reverse transcriptase inhibitors has been limited bg the emergence of resistant viral variants. Similarly, variants expressing resistance to protease inhibitors have been derived in cell culture(1-10). We now report the characterization of resistant variants isolated from patients undergoing therapy with the protease inhibitor MX-639 (formerly designated L-735,524). Five of these variants, isolated from four patients, exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors. This suggests that combination therapy with multiple protease inhibitors may not prevent loss of antiviral activity resulting from resistance selection. In addition, previous therapy with one compound may abrogate the benefit of subsequent treatment with a second inhibitor.	MERCK SHARP & DOHME LTD,RES LABS,DEPT CLIN PHARMACOL,W POINT,PA 19486; THOMAS JEFFERSON UNIV,DIV INFECT DIS,PHILADELPHIA,PA 19107; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294	Merck & Company; Jefferson University; University of Alabama System; University of Alabama Birmingham	CONDRA, JH (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486, USA.		Rhodes, Andrew/G-4265-2011	Rhodes, Andrew/0000-0002-8737-574X				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BYRNES VW, 1993, ANTIMICROB AGENTS CH, V37, P1576, DOI 10.1128/AAC.37.8.1576; CHEN CM, J CELL BIOCHEM, V18, P16694; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001; ELFARRASH MA, 1994, J VIROL, V68, P233, DOI 10.1128/JVI.68.1.233-239.1994; GETMAN DP, 1993, J MED CHEM, V36, P288, DOI 10.1021/jm00054a014; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; KEMPF DJ, 1993, ABSTR PAP AM CHEM S, V206, P119; KEMPF DJ, 1994, J CELL BIOCHEM, V18, P130; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MYERS G, 1993, HUMAN RETROVIRUSES A; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; OTTO MJ, 1993, ANTIMICROB AGENTS CH, V37, P2606, DOI 10.1128/AAC.37.12.2606; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; SINGH M, 1993, J CELL BIOCH E S, V17, P86; TISDALE M, 1994, 3RD INT WORKSH HIV D, P14; TUNG RD, 1994, 10TH INT C AIDS, P33; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WINSLOW DL, 1994, AIDS, V8, P753, DOI 10.1097/00002030-199406000-00005; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	28	890	920	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					569	571		10.1038/374569a0	http://dx.doi.org/10.1038/374569a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700387				2022-12-01	WOS:A1995QR06900060
J	FUNATSU, T; HARADA, Y; TOKUNAGA, M; SAITO, K; YANAGIDA, T				FUNATSU, T; HARADA, Y; TOKUNAGA, M; SAITO, K; YANAGIDA, T			IMAGING OF SINGLE FLUORESCENT MOLECULES AND INDIVIDUAL ATP TURNOVERS BY SINGLE MYOSIN MOLECULES IN AQUEOUS-SOLUTION	NATURE			English	Article							ACTIN-FILAMENTS; INVITRO; SUBFRAGMENT-1; MICROSCOPY; HYDROLYSIS; MOVEMENT	VISUALIZATION of single actin filaments by fluorescence microscopy(1) led to the development of new in vitro assays for analysing actomyosin-based motility at the molecular level(2-5). The ability to manipulate actin filaments with a microneedle(6,7) or an optical trap(8) combined with position-sensitive detectors has enabled direct measurements of nanometre displacements and piconewton forces exerted by individual myosin molecules. To elucidate how myosin generates movement, it is necessary to understand how ATP hydrolysis is coupled to mechanical work at the level of the single molecule. But the most sensitive microscopic ATPase assay available still requires over 1,000 myosin(9). To enhance the sensitivity of such assays, we have refined epifluorescence and total internal reflection microscopies to visualize single fluorescent dye molecules. We report here that this approach can be used directly to image single fluorescently labelled myosin molecules and detect individual ATP turnover reactions. In contrast to pre,viously reported single fluorescent molecule imaging methods, which used specimens immobilized on an air-dried surface(10-12), method allows video-rate imaging of single molecules in aqueous solution, and hence can be applied to the study of man types of enzymes and biomolecules.	OSAKA UNIV, DEPT BIOPHYS ENGN, TOYONAKA, OSAKA 560, JAPAN	Osaka University	FUNATSU, T (corresponding author), JRDC, ERATO, BIOMOTRON PROJECT, SENBA HIGASHI 2-4-14, MINO, OSAKA 562, JAPAN.		Yanagida, Toshio/D-1919-2009; Funatsu, Takashi/Q-1404-2015	Funatsu, Takashi/0000-0002-9656-8308; Tokunaga, Makio/0000-0003-4586-8922				AXELROD D, 1989, METHOD CELL BIOL, V30, P245; Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HARADA Y, 1988, CELL MOTIL CYTOSKEL, V10, P71, DOI 10.1002/cm.970100112; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; ISHIKAWA M, 1994, JPN J APPL PHYS 1, V33, P1571, DOI 10.1143/JJAP.33.1571; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LINDBERG M, 1975, EUR J BIOCHEM, V53, P481, DOI 10.1111/j.1432-1033.1975.tb04089.x; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; SOUTHWICK PL, 1990, CYTOMETRY, V11, P418, DOI 10.1002/cyto.990110313; SOWERBY AJ, 1993, J MOL BIOL, V234, P114, DOI 10.1006/jmbi.1993.1567; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	24	834	884	3	260	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	1995	374	6522					555	559		10.1038/374555a0	http://dx.doi.org/10.1038/374555a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700383				2022-12-01	WOS:A1995QR06900056
J	HABER, DA				HABER, DA			TELOMERES, CANCER, AND IMMORTALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN FIBROBLASTS				HABER, DA (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02129, USA.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428	7	25	30	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					955	956		10.1056/NEJM199504063321412	http://dx.doi.org/10.1056/NEJM199504063321412			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877656				2022-12-01	WOS:A1995QP89300012
J	HE, ZG; HENRICKSEN, LA; WOLD, MS; INGLES, CJ				HE, ZG; HENRICKSEN, LA; WOLD, MS; INGLES, CJ			RPA INVOLVEMENT IN THE DAMAGE-RECOGNITION AND INCISION STEPS OF NUCLEOTIDE EXCISION-REPAIR	NATURE			English	Article							REPLICATION PROTEIN-A; DNA BINDING-PROTEIN; SIMIAN VIRUS-40 DNA; PIGMENTOSUM GROUP-G; XERODERMA-PIGMENTOSUM; INVITRO; COMPLEMENTATION; SUBUNIT; VP16; P53	HUMAN replication protein (RPA) functions in DNA replication(1-4), homologous recombination(5) and nucleotide excision repair(6). This multisubunit single-stranded DNA-binding protein(1,2) may be required to make unique protein-protein contacts because heterologous single-stranded binding proteins cannot substitute for RPA in these diverse DNA transactions(5-7). We report here that, by using affinity chromatography and immunoprecipitation, we found that human RPA bound specifically and directly to two excision repair proteins, the xeroderma pigmentosum damage-recognition protein XPA (refs 8, 9) and the endonuclease XPG (refs 10-13). Although it had been suggested that RPA might function before the DNA synthesis repair stage(14.15), our finding that a complex of RPA and XPA showed a striking cooperativity in binding to DNA lesions indicates that RPA may function at the very earliest stage of excision repair. In addition, by binding XPG, RPA may target this endonuclease to damaged DNA.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1L6,CANADA; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Toronto; University of Toronto; University of Iowa			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	30	370	383	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					566	569		10.1038/374566a0	http://dx.doi.org/10.1038/374566a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700386				2022-12-01	WOS:A1995QR06900059
J	KRIEG, AM; YI, AK; MATSON, S; WALDSCHMIDT, TJ; BISHOP, GA; TEASDALE, R; KORETZKY, GA; KLINMAN, DM				KRIEG, AM; YI, AK; MATSON, S; WALDSCHMIDT, TJ; BISHOP, GA; TEASDALE, R; KORETZKY, GA; KLINMAN, DM			CPG MOTIFS IN BACTERIAL-DNA TRIGGER DIRECT B-CELL ACTIVATION	NATURE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; BINDING; OLIGONUCLEOTIDES; PHOSPHOROTHIOATE; STIMULATION; LYMPHOCYTES; FRAGMENTS; MICE	UNMETHYLATED CpG dinucleotides are more frequent in the genomes of bacteria and viruses than of vertebrates. We report here that bacterial DNA and synthetic oligodeoxynucleotides containing unmethylated CPG dinucleotides induce murine B cells to proliferate and secrete immunoglobulin in vitro and in vivo. This activation is enhanced by simultaneous signals delivered through the antigen receptor. Optimal B-cell activation requires a DNA motif in which an unmethylated CpG dinucleotide is flanked by two 5' purines and two 3' py,rimidines. Oligodeoxynucleotides containing this CpG motif induce more than 95% of all spleen B cells to enter the cell cycle. These data suggest a possible evolutionary link between immune defence based on the recognition of microbial DNA and the phenomenon of CpG suppression' in vertebrates. The potent immune activation by CpG oligonucleotides has implications for the design and interpretation of studies using 'antisense' oligonucleotides and points to possible new applications as adjuvants.	UNIV IOWA,COLL MED,DEPT PATHOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT MICROBIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL,IOWA CITY,IA 52242; VET AFFAIRS MED CTR,IOWA CITY,IA 52246; US FDA,CTR BIOL EVALUAT & RES,RETROVIRAL IMMUNOL SECT,BETHESDA,MD 20892	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Food & Drug Administration (FDA)	KRIEG, AM (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Koretzky, Gary/AAU-5381-2021; Krieg, Arthur M/K-8109-2019; Krieg, Art/R-6166-2019	Waldschmidt, Thomas/0000-0001-6147-6991; Teasdale, Rebecca M./0000-0002-1981-7032; Bishop, Gail/0000-0002-1291-5078				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Agrawal S, 1992, Antisense Res Dev, V2, P261; Bayever E, 1992, Antisense Res Dev, V2, P109; Bayever E, 1993, Antisense Res Dev, V3, P383; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BISHOP GA, 1991, J IMMUNOL, V147, P1107; CARDON LR, 1994, P NATL ACAD SCI USA, V91, P3799, DOI 10.1073/pnas.91.9.3799; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DARZYNKIEWICZ Z, 1976, P NATL ACAD SCI USA, V73, P2881, DOI 10.1073/pnas.73.8.2881; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; HAN J, 1994, ANTISENSE RES DEV, V4, P53, DOI 10.1089/ard.1994.4.53; KLINMAN DM, 1990, J IMMUNOL, V144, P506; KRAPF F, 1989, CLIN EXP IMMUNOL, V75, P336; KRIEG AM, 1989, J IMMUNOL, V143, P2448; KRIEG AM, 1992, IMMUNOMETHODS, V1, P191; LEIBSON HJ, 1981, J EXP MED, V154, P1681, DOI 10.1084/jem.154.5.1681; LISZIEWICZ J, 1994, P NATL ACAD SCI USA, V91, P7942, DOI 10.1073/pnas.91.17.7942; MARRACK P, 1994, CELL, V76, P323, DOI 10.1016/0092-8674(94)90339-5; Matson S, 1992, Antisense Res Dev, V2, P325; MESSINA JP, 1991, J IMMUNOL, V147, P1759; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; RICHARDSON B, 1990, ARTHRITIS RHEUM, V33, P1665, DOI 10.1002/art.1780331109; SANO H, 1989, SCAND J IMMUNOL, V30, P51, DOI 10.1111/j.1365-3083.1989.tb01188.x; SANO H, 1983, J IMMUNOL, V130, P187; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Zhao Q, 1993, Antisense Res Dev, V3, P53	29	2869	3397	8	171	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					546	549		10.1038/374546a0	http://dx.doi.org/10.1038/374546a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700380				2022-12-01	WOS:A1995QR06900053
J	LOMBARDI, V; PIAZZESI, G; FERENCZI, MA; THIRLWELL, H; DOBBIE, I; IRVING, M				LOMBARDI, V; PIAZZESI, G; FERENCZI, MA; THIRLWELL, H; DOBBIE, I; IRVING, M			ELASTIC DISTORTION OF MYOSIN HEADS AND REPRIMING OF THE WORKING STROKE IN MUSCLE	NATURE			English	Article							CONTRACTING MUSCLE; STRIATED-MUSCLE; FIBERS; FROG; TRANSIENTS; MECHANISM	MUSCLE contraction is driven by a cyclical interaction between the globular head domain of myosin and the actin filaments(1-6). We used quick stretches of 5 nm per half sarcomere to synchronize the movements of myosin heads in active single muscle fibres(5,7,8). The intensity of the 14.5 nm X-ray reflection decreased during the stretch, showing that the instantaneous elasticity of muscle(1,5) involves distortion of myosin heads. Head movement continued at about 1,500 s(-1) after the stretch, accompanied by partial force recovery. This indicates a reversal of the force-generating 'working stroke' in the myosin heads(5,8,9) that is smaller and faster than assumed previously(5,10,11). By 50 ms after the stretch, myosin heads have regained both their original conformation and the ability to execute a normal working stroke. This 'repriming' process is slower than that following shortening(12) but much faster than the ATP turnover rate per myosin head.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; UNIV LONDON KINGS COLL,RANDALL INST,LONDON WC2B 5RL,ENGLAND	MRC National Institute for Medical Research; University of London; King's College London	LOMBARDI, V (corresponding author), UNIV FLORENCE,DIPARTIMENTO SCI FISIOL,VIALE GB MORGAGNI 63,I-50134 FLORENCE,ITALY.		Ferenczi, Michael/F-9510-2015	Ferenczi, Michael/0000-0002-0349-331X; Dobbie, Ian/0000-0002-5531-5865	Telethon [239] Funding Source: Medline	Telethon(Fondazione Telethon)		Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; Curtin N A, 1975, J Mechanochem Cell Motil, V3, P147; EISENBERG E, 1978, PROG BIOPHYS MOL BIO, V33, P55; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1981, J PHYSIOL-LONDON, V317, pP12; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1981, J PHYSIOL-LONDON, V305, pP15; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; HUXLEY HE, 1982, J MOL BIOL, V159, P637; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; PIAZZESI G, 1992, J PHYSIOL-LONDON, V445, P659, DOI 10.1113/jphysiol.1992.sp018945; PIAZZESI G, 1995, BIOPHYS J, V98, pS92; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765	21	99	101	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					553	555		10.1038/374553a0	http://dx.doi.org/10.1038/374553a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700382				2022-12-01	WOS:A1995QR06900055
J	RIDKER, PM; HENNEKENS, CH; LINDPAINTER, K; STAMPFER, MJ; EISENBERG, PR; MILETICH, JP				RIDKER, PM; HENNEKENS, CH; LINDPAINTER, K; STAMPFER, MJ; EISENBERG, PR; MILETICH, JP			MUTATION IN THE GENE CODING FOR COAGULATION-FACTOR-V AND THE RISK OF MYOCARDIAL-INFARCTION, STROKE, AND VENOUS THROMBOSIS IN APPARENTLY HEALTHY-MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POOR ANTICOAGULANT RESPONSE; DEEP-VEIN THROMBOSIS; ACTIVATED PROTEIN-C; PLASMINOGEN-ACTIVATOR; HEART-DISEASE; THROMBOPHILIA; FIBRINOGEN; INHIBITOR; PLASMA	Background. A specific point mutation in the gene coding for coagulation factor V is associated with resistance to degradation by activated protein C, a recently described abnormality of coagulation that may be associated with an increased risk of venous thrombosis. Whether this mutation also predisposes patients to arterial thrombosis is unknown, as is the value of screening for the mutation in order to define the risk of venous thrombosis among unselected healthy people. Methods. Among 14,916 apparently healthy men in the Physicians' Health Study who provided base-line blood samples, 374 had myocardial infarctions, 209 had strokes, and 121 had deep venous thrombosis, pulmonary embolism, or both, during a mean follow-up of 8.6 years. We determined whether a mutation at nucleotide position 1691 of the factor V gene was present or absent in these 704 men and in an equal number of matched participants who remained free of vascular disease. Results. The prevalence of heterozygosity for the mutation among men who had myocardial infarctions (6.1 percent, P=0.9) or strokes (4.3 percent, P=0.4) was similar to that among men who remained free of vascular disease (6.0 percent). However, the prevalence of the mutation was significantly higher among men who had venous thrombosis, pulmonary embolism, or both (11.6 percent, P=0.02). In adjusted analyses, the relative risk of venous thrombosis among men with the mutation was 2.7 (95 percent confidence interval, 1.3 to 5.6; P=0.008). This increased risk was seen with primary venous thrombosis (relative risk, 3.5; 95 percent confidence interval, 1.5 to 8.4; P=0.004) but not with secondary venous thrombosis (relative risk, 1.7; 95 percent confidence interval, 0.6 to 5.3; P=0.3), and it was most apparent among older men. Specifically, the prevalence of the mutation among men over the age of 60 in whom primary venous thrombosis developed was 25.8 percent (relative risk, 7.0; 95 percent confidence interval, 2.6 to 19.1; P<0.001). Conclusions. In a large cohort of apparently healthy men, the presence of a specific point mutation in the factor V gene was associated with an increased risk of venous thrombosis, particularly primary venous thrombosis. The presence of the mutation was not associated with an increased risk of myocardial infarction or stroke. This mutation appears to be the most common inherited factor thus far recognized that predisposes patients to venous thrombosis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC DIS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115; CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV LAB MED,ST LOUIS,MO 63110	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL-26490, HL-34595, HL-14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R01HL034595] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P257; FOWKES FGR, 1993, LANCET, V342, P84, DOI 10.1016/0140-6736(93)91288-W; GOLDHABER SZ, 1985, PULMONARY EMBOLISM D; GRIFFIN JH, 1993, BLOOD, V82, P1989; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; Hennekens C., 1987, EPIDEMIOLOGY MED; HIRSH J, 1981, VENOUS THROMBOEMBOLI; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; PRANDONI P, 1992, NEW ENGL J MED, V327, P11228; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, CIRCULATION, V90, P2236, DOI 10.1161/01.CIR.90.5.2236; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8; 1971, ISCHEMIC HEART DISEA	29	986	1009	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					912	917		10.1056/NEJM199504063321403	http://dx.doi.org/10.1056/NEJM199504063321403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877648				2022-12-01	WOS:A1995QP89300003
J	SABERI, K; HAFTER, ER				SABERI, K; HAFTER, ER			A COMMON NEURAL CODE FOR FREQUENCY-MODULATED AND AMPLITUDE-MODULATED SOUNDS	NATURE			English	Article							INFERIOR COLLICULUS; AUDITORY-CORTEX; VISUAL-SYSTEM; NEURONS; SENSITIVITY; CAT; AM; RESPONSES; PATTERNS; STIMULI	MOST naturally occurring sounds are modulated in amplitude or frequencg; important examples include animal vocalizations and species-specific communication signals in mammals, insects, reptiles, birds and amphibians(1-9). Deciphering the information from amplitude-modulated (AM) sounds is a well-understood process, requiring a phase locking of primary auditory afferents to the modulation envelopes(10-12). The mechanism for decoding frequency modulation (FM) is not as clear because the FM envelope is flat (Fig. 1). One biological solution is to monitor amplitude fluctuations in frequency-tuned cochlear filters as the instantaneous frequency of the FM sweeps through the passband of these filters, This view postulates an FM-to-AM transduction whereby a change in frequency is transmitted as a change in amplitude(13,14). This is an appealing idea because, if such transduction occurs early in the auditory pathway, it provides a neurally economical solution to how the auditory system encodes these important sounds. Here we illustrate that an FM and AM sound must be transformed into a common neural code in the brain stem. Observers can accurately determine if the phase of an FM presented to one ear is leading or lagging, by only a fraction of a millisecond, the phase of an AM presented to the other ear. A single intracranial image is perceived, the spatial position of which is a function of this phase difference.	UNIV CALIF BERKELEY,DEPT PSYCHOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	SABERI, K (corresponding author), UNIV FLORIDA,DEPT PSYCHOL,CTR HEARING RES,GAINESVILLE,FL 32611, USA.		Saberi, Kourosh/GXG-0944-2022					BAILEY WJ, 1993, J INSECT BEHAV, V6, P141, DOI 10.1007/BF01051500; BRILLET C, 1991, Bioacoustics, V3, P33; CARLSON C R, 1980, Investigative Ophthalmology and Visual Science, P165; CARR CE, 1990, J NEUROSCI, V10, P3227; COSCIA E M, 1991, Bioacoustics, V3, P275; DEAR SP, 1993, NATURE, V364, P620, DOI 10.1038/364620a0; HENNING GB, 1975, VISION RES, V15, P887, DOI 10.1016/0042-6989(75)90228-X; HENNING GB, 1980, J ACOUST SOC AM, V68, P446, DOI 10.1121/1.384756; HUBER F, 1985, SCI AM, V253, P60, DOI 10.1038/scientificamerican1285-60; JAMAR JHT, 1984, VISION RES, V24, P243, DOI 10.1016/0042-6989(84)90126-3; JAVEL E, 1980, J ACOUST SOC AM, V68, P133, DOI 10.1121/1.384639; KLUMP GM, 1992, ADV BIOSCI, V83, P353; KUWADA S, 1979, SCIENCE, V206, P586, DOI 10.1126/science.493964; Rayleigh,, 1907, PHILOS MAG, V13, P214, DOI 10.1080/14786440709463595; MASATAKA N, 1983, Primates, V24, P40, DOI 10.1007/BF02381452; MENDELSON JR, 1985, BRAIN RES, V327, P331, DOI 10.1016/0006-8993(85)91530-6; RAYLEIGH, 1976, NATURE, V14, P32; REES A, 1983, HEARING RES, V10, P301, DOI 10.1016/0378-5955(83)90095-3; ROBISSON P, 1993, ETHOLOGY, V94, P279; RYAN MJ, 1988, SCIENCE, V240, P1786, DOI 10.1126/science.240.4860.1786; Schreiner CE, 1988, AUDITORY FUNCTION, P337; SHU ZJ, 1993, NATURE, V364, P721, DOI 10.1038/364721a0; SIMMONS JA, 1979, SCIENCE, V203, P16, DOI 10.1126/science.758674; SMITH RL, 1980, HEARING RES, V2, P123, DOI 10.1016/0378-5955(80)90034-9; WHITFIEL.IC, 1965, J NEUROPHYSIOL, V28, P655, DOI 10.1152/jn.1965.28.4.655; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465; ZHOU YX, 1993, SCIENCE, V261, P98, DOI 10.1126/science.8316862; Zwicker E, 1952, ACUSTICA          S3, V2, P125	28	78	78	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					537	539		10.1038/374537a0	http://dx.doi.org/10.1038/374537a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700378				2022-12-01	WOS:A1995QR06900050
J	SCHWARTZ, RS				SCHWARTZ, RS			MOLECULAR MEDICINE - JUMPING GENES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Keller E.F., 1984, FEELING ORGANISM 10; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0	3	9	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					941	944		10.1056/NEJM199504063321408	http://dx.doi.org/10.1056/NEJM199504063321408			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877653				2022-12-01	WOS:A1995QP89300008
J	SHEETS, MD; WU, M; WICKENS, M				SHEETS, MD; WU, M; WICKENS, M			POLYADENYLATION OF C-MOS MESSENGER-RNA AS A CONTROL POINT IN XENOPUS MEIOTIC MATURATION	NATURE			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; UNWINDING ACTIVITY; OOCYTE MATURATION; POLY(A) ADDITION; ANTISENSE RNA; CELL-CYCLE; INVITRO	c-mos protein, encoded by a proto-oncogene, is essential for the meiotic maturation of frog oocytes. Polyadenylation of c-mos messenger RNA is shown here to be a pivotal regulatory step in meiotic maturation. Maturation is prevented by selective amputation of polyadenylation signals from c-mos mRNA. Injection of a prosthetic RNA, which restores c-mos polyadenylation signals by base pairing to the amputated mRNA, rescues maturation and can stimulate translation in trans. Prosthetic RNAs may provide a general strategy by which to alter patterns of mRNA expression in vivo.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Berkeley								AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; Bachvarova R, 1985, Dev Biol (N Y 1985), V1, P453; BALLANTYNE S, IN PRESS RNA; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass Brenda L., 1992, Seminars in Developmental Biology, V3, P425; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; Maller J L, 1985, Dev Biol (N Y 1985), V1, P289; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V333, P519; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SMITH RC, 1990, DEVELOPMENT, V110, P769; STANDART N, 1994, BIOCHIMIE, V78, P867; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; VANDEWOUDE GF, 1994, NATURE, V370, P20, DOI 10.1038/370020a0; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1993, NATURE, V363, P305, DOI 10.1038/363305a0; WICKENS M, 1992, SEM DEV BIOL, V3, P399; Wickens Marvin, 1992, Seminars in Developmental Biology, V3, P363; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	36	202	203	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					511	516		10.1038/374511a0	http://dx.doi.org/10.1038/374511a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700377				2022-12-01	WOS:A1995QR06900042
J	SINGH, P; COE, J; HONG, WJ				SINGH, P; COE, J; HONG, WJ			A ROLE FOR RETINOBLASTOMA PROTEIN IN POTENTIATING TRANSCRIPTIONAL ACTIVATION BY THE GLUCOCORTICOID RECEPTOR	NATURE			English	Article							GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; ADENOVIRUS E1A; LARGE-T; PHOSPHORYLATION; TRANSFORMATION; EXPRESSION; GROWTH; FAMILY	THE Saccharomyces cerevisiae SNF2/SWI2 protein is essential for the regulated expression of a variety of genes(1,2). A human SW12/SNF2 homologue, hBrm, is a positive participant in glucocorticoid-receptor-mediated transcription(3), but its mechanism of action is not known. The retinoblastoma protein, RB, has also been shown to stimulate the transcription of several genes(4-10), although the target for RB has not been identified in any of these transcriptional events. Here we show that RB upregulates glucocorticoid-receptor-mediated transcription. The effect of either RB or hBrm is dependent on the presence of the other. Furthermore, we demonstrate that RB and hBrm interact with one another in vitro and in vivo. These results highlight a new role for RB, which is to interact with hBrm in order to potentiate glucocorticoid-receptor-activated transcription.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			HONG, Wanjin/E-9927-2010					BOCCO JL, 1993, ONCOGENE, V8, P2977; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; HARPER JW, 1993, CELL, V75, P805; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LU YM, 1994, ONCOGENE, V9, P1015; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SCHEFFNER M, 1989, P NATL ACAD SCI USA, V88, P5523; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	26	169	171	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					562	565		10.1038/374562a0	http://dx.doi.org/10.1038/374562a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700385				2022-12-01	WOS:A1995QR06900058
J	STAMPF, DR; FELDER, CE; SUSSMAN, JL				STAMPF, DR; FELDER, CE; SUSSMAN, JL			PDBBROWSE - A GRAPHICS INTERFACE TO THE BROOKHAVEN PROTEIN DATA-BANK	NATURE			English	Article									WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	STAMPF, DR (corresponding author), BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973, USA.			Sussman, Joel/0000-0003-0306-3878				BARTON GJ, 1994, TRENDS BIOCHEM SCI, V19, P554, DOI 10.1016/0968-0004(94)90060-4; Ousterhout J. K., 1994, TCL TK TOOLKIT; PEITSCH MC, 1995, TRENDS BIOCHEM SCI, V20, P82, DOI 10.1016/S0968-0004(00)88963-X; SCHATZ BR, 1994, SCIENCE, V265, P895, DOI 10.1126/science.265.5174.895; SCHWARTZ RL, 1992, PROGRAMMING PERL; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899	6	27	28	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					572	574		10.1038/374572a0	http://dx.doi.org/10.1038/374572a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700388				2022-12-01	WOS:A1995QR06900061
J	TECOTT, LH; SUN, LM; AKANA, SF; STRACK, AM; LOWENSTEIN, DH; DALLMAN, MF; JULIUS, D				TECOTT, LH; SUN, LM; AKANA, SF; STRACK, AM; LOWENSTEIN, DH; DALLMAN, MF; JULIUS, D			EATING DISORDER AND EPILEPSY IN MICE LACKING 5-HT2C SEROTONIN RECEPTORS	NATURE			English	Article							MESSENGER-RNA; NERVOUS-SYSTEM; RAT-BRAIN	SEROTONIN (5-hydroxytryptamine, 5-HT) is a monoaminergic neurotransmitter that is believed to modulate numerous sensory, motor and behavioural processes in the mammalian nervous system(1-3). These diverse responses are elicited through the activation of a large family of receptor subtypes(4). The complexity of this signalling system and the paucity of selective drugs have made it difficult to define specific roles for 5-HT receptor subtypes, or to determine bow serotonergic drugs modulate mood and behaviour. To address these issues, we have generated mutant mice lacking functional 5-HT2C receptors (previously termed 5-HT1C), prominent G-protein-coupled receptors that are widely expressed throughout the brain and spinal cord and which have been proposed to mediate numerous central nervous system (CNS) actions of serotonin(3.5-6). Here we show that 5-HT2C receptor-deficient mice are overweight as a result of abnormal control of feeding behaviour, establishing a role for this receptor in the serotonergic control of appetite. Mutant animals are also prone to spontaneous death from seizures, suggesting that 5-HT2C receptors mediate tonic inhibition of neuronal network excitability.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BLUNDELL JE, 1992, AM J CLIN NUTR, V55, P155, DOI 10.1093/ajcn/55.1.155s; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; DAILEY JW, 1987, FASEB J, V46, P706; ENGEL J, 1989, SEIZURES EPILEPSY; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; HIMMSHAGEN J, 1991, FRONT NEUROENDOCRIN, V12, P38; HOFFMAN BJ, 1989, FEBS LETT, V247, P453, DOI 10.1016/0014-5793(89)81390-0; JACOBS BL, 1984, HALLUCINOGENS NEUROC, P183; JOBE PC, 1973, LIFE SCI, V13, P1, DOI 10.1016/0024-3205(73)90271-3; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KENNETT GA, 1991, BRIT J PHARMACOL, V103, P2016, DOI 10.1111/j.1476-5381.1991.tb12369.x; KILIAN M, 1973, NEUROPHARMACOLOGY, V12, P681, DOI 10.1016/0028-3908(73)90121-4; KITCHENER SJ, 1994, PSYCHOPHARMACOLOGY, V113, P369, DOI 10.1007/BF02245211; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Milatovich Athena, 1992, Human Molecular Genetics, V1, P681, DOI 10.1093/hmg/1.9.681; MOLINEAUX SM, 1989, P NATL ACAD SCI USA, V86, P6793, DOI 10.1073/pnas.86.17.6793; ORLOFF MJ, 1949, P SOC EXP BIOL MED, V70, P254; PARKINSON WL, 1990, AM J PHYSIOL, V259, pR829, DOI 10.1152/ajpregu.1990.259.4.R829; POMPEIANO M, 1994, MOL BRAIN RES, V23, P163, DOI 10.1016/0169-328X(94)90223-2; SAMANIN R, 1979, N-S ARCH PHARMACOL, V308, P159, DOI 10.1007/BF00499059; SLEIGHT AJ, 1991, SEROTONIN RECEPTOR S, P211; SPARKS DL, 1985, PHARMACOL BIOCHEM BE, V23, P753, DOI 10.1016/0091-3057(85)90067-X; STRACK AM, 1995, AM J PHYSIOL-REG I, V268, pR183, DOI 10.1152/ajpregu.1995.268.1.R183; Tecott L H, 1993, Curr Opin Neurobiol, V3, P310, DOI 10.1016/0959-4388(93)90122-F; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; THOMAS T, 1988, DEV BIOL, V128, P415, DOI 10.1016/0012-1606(88)90303-X; Wilkinson LO, 1991, SEROTONIN RECEPTOR S, P147; WURTMAN J, 1993, NEUROPSYCHOPHARMACOL, V9, P201, DOI 10.1038/npp.1993.56; YU L, 1991, MOL BRAIN RES, V11, P143, DOI 10.1016/0169-328X(91)90116-F	30	1061	1125	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	1995	374	6522					542	546		10.1038/374542a0	http://dx.doi.org/10.1038/374542a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700379				2022-12-01	WOS:A1995QR06900052
J	TJOELKER, LW; WILDER, C; EBERHARDT, C; STAFFORINI, DM; DIETSCH, G; SCHIMPF, B; HOOPER, S; LETRONG, H; COUSENS, LS; ZIMMERMAN, GA; YAMADA, Y; MCINTYRE, TM; PRESCOTT, SM; GRAY, PW				TJOELKER, LW; WILDER, C; EBERHARDT, C; STAFFORINI, DM; DIETSCH, G; SCHIMPF, B; HOOPER, S; LETRONG, H; COUSENS, LS; ZIMMERMAN, GA; YAMADA, Y; MCINTYRE, TM; PRESCOTT, SM; GRAY, PW			ANTIINFLAMMATORY PROPERTIES OF A PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE	NATURE			English	Article							PAF ACETYLHYDROLASE; PLASMA; CELLS; PHOSPHOLIPIDS; SECRETE; RELEASE	PLATELET-ACTIVATING factor (PAF) is a potent pro-inflammatory phospholipid that activates cells involved in inflammation(1,2). The biological activity of PAF depends on its structural features, namely an ether linkage at the sn-1 position and an acetate group at the sn-2 position. The actions of PAF are abolished by hydrolysis of the acetyl residue, a reaction catalysed by PAF acetylhydrolase. There are at least two forms of this enzyme-one intracellular and another that circulates in plasma and is likely to regulate inflammation. Here we report the molecular cloning and characterization of the human plasma PAF acetylhydrolase. The unique sequence contains a Gly-Xaa-Ser-Xaa-Gly motif commonly found in lipases. Recombinant PAF acetylhydrolase has the substrate specificity and lipoprotein association of the native enzyme, and blocks inflammation in vivo: it markedly decreases vascular leakage in pleurisy and paw oedema, suggesting that PAF acetylhydrolase might be a useful therapy for severe acute inflammation.	UNIV UTAH,ECCLES INST HUMAN GENET,PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,INST CARDIOVASC RES & TRAINING,SALT LAKE CITY,UT 84112; ICOS CORP,BOTHELL,WA 98021	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Icos Corporation								BLANK ML, 1981, J BIOL CHEM, V256, P175; CHAPUS C, 1988, BIOCHIMIE, V70, P1223, DOI 10.1016/0300-9084(88)90188-5; CYGLER M, 1993, PROTEIN SCI, V2, P366; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HENRIQUES MGMO, 1992, BRIT J PHARMACOL, V106, P579, DOI 10.1111/j.1476-5381.1992.tb14378.x; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; MAKI N, 1988, P NATL ACAD SCI USA, V85, P728, DOI 10.1073/pnas.85.3.728; MIOZZARI GF, 1978, J BACTERIOL, V133, P1457, DOI 10.1128/JB.133.3.1457-1466.1978; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; PATEL KD, 1992, J BIOL CHEM, V267, P15168; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; VENABLE ME, 1993, J LIPID RES, V34, P691; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YOSHIDA JI, 1986, J PHARM PHARMACOL, V38, P878, DOI 10.1111/j.2042-7158.1986.tb03375.x; ZIMMERMAN GA, 1992, INFLAMMATION BASIC P, V2, P149	27	447	482	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					549	553		10.1038/374549a0	http://dx.doi.org/10.1038/374549a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700381				2022-12-01	WOS:A1995QR06900054
J	HAMILTON, VH; RACICOT, FE; ZOWALL, H; COUPAL, L; GROVER, SA				HAMILTON, VH; RACICOT, FE; ZOWALL, H; COUPAL, L; GROVER, SA			THE COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITORS TO PREVENT CORONARY HEART-DISEASE - ESTIMATING THE BENEFITS OF INCREASING HDL-C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH BLOOD CHOLESTEROL; STAGE RENAL-DISEASE; HYPERCHOLESTEROLEMIA; MANAGEMENT; LEVEL; CARE; RISK	Objective.-To evaluate the lifetime cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors for treatment of high blood cholesterol levels. Design.-We added cost data to a validated coronary heart disease (CHD) prevention computer model that estimates the benefits of lifelong risk factor modification. The updated model takes into account the costs of cholesterol reduction, the savings in CHD health care costs attributable to intervention, the additional non-CHD costs resulting from patients' living longer, and the beneficial effects of reducing CHD risk by reducing total cholesterol and increasing high-density lipoprotein cholesterol (HDL-C). Patients.-Men and women aged 30 to 70 years who were free of CHD, had total cholesterol levels equal to the 90th percentile of the US distribution in their age and sex group, had HDL-C levels equal to the mean of the US distribution in their age and sex group, and were either with or without additional CHD risk factors. Intervention.-Use of 20 mg of lovastatin per day, which on average reduces total serum cholesterol by 17% and increases HDL-C by 7%. Main Outcome Measures.-Cost per year of life saved after discounting benefits and costs by 5% annually. Results.-The increase in HDL-C associated with lovastatin lowered cost-effectiveness ratios by approximately 40%, such that the treatment of hypercholesterolemia was relatively cost-effective for men (as low as $20 882 per year of life saved at age 50 years) and women ($36 627 per year of life saved at age 60 years) with additional risk factors. Non-CHD costs resulting from longer life expectancy after intervention added at most 23% to the cost-effectiveness ratios for patients who began treatment at age 70 years, and as little as 3% for patients at age 30 years. Conclusion.-The cost-effectiveness of HMG-CoA reductase inhibitors varied widely by age and sex and was sensitive to the presence of non-lipid CHD risk factors. The additional non-CHD costs due to increased life expectancy may be significant for the elderly, Accounting for the drug effects of raising HDL-C levels increased the proportion of the population for which medication treatment was relatively cost-effective.	MONTREAL GEN HOSP,CTR ANAL COST EFFECT CARE,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,CTR CARDIOVASC RICK ASSESSMENT,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT ECON,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University			Racicot, François-Éric/O-3079-2019	Coupal, Louis/0000-0003-0828-9665				BARER ML, 1987, SOC SCI MED, V24, P851, DOI 10.1016/0277-9536(87)90186-9; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Gorecki P. K., 1992, CONTROLLING DRUG EXP; GREGOR RD, 1990, NOVA SCOTIA MED J, V69, P146; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; GROVER SA, 1994, DRUG SAFETY, V10, P301, DOI 10.2165/00002018-199410040-00004; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; KANNEL WB, 1988, NIH882969 NAT HEART; KANNEL WB, 1987, US DHEW NIH872284 PU; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MIELE NF, 1992, JAMA-J AM MED ASSOC, V267, P507, DOI 10.1001/jama.1992.03480040055017; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; Russell LB., 1986, IS PREVENTION BETTER; SCHULMAN KA, 1990, JAMA-J AM MED ASSOC, V264, P3025, DOI 10.1001/jama.264.23.3025; 1992, HLTH REP, V4, P8; 1989, MANUEL MED OMNIPRACT; 1989, HLTH REP S, V1; 1989, SCHEDULE BENEFITS PH; 1991, STATISTIQUES ANN, P77; 1981, 82538 STAT CAN CAT; [No title captured]; 1991, HLTH REP S5, V3, P32; 1992, HLTH REP, V4, P339; 1993, VITAL HLTH STAT 242, V11; 1989, 84532 STAT CAN HLTH; 1991, HLTH REP, V3, P229	40	80	80	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1032	1038		10.1001/jama.273.13.1032	http://dx.doi.org/10.1001/jama.273.13.1032			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897787				2022-12-01	WOS:A1995QP89000034
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSAL TO REQUIRE EVIDENCE OF EFFECTIVENESS OF SPERMICIDES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-01	WOS:A1995QP89000008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR ADVANCED PANCREATIC-CANCER AUTHORIZED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-01	WOS:A1995QP89000009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MONOCLONAL-ANTIBODY LICENSED FOR USE IN ANGIOPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,560 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-01	WOS:A1995QP89000007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR AIDS-RELATED WASTING AUTHORIZED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-01	WOS:A1995QP89000006
J	WRIGHT, SW; EDWARDS, KM; DECKER, MD; ZELDIN, MH				WRIGHT, SW; EDWARDS, KM; DECKER, MD; ZELDIN, MH			PERTUSSIS INFECTION IN ADULTS WITH PERSISTENT COUGH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							OUTBREAK; DIAGNOSIS; FACILITY	Objective.-To determine the prevalence of Bordetella pertussis infection in adult patients with persistent cough. Design.-Prospective case series. Setting.-Urban university hospital emergency department. Patients.-Convenience sample of 75 patients aged 18 years or older with a cough lasting 2 weeks or longer. Serum specimens from 67 patients without respiratory complaints were used to develop reference values. Interventions.-In patients with cough, nasopharyngeal culture and direct fluorescent antibody testing for B pertussis were performed and serum samples were obtained at the first visit and 1 month later. Serum specimens were assayed for antibody to pertussis toxin (PT) and filamentous hemagglutinin (FHA). Main Outcome Measures.-A subject with one or more of the following was defined as having a pertussis infection: a positive B pertussis culture result, a fourfold change in PT or FHA titer, and/or a single PT or FHA titer at least 2 SDs greater than the geometric mean of the control group. Results.-No subject tested culture positive for B pertussis. Sixteen (21%) (95% confidence interval [CI], 13% to 32%) of 75 subjects met the serologic criteria for pertussis infection; for 13 (81%; 95% CI, 54% to 96%) of the 16, the criteria were met by the initial serum specimen. In contrast, the geometric mean levels of antibody to PT and FHA for the remaining 59 subjects with cough did not differ from those of the control group. Clinical symptoms and the lymphocyte count did not differentiate patients with pertussis from those without the disease. Conclusion.-Pertussis is a common cause of persistent cough in adults and should be considered in the differential diagnosis. Clinical symptoms, pertussis culture, direct fluorescent antibody testing, and lymphocytosis are of limited value in making the diagnosis.	VANDERBILT UNIV,MED CTR,DEPT PEDIAT,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT PREVENT MED,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT MED,DIV INFECT DIS,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University	WRIGHT, SW (corresponding author), VANDERBILT UNIV,MED CTR,DEPT EMERGENCY MED,703 OXFORD HOUSE,NASHVILLE,TN 37232, USA.			Decker, Michael/0000-0003-1008-7472	PHS HHS [N0I-M-02645] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADDISS DG, 1991, J INFECT DIS, V164, P704, DOI 10.1093/infdis/164.4.704; BRAMAN SS, 1985, PRIMARY CARE, V12, P217; CHERRY JD, 1989, WESTERN J MED, V150, P319; CHRISTIE CDC, 1994, NEW ENGL J MED, V331, P16, DOI 10.1056/NEJM199407073310104; CROMER BA, 1993, AM J DIS CHILD, V147, P575, DOI 10.1001/archpedi.1993.02160290081031; EDWARDS KM, 1993, JAMA-J AM MED ASSOC, V269, P53, DOI 10.1001/jama.269.1.53; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; HE QS, 1994, J PEDIATR-US, V124, P421, DOI 10.1016/S0022-3476(94)70365-5; HERWALDT LA, 1993, JAMA-J AM MED ASSOC, V269, P93, DOI 10.1001/jama.269.1.93; HERWALDT LA, 1991, ARCH INTERN MED, V109, P1510; LINNEMANN CC, 1977, ANNU REV MED, V28, P179, DOI 10.1146/annurev.me.28.020177.001143; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; MERTSOLA J, 1983, J PEDIATR-US, V103, P359, DOI 10.1016/S0022-3476(83)80403-X; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; PATRIARCA PA, 1988, AM J PUBLIC HEALTH, V78, P833, DOI 10.2105/AJPH.78.7.833; ROBERTSON PW, 1987, MED J AUSTRALIA, V147, P522; STEKETEE RW, 1988, J INFECT DIS, V157, P441, DOI 10.1093/infdis/157.3.441; STEKETEE RW, 1988, J INFECT DIS, V157, P434, DOI 10.1093/infdis/157.3.434; 1994, MMWR-MORBID MORTAL W, V42, P959; 1994, MMWR-MORBID MORTAL W, V42, P952	23	194	207	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1044	1046		10.1001/jama.273.13.1044	http://dx.doi.org/10.1001/jama.273.13.1044			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897789				2022-12-01	WOS:A1995QP89000036
J	AGUNDEZ, JAG; LEDESMA, MC; BENITEZ, J; LADERO, JM; RODRIGUEZLESCURE, A; DIAZRUBIO, E; DIAZRUBIO, M				AGUNDEZ, JAG; LEDESMA, MC; BENITEZ, J; LADERO, JM; RODRIGUEZLESCURE, A; DIAZRUBIO, E; DIAZRUBIO, M			CYP2D6 GENES AND RISK OF LIVER-CANCER	LANCET			English	Note							DEBRISOQUINE; AMPLIFICATION; PHENOTYPE	We have studied by use of PCR and Xbal and EcoRI restriction-fragment-length polymorphism whether mutations at the polymorphic CYP2D6 (debrisoquine hydroxylase) gene locus are associated with liver cancer. The frequency of CYP2D6 genes containing inactivating mutations was lower among 75 liver cancer patients than 200 healthy controls, and 40 cirrhotic subjects that did not develop liver cancer (frequency for carriers of two or more functional genes was 95% vs 74% vs 78%, respectively). Subjects who were homozygous for functional CYP2D6 genes appear to be at higher risk of developing primary liver cancer (odds ratio 6.40 [95% CI] 2.4-17.5).	UNIV EXTREMADURA,SCH MED,DEPT PHARMACOL,E-06071 BADAJOZ,SPAIN; UNIV COMPLUTENSE MADRID,SAN CARLOS UNIV HOSP,SERV ONCOL,MADRID,SPAIN; UNIV COMPLUTENSE MADRID,SAN CARLOS UNIV HOSP,SERV GASTROENTEROL,MADRID,SPAIN	Universidad de Extremadura; Complutense University of Madrid; Hospital Clinico San Carlos; Complutense University of Madrid; Hospital Clinico San Carlos			Rodríguez-Lescure, Álvaro/AAB-7039-2019; Agúndez, José A. G./A-5503-2008; Diaz-Rubio, Manuel/B-5359-2010; Ledesma, M  Carmen/K-1689-2017	Rodríguez-Lescure, Álvaro/0000-0002-6823-5290; Agúndez, José A. G./0000-0001-6895-9160; Ledesma, M  Carmen/0000-0001-5546-0598; Diaz-Rubio, Eduardo/0000-0003-2792-5348				AGUNDEZ JAG, 1994, CLIN PHARMACOL THER, V55, P10, DOI 10.1038/clpt.1994.3; AGUNDEZ JAG, IN PRESS CLIN PHARM; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P4790, DOI 10.1073/pnas.87.12.4790; BROLY F, 1991, DNA CELL BIOL, V10, P545, DOI 10.1089/dna.1991.10.545; CAPORASO N, 1991, PHARMACOGENETICS, V1, P4, DOI 10.1097/00008571-199110000-00003; CRESPI CL, 1991, CARCINOGENESIS, V12, P1197, DOI 10.1093/carcin/12.7.1197; HEIM M, 1990, LANCET, V336, P529, DOI 10.1016/0140-6736(90)92086-W; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; TYNDALE R, 1991, PHARMACOGENETICS, V1, P26, DOI 10.1097/00008571-199110000-00005; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035	10	60	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					830	831		10.1016/S0140-6736(95)92965-7	http://dx.doi.org/10.1016/S0140-6736(95)92965-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898230				2022-12-01	WOS:A1995QQ19500010
J	ALDERDICE, F; RENFREW, M; MARCHANT, S; ASHURST, H; HUGHES, P; BERRIDGE, G; GARCIA, J				ALDERDICE, F; RENFREW, M; MARCHANT, S; ASHURST, H; HUGHES, P; BERRIDGE, G; GARCIA, J			LABOR AND BIRTH IN WATER IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford			Renfrew, Mary/A-2440-2010; Alderdice, Fiona A/F-5748-2010	Alderdice, Fiona/0000-0003-2404-5644; Renfrew, Mary/0000-0003-2905-403X				MCCANDLISH R, 1993, BIRTH-ISS PERINAT C, V20, P79, DOI 10.1111/j.1523-536X.1993.tb00421.x; 1992, 2ND HOUS COMM HLTH C	2	29	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					837	837		10.1136/bmj.310.6983.837	http://dx.doi.org/10.1136/bmj.310.6983.837			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QQ857	7711622	Green Published			2022-12-01	WOS:A1995QQ85700020
J	COLDITZ, GA; WILLETT, WC; ROTNITZKY, A; MANSON, JE				COLDITZ, GA; WILLETT, WC; ROTNITZKY, A; MANSON, JE			WEIGHT-GAIN AS A RISK FACTOR FOR CLINICAL DIABETES-MELLITUS IN WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						WEIGHT GAIN; DIABETES MELLITUS; BODY MASS INDEX; AGE FACTORS; RISK FACTORS	GUIDELINES; AMERICANS; MASS	Objective: To examine the relation between adult weight change and the risk for clinical diabetes mellitus among middle-aged women. Design: Prospective cohort study with follow-up from 1976 to 1990. Setting: if U.S. states. Participants: 114 281 female registered nurses aged 30 to 55 years who did not have diagnosed diabetes mellitus, coronary heart disease, stroke, or cancer in 1976. Outcome Measures: Non-insulin-dependent diabetes mellitus. Results: 2204 cases of diabetes were diagnosed during 1.49 million person-years of follow-up. After adjustment for age, body mass index was the dominant predictor of risk for diabetes mellitus. Risk increased with greater body mass index, and even women with average weight (body mass index, 24.0 kg/m(2)) had an elevated risk. Compared with women with stable weight (those who gained or lost less than 5 kg between age 18 years and 1976) and after adjustment for age and body mass index at age 18 years, the relative risk for diabetes mellitus among women who had a weight gain of 5.0 to 7.9 kg was 1.9 (95% CI, 1.5 to 2.3). The corresponding relative risk for women who gained 8.0 to 10.9 kg was 2.7 (CI, 2.1 to 3.3). In contrast, women who lost more than 5.0 kg reduced their risk for diabetes mellitus by 50% or more. These results were independent of family history of diabetes. Conclusion: The excess risk for diabetes with even modest and typical adult weight gain is substantial. These findings support the importance of maintaining a constant body weight throughout adult life and suggest that the 1990 U.S. Department of Agriculture guidelines that allow a substantial weight gain after 35 years of age are misleading.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR & EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	COLDITZ, GA (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40935] Funding Source: Medline; NIDDK NIH HHS [DK36798, P30-DK-46200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK036798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BERGER M, 1975, RECENT ADV OBESITY R, P128; BRAY GA, 1992, AM J CLIN NUTR, V55, P481, DOI 10.1093/ajcn/55.2.481a; BRAY GA, 1992, INT J OBESITY, V16, pS13; CALLAWAY CW, 1991, AM J CLIN NUTR, V54, P171, DOI 10.1093/ajcn/54.1.171a; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; HARLAN WR, 1988, AM J EPIDEMIOL, V128, P1065; HARRIS M, 1979, DIABETES, V28, P1039; HOLBROOK TL, 1989, INT J OBESITY, V13, P723; MANSON JE, 1994, AM J EPIDEMIOL, V139, pS46; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROTH A, 1977, PHS HRP0900603, P182; SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033, DOI 10.1093/ajcn/55.6.1033; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT W, 1994, AM J EPIDEMIOL, V139, pS25; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102; 1990, REPORT CRUDELINES AD; 1987, DHHS PHS871688 US DE	20	1303	1358	2	63	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					481	486		10.7326/0003-4819-122-7-199504010-00001	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872581				2022-12-01	WOS:A1995QP00800001
J	EVANS, JM; OFALLON, WM; HUNDER, GG				EVANS, JM; OFALLON, WM; HUNDER, GG			INCREASED INCIDENCE OF AORTIC-ANEURYSM AND DISSECTION IN GIANT-CELL (TEMPORAL) ARTERITIS - A POPULATION-BASED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							BIOPSY; COUNTY	Objective: To determine the frequency of aneurysm and dissection of the aorta in patients with giant cell arteritis and to assess the effects of these events on these patients. Design: Population-based cohort study. Setting: A multispecialty and a primary care clinic in southern Minnesota. Patients: 96 residents of Olmsted County, Minnesota, who developed giant cell arteritis between 1950 and 1985, The presence of aortic aneurysm, dissection, or both was confirmed using computed tomography, ultrasonography, angiography, or autopsy. Results: 11 of the 96 patients were found to have thoracic aortic aneurysms. In 2 of these patients, the aneurysms were detected when giant cell arteritis was diagnosed. In the remaining 9 patients, the aneurysms occurred a median of 5.8 years after giant cell arteritis was diagnosed. Six of the 11 died suddenly of acute thoracic aortic dissection. Five patients who did not have thoracic aortic aneurysms developed isolated abdominal aortic aneurysms a median of 2.5 years after giant cell arteritis was diagnosed. The incidence of thoracic aortic aneurysm in patients with giant cell arteritis was 999 per 100 000 person-years; the incidence of abdominal aortic aneurysm in these patients was 555 per 100 000 person-years. Compared with all persons of the same age and sex living in Olmsted County, patients with giant cell arteritis were 17.3 times (95% CI, 7.9 to 33.0) more likely to develop thoracic aortic aneurysm and 2.4 times (CI, 0.8 to 5.5) more likely to develop isolated abdominal aortic aneurysm. Conclusions: Giant cell arteritis is associated with a markedly increased risk for the development of aortic aneurysm, which is often a late complication and may cause death.	MAYO CLIN & MAYO FDN, DEPT MED, DIV RHEUMATOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, DIV COMMUNITY MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic								AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; ANIA BJ, 1994, MAYO CLIN PROC, V69, P730, DOI 10.1016/S0025-6196(12)61089-1; BICKERSTAFF LK, 1982, SURGERY, V92, P1103; BOESEN P, 1987, ARTHRITIS RHEUM, V30, P294, DOI 10.1002/art.1780300308; CALAMIA KT, 1981, ARTHRITIS RHEUM, V24, P1414, DOI 10.1002/art.1780241113; CASELLI RJ, 1988, NEUROLOGY, V38, P352, DOI 10.1212/WNL.38.3.352; DEBAKEY ME, 1965, J THORAC CARDIOV SUR, V49, P130, DOI 10.1016/S0022-5223(19)33323-9; EVANS JM, 1994, ARTHRITIS RHEUM-US, V37, P1539, DOI 10.1002/art.1780371020; FABER LP, 1991, AM CANCER SOC TXB CL, P194; HEALEY LA, 1980, ARTHRITIS RHEUM, V23, P641, DOI 10.1002/art.1780230605; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; KLEIN RG, 1976, MAYO CLIN PROC, V51, P504; KLEIN RG, 1975, ANN INTERN MED, V83, P806, DOI 10.7326/0003-4819-83-6-806; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MAGAREY FR, 1950, J PATHOL BACTERIOL, V62, P445, DOI 10.1002/path.1700620318; MCMILLAN GC, 1950, ARCH PATHOL, V49, P63; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; NORDBORG E, 1990, J INTERN MED, V227, P233, DOI 10.1111/j.1365-2796.1990.tb00150.x; PONGE T, 1988, J RHEUMATOL, V15, P997; REID JVO, 1957, BRIT HEART J, V19, P206; ROCCELLA EJ, 1986, JAMA-J AM MED ASSOC, V256, P70; SPROUL EE, 1942, NY J MED, V42, P345	23	413	424	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					502	507		10.7326/0003-4819-122-7-199504010-00004	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872584				2022-12-01	WOS:A1995QP00800004
J	GLYNN, RJ; FIELD, TS; ROSNER, B; HEBERT, PR; TAYLOR, JO; HENNEKENS, CH				GLYNN, RJ; FIELD, TS; ROSNER, B; HEBERT, PR; TAYLOR, JO; HENNEKENS, CH			EVIDENCE FOR A POSITIVE LINEAR RELATION BETWEEN BLOOD-PRESSURE AND MORTALITY IN ELDERLY PEOPLE	LANCET			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; HYPERTENSION; RISK; REDUCTION; SURVIVAL	Many studies of blood pressure in the elderly have found higher death rates in groups with the lowest blood pressure than in those with intermediate values. In a large community study, we examined whether these findings are real or artifacts of short follow-up, co-morbidity, or low blood pressure in people near death. In 1982-83, we assessed drug use, medical history, disability, physical function, and blood pressure in 3657 residents of East Boston, Massachusetts, aged 65 and older. We identified all deaths (1709) up to 1992 and followed up survivors for an average of 10.5 (range 9.5-11.0) years. After adjustment for confounding variables (including frailty and disorders such as congestive heart failure and myocardial infarction) and exclusion of deaths within the first 3 years of follow-up, higher systolic pressure predicted linear increases in cardiovascular (p<0.0001) and total (p<0.0007) mortality. Higher diastolic pressure predicted increases in cardiovascular (p=0.006) but not total (p=0.48) mortality. These results differed from those for the first 3 years, during which groups with the lowest systolic and diastolic pressures had the highest death rates. In the long term, lower blood pressure in old age, as in middle age, is associated with better survival. Short-term findings may differ because of associations of co-morbidity and frailty with blood pressure near death. Overall, the findings support recommendations to treat high blood pressure in elderly people.	BRIGHAM & WOMENS HOSP, E BOSTON NEIGHBOURHOOD HLTH CTR, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	GLYNN, RJ (corresponding author), BRIGHAM & WOMENS HOSP, DIV PREVENT MED, BOSTON, MA 02215 USA.				NIA NIH HHS [AG12106, AG02107] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; [Anonymous], 1991, JAMA, V265, P3255; Benfante R, 1992, Ann Epidemiol, V2, P273; BISHOP YM, 1980, DISCRETE MULTIVARIAT, P492; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BULPITT CJ, 1992, J HYPERTENSION S7, V10, P545; COOPE J, 1988, J HUM HYPERTENS, V2, P79; COOPE J, 1987, LANCET, V1, P1380; CORNONIHUNTLEY JC, 1986, NIH862443 PUBL; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; FRY J, 1974, LANCET, V2, P431; GLYNN RJ, 1993, AM J EPIDEMIOL, V138, P365, DOI 10.1093/oxfordjournals.aje.a116869; HARRIS T, 1985, HYPERTENSION, V7, P118, DOI 10.1161/01.HYP.7.1.118; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; HUGHES MD, 1993, BIOMETRICS, V49, P1056, DOI 10.2307/2532247; LANGER RD, 1989, BRIT MED J, V298, P1356, DOI 10.1136/bmj.298.6684.1356; LINDHOLM L, 1986, FAM PRACT, V3, P3, DOI 10.1093/fampra/3.1.3; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; SIEGEL D, 1987, AM J EPIDEMIOL, V126, P385, DOI 10.1093/oxfordjournals.aje.a114670; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; TAYLOR JO, 1991, AM J EPIDEMIOL, V134, P489, DOI 10.1093/oxfordjournals.aje.a116121; 1994, HLTH US 1993; 1978, J CHRON DIS, V31, P651	30	148	150	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	1995	345	8953					825	829		10.1016/S0140-6736(95)92964-9	http://dx.doi.org/10.1016/S0140-6736(95)92964-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898229				2022-12-01	WOS:A1995QQ19500009
J	HARRIS, MA; SULLIVAN, CE				HARRIS, MA; SULLIVAN, CE			SLEEP PATTERN AND SUPPLEMENTARY OXYGEN REQUIREMENTS IN INFANTS WITH CHRONIC NEONATAL LUNG-DISEASE	LANCET			English	Note							AROUSAL RESPONSES	Seven infants with chronic neonatal lung disease and baseline oxygen saturation greater than 90% were studied with overnight polysomnography in their prescribed oxygen environment, and on a second night with 0.25 L/min additional oxygen. All had sleep fragmentation and decreased rapid-eye-movement (REM) sleep, which was reversed after the increased oxygen. Sleep duration (p<0.003), percentage REM sleep (p<0.001), and mean REM sleep period length (p<0.001) were increased, and arousals in REM sleep decreased (p<0.05), with improved oxygenation. We conclude that, in infants with chronic neonatal lung disease, arousal mechanisms minimise oxygen desaturation but induce sleep disruption.	ROYAL ALEXANDRA HOSP CHILDREN,DAVID READ PAEDIAT SLEEP DISORDERS CTR,MATL SIDS COUNCIL,SYDNEY,NSW,AUSTRALIA				Harris, Margaret-Anne/G-9627-2014					COONS S, 1987, SLEEP ITS DISORDERS, P17; ISSA FG, 1987, J APPL PHYSIOL, V62, P1832, DOI 10.1152/jappl.1987.62.5.1832; SCHER MS, 1992, SLEEP, V15, P195, DOI 10.1093/sleep/15.3.195; SELL EJ, 1988, BRONCHOPULMONARY DYS, P403; VOHR BR, 1982, AM J DIS CHILD, V136, P443, DOI 10.1001/archpedi.1982.03970410061015; WARD SLD, 1992, PEDIATRICS, V89, P860; WILLIAMS GR, 1989, AUST PAEDIATR J, V25, P370	7	33	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					831	832		10.1016/S0140-6736(95)92966-5	http://dx.doi.org/10.1016/S0140-6736(95)92966-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898231				2022-12-01	WOS:A1995QQ19500011
J	JADHAV, S				JADHAV, S			THE GHOSTBUSTERS OF PSYCHIATRY	LANCET			English	Editorial Material											JADHAV, S (corresponding author), UCL, DEPT PSYCHIAT, LONDON, ENGLAND.		jadhav, sushrut/B-8249-2009	jadhav, sushrut/0000-0001-5325-8687				BLUE I, 1994, BRIT J PSYCHIAT, V165, P9, DOI 10.1192/bjp.165.1.9; COLEMAN J, 1994, TREATING SURVIVORS S; Good B. J., 1994, MED RATIONALITY EXPE; HALE AS, 1994, BRIT J PSYCHIAT, V165, P386, DOI 10.1192/bjp.165.3.386; JADHAV S, 1994, PSYCHIATR B, V18, P572; Kakar Sudhir., 1982, SHAMANS MYSTICS DOCT; LEWIS IM, 1966, MAN, V1, P307, DOI 10.2307/2796794; LITTLEWOOD R, 1991, LANCET, V337, P1013, DOI 10.1016/0140-6736(91)92668-R; MULHERN S, 1991, PSYCHIAT CLIN N AM, V14, P769; Turner V.W., 1964, MAGIC FAITH HEALING; Vitebsky, 1993, DIALOGUES DEAD DISCU; WEISS MG, 1992, BRIT J PSYCHIAT, V160, P819, DOI 10.1192/bjp.160.6.819	12	7	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 1	1995	345	8953					808	810		10.1016/S0140-6736(95)92959-2	http://dx.doi.org/10.1016/S0140-6736(95)92959-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QQ195	7898225				2022-12-01	WOS:A1995QQ19500004
J	JAVAHERI, S; PARKER, TJ; WEXLER, L; MICHAELS, SE; STANBERRY, E; NISHYAMA, H; ROSELLE, GA				JAVAHERI, S; PARKER, TJ; WEXLER, L; MICHAELS, SE; STANBERRY, E; NISHYAMA, H; ROSELLE, GA			OCCULT SLEEP-DISORDERED BREATHING IN STABLE CONGESTIVE-HEART-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Article						HEART FAILURE, CONGESTIVE; VENTRICULAR FUNCTION, LEFT; SLEEP APNEA SYNDROMES; CHEYNE-STOKES RESPIRATION; OXYHEMOGLOBINS	CHEYNE-STOKES RESPIRATION; APNEA; ABNORMALITIES; VENTILATION; OXYGEN	Objective: To determine the prevalence and effect of sleep-disordered breathing in ambulatory patients with stable, optimally treated congestive heart failure. Design: A prospective, longitudinal study. Setting: Referral sleep laboratory of a Department of Veterans Affairs medical center. Patients: 42 of the 48 eligible patients with stable congestive heart failure and left ventricular systolic dysfunction (left ventricular ejection fraction less than or equal to 45%). Measurements: After an adaptation night, polysomnography and Holter monitoring were done in the sleep laboratory. Arterial blood gases and pH were measured, and cardiac radionuclide ventriculography and pulmonary, renal, and thyroid function tests were done. Results: Patients were divided into two groups. Group I (n = 23) had an hourly rate of apnea and hypopnea (apnea-hypopnea index) of 20 episodes per hour or less; group II (n = 19 [45%; CI, 30% to 60%]) had an index of more than 20 episodes per hour. In group II, the index varied from 26.5 to 82.2 episodes per hour (mean +/- SD, 44 +/- 13 episodes per hour; CI, 38 to 51 episodes per hour). Group II had significantly more arousals (24 +/- 12 compared with 3 +/- 3 in group I) that were directly attributable to episodes of apnea and hypopnea, longer periods of time with an arterial oxyhemoglobin saturation of less than 90% (23% +/- 24% of total sleep time compared with 2% +/- 4%), lower arterial oxyhemoglobin saturation during sleep (74% +/- 13% compared with 87% +/- 4%), lower left ventricular ejection fraction (22% +/- 9% compared with 30% +/- 10%), and a significantly increased number of episodes of nocturnal ventricular arrhythmias. Multiple regression analyses showed that left Ventricular systolic dysfunction was an independent risk factor for sleep apnea in patients with congestive heart failure. Conclusions: The prevalence of severe occult sleep-disordered breathing is high in ambulatory patients with stable, optimally treated chronic congestive heart failure. The breathing episodes are associated with severe nocturnal arterial blood oxyhemoglobin desaturation and excessive arousals. Severe untreated sleep-disordered breathing may adversely affect left ventricular function, resulting in a vicious cycle that could contribute to death in patients with congestive heart failure. Prospective, longitudinal studies on survival are needed.	VET AFFAIRS MED CTR, SERV PHARM, CINCINNATI, OH 45220 USA; UNIV CINCINNATI, COLL MED, CINCINNATI, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	JAVAHERI, S (corresponding author), VET AFFAIRS MED CTR, PULM SECT 111F, SLEEP DISORDERS LAB, 3200 VINE ST, CINCINNATI, OH 45220 USA.							Ancoli-Israel S, 1989, Clin Geriatr Med, V5, P347; [Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1992, SLEEP, V15, P174; BLUMBERG H, 1980, J AUTONOM NERV SYST, V2, P223, DOI 10.1016/0165-1838(80)90013-2; BRADLEY TD, 1992, CLIN CHEST MED, V13, P459; CHERNIACK NS, 1981, NEW ENGL J MED, V305, P325; DARK DS, 1987, CHEST, V91, P833, DOI 10.1378/chest.91.6.833; DOWDELL WT, 1990, AM REV RESPIR DIS, V141, P871, DOI 10.1164/ajrccm/141.4_Pt_1.871; DOWDELL WT, 1992, AM REV RESPIR DIS, V145, P137, DOI 10.1164/ajrccm/145.1.137; FINDLEY LJ, 1985, SOUTH MED J, V78, P11, DOI 10.1097/00007611-198501000-00004; FLEMONS WW, 1994, PRINCIPLES PRACTICE, P824; FLETCHER EC, 1992, HYPERTENSION, V19, P555, DOI 10.1161/01.HYP.19.6.555; FRANCIS GS, 1986, AM J CARDIOL, V57, pB3, DOI 10.1016/0002-9149(86)90991-4; HANLY P, 1993, CHEST, V104, P1079, DOI 10.1378/chest.104.4.1079; HANLY PJ, 1989, ANN INTERN MED, V111, P777, DOI 10.7326/0003-4819-111-10-777; HANLY PJ, 1989, CHEST, V96, P480, DOI 10.1378/chest.96.3.480; Harrison TR, 1934, ARCH INTERN MED, V53, P891, DOI 10.1001/archinte.1934.00160120085009; HARVEY RM, 1971, CHEST, V59, P82, DOI 10.1378/chest.59.1.82; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; JAVAHERI S, 1990, RESP PHYSIOL, V81, P359, DOI 10.1016/0034-5687(90)90116-G; MASSUMI RA, 1968, CHEST, V54, P21; PACKER M, 1985, CIRCULATION, V72, P681, DOI 10.1161/01.CIR.72.4.681; PHILLIPSON EA, 1994, TXB RESP MED, P2301; PICKERING TG, 1978, AM J MED, V65, P575, DOI 10.1016/0002-9343(78)90844-6; REES PJ, 1979, LANCET, V2, P1315; ROSE CE, 1983, AM J PHYSIOL, V245, pH924, DOI 10.1152/ajpheart.1983.245.6.H924; ROTH T, 1994, PRINCIPLES PRACTICE, P40; SKATRUD JB, 1983, J APPL PHYSIOL, V55, P813, DOI 10.1152/jappl.1983.55.3.813; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; YASUMA F, 1989, JPN CIRC J, V53, P1506, DOI 10.1253/jcj.53.1506; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZARET BL, 1992, HEART DISEASE TXB CA, P276; 1988, SAS STAT USERS GUIDE	36	205	230	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					487	492		10.7326/0003-4819-122-7-199504010-00002	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872582				2022-12-01	WOS:A1995QP00800002
J	KUMAR, L				KUMAR, L			SECONDARY LEUKEMIA AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION	LANCET			English	Editorial Material							HODGKINS-DISEASE; LEUKEMIA; THERAPY; DRUG				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI,INDIA.							ARMITAGE J, 1993, P AN M AM SOC CLIN, V12, P363; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; CANNELL PK, 1992, BONE MARROW TRANSPL, V9, P301; CHAN T, 1994, BONE MARROW TRANSPL, V13, P145; CHOPRA R, 1993, BLOOD, V81, P1137; International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993, NEW ENGL J MED, V329, P987; LEVINE EG, 1992, SEMIN ONCOL, V19, P47; MAROLLEAU JP, 1993, J CLIN ONCOL, V11, P590, DOI 10.1200/JCO.1993.11.3.590; MILLER JS, 1994, BLOOD, V83, P3780; SOUTAR RL, 1991, BRIT MED J, V303, P123, DOI 10.1136/bmj.303.6794.123-c; STONE RM, 1994, BLOOD, V83, P3437; TRAWEEK ST, 1993, BLOOD S, V82, P455	12	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					810	810		10.1016/S0140-6736(95)92960-6	http://dx.doi.org/10.1016/S0140-6736(95)92960-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898226				2022-12-01	WOS:A1995QQ19500005
J	LOVEDAY, C; KAYE, S; TENANTFLOWERS, M; SEMPLE, M; AYLIFFE, U; WELLER, IVD; TEDDER, RS				LOVEDAY, C; KAYE, S; TENANTFLOWERS, M; SEMPLE, M; AYLIFFE, U; WELLER, IVD; TEDDER, RS			HIV-1 RNA SERUM-LOAD AND RESISTANT VIRAL GENOTYPES DURING EARLY ZIDOVUDINE THERAPY	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIAL; HIGH-LEVEL RESISTANCE; AIDS-RELATED COMPLEX; REVERSE-TRANSCRIPTASE; PLASMA VIREMIA; DOUBLE-BLIND; TYPE-1; AZT; 3'-AZIDO-3'-DEOXYTHYMIDINE	The response of HIV-1 to initial zidovudine (ZDV) treatment was assessed in 11 patients with severe HIV disease. We quantified serum HIV-1 concentrations and mutations associated with ZDV resistance by culture-independent methods. There was a prompt fall in serum HIV-1 RNA within 1-2 days of treatment with maximum suppression by seven days, which was paralleled by changes in serum p24 antigen (p24 Ag). Serum RNA started to return to pretreatment levels within weeks. The HIV reverse transcriptase (RT) gene in most patients developed mutations associated with drug resistance within months and as early as 25 days on therapy in one patient. The codon changes were not sufficient to explain the early return of serum HIV-1 RNA levels and their patterns continued to evolve after patients stopped taking ZDV. The significance of these findings is discussed in relation to the limited long-term efficacy of ZDV. The dynamic time course of viral load and RT responses to ZDV is of particular importance in short-term interventions such as pregnancy.	UCL, SCH MED, ACAD DEPT GENITOURINARY MED, LONDON, ENGLAND; UCL HOSP, LONDON, ENGLAND; CAMDEN & ISLIMGTON COMMUNITY HLTH SERV TRUSTS, LONDON, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	LOVEDAY, C (corresponding author), UCL, SCH MED, DIV VIROL, LONDON, ENGLAND.		Semple, Malcolm Gracie/A-8790-2008	Semple, Malcolm Gracie/0000-0001-9700-0418; Tedder, Richard/0000-0002-9672-5721	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; BOUCHER CAB, THESIS U AMSTERDAM, P105; BUKRINSKY M, 1993, J VIROL, V67, P6863, DOI 10.1128/JVI.67.11.6863-6865.1993; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOPER DA, 1994, AIDS S4, V3; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KAYE S, 1992, J MED VIROL, V37, P241, DOI 10.1002/jmv.1890370402; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KOZEL MJ, 1993, J INFECT DIS, V167, P526; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LARDER BA, 1994, AIDS S4, V8; LOVEDAY C, 1993, J VIROL METHODS, V41, P181, DOI 10.1016/0166-0934(93)90125-B; LOVEDAY C, 1994, 3RD INT WORKSH HIV D; LOVEDAY C, 1995, 1994 ANN SCI M ASS C; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; RICHMAN DD, 1990, REV INFECT DIS S5, V12, P507; SAAG M, 1991, J INFECT DIS, V165, P72; SCHUUMAN R, 1994, 3RD INT WORKSH HIV D; SELIGMANN M, 1994, LANCET, V343, P871; SEMPLE MG, 1993, J VIROL METHODS, V41, P167, DOI 10.1016/0166-0934(93)90124-A; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006; 1994, LANCET, V344, P207; 1987, MMWR-MORBID M     S1, V36, P1	32	95	95	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 1	1995	345	8953					820	824		10.1016/S0140-6736(95)92963-0	http://dx.doi.org/10.1016/S0140-6736(95)92963-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7534858				2022-12-01	WOS:A1995QQ19500008
J	MEURMAN, JH; RAJASUO, A; MURTOMAA, H; SAVOLAINEN, S				MEURMAN, JH; RAJASUO, A; MURTOMAA, H; SAVOLAINEN, S			RESPIRATORY-TRACT INFECTIONS AND CONCOMITANT PERICORONITIS OF THE WISDOM TEETH	BRITISH MEDICAL JOURNAL			English	Article							3RD MOLARS	Objective-To discover if there is an association between respiratory tract infections and pericoronitis of erupting third molars in young adults. Design-Data from male military conscripts' medical records w ere collected over five years and the incidence of respiratory tract infection before and after acute pericoronitis (191 cases) and before and after standard (722 cases) and operative (741) extractions compared with that in controls (n=703) who had no infections in the third molar regions. Subjects-14 500 male military conscripts aged 20. Setting-Garrisons in Valkeala and Kouvola, Finland. Results-The incidence of respiratory tract infection was significantly higher during the two weeks before acute pericoronitis was diagnosed compared with that in controls. The highest incidence was observed in the three days before pericoronitis (odds ratio 6.8; 95% confidence interval 3.0 to 15.0). The incidence was also increased in the first week after pericoronitis (odds ratio 3.7; 1.6 to 8.4) and three days before (odds ratio 2.6; 0.9 to 7.5) and during the first week after extraction of third molars (odds ratio 2.6; 1.3 to 5.3). Conclusions-Respiratory tract infection may precipitate and occur concomitantly with acute pericoronitis. Third molar surgery for pericoronitis, on the other hand, may trigger respiratory tract infection.	VALKEALA MIL HOSP,VALKEALA,FINLAND; UNIV HELSINKI,INST DENT,HELSINKI,FINLAND; CENT MIL HOSP,HELSINKI,FINLAND	University of Helsinki	MEURMAN, JH (corresponding author), UNIV KUOPIO,FAC DENT,POB 1627,SF-70211 KUOPIO,FINLAND.			Meurman, Jukka/0000-0001-6702-6836				ALMADORI G, 1988, INT J PEDIATR OTORHI, V15, P157, DOI 10.1016/0165-5876(88)90067-5; BEAN LR, 1971, J AM DENT ASSOC, V83, P1074, DOI 10.14219/jada.archive.1971.0439; DEGRE M, 1986, SCAND J INFECT DIS S, V49, P140; DIXON RE, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90363-8; GURALNICK W, 1984, BRIT DENT J, V156, P389, DOI 10.1038/sj.bdj.4805380; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; HURLEN B, 1984, ORAL SURG ORAL MED O, V58, P522, DOI 10.1016/0030-4220(84)90072-0; Kay L W, 1966, Br J Oral Surg, V3, P188; KREKMANOV L, 1986, INT J ORAL MAX SURG, V15, P25, DOI 10.1016/S0300-9785(86)80007-2; LUDWICK WE, 1974, MIL MED, V139, P121; MACGREGOR AJ, 1970, J ORAL SURG, V28, P885; Marsland D W, 1976, J Fam Pract, V3, P25; MOMBELLI A, 1990, J CLIN PERIODONTOL, V17, P48, DOI 10.1111/j.1600-051X.1990.tb01047.x; NITZAN DW, 1985, J ORAL MAXIL SURG, V43, P510, DOI 10.1016/S0278-2391(85)80029-X; PARNELL JL, 1966, NEW ENGL J MED, V274, P979, DOI 10.1056/NEJM196605052741801; PIIRONEN J, 1981, Proceedings of the Finnish Dental Society, V77, P278; RAJASUO A, 1991, MIL MED, V156, P16, DOI 10.1093/milmed/156.1.16; RAJASUO A, 1994, THESIS U HELSINKI; van Cauwenberge P B, 1985, Rhinology, V23, P273; VENTA I, 1993, THESIS U HELSINKI; WADE WG, 1991, ORAL MICROBIOL IMMUN, V6, P310, DOI 10.1111/j.1399-302X.1991.tb00499.x; 1993, ANNUAL REPORTS HLTH; 1977, MANUAL INT STATISTIC, V1	23	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					834	836		10.1136/bmj.310.6983.834	http://dx.doi.org/10.1136/bmj.310.6983.834			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711620	Green Published			2022-12-01	WOS:A1995QQ85700018
J	PETTIFOR, JM; BIKLE, DD; CAVALEROS, M; ZACHEN, D; KAMDAR, MC; ROSS, FP				PETTIFOR, JM; BIKLE, DD; CAVALEROS, M; ZACHEN, D; KAMDAR, MC; ROSS, FP			SERUM LEVELS OF FREE 1,25-DIHYDROXYVITAMIN-D IN VITAMIN-D TOXICITY	ANNALS OF INTERNAL MEDICINE			English	Note							D-BINDING PROTEIN; HYPERVITAMINOSIS-D; ASSAY; METABOLITES	Objective: To determine the serum level of free 1,25-dihydroxyvitamin D [1,25-(OH)(2)D] in patients with vitamin D toxicity and to assess the in vitro effect of differing concentrations of vitamin D metabolites on the free serum levels of 1,25-(OH)(2)D. Design: 1) A case study of patients hospitalized with Vitamin D toxicity after accidentally ingesting a veterinary vitamin D concentrate and 2) an in vitro experiment in which vitamin D metabolites in various concentrations were added to normal serum and their effect was noted on percentage of free 1,25-(OH)(2)D. Patients: 11 patients (age range, 8 to 69 years) were studied 10 to 40 days after hospitalization for hypercalcemia. Measurements: Serum total 25-hydroxyvitamin D (25-OHD) and 1,25-(OH)(2)D levels were measured by radioreceptor assays. The percentage of free 1,25(OH)(2)D was measured by centrifugal ultrafiltration isodialysis and was used to calculate actual free 1,25(OH)(2)D levels. In the in vitro studies, vitamin D metabolites [25-OHD; 24,25-(OH)(2)D; 25,26-(OH)(2)D; and 25-OHD-26,23 lactone] were added to normal serum in concentrations expected to occur with vitamin D toxicity. The percentage of free 1,25-(OH)(2)D was measured by isodialysis. Results: All patients presented with marked hypercalcemia (mean calcium level, 3.99 +/- 0.33 mmol/L). Serum 25-OHD levels ranged from 847 to 1652 nmol/L, and total 1,25-(OH)(2)D levels (mean, 106 +/- 86 pmol/L) were elevated in only three patients. The percentage of free 1,25-(OH)(2)D (mean, 1.023% +/- 0.366%) was elevated in all nine patients in whom it was measured. Actual free 1,25-(OH)(2)D levels (mean, 856 +/- 600 fmol/L) were elevated in six of the nine patients. Total 1,25(OH)(2)D levels were correlated with 25-OHD levels (r = 0.66; P= 0.03), whereas total and free 1,25-(OH)(2)D levels were highly correlated (r = 0.957; P < 0.001). In the in vitro studies, the percentage of free 1,25-(OH)(2)D increased after 25-OHD or 24,25-(OH)(2)D was added. Conclusions: Although the patients had normal or near-normal total 1,25-(OH)(2)D values, most patients had elevated free 1,25-(OH)(2)D levels. These findings suggest that elevated free 1,25-(OH)(2)D levers might play a role in the pathogenesis of hypercalcemia in vitamin D toxicity.	UNIV WITWATERSRAND, JOHANNESBURG, SOUTH AFRICA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; UNIV NATAL, DURBAN 4001, SOUTH AFRICA	University of Witwatersrand; University of California System; University of California San Francisco; University of Kwazulu Natal			Pettifor, John/M-4579-2019	Pettifor, John/0000-0003-1155-0334				BIKLE DD, 1985, J CLIN ENDOCR METAB, V61, P969, DOI 10.1210/jcem-61-5-969; BIKLE DD, 1984, J CLIN INVEST, V74, P1966, DOI 10.1172/JCI111617; BIKLE DD, 1986, J CLIN ENDOCR METAB, V63, P954, DOI 10.1210/jcem-63-4-954; BOUILLON R, 1977, J CLIN ENDOCR METAB, V45, P225, DOI 10.1210/jcem-45-2-225; CHAPUY MC, 1990, METABOLIC MOL BASIS, P1824; COUNTS SJ, 1975, ANN INTERN MED, V82, P196, DOI 10.7326/0003-4819-82-2-196; HADDAD JG, 1971, J CLIN ENDOCR METAB, V33, P992, DOI 10.1210/jcem-33-6-992; HORST RL, 1979, BIOCHEM BIOPH RES CO, V89, P286, DOI 10.1016/0006-291X(79)90976-8; HORST RL, 1981, J CLIN INVEST, V67, P274, DOI 10.1172/JCI110023; HUGHES MR, 1976, J CLIN INVEST, V58, P61, DOI 10.1172/JCI108459; JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801; MASON RS, 1980, CLIN CHEM, V26, P444; MAWER EB, 1985, CLIN SCI, V68, P135, DOI 10.1042/cs0680135; ORIORDAN JLH, 1982, VITAMIN D CHEM BIOCH, P751; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; SHEPARD RM, 1980, ARCH BIOCHEM BIOPHYS, V202, P43, DOI 10.1016/0003-9861(80)90404-X; VIETH R, 1990, BONE MINER, V11, P267, DOI 10.1016/0169-6009(90)90023-9	17	88	91	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					511	513		10.7326/0003-4819-122-7-199504010-00006	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872586				2022-12-01	WOS:A1995QP00800006
J	PISACANE, A; DELUCA, U; IMPAGLIAZZO, N; RUSSO, M; DECAPRIO, C; CARACCIOLO, G				PISACANE, A; DELUCA, U; IMPAGLIAZZO, N; RUSSO, M; DECAPRIO, C; CARACCIOLO, G			BREAST-FEEDING AND ACUTE APPENDICITIS	BRITISH MEDICAL JOURNAL			English	Article									OSPED SANTOBONO,DIV CHIRURG,USL REG CAMPANIA 40,NAPLES,ITALY		PISACANE, A (corresponding author), UNIV NAPLES,DEPT PEDIAT,I-80131 NAPLES,ITALY.							BARKER DJP, 1985, BRIT MED J, V290, P1125, DOI 10.1136/bmj.290.6475.1125; COGGON D, 1991, J EPIDEMIOL COMMUN H, V45, P244, DOI 10.1136/jech.45.3.244; GOLDMAN AS, 1993, PEDIATR INFECT DIS J, V12, P664, DOI 10.1097/00006454-199308000-00008; HEATON KW, 1987, BRIT MED J, V294, P1632, DOI 10.1136/bmj.294.6588.1632; NELSON M, 1986, J EPIDEMIOL COMMUN H, V40, P316, DOI 10.1136/jech.40.4.316	5	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					836	837		10.1136/bmj.310.6983.836	http://dx.doi.org/10.1136/bmj.310.6983.836			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711621	Green Published			2022-12-01	WOS:A1995QQ85700019
J	TZOURIO, C; TEHINDRAZANARIVELO, A; IGLESIAS, S; ALPEROVITCH, A; CHEDRU, F; DANGLEJANCHATILLON, J; BOUSSER, MG				TZOURIO, C; TEHINDRAZANARIVELO, A; IGLESIAS, S; ALPEROVITCH, A; CHEDRU, F; DANGLEJANCHATILLON, J; BOUSSER, MG			CASE-CONTROL STUDY OF MIGRAINE AND RISK OF ISCHEMIC STROKE IN YOUNG-WOMEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLATELET AGGREGABILITY; PREVALENCE; FEATURES; ADULTS	Objective-To determine whether migraine is a risk factor for ischaemic stroke in young women. Design-A case-control study. Setting-Five hospitals in Paris and suburbs. Subjects-72 women aged under 45 with ischaemic stroke and 173 controls randomly selected from women hospitalised in the same centres. Main outcome measures-Ischaemic stroke confirmed by cerebral computerised tomography or magnetic resonance imaging; history of headache recorded with structured interview, and diagnosis of migraine assessed by reproducibility study. Results-Ischaemic stroke was strongly associated with migraine, both migraine without aura (odds ratio 3.0 (95% confidence interval 1.5 to 5.8)) and migraine with aura (odds ratio 6.2 (2.1 to 18.0)). The risk of ischaemic stroke was substantially increased for migrainous women who were using oral contraceptives (odds ratio 13.9) or who were heavy smokers (greater than or equal to 20 cigarettes/day) (odds ratio 10.2). Conclusions-These results indicate an independent association between migraine and the risk of ischaemic stroke in young women. Although the absolute risk of ischaemic stroke in young women with migraine is low, the reduction of known risk factors for stroke, in particular smoking and use of oral contraceptives, should be considered in this group.	HOP ST ANTOINE, SERV NEUROL, F-75571 PARIS, FRANCE; HOP MEAUX, SERV NEUROL, MEAUX, FRANCE; HOP VERSAILLES, SERV NEUROL, VERSAILLES, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre Hospitalier de Versailles	TZOURIO, C (corresponding author), INSERM, U360, UNITE RECH EPIDEMIOL NEUROL & PSYCHOPATHOL, F-94807 VILLEJUIF, FRANCE.		Tzourio, christophe/L-6344-2019; Tzourio, christophe/B-4015-2009; Tzourio, Christophe I/B-7459-2008	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; 				[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; BRESLOW N. E., 1980, STATISTICAL METHODS; COUCH JR, 1977, NEUROLOGY, V27, P843, DOI 10.1212/WNL.27.9.843; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; Gawel M J, 1982, Adv Neurol, V33, P237; HENRICH JB, 1989, J CLIN EPIDEMIOL, V42, P773, DOI 10.1016/0895-4356(89)90075-9; HENRY P, 1992, CEPHALALGIA, V12, P229, DOI 10.1046/j.1468-2982.1992.1204229.x; KALENDOVSKY Z, 1975, ARCH NEUROL-CHICAGO, V32, P13, DOI 10.1001/archneur.1975.00490430035004; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LEVINE SR, 1989, ANN NEUROL, V26, P386, DOI 10.1002/ana.410260312; LIDEGAARD O, 1987, ACTA NEUROL SCAND, V75, P427, DOI 10.1111/j.1600-0404.1987.tb05473.x; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; MARINI C, 1993, NEUROEPIDEMIOLOGY, V12, P70, DOI 10.1159/000110303; MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751; PEARSON AC, 1991, J AM COLL CARDIOL, V18, P1223, DOI 10.1016/0735-1097(91)90539-L; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; SCHOENBERG BS, 1970, NEUROLOGY, V20, P181, DOI 10.1212/WNL.20.2.181; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TATEMICHI TK, 1992, STROKE PATHOPHYSIOLO, P761; TZOURIO C, 1993, BMJ-BRIT MED J, V307, P289, DOI 10.1136/bmj.307.6899.289; 1990, SAS USERS GUIDE STAT, V1	21	352	363	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	1995	310	6983					830	833		10.1136/bmj.310.6983.830	http://dx.doi.org/10.1136/bmj.310.6983.830			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711619	Green Published			2022-12-01	WOS:A1995QQ85700017
J	WEIL, J; COLINJONES, D; LANGMAN, M; LAWSON, D; LOGAN, R; MURPHY, M; RAWLINS, M; VESSEY, M; WAINWRIGHT, P				WEIL, J; COLINJONES, D; LANGMAN, M; LAWSON, D; LOGAN, R; MURPHY, M; RAWLINS, M; VESSEY, M; WAINWRIGHT, P			PROPHYLACTIC ASPIRIN AND RISK OF PEPTIC-ULCER BLEEDING	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTI-INFLAMMATORY DRUGS; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; CONTROLLED TRIAL; MORTALITY; ACID	Objective-To determine the risks of hospitalisation for bleeding peptic ulcer with the current prophylactic aspirin regimens of 300 mg daily or less. Design-A case-control study with hospital and community controls. Setting-Hospitals in Glasgow, Newcastle, Nottingham, Oxford, and Portsmouth. Subjects-1121 patients with gastric or duodenal ulcer bleeding matched with hospital and community controls. Results-144 (12.8%) cases had been regular users of aspirin (taken at least five days a week for at least the previous month) compared with 101 (9.0%) hospital and 77 (7.8%) community controls. Odds ratios were raised for all doses of aspirin taken, whether compared with hospital or community controls (compared with combined controls: 75 mg, 2.3 (95% confidence interval 1.2 to 4.3); 150 mg, 3.2 (1.7 to 6.5); 300 mg, 3.9 (2.5 to 6.3)). Results were not explained by confounding influences of age, sex, prior ulcer history or dyspepsia, or concurrent nonaspirin non-steroidal anti-inflammatory drug use. Risks seemed particularly high in patients who took non-aspirin non-steroidal anti-inflammatory drugs concurrently. Conclusion-No conventionally used prophylactic aspirin regimen seems free of the risk of peptic ulcer complications.	UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; W MIDLANDS REG HLTH AUTHOR, PUBL HLTH MED, BIRMINGHAM, W MIDLANDS, ENGLAND; QUEEN ALEXANDRA HOSP, PORTSMOUTH PO6 3LY, HANTS, ENGLAND; ROYAL INFIRM, GLASGOW G4 0SF, LANARK, SCOTLAND; UNIV NOTTINGHAM, NOTTINGHAM NG7 2UH, ENGLAND; UNIV OXFORD, HLTH CARE EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND; UNIV NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; UNIV OXFORD, RADCLIFFE INFIRM, OXFORD OX2 6HE, ENGLAND; UNIV BIRMINGHAM, INST CANC STUDIES, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND	University of Birmingham; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Royal Infirmary of Edinburgh; University of Nottingham; University of Oxford; Newcastle University - UK; Radcliffe Infirmary; University of Oxford; University of Birmingham								ALVAREZ AS, 1958, LANCET, V2, P179; [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; [Anonymous], 1991, Lancet, V338, P1345; [Anonymous], 1980, CIRCULATION, V62, P449; BJARNASON I, 1988, GASTROENTEROLOGY, V94, P1070, DOI 10.1016/0016-5085(88)90568-9; BJARNASON I, 1987, GASTROENTEROLOGY, V93, P480, DOI 10.1016/0016-5085(87)90909-7; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BREDDIN K, 1980, HAEMOSTASIS, V9, P325; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; COGGON D, 1982, GUT, V23, P340, DOI 10.1136/gut.23.4.340; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1979, LANCET, V2, P1313; FAULKNER G, 1988, BRIT MED J, V297, P1311, DOI 10.1136/bmj.297.6659.1311; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; LANGMAN MJS, 1985, BRIT MED J, V290, P347, DOI 10.1136/bmj.290.6465.347; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; PETERSEN P, 1989, LANCET, V1, P175; PRITCHARD PJ, 1989, BRIT MED J, V298, P493; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; SHORROCK C J, 1992, Gastroenterology, V102, pA165; SOMERVILLE K, 1986, LANCET, V1, P462; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; The Aspirin Myocardial Infarction Study: final results, 1980, CIRCULATION S5, V62, pV79; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WALLENTIN L, 1990, LANCET, V336, P827; 1976, J CHRON DIS, V29, P625	31	459	480	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	1995	310	6983					827	830		10.1136/bmj.310.6983.827	http://dx.doi.org/10.1136/bmj.310.6983.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711618	Green Published			2022-12-01	WOS:A1995QQ85700016
J	AULD, DS; SCHIMMEL, P				AULD, DS; SCHIMMEL, P			SWITCHING RECOGNITION OF 2 TRANSFER-RNA SYNTHETASES WITH AN AMINO-ACID SWAP IN A DESIGNED PEPTIDE	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; GLUTAMINYL-TRANSFER RNA; ESCHERICHIA-COLI; BINDING-SITE; ANTICODON BINDING; SEQUENCES; PROTEIN; IDENTIFICATION; AMINOACYLATION; CODON	The genetic code is based on specific interactions between transfer RNA (tRNA) synthetases and their cognate tRNAs. The anticodons for methionine and isoleucine tRNAs differ by a single nucleotide, and changing this nucleotide in an isoleucine tRNA is sufficient to change aminoacylation specificity to methionine. Results of combinatorial mutagenesis of an anticodon-binding-helix loop peptide were used to design a hybrid sequence composed of amino acid residues from methionyl- and isoleucyl-tRNA synthetases. When the hybrid sequence was transplanted into isoleucyl-tRNA synthetase, active enzyme was generated in vivo and in vitro. The transplanted peptide did not confer function to methionyl-tRNA synthetase, but the substitution of a single amino acid within the transplanted peptide conferred methionylation and prevented isoleucylation. Thus, the swap of a single amino acid in the transplanted peptide switches specificity between anticodons that differ by one nucleotide.			AULD, DS (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER DG, 1982, EUR J BIOCHEM, V127, P449; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; GHOSH G, 1990, BIOCHEMISTRY-US, V29, P2220, DOI 10.1021/bi00461a003; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; IACCARINO M, 1971, J BACTERIOL, V105, P527, DOI 10.1128/JB.105.2.527-537.1971; KIM S, 1993, P NATL ACAD SCI USA, V90, P10046, DOI 10.1073/pnas.90.21.10046; KIM SH, 1994, BIOCHEMISTRY-US, V33, P11040, DOI 10.1021/bi00202a025; KIM SH, 1992, J BIOL CHEM, V267, P15563; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRO JA, 1993, P NATL ACAD SCI USA, V90, P2261, DOI 10.1073/pnas.90.6.2261; MEINNEL T, 1991, P NATL ACAD SCI USA, V88, P291, DOI 10.1073/pnas.88.1.291; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; SCHIMMEL P, 1992, PROTEIN SCI, V1, P1387, DOI 10.1002/pro.5560011018; SCHMIDT E, 1993, P NATL ACAD SCI USA, V90, P6919, DOI 10.1073/pnas.90.15.6919; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; VALENZUELA D, 1986, BIOCHEMISTRY-US, V25, P4555, DOI 10.1021/bi00364a015; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	25	43	44	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1994	1996		10.1126/science.7701322	http://dx.doi.org/10.1126/science.7701322			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701322				2022-12-01	WOS:A1995QQ06800044
J	BENTLEY, GA; BOULOT, G; KARJALAINEN, K; MARIUZZA, RA				BENTLEY, GA; BOULOT, G; KARJALAINEN, K; MARIUZZA, RA			CRYSTAL-STRUCTURE OF THE BETA-CHAIN OF A T-CELL ANTIGEN RECEPTOR	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; COMPLEX; RESOLUTION; REGION; FAB; IMMUNOGLOBULINS; RECOGNITION; SPECIFICITY; REFINEMENT; EXPRESSION	The crystal structure of the extracellular portion of the beta chain of a murine T cell antigen receptor (TCR), determined at a resolution of 1.7 angstroms, shows structural homology to immunoglobulins. The structure of the first and second hypervariable loops suggested that, in general, they adopt more restricted sets of conformations in TCR beta chains than those found in immunoglobulins; the third hypervariable loop had certain structural characteristics in common with those of immunoglobulin heavy chain variable domains. The variable and constant domains were in close contact, presumably restricting the flexibility of the beta chain. This may facilitate signal transduction from the TCR to the associated CD3 molecules in the TCR-CD3 complex.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850		BENTLEY, GA (corresponding author), INST PASTEUR,CNRS,UNITE IMMUNOL STRUCT 359,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Bentley, Graham/B-3623-2011; Karjalainen, Klaus/A-2206-2011					[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BOULOT G, 1994, J MOL BIOL, V235, P795, DOI 10.1006/jmbi.1994.1037; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1991, J MOL BIOL, V211, P239; CASORATI G, 1993, EUR J IMMUNOL, V23, P586, DOI 10.1002/eji.1830230246; CAZENAVE PA, 1990, CELL, V63, P717, DOI 10.1016/0092-8674(90)90138-5; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FIELDS BA, 1994, J MOL BIOL, V239, P339, DOI 10.1006/jmbi.1994.1373; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOCHSTENBACH F, 1990, J CLIN IMMUNOL, V10, P1, DOI 10.1007/BF00917493; JORES R, 1990, P NATL ACAD SCI USA, V87, P9138, DOI 10.1073/pnas.87.23.9138; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KANG JS, 1994, J IMMUNOL, V152, P5305; KARJALAINEN K, 1994, CURR OPIN IMMUNOL, V6, P9, DOI 10.1016/0952-7915(94)90027-2; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KUBO RT, 1989, J IMMUNOL, V142, P2736; LESK AM, 1988, NATURE, V335, P188, DOI 10.1038/335188a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PATTEN PA, 1993, J IMMUNOL, V150, P2281; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SAUL FA, 1992, PROTEINS, V14, P363, DOI 10.1002/prot.340140305; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SIMON T, 1990, EMBO J, V9, P1056; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	39	257	259	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1984	1987		10.1126/science.7701320	http://dx.doi.org/10.1126/science.7701320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701320				2022-12-01	WOS:A1995QQ06800041
J	DALLOS, P; EVANS, BN				DALLOS, P; EVANS, BN			HIGH-FREQUENCY MOTILITY OF OUTER HAIR-CELLS AND THE COCHLEAR AMPLIFIER	SCIENCE			English	Article							GUINEA-PIG COCHLEA; ELECTROKINETIC SHAPE CHANGES; MECHANICAL RESPONSES; CURRENTS; ELECTROMOTILITY; SENSITIVITY; PHASE; ORGAN; CORTI	Outer hair cells undergo somatic elongation-contraction cycles in vitro when electrically stimulated. This ''electromotile'' response is assumed to underlie the high sensitivity and frequency selectivity of amplification in the mammalian cochlea. This process, presumably operating on a cycle-by-cycle basis at the frequency of the stimulus, is believed to provide mechanical feedback in vivo. However, if driven by the receptor potential of the cell, the mechanical feedback is expected to be severely attenuated at high frequencies because of electrical low-pass filtering by the outer hair cell basolateral membrane. It is proposed that electromotility at high frequencies is driven instead by extracellular potential gradients across the hair cell, and it is shown that this driving voltage is not subject to low-pass filtering and is sufficiently large. It is further shown that if the filtering properties of the cell membrane are canceled, taking advantage of the electrical characteristics of isolated outer hair cells in a partitioning glass microchamber, then the lower bound of the motor's bandwidth is approximately 22 kilohertz, a number determined only by the limitations of our instrumentation.	NORTHWESTERN UNIV,DEPT COMMUN SCI & DISORDERS,EVANSTON,IL 60208	Northwestern University	DALLOS, P (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,AUDIOL PHYSIOL LAB,HUGH KNOWLES CTR,EVANSTON,IL 60208, USA.		Dallos, Peter/Q-9360-2019	Dallos, Peter/0000-0002-9731-6591				Ashmore J. F., 1989, COCHLEAR MECH, P107; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASHMORE JF, 1986, NATURE, V322, P368, DOI 10.1038/322368a0; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CANNON MW, 1976, THESIS SYRACUSE U SY; CHEATHAM MA, UNPUB; Cooper N. P., 1993, BIOPHYSICS HAIR CELL, P249; CROWLEY DE, 1966, J COMP PHYSIOL PSYCH, V62, P427, DOI 10.1037/h0023953; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1993, J NEUROPHYSIOL, V70, P299, DOI 10.1152/jn.1993.70.1.299; DALLOS P, 1985, J NEUROSCI, V5, P1591; DALLOS P, 1992, J NEUROSCI, V12, P4575; DALLOS P, 1983, HEARING RES, V12, P89, DOI 10.1016/0378-5955(83)90120-X; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; Davis H, 1981, Am J Otolaryngol, V2, P153, DOI 10.1016/S0196-0709(81)80034-8; Evans B.N., 1989, COCHLEAR MECHANISMS, P205; EVANS BN, 1993, P NATL ACAD SCI USA, V90, P8347, DOI 10.1073/pnas.90.18.8347; EVANS BN, 1991, HEARING RES, V52, P288, DOI 10.1016/0378-5955(91)90019-6; Fay R. R., 1988, HEARING VERTEBRATES; FORGE A, 1991, CELL TISSUE RES, V265, P473, DOI 10.1007/BF00340870; GEISLER CD, 1990, HEARING RES, V44, P241, DOI 10.1016/0378-5955(90)90084-3; GITTER AH, 1988, BASIC ISSUES HEARING, P32; HOPKINS CD, 1981, AM ZOOL, V21, P211; HOUSLEY GD, 1992, J PHYSIOL-LONDON, V448, P73, DOI 10.1113/jphysiol.1992.sp019030; HUBBARD AE, 1983, SCIENCE, V222, P510, DOI 10.1126/science.6623090; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; KACHAR B, 1986, NATURE, V322, P365, DOI 10.1038/322365a0; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; KOSSL M, 1992, HEARING RES, V60, P156, DOI 10.1016/0378-5955(92)90018-I; KOSSL M, 1992, J NEUROSCI, V12, P1575; MAMMANO F, 1993, NATURE, V365, P838, DOI 10.1038/365838a0; Marmarelis P.Z., 1978, ANAL PHYSL SYSTEMS; Moller A R, 1974, Scand J Rehabil Med Suppl, V3, P37; MOUNTAIN DC, 1993, BIOPHYSICS HAIR CELL, P361; NUTTALL AL, 1993, BIOPHYSICS HAIR CELL, P288; POLLAK G, 1972, SCIENCE, V176, P66, DOI 10.1126/science.176.4030.66; RUSSELL IJ, 1992, P ROY SOC B-BIOL SCI, V247, P97, DOI 10.1098/rspb.1992.0014; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SANTOS-SACCHI J, 1989, J NEUROSCI, V9, P2954; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; SANTOS-SACCHI J, 1992, J NEUROSCI, V12, P1906; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; YATES GK, 1993, BIOPHYSICS HAIR CELL, P352; ZENNER HP, 1986, HEARING RES, V22, P83, DOI 10.1016/0378-5955(86)90082-1	44	261	267	1	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					2006	2009		10.1126/science.7701325	http://dx.doi.org/10.1126/science.7701325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701325				2022-12-01	WOS:A1995QQ06800048
J	KUIDA, K; LIPPKE, JA; KU, G; HARDING, MW; LIVINGSTON, DJ; SU, MSS; FLAVELL, RA				KUIDA, K; LIPPKE, JA; KU, G; HARDING, MW; LIVINGSTON, DJ; SU, MSS; FLAVELL, RA			ALTERED CYTOKINE EXPORT AND APOPTOSIS IN MICE DEFICIENT IN INTERLEUKIN-1-BETA CONVERTING-ENZYME	SCIENCE			English	Article							DEATH GENE CED-3; CELL-DEATH; PRECURSOR; PROTEASE; ELEGANS; BCL-2; FAS; SPECIFICITY; ACTIVATION; IL-1-ALPHA	The interleukin-1 beta (IL-1 beta) converting enzyme (ICE) processes the inactive IL-1 beta precursor to the proinflammatory cytokine. Adherent monocytes from mice harboring a disrupted ICE gene (ICE(-/-)) did not export IL-1 beta or interleukin-1 alpha (IL-1 alpha) after stimulation with lipopolysaccharide. Export of tumor necrosis factor-alpha and interleukin-6 (IL-6) from these cells was also diminished. Thymocytes from ICE(-/-) mice were sensitive to apoptosis induced by dexamethasone or ionizing radiation, but were resistant to apoptosis induced by Fas antibody. Despite this defect in apoptosis, ICE(-/-) mice proceed normally through development.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Vertex Pharmaceuticals; Howard Hughes Medical Institute; Yale University; Yale University			Roszak, Joanna/F-4003-2010					AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1984, J IMMUNOL, V132, P38; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FAUCHEU C, UNPUB; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOWARD AD, 1991, J IMMUNOL, V147, P2964; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VELS DJ, 1993, CELL, V75, P229; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	42	1451	1484	0	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					2000	2003		10.1126/science.7535475	http://dx.doi.org/10.1126/science.7535475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7535475				2022-12-01	WOS:A1995QQ06800046
J	MARTI, K; KIM, JS; THAKUR, AN; MCCOY, TJ; KEIL, K				MARTI, K; KIM, JS; THAKUR, AN; MCCOY, TJ; KEIL, K			SIGNATURES OF THE MARTIAN ATMOSPHERE IN GLASS OF THE ZAGAMI METEORITE	SCIENCE			English	Article							NOBLE-GASES; SHERGOTTITE METEORITES; SNC METEORITES; ORIGIN; NITROGEN; MARS; PETROGENESIS; EETA-79001; ABUNDANCES; XENON	Isotopic signatures of nitrogen, argon, and xenon have been determined in separated millimeter-sized pockets of shock-melted glass in a recently identified lithology of the meteorite Zagami, a shergottite. The ratio of nitrogen-15 to nitrogen-14, which is at least 282 per mil larger than the terrestrial value, the ratio of xenon-129 to xenon-132 = 2.40, and the argon isotopic abundances match the signatures previously observed in the glassy lithology of the Antarctic shergottite EETA 79001. These results show that the signatures in EETA 79001 are not unique but characterize the trapped gas component in shock-melted glass of shergottites. The isotopic and elemental ratios of nitrogen, argon, and xenon closely resemble the Viking spacecraft data for the martian atmosphere and provide compelling evidence for a martian origin of the two shergottites and, by extension, of the meteorites in the shergottites-nakhlites-chassignites (SNC) group.	UNIV HAWAII MANOA,HAWAII CTR VOLCANOL,HONOLULU,HI 96822; UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,CALIF SPACE INST,LA JOLLA,CA 92093; UNIV HAWAII MANOA,SCH OCEAN & EARTH SCI & TECHNOL,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822	University of Hawaii System; University of Hawaii Manoa; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Hawaii System; University of Hawaii Manoa	MARTI, K (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.			McCoy, Timothy/0000-0002-4573-3553				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BECKER RH, 1984, EARTH PLANET SC LETT, V69, P225, DOI 10.1016/0012-821X(84)90183-3; BECKER RH, 1993, METEORITICS, V28, P637, DOI 10.1111/j.1945-5100.1993.tb00634.x; BIEMANN K, 1976, SCIENCE, V194, P76, DOI 10.1126/science.194.4260.76; BOGARD DD, 1986, J GEOPHYS RES-SOLID, V91, pE99, DOI 10.1029/JB091iB13p00E99; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; BOGARD DD, 1984, GEOCHIM COSMOCHIM AC, V48, P1723, DOI 10.1016/0016-7037(84)90028-0; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.ea.21.050193.000555; Dreibus G., 1982, LUNAR PLANETARY SCI, P186; EPSTEIN S, 1971, GEOCHIM COSM SUPPL, V2, P1421; EUGSTER O, 1994, METEORITICS, V29, P464; JAGOUTZ E, 1989, GEOCHIM COSMOCHIM AC, V53, P2429, DOI 10.1016/0016-7037(89)90363-3; KIM J, UNPUB; KIM JS, 1992, P LUNAR PLANET SCI, V22, P145; KIM JS, 1994, LUNAR PLANET SCI, V25, P701; MCCOY TJ, 1992, GEOCHIM COSMOCHIM AC, V56, P3571, DOI 10.1016/0016-7037(92)90400-D; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MCSWEEN HY, 1983, GEOCHIM COSMOCHIM AC, V47, P1501, DOI 10.1016/0016-7037(83)90309-5; NAKAMURA N, 1982, METEORITICS, V17, P257; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; OTT U, 1988, GEOCHIM COSMOCHIM AC, V52, P1937, DOI 10.1016/0016-7037(88)90017-8; OWEN T, 1976, SCIENCE, V193, P801, DOI 10.1126/science.193.4255.801; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; Owen T., 1977, J GEOPHYS RES, V82, P4635, DOI DOI 10.1029/JS082I028P04635; SHIH CY, 1982, GEOCHIM COSMOCHIM AC, V46, P2323, DOI 10.1016/0016-7037(82)90205-8; STOEFFLER D, 1986, GEOCHIM COSMOCHIM AC, V50, P889; STOLPER E, 1979, GEOCHIM COSMOCHIM AC, V43, P1475, DOI 10.1016/0016-7037(79)90142-X; SWINDLE TD, 1986, GEOCHIM COSMOCHIM AC, V50, P1001, DOI 10.1016/0016-7037(86)90381-9; Wadhwa M., 1993, METEORITICS, V28, P453; WALKER D, 1979, LUNAR PLANET SCI, V10, P1274; Wasson J.T., 1979, ASTEROIDS, P926; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WIENS RC, 1988, GEOCHIM COSMOCHIM AC, V52, P295, DOI 10.1016/0016-7037(88)90085-3; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1	34	96	96	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1981	1984		10.1126/science.7701319	http://dx.doi.org/10.1126/science.7701319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701319				2022-12-01	WOS:A1995QQ06800040
J	NUREKI, O; VASSYLYEV, DG; KATAYANAGI, K; SHIMIZU, T; SEKINE, S; KIGAWA, T; MIYAZAWA, T; YOKOYAMA, S; MORIKAWA, K				NUREKI, O; VASSYLYEV, DG; KATAYANAGI, K; SHIMIZU, T; SEKINE, S; KIGAWA, T; MIYAZAWA, T; YOKOYAMA, S; MORIKAWA, K			ARCHITECTURES OF CLASS-DEFINING AND SPECIFIC DOMAINS OF GLUTAMYL-TRANSFER-RNA SYNTHETASE	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; THERMUS-THERMOPHILUS HB8; DATA-COLLECTION SYSTEM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DIFFRACTION DATA; GLTX-GENE; MACROMOLECULAR CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE; WEISSENBERG CAMERA	The crystal structure of a class I aminoacyl-transfer RNA synthetase, glutamyl-tRNA synthetase (GluRS) from Thermus thermophilus, was solved and refined at 2.5 Angstrom resolution. The amino-terminal half of GluRS shows a geometrical similarity with that of Escherichia coli glutaminyl-tRNA synthetase (GlnRS) of the same subclass in class I, comprising the class I-specific Rossmann fold domain and the intervening subclass-specific alpha/beta domain. These domains were found to have two GluRS-specific, secondary-structure insertions, which then participated in the specific recognition of the D and acceptor stems of tRNA(Glu) as indicated by mutagenesis analyses based on the docking properties of GluRS and tRNA. In striking contrast to the beta-barrel structure of the GlnRS carboxyl-terminal half, the GluRS carboxyl-terminal half displayed an all-alpha-helix architecture, an alpha-helix cage, and mutagenesis analyses indicated that it had a role in the anticodon recognition.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,SCH SCI,DEPT BIOCHEM & BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Yokoyama, Shigeyuki/N-6911-2015; Kigawa, Takanori/A-7679-2010; Vassylyev, Dmitry/A-9005-2008; Sekine, Shun-ichi/N-5450-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kigawa, Takanori/0000-0003-0146-9719; Sekine, Shun-ichi/0000-0001-8174-8704				BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRETON R, 1990, J BIOL CHEM, V265, P18248; BRETON R, 1986, J BIOL CHEM, V261, P610; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CAVARELLI J, 1992, NATURE, V362, P181; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FETT R, 1991, J BIOL CHEM, V266, P1448; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; HARAYOKOYAMA M, 1984, J BIOCHEM, V96, P1599, DOI 10.1093/oxfordjournals.jbchem.a134990; HARAYOKOYAMA M, 1985, THESIS U TOKYO TOKYO; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABERGE S, 1989, J BACTERIOL, V171, P3926, DOI 10.1128/jb.171.7.3926-3932.1989; LAMOUR V, 1994, P NATL ACAD SCI USA, V91, P8670, DOI 10.1073/pnas.91.18.8670; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P436; NAKAMURA H, 1987, J PHYS SOC JPN, V56, P1609, DOI 10.1143/JPSJ.56.1609; NUREKI O, 1992, EUR J BIOCHEM, V204, P465, DOI 10.1111/j.1432-1033.1992.tb16656.x; NUREKI O, UNPUB; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OTOWINOWSKI Z, 1988, NATURE, V335, P321; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PUTNEY SD, 1981, SCIENCE, V213, P1497, DOI 10.1126/science.7025207; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; Sekine S., UNPUB; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STEITZ TA, 1982, P NATL ACAD SCI-BIOL, V79, P3097, DOI 10.1073/pnas.79.10.3097; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; TANAKA I, 1990, J APPL CRYSTALLOGR, V23, P334, DOI 10.1107/S0021889890004009; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITE BN, 1972, CAN J BIOCHEM CELL B, V50, P600, DOI 10.1139/o72-082; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; YAMAO F, 1982, J BIOL CHEM, V257, P1639; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	56	132	135	0	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1958	1965		10.1126/science.7701318	http://dx.doi.org/10.1126/science.7701318			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701318				2022-12-01	WOS:A1995QQ06800034
J	VALDIVIA, HH; KAPLAN, JH; ELLISDAVIES, GCR; LEDERER, WJ				VALDIVIA, HH; KAPLAN, JH; ELLISDAVIES, GCR; LEDERER, WJ			RAPID ADAPTATION OF CARDIAC RYANODINE RECEPTORS - MODULATION BY MG2+ AND PHOSPHORYLATION	SCIENCE			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; DEPENDENT PROTEIN-KINASE; RAT VENTRICULAR MYOCYTES; SKELETAL-MUSCLE; ADENINE-NUCLEOTIDE; SINGLE-CHANNEL; CA-2+ RELEASE; HEART-MUSCLE; CA2+ RELEASE	Channel adaptation is a fundamental feature of sarcoplasmic reticulum calcium release channels (called ryanodine receptors, RyRs). It permits successive increases in the intracellular concentration of calcium (Ca2+) to repeatedly but transiently activate channels. Adaptation of RyRs in the absence of magnesium (Mg2+) and adenosine triphosphate is an extremely slow process (taking seconds). Photorelease of Ca2+ from nitrophenyl-EGTA, a photolabile Ca2+ chelator, demonstrated that RyR adaptation is rapid (milliseconds) in canine heart muscle when physiological Mg2+ concentrations are present. Phosphorylation of the RyR by protein kinase A increased the responsiveness of the channel to Ca2+ and accelerated the kinetics of adaptation. These properties of the RyR from heart may also be relevant to other cells in which multiple agonist-dependent triggering events regulate cellular functions.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Pennsylvania			Lederer, William/B-1285-2010	Kaplan, Jack/0000-0002-7048-6574	NHLBI NIH HHS [HL25675, R01 HL025675, R01 HL036974, R01 HL030315, HL36974, R37 HL036974, HL30315] Funding Source: Medline; NIGMS NIH HHS [R01 GM053395, R01 GM039500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315, R01HL036974, R01HL025675, R37HL036974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500, R01GM053395] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARO I, 1993, J PHYSIOL-LONDON, V465, P21, DOI 10.1113/jphysiol.1993.sp019664; BERS DM, 1989, AM J PHYSIOL, V256, pC109, DOI 10.1152/ajpcell.1989.256.1.C109; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; CALLEWAERT G, 1988, P NATL ACAD SCI USA, V85, P2009, DOI 10.1073/pnas.85.6.2009; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HOLMBERG SRM, 1990, BIOCHIM BIOPHYS ACTA, V1022, P187, DOI 10.1016/0005-2736(90)90113-3; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDERER WJ, 1990, SCIENCE, V251, P1371; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; OBRIEN PJ, 1986, CAN J VET RES, V50, P318; ONEILL SC, 1990, AM J PHYSIOL, V258, pC1165, DOI 10.1152/ajpcell.1990.258.6.C1165; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; STRAND MA, 1993, BIOCHIM BIOPHYS ACTA, V1175, P319, DOI 10.1016/0167-4889(93)90224-D; TAKASAGO T, 1989, J BIOCHEM-TOKYO, V106, P872, DOI 10.1093/oxfordjournals.jbchem.a122945; TATE CA, 1985, J BIOL CHEM, V260, P9618; TINKER A, 1992, J GEN PHYSIOL, V100, P479, DOI 10.1085/jgp.100.3.479; VALDIVIA HH, 1991, J BIOL CHEM, V266, P19135; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; VALDIVIA HH, UNPUB; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; YATANI A, 1988, J BIOL CHEM, V263, P9887	32	312	322	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1997	2000		10.1126/science.7701323	http://dx.doi.org/10.1126/science.7701323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701323	Green Accepted			2022-12-01	WOS:A1995QQ06800045
J	YAO, RJ; COOPER, GM				YAO, RJ; COOPER, GM			REQUIREMENT FOR PHOSPHATIDYLINOSITOL-3 KINASE IN THE PREVENTION OF APOPTOSIS BY NERVE GROWTH-FACTOR	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; TRK PROTOONCOGENE PRODUCT; PC12 CELLS; NEURONAL DIFFERENTIATION; TYROSINE KINASE; FACTOR RECEPTOR; PHEOCHROMOCYTOMA CELLS; PDGF RECEPTOR; BINDING-SITE; MAP KINASE	Nerve growth factor (NGF) induces both differentiation and survival of neurons by binding to the Trk receptor protein tyrosine kinase. Although Pas is required for differentiation, it was not required for NGF-mediated survival of rat pheochromocytoma PC-12 cells in serum-free medium. However, the ability of NGF to prevent apoptosis (programmed cell death) was inhibited by wortmannin or LY294002, two specific inhibitors of phosphatidylinositol (PI)-3 kinase. Moreover, platelet-derived growth factor (PDGF) prevented apoptosis of PC-12 cells expressing the wild-type PDGF receptor, but not of cells expressing a mutant receptor that failed to activate PI-3 kinase. Cell survival thus appears to be mediated by a PI-3 kinase signaling pathway distinct from the pathway that mediates differentiation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO R, UNPUB	52	1254	1331	1	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					2003	2006		10.1126/science.7701324	http://dx.doi.org/10.1126/science.7701324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701324				2022-12-01	WOS:A1995QQ06800047
J	ZHANG, XK; BLENIS, J; LI, HC; SCHINDLER, C; CHENKIANG, S				ZHANG, XK; BLENIS, J; LI, HC; SCHINDLER, C; CHENKIANG, S			REQUIREMENT OF SERINE PHOSPHORYLATION FOR FORMATION OF STAT-PROMOTER COMPLEXES	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; GROWTH-FACTOR; PROTEIN-PHOSPHORYLATION; INTERFERON-GAMMA; IFN-GAMMA; BINDING; GENE; INTERLEUKIN-6; ACTIVATION	Members of the interleukin-6 family of cytokines bind to and activate receptors that contain a common subunit, gp130. This leads to the activation of Stat3 and Stat1, two cytoplasmic signal transducers and activators of transcription (STATs), by tyrosine phosphorylation. Serine phosphorylation of Stat3 was constitutive and was enhanced by signaling through gp130. In cells of lymphoid and neuronal origins, inhibition of serine phosphorylation prevented the formation of complexes of DNA with Stat3-Stat3 but not with Stat3-Stat1 or Stat1-Stat1 dimers. In vitro serine dephosphorylation of Stat3 also inhibited DNA binding of Stat3-Stat3. The requirement of serine phosphorylation for Stat3-Stat3.DNA complex formation was inversely correlated with the affinity of Stat3-Stat3 for the binding site. Thus, serine phosphorylation appears to enhance or to be required for the formation of stable Stat3-Stat3 DNA complexes.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University					NATIONAL CANCER INSTITUTE [R37CA046595, R01CA046595] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595] Funding Source: Medline; NHLBI NIH HHS [HL 21006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LI HC, 1981, ARCH BIOCHEM BIOPHYS, V207, P270, DOI 10.1016/0003-9861(81)90034-5; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P4371; NATKUNAM Y, 1994, J IMMUNOL, V153, P3476; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; ZHANG X, UNPUB; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	33	517	525	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1990	1994		10.1126/science.7701321	http://dx.doi.org/10.1126/science.7701321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701321				2022-12-01	WOS:A1995QQ06800043
J	ACHESON, A; CONOVER, JC; FANDL, JP; DECHIARA, TM; RUSSELL, M; THADANI, A; SQUINTO, SP; YANCOPOULOS, GD; LINDSAY, RM				ACHESON, A; CONOVER, JC; FANDL, JP; DECHIARA, TM; RUSSELL, M; THADANI, A; SQUINTO, SP; YANCOPOULOS, GD; LINDSAY, RM			A BDNF AUTOCRINE LOOP IN ADULT SENSORY NEURONS PREVENTS CELL DEATH	NATURE			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; MESSENGER-RNA; DOPAMINERGIC-NEURONS; BRAIN; RECEPTOR; TRKB; NGF; CELLS	DURING the initial phase of their development, sensory neurons of the dorsal root ganglion (DRG) require target-derived trophic support for their survival(1-3), but as they mature they lose this requirement. Because many of these neurons express BDNF (brain-derived neurotrophic factor) messenger RNA(4,5) we hypothesized that BDNF might act as an autocrine survival factor in adult DRG neurons, thus explaining their lack of dependence on exogenous growth factors. When cultured adult DRG cells were treated with antisense oligonucleotides to BDNF, expression of BDNF protein was reduced by 80%, and neuronal survival was reduced by 35%. These neurons could be rescued by exogenous BDNF or neurotrophin-3, but not by other growth factors. Similar results were obtained with single-neuron microcultures, whereas microcultures derived from mutant mice lacking BDNF were unaffected by antisense oligonucleotides. Our results strongly support an autocrine role for BDNF in mediating the survival of a subpopulation of adult DRG neurons.			ACHESON, A (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022	Conover, Joanne/0000-0003-0375-0141				ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; AGRIS CH, 1986, BIOCHEMISTRY-US, V25, P6268, DOI 10.1021/bi00368a065; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; DOHERTY P, 1987, J NEUROCHEM, V49, P1676, DOI 10.1111/j.1471-4159.1987.tb02425.x; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GALL CM, 1992, MOL CELL NEUROSCI, V3, P56, DOI 10.1016/1044-7431(92)90009-Q; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, J NEUROSCI, V13, P3394; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON EM, 1986, TRENDS NEUROSCI, V9, P33, DOI 10.1016/0166-2236(86)90012-3; JOHNSON EM, 1985, NATURE, V314, P751, DOI 10.1038/314751a0; JONES KR, 1994, CELL, V76, P889; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Lindsay RM, 1992, SENSORY NEURONS DIVE, P404; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORRISON RS, 1991, J BIOL CHEM, V266, P728; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; WUPONG S, 1992, PHARMACEUT RES, V9, P1010, DOI 10.1023/A:1015846209681; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	30	620	640	1	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					450	453		10.1038/374450a0	http://dx.doi.org/10.1038/374450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700353				2022-12-01	WOS:A1995QP89900057
J	DONAHUE, TM				DONAHUE, TM			EVOLUTION OF WATER RESERVOIRS ON MARS FROM D/H RATIOS IN THE ATMOSPHERE AND CRUST	NATURE			English	Article							MARTIAN ATMOSPHERE; ESCAPE; ABUNDANCE; HYDROGEN; HDO	ANCIENT fluvial networks on the surface of Mars suggest that it was warm and wet over three billion years ago. Surface features resembling massive outflow channels provide evidence that, even more recently, the martian crust contained the equivalent of a planet-wide reservoir of water several hundred metres deep(1,2). But arguments based on the isotopic fractionation(3,4) and present-day escape rate of hydrogen in the martian atmosphere require only 0.5 metres of crustal water today and about six metres in the past(5). An additional constraint on the evolution of the isotopic composition of martian water has recently been obtained(6) from measurements of the deuterium to hydrogen ratio of hydrous minerals in the SNC meteorites-meteorites that almost certainly originated on Mars. Here I show that these new data require that the modern crustal reservoirs of martian water must be quite large, at least several metres in global-equivalent depth. The deuterium enrichment of the present martian atmosphere then implies that the reservoir of crustal water on ancient Mars was several hundred metres deep, consistent with the geological evidence(3,4).			DONAHUE, TM (corresponding author), UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109, USA.							ATREYA SK, 1994, J GEOPHYS RES-PLANET, V99, P13133, DOI 10.1029/94JE01085; Bjoraker G. L., 1989, B AM ASTRON SOC, V21, P990; CARR MH, 1987, NATURE, V326, P30, DOI 10.1038/326030a0; CARR MH, 1990, ICARUS, V87, P210, DOI 10.1016/0019-1035(90)90031-4; CARR MH, 1979, J GEOPHYS RES, V84, P2995, DOI 10.1029/JB084iB06p02995; FOX JL, 1993, GEOPHYS RES LETT, V20, P1747, DOI 10.1029/93GL01118; HUNTEN DM, 1973, J ATMOS SCI, V30, P1481, DOI 10.1175/1520-0469(1973)030<1481:TEOLGF>2.0.CO;2; HUNTEN DM, 1973, J ATMOS SCI, V30, P736; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; KRASNOPOLSKY VA, 1993, ICARUS, V101, P33, DOI 10.1006/icar.1993.1003; LIU SC, 1976, ICARUS, V28, P231, DOI 10.1016/0019-1035(76)90035-X; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; MCELROY MB, 1972, SCIENCE, V177, P986, DOI 10.1126/science.177.4053.986; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9	19	52	52	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					432	434		10.1038/374432a0	http://dx.doi.org/10.1038/374432a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700352	Green Submitted			2022-12-01	WOS:A1995QP89900051
J	DUPONT, HL; CHAPPELL, CL; STERLING, CR; OKHUYSEN, PC; ROSE, JB; JAKUBOWSKI, W				DUPONT, HL; CHAPPELL, CL; STERLING, CR; OKHUYSEN, PC; ROSE, JB; JAKUBOWSKI, W			THE INFECTIVITY OF CRYPTOSPORIDIUM-PARVUM IN HEALTHY-VOLUNTEERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRINKING-WATER; INVITRO EXCYSTATION; OUTBREAK; OOCYSTS; IMMUNOCOMPETENT; GIARDIA; DISINFECTANTS; VIABILITY; OZONE; MICE	Background. Small numbers of Cryptosporidium parvum oocysts can contaminate even treated drinking water, and ingestion of oocysts can cause diarrheal disease in normal as well as immunocompromised hosts. Since the number of organisms necessary to cause infection in humans is unknown, we performed a study to determine the infective dose of the parasite in healthy adults. Methods. After providing informed consent, 29 healthy volunteers without evidence of previous C. parvum infection, as determined by the absence of anti-cryptosporidium-specific antibodies, were given a single dose of 30 to 1 million C. parvum oocysts obtained from a calf. They were then monitored for oocyst excretion and clinical illness for eight weeks. Household contacts were monitored for secondary spread. Reuslts. Of the 16 subjects who received an intended dose of 300 or more oocysts, 14 (88 percent) became infected. After a dose of 30 oocysts, one of five subjects (20 percent) became infected, whereas at a dose of 1000 or more oocysts, seven of seven became infected. The median infective dose, calculated by linear regression, was 132 oocysts. Of the 18 subjects who excreted oocysts after the challenge dose, 11 had enteric symptoms and 7 (39 percent) had clinical cryptosporidiosis, consisting of diarrhea plus at least one other enteric symptom. All recovered, and there were no secondary cases of diarrhea among household contacts. Conclusions. In healthy adults with no serologic evidence of past infection with C. parvum, a low dose of C. parvum oocysts is sufficient to cause infection.	UNIV TEXAS, SCH MED, HOUSTON, TX USA; UNIV TEXAS, SCH PUBL HLTH, HOUSTON, TX USA; UNIV ARIZONA, TUCSON, AZ USA; UNIV S FLORIDA, TAMPA, FL USA; US EPA, CINCINNATI, OH 45268 USA	University of Texas System; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Arizona; State University System of Florida; University of South Florida; United States Environmental Protection Agency			DuPont, Herbert/AAH-6776-2021	Okhuysen, Pablo/0000-0002-1596-3411	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002558] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR-02558] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANGUS KW, 1982, RES VET SCI, V33, P379, DOI 10.1016/S0034-5288(18)32320-8; ARROWOOD MJ, 1987, J PARASITOL, V73, P314, DOI 10.2307/3282084; BLACKLOW NR, 1979, J CLIN MICROBIOL, V10, P903, DOI 10.1128/JCM.10.6.903-909.1979; CAMPBELL AT, 1992, APPL ENVIRON MICROB, V58, P3488, DOI 10.1128/AEM.58.11.3488-3493.1992; CAMPBELL I, 1982, VET REC, V111, P414, DOI 10.1136/vr.111.18.414; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; DUPONT HL, 1992, CLIN INFECT DIS, V15, pS228, DOI 10.1093/clind/15.Supplement_1.S228; FINCH GR, 1993, APPL ENVIRON MICROB, V59, P4203, DOI 10.1128/AEM.59.12.4203-4210.1993; GOODGAME RW, 1993, J INFECT DIS, V167, P704, DOI 10.1093/infdis/167.3.704; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; ISAACRENTON JL, 1987, LANCET, V1, P973; JOKIPII L, 1985, GASTROENTEROLOGY, V89, P838, DOI 10.1016/0016-5085(85)90581-5; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; KUHLS TL, 1994, CLIN INFECT DIS, V18, P731, DOI 10.1093/clinids/18.5.731; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; Lederberg J., 1992, EMERGING INFECT MICR; LENGERICH EJ, 1993, J INFECT DIS, V167, P1252, DOI 10.1093/infdis/167.5.1252; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MADORE MS, 1987, J PARASITOL, V73, P702, DOI 10.2307/3282398; MOON HW, 1988, INFECT IMMUN, V56, P649, DOI 10.1128/IAI.56.3.649-653.1988; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; REGLI S, 1991, J AM WATER WORKS ASS, V83, P76, DOI 10.1002/j.1551-8833.1991.tb07252.x; RENDTORFF ROBERT C., 1954, AMER JOUR HYG, V59, P209; ROSE JB, 1991, AM J PUBLIC HEALTH, V81, P709, DOI 10.2105/AJPH.81.6.709; TANGERMANN RH, 1991, AM J EPIDEMIOL, V133, P471, DOI 10.1093/oxfordjournals.aje.a115914; UNGAR BLP, 1989, ARCH INTERN MED, V149, P894, DOI 10.1001/archinte.149.4.894; UNGAR BLP, 1986, J INFECT DIS, V153, P570, DOI 10.1093/infdis/153.3.570; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; WOODMANSEE DB, 1987, J PROTOZOOL, V34, P398, DOI 10.1111/j.1550-7408.1987.tb03199.x	31	689	737	2	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					855	859		10.1056/NEJM199503303321304	http://dx.doi.org/10.1056/NEJM199503303321304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7870140	Bronze			2022-12-01	WOS:A1995QP22800004
J	FISCHER, KD; ZMUIDZINAS, A; GARDNER, S; BARBACID, M; BERNSTEIN, A; GUIDOS, C				FISCHER, KD; ZMUIDZINAS, A; GARDNER, S; BARBACID, M; BERNSTEIN, A; GUIDOS, C			DEFECTIVE T-CELL RECEPTOR SIGNALING AND POSITIVE SELECTION OF VAV-DEFICIENT CD4(+) CD8(+) THYMOCYTES	NATURE			English	Article							TYROSINE KINASE; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; B-CELLS; PHOSPHORYLATION; ACTIVATION; MICE	DURING lymphocyte development, cellular proliferation and positive and negative selection events ensure the production of T and B lymphocytes bearing highly diverse, but self-tolerant, repertoires of antigen receptors(1,2). These processes are initiated when engagement of growth-factor receptors, or the T-3,T-4 and B-5 lymphocyte antigen receptors, induces tyrosine phosphorylation of specific SH2- and SH3-domain-containing cytoplasmic proteins, including Vav(3,6,7). Here we show that vav(-/-) embryonic stern cells generate only limited numbers of immature and mature T and B lymphocytes in the RAG-2 blastocyst complementation assays. Furthermore, Vav-deficient T lymphocytes showed severely impaired antigen receptor signalling. Finally, we demonstrate that Vav-dependent signalling pathways regulate maturation, but not CD4/ CD8 lineage commitment, during T-cell-receptor-mediated positive selection of immature CD4(+)CD8(+) precursors into mature CD4(+)CD8(-) or CD4(-)CD8(+) T cells.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAM MOLEC BIOL & CANC,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A1,CANADA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; HOSP SICK CHILDREN,RES INST,DIV IMMUNOL & CANC,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5S 1A1,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Bristol-Myers Squibb; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ADAMS JM, 1992, ONCOGENE, V7, P611; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GODFREY DI, 1992, J IMMUNOL, V149, P2281; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1993, MOL MECHANISMS IMMUN, P137; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; ROLINK A, 1991, EUR J IMMUNOL, V21, P2609, DOI 10.1002/eji.1830211044; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; VONBOEHMER H, CELL, V219, P94; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZMUIDZINAS A, 1995, EMBO J, V14, P1	30	282	283	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					474	477		10.1038/374474a0	http://dx.doi.org/10.1038/374474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700360				2022-12-01	WOS:A1995QP89900064
J	FRASCH, M				FRASCH, M			INDUCTION OF VISCERAL AND CARDIAC MESODERM BY ECTODERMAL DPP IN THE EARLY DROSOPHILA EMBRYO	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; HOMEOBOX-CONTAINING GENE; VENTRALIZING FACTOR; BETA FAMILY; GERM LAYERS; CELL FATES; XENOPUS; EXPRESSION; PATTERN; REPRESSION	AFTER gastrulation, progenitor cells of the cardiac, visceral and body wall musculature arise at defined positions within the mesodermal layer of the Drosophila embryo(1-4). The regulatory mechanisms underlying this process of pattern formation are largely unknown, although ablation experiments carried out in other insects indicate that inductive influences from ectodermal cells have major roles in embryonic mesoderm differentiation(5,6). An early and important event in the regional subdivision of the mesoderm is the restriction of tinman expression to dorsal mesodermal cells(2,3). Genetic analysis has shown that this homeobox gene controls the formation of the visceral musculature and the heart from dorsal portions of the mesoderm(3,7). We now show that an inductive signal from dorsal ectodermal cells is required for activation of tinman in the underlying mesoderm and present evidence that Decapentaplegic (Dpp), a member of the transforming growth factor-beta superfamily(8), serves as a signalling molecule in this process. This demonstrates that the spatial expression of dpp in the ectoderm determines which cells of the mesoderm become competent to develop into visceral mesoderm and the heart.			FRASCH, M (corresponding author), CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029, USA.		Frasch, Manfred/H-7002-2013	Frasch, Manfred/0000-0003-1373-9798				ANDERSON MG, 1995, GENE DEV, V9, P123, DOI 10.1101/gad.9.1.123; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Bate Michael, 1993, P1013; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAND AH, 1993, DEVELOPMENT, V118, P401; DALE L, 1992, DEVELOPMENT, V115, P573; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; Haget A., 1953, Bulletin Biol Paris, V87, P123; HOCH M, 1990, EMBO J, V9, P2587, DOI 10.1002/j.1460-2075.1990.tb07440.x; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IP YT, 1991, CELL, V64, P439; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; JONES CM, 1992, DEVELOPMENT, V115, P639; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LOGAN M, 1993, DEVELOPMENT, V118, P865; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Poulson D. F., 1950, BIOL DROSOPHILA, P168; Seidel F, 1940, NATURWISSENSCHAFTEN, V28, P433, DOI 10.1007/BF01557878; SMITH JC, 1987, DEVELOPMENT, V99, P3; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; WHARTON KA, 1993, DEVELOPMENT, V117, P807	30	352	355	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					464	467		10.1038/374464a0	http://dx.doi.org/10.1038/374464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700357				2022-12-01	WOS:A1995QP89900061
J	HAMILTON, SR; LIU, B; PARSONS, RE; PAPADOPOULOS, N; JEN, J; POWELL, SM; KRUSH, AJ; BERK, T; COHEN, Z; TETU, B; BURGER, PC; WOOD, PA; TAQI, F; BOOKER, SV; PETERSEN, GM; OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; VOGELSTEIN, B; KINZLER, KW				HAMILTON, SR; LIU, B; PARSONS, RE; PAPADOPOULOS, N; JEN, J; POWELL, SM; KRUSH, AJ; BERK, T; COHEN, Z; TETU, B; BURGER, PC; WOOD, PA; TAQI, F; BOOKER, SV; PETERSEN, GM; OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; VOGELSTEIN, B; KINZLER, KW			THE MOLECULAR-BASIS OF TURCOTS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; NONPOLYPOSIS COLORECTAL-CANCER; AUTOSOMAL DOMINANT; GARDNERS-SYNDROME; COLON-CANCER; BRAIN-TUMORS; MUTATIONS; GENE; LOCUS; IDENTIFICATION	Background. Turcot's syndrome is characterized clinically by the concurrence of a primary brain tumor and multiple colorectal adenomas. We attempted to define the syndrome at the molecular level. Methods. Fourteen families with Turcot's syndrome identified in two registries and the family originally described by Turcot and colleagues were studied. Germ-line mutations in the adenomatous polyposis coli (APC) gene characteristic of familial adenomatous polyposis were evaluated, as well as DNA replication errors and germline mutations in nucleotide mismatch-repair genes characteristic of hereditary nonpolyposis colorectal cancer. In addition, a formal risk analysis for brain tumors in familial adenomatous polyposis was performed with a registry data base. Results. Genetic abnormalities were identified in 13 of the 14 registry families. Germ-line APC mutations were detected in 10. The predominant brain tumor in these 10 families was medulloblastoma (11 of 14 patients, or 79 percent), and the relative risk of cerebellar medulloblastoma in patients with familial adenomatous polyposis was 92 times that in the general population (95 percent confidence interval, 29 to 269; P<0.001). In contrast, the type of brain tumor in the other four families was glioblastoma multiforme. The glioblastomas and colorectal tumors in three of these families and in the original family studied by Turcot had replication errors characteristic of hereditary nonpolyposis colorectal cancer. In addition, germ-line mutations in the mismatch-repair gene hMLH1 or hPMS2 were found in two families. Conclusions. The association between brain tumors and multiple colorectal adenomas can result from two distinct types of germ-line defects: mutation of the APC gene or mutation of a mismatch-repair gene. Molecular diagnosis may contribute to the appropriate care of affected patients.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV MED GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,DIV NEUROPATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; MT SINAI HOSP,FAMILIAL GASTROINTESTINAL CANC REGISTRY,TORONTO,ON M5G 1X5,CANADA; HOTEL DIEU QUEBEC,ANAT PATHOL LAB,QUEBEC CITY,PQ,CANADA; STRATTON VET AFFAIRS MED CTR,DEPT MED,DIV MED ONCOL,ALBANY,NY; ALBANY MED COLL,ALBANY,NY	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Laval University; Albany Medical College	HAMILTON, SR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,DIV GASTROINTESTINAL & LIVER PATHOL,ROSS BLDG,RM 632,BALTIMORE,MD 21205, USA.		Papadopoulos, Nickolas/K-7272-2012	Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R01CA047527, R37CA057345, R01CA057345, R01CA045831] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345, CA47527, CA45831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAUGHMAN FA, 1969, NEW ENGL J MED, V281, P1345, DOI 10.1056/NEJM196912112812407; BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; BLAIR NP, 1980, AM J OPHTHALMOL, V90, P661, DOI 10.1016/S0002-9394(14)75133-5; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUSSEY HJR, 1975, FAMILIAL POLYPOSIS C, P23; BUSSEY HJR, 1975, FAMILIAL POLYPOSIS C, P10; COHEN SB, 1982, J MED GENET, V19, P193, DOI 10.1136/jmg.19.3.193; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; COSTA OL, 1987, DIS COLON RECTUM, V30, P391, DOI 10.1007/BF02555461; CRAIL H W, 1949, U S Nav Med Bull, V49, P123; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, 1994, CELL, V77, pA166; GIARDIELLO FM, 1991, J PEDIATR-US, V119, P766, DOI 10.1016/S0022-3476(05)80297-5; GIARDIELLO FM, 1993, GUT, V34, P1394, DOI 10.1136/gut.34.10.1394; GIARDIELLO FM, 1993, GASTROENTEROLOGY, V105, P1550, DOI 10.1016/0016-5085(93)90164-8; GIARDIELLO FM, 1991, GUT, V32, P1170, DOI 10.1136/gut.32.10.1170; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GURBUZ AK, 1994, GUT, V35, P377, DOI 10.1136/gut.35.3.377; HAGGITT RC, 1986, AM J SURG PATHOL, V10, P871, DOI 10.1097/00000478-198612000-00006; HAMILTON SR, 1979, GASTROENTEROLOGY, V77, P1252; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ITOH H, 1993, INT J COLORECTAL DIS, V8, P87, DOI 10.1007/BF00299334; JARVIS L, 1988, DIS COLON RECTUM, V31, P907, DOI 10.1007/BF02554859; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KIKUCHI T, 1993, CANCER RES, V53, P957; KIM HG, 1994, AM J PATHOL, V145, P148; KINGSTON JE, 1983, ARCH DIS CHILD, V58, P959, DOI 10.1136/adc.58.12.959; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KROPILAK M, 1989, DIS COLON RECTUM, V32, P778, DOI 10.1007/BF02562128; LASSER DM, 1994, NEUROLOGY, V44, P1083, DOI 10.1212/WNL.44.6.1083; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEWIS JH, 1983, CANCER, V51, P524, DOI 10.1002/1097-0142(19830201)51:3<524::AID-CNCR2820510326>3.0.CO;2-I; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MCKUSICK VA, 1962, JAMA-J AM MED ASSOC, V182, P271, DOI 10.1001/jama.1962.03050420047012; MINAMI T, 1990, JPN J MED, V29, P391; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NEWTON HB, 1991, CANCER, V68, P1633, DOI 10.1002/1097-0142(19911001)68:7<1633::AID-CNCR2820680728>3.0.CO;2-1; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARAF F, 1994, GASTROEN CLIN BIOL, V18, P297; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PIERCE E R, 1970, Clinical Genetics, V1, P65; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RADIN DR, 1984, AM J ROENTGENOL, V142, P475, DOI 10.2214/ajr.142.3.475; ROCHLITZ CF, 1993, BRIT J CANCER, V68, P519, DOI 10.1038/bjc.1993.379; ROSENFELD M, 1991, Neurology, V41, P304; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; RUTZ HP, 1991, J NEUROSURG, V74, P813, DOI 10.3171/jns.1991.74.5.0813; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TITHECOTT GA, 1989, J PEDIATR SURG, V24, P1189, DOI 10.1016/S0022-3468(89)80117-4; TOPS CMJ, 1992, AM J MED GENET, V43, P888, DOI 10.1002/ajmg.1320430528; TRABOULSI EI, 1987, NEW ENGL J MED, V316, P661, DOI 10.1056/NEJM198703123161104; TURCOT J, 1959, Dis Colon Rectum, V2, P465, DOI 10.1007/BF02616938; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#	72	781	821	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					839	847		10.1056/NEJM199503303321302	http://dx.doi.org/10.1056/NEJM199503303321302			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7661930				2022-12-01	WOS:A1995QP22800002
J	QIU, RG; CHEN, J; KIRN, D; MCCORMICK, F; SYMONS, M				QIU, RG; CHEN, J; KIRN, D; MCCORMICK, F; SYMONS, M			AN ESSENTIAL ROLE FOR RAC IN RAS TRANSFORMATION	NATURE			English	Article							EXPRESSION; CELLS	THE GTPase Rac(1) is a key component in the reorganization of the actin cytoskeleton that is induced by growth factors or oncogenic Ras(1). Here we investigate the role of Rac(1) in cell transformation and show that Rat(1) fibroblasts expressing activated Val-12 Rac(1) (Rac(1) with valine at residue 12) display all the hallmarks of malignant transformation. In a focus-forming assay in NIH3T3 fibroblasts to measure the efficiency of transformation, we found that dominant-negative Asn-17 Rac(1) inhibited focus formation by oncogenic Ras, but not by RafCAAX, a Raf kinase targeted to the plasma membrane by virtue of the addition of a carboxyterminal localization signal from K-Ras. This indicates that Rac is essential for transformation by Ras. In addition, Val-12 Rac(1) synergizes strongly with RafCAAX in focus-formation assays, indicating that oncogenic Ras drives both the Rac and MAP-kinase pathways, which cooperate to cause transformation.			QIU, RG (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.							AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; HAWKINS PT, IN PRESS CURR BIOL; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SELF AJ, 1993, ONCOGENE, V8, P655; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320	19	770	780	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					457	459		10.1038/374457a0	http://dx.doi.org/10.1038/374457a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700355				2022-12-01	WOS:A1995QP89900059
J	ROSEN, MK; YAMAZAKI, T; GISH, GD; KAY, CM; PAWSON, T; KAY, LE				ROSEN, MK; YAMAZAKI, T; GISH, GD; KAY, CM; PAWSON, T; KAY, LE			DIRECT DEMONSTRATION OF AN INTRAMOLECULAR SH2-PHOSPHOTYROSINE INTERACTION IN THE CRK PROTEIN	NATURE			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; SH3 DOMAINS; V-CRK; BINDING; SRC; IDENTIFICATION; PRODUCT; PEPTIDE	MANY signal transduction processes are mediated by the binding Of Src-homology-2 (SH2) domains to phosphotyrosine (pTyr)-containing proteins(1). Although most SH2-pTyr interactions occur between tao different types of molecules, some appear to involve only a single molecular type. It has been proposed that the enzymatic activity and substrate recognition of the Src-family kinases(2-4), and the protein-binding and transforming activity of Crk-family adaptor proteins(5), are regulated by intramolecular SH2-pTyr interactions. In addition, the DNA-binding activity of Stat transcription factors seems to be regulated by SH2-mediated homodimerization(6). Here we examine the phosphorylated and non-phosphorylated forms of murine Crk II (p-mCrk and mCrk, respectively)(7-9) using a combination of physical techniques. The Crk protein contains a single SH2 domain and two SH3 domains in the order SH2-SH3-SH3. There is a tyrosine-phosphorylation site between the two SH3 domains at residue 221 which is phosphorylated in vivo by the Abl tyrosine kinase(5). Using NMR spectroscopic analysis, we show here that the SH2 domain of purified p-mCrk is bound to pTyr, and by hydrodynamic measurements that the phosphorylated protein is monomeric, These results provide direct demonstration of an intramolecular SH2-pTyr interaction in a signalling molecule.	UNIV TORONTO, DEPT MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT CHEM & BIOCHEM, TORONTO, ON M5S 1A8, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOLEC BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV ALBERTA, DEPT BIOCHEM, MRC, PROT STRUCT & FUNCT GRP, EDMONTON, AB T6G 2H7, CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Alberta	ROSEN, MK (corresponding author), UNIV TORONTO, PROT ENGN NETWORK CTR EXCELLENCE, MED SCI BLDG, TORONTO, ON M5S 1A8, CANADA.		Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; ODA T, 1994, J BIOL CHEM, V269, P22925; OGAWA S, 1994, ONCOGENE, V9, P1669; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VOGEL HJ, 1989, METHOD ENZYMOL, V177, P263; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YU HT, 1994, NAT STRUCT BIOL, V1, P417, DOI 10.1038/nsb0794-417; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	27	106	108	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	1995	374	6521					477	479		10.1038/374477a0	http://dx.doi.org/10.1038/374477a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700361				2022-12-01	WOS:A1995QP89900065
J	SATOKATA, I; BENSON, G; MAAS, R				SATOKATA, I; BENSON, G; MAAS, R			SEXUALLY DIMORPHIC STERILITY PHENOTYPES IN HOXA10-DEFICIENT MICE	NATURE			English	Article							TESTICULAR DESCENT; MOUSE EMBRYOS; GENE; INVITRO	THE Abdominal B (AbdB) genes constitute a distinct subfamily of homeobox genes that exhibit posterior domains of expression(1,2), including the genital imaginal disc in Drosophila and the developing urogenital system in vertebrates(3,4). We have mutated the AbdB gene Hoxa10 in mice, We report here that homozygotes are fully viable and show an anterior homeotic transformation of lumbar vertebrae. All male homozygotes manifest bilateral cryptorchidism resulting in severe defects in spermatogenesis and increasing sterility with age. Female homozygotes ovulate normally, but about 80% are sterile because of death of embryos between days 2.5 and 3.5 post coitum. This coincides spatially and temporally with expression of maternal Hoxa10 in distal oviductal and uterine epithelium. These results indicate a role for AbdB Hox genes in male and female fertility and suggest that maternal Hoxa10 is required to regulate the expression of a factor that affects the viability of preimplantation embryos.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV GENET,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute								ADAMSON ED, 1993, J CELL BIOCHEM, V53, P280, DOI 10.1002/jcb.240530403; BENSON GV, 1995, MOL CELL BIOL, V15, P1591; BOWMAN P, 1970, J EMBRYOL EXP MORPH, V24, P203; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BROWN JJG, 1991, DEVELOPMENT, V112, P99; CLENICKER S, 1987, GENE DEV, V1, P111; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; ERBACH G, 1994, J BIOL REPROD, V50, P1027; Hogan B, 1986, MANIPULATING MOUSE E, P89; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; Kaufman M.H., 1992, ATLAS MOUSE DEV; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; PARK WH, 1991, J PEDIATR SURG, V26, P615, DOI 10.1016/0022-3468(91)90721-5; POLLARD J, 1991, UTERINE EMBRYONIC FA, P109; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; SAKKAS D, 1990, J REPROD FERTIL, V90, P109, DOI 10.1530/jrf.0.0900109; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Schultz G A, 1993, Oxf Rev Reprod Biol, V15, P43; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; WELLS LJ, 1944, ANAT REC, V88, P465; WENSING CJG, 1988, HORM RES, V30, P144, DOI 10.1159/000181051	24	435	456	3	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					460	463		10.1038/374460a0	http://dx.doi.org/10.1038/374460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700356				2022-12-01	WOS:A1995QP89900060
J	SHAWLOT, W; BEHRINGER, RR				SHAWLOT, W; BEHRINGER, RR			REQUIREMENT FOR LIM1 IN HEAD-ORGANIZER FUNCTION	NATURE			English	Article							HOMEO-BOX GENE; MOUSE EMBRYOS; EXPRESSION PATTERN; FROG EMBRYOS; INDUCTION; DOMAIN; CELLS; GASTRULATION; HOMEODOMAIN; ELEGANS	Lim1 is a homeobox gene expressed in the organizer region of mouse embryos. To investigate the role of Lim1 during embryogenesis, a targeted deletion of the Lim1 gene was generated in embryonic stem cells. Embryos homozygous for the null allele lacked anterior head structures but the remaining body axis developed normally. A partial secondary axis developed anteriorly in some mutant embryos. Lim1 is thus an essential regulator of the vertebrate head organizer.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, DEVELOPMENT, V120, P2979; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BEDDINGTON RSP, 1992, POSTIMPLANTATION DEV, P55; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CONLON FL, 1994, DEVELOPMENT, V120, P1919; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERHART J, 1991, GASTRULATION MOVEMEN, P57; GONT LK, 1993, DEVELOPMENT, V119, P991; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JURAND A, 1974, J EMBRYOL EXP MORPH, V32, P1; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEIR S, 1982, DIFFERENTIATION, V117, P96; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SASAKI H, 1993, DEVELOPMENT, V118, P47; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SORIANO P, 1991, CELL, V64, P694; Spemann H, 1927, NATURWISSENSCHAFTEN, V15, P946, DOI 10.1007/BF01506755; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; TAIRA M, 1994, DEVELOPMENT, V120, P1525; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAM PPL, 1992, POSTIMPLANTATION DEV, P27; THEILER K, 1989, HOUSE MOUSE; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WADDINGTON CH, 1932, J EXP BIOL, V10, P38; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YAMADA T, 1994, DEVELOPMENT, V120, P3051; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	50	643	654	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					425	430		10.1038/374425a0	http://dx.doi.org/10.1038/374425a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700351				2022-12-01	WOS:A1995QP89900049
J	TARAKHOVSKY, A; TURNER, M; SCHAAL, S; MEE, PJ; DUDDY, LP; RAJEWSKY, K; TYBULEWICZ, VLJ				TARAKHOVSKY, A; TURNER, M; SCHAAL, S; MEE, PJ; DUDDY, LP; RAJEWSKY, K; TYBULEWICZ, VLJ			DEFECTIVE ANTIGEN RECEPTOR-MEDIATED PROLIFERATION OF B-CELLS AND T-CELLS IN THE ABSENCE OF VAV	NATURE			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; SIGNALING PROTEINS; MICE; GENE; ACTIVATION; LACKING; DOMAIN; SH2	CROSSLINKING of B- or T-cell antigen receptors results in the rapid tyrosine phosphorylation of a number of proteins, including Vav, a protein expressed in cells of the haematopoietic system contains an array of structural motifs that include Src-homology domains SH2/SH3(4) and regions of homology to the guanine-nucleotide-exchange nucleotide-exchange protein Dbl, pleckstrin and protein kinase C (refs 5-9). Using the RAG-complementation approach(10), we have analysed in vivo differentiation and in vitro responses of B- and T-lineage cells generated by injection of embryonic stem cells homozygous for a null mutation in the vav gene into blastocysts of RAG-1- or RAG-2-deficient mice. Here we report that antigen receptor-mediated proliferative responses of B and T cells in vitro are severely reduced in the absence of Vav. We also suggest a direct link between the low proliferative response of Vav-deficient B and T cells and the reduced number of these cells in peripheral lymphoid organs of chimaeric mice.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	TARAKHOVSKY, A (corresponding author), UNIV COLOGNE,INST GENET,WEYERTAL 121,D-50931 COLOGNE,GERMANY.		Turner, Martin/N-9976-2014	Turner, Martin/0000-0002-3801-9896; Tybulewicz, Victor/0000-0003-2439-0798; Rajewsky, Klaus/0000-0002-6633-6370				ADAMS JM, 1992, ONCOGENE, V7, P611; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN J, 1994, TRANSGENESIS TARGETE, P35; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; GALLAND F, 1992, ONCOGENE, V7, P585; GRUTZMANN R, 1981, THESIS U COLOGNE GER; JUNG S, 1994, J EXP MED, V179, P2023, DOI 10.1084/jem.179.6.2023; KANTOR AB, 1992, P NATL ACAD SCI USA, V89, P3320, DOI 10.1073/pnas.89.8.3320; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; PARSON M, 1986, GENETICS MOL IMMUNOL, V3; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMITH L, 1986, GENETICS MOL IMMUNOL, V3; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	30	397	403	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					467	470		10.1038/374467a0	http://dx.doi.org/10.1038/374467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700358				2022-12-01	WOS:A1995QP89900062
J	WELSH, JP; LANG, EJ; SUGIHARA, I; LLINAS, R				WELSH, JP; LANG, EJ; SUGIHARA, I; LLINAS, R			DYNAMIC ORGANIZATION OF MOTOR CONTROL WITHIN THE OLIVOCEREBELLAR SYSTEM	NATURE			English	Article							INFERIOR OLIVARY NEURONS; CEREBELLAR; RAT; INVITRO; NUCLEUS; CAT	WHAT is the role of the cerebellum in motor coordination? Such coordination depends upon the integrity of the inferior olive, a major cerebellar afferent, as its lesion produces ataxic and dysmetric movement abnormalities(1,2). Using multiple-microelectrode recordings, we report here that there are domains of Purkinje cell activity that are generated by olivary input during skilled tongue movements in rats, Such activity domains are highly rhythmic and time-locked to movement, Patterns of synchronous olivocerebellar activity are geometrically complex and can change during a sequence of movements. The results support the view that the inferior olive organizes movement in time, by entraining motor-neuronal firing through rhythmic activation of the cerebellum, and in space, by synchronously activating cell ensembles that allow the use of individual muscles. Dynamic repatterning of olivocerebellar synchrony may allow different combinations of muscles to be used for movements intended to have varying spatial structures.			WELSH, JP (corresponding author), NYU,MED CTR,DEPT PHYSIOL & NEUROSCI,550 1ST AVE,NEW YORK,NY 10016, USA.		Lang, Eric J/A-1136-2017	Lang, Eric J/0000-0002-8524-9854				BOX GEP, 1994, TIME SERIES ANAL; Brooks VB, 1981, HDB PHYSL NERVOUS SY, V2, P877; BUISSERETDELMAS C, 1993, PROG NEUROBIOL, V40, P63, DOI 10.1016/0301-0082(93)90048-W; CICERATA F, 1992, EXPL BRAIN RES, V89, P352; DESCLIN JC, 1974, BRAIN RES, V77, P365, DOI 10.1016/0006-8993(74)90628-3; DEZEEUW CI, 1989, J COMP NEUROL, V284, P12, DOI 10.1002/cne.902840103; ECCLES JC, 1966, J PHYSIOL-LONDON, V182, P268, DOI 10.1113/jphysiol.1966.sp007824; GERSTEIN GL, 1960, BIOPHYS J, V1, P15, DOI 10.1016/S0006-3495(60)86872-5; KEEHN JD, 1960, SCIENCE, V132, P739, DOI 10.1126/science.132.3429.739; KING JS, 1976, J COMP NEUROL, V165, P387, DOI 10.1002/cne.901650307; LANG E I, 1990, Society for Neuroscience Abstracts, V16, P894; Larsell O., 1970, COMP ANATOMY HISTOLO; LLINAS R, 1989, EUR J NEUROSCI, V1, P587, DOI 10.1111/j.1460-9568.1989.tb00365.x; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P549, DOI 10.1113/jphysiol.1981.sp013763; LLINAS R, 1986, J PHYSIOL-LONDON, V376, P163, DOI 10.1113/jphysiol.1986.sp016147; LLINAS R, 1991, MOTOR CONTROL CONCEP, P223; MURPHY MG, 1971, ARCH NEUROL-CHICAGO, V24, P145, DOI 10.1001/archneur.1971.00480320073007; SASAKI K, 1989, EUR J NEUROSCI, V1, P572, DOI 10.1111/j.1460-9568.1989.tb00364.x; SOTELO C, 1974, J NEUROPHYSIOL, V37, P541, DOI 10.1152/jn.1974.37.3.541; SOTELO C, 1986, J COMP NEUROL, V252, P32, DOI 10.1002/cne.902520103; SUGIHARA I, 1993, J PHYSIOL-LONDON, V470, P243, DOI 10.1113/jphysiol.1993.sp019857; VALLBO AB, 1993, J PHYSIOL-LONDON, V469, P673, DOI 10.1113/jphysiol.1993.sp019837; WILSON WC, 1945, J COMP NEUROL, V83, P69, DOI 10.1002/cne.900830104; Winer BJ., 1971, STAT PRINCIPLES EXPT; ZIEGLER HP, 1991, THIRST PHYSL PSYCHOL, P241	25	500	504	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					453	457		10.1038/374453a0	http://dx.doi.org/10.1038/374453a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700354				2022-12-01	WOS:A1995QP89900058
J	ZHANG, R; ALT, FW; DAVIDSON, L; ORKIN, SH; SWAT, W				ZHANG, R; ALT, FW; DAVIDSON, L; ORKIN, SH; SWAT, W			DEFECTIVE SIGNALING THROUGH THE T-CELL AND B-CELL ANTIGEN RECEPTORS IN LYMPHOLD CELLS LACKING THE VAV PROTOONCOGENE	NATURE			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; CROSS-LINKING; EXPRESSION; KINASE; CD40; REARRANGEMENT; STIMULATION; REQUIREMENT	THE product of the vav proto-oncogene(1), p95(vav) or Vav, is tyrosine phosphorylated upon stimulation of T and B cells by antigen(2-4) and other(5-8) receptors, and contains motifs associated,vith signal transduction(1,9-11). To determine its role in vivo, we used vav-gene-targeted embryonic stem(12) cells and RAG-2(-/-) blastocyst complementation(13). The vav(-/-)-RAG-2(-/-) chimaeras displayed thymic atrophy with reduced numbers of peripheral T cells. Whereas the total number of B cells was normal, the subset of peritoneal B-1 (CD5(+))(14) cells was missing. The vav(-/-) T and B cells were hyporeactive when stimulated through antigen receptors, but vav(-/-) T cells proliferated on exposure to phorbol ester and calcium ionophore(15), whereas B cells responded normally to bacterial mitogen, lipopolysaccharide or the CD40 ligand(16-18). Thus, we have established here a functional role for vav in the control of T- and B-cell development and activation.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)								ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; HERZENBERG LA, 1993, IMMUNOL TODAY, V14, P79, DOI 10.1016/0167-5699(93)90063-Q; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIENER PA, 1993, J BIOL CHEM, V268, P24442; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; MANDLER R, 1993, J EXP MED, V178, P1577, DOI 10.1084/jem.178.5.1577; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PIATANIAS LC, 1994, J BIOL CHEM, V269, P3143; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TESTI R, 1989, J IMMUNOL, V142, P1854; VONBOEHMER H, 1981, IMMUNOL REV, V54, P27; Weiss A, 1991, Semin Immunol, V3, P313; ZHANG R, 1994, P NATL ACAD SCI USA, V91, P12755, DOI 10.1073/pnas.91.26.12755	26	377	383	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					470	473		10.1038/374470a0	http://dx.doi.org/10.1038/374470a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700359				2022-12-01	WOS:A1995QP89900063
J	BUTLER, C; PETERS, J; STOTT, N				BUTLER, C; PETERS, J; STOTT, N			GLYCATED HEMOGLOBIN AND METABOLIC CONTROL OF DIABETES-MELLITUS - EXTERNAL VERSUS LOCALLY ESTABLISHED CLINICAL TARGETS FOR PRIMARY-CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MICROVASCULAR COMPLICATIONS; TASK-PERFORMANCE; GENERAL-PRACTICE; HEMOGLOBIN	Objectives-To examine current targets for glycated haemoglobin as a marker for metabolic control in diabetes mellitus in relation to datasets from several areas, and to consider whether target setting could be improved. Design-Data collected from enhanced care records of general practices for a representative community based sample of people with diabetes. Setting and subjects-3022 people with diabetes on the lists of 37 general practices (total list size 222 550) in South Glamorgan in 1992; samples of glycated haemoglobin had been processed at two laboratories with different methodologies and reference ranges. Main outcome measures-Last glycated haemoglobin level measured in subjects for 1992 and published data from other studies considered in relation to existing goals and standards for the metabolic control of diabetes. Results-An ascertainment rate for people with diabetes of 1.36% was obtained. The rate of data capture for haemoglobin A1 was 75.7%, and the mean level for study samples was 10.5% at one laboratory and 10.0% at the other (similar values to those of comparable studies). These mean levels of haemoglobin A1 in representative populations of people with diabetes are poor or very. poor according to published standards, including those of the British Diabetic Association. These findings are set in the context of the psychology of goal setting and performance in complex clinical situations. Conclusion-Targets for clinical care that are set in the absence of normative data and local feasibility assessments should be treated with caution. Targets are more likely to enhance health care if target setters recognise the importance of psychological aspects of goal setting and motivation.	UNIV WALES HOSP, DEPT MED, CARDIFF CF4 4XW, S GLAM, WALES	Cardiff University	BUTLER, C (corresponding author), UNIV WALES COLL MED, LLANEDEYRN HLTH CTR, DEPT GEN PRACTICE, CARDIFF CF3 7PN, S GLAM, WALES.			Butler, Christopher/0000-0002-0102-3453				ALBERTI KGMM, 1994, DIABETIC MED, V11, P899, DOI 10.1111/j.1464-5491.1994.tb00376.x; AMER DIABET ASSOC, 1993, DIABETES, V42, P1555; [Anonymous], 1994, Diabetes Care, V17, P616; BANDURA A, 1991, NEBR SYM MOTIV, V38, P69; BOULTON AJM, 1993, DIABETIC MED, V10, P687, DOI 10.1111/j.1464-5491.1993.tb00148.x; DAY JL, 1992, DIABETIC MED, V9, P855, DOI 10.1111/j.1464-5491.1992.tb01905.x; DECI EL, 1971, J PERS SOC PSYCHOL, V18, P105, DOI 10.1037/h0030644; Deci EL, 1991, NEBR SYM MOTIV, P237; EARLEY PC, 1989, J APPL PSYCHOL, V74, P24, DOI 10.1037/0021-9010.74.1.24; FARMER A, 1991, BRIT J GEN PRACT, V41, P135; GROL R, 1993, BRIT J GEN PRACT, V43, P146; HAINES A, 1992, 58 ROYAL COLL GEN PR; HIGGS ER, 1992, DIABETIC MED, V9, P550, DOI 10.1111/j.1464-5491.1992.tb01837.x; HOWITT AJ, 1993, BRIT MED J, V307, P1046, DOI 10.1136/bmj.307.6911.1046; Krans H., 1992, DIABETES CARE RES EU; LARSEN ML, 1990, NEW ENGL J MED, V323, P1021, DOI 10.1056/NEJM199010113231503; LESTER E, 1989, ANN CLIN BIOCHEM, V26, P213, DOI 10.1177/000456328902600301; LOCKE EA, 1981, PSYCHOL BULL, V90, P125, DOI 10.1037/0033-2909.90.1.125; McWhinney I. R., 1981, TXB FAMILY MED; MORRIS LS, 1993, CLIN THER, V15, P593; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; NEIL HAW, 1989, DIABETIC MED, V6, P608, DOI 10.1111/j.1464-5491.1989.tb01237.x; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PICKUP JC, 1993, DIABETIC MED, V10, P402, DOI 10.1111/j.1464-5491.1993.tb00090.x; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STOTT NCH, 1994, 1988 1933 U WAL COLL; TUCKET D, 1985, M EXPERTS; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Vroom V.H., 1964, WORK MOTIVATION; WILLIAMS G, 1994, LANCET, V343, P95, DOI 10.1016/S0140-6736(94)90822-2; WOOD RE, 1987, J APPL PSYCHOL, V72, P416, DOI 10.1037/0021-9010.72.3.416; 1993, BRIT MED J, V307, P1542; [No title captured]; 1993, RECOMMENDATIONS MANA	36	37	37	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	1995	310	6982					784	788		10.1136/bmj.310.6982.784	http://dx.doi.org/10.1136/bmj.310.6982.784			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP609	7677834	Green Published			2022-12-01	WOS:A1995QP60900024
J	CARROLL, D; SMITH, GD; SHEFFIELD, D; SHIPLEY, MJ; MARMOT, MG				CARROLL, D; SMITH, GD; SHEFFIELD, D; SHIPLEY, MJ; MARMOT, MG			PRESSOR REACTIONS TO PSYCHOLOGICAL STRESS AND PREDICTION OF FUTURE BLOOD-PRESSURE - DATA FROM THE WHITEHALL-II STUDY	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR REACTIVITY; ESSENTIAL-HYPERTENSION; MENTAL STRESS; STABILITY; DISEASE	Objective-To examine whether reactions of blood pressure to future blood pressure. Design-Blood pressure was recorded at a medical screening examination after which presser reactions to a psychological stress task were determined. Follow up measurement of blood pressure was undertaken, on average, 4.9 years later. Setting-20 civil service departments in London. Subjects-1003 male civil servants aged between 35 and 55 years at entry to the study. Main outcome measure-Blood pressure at follow up screening. Results-Reactions of systolic blood pressure to stress correlated positively with systolic blood pressure at follow up screening (r = 0.22, P < 0.01). The dominant correlate of follow up blood pressure was blood pressure at initial screening (r = 0.60 P < 0.01 between initial and follow up systolic blood pressure; r = 0.59, P < 0.01 between initial and follow up diastolic blood pressure). Stepwise multiple regression analysis indicated that reactions to the stressor provided minimal prediction of follow up blood pressure over and above that afforded by blood pressure at initial screening. In the case of follow up systolic blood pressure, systolic reactions to stress accounted for only 1% of follow up variance; systolic blood pressure at initial screening accounted for 34%. With regard to diastolic blood pressure at follow up, the independent contribution from diastolic reactions to stress was less than 1%. Conclusion-Pressor reactions to psychological stress provide minimal independent prediction of blood pressure at follow up. Measurement of reactivity is not a useful clinical index of the course of future blood pressure.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,AVON,ENGLAND; UNIV LONDON UNIV COLL,UNIV COLL & MIDDLESEX SCH MED,DEPT EPIDEMIOL & PUBL HLTH,LONDON WC1E 6BT,ENGLAND	University of Bristol; University of London; University College London	CARROLL, D (corresponding author), GLASGOW CALDONIAN UNIV,DEPT PSYCHOL,GLASGOW G4 0BA,LANARK,SCOTLAND.		Davey Smith, George/A-7407-2013; Marmot, M G/Y-3920-2019	Davey Smith, George/0000-0002-1407-8314; Marmot, M G/0000-0002-2431-6419; Sheffield, David/0000-0001-9121-1783	Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310-04] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome Trust); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG HG, 1950, AM HEART J, V39, P484, DOI 10.1016/0002-8703(50)90246-8; BORGHI C, 1986, J CARDIOVASC PHARM, V8, pS138, DOI 10.1097/00005344-198608005-00030; CARROLL D, 1991, PSYCHOPHYSIOLOGY, V28, P438, DOI 10.1111/j.1469-8986.1991.tb00728.x; CARROLL D, 1986, PSYCHOPHYSIOLOGY, V23, P174, DOI 10.1111/j.1469-8986.1986.tb00613.x; CORESH J, 1992, HYPERTENSION, V19, P218; DITTO B, 1986, PSYCHOPHYSIOLOGY, V23, P62, DOI 10.1111/j.1469-8986.1986.tb00596.x; DRUMMOND PD, 1985, PSYCHOPHYSIOLOGY, V22, P621, DOI 10.1111/j.1469-8986.1985.tb01656.x; EICH RH, 1967, J CHRON DIS, V20, P583, DOI 10.1016/0021-9681(67)90035-5; FALKNER B, 1981, HYPERTENSION, V3, P521, DOI 10.1161/01.HYP.3.5.521; FREDRIKSON M, 1982, BIOL PSYCHOL, V15, P63, DOI 10.1016/0301-0511(82)90031-X; FREDRIKSON M, 1990, Annals of Behavioral Medicine, V12, P30, DOI 10.1207/s15324796abm1201_3; GALLACHER JEJ, 1985, J EPIDEMIOL COMMUNIT, V39, P200; HARLAN WR, 1964, AM J CARDIOL, V13, P683, DOI 10.1016/0002-9149(64)90205-X; HASTRUP JL, 1980, PSYCHOPHYSIOLOGY, V17, P317; HAYES RJ, 1988, STAT MED, V7, P915, DOI 10.1002/sim.4780070903; HOROWITZ RI, 1984, HYPERTENSION, V6, P295; KEYS A, 1971, ARCH INTERN MED, V128, P201, DOI 10.1001/archinte.1971.00310200037002; LIGHT KC, 1981, PSYCHOPHYSIOLOGY, V18, P216, DOI 10.1111/j.1469-8986.1981.tb03021.x; LIGHT KC, 1992, PSYCHOSOM MED, V54, P217, DOI 10.1097/00006842-199203000-00007; LLABRE MM, 1991, PSYCHOPHYSIOLOGY, V28, P701, DOI 10.1111/j.1469-8986.1991.tb01017.x; MANUCK S B, 1990, Annals of Behavioral Medicine, V12, P17, DOI 10.1207/s15324796abm1201_2; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MATTHEWS KA, 1993, HYPERTENSION, V22, P479, DOI 10.1161/01.HYP.22.4.479; MCKINNEY ME, 1985, PSYCHOPHYSIOLOGY, V22, P453, DOI 10.1111/j.1469-8986.1985.tb01632.x; MENKES MS, 1989, HYPERTENSION, V14, P524, DOI 10.1161/01.HYP.14.5.524; MURPHY JK, 1991, PSYCHOPHYSIOLOGY, V28, P447, DOI 10.1111/j.1469-8986.1991.tb00730.x; Obrist P.A., 1981, CARDIOVASCULAR PSYCH, DOI [10.1007/978-1-4684-8491-5, DOI 10.4324/9781315081762]; OLDHAM PD, 1962, J CHRON DIS, V15, P969, DOI 10.1016/0021-9681(62)90116-9; PARATI G, 1988, J HYPERTENS, V6, P481, DOI 10.1097/00004872-198806000-00008; PICKERING T G, 1990, Annals of Behavioral Medicine, V12, P3, DOI 10.1207/s15324796abm1201_1; Pickering TG, 1991, AM J HYPERTENS, V4, P611; Raven J.C., 1960, GUIDE STANDARD PROGR; ROGERS S, 1988, J EPIDEMIOL COMMUN H, V42, P321, DOI 10.1136/jech.42.4.321; SHERWOOD A, 1990, INT J PSYCHOPHYSIOL, V10, P95, DOI 10.1016/0167-8760(90)90050-N; THOMAS CB, 1982, JOHNS HOPKINS MED J, V151, P93; Turner J., 1992, INDIVIDUAL DIFFERENC; WOOD DL, 1984, HYPERTENSION, V6, P301, DOI 10.1161/01.HYP.6.3.301	37	111	112	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					771	776		10.1136/bmj.310.6982.771	http://dx.doi.org/10.1136/bmj.310.6982.771			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP609	7711581	Green Published			2022-12-01	WOS:A1995QP60900017
J	CONTER, V; CORTINOVIS, I; ROGARI, P; RIVA, L				CONTER, V; CORTINOVIS, I; ROGARI, P; RIVA, L			WEIGHT GROWTH IN INFANTS BORN TO MOTHERS WHO SMOKED DURING PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							MATERNAL SMOKING; BIRTH-WEIGHT; AGE; CHILD	Objective-To determine whether maternal smoking during pregnancy causes impairment in grow-th after birth. Design-Longitudinal study. Setting-Six medical university centres of six towns of north, central, and south Italy. Subjects-12 987 babies (10 238 born from nonsmoking mothers, 2276 from mothers smoking one to nine cigarettes a day, and 473 from mothers smoking greater than or equal to 10 cigarettes a day) entered the study. Main outcome measures-Difference in weight gain between children born to smoking mothers and those born to non-smoking mothers. Weight was measured at birth and at 3 and 6 months of age. Maternal smoking habit was derived from interview on third or fourth day after delivery. Results-Compared with children born to mothers who did not smoke during pregnancy, the birth weights of children born to mothers who smoked up to nine cigarettes a day were 88 g (girls) and 107 g (boys) lower; in children born to mothers who smoked greater than or equal to 10 cigarettes a day weights were 168 g and 247 g lower. At six months of age for the first group the mean weight for girls was 9 g (95% confidence interval -47 g to 65 g) higher and for boys 64 g (-118 g to -10 g) lower than that of children born to mothers who did not smoke. The corresponding figures for the second group were 38 g (-141 g to 85 g) lower for girls and 24 g (-136 g to 88 g) lower for boys. Conclusions-The deficits of weight at birth in children born to mothers who smoked during pregnancy are overcome by 6 months of age. These deficits are probably not permanent when smoking habit during pregnancy is not associated with other unfavourable variables (such as lower socioeconomic class).	UNIV MILAN,IST STAT MED & BIOMETRIA,I-20133 MILAN,ITALY; OSPED SAN GERARDO,DEPT PAEDIAT,MONZA,ITALY; OSPED MELEGNANO,DEPT PAEDIAT,MELEGNANO,ITALY	University of Milan; San Gerardo Hospital			Ivan, Cortinovis/M-9301-2017	Ivan, Cortinovis/0000-0001-8750-302X				BARR HM, 1984, PEDIATRICS, V74, P336; BORACCHI P, 1986, Genus, V42, P53; BUTLER NR, 1972, BMJ-BRIT MED J, V2, P127, DOI 10.1136/bmj.2.5806.127; BUTLER NR, 1973, BRIT MED J, V4, P573, DOI 10.1136/bmj.4.5892.573; Cortinovis I., 1993, Acta Medica Auxologica (Milan), V25, P13; CORTINOVIS I, 1986, Genus, V42, P13; De Scrilli A, 1986, Genus, V42, P37; FOGELMAN KR, 1988, BRIT MED J, V297, P1233, DOI 10.1136/bmj.297.6658.1233; FOX NL, 1990, INT J EPIDEMIOL, V19, P66, DOI 10.1093/ije/19.1.66; HARDY JB, 1972, LANCET, V2, P1332; MILANI S, 1983, SOC SCI MED, V17, P803, DOI 10.1016/0277-9536(83)90031-X; RANTAKALLIO P, 1983, ACTA PAEDIATR SCAND, V72, P747, DOI 10.1111/j.1651-2227.1983.tb09805.x; RONA RJ, 1985, INT J EPIDEMIOL, V2, P402; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; 1982, B MENSILE STATISTI S	15	70	70	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					768	771		10.1136/bmj.310.6982.768	http://dx.doi.org/10.1136/bmj.310.6982.768			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711580	Green Published			2022-12-01	WOS:A1995QP60900016
J	COOPER, C; KANIS, JA; COMPSTON, J				COOPER, C; KANIS, JA; COMPSTON, J			HOW TO ASSESS DRUG EFFICACY IN OSTEOPOROSIS	LANCET			English	Editorial Material							POPULATION		UNIV SHEFFIELD,SCH MED,DEPT HUMAN METAB & CLIN BIOCHEM,WHO COLLABORATING CTR METAB BONE DIS,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND; UNIV CAMBRIDGE,SCH MED,DEPT MED,CAMBRIDGE,ENGLAND	University of Sheffield; World Health Organization; University of Cambridge	COOPER, C (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; COOPER C, 1992, TRENDS ENDOCRIN MET, V3, P224, DOI 10.1016/1043-2760(92)90032-V; KANIS JA, 1993, DRUG AGING, V3, P391, DOI 10.2165/00002512-199303050-00001; KLEEREKOPER M, 1990, OSTEOPOROSIS INT, V1, P155; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; 1994, GUIDELINES PRECLINIC; 1994, WHO TECH REPORT SERI, V843	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					743	744		10.1016/S0140-6736(95)90635-5	http://dx.doi.org/10.1016/S0140-6736(95)90635-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891482				2022-12-01	WOS:A1995QN70100006
J	DUPIN, N; GRANDADAM, M; CALVEZ, V; GORIN, I; AUBIN, JT; HAVARD, S; LAMY, F; LEIBOWITCH, M; HURAUX, JM; ESCANDE, JP; AGUT, H				DUPIN, N; GRANDADAM, M; CALVEZ, V; GORIN, I; AUBIN, JT; HAVARD, S; LAMY, F; LEIBOWITCH, M; HURAUX, JM; ESCANDE, JP; AGUT, H			HERPESVIRUS-LIKE DNA-SEQUENCES IN PATIENTS WITH MEDITERRANEAN KAPOSIS-SARCOMA	LANCET			English	Note								DNA sequences closely related to herpesvirus-like sequences have been found in AIDS-associated Kaposi's sarcoma. Using PCR, we found herpesvirus-like DNA sequences in Kaposi's lesions and normal adjacent skin in five patients with Mediterranean Kaposi's sarcoma. We did not find these sequences in tissues from patients without Kaposi's sarcoma. Semi-quantitative PCR revealed many more herpesvirus-like sequences in Kaposi's lesions than in unaffected skin. Our results reinforce the hypothesis that an infectious agent closely related to gamma-herpesvirus is implicated in the pathogenesis of Mediterranean and AIDS-associated Kaposi's sarcoma.	GRP HOSP PITIE SALPETRIERE,VIROL LAB,CNRS,EP 57,F-75634 PARIS,FRANCE; TARNIER HOSP,DEPT DERMATOL,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			GRANDADAM, Marc/GNP-7470-2022	Dupin, Nicolas/0000-0002-6237-4951				CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; LAURE F, 1988, LANCET, V2, P538; SAIKI RK, 1988, SCIENCE, V39, P487; SCHULZ TF, 1995, NATURE, V373, P17, DOI 10.1038/373017a0; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	7	353	364	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					761	762		10.1016/S0140-6736(95)90642-8	http://dx.doi.org/10.1016/S0140-6736(95)90642-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891488				2022-12-01	WOS:A1995QN70100013
J	HARGREAVES, MR; FIROOZAN, S; FORFAR, JC				HARGREAVES, MR; FIROOZAN, S; FORFAR, JC			PRESCRIPTION OF REGULAR ASPIRIN IN PATIENTS WITH CHEST PAIN REFERRED TO A CARDIOLOGY OUTPATIENT-CLINIC	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANGINA; TRIAL				HARGREAVES, MR (corresponding author), JOHN RADCLIFFE HOSP, DEPT CARDIAC, OXFORD OX3 9DU, ENGLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; CANNON PJ, 1988, LANCET, V1, P979; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835	4	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	1995	310	6982					777	777		10.1136/bmj.310.6982.777	http://dx.doi.org/10.1136/bmj.310.6982.777			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711583	Green Published			2022-12-01	WOS:A1995QP60900019
J	HUANG, YQ; LI, JJ; KAPLAN, MH; POIESZ, B; KATABIRA, E; ZHANG, WC; FEINER, D; FRIEDMANKIEN, AE				HUANG, YQ; LI, JJ; KAPLAN, MH; POIESZ, B; KATABIRA, E; ZHANG, WC; FEINER, D; FRIEDMANKIEN, AE			HUMAN HERPESVIRUS-LIKE NUCLEIC-ACID IN VARIOUS FORMS OF KAPOSIS-SARCOMA	LANCET			English	Note								The association between a new human herpesvirus-like agent and various forms of Kaposi's sarcoma was examined by PCR. The DNA sequences of this agent were detected in 7 of 8 classic Kaposi's sarcoma specimens, 12 of 12 AIDS-associated specimens from the United States, and 7 of 10 specimens from African endemic Kaposi's sarcoma. Polymorphism of the herpesvirus-like DNA in the Kaposi's tissue from different populations was observed by both single-strand conformational polymorphism and direct sequencing. Furthermore, the presence and expression of the virus was detected in some Kaposi's tumours by Southern and northern blotting. This herpesvirus may be involved in the pathogenesis of different kinds of Kaposi's sarcoma seen among distinct and unrelated populations.	NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; N SHORE UNIV HOSP,DEPT MED,MANHASSET,NY; SUNY HLTH SCI CTR,CTR REG ONCOL,SYRACUSE,NY 13210; MULAGO HOSP,DEPT MED,WHO,KAMPALA,UGANDA	New York University; New York University; Northwell Health; North Shore University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Mulago National Referral Hospital; World Health Organization				Friedman Kien, Alvin/0000-0002-5854-2852				ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Buchbinder Aby, 1992, Current Opinion in Oncology, V4, P867, DOI 10.1097/00001622-199210000-00009; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; LI JJ, 1992, J CLIN MICROBIOL, V30, P1051, DOI 10.1128/JCM.30.5.1051-1055.1992; Miles Steven A., 1992, Current Opinion in Oncology, V4, P875, DOI 10.1097/00001622-199210000-00010; NICOLAIDES A, 1994, ANTICANCER RES, V14, P921; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	8	406	413	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					759	761		10.1016/S0140-6736(95)90641-X	http://dx.doi.org/10.1016/S0140-6736(95)90641-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891487	hybrid			2022-12-01	WOS:A1995QN70100012
J	MACSWEENEY, EJ; OADES, PJ; BUCHDAHL, R; ROSENTHAL, M; BUSH, A				MACSWEENEY, EJ; OADES, PJ; BUCHDAHL, R; ROSENTHAL, M; BUSH, A			RELATION OF THICKENING OF COLON WALL TO PANCREATIC-ENZYME TREATMENT IN CYSTIC-FIBROSIS	LANCET			English	Article							TRANSIT-TIME; CHILDREN; APPENDICITIS	Fibrotic strictures of the colon in association with colon-wall thickening on abdominal ultrasound have been described in children with cystic fibrosis. We determined the prevalence of colon-wall thickening in 99 children with cystic fibrosis (aged 6 months to 17 years, 45 male) and 38 healthy controls (aged 1 month to 39 years, 21 male). In controls, peristalsis was uniformly rapid and maximum wall thickness of the fully relaxed colon was 0.8 mm (median 0.6 mm). 24% of the patients had a colon-wall thickness of 1.5 mm or more (maximum 3.4 mm); 48% of children on high-strength pancreatin receiving more than 265 units/kg per day of protease had thickening of more than 1.5 mm compared with less than 12% of children on any other dose. Children on high-strength pancreatin were 5.2 (95% CI 1.2-21) times more likely to have colon-wall thickness of 1.5 mm or more than children taking less than 265 units/kg per day of protease in a standard-strength preparation. This risk rose to 10 (2.5-39) times more likely if laxatives were taken with a high-strength preparation. Lipase or amylase intake, age, sex, genotype, and other medical or drug history were not significantly associated with colon-wall thickening. 1 child required a hemicolectomy for bowel obstruction and another developed haemorrhagic colitis. In 17 children, 2 months after stopping high-strength, high protease, preparations and efforts to reduce enzyme intake, colon-wall thickness had regressed from a median 2.0 mm (range 1.0-3.4) to 1.8 mm (0.9-2.7) (p=0.005). The use of high-strength pancreatin preparations in conjunction with a high protease intake probably causes thickening of the wall of the colon.	ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT PAEDIAT RESP MED,LONDON SW3 6NP,ENGLAND; RIVERSIDE HOSP,DEPT RADIOL,LONDON,ENGLAND	Imperial College London				Oades, Patrick/0000-0001-5265-6923				Atkinson SN., 1991, EUR J CLIN RES, V1, P37; BALI A, 1983, BRIT MED J, V287, P1011, DOI 10.1136/bmj.287.6398.1011; BOWLER IM, 1993, ARCH DIS CHILD, V68, P227, DOI 10.1136/adc.68.2.227; CAMPBELL CA, 1994, LANCET, V343, P109; CRADY SK, 1993, ANN EMERG MED, V22, P1125, DOI 10.1016/S0196-0644(05)80976-X; DALZELL AM, 1990, ARCH DIS CHILD, V65, P585, DOI 10.1136/adc.65.6.585; DALZELL AM, 1990, ARCH DIS CHILD, V65, P540, DOI 10.1136/adc.65.5.540; Feigelson J, 1990, Acta Univ Carol Med (Praha), V36, P144; GROSS K, 1985, J PEDIATR SURG, V20, P431, DOI 10.1016/S0022-3468(85)80235-9; HOLMES M, 1991, ARCH DIS CHILD, V66, P726, DOI 10.1136/adc.66.6.726; INNES JA, 1994, LANCET, V343, P599; KEDAR RP, 1994, CLIN RADIOL, V49, P24, DOI 10.1016/S0009-9260(05)82909-5; KEELING JW, 1992, OXFORD TXB PATHOLOGY, P1192; KNABE N, 1994, LANCET, V343, P1230, DOI 10.1016/S0140-6736(94)92443-0; MAHONY MJ, 1994, LANCET, V343, P600; MILLA CE, 1994, LANCET, V343, P599, DOI 10.1016/S0140-6736(94)91551-2; MORRISON G, 1991, LANCET, V338, P1596, DOI 10.1016/0140-6736(91)92421-W; OADES PJ, 1994, LANCET, V343, P109, DOI 10.1016/S0140-6736(94)90836-2; OKEEFFE FN, 1991, RADIOLOGY, V178, P827, DOI 10.1148/radiology.178.3.1994426; ROBINSON PJ, 1990, ARCH DIS CHILD, V65, P311, DOI 10.1136/adc.65.3.311; SIEGEL MJ, 1991, JAMA-J AM MED ASSOC, V266, P1987, DOI 10.1001/jama.266.14.1987; SIVIT CJ, 1993, AM J ROENTGENOL, V161, P147, DOI 10.2214/ajr.161.1.8517294; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; TAYLOR CJ, 1994, LANCET, V343, P110; ZENTLERMUNRO PL, 1987, GUT, V28, P1531, DOI 10.1136/gut.28.11.1531; ZENTLERMUNRO PL, 1984, GUT, V25, P500, DOI 10.1136/gut.25.5.500; 1994, DATA SHEET CONPENDIU, P385	27	62	62	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					752	756						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7534369				2022-12-01	WOS:A1995QN70100010
J	MADHAVAN, S; STOCKWELL, D; COHEN, H; ALDERMAN, MH				MADHAVAN, S; STOCKWELL, D; COHEN, H; ALDERMAN, MH			RENAL-FUNCTION DURING ANTIHYPERTENSIVE TREATMENT	LANCET			English	Article							BLOOD-PRESSURE; ESSENTIAL-HYPERTENSION; WORK SITE; DISEASE; RISK	To determine the association of renal function and the course of blood pressure in antihypertensive therapy, we studied the changes in serum creatinine as a measure of renal function and in-treatment blood pressure in black and white hypertensive patients. We measured serum creatinine in 2125 mild and moderately hypertensive men during treatment over an average of 5 years. Both unadjusted mean initial and final serum creatinine of 758 blacks (113 and 117 mu mol/L respectively) were significantly higher than those of 1367 whites (108 and 107 mu mol/L), with a small increase of 4 mu mol/L (p<0.01) for blacks and a fall of 0.9 mu mol/L (p>0.05) for whites. Less than 2% of all patients attained or remained at a final serum creatinine of 177 mu mol/L or more. Of this small group (3% blacks, 1.4% whites), 31% had proteinuria at entry. After stratification by in-treatment diastolic blood pressure (<95 and greater than or equal to 95 mm Hg) in each race, mean slopes of reciprocal serum creatinine were estimated, adjusting for age at entry, initial serum creatinine, diastolic pressure, and body-mass index by analysis of covariance. The two adjusted mean slopes did not differ significantly within each race. Multiple regression analysis confirmed that in-treatment diastolic pressure was not independently associated with final serum creatinine. The change in renal function was most likely a reflection of regression towards the mean, and does not support the view that antihypertensive treatment is an important determinant of renal function in mild-to-moderate hypertensive patients. Patients with substantial renal insufficiency may have pre-existing intrinsic renal disease.			MADHAVAN, S (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.			Cohen, Hillel/0000-0002-4524-0898				ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; BRAZY PC, 1990, KIDNEY INT, V37, P1113, DOI 10.1038/ki.1990.93; DUSTAN HP, 1987, AM J CARDIOL, V60, pI73; LUKE RG, 1993, HYPERTENSION, V21, P380, DOI 10.1161/01.HYP.21.3.380; MADHAVAN S, 1994, HYPERTENSION, V23, P395, DOI 10.1161/01.HYP.23.3.395; MITCH WE, 1976, LANCET, V2, P1326; NOLAN CR, 1992, RENAL ELECTROLYTE DI, V9, P447; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P1272, DOI 10.1001/jama.269.10.1272; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; ROLLINGTON F, 1987, AM J PUBLIC HEALTH, V77, P864; ROSANSKY SJ, 1990, ARCH INTERN MED, V150, P2073, DOI 10.1001/archinte.150.10.2073; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; SELDIN DW, 1992, KIDNEY PHYSL PATHOPH, P947; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; Snedecor G.W., 1980, STAT METHODS, V7; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250	19	66	67	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	1995	345	8952					749	751		10.1016/S0140-6736(95)90638-X	http://dx.doi.org/10.1016/S0140-6736(95)90638-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891485				2022-12-01	WOS:A1995QN70100009
J	MARSH, GN; DAWES, ML				MARSH, GN; DAWES, ML			ESTABLISHING A MINOR ILLNESS NURSE IN A BUSY GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study the feasibility of a practice nurse caring for patients with minor illnesses. Design-Nurse given training in dealing with patients with minor illnesses. Patients requesting a same day appointment were offered a nurse consultation. Setting-Group practice in Stockton on Tees. Main outcome measures-Number of consultations which required a doctor contact, treatment, and rate of reconsultation. Results-Of 696 consultations in six months, 602 (86%) required no doctor contact. 549 (79%) patients did not reconsult about that episode of illness, and 343 (50%) patients were given advice on self care only. Conclusion-Trained nurses could diagnose and treat a large proportion of patients currently consulting general practitioners about minor illness provided that the nurse has immediate access to a doctor.			MARSH, GN (corresponding author), NORTON MED CTR,STOCKTON ON TEES TS20 1AN,CLEVELAND,ENGLAND.			Dawes, Martin/0000-0003-3624-2477				ATKIN K, 1993, NURSES COUNT NATIONA; BARNES G, 1985, J ROY COLL GEN PRACT, V35, P447; BOWLING A, 1988, NURSE FAMILY PRACTIC; CHAN CA, 1994, BR J GEN PRACT, V44, P263; JEWELL D, 1988, PRACTITIONER, V232, P484; JEWELL D, 1994, BRIT MED J, V308, P735, DOI 10.1136/bmj.308.6931.735; MARSH GN, 1991, EFFICIENT CARE GENER; READ SM, 1992, BRIT MED J, V305, P1466, DOI 10.1136/bmj.305.6867.1466; ROSS FM, 1994, BRIT J GEN PRACT, V44, P15; WAINE C, 1992, DIABETES GENERAL PRA; 1994, STATISTICAL B, V4	11	42	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					778	780		10.1136/bmj.310.6982.778	http://dx.doi.org/10.1136/bmj.310.6982.778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711584	Green Published			2022-12-01	WOS:A1995QP60900021
J	MCNAMEE, D				MCNAMEE, D			TAXOLS PEDIGREE	LANCET			English	Editorial Material																		1995, NATURE, V374, P11; 1995, NATURE, V374, P208	2	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					743	743		10.1016/S0140-6736(95)90634-7	http://dx.doi.org/10.1016/S0140-6736(95)90634-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891481				2022-12-01	WOS:A1995QN70100005
J	ABOUSSEKHRA, A; BIGGERSTAFF, M; SHIVJI, MKK; VILPO, JA; MONCOLLIN, V; PODUST, VN; PROTIC, M; HUBSCHER, U; EGLY, JM; WOOD, RD				ABOUSSEKHRA, A; BIGGERSTAFF, M; SHIVJI, MKK; VILPO, JA; MONCOLLIN, V; PODUST, VN; PROTIC, M; HUBSCHER, U; EGLY, JM; WOOD, RD			MAMMALIAN DNA NUCLEOTIDE EXCISION-REPAIR RECONSTITUTED WITH PURIFIED PROTEIN-COMPONENTS	CELL			English	Article							CELL NUCLEAR ANTIGEN; PIGMENTOSUM GROUP-F; BINDING-PROTEIN; DAMAGED DNA; REPLICATION PROTEIN; POLYMERASE-DELTA; TRANSCRIPTION FACTOR; PRIMATE CELLS; LIGASE-I; PURIFICATION	Nucleotide excision repair is the principal way by which human cells remove UV damage from DNA. Human cell extracts were fractionated to locate active components, including xeroderma pigmentosum (XP) and ERCC factors. The incision reaction was then reconstituted with the purified proteins RPA, XPA, TFIIH (containing XPB and XPD), XPC, UV-DDB, XPG, partially purified ERCC1/XPF complex, and a factor designated IF7. UV-DDB (related to XPE protein) stimulated repair but was not essential. ERCC1- and XPF-correcting activity copurified with an ERCC1-binding polypeptide of 110 kDa that was absent in XP-F cell extract. Complete repair synthesis was achieved by combining these factors with DNA polymerase epsilon, RFC, PCNA, and DNA ligase I. The reconstituted core reaction requires about 30 polypeptides.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV ZURICH IRCHEL,DEPT VET BIOCHEM,CH-8057 ZURICH,SWITZERLAND; NICHHD,DNA REPLICAT REPAIR & MUTAGENESIS,BETHESDA,MD 20892; TAMPERE UNIV HOSP,DEPT CLIN CHEM,SF-33521 TAMPERE,FINLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Zurich; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tampere University; Tampere University Hospital			MONCOLLIN, Vincent/R-1941-2017; Wood, Richard D/M-6319-2018	MONCOLLIN, Vincent/0000-0002-4163-0231; Wood, Richard D/0000-0002-9495-6892				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; CALSOU P, 1994, BIOCHEM BIOPH RES CO, V202, P788, DOI 10.1006/bbrc.1994.1999; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FELDBERG RS, 1976, BIOCHEMISTRY-US, V15, P2402, DOI 10.1021/bi00656a024; FLORES O, 1992, J BIOL CHEM, V267, P2786; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; GERARD M, 1991, J BIOL CHEM, V266, P20940; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MIURA M, 1992, J CELL PHYSIOL, V150, P370, DOI 10.1002/jcp.1041500221; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; REARDON JT, 1993, J BIOL CHEM, V268, P21301; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22729; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TREIBER DK, 1992, NUCLEIC ACIDS RES, V20, P5805, DOI 10.1093/nar/20.21.5805; VANASSENDELFT GB, 1993, NUCLEIC ACIDS RES, V21, P3399, DOI 10.1093/nar/21.15.3399; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WAGA S, 1994, J BIOL CHEM, V269, P10923; WEEDA G, 1993, SEMIN CANCER BIOL, V4, P105; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	57	738	761	5	88	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					859	868		10.1016/0092-8674(95)90289-9	http://dx.doi.org/10.1016/0092-8674(95)90289-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697716	Bronze			2022-12-01	WOS:A1995QP61200005
J	BABA, TW; JEONG, YS; PENNINCK, D; BRONSON, R; GREENE, MF; RUPRECHT, RM				BABA, TW; JEONG, YS; PENNINCK, D; BRONSON, R; GREENE, MF; RUPRECHT, RM			PATHOGENICITY OF LIVE, ATTENUATED SIV AFTER MUCOSAL INFECTION OF NEONATAL MACAQUES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; INDEPENDENT DOWN-REGULATION; VIRION-ASSOCIATED PROTEIN; CELL-SURFACE CD4; MUTATIONAL ANALYSIS; NEF-PROTEIN; THROMBOCYTOPENIC PURPURA; RHESUS MACAQUES; HOMOSEXUAL MEN	Adult macaques do not develop disease after infection with a nef deletion mutant of the simian immunodeficiency virus (SIV) and are protected against challenge with pathogenic virus. This finding led to the proposal to use nef-deleted viruses as live, attenuated vaccines to prevent human acquired immunodeficiency syndrome (AIDS). In contrast, neonatal macaques developed persistently high levels of viremia after oral exposure to an SIV nef, vpr, and negative regulatory element (NRE) deletion mutant. Severe hemolytic anemia, thrombocytopenia, and CD4(+) T cell depletion were observed, indicating that neither nef nor vpr determine pathogenicity in neonates. Because such constructs have retained their pathogenic potential, they should not be used as candidate live, attenuated virus vaccines against human AIDS.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,VIRAL PATHOGENESIS LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT PEDIAT,DIV NEWBORN MED,BOSTON,MA 02111; MASSACHUSETTS GEN HOSP,DEPT OBSTET & GYNECOL,BOSTON,MA 02114; TUFTS UNIV,SCH VET MED,DEPT RADIOL,GRAFTON,MA 01536; TUFTS UNIV,SCH VET MED,DEPT VET PATHOL,BOSTON,MA 02111	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Tufts University; Harvard University; Massachusetts General Hospital; Tufts University; Tufts University			Abrams, William R/A-5782-2008		PHS HHS [R01-A132330, R01-A135533] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AYEHUNIE S, UNPUB; BABA T, UNPUB; BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; BABA TW, 1993, J WOMENS HEALTH, V2, P231; BACHELERIE F, 1990, J VIROL, V64, P3059, DOI 10.1128/JVI.64.6.3059-3062.1990; BARRY PA, 1990, J MED PRIMATOL, V19, P327; BOLOGNESI DP, 1994, J NIH RES, V6, P55; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; CHINNECK JW, 1994, COMPUT OPER RES, V21, P1, DOI 10.1016/0305-0548(94)90057-4; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DENNY TN, 1990, PEDIATR RES, V27, pA155; Desrosiers R.C., 1994, J NIH RES, V6, P54; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P1457, DOI 10.1089/aid.1992.8.1457; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1994, AIDS RES HUM RETROV, V10, P221; DESROSIERS RC, 1994, 7TH ANN M NAT COOP V; FAZELY F, 1993, J ACQ IMMUN DEF SYND, V6, P107; FERNIE S, 1994, J TOXICOL ENV HLTH, V45, P53; FORSTER SM, 1987, AIDS, V1, P235; FOX CH, 1993, CURRENT PROTOCOLS IM; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; GOLDSWEIG HG, 1986, AM J HEMATOL, V21, P243, DOI 10.1002/ajh.2830210303; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HU SL, 1993, HIV MOL ORG PATHOGEN; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KLEGANOFF SJ, 1994, P NATL ACAD SCI USA, V91, P10615; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; LAIRMORE MD, 1990, AIDS RES HUM RETROV, V6, P1233, DOI 10.1089/aid.1990.6.1233; LAIRMORE MD, 1993, AIDS RES HUM RETROV, V9, P565, DOI 10.1089/aid.1993.9.565; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LITTMAN DR, 1994, CURR BIOL, V4, P618, DOI 10.1016/S0960-9822(00)00135-4; LU YC, 1989, J VIROL, V63, P4115, DOI 10.1128/JVI.63.9.4115-4119.1989; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; Mann J., 1992, AIDS WORLD GLOBAL RE; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MORRIS L, 1982, ANN INTERN MED, V96, P714, DOI 10.7326/0003-4819-96-6-714; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; OHKAWA S, 1990, FASEB J, V4, pA2264; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; RASZKA WV, 1994, PEDIATR INFECT DIS J, V13, P70, DOI 10.1097/00006454-199401000-00015; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; RUPRECHT RM, 1990, J ACQ IMMUN DEF SYND, V3, P591; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; RUPRECHT RM, 1994, DNA CELL BIOL, V13, P59, DOI 10.1089/dna.1994.13.59; SAVONA S, 1985, ANN INTERN MED, V102, P737, DOI 10.7326/0003-4819-102-6-737; SCHREIBNER ZA, 1983, BLOOD S, V92, pA117; SHIBATA R, 1990, J MED PRIMATOL, V19, P217; SHIBATA R, 1990, J VIROL, V64, P742, DOI 10.1128/JVI.64.2.742-747.1990; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SOSA MAG, 1991, AIDS RES HUM RETROV, V7, P859, DOI 10.1089/aid.1991.7.859; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TOY PTCY, 1985, AM J HEMATOL, V19, P145, DOI 10.1002/ajh.2830190206; TRAINADORGE V, 1992, AIDS RES HUM RETROV, V8, P97, DOI 10.1089/aid.1992.8.97; VIGLIANTI GA, 1988, J VIROL, V62, P4523, DOI 10.1128/JVI.62.12.4523-4532.1988; WALSH C, 1985, ANN INTERN MED, V103, P542, DOI 10.7326/0003-4819-103-4-542; WEBER JN, 1987, LANCET, V1, P121; Weiss R, 1984, RNA TUMOR VIRUSES; WILLIAMSHERMAN D, 1993, 9TH INT C AIDS BERL; WYAND MS, 1994, 1994 C ADV AIDS VACC; YU M, 1994, J NIH RES, V6, P20; YU XF, 1988, NATURE, V335, P262, DOI 10.1038/335262a0; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813	72	453	466	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1820	1825		10.1126/science.7892606	http://dx.doi.org/10.1126/science.7892606			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892606				2022-12-01	WOS:A1995QN70200039
J	BROWN, NL; SATTLER, CA; PADDOCK, SW; CARROLL, SB				BROWN, NL; SATTLER, CA; PADDOCK, SW; CARROLL, SB			HAIRY AND EMC NEGATIVELY REGULATE MORPHOGENETIC FURROW PROGRESSION IN THE DROSOPHILA EYE	CELL			English	Article							POLARITY GENE HEDGEHOG; CELL-INTERACTIONS; PATTERN-FORMATION; NERVOUS-SYSTEM; PRONEURAL GENE; ACHAETE; EXTRAMACROCHAETAE; DIFFERENTIATION; EXPRESSION; RETINA	The initial steps of pattern formation in the developing Drosophila eye involve the coordination of cell cycles, changes in cell shape, and the specification of the R8 photoreceptor cell. These events begin several cell rows ahead of the morphogenetic furrow and are positively regulated by secreted signaling proteins and the proneural HLH transcription factor atonal (ate). Two HLH regulatory proteins that function to suppress neuronal development in other tissues, extra macrochaetae (emc) and hairy (h), are expressed ahead of the morphogenetic furrow. While neither h nor emc is required for photoreceptor cell determination, in emc-h-clones the morphogenetic furrow and differentiated eye field advance up to eight ommatidial rows ahead of adjacent wild-type tissue. This indicates that morphogenetic furrow progression and neuronal differentiation are negatively regulated by a combination of anteriorly expressed HLH regulatory proteins.	UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV WISCONSIN,BOCK LABS,MADISON,WI 53706; UNIV WISCONSIN,MCARDLE LAB,MADISON,WI 53706	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			, Nadean/HCH-9314-2022		NCI NIH HHS [CA-07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BLAIR S, 1992, DEVELOPMENT, V119, P339; BODENSTEIN D, 1953, INSECT PHYSL, P822; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BROWN NL, 1991, DEVELOPMENT, V113, P1245; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P246; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; ELLIS HM, 1994, MECH DEVELOP, V47, P65, DOI 10.1016/0925-4773(94)90096-5; GARCIAALONSO L, 1988, ROUX ARCH DEV BIOL, V197, P328; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; NOWEL MS, 1980, J EMBRYOL EXP MORPH, V60, P329; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; ORENIC TV, 1993, DEVELOPMENT, V118, P9; PADDOCK SW, 1993, BIOTECHNIQUES, V1, P442; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; SHELTON PMJ, 1974, J EMBRYOL EXP MORPH, V32, P337; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WHITE RH, 1963, J EXP ZOOL, V148, P223; WOLFF T, 1991, DEVELOPMENT, V113, P841; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	43	121	122	1	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					879	887		10.1016/0092-8674(95)90291-0	http://dx.doi.org/10.1016/0092-8674(95)90291-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697718	Bronze			2022-12-01	WOS:A1995QP61200007
J	CHENG, Y; DAHLBERG, JE; LUND, E				CHENG, Y; DAHLBERG, JE; LUND, E			DIVERSE EFFECTS OF THE GUANINE-NUCLEOTIDE EXCHANGE FACTOR RCC1 ON RNA TRANSPORT	SCIENCE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; VESICULAR STOMATITIS-VIRUS; CHROMOSOME CONDENSATION; MESSENGER-RNA; BINDING PROTEIN; PORE COMPLEX; CELL-CYCLE; DNA; REGULATOR; MUTANT	Transport of RNAs within nuclei and through nuclear pore complexes (NPCs) are essential, but poorly understood, steps in gene expression. In experiments with mammalian cells, RCC1, the abundant nuclear guanine nucleotide exchange factor for the guanosine triphosphatase Ran/TC4, was shown to be required for nucleocytoplasmic transport of precursors of spliceosomal small nuclear RNAs (snRNAs), intranuclear transport of U3 snRNA, and processing of ribosomal RNAs, but not for export of transfer RNAs. It is proposed that guanosine triphosphate (GTP)-bound Ran/TC4 associates with ribonucleoprotein particles (RNPs) during intranuclear movement, and that GTP hydrolysis promotes deposition of RNPs at targeted sites such as NPCs or nucleoli.	UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM 30220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BRINGMANN P, 1983, EMBO J, V2, P1129, DOI 10.1002/j.1460-2075.1983.tb01557.x; Cheng Y., UNPUB; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CRONE DE, 1989, J VIROL, V63, P4172, DOI 10.1128/JVI.63.10.4172-4180.1989; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ELLIOTT DJ, 1994, CURR OPIN GENET DEV, V4, P305, DOI 10.1016/S0959-437X(05)80058-9; FILIPOWICZ W, 1993, MOL BIOL REP, V18, P149, DOI 10.1007/BF00986770; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; FRESCO LD, 1987, MOL CELL BIOL, V7, P1148, DOI 10.1128/MCB.7.3.1148; GURNEY T, 1980, J CELL BIOL, V87, P398, DOI 10.1083/jcb.87.2.398; HUANG SD, COMMUNICATION; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Maquat LE, 1991, CURR OPIN CELL BIOL, V3, P1004, DOI 10.1016/0955-0674(91)90121-E; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MUNNS TW, 1982, BIOCHEMISTRY-US, V21, P2922, DOI 10.1021/bi00541a018; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PATTON JR, 1987, MOL CELL BIOL, V7, P4030, DOI 10.1128/MCB.7.11.4030; Reddy R, 1988, STRUCTURE FUNCTION M, P1, DOI [10.1007/978-3-642-73020-7_1, 10.1007/978-3-642-73020-7_1.]; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; ROSBASH M, 1993, CELL, V75, P399, DOI 10.1016/0092-8674(93)90373-X; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; TARTAKOFF A, COMMUNICATION; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604; ZIEVE GW, 1987, J CELL PHYSIOL, V131, P247, DOI 10.1002/jcp.1041310215	48	113	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1807	1810		10.1126/science.7534442	http://dx.doi.org/10.1126/science.7534442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7534442				2022-12-01	WOS:A1995QN70200035
J	CHONG, JHA; TAPIARAMIREZ, J; KIM, S; TOLEDOARAL, JJ; ZHENG, YC; BOUTROS, MC; ALTSHULLER, YM; FROHMAN, MA; KRANER, SD; MANDEL, G				CHONG, JHA; TAPIARAMIREZ, J; KIM, S; TOLEDOARAL, JJ; ZHENG, YC; BOUTROS, MC; ALTSHULLER, YM; FROHMAN, MA; KRANER, SD; MANDEL, G			REST - A MAMMALIAN SILENCER PROTEIN THAT RESTRICTS SODIUM-CHANNEL GENE-EXPRESSION TO NEURONS	CELL			English	Article							NERVE GROWTH-FACTOR; RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; AMPLIFICATION; INITIATION; REPRESSION; EUKARYOTES; ELEMENT; CELLS; YEAST	Expression of the type II voltage-dependent sodium channel gene is restricted to neurons by a silencer element active in nonneuronal cells. We have cloned cDNA coding for a transcription factor (REST) that binds to this silencer element. Expression of a recombinant REST protein confers the ability to silence type II reporter genes in neuronal cell types lacking the native REST protein, whereas expression of a dominant negative form of REST in nonneuronal cells relieves silencing mediated by the native protein. REST transcripts in developing mouse embryos are detected ubiquitously outside of the nervous system. We propose that expression of the type II sodium channel gene in neurons reflects a default pathway that is blocked in nonneuronal cells by the presence of REST.	SUNY STONY BROOK,DEPT PHARMACOL,STONY BROOK,NY 11794; UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of Pennsylvania	CHONG, JHA (corresponding author), SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794, USA.		Toledo-Aral, Juan J/F-2613-2015; IBIS, TERAPIA CELULA/P-3297-2015; Boutros, Michael/C-3566-2008	Toledo-Aral, Juan J/0000-0001-7512-7135; Boutros, Michael/0000-0002-9458-817X; Tapia, Jose/0000-0002-4641-7181				BARTEL PL, 1994, CELLULAR INTERACTION, P153; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DARCANGELO G, 1993, J CELL BIOL, V4, P915; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREEN JBA, 1994, CELL, V77, P317, DOI 10.1016/0092-8674(94)90145-7; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; JAN YN, 1995, NEURON, V14, P1; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KRANER S, 1991, BIOMED RES-TOKYO, V12, P27; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEWIN G, 1994, CELL, V79, P935; LI KJ, 1993, SCIENCE, V262, P1870; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LINDSELL P, 1994, J PHYSL, V480, P405; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NEDIVI E, 1992, J NEUROSCI, V12, P691; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P998; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F., 1986, METHODS YEAST GENETI; TOLEDOARAL JJ, 1995, NEURON, V14, P607, DOI 10.1016/0896-6273(95)90317-8; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; ZHAO C, 1995, NATURE, V373, P74, DOI 10.1038/373074a0	46	896	915	1	31	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					949	957		10.1016/0092-8674(95)90298-8	http://dx.doi.org/10.1016/0092-8674(95)90298-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697725	hybrid			2022-12-01	WOS:A1995QP61200014
J	CONSTANTZ, BR; ISON, IC; FULMER, MT; POSER, RD; SMITH, ST; VANWAGONER, M; ROSS, J; GOLDSTEIN, SA; JUPITER, JB; ROSENTHAL, DI				CONSTANTZ, BR; ISON, IC; FULMER, MT; POSER, RD; SMITH, ST; VANWAGONER, M; ROSS, J; GOLDSTEIN, SA; JUPITER, JB; ROSENTHAL, DI			SKELETAL REPAIR BY IN-SITU FORMATION OF THE MINERAL PHASE OF BONE	SCIENCE			English	Article								A process has been developed for the in situ formation of the mineral phase of bone. inorganic calcium and phosphate sources are combined to form a paste that is surgically implanted by injection. Under physiological conditions, the material hardens in minutes concurrent with the formation of dahllite. After 12 hours, dahllite formation was nearly complete, and an ultimate compressive strength of 55 megapascals was achieved. The composition and crystal morphology of the dahllite formed are similar to those of bone. Animal studies provide evidence that the material is remodeled in vivo. A novel approach to skeletal repair is being tested in human trials for various applications; in one of the trials the new biomaterial is being percutaneously placed into acute fractures. After hardening, it serves as internal fixation to maintain proper alignment while healing occurs.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; UNIV MICHIGAN,ORTHORPAED SURG SECT,ANN ARBOR,MI 48109; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Stanford University; University of Michigan System; University of Michigan; Harvard University; Massachusetts General Hospital	CONSTANTZ, BR (corresponding author), NORIAN CORP,CUPERTINO,CA 95014, USA.							ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; CONSTANTZ BR, 1992, MATER RES SOC SYMP P, V252, P79; Cullity B.D, 1978, ELEMENTS XRAY DIFFRA, V2nd ed., P99; DIAS JJ, 1987, INJURY, V18, P304, DOI 10.1016/0020-1383(87)90047-7; Fess EE., 1992, CLIN ASSESSMENT RECO, P41; FRANKENBURG EP, 1994, 40TH T ANN M ORTH RE, V19, P157; GLIMCHER MJ, 1981, J CRYST GROWTH, V53, P100, DOI 10.1016/0022-0248(81)90058-0; JUPITER JB, 1991, J BONE JOINT SURG AM, V73A, P461, DOI 10.2106/00004623-199173030-00019; MCCONNELL D, 1952, J DENT RES, V31, P53, DOI 10.1177/00220345520310012301; NELSON DGA, 1981, J DENT RES, V60, P1621, DOI 10.1177/002203458106000312011; Pool C, 1973, J Bone Joint Surg Br, V55, P540; Posner A. S., 1984, Phosphate Minerals, P330; POST JE, 1989, REV MINERAL, V20, P277; REY C, 1991, CALCIFIED TISSUE INT, V49, P251, DOI 10.1007/BF02556214; ROHL L, 1991, J BIOMECH, V24, P1143, DOI 10.1016/0021-9290(91)90006-9; SCHLESINGER PH, 1991, AM J PHYS, V260, pC1315; SCHMALHOLZ A, 1990, CLIN ORTHOP RELAT R, V254, P236; Vaes G., 1988, CLIN ORTHOP RELAT R, V231, P239; Weiner S., 1989, BIOMINERALIZATION, P144; Wolff J., 1892, TRANSFORMATION KNOCH	20	608	668	2	93	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1796	1799		10.1126/science.7892603	http://dx.doi.org/10.1126/science.7892603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892603				2022-12-01	WOS:A1995QN70200031
J	ERNST, JA; CLUBB, RT; ZHOU, HX; GRONENBORN, AM; CLORE, GM				ERNST, JA; CLUBB, RT; ZHOU, HX; GRONENBORN, AM; CLORE, GM			DEMONSTRATION OF POSITIONALLY DISORDERED WATER WITHIN A PROTEIN HYDROPHOBIC CAVITY BY NMR	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; FOLDING THERMODYNAMICS; TRYPSIN-INHIBITOR; CRYSTAL-STRUCTURE; AQUEOUS-SOLUTION; INTERLEUKIN-1-BETA; HYDRATION; SPECTROSCOPY; RESOLUTION; MOLECULES	The presence and location of water of hydration (thai is, bound water) in the solution structure of human interleukin-1 beta (hIL-1 beta) was investigated with water-selective two-dimensional heteronuclear magnetic resonance spectroscopy. It is shown here that in addition to water al the surface of the protein and ordered internal water molecules involved in bridging hydrogen bonds, positionally disordered water is present within a large, naturally occurring hydrophobic cavity located at the center oi the molecule. These water molecules of hydration have residency times in the range of 1 to 2 nanoseconds to 100 to 200 microseconds and can be readily detected by nuclear magnetic resonance (NMR). Thus, large hydrophobic cavities in proteins may not be truly empty, as analysis oi crystal structures appears to show, but may contain mobile water molecules that are crystallographically invisible but detectable by NMR.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Zhou, Huan-Xiang/M-5170-2016; Zhou, Huan-Xiang/AAH-9836-2020; zhou, huan/GYJ-4398-2022; Clore, G. Marius/A-3511-2008	Zhou, Huan-Xiang/0000-0001-9020-0302; Zhou, Huan-Xiang/0000-0001-9020-0302; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				Ben-Naim A.Y., 2013, SOLVATION THERMODYNA; BENNAIM A, 1984, J CHEM PHYS, V81, P2016, DOI 10.1063/1.447824; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1994, STRUCTURE, V2, P89, DOI 10.1016/S0969-2126(00)00011-3; DELAGLIO F, 1994, 35TH P EXP NUCL MAGN, P262; EDSALL JT, 1983, ADV BIOPHYS, V16, P53; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FINNEY JL, 1977, PHILOS T ROY SOC B, V278, P3, DOI 10.1098/rstb.1977.0029; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRZESIEK S, 1994, J AM CHEM SOC, V116, P1581, DOI 10.1021/ja00083a058; GRZESIEK S, 1993, J BIOMOL NMR, V3, P627; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; JEFFERY GA, 1994, HYDROGEN BONDING BIO, V14, P770; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; KARPLUS PA, 1994, CURR OPIN STRUC BIOL, V4, P770, DOI 10.1016/S0959-440X(94)90178-3; KOSSIAKOFF AA, 1992, PROTEINS, V12, P223, DOI 10.1002/prot.340120303; LEE TW, 1970, J CHEM PHYS, V52, P6353; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; Lovas F. J., 1978, Journal of Physical and Chemical Reference Data, V7, P1445, DOI 10.1063/1.555588; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MCLACHLAN AD, 1979, J MOL BIOL, V133, P557, DOI 10.1016/0022-2836(79)90408-X; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ONESTI S, 1991, J MOL BIOL, V217, P153, DOI 10.1016/0022-2836(91)90618-G; OTTING G, 1989, J AM CHEM SOC, V111, P1871, DOI 10.1021/ja00187a050; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PRATT LR, 1980, J CHEM PHYS, V73, P3430, DOI 10.1063/1.440540; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; RAVISHANKER G, 1982, FARADAY S CHEM SER, V17, P70; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WALSHAW J, 1993, J MOL BIOL, V231, P392, DOI 10.1006/jmbi.1993.1290; Westhof E., 1993, WATER BIOL MACROMOLE; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; WOLFENDEN R, 1994, SCIENCE, V265, P936, DOI 10.1126/science.8052849; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHOU HX, 1993, BIOPHYS J, V65, P955, DOI 10.1016/S0006-3495(93)81094-4; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	49	238	243	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1813	1817		10.1126/science.7892604	http://dx.doi.org/10.1126/science.7892604			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892604				2022-12-01	WOS:A1995QN70200037
J	FOURCADE, O; SIMON, MF; VIODE, C; RUGANI, N; LEBALLE, F; RAGAB, A; FOURNIE, B; SARDA, L; CHAP, H				FOURCADE, O; SIMON, MF; VIODE, C; RUGANI, N; LEBALLE, F; RAGAB, A; FOURNIE, B; SARDA, L; CHAP, H			SECRETORY PHOSPHOLIPASE A(2) GENERATES THE NOVEL LIPID MEDIATOR LYSOPHOSPHATIDIC ACID IN MEMBRANE MICROVESICLES SHED FROM ACTIVATED CELLS	CELL			English	Article							HUMAN-ERYTHROCYTES; PLASMA-MEMBRANE; RED-CELL; PURIFIED PHOSPHOLIPASES; ASYMMETRIC DISTRIBUTION; PROCOAGULANT ACTIVITY; PLATELET AGGREGATION; POSSIBLE INVOLVEMENT; II PHOSPHOLIPASE-A2; EXPRESSION	Nonpancreatic secretory phospholipase A(2) (sPLA(2)) displays proinflammatory properties; however, its physiological substrate is not identified. Although inactive toward intact cells, sPLA(2) hydrolyzed phospholipids in membrane microvesicles shed from Ca2+-loaded erythrocytes as well as from platelets and from whole blood cells challenged with inflammatory stimuli. sPLA(2) was stimulated upon degradation of sphingomyelin (SPH) and produced lysophosphatidic acid (LPA), which induced platelet aggregation. Finally, lysophospholipid-containing vesicles and sPLA(2) were detected in inflammatory fluids in relative proportions identical to those used in vitro. We conclude that upon loss of phospholipid asymmetry, cell-derived microvesicles provide a preferential substrate for sPLA(2). SPH hydrolysis, which is provoked by various cytokines, regulates sPLA(2) activity, and the novel lipid mediator LPA can be generated by this pathway.	HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE; FAC ST CHARLES,INST CHIM BIOL,F-13331 MARSEILLE 3,FRANCE; HOP PURPAN,SERV RHUMATOL,F-31059 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse								AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; ALLAN D, 1981, BIOCHEM J, V198, P433, DOI 10.1042/bj1980433; ALLAN D, 1975, NATURE, V258, P348, DOI 10.1038/258348a0; ALLAN D, 1980, BIOCHEM J, V188, P881, DOI 10.1042/bj1880881; ALLAN D, 1976, BIOCHEM J, V156, P225, DOI 10.1042/bj1560225; ARDLIE NG, 1970, BRIT J HAEMATOL, V19, P7, DOI 10.1111/j.1365-2141.1970.tb01596.x; ARVAND M, 1990, J BIOL CHEM, V265, P14377; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P4917, DOI 10.1073/pnas.90.11.4917; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BEVERS EM, 1992, BLOOD, V79, P380, DOI 10.1182/blood.V79.2.380.380; BHAKDI S, 1994, MED MICROBIOL IMMUN, V183, P119, DOI 10.1007/BF00196048; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA R, 1987, BIOCHIM BIOPHYS ACTA, V902, P253, DOI 10.1016/0005-2736(87)90303-8; CHANG CP, 1993, J BIOL CHEM, V268, P7171; CHAP HJ, 1977, BIOCHIM BIOPHYS ACTA, V467, P146, DOI 10.1016/0005-2736(77)90192-4; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1994, J BIOL CHEM, V269, P2399; DEVAUX PF, 1993, CURR OPIN STRUC BIOL, V3, P489, DOI 10.1016/0959-440X(93)90072-S; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FADOK VA, 1992, J IMMUNOL, V149, P4029; FRANKEN PA, 1992, EUR J BIOCHEM, V203, P89, DOI 10.1111/j.1432-1033.1992.tb19832.x; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIDI R, 1993, J IMMUNOL, V151, P5613; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUCO G, 1978, BIOCHIMIE, V60, P653, DOI 10.1016/S0300-9084(78)80784-6; MINTA JO, 1983, METHOD ENZYMOL, V93, P375; MIYAKE A, 1994, EUR J PHARMACOL, V253, P155; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NICULESCU F, 1993, J IMMUNOL, V150, P214; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; PFEILSCHIFTER J, 1994, J CLIN INVEST, V92, P2516; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; RANSAC S, 1992, EUR J BIOCHEM, V204, P793, DOI 10.1111/j.1432-1033.1992.tb16697.x; RAVAL PJ, 1984, BIOCHIM BIOPHYS ACTA, V772, P192, DOI 10.1016/0005-2736(84)90043-9; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; RUGANI N, 1992, J CHROMATOGR-BIOMED, V583, P246, DOI 10.1016/0378-4347(92)80560-D; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SCHWARTZ RS, 1985, J CLIN INVEST, V75, P1965, DOI 10.1172/JCI111913; SCOTT S, 1984, BIOCHEM J, V224, P285, DOI 10.1042/bj2240285; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHUKLA SD, 1978, BIOCHIM BIOPHYS ACTA, V512, P341, DOI 10.1016/0005-2736(78)90258-4; SIMON MF, 1982, BIOCHEM BIOPH RES CO, V108, P1743, DOI 10.1016/S0006-291X(82)80113-7; STEIN JM, 1991, BIOCHEM J, V274, P381, DOI 10.1042/bj2740381; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; THANNHAUSER TW, 1985, BIOCHEMISTRY-US, V24, P7681, DOI 10.1021/bi00347a027; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	70	473	481	0	14	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					919	927		10.1016/0092-8674(95)90295-3	http://dx.doi.org/10.1016/0092-8674(95)90295-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697722	Bronze			2022-12-01	WOS:A1995QP61200011
J	HALDER, G; CALLAERTS, P; GEHRING, WJ				HALDER, G; CALLAERTS, P; GEHRING, WJ			INDUCTION OF ECTOPIC EYES BY TARGETED EXPRESSION OF THE EYELESS GENE IN DROSOPHILA	SCIENCE			English	Article							MEDIATED ENHANCER DETECTION; HOMEOBOX-CONTAINING GENE; BASE-PAIRS; HOX CODES; MELANOGASTER; ANTENNAPEDIA; REGION; TRANSFORMATIONS; CHROMOSOME; VERTEBRAE	The Drosophila gene eyeless (ey) encodes a transcription factor with both a paired domain and a homeodomain. It is homologous to the mouse Small eye (Pax-6) gene and to the Aniridia gene in humans. These genes share extensive sequence identity, the position of three intron splice sites is conserved, and these genes are expressed similarly in the developing nervous system and in the eye during morphogenesis. Loss-of-function mutations in both the insect and in the mammalian genes have been shown to lead to a reduction or absence of eye structures, which suggests that ey functions in eye morphogenesis. By targeted expression of the ey com plementary DNA in various imaginal disc primordia of Drosophila, ectopic eye structures were induced on the wings, the legs, and on the antennae. The ectopic eyes appeared morphologically normal and consisted of groups of fully differentiated ommatidia with a complete set of photoreceptor cells. These results support the proposition that ey is the master control gene for eye morphogenesis, Because homologous genes are present in vertebrates, ascidians, insects, cephalopods, and nemerteans, ey may function as a master control gene throughout the metazoa.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel			Halder, Georg/F-2966-2015; Callaerts, Patrick/I-8118-2013	Halder, Georg/0000-0001-7580-3236; Callaerts, Patrick/0000-0003-4530-4561				[Anonymous], COMMUNICATION; ASHBURNER M, 1989, LABORATORY MANUAL; BACHILLER D, 1994, EMBO J, V13, P1930, DOI 10.1002/j.1460-2075.1994.tb06462.x; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOSSY B, 1984, EMBO J, V3, P2537, DOI 10.1002/j.1460-2075.1984.tb02169.x; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRIDGES CB, 1935, Z BIOL, V4, P401; CALLAERTS P, UNPUB; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; Dickson Barry, 1993, P1327; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; GAUSZ J, 1986, GENETICS, V112, P65; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GIBSON G, 1988, DEVELOPMENT, V102, P657; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; HALL LMC, 1983, J MOL BIOL, V169, P83, DOI 10.1016/S0022-2836(83)80176-4; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOCHMANN B, 1971, GENETICS, V62, P235; Hoge MA, 1915, AM NAT, V49, P47, DOI 10.1086/279455; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cellbio.8.1.227; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAMKA M, 1992, DEVELOPMENT, V116, P8412; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, P1133; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Meinertzhagen Ian A., 1993, P1363; MIRKOVITCH J, 1986, J MOL BIOL, V190, P255, DOI 10.1016/0022-2836(86)90296-2; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SERIKAKU MA, 1994, GENETICS, V138, P1137; Spemann H., 1938, EMBRYONIC DEV INDUCT; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; WOLFF R, 1993, DEV DROSOPHILA MELAN, P1277; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	53	1152	1195	3	166	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1788	1792		10.1126/science.7892602	http://dx.doi.org/10.1126/science.7892602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892602				2022-12-01	WOS:A1995QN70200029
J	JO, K; TOPAL, MD				JO, K; TOPAL, MD			DNA TOPOISOMERASE AND RECOMBINASE ACTIVITIES IN NAE-I RESTRICTION-ENDONUCLEASE	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; RECOGNITION SITES; ECORII; CONFORMATION; INTEGRATION; SPERMIDINE; ACTIVATION; MECHANISM; CLEAVAGE; BINDING	Nae I endonuclease must bind to two DNA sequences for cleavage. Examination of the amino acid sequence of Nae I uncovered similarity to the active site of human DNA ligase I, except for leucine 43 in Nae I instead of the lysine essential for ligase activity. Changing leucine 43 to lysine 43 (L43K) changed Nae I activity: Nae I-L43K relaxed supercoiled DNA to yield DNA topoisomers and recombined DNA to give dimeric molecules. Interruption of the reactions of Nae I and Nae I-L43K with DNA demonstrated transient protein-DNA covalent complexes. These findings imply coupled endonuclease and ligase domains and link Nae I endonuclease to the topoisomerase and recombinase protein families.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARBER W, 1990, J STRUCT BIOL, V104, P107, DOI 10.1016/1047-8477(90)90064-J; BAXTER BK, 1993, BIOCHEMISTRY-US, V32, P8291, DOI 10.1021/bi00083a033; CHANG S, 1977, P NATL ACAD SCI USA, V74, P4811, DOI 10.1073/pnas.74.11.4811; COLUMNA EA, 1993, ENVIRON MOL MUTAGEN, V22, P26, DOI 10.1002/em.2850220106; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; CRAIG NL, 1988, ANNU REV GENET, V22, P77; GABBARA S, 1992, J BIOL CHEM, V267, P18623; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HOLTZ JK, 1994, J BIOL CHEM, V269, P27286; Kornberg A., 1991, DNA REPLICATION; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PICHEL JG, 1993, ONCOGENE, V8, P3333; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; ROBERTS RJ, 1976, CRC CR REV BIOCH MOL, V4, P123, DOI 10.3109/10409237609105456; SAUER B, 1990, New Biologist, V2, P441; SCHIESTL RH, 1991, P NATL ACAD SCI USA, V88, P7585, DOI 10.1073/pnas.88.17.7585; THRESHER R, 1992, METHOD ENZYMOL, V211, P481; TOPAL MD, 1993, NUCLEIC ACIDS RES, V21, P2599, DOI 10.1093/nar/21.11.2599; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019; YANG CC, 1994, BIOCHEMISTRY-US, V33, P14918, DOI 10.1021/bi00253a031	27	54	55	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1817	1820		10.1126/science.7892605	http://dx.doi.org/10.1126/science.7892605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892605				2022-12-01	WOS:A1995QN70200038
J	KUMAR, J; YU, H; SHEETZ, MP				KUMAR, J; YU, H; SHEETZ, MP			KINECTIN, AN ESSENTIAL ANCHOR FOR KINESIN-DRIVEN VESICLE MOTILITY	SCIENCE			English	Article							CYTOPLASMIC DYNEIN; AXONAL-TRANSPORT; MOTOR; MICROTUBULES; CELLS; ORGANELLES; PROTEINS; MOVEMENT; GRANULES; INVITRO	The membrane anchor for the molecular motor kinesin is a critical site involved in intracellular membrane trafficking. Monoclonal antibodies specific for the; cytoplasmic surface of chick brain microsomes were used to define proteins involved in microtubule-dependent transport. One of four antibodies tested inhibited plus-end-directed vesicle motility by approximately 90 percent even as a monovalent Fab fragment and reduced kinesin binding to vesicles. This antibody bound to the cytoplasmic domain of kinectin, an integral membrane protein of the endoplasmic reticulum that binds to kinesin. Thus, kinectin acted as a membrane anchor protein for kinesin-driven vesicle motility.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University			Yu, Hanry/C-7375-2011; Yu, Hanry/C-1031-2013; Yu, Hanry/L-6050-2019	Yu, Hanry/0000-0002-0339-3685; Yu, Hanry/0000-0002-0339-3685	NINDS NIH HHS [NS 23345] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023345] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BURKHARDT JK, 1993, J CELL SCI, V104, P151; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; KUMAR J, UNPUB; LACEY ML, 1994, CELL MOTIL CYTOSKEL, V28, P205, DOI 10.1002/cm.970280304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SHEETZ MP, 1986, J CELL SCI, P181; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; YU H, 1992, J BIOL CHEM, V267, P20457; YU H, IN PRESS MOL BIOL CE	29	135	137	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1834	1837		10.1126/science.7892610	http://dx.doi.org/10.1126/science.7892610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892610				2022-12-01	WOS:A1995QN70200043
J	LETSOU, A; ARORA, K; WRANA, JL; SIMIN, K; TWOMBLY, V; JAMAL, J; STAEHLINGHAMPTON, K; HOFFMANN, FM; GELBART, WM; MASSAGUE, J; OCONNOR, MB				LETSOU, A; ARORA, K; WRANA, JL; SIMIN, K; TWOMBLY, V; JAMAL, J; STAEHLINGHAMPTON, K; HOFFMANN, FM; GELBART, WM; MASSAGUE, J; OCONNOR, MB			DROSOPHILA DPP SIGNALING IS MEDIATED BY THE PUNT GENE-PRODUCT - A DUAL LIGAND-BINDING TYPE-II RECEPTOR OF THE TGF-BETA RECEPTOR FAMILY	CELL			English	Article							GROWTH-FACTOR-BETA; VISCERAL MESODERM; ACTIVIN RECEPTOR; GERM LAYERS; MELANOGASTER; EXPRESSION; KINASE; EMBRYOS; PATTERN; COMPLEX	Signaling by TGF beta-related factors requires ligand-induced association between type I and type II transmembrane serine/threonine kinases. In Drosophila, the saxophone (sax) and thick veins (tkv) genes encode type I receptors that mediate signaling by decapentaplegic (dpp), a member of the bone morphogenetic protein (BMP) subgroup of TGF beta-type factors. In this report, we demonstrate that the Drosophila punt gene encodes atr-ll, a previously described type II receptor that on its own is able to bind activin but not BMP2, a vertebrate ortholog of dpp. Mutations in punt produce phenotypes similar to those exhibited by tkv, sax, and dpp mutants. Furthermore, punt will bind BMP2 in concert with tkv or sax, forming complexes with these receptors. We suggest that punt functions as a type II receptor for dpp and propose that BMP signaling in vertebrates may also involve sharing of type II receptors by diverse ligands.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,GENET LAB,MADISON,WI 53706	University of California System; University of California Irvine; University of California System; University of California Irvine; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Harvard University; University of Wisconsin System; University of Wisconsin Madison	LETSOU, A (corresponding author), UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Wrana, Jeffrey/F-8857-2013; O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506; Massague, Joan/0000-0001-9324-8408; Hoffmann, F. Michael/0000-0002-2770-9656				AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; CHOU TB, 1993, DEVELOPMENT, V119, P1359; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Maniatis T., 1982, MOL CLONING; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NUSSLEINVOLHARD C, 1984, W ROUXS ARCH DEV BIO, V183, P267; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTO.K, 1994, DEV BIOL, V164, P502; STAEHLINGHAMPTO.K, 1994, NATURE, V372, P783; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TERRACOL R, 1994, GENETICS, V138, P165; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	50	236	243	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					899	908		10.1016/0092-8674(95)90293-7	http://dx.doi.org/10.1016/0092-8674(95)90293-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697720	Bronze			2022-12-01	WOS:A1995QP61200009
J	LIN, D; SUGAWARA, T; STRAUSS, JF; CLARK, BJ; STOCCO, DM; SAENGER, P; ROGOL, A; MILLER, WL				LIN, D; SUGAWARA, T; STRAUSS, JF; CLARK, BJ; STOCCO, DM; SAENGER, P; ROGOL, A; MILLER, WL			ROLE OF STEROIDOGENIC ACUTE REGULATORY PROTEIN IN ADRENAL AND GONADAL STEROIDOGENESIS	SCIENCE			English	Article							CHAIN CLEAVAGE ENZYME; LEYDIG TUMOR-CELLS; MITOCHONDRIAL PROTEINS; CHOLESTEROL; HYPERPLASIA; PRECURSORS; MOVEMENT; PATIENT; GENES	Congenital lipoid adrenal hyperplasia is an autosomal recessive disorder that is characterized by impaired synthesis of all adrenal and gonadal steroid hormones. In three unrelated individuals with this disorder, steroidogenic acute regulatory protein, which enhances the mitochondrial conversion of cholesterol into pregnenolone, was mutated and nonfunctional, providing genetic evidence that this protein is indispensable for normal adrenal and gonadal steroidogenesis.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104; TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & CELL BIOL,LUBBOCK,TX 79430; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; UNIV VIRGINIA,HLTH SCI CTR,DEPT PEDIAT,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143	University of Pennsylvania; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Virginia; University of Virginia; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LIN, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,CHILD HLTH RES CTR,CORE LAB,SAN FRANCISCO,CA 94143, USA.		Miller, Walter L/J-3696-2012; Rogol, A.D./H-5871-2019	Rogol, A.D./0000-0002-7526-3142; Clark, Barbara/0000-0003-1558-1904	NICHD NIH HHS [HD 07688, HD 28825, HD 06274] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028825] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; DEGENHART HJ, 1972, ACTA ENDOCRINOL-COP, V71, P215; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HAUFFA BP, 1985, CLIN ENDOCRINOL, V23, P481, DOI 10.1111/j.1365-2265.1985.tb01107.x; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KOIZUMI S, 1977, CLIN CHIM ACTA, V77, P301; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LIN D, 1993, GENOMICS, V18, P643, DOI 10.1016/S0888-7543(05)80367-2; LIN D, 1991, J CLIN INVEST, V88, P1955, DOI 10.1172/JCI115520; Lin D.Y., UNPUB; MELLON SH, 1994, J CLIN ENDOCR METAB, V78, P1003, DOI 10.1210/jc.78.5.1003; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; SAENGER P, 1995, J CLIN ENDOCR METAB, V80, P200, DOI 10.1210/jc.80.1.200; SAKAI Y, 1994, J CLIN ENDOCR METAB, V79, P1198, DOI 10.1210/jc.79.4.1198; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; STOCCO DM, 1993, ENDOCRINOLOGY, V132, P959, DOI 10.1210/en.132.3.959; STRAUSS JF, 1995, ENDOCRINOLOGY, V3, P2171; SUGAWARA T, IN PRESS P NATL ACAD; TOAFF ME, 1982, ENDOCRINOLOGY, V111, P1785, DOI 10.1210/endo-111-6-1785	23	790	816	0	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1828	1831		10.1126/science.7892608	http://dx.doi.org/10.1126/science.7892608			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892608				2022-12-01	WOS:A1995QN70200041
J	LORENZ, M; JUNG, S; RADBRUCH, A				LORENZ, M; JUNG, S; RADBRUCH, A			SWITCH TRANSCRIPTS IN IMMUNOGLOBULIN CLASS SWITCHING	SCIENCE			English	Article							HEAVY-CHAIN TRANSCRIPTS; RESTING B-CELLS; MAMMALIAN-CELLS; STEM-CELLS; RECOMBINATION; GENE; INDUCTION; INTERLEUKIN-4; REGION; REARRANGEMENT	B cells can exchange gene segments for the constant region of the immunoglobulin heavy chain, altering the class and effector function of the antibodies that they produce. Class switching is directed to distinct classes by cytokines, which induce transcription of the targeted DNA sequences. These transcripts are processed, resulting in spliced ''switch'' transcripts. Switch recombination can be directed to immunoglobulin G1 (IgG1) by the heterologous human metallothionein IIA promoter in mutant mice. Induction of the structurally conserved, spliced switch transcripts is sufficient to target switch recombination to IgG1, whereas transcription alone is not.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91120 JERUSALEM, ISRAEL	University of Cologne; Hebrew University of Jerusalem			Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716; Radbruch, Andreas/0000-0001-5753-0000				ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; BERTON MT, 1990, J EXP MED, V172, P375, DOI 10.1084/jem.172.1.375; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; ESSER C, 1989, EMBO J, V8, P483, DOI 10.1002/j.1460-2075.1989.tb03401.x; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; ILLGES H, 1992, MOL IMMUNOL, V29, P1265, DOI 10.1016/0161-5890(92)90063-4; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KEPRON MR, 1989, J IMMUNOL, V143, P334; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAYTON JE, 1984, J EXP MED, V160, P1850, DOI 10.1084/jem.160.6.1850; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MOWATT MR, 1986, J IMMUNOL, V136, P2674; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; SCHMITZ J, 1990, INT IMMUNOL, V144, P952; SCROCH P, 1993, PROG CLIN BIOL RES, V380, P113; SEVERINSON E, 1990, EUR J IMMUNOL, V20, P1079, DOI 10.1002/eji.1830200520; SEVERINSONGRONOWICZ E, 1979, J IMMUNOL, V123, P2057; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; SWAPAN KD, 1990, J BIOL CHEM, V265, P15267; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; XU LX, 1993, P NATL ACAD SCI USA, V90, P3705, DOI 10.1073/pnas.90.8.3705; Xu M, 1990, Dev Immunol, V1, P11, DOI 10.1155/1990/47659; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x	36	210	213	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1825	1828		10.1126/science.7892607	http://dx.doi.org/10.1126/science.7892607			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892607				2022-12-01	WOS:A1995QN70200040
J	MOL, CD; ARVAI, AS; SLUPPHAUG, G; KAVLI, B; ALSETH, I; KROKAN, HE; TAINER, JA				MOL, CD; ARVAI, AS; SLUPPHAUG, G; KAVLI, B; ALSETH, I; KROKAN, HE; TAINER, JA			CRYSTAL-STRUCTURE AND MUTATIONAL ANALYSIS OF HUMAN URACIL-DNA GLYCOSYLASE - STRUCTURAL BASIS FOR SPECIFICITY AND CATALYSIS	CELL			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; VACCINIA VIRUS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; MISMATCH-REPAIR; CODING SEQUENCE; GENE; GENOME; ENZYME	Crystal structures of the DNA repair enzyme human uracil-DNA glycosylase (UDG), combined with mutational analysis, reveal the structural basis for the specificity of the enzyme. Within the classic alpha/beta told of UDG, sequence-conserved residues form a positively charged, active-site groove the width of duplex DNA, at the C-terminal edge of the central four-stranded parallel beta sheet. In the UDG-6-aminouracil complex, uracil binds at the base of the groove within a rigid preformed pocket that confers selectivity for uracil over other bases by shape complementarity and by main chain and Asn-204 side chain hydrogen bonds. Main chain nitrogen atoms are positioned to stabilize the oxyanion intermediate generated by His-268 acting via nucleophilic attack or general base mechanisms. Specific binding of uracil flipped out from a DNA duplex provides a structural mechanism for damaged base recognition.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV TRONDHEIM, UNIGEN CTR MOLEC BIOL, N-7005 TRONDHEIM, NORWAY	Scripps Research Institute			Tainer, John/GWQ-4878-2022; Slupphaug, Geir/AAN-3794-2020	Tainer, John/0000-0003-1659-2429; Slupphaug, Geir/0000-0002-7498-3500	NIGMS NIH HHS [GM 46312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CROUZET J, 1990, J BACTERIOL, V172, P5980, DOI 10.1128/jb.172.10.5980-5990.1990; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; ELLIS SR, 1989, MOL CELL BIOL, V9, P1611, DOI 10.1128/MCB.9.4.1611; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HAUG T, 1994, FEBS LETT, V353, P180, DOI 10.1016/0014-5793(94)01042-0; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; KUHN LA, 1992, J MOL BIOL, V228, P13, DOI 10.1016/0022-2836(92)90487-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEJEAN V, 1990, NUCLEIC ACIDS RES, V18, P6693, DOI 10.1093/nar/18.22.6693; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MULLER SJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P197, DOI 10.1016/0167-4781(91)90055-Q; MYERS LC, 1994, CURR OPIN STRUC BIOL, V4, P51, DOI 10.1016/S0959-440X(94)90059-0; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; PERCIVAL KJ, 1989, J BIOL CHEM, V264, P2593; READ RJ, 1975, ACTA CRYSTALLOGR A, V42, P140; RICHARDSON JS, 1990, PREDICTION PROTEIN S, P2; ROSEMAN NA, 1987, J VIROL, V61, P1398, DOI 10.1128/JVI.61.5.1398-1406.1987; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SHCHELKUNOV SN, 1993, DOKL AKAD NAUK+, V328, P629; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; TALPAERTBORLE M, 1982, J BIOL CHEM, V257, P1208; TARTAGLIA J, 1990, J GEN VIROL, V71, P1517, DOI 10.1099/0022-1317-71-7-1517; TELFORD EAR, 1992, VIROLOGY, V189, P304, DOI 10.1016/0042-6822(92)90706-U; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; WITTWER CU, 1985, BIOCHIM BIOPHYS ACTA, V832, P308, DOI 10.1016/0167-4838(85)90264-X; WORRAD DM, 1988, J VIROL, V62, P4774, DOI 10.1128/JVI.62.12.4774-4777.1988; YASUI A, 1992, MUTAT RES, V273, P231, DOI 10.1016/0921-8777(92)90084-G; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	59	339	351	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 24	1995	80	6					869	878		10.1016/0092-8674(95)90290-2	http://dx.doi.org/10.1016/0092-8674(95)90290-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697717	Bronze			2022-12-01	WOS:A1995QP61200006
J	REAUME, AG; DESOUSA, PA; KULKARNI, S; LANGILLE, BL; ZHU, DG; DAVIES, TC; JUNEJA, SC; KIDDER, GM; ROSSANT, J				REAUME, AG; DESOUSA, PA; KULKARNI, S; LANGILLE, BL; ZHU, DG; DAVIES, TC; JUNEJA, SC; KIDDER, GM; ROSSANT, J			CARDIAC MALFORMATION IN NEONATAL MICE LACKING CONNEXIN43	SCIENCE			English	Article							GAP JUNCTION PROTEIN; MOUSE PREIMPLANTATION EMBRYOS; RAT-HEART; EXPRESSION; COMMUNICATION; CELLS; CHICK; MYOCARDIUM; PREGNANCY; TISSUES	Gap junctions are made up of connexin proteins, which comprise a multigene family in mammals. Targeted mutagenesis of connexin43 (Cx43), one of the most prevalent connexin proteins, showed that its absence was compatible with survival of mouse embryos to term, even though mutant cell lines showed reduced dye coupling in vitro. However, mutant embryos died at birth, as a result of a failure in pulmonary gas exchange caused by a swelling and blockage of the right ventricular outflow tract from the heart. This finding suggests that Cx43 plays an essential role in heart development but that there is functional compensation among connexins in other parts of the developing fetus.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV WESTERN ONTARIO, DEPT ZOOL, LONDON, ON N6A 5B7, CANADA; UNIV WESTERN ONTARIO, MOLEC GENET UNIT, LONDON, ON N6A 5B7, CANADA; MAX BELL RES CTR, TORONTO GEN DIV, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, DEPT PATHOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto			De Sousa, Paul A/H-7416-2013	De Sousa, Paul A/0000-0003-0745-2504; Juneja, Subhash/0000-0002-8536-5724				BASTIDE B, 1993, CIRC RES, V73, P1138, DOI 10.1161/01.RES.73.6.1138; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEVILACQUA A, 1989, P NATL ACAD SCI USA, V86, P5444, DOI 10.1073/pnas.86.14.5444; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BISHOP SP, 1990, CIRC RES, V66, P84, DOI 10.1161/01.RES.66.1.84; BOCKMAN DE, 1987, AM J ANAT, V180, P332; BRITZCUNNINGHAM SH, 1993, MOL BIOL CELL, V4, P329; CAVENEY S, 1985, ANNU REV PHYSIOL, V47, P319; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CLARK EB, 1989, AM J PHYSIOL, V257, pH55, DOI 10.1152/ajpheart.1989.257.1.H55; DEALY CN, 1994, DEV DYNAM, V199, P156, DOI 10.1002/aja.1001990208; DESOUSA PA, 1993, DEVELOPMENT, V117, P1355; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FISHMAN GI, 1991, CIRC RES, V68, P782, DOI 10.1161/01.RES.68.3.782; GOURDIE RG, 1993, CIRC RES, V72, P278, DOI 10.1161/01.RES.72.2.278; GOURDIE RG, 1993, J CELL SCI, V105, P985; GOURDIE RG, 1992, ANAT EMBRYOL, V185, P363; GREEN CR, 1988, BIOESSAYS, V8, P7, DOI 10.1002/bies.950080103; GROS D, 1994, CIRC RES, V74, P839, DOI 10.1161/01.RES.74.5.839; HURLE JM, 1979, J ANAT, V129, P427; KANTER HL, 1992, CIRC RES, V70, P438, DOI 10.1161/01.RES.70.2.438; KANTER HL, 1993, CIRC RES, V73, P344, DOI 10.1161/01.RES.73.2.344; LAIRD DW, 1990, J CELL SCI, V97, P109; LANGILLE BL, 1981, CIRC RES, V48, P481, DOI 10.1161/01.RES.48.4.481; Larsen WJ, 1993, HUMAN EMBRYOLOGY; LEE S, 1987, CELL, V51, P851, DOI 10.1016/0092-8674(87)90108-5; MCLACHLIN JR, 1986, DEV BIOL, V117, P146, DOI 10.1016/0012-1606(86)90357-X; MEDA P, 1993, ENDOCRINOLOGY, V133, P2371, DOI 10.1210/en.133.5.2371; MINKOFF R, 1993, CIRC RES, V73, P71, DOI 10.1161/01.RES.73.1.71; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAUS CCG, 1992, CELL MOL NEUROBIOL, V12, P163, DOI 10.1007/BF00713370; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; NISHI M, 1991, DEV BIOL, V146, P117, DOI 10.1016/0012-1606(91)90452-9; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PEXEIDER T, 1975, ADV ANAT EMBRYOL CEL, V51, P6; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; RISEK B, 1991, DEVELOPMENT, V113, P165; RISEK B, 1992, DEVELOPMENT, V116, P639; RUANGVORAVAT CP, 1992, DEV DYNAM, V194, P261, DOI 10.1002/aja.1001940403; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; SAFFITZ JE, 1994, CIRC RES, V74, P1065, DOI 10.1161/01.RES.74.6.1065; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; VALDIMARSSON G, 1993, MOL REPROD DEV, V36, P7, DOI 10.1002/mrd.1080360103; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; VANKEMPEN MJA, 1991, CIRC RES, V68, P1638, DOI 10.1161/01.RES.68.6.1638; VUILLEMIN M, 1989, AM J ANAT, V184, P114, DOI 10.1002/aja.1001840203; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WURST W, 1993, GENE TARGETING PRACT, P31	52	1040	1080	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1831	1834		10.1126/science.7892609	http://dx.doi.org/10.1126/science.7892609			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892609				2022-12-01	WOS:A1995QN70200042
J	YANG, YZ; NISWANDER, L				YANG, YZ; NISWANDER, L			INTERACTION BETWEEN THE SIGNALING MOLECULES WNT7A AND SHH DURING VERTEBRATE LIMB DEVELOPMENT - DORSAL SIGNALS REGULATE ANTEROPOSTERIOR PATTERNING	CELL			English	Article							APICAL ECTODERMAL RIDGE; CHICK-EMBRYO; BUD CELLS; MOUSE; GENES; EXPRESSION; SPECIFICATION; DROSOPHILA	Growth and patterning of the vertebrate limb are controlled by the ridge, posterior mesenchyme, and nonridge ectoderm. Fibroblast growth factor 4 (FGF4) and Sonic hedgehog (SHH) can mediate signaling from the ridge and posterior mesenchyme, respectively. Here we show that do rsal ectoderm is required together with FGF4 to maintain Shh expression. Removal of dorsal ectoderm results in loss of posterior skeletal elements, which can be rescued by exogenous SHH. Wnt7a, which is expressed in dorsal ectoderm, provides the signal required for Shh expression and formation of posterior structures. These results provide evidence that all three axes (dorsoventral, proximodistal, and anteroposterior) are intimately linked by the respective signals WNT7a, FGF4, and SHH during limb outgrowth and patterning.	MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON R, 1993, DEVELOPMENT, V117, P1421; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HELMS J, 1994, DEVELOPMENT, V120, P3267; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MARTIN P, 1986, DEV BIOL, V118, P233, DOI 10.1016/0012-1606(86)90091-6; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARR BA, 1993, DEVELOPMENT, V119, P247; PARR BA, 1995, IN PRESS NATURE; PAUTOU MP, 1977, VERTEBRATE LIMB SOMI, P257; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199	41	271	279	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					939	947		10.1016/0092-8674(95)90297-X	http://dx.doi.org/10.1016/0092-8674(95)90297-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697724	hybrid			2022-12-01	WOS:A1995QP61200013
J	ANSARI, AZ; BRADNER, JE; OHALLORAN, TV				ANSARI, AZ; BRADNER, JE; OHALLORAN, TV			DNA-BEND MODULATION IN A REPRESSOR-TO-ACTIVATOR SWITCHING MECHANISM	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; MER PROMOTER; COMPLEX; DISTORTION; DIRECTION	RECENT discoveries of activator proteins that distort DNA but bear no obvious activation domains have focused attention on the role of DNA structure in transcriptional regulation(1). Here we describe how the transcription factor MerR can mediate repression as well as activation through stereospecific modulation of DNA structure. The repressor form of MerR binds between the -10 and -35 promoter elements of the bacterial mercury-detoxification genes, P-T, allowing RNA polymerase to form an inactive complex with P-T and MerR at this stress-inducible promoter(2,3). Upon mercuric ion binding, Hg-MerR converts this polymerase complex into the transcriptionally active or 'open' form(2-4). We show here that MerR bends DNA towards itself in a manner similar to the bacterial catabolite-activator protein CAP, namely at two loci demarked by DNase I sensitivity, and that the activator conformation, Hg-MerR, relaxes these bends. This activator-induced unbending, when coupled with the previously described untwisting of the operator(5), remodels the promoter and makes it a better template for the poised polymerase.	NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University; Northwestern University			Ansari, Aseem/AAF-4945-2019; O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; ANSARI AZ, 1994, TRANSCRIPTION MECHAN, P369; BOROWIEC JA, 1986, BIOCHEMISTRY-US, V25, P5051, DOI 10.1021/bi00366a012; BURKHOFF AM, 1989, NATURE, V331, P455; COMESS KM, 1994, BIOCHEMISTRY-US, V33, P4175, DOI 10.1021/bi00180a010; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; HIDALGO E, 1993, EMBO J, V13, P138; HOGAN ME, 1989, P NATL ACAD SCI USA, V86, P9273, DOI 10.1073/pnas.86.23.9273; HUNTER CA, 1993, J MOL BIOL, V256, P1025; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; LAHM A, 1991, NUCLEIC ACIDS MOL BI, V5, P171; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; Ptashne M, 1986, GENETIC SWITCH, P13; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	31	184	186	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					371	375						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885478				2022-12-01	WOS:A1995QN63000063
J	CHEN, JJ; JACKSON, PK; KIRSCHNER, MW; DUTTA, A				CHEN, JJ; JACKSON, PK; KIRSCHNER, MW; DUTTA, A			SEPARATE DOMAINS OF P21 INVOLVED IN THE INHIBITION OF CDK KINASE AND PCNA	NATURE			English	Article							DNA-REPLICATION; P53	THE protein p21 (WAF1, CIP1 or sdi1), induced by the tumour-suppressor protein p53, interacts with and inhibits two different targets essential for cell-cycle progression(1-8). One of these is the cyclin-Cdk family of kinases and the other is the essential DNA replication factor, proliferating-cell nuclear antigen (PCNA). We report here that separate domains of p21 are responsible for interacting with and inhibiting the two targets. An amino-terminal domain inhibits cyclin-Cdk kinases and a carboxy-terminal domain inhibits PCNA. Using these separated domains, we have determined that p21 inhibits different biological systems through different targets. The PCNA-binding domain is sufficient for inhibition of DNA replication based on sinian virus 40, whereas the Cdk2-binding domain is sufficient for inhibition of DNA replication based on Xenopus egg extract and for growth suppression in transformed human cells.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV MOLEC ONCOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Jackson, Peter/0000-0002-1742-2539				DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1922, EMBO J, V11, P2189; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	16	524	542	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					386	388		10.1038/374386a0	http://dx.doi.org/10.1038/374386a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885482				2022-12-01	WOS:A1995QN63000067
J	GERGEN, P; MCQUILLAN, GM; KIELY, M; EZZATIRICE, TM; SUTTER, RW; VIRELLA, G				GERGEN, P; MCQUILLAN, GM; KIELY, M; EZZATIRICE, TM; SUTTER, RW; VIRELLA, G			A POPULATION-BASED SEROLOGIC SURVEY OF IMMUNITY TO TETANUS IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIPHTHERIA IMMUNITY; VACCINATION; CHILDREN; REVACCINATION; IMMUNIZATION; ADULTS	Background. Vaccination rates are frequently considered a surrogate measure of protection. To provide more accurate estimates, serum levels of antibody against tetanus were measured as part of the third National Health and Nutrition Examination Survey (NHANES III), which studied a representative sample of the civilian, noninstitutionalized population of the United States. Methods. We measured tetanus antitoxin using a solid-phase enzyme immunoassay in serum samples from 10,618 persons six years of age and older who were examined during phase 1 of NHANES III in 1988 to 1991. Results. Overall, 69.7 percent of Americans six years of age and older had protective levels of tetanus antibodies (>0.15 IU per milliliter). The rate decreased from 87.7 percent among those 6 to 11 years of age to 27.8 percent among those 70 years of age or older, Among children 6 to 16 years of age, 82.2 percent had protective levels of tetanus antibodies, with little variation according to race or ethnicity. More men than women were immune (79.0 percent vs. 62.4 percent). Mexican Americans had a significantly lower rate of immunity (57.9 percent, P<0.05) than either non-Hispanic whites (72.7 percent) or non-Hispanic blacks (68.1 percent). Those with a history of military service, higher levels of education, or incomes above the poverty level were more likely to have protective antibody levels. Although the prevalence of immunity declined rapidly starting at the age of 40 years, most of the 107 cases of tetanus (with 20 deaths) reported in 1989 and 1990 occurred in persons 60 years of age or older, Conclusions. Despite the fact that effective vaccines against tetanus have been available since the 1940s, many Americans do not have immunity to tetanus, and the rates are lowest among the elderly There is an excellent correlation between vaccination rates (96 percent) and immunity (96 percent) among six-year-olds. However, antibody levels decline over time, and one fifth of older children (10 to 16 years of age) do not have protective antibody levels.	NIAID,BETHESDA,MD 20892; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,HYATTSVILLE,MD 20782; US MATERNAL & CHILD HLTH BUR,ROCKVILLE,MD; CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,ATLANTA,GA 30333; MED UNIV S CAROLINA,DEPT MICROBIOL & IMMUNOL,CHARLESTON,SC 29425	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Medical University of South Carolina								BALESTRA DJ, 1993, J GEN INTERN MED, V8, P405, DOI 10.1007/BF02599616; CROSSLEY K, 1979, JAMA-J AM MED ASSOC, V242, P2298, DOI 10.1001/jama.242.21.2298; EZZATI T, 1993, 1992 P SURV RES METH, P339; HINMAN AR, 1991, AM J DIS CHILD, V145, P559, DOI 10.1001/archpedi.1991.02160050085023; KAHN HA, 1989, STATISTICAL METHODS; KHARE M, 1994, IN PRESS 1994 P SURV; MARKS JS, 1979, PEDIATRICS, V64, P304; MYERS MG, 1982, JAMA-J AM MED ASSOC, V248, P2478, DOI 10.1001/jama.248.19.2478; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; PETER G, 1994, 1994 RED BOOK REPORT, P458; Prevots Rebecca, 1992, Morbidity and Mortality Weekly Report, V41, P1; RUBEN FL, 1973, B WORLD HEALTH ORGAN, V48, P175; SHAH BV, 1991, SUDAAN USERS MANUAL; SIMONSEN O, 1989, DAN MED BULL, V36, P24; SIMONSEN O, 1986, J BIOL STAND, V14, P231, DOI 10.1016/0092-1157(86)90008-9; SIMONSEN O, 1986, ACTA PATH MICRO IM C, V94, P77; SIMONSEN O, 1984, LANCET, V2, P1240; SUTTER RW, 1990, AM J EPIDEMIOL, V131, P132, DOI 10.1093/oxfordjournals.aje.a115466; VIRELLA G, 1991, J CLIN LAB ANAL, V5, P43, DOI 10.1002/jcla.1860050108; VOLK VK, 1962, PUBLIC HEALTH REP, V77, P185, DOI 10.2307/4591451; WEISS BP, 1983, AM J PUBLIC HEALTH, V73, P802, DOI 10.2105/AJPH.73.7.802; 1994, MMWR-MORBID MORTAL W, V43, P282; 1994, MMWR-MORBID MORTAL W, V43, P57; 1992, DHHS PHS921387 NAT C; 1994, MMWR-MORBID MORTAL W, V43, P1; 1989, CURRENT POPULATION P, V60; 1994, MMWR-MORBID MORTAL W, V42, P985; 1988, CURRENT POPULATION P, V60; 1993, STATE IMMUNIZATION 1; 1993, 1993 WORLD BANK DEV, P8; 1991, CURRENT POPULATION P, V60; 1992, MMWR-MORBID MORTAL W, V41, P67; 1994, MMWR-MORBID MORTAL W, V43, P556	33	249	255	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					761	766		10.1056/NEJM199503233321201	http://dx.doi.org/10.1056/NEJM199503233321201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862178	Green Published			2022-12-01	WOS:A1995QN44200001
J	MATZUK, MM; KUMAR, TR; VASSALLI, A; BICKENBACH, JR; ROOP, DR; JAENISCH, R; BRADLEY, A				MATZUK, MM; KUMAR, TR; VASSALLI, A; BICKENBACH, JR; ROOP, DR; JAENISCH, R; BRADLEY, A			FUNCTIONAL-ANALYSIS OF ACTIVINS DURING MAMMALIAN DEVELOPMENT	NATURE			English	Article							PREIMPLANTATION MOUSE EMBRYOS; XENOPUS EMBRYOGENESIS; AXIAL STRUCTURES; EXPRESSION; MESODERM; INHIBIN; CLONING; INDUCE; GENES	ACTIVINS are dimeric (beta A beta A; beta B beta B; beta A beta B) members of the transforming growth factor-beta superfamily(1). They are widely expressed during murine development(1-6), are highly conserved during vertebrate evolution(1,7-11), and may be involved in mesoderm induction and neurulation in Xenopus laevis and Oryzias latipes(10-17). To investigate the function of mammalian activins in vivo, we generated mice with mutations either in activin-beta A or in both activin-beta A and activin-beta B. Activin-beta A-deficient mice develop to term but die within 24 h of birth. They lack whiskers and lower incisors and have defects in their secondary palates, including cleft palate, demonstrating that activin-beta A must have a role during craniofacial development. Mice lacking both activin subunits show the defects of both individual mutants but no additional defects, indicating that there is no functional redundancy between these proteins during embryogenesis. In contrast to observations in lower vertebrates(10-17), zygotic expression of activins is not essential for mesoderm formation in mice.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	MATZUK, MM (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.		Vassalli, Anne/M-7866-2016	Vassalli, Anne/0000-0002-5314-5620; Bradley, Allan/0000-0002-2349-8839				ALBANO RM, 1994, DEVELOPMENT, V120, P803; ALBANO RM, 1993, DEVELOPMENT, V117, P711; BRADLEY A, 1987, TERATOCARCINOMAS EMB; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CONLON FL, 1994, DEVELOPMENT, V120, P1919; ESCH FS, 1987, MOL ENDOCRINOL, V1, P388, DOI 10.1210/mend-1-5-388; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; GE W, 1993, BIOCHEM BIOPH RES CO, V193, P711, DOI 10.1006/bbrc.1993.1683; GLUECKSOHN, 1961, MNI, V25, P12; GORLIN RJ, 1990, OXFORD MONOGRAPHS ME, V19, P693; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LU RZ, 1993, BIOL REPROD, V49, P1163, DOI 10.1095/biolreprod49.6.1163; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; MANOVA K, 1992, MECH DEVELOP, V36, P141, DOI 10.1016/0925-4773(92)90065-R; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE WW, 1990, PEPTIDE GROWTH FACTO, V2; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WITTBRODT J, 1994, GENE DEV, V8, P1448, DOI 10.1101/gad.8.12.1448; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	31	497	508	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					354	356		10.1038/374354a0	http://dx.doi.org/10.1038/374354a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885473				2022-12-01	WOS:A1995QN63000058
J	MATZUK, MM; KUMAR, TR; BRADLEY, A				MATZUK, MM; KUMAR, TR; BRADLEY, A			DIFFERENT PHENOTYPES FOR MICE DEFICIENT IN EITHER ACTIVINS OR ACTIVIN RECEPTOR-TYPE-II	NATURE			English	Article							EXPRESSION; GENE; RAT; INHIBIN	ACTIVINS are believed to initiate a signal transduction cascade by binding to serine/threonine kinase receptors types I and II1-3. Activins(4) bind to several different receptors in vitro(1-3), but the significance of this interaction in vivo has not been confirmed. To test the function of the type II activin receptor (ActRcII) in mammalian development and reproduction, we generated a null mutation in the ActRcII gene in mice using embryonic stem cell technology. We expected ActRcII-deficient mice to phenocopy activin-deficient mice. A few ActRcII-deficient mice had skeletal and facial abnormalities reminiszzcent of the Pierre-Robin syndrome in humans(5,6), but most lacked these defects and developed into adults; their follicle-stimulating hormone was suppressed, and their reproductive performance was defective. These findings confirm a role of ActRcII in activin signalling in pituitary gonadotrophs. The striking lack of overlap between phenotypes of ActRcII-deficient and activin-deficient mice suggests that the ligands that signal through ActRcII during embryonic development are not activins.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	MATZUK, MM (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.			Bradley, Allan/0000-0002-2349-8839				BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CAMERON VA, 1994, ENDOCRINOLOGY, V134, P799, DOI 10.1210/en.134.2.799; CAOUETTELABERGE L, 1994, PLAST RECONSTR SURG, V93, P934, DOI 10.1097/00006534-199404001-00006; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CLARKE L, 1988, TERATOLOGY, V38, P565, DOI 10.1002/tera.1420380604; DEWINTER JP, 1992, MOL CELL ENDOCRINOL, V83, pR1, DOI 10.1016/0303-7207(92)90201-G; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; FENG ZM, 1993, ENDOCRINOLOGY, V132, P2593, DOI 10.1210/en.132.6.2593; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; KAIPIA A, 1994, ENDOCRINOLOGY, V134, P2165, DOI 10.1210/en.134.5.2165; KUMAR TR, 1992, MOL ENDOCRINOL, V6, P81, DOI 10.1210/me.6.1.81; MATHER JP, 1990, ENDOCRINOLOGY, V127, P3206, DOI 10.1210/endo-127-6-3206; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1992, BIOCHEM BIOPH RES CO, V185, P404, DOI 10.1016/S0006-291X(05)81000-9; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAMIREZSOLIS R, 1993, CELL, V83, P279; RITZEN EM, 1989, TESTIS, P269; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHIKONE T, 1994, MOL ENDOCRINOL, V8, P983, DOI 10.1210/me.8.8.983; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; VALE W, 1990, PEPTIDE GROWTH FACTO, V2, P211; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WOODRUFF TK, 1990, ENDOCRINOLOGY, V127, P3196, DOI 10.1210/endo-127-6-3196	28	481	515	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					356	360		10.1038/374356a0	http://dx.doi.org/10.1038/374356a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885474				2022-12-01	WOS:A1995QN63000059
J	MATZUK, MM; LU, NF; VOGEL, H; SELLHEYER, K; ROOP, DR; BRADLEY, A				MATZUK, MM; LU, NF; VOGEL, H; SELLHEYER, K; ROOP, DR; BRADLEY, A			MULTIPLE DEFECTS AND PERINATAL DEATH IN MICE DEFICIENT IN FOLLISTATIN	NATURE			English	Article							ACTIVIN-BINDING PROTEIN; EMBRYONIC-DEVELOPMENT; RAT FOLLISTATIN; MESSENGER-RNA; EXPRESSION; RECEPTOR; INHIBIN	FOLLISTATIN, an activin-binding protein and activin antagonist in vitro(1,2), can bind to heparan sulphate proteoglycans(3) and may function in vivo to present activins to their receptors. In the mouse, follistatin messenger RNA is first detected in the deciduum (on embryonic day 5.5), and later in the developing hindbrain, somites, vibrissae, teeth, epidermis and muscle(4-11). In Xenopus laevis, overexpression of follistatin leads to induction of neural tissue(12). Here we use loss-of-function mutant mice to investigate the function of follistatin in mammals. We find that follistatin-deficient mice are retarded in their growth, have decreased mass of the diaphragm and intercostal muscles, shiny taut skin, skeletal defects of the hard palate and the thirteenth pair of ribs, their whisker and tooth development is abnormal, they fail to breathe, and die within hours of birth. These defects are more widespread than those seen in activin-deficient mutant mite, indicating that follistatin may modulate the actions of several members of the transforming growth factor-beta family.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	MATZUK, MM (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.			Bradley, Allan/0000-0002-2349-8839; Vogel, Otto Hannes/0000-0002-0960-3508				ALBANO RM, 1994, DEVELOPMENT, V120, P803; CHISAKA O, 1992, NATURE, V335, P516; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; HASHIMOTO M, 1992, J BIOL CHEM, V267, P7203; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; MICHEL U, 1990, BIOCHEM BIOPH RES CO, V173, P401, DOI 10.1016/S0006-291X(05)81072-1; MICHEL U, 1991, BIOCHEM BIOPH RES CO, V180, P223, DOI 10.1016/S0006-291X(05)81280-X; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PIERARDFRANCHIM.C, 1992, J PATHOL, V167, P2223; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAMIREZSOLIS R, 1993, CELL, V83, P279; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P652; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; VANDENEIJNDENVA.AJ, 1992, DEV BIOL, V154, P356; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397	23	488	514	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					360	363		10.1038/374360a0	http://dx.doi.org/10.1038/374360a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885475				2022-12-01	WOS:A1995QN63000060
J	MOL, CD; KUO, CF; THAYER, MM; CUNNINGHAM, RP; TAINER, JA				MOL, CD; KUO, CF; THAYER, MM; CUNNINGHAM, RP; TAINER, JA			STRUCTURE AND FUNCTION OF THE MULTIFUNCTIONAL DNA-REPAIR ENZYME EXONUCLEASE-III	NATURE			English	Article							ESCHERICHIA-COLI; RESOLUTION; SEQUENCE; CDNA; REFINEMENT; HOMOLOGY; COMPLEX	THE repair of DNA requires the removal of abasic sites, which are constantly generated in vivo both spontaneously(1) and by enzymatic removal of uracil(2), and of bases damaged by active oxygen species, alkylating agents and ionizing radiation The major apurinic/apyrimidinic (AP) DNA-repair endonuclease in Escherichia coli is the multifunctional enzyme exonuclease In, which also exhibits 3'-repair diesterase, 3'-->5' exonuclease, 3'-phosphomonoesterase and ribonuclease activities(5). We report here the 1.7 Angstrom resolution crystal structure of exonuclease III which reveals a 2-fold symmetric, four-layered ap fold,vith similarities to both deoxyribonuclease I-6 and RNase H-7. In the ternary complex determined at 2.6 Angstrom resolution, Mn2+ and dCMP bind to exonuclease III at one end of the alpha beta-sandwich, in a region dominated by positive electrostatic potential. Residues conserved among AP endonucleases from bacteria to man cluster within this active site and appear to participate in phosphate-bond cleavage at AP sites through a nucleophilic attack facilitated by a single bound metal ion.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SUNY ALBANY, CTR BIOCHEM & BIOPHYS, DEPT BIOL SCI, ALBANY, NY 12222 USA	Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KAYANA S, 1991, EUR J BIOCHEM, V198, P437; KUO CF, 1993, J MOL BIOL, V229, P239, DOI 10.1006/jmbi.1993.1021; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SAPORITO SM, 1988, J BACTERIOL, V170, P4542, DOI 10.1128/jb.170.10.4542-4547.1988; SEKI S, 1991, J BIOL CHEM, V266, P20797; TAYLOR AF, 1982, J BACTERIOL, V151, P351, DOI 10.1128/JB.151.1.351-357.1982; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V	24	338	363	1	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					381	386		10.1038/374381a0	http://dx.doi.org/10.1038/374381a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885481				2022-12-01	WOS:A1995QN63000066
J	PARR, BA; MCMAHON, AP				PARR, BA; MCMAHON, AP			DORSALIZING SIGNAL WNT-7A REQUIRED FOR NORMAL POLARITY OF D-V AND A-P AXES OF MOUSE LIMB	NATURE			English	Article							APICAL ECTODERMAL RIDGE; CHICK LIMB; PATTERN-FORMATION; BUD CELLS; MORPHOGENESIS; INFORMATION; OUTGROWTH; MESODERM; DOMAINS; EMBRYOS	FORMATION Of the vertebrate limb requires specification of cell position along three axes(1). Proximal-distal identity is regulated by the apical ectodermal ridge (AER) at the distal tip of the growing limb(2-6). Anterior-posterior identity is controlled by signals from the zone of polarizing activity (ZPA) within the posterior limb mesenchyme(7-9). Dorsal-ventral identity is regulated by ectodermally derived signals(10-14). Recent studies have begun to identify signalling molecules that may mediate these patterning activities. Members of the fibroblast growth factor (FGF) family are expressed in the AER and can mimic its proximal-distal signalling activity(15,16). Similarly, the gene Sonic hedgehog (Shh) is expressed in the ZPA, and Shh-expressing cells, like ZPA cells, can cause digit duplications when transplan ted to the anterior limb margin. In contrast, no signal has yet been identified for the dorsal-ventral axis, although Wnt-7a is expressed in the dorsal ectoderm, suggesting that it mag play such a role(19,20). To test this possibility, we have generated mice lacking Wnt-7a activity. The limb mesoderm of these mice shows dorsal-to-ventral transformations of cell fate, indicating that Wnt-7a is a dorsalizing signal. Many mutant mice also lack posterior digits, demonstrating that Wnt-7a is also required for anterior-posterior patterning. We propose that normal limb development requires interactions between the signalling systems for these two axes.			PARR, BA (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, 16 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020					ANDERSON R, 1993, DEVELOPMENT, V117, P1421; BULFONE A, 1993, MECH DEVELOP, V40, P129, DOI 10.1016/0925-4773(93)90071-5; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FINCH RA, 1971, J EXP ZOOL, V176, P397, DOI 10.1002/jez.1401760403; GEDUSPAN JS, 1987, DEV BIOL, V124, P398, DOI 10.1016/0012-1606(87)90492-1; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; GLOBUS M, 1976, DIFFERENTIATION, V6, P91, DOI 10.1111/j.1432-0436.1976.tb01474.x; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LYONS KM, 1990, DEVELOPMENT, V109, P833; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; PARR BA, 1993, DEVELOPMENT, V119, P247; REITER RS, 1982, DEV BIOL, V93, P28, DOI 10.1016/0012-1606(82)90235-4; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SMITH JC, 1978, NATURE, V272, P612, DOI 10.1038/272612a0; STARK RJ, 1974, DEV BIOL, V38, P51, DOI 10.1016/0012-1606(74)90258-9; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; YANG Y, IN PRESS CELL	31	594	610	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	1995	374	6520					350	353		10.1038/374350a0	http://dx.doi.org/10.1038/374350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885472				2022-12-01	WOS:A1995QN63000057
J	PARSONS, CA; STASIAK, A; BENNETT, RJ; WEST, SC				PARSONS, CA; STASIAK, A; BENNETT, RJ; WEST, SC			STRUCTURE OF A MULTISUBUNIT COMPLEX THAT PROMOTES DNA BRANCH MIGRATION	NATURE			English	Article							ESCHERICHIA-COLI; RUVB PROTEINS; HOLLIDAY JUNCTION; HELICASE	THE RuvA and RuvB proteins of Escherichia coli, which are induced in response to DNA damage, are important in the formation of heteroduplex DNA during genetic recombination and related recombinational repair processes(1). In vitro studies show that RuvA binds Holliday junctions(2-5) and acts as a specificity factor that targets the RuvB ATPase, a hexameric ring protein(6,7), to the junction. Together, RuvA and RuvB promote branch migration, an ATP-dependent reaction that increases the length of the heteroduplex DNA(3,8-10). Electron microscopic visualization of RuvAB now provides a new insight into the mechanism of this process. We observe the formation of a tripartite protein complex in which RuvA binds the crossover and is sandwiched between two hexameric rings of RuvB. The Holliday junction within this complex adopts a square-planar structure. We propose a molecular model for branch migration, a unique feature of which is the role played by the two oppositely oriented RuvB ring motors.	IMPERIAL CANC RES FUND,GENET RECOMBINAT LAB,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV LAUSANNE,ULTRASTRUCT ANAL LAB,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne			Stasiak, Andrzej/E-5551-2010	Stasiak, Andrzej/0000-0002-0398-1989; West, Stephen/0000-0001-8848-9418; Bennett, Richard/0000-0001-7563-484X				ADAMS DE, 1995, J MOL BIOL, V247, P404, DOI 10.1006/jmbi.1995.0149; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; IYPE LE, 1994, J BIOL CHEM, V269, P24967; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; MCCULLOCH R, 1994, EMBO J, V13, P1844, DOI 10.1002/j.1460-2075.1994.tb06453.x; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17179; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6	22	161	161	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					375	378		10.1038/374375a0	http://dx.doi.org/10.1038/374375a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885479				2022-12-01	WOS:A1995QN63000064
J	PORTER, JA; VONKESSLER, DP; EKKER, SC; YOUNG, KE; LEE, JJ; MOSES, K; BEACHY, PA				PORTER, JA; VONKESSLER, DP; EKKER, SC; YOUNG, KE; LEE, JJ; MOSES, K; BEACHY, PA			THE PRODUCT OF HEDGEHOG AUTOPROTEOLYTIC CLEAVAGE ACTIVE IN LOCAL AND LONG-RANGE SIGNALING	NATURE			English	Article							POLARITY GENE HEDGEHOG; DROSOPHILA-EMBRYO; TRANSFORMATION; CUTICLE; VECTORS; LARVAL	THE secreted protein products of the hedgehog (hh) gene family are associated with local and long-range signalling activities that are responsible far developmental patterning in multiple systems, including Drosophila embryonic and larval tissues(1-8) and vertebrate neural tube, limbs and somites(9-15). In a process that is critical for full biological activity, the hedgehog protein (Hh) undergoes autoproteolysis to generate two biochemically distinct products, an 18K amino-terminal fragment, N, and a 25K carboxy-terminal fragment, C (ref. 16); mutations that block autoproteolysis impair Hh function. We have identified the site of autoproteolytic cleavage and find that it is broadly conserved throughout the hedgehog family. Knowing the site of cleavage, we were able to test the function of the N and C cleavage products in Drosophila assays. We show here that the N product is the active species in both local and long-range signalling. Consistent with this, all twelve mapped hedgehog mutations either affected the structure of the N product directly or otherwise blocked the release of N from the Hh precursor as a result of deletion or alteration of sequences in the C domain.	UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of Southern California	PORTER, JA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.			Ekker, Stephen/0000-0003-0726-4212				ASHBURNER M, 1989, DROSOPHILA LABORATOR; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHANG DT, 1994, DEVELOPMENT, V120, P3339; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOONIN EV, IN PRESS TRENDS BIOC; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1988, GENETICS, V120, P1061; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDERSLICE P, 1988, J BIOL CHEM, V263, P10583; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x	26	437	466	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					363	366		10.1038/374363a0	http://dx.doi.org/10.1038/374363a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885476				2022-12-01	WOS:A1995QN63000061
J	SCHEFFZEK, K; KLEBE, C; FRITZWOLF, K; KABSCH, W; WITTINGHOFER, A				SCHEFFZEK, K; KLEBE, C; FRITZWOLF, K; KABSCH, W; WITTINGHOFER, A			CRYSTAL-STRUCTURE OF THE NUCLEAR RAS-RELATED PROTEIN RAN IN ITS GDP-BOUND FORM	NATURE			English	Article							ELONGATION-FACTOR TU; ESCHERICHIA-COLI; AMINO-ACIDS; REGULATOR; BINDING; DOMAIN; LOCATION; RAN/TC4; RCC1	THE Ran proteins constitute a distinct branch of the superfamily of Ras-related GTP-binding proteins(1) which function as molecular switches cycling between GTP-bound 'on' and GDP-bound 'off' states(2). Ran is located predominantly in the nucleus of eukaryotic cells(3) and is involved in the nuclear import of proteins(4,5) as well as in control of DNA synthesis and of cell-cycle progression(6-8). We report here the crystal structure at 2.3 Angstrom resolution of human Ran (M(r) 24K) complexed with GDP and Mg2+. This structure reveals a similarity with the Ras core (G-domain) but with significant variations in regions involved in GDP and Mg2+ coordination (switch I and switch II regions in Ras)(9,10), suggesting that there could be major conformational changes upon GTP binding. In addition to the G-domain, an extended chain and an alpha-helix were identified at the carboxy terminus. The amino-terminal (amino-acid residues (1)MAAQGEP(7)) stretch and the acidic tail ((211)DEDDDL(216)) appear to be flexible in the crystal structure.	MAX PLANK INST MOLEK PHYSIOL, STRUKT BIOL ABT, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, BIOPHYS ABT, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Max Planck Society								AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER A, 1993, XPLOR VERSION 3 1; CLARKE PR, IN PRESS J CELL SCI; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KOMBLUTH S, 1994, J CELL BIOL, V125, P705; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	30	172	176	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	1995	374	6520					378	381		10.1038/374378a0	http://dx.doi.org/10.1038/374378a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885480				2022-12-01	WOS:A1995QN63000065
J	SHAPIRO, L; FANNON, AM; KWONG, PD; THOMPSON, A; LEHMANN, MS; GRUBEL, G; LEGRAND, JF; ALSNIELSEN, J; COLMAN, DR; HENDRICKSON, WA				SHAPIRO, L; FANNON, AM; KWONG, PD; THOMPSON, A; LEHMANN, MS; GRUBEL, G; LEGRAND, JF; ALSNIELSEN, J; COLMAN, DR; HENDRICKSON, WA			STRUCTURAL BASIS OF CELL-CELL ADHESION BY CADHERINS	NATURE			English	Article							INTERCELLULAR ADHERENS JUNCTIONS; EXPRESSION; IDENTIFICATION; MOLECULE	Crystal structures of the amino-terminal domain of N-cadherin provide a picture at the atomic level of a specific adhesive contact between cells. A repeated set of dimer interfaces is common to the structure in three lattices. These interactions combine to form a linear zipper of molecules that mirrors the linear structure of the intracellular filaments with which cadherins associate. This cell-adhesion zipper may provide a mechanism to marshal individual molecular adhesive interactions into strong bonds between cells.	COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; EUROPEAN MOLEC BIOL LAB,F-38042 GRENOBLE,FRANCE; EUROPEAN SYNCHROTRON RADIAT FACIL,F-38043 GRENOBLE,FRANCE; INST MAX VON LAUE PAUL LANGEVIN,F-38042 GRENOBLE,FRANCE; UNIV GRENOBLE 1,SPECTROMETRIE PHYS LAB,CNRS,URA 8,F-38402 ST MARTIN DHERES,FRANCE; RISO NATL LAB,DK-4000 ROSKILDE,DENMARK	Columbia University; Howard Hughes Medical Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF); Institut Laue-Langevin (ILL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Technical University of Denmark	SHAPIRO, L (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,630 W 168TH ST,NEW YORK,NY 10032, USA.		Shapiro, Lawrence/AAE-7172-2019					AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CAMPBELL RD, 1971, ORIGIN CONTINUITY DE; CCP4, 1979, CCP4 SUITE PROGRAMS; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FAWCETT DW, 1958, ATLAS FINE STRUCTURE, P365; FREUND AK, 1993, SPIE P, V1997, P223; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Galtsoff PS, 1925, J EXP ZOOL, V42, P183, DOI 10.1002/jez.1400420109; GRUBEL G, 1994, PHYSIQUE 4, V4, P27; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1979, BIOPOLYMERS, V22, P2577; KELLY DE, 1966, J CELL BIOL, V28, P51, DOI 10.1083/jcb.28.1.51; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACLARE JL, 1994, J SYNCHROTRON RADIAT, V1, P12, DOI 10.1107/S0909049594006564; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McNutt N S, 1970, Am J Cardiol, V25, P169, DOI 10.1016/0002-9149(70)90577-1; McNutt N S, 1973, Prog Biophys Mol Biol, V26, P45; Nagafuchi A, 1993, Semin Cell Biol, V4, P175, DOI 10.1006/scel.1993.1021; NICHOLLS A, 1989, PROTEINS, V11, P281; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; POKUTTA S, 1994, EUR J BIOCH; ROGERS DC, 1965, J ULTRA MOL STRUCT R, V13, P478, DOI 10.1016/S0022-5320(65)90010-9; SHAPIRO L, IN PRESS P NATN ACAD; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1990, COLD SH Q B, V55, P319; TONG KI, 1994, FEBS LETT, V352, P318; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; VOLK T, 1986, J CELL BIOL, V103, P1451, DOI 10.1083/jcb.103.4.1451; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7; [No title captured]	51	962	1003	2	80	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					327	337		10.1038/374327a0	http://dx.doi.org/10.1038/374327a0			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885471				2022-12-01	WOS:A1995QN63000051
J	SIMONDS, RJ; LINDEGREN, ML; THOMAS, P; HANSON, D; CALDWELL, B; SCOTT, G; ROGERS, M				SIMONDS, RJ; LINDEGREN, ML; THOMAS, P; HANSON, D; CALDWELL, B; SCOTT, G; ROGERS, M			PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA AMONG CHILDREN WITH PERINATALLY ACQUIRED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV-INFECTION; CHEMOPROPHYLAXIS; POPULATION; AIDS	Background. Pneumocystis carinii pneumonia (PCP) remains a common and often fatal opportunistic infection among children infected with the human immunodeficiency virus (HIV). HIV-infected infants between three and six months of age are particularly vulnerable. Current guidelines recommend prophylaxis in children from birth to 11 months old who have CD4+ counts below 1500 cells per cubic millimeter. Methods. We used national surveillance data to estimate the annual incidence of PCP among children less than one year old. We reviewed the medical records of 300 children given a diagnosis of PCP between January 1991 and June 1993 to determine why treatment according to the 1991 guidelines for prophylaxis against PCP either was not given or failed to prevent the disease. Results. In our study the incidence of PCP in the first year of life among infants born to HIV-infected mothers changed little between 1989 and 1992. Among 7080 children born to HIV-infected mothers in 1992, PCP developed in 2.4 percent. Of 300 children with PCP diagnosed from January 1991 through June 1993, 199 (66 percent) had never received prophylaxis, and for 118 of those children (59 percent) exposure to HIV was first identified 30 days or less before the diagnosis of PCP, Among 129 children less than one year old, the CD4+ count declined by an estimated 967 cells per cubic millimeter (95 percent confidence interval, 724 to 1210 cells per cubic millimeter) during the three months before the diagnosis of PCP, Among infants in whom CD4+ counts were determined within one month of the diagnosis of PCP, 18 percent (20 of 113) had at least 1500 cells per cubic millimeter, a level higher than the currently recommended threshold for prophylaxis. Conclusions. In the United States the incidence of PCP among HIV-infected infants has not declined. If this infection is to be prevented, infants exposed to HIV must be identified earlier, and prophylaxis must be offered to more children than the guidelines currently recommend.	NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA; UNIV MIAMI, SCH MED, DEPT PEDIAT, MIAMI, FL USA	New York City Department of Health & Mental Hygiene; University of Miami	SIMONDS, RJ (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV HIV AIDS, 1600 CLIFTON RD, MAILSTOP E-45, ATLANTA, GA 30333 USA.							[Anonymous], 1991, MMWR Recomm Rep, V40, P1; CALDWELL B, 1994, 34TH INT C ANT AG CH; CALDWELL B, 1994, 34TH INT C ANT AG CH, P36; CALDWELL MB, 1992, PEDIATRICS, V90, P603; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P1484, DOI 10.1001/jama.267.11.1484; DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P3154; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HSU HW, 1992, PEDIATR INFECT DIS J, V11, P941, DOI 10.1097/00006454-199211110-00007; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; ISRAELE V, 1992, pB233; Karon J M, 1992, MMWR Recomm Rep, V41, P1; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; MCKINNEY RE, 1992, PEDIATR INFECT DIS J, V11, P639; MOFENSON LM, 1993, J ACQ IMMUN DEF SYND, V6, P1103; NEWELL ML, 1994, BRIT MED J, V308, P437; OLESKE J, 1994, CLIN INFECT DIS, V19, P611; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; RUEBUSH TK, 1978, AM J DIS CHILD, V132, P143, DOI 10.1001/archpedi.1978.02120270041009; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018, DOI 10.1097/00006454-199211120-00006	26	67	67	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					786	790		10.1056/NEJM199503233321206	http://dx.doi.org/10.1056/NEJM199503233321206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862183				2022-12-01	WOS:A1995QN44200006
J	SNYDER, EY; TAYLOR, RM; WOLFE, JH				SNYDER, EY; TAYLOR, RM; WOLFE, JH			NEURAL PROGENITOR-CELL ENGRAFTMENT CORRECTS LYSOSOMAL STORAGE THROUGHOUT THE MPS-VII MOUSE-BRAIN	NATURE			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; BETA-GLUCURONIDASE DEFICIENCY; BONE-MARROW TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; GENE-TRANSFER; MICE; IMPLANTATION; SPLEEN; LINES; MODEL	MANY metabolic diseases affecting the central nervous system are refractory to treatment because the blood-brain barrier restricts entry of therapeutic molecules. It may be possible to deliver therapeutic gene products directly to the brain by transplantation of neural progenitor cells, which can integrate into the murine central nervous system in a cytoarchitecturally appropriate manner(1-7). We tested this approach in mucopolysaccharidosis VII (Sly disease), a lysosomal storage disorder of humans, dogs and mice caused by an inherited deficiency of beta-glucuronidase(8-10). Lysosomal accumulation of glycosaminoglycans occurs in the brain and other tissues, causing a fatal progressive degenerative disorder, including mental retardation(11). Treatments are designed to provide a source of normal enzyme for uptake by diseased cells(12-20). We report here that by transplanting beta-glucuronidase-expressing neural progenitors into the cerebral ventricles of newborn mice, donor cells engrafted throughout the neuraxis. At maturity, donor-derived cells were present as normal constituents of diverse brain regions. beta-Glucuronidase activity was expressed along the entire neuraxis, resulting in widespread correction of lysosomal storage in neurons and glia in affected mice.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; UNIV PENN,SCH VET MED,PATHOL LAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH VET MED,MED GENET SECT,PHILADELPHIA,PA 19104	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Pennsylvania; University of Pennsylvania								ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANTON R, 1994, EXP NEUROL, V127, P207, DOI 10.1006/exnr.1994.1097; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; BIRKENMEIER EH, 1991, BLOOD, V78, P3081; BREAKEFIELD XO, 1993, NAT GENET, V3, P187, DOI 10.1038/ng0393-187; CHRISTIE D, 1994, ARCH DIS CHILD, V70, P275, DOI 10.1136/adc.70.4.275; FISHER LJ, 1994, FASEB J, V8, P489, DOI 10.1096/fasebj.8.8.8181667; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; HASKINS M, 1991, TREATMENT GENETIC DI, P183; HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450-198418100-00014; KITCHENS DL, 1994, J NEUROBIOL, V25, P797, DOI 10.1002/neu.480250705; KYLE JW, 1990, P NATL ACAD SCI USA, V87, P3914, DOI 10.1073/pnas.87.10.3914; MACKLIS JD, 1994, EXP NEUROL, V129, P9; MARECHAL V, 1993, BLOOD, V82, P1358; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; ONNIFER SM, 1993, EXP NEUROL, V122, P130; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; SANDS MS, 1993, P NATL ACAD SCI USA, V90, P6567, DOI 10.1073/pnas.90.14.6567; SANDS MS, 1993, LAB INVEST, V68, P676; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; Snyder E. Y., 1993, Society for Neuroscience Abstracts, V19, P613; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SNYDER EY, 1992, SEMIN PERINATOL, V16, P106; SUHR ST, 1993, ARCH NEUROL-CHICAGO, V50, P1252, DOI 10.1001/archneur.1993.00540110122012; TAYLOR RM, 1994, EXP CELL RES, V214, P606, DOI 10.1006/excr.1994.1298; VOGLER C, 1990, AM J PATHOL, V136, P207; VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450-199312000-00028; WOLFE JH, 1995, GENE THER, V2, P70; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFE JH, 1992, NATURE, V360, P749, DOI 10.1038/360749a0; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	34	397	412	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					367	370		10.1038/374367a0	http://dx.doi.org/10.1038/374367a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885477				2022-12-01	WOS:A1995QN63000062
J	WILLIAMS, RS				WILLIAMS, RS			BOOSTING CARDIAC CONTRACTILITY WITH GENES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											WILLIAMS, RS (corresponding author), UNIV TEXAS,SW MED CTR,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017	1	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					817	818		10.1056/NEJM199503233321212	http://dx.doi.org/10.1056/NEJM199503233321212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862189				2022-12-01	WOS:A1995QN44200012
J	HURIE, MB; GENNIS, MA; HERNANDEZ, LV; DINDZANS, VJ; DAVIS, JP				HURIE, MB; GENNIS, MA; HERNANDEZ, LV; DINDZANS, VJ; DAVIS, JP			PREVALENCE OF HEPATITIS-B MARKERS AND MEASLES, MUMPS, AND RUBELLA ANTIBODIES AMONG JEWISH REFUGEES FROM THE FORMER SOVIET-UNION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SEROSURVEY; RECRUITS	Objective.-To assess the prevalence of hepatitis B virus (HBV) infection and immunity to measles, mumps, and rubella among refugees from the former Soviet Union (FSU). Design.-Descriptive study. Setting.-Soviet Immigrant Health Care Program, Sinai Samaritan Hospital, Milwaukee, Wis. Patients.-Consecutive sample of 496 Jewish refugees from the FSU presenting for new arrival screening from December 1, 1990, through January 11, 1993. Outcome Measures.-Hepatitis B surface antigen (HBsAg), hepatitis B core antibody, hepatitis B surface antibody, and measles, mumps, and rubella antibodies. Results.-At least one hepatitis B marker was detected in 22% of the refugees, and HBsAg was detected in 0.4%. The rate of HBV infection (any marker present) increased with increasing age, ranging from 4% among those aged 0 through 19 years to 31% among those aged 50 through 59 years (chi(2) test for trend, 13.5; P<.001). Among those aged 0 through 19 years, 19% lacked antibody to measles, 8% lacked antibody to mumps, and 13% lacked antibody to rubella. Refugees who were less than 30 years of age were more than twice as likely to lack antibodies to measles, mumps, or rubella compared with those who were 30 years of age or older (relative risk, 2.8; 95% confidence interval, 1.8 to 4.2; P<.001). Conclusions.-In our sample of Jewish refugees from the FSU (primarily Ukraine, Russia, and Belorussia), the rate of HBsAg positivity was low, suggesting that routine screening for HBV infection is not needed. Seronegativity to measles, mumps, and rubella was relatively common among those less than 30 years old. Those refugees who were born after 1957 should be given combined measles, mumps, and rubella vaccine unless their written documentation indicates previous receipt of these antigens according to the immunization schedule recommended in the United States.	UNIV WISCONSIN, SCH MED, SINAI SAMARITAN MED CTR, MILWAUKEE, WI USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI USA; UNIV WISCONSIN, DEPT PREVENT MED, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Milwaukee; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	HURIE, MB (corresponding author), BUR PUBL HLTH, WISCONSIN DIV HLTH, COMMUN DIS SECT, 1414 E WASHINGTON AVE, ROOM 167, MADISON, WI 53703 USA.							[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Brinton K, 1992, Nurse Pract, V17, P21, DOI 10.1097/00006205-199204000-00008; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; KNAUS W, 1981, INSIDE RUSSIAN MED, P137; MAYNARD JE, 1989, REV INFECT DIS, V11, pS574; MILLER B, 1990, TB NOTES         SUM, P9; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; SEALE JR, 1987, J ROY SOC MED, V80, P301, DOI 10.1177/014107688708000515; SOBESLAVSKY O, 1980, B WORLD HEALTH ORGAN, V58, P621; STRUEWING JP, 1993, AM J PUBLIC HEALTH, V83, P1717, DOI 10.2105/AJPH.83.12.1717; 1992, MMWR-MORBID MORTAL W, V41, P89; 1989, MMWR-MORBID MORTAL W, V38, P818; 1991, MMWR-MORBID MORTAL W, V40, P784; 1993, REFUGEE REP, V14, P8	14	6	6	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					954	956		10.1001/jama.273.12.954	http://dx.doi.org/10.1001/jama.273.12.954			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884955				2022-12-01	WOS:A1995QM17300031
J	SMALL, GW; MAZZIOTTA, JC; COLLINS, MT; BAXTER, LR; PHELPS, ME; MANDELKERN, MA; KAPLAN, A; LARUE, A; ADAMSON, CF; CHANG, L; GUZE, BH; CORDER, EH; SAUNDERS, AM; HAINES, JL; PERICAKVANCE, MA; ROSES, AD				SMALL, GW; MAZZIOTTA, JC; COLLINS, MT; BAXTER, LR; PHELPS, ME; MANDELKERN, MA; KAPLAN, A; LARUE, A; ADAMSON, CF; CHANG, L; GUZE, BH; CORDER, EH; SAUNDERS, AM; HAINES, JL; PERICAKVANCE, MA; ROSES, AD			APOLIPOPROTEIN-E TYPE-4 ALLELE AND CEREBRAL GLUCOSE-METABOLISM IN RELATIVES AT RISK FOR FAMILIAL ALZHEIMER-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON EMISSION TOMOGRAPHY; SENILE DEMENTIA; ONSET; GENE; CHROMOSOME-14; RELIABILITY; PREVALENCE; EPSILON-4; PATTERNS; REGIONS	Objective.-Cerebral parietal hypometabolism and left-right asymmetry occur early in the course of Alzheimer disease (AD), and the apolipoprotein E type 4 allele (APOE epsilon 4) is a risk factor for familial AD. To determine if APOE epsilon 4 is associated with lowered brain function in nondemented relatives at risk for familiar AD, we studied 12 relatives with APOE epsilon 4 and 19 relatives without APOE epsilon 4. We also compared them with seven patients with probable AD. Design.-After grouping subjects according to diagnosis and genotype, brain function measures were compared among groups. Setting.-University medical center. Patients.-At-risk subjects had mild memory complaints, normal cognitive performance, and at least two relatives with AD. Subjects with APOE epsilon 4 did not differ from those without APOE epsilon 4 in mean age at examination (56.4 vs 55.5 years) or in neuropsychological performance (mean Mini-Mental State Examination score, 28.8 vs 29.3). Main Outcome Measures.-Cerebral glucose metabolism was measured using positron emission tomography and fludeoxyglucose F 18. Results.-Parietal metabolism was significantly lower and left-right parietal asymmetry was significantly higher in at-risk subjects with APOE epsilon 4 compared with those without APOE epsilon 4, Patients with dementia had significantly lower parietal metabolism than did at-risk subjects with APOE epsilon 4. Conclusions.-These results suggest that the inheritance of APOE epsilon 4 is associated with reduced cerebral parietal metabolism and increased asymmetry in nondemented relatives at risk for probable AD, Longitudinal study will determine if glucose metabolic measures provide a means to monitor experimental treatment responses during the early phases of the disorder.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT RADIOL SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV BRAIN MAPPING,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,CTR ALZHEIMERS DIS,LOS ANGELES,CA 90024; VET AFFAIRS MED CTR,LOS ANGELES,CA; UNIV CALIF IRVINE,DEPT PHYS,IRVINE,CA; UNIV NEW MEXICO,DEPT PSYCHIAT,ALBUQUERQUE,NM; DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZHEIMERS DIS RES CTR,DURHAM,NC; DUKE UNIV,MED CTR,DIV NEUROL,DURHAM,NC; DUKE UNIV,MED CTR,DIV NEUROBIOL,DURHAM,NC; MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Irvine; University of New Mexico; Duke University; Duke University; Duke University; Harvard University; Massachusetts General Hospital	SMALL, GW (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024, USA.		Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH046424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U24AG021886, P30AG010123] Funding Source: NIH RePORTER; NIA NIH HHS [AG05128, AG10123, U24 AG021886] Funding Source: Medline; NIMH NIH HHS [1R29 MH46424] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AZARI NP, 1993, J CEREBR BLOOD F MET, V13, P438, DOI 10.1038/jcbfm.1993.58; BACHMAN DL, 1992, NEUROLOGY, V42, P115, DOI 10.1212/WNL.42.1.115; BARRIO JR, 1981, J NUCL MED, V22, P372; BAXTER LR, 1987, PSYCHIAT RES, V21, P237, DOI 10.1016/0165-1781(87)90028-X; Benton A., 1978, MULTILINGUAL APHASIA; BLASS JP, 1993, ALZ DIS ASSOC DIS, V6, P205; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; DAVIS PC, 1992, NEUROLOGY, V42, P1676, DOI 10.1212/WNL.42.9.1676; DELEON MJ, 1993, AM J NEURORADIOL, V14, P897; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILEWSKI MJ, 1990, PSYCHOL AGING, V5, P482, DOI 10.1037/0882-7974.5.4.482; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRADY CL, 1988, J CLIN EXP NEUROPSYC, V10, P576, DOI 10.1080/01688638808402796; GRADY CL, 1993, NEUROBIOL AGING, V14, P35, DOI 10.1016/0197-4580(93)90018-7; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HART RP, 1987, PSYCHOL AGING, V2, P111, DOI 10.1037/0882-7974.2.2.111; HAXBY JV, 1990, ARCH NEUROL-CHICAGO, V47, P753, DOI 10.1001/archneur.1990.00530070043010; HENRY TR, 1990, J CEREBR BLOOD F MET, V10, P748, DOI 10.1038/jcbfm.1990.128; HERHOLZ K, 1993, J NUCL MED, V34, P1460; HIXSON JE, 1990, J LIPID RES, V31, P545; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; KILLIANY RJ, 1993, ARCH NEUROL-CHICAGO, V50, P949, DOI 10.1001/archneur.1993.00540090052010; KUHL DE, 1987, J CEREB BLOOD FLOW M, V7, pS406; LIU CK, 1992, NEUROLOGY, V42, P138, DOI 10.1212/WNL.42.1.138; MASUR DM, 1989, J CLIN EXP NEUROPSYC, V11, P615, DOI 10.1080/01688638908400920; MAX W, 1993, NEUROLOGY, V43, pS6; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAZZIOTTA J C, 1986, P493; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MULLERGARTNER HW, 1992, J CEREBR BLOOD F MET, V12, P571, DOI 10.1038/jcbfm.1992.81; Osterrieth P. A., 1944, ARCHIVESPSYCHOLOGIE, V30, P206; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; PHELPS ME, 1981, J CEREB BLOOD FLOW M, V2, P113; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; SAMBROOK J, 1989, MOL CLONING LABORATO, pB24; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SMALL GW, 1989, ARCH GEN PSYCHIAT, V46, P527; SMALL GW, 1992, PSYCHIAT RES-NEUROIM, V45, P177, DOI 10.1016/0925-4927(92)90025-Y; SMALL GW, 1994, INT PSYCHOGERIATR, V6, P21; SMALL GW, 1988, ARCH GEN PSYCHIAT, V46, P945; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STORANDT M, 1984, ARCH NEUROL-CHICAGO, V41, P497, DOI 10.1001/archneur.1984.04050170043013; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CMG, 1991, INT J EPIDEMIOL S2, V20, pS48; VANGORP WG, 1990, DEV NEUROPSYCHOL, V6, P279, DOI 10.1080/87565649009540467; Wechsler, 2012, WECHSLER ADULT INTEL, DOI 10.1037/t15169-000; Wechsler D, 1981, ADULT INTELLIGENCE S; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; 1988, ALZ DIS ASSOC DIS, V2, P4; 1993, LANCET, V342, P737	59	497	512	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					942	947		10.1001/jama.273.12.942	http://dx.doi.org/10.1001/jama.273.12.942			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM173	7884953				2022-12-01	WOS:A1995QM17300029
J	ALMROTH, S; LATHAM, MC				ALMROTH, S; LATHAM, MC			RATIONAL HOME MANAGEMENT OF DIARRHEA	LANCET			English	Editorial Material							CHILDHOOD DIARRHEA; HEALTH-EDUCATION; MOTHERS; DISEASE		CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Cornell University								[Anonymous], 1978, LANCET, V2, P300; BARROS FC, 1991, B WORLD HEALTH ORGAN, V69, P59; Benakappa D G, 1990, Indian J Pediatr, V57, P21, DOI 10.1007/BF02722124; BENTLEY ME, 1988, SOC SCI MED, V27, P75, DOI 10.1016/0277-9536(88)90165-7; BENTLEY ME, 1988, SOC SCI MED, V27, P107, DOI 10.1016/0277-9536(88)90168-2; CHUNG AW, 1948, J PEDIATR-US, V33, P1, DOI 10.1016/S0022-3476(48)80147-2; CHUNG AW, 1948, J PEDIATR-US, V33, P14, DOI 10.1016/S0022-3476(48)80148-4; FIELD M, 1977, NEW ENGL J MED, V297, P1121, DOI 10.1056/NEJM197711172972011; GREEN EC, 1985, SOC SCI MED, V20, P277, DOI 10.1016/0277-9536(85)90242-4; GREENOUGH WB, 1987, CEREAL BASED ORAL RE, P52; HOYLE B, 1980, AM J CLIN NUTR, V33, P2365, DOI 10.1093/ajcn/33.11.2365; HUFFMAN SL, 1991, J DIARRHOEAL DIS RES, V9, P295; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; Mahalanabis D, 1983, J Diarrhoeal Dis Res, V1, P76; MARTINEZ H, 1991, J DIARRHOEAL DIS RES, V9, P235; MULL JD, 1984, J FAM PRACTICE, V18, P485; OYOO A, 1991, HEALTH POLICY PLANN, V6, P380, DOI 10.1093/heapol/6.4.380; RASHEED P, 1993, SOC SCI MED, V36, P373, DOI 10.1016/0277-9536(93)90022-V; SCHULTZ SG, 1977, AM J PHYSIOL, V233, pE249, DOI 10.1152/ajpendo.1977.233.4.E249; Tulloch J, 1987, World Health Stat Q, V40, P110; WILSON R, 1989, CEREAL BASED ORAL RE, P13; 1993, SELECTION FLUIDS FOO; 1983, LANCET, V2, P259; 1990, WHO1988 1989 PROGR C; 1987, DECISION PROCESS EST; 1978, WHO CHRON, V32, P369; 1993, WHO1992 PROGR CONTR	27	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	1995	345	8951					709	711		10.1016/S0140-6736(95)90873-0	http://dx.doi.org/10.1016/S0140-6736(95)90873-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM732	7885128				2022-12-01	WOS:A1995QM73200014
J	ATEENYIAGABA, C				ATEENYIAGABA, C			CONJUNCTIVAL SQUAMOUS-CELL CARCINOMA-ASSOCIATED WITH HIV-INFECTION IN KAMPALA, UGANDA	LANCET			English	Note								The incidence of conjunctival squamous-cell carcinoma in Kampala, Uganda, was steady at around 6 per million per year from 1970 until 1988, but has increased six-fold since then to 35 per million per year in 1992. Among 48 patients with conjunctival tumours seen at the ophthalmology clinic of the New Mulago Hospital from 1990 to 1991, 75% were HIV seropositive, compared with a 19% seropositivity rate among 48 matched controls (relative risk 13.0, 95% Cl 4.5-39.4, p<0.0001). The recent epidemic of conjunctival tumours in Uganda (and in neighbouring countries) appears to be largely due to the epidemic of HIV infection. Other factors that may contribute to the high incidence of these tumours in equatorial Africa may be exposure to ultraviolet light and conjunctival papillomavirus infection.			ATEENYIAGABA, C (corresponding author), MAKERERE UNIV,SCH MED,DEPT OPHTHALMOL,POB 7022,KAMPALA,UGANDA.							KESTELYN P, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91562-O; KIM RY, 1990, AM J OPHTHALMOL, V109, P231, DOI 10.1016/S0002-9394(14)75997-5; TEMPLETON A, 1973, RECENT RESULTS CANC, V43, P203; TRITTEN JJ, 1994, KLIN MONATSBL AUGENH, V204, P453, DOI 10.1055/s-2008-1045463; WINWARD KE, 1989, AM J OPHTHALMOL, V107, P554, DOI 10.1016/0002-9394(89)90508-4	5	113	118	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					695	696		10.1016/S0140-6736(95)90870-6	http://dx.doi.org/10.1016/S0140-6736(95)90870-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885126				2022-12-01	WOS:A1995QM73200011
J	BARKER, DJP; MARTYN, CN; OSMOND, C; WIELD, GA				BARKER, DJP; MARTYN, CN; OSMOND, C; WIELD, GA			ABNORMAL LIVER GROWTH IN-UTERO AND DEATH FROM CORONARY HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE				BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BOCHNER CJ, 1987, AM J OBSTET GYNECOL, V157, P703, DOI 10.1016/S0002-9378(87)80033-9; Gruenwald P, 1974, CIBA F S, V27, P3; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x	5	72	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					703	704		10.1136/bmj.310.6981.703	http://dx.doi.org/10.1136/bmj.310.6981.703			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711538	Green Published			2022-12-01	WOS:A1995QN46100020
J	BRAUN, S; CROIZAT, B; LAGRANGE, MC; WARTER, JM; POINDRON, P				BRAUN, S; CROIZAT, B; LAGRANGE, MC; WARTER, JM; POINDRON, P			CONSTITUTIVE MUSCULAR ABNORMALITIES IN CULTURE IN SPINAL MUSCULAR-ATROPHY	LANCET			English	Note								To explore the cause of spinal muscular atrophy (SMA), we used an in-vitro model of nerve-muscle co-cultures in which motoneurons were normal and satellite cells were obtained from SMA patients. In co-cultures initiated with satellite cells from type I and type II SMA patients only, we observed degeneration of the innervated fibres after 1-3 weeks of nerve-muscle co-culture. This process involved vacuolisation, disorganisation, and death of the innervated muscle fibres. This observation points to a muscular implication in the severe forms of SMAs.	UNIV LOUIS PASTEUR STRASBOURG 1,UFR SCI,DEPT IMMUNOL & IMMUNOPHARMACOL,F-67401 ILLKIRCH GRAFFENS,FRANCE; ASSOC FRANCAISE MYOPATHIES,PARIS,FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Braun, Serge/ABC-4313-2021					ASKANAS V, 1987, J NEUROCYTOL, V16, P523, DOI 10.1007/BF01668506; Askanas V, 1992, HDB CLIN NEUROL, P85; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; HENDERSON CE, 1988, REV NEUROL, V144, P730; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982	5	84	84	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					694	695		10.1016/S0140-6736(95)90869-2	http://dx.doi.org/10.1016/S0140-6736(95)90869-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7741893				2022-12-01	WOS:A1995QM73200010
J	GONZALES, R; SANDE, M				GONZALES, R; SANDE, M			WHAT WILL IT TAKE TO STOP PHYSICIANS FROM PRESCRIBING ANTIBIOTICS IN ACUTE BRONCHITIS	LANCET			English	Editorial Material							ERYTHROMYCIN				GONZALES, R (corresponding author), SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110, USA.							BRICKFIELD FX, 1986, J FAM PRACTICE, V23, P119; DUNLAY J, 1987, J FAM PRACTICE, V25, P137; FRANKS P, 1984, J FAM PRACTICE, V19, P185; HOWIE JGR, 1970, LANCET, V2, P1099; KAYSER FH, 1990, EUR J CLIN MICROBIOL, V9, P810, DOI 10.1007/BF01967379; MASON EO, 1992, ANTIMICROB AGENTS CH, V36, P1703, DOI 10.1128/AAC.36.8.1703; NORDENSTAM I, 1992, SWEDISH STATISTICS M; ORR PH, 1993, J FAM PRACTICE, V36, P507; PARKINSON AJ, 1994, J INFECT DIS, V170, P461, DOI 10.1093/infdis/170.2.461; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; VERHEIJ TJM, 1990, FAM PRACT, V7, P175, DOI 10.1093/fampra/7.3.175; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; WILLIAMSON HA, 1984, J FAM PRACTICE, V19, P185	13	93	95	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					665	666		10.1016/S0140-6736(95)90861-7	http://dx.doi.org/10.1016/S0140-6736(95)90861-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885119				2022-12-01	WOS:A1995QM73200002
J	GRECO, L; POWER, C; PECKHAM, C				GRECO, L; POWER, C; PECKHAM, C			ADULT OUTCOME OF NORMAL-CHILDREN WHO ARE SHORT OR UNDERWEIGHT AT AGE 7 YEARS	BRITISH MEDICAL JOURNAL			English	Article							GROWTH; NEWCASTLE; TYNE; COMMUNITY; HEIGHT; BIRTH	Objectives-To evaluate the adult growth outcome (at age 23) of children who are short or underweight at age 7 years in whom no identifiable pathological cause exists for their poor growth. Design-Longitudinal follow up of a birth cohort. Setting-The national child development study (1958 birth cohort) of Great Britain. Subjects-523 children with a height or a weight below the fifth centile at age 7. Of these, 70 (13 . 4%) were excluded because they had a longstanding illness that could account for their poor growth. The remaining 453 subjects, who were followed to age 23, provided the base group from which those with additional data, such as parental height, were obtained. Results-55/174 (31 . 6%) boys who were short at age 7 became short men; 60/211 (28 . 4%) girls who were short at age 7 became short women. Among boys who were underweight at age 7, 46/160 (28 . 7%) were still underweight at age 23, while 61/200 (30 . 5%) girls underweight at age 7 became underweight women. Having short parents did not increase the probability of being small as an adult. Children with delayed puberty were as likely to remain small as those in whom puberty was not delayed. Conclusions-One in three normal children who was short or underweight at age 7 became a short or underweight adult. This informs the management of short children and may be valuable when prolonged growth hormone treatment for short stature is being considered.	INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,LONDON WC1 1EH,ENGLAND	University of London; University College London	GRECO, L (corresponding author), UNIV NAPLES FEDERICO II,VIA PANSINI,I-80131 NAPLES,ITALY.							ALBERMAN E, 1991, ANN HUM BIOL, V18, P27; BAILEY BJR, 1994, ANN HUM BIOL, V21, P1, DOI 10.1080/03014469400003032; BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; BROOK CGD, 1991, ARCH DIS CHILD, V66, P85, DOI 10.1136/adc.66.1.85; BUTLER GE, 1990, ANN HUM BIOL, V17, P177, DOI 10.1080/03014469000000952; FERRI E, 1993, LIFE 3O 5TH FOLLOW U; FOGELMAN K, 1983, GROWING UP GREAT BRI; GOLDSTEIN H, 1971, HUM BIOL, V43, P92; GRECO L, 1990, ARCH DIS CHILD-FETAL, V65, P373, DOI 10.1136/adc.65.4_Spec_No.373; GULLIFORD MC, 1991, ARCH DIS CHILD, V66, P235, DOI 10.1136/adc.66.2.235; HERMANUSSEN M, 1988, ANN HUM BIOL, V15, P103, DOI 10.1080/03014468800009521; HINDMARSH PC, 1988, ACTA PEDIATR SCAND S, V343, P73; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; LACEY KA, 1974, ARCH DIS CHILD, V49, P417, DOI 10.1136/adc.49.6.417; LACEY KA, 1974, LANCET, V1, P42; MILLER FJW, 1972, BRIT J PREV SOC MED, V26, P224; MILNER RDG, 1986, LANCET, V1, P483; PINTOR C, 1989, LANCET, V1, P1226; POWER C, 1991, HLTH CLASS EARLY YEA; POWER C, 1988, INT J OBESITY, V2, P445; RONA RJ, 1981, BRIT MED BULL, V37, P265, DOI 10.1093/oxfordjournals.bmb.a071713; ROSENBAUM S, 1986, ANN HUM BIOL, V12, P115; SKUSE DH, 1985, ARCH DIS CHILD, V60, P173, DOI 10.1136/adc.60.2.173; STARK O, 1981, BMJ-BRIT MED J, V283, P13, DOI 10.1136/bmj.283.6283.13; VOSS LD, 1992, BMJ-BRIT MED J, V305, P1400, DOI 10.1136/bmj.305.6866.1400	26	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					696	700		10.1136/bmj.310.6981.696	http://dx.doi.org/10.1136/bmj.310.6981.696			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711536	Green Published			2022-12-01	WOS:A1995QN46100018
J	HAMILTON, MI; DICK, R; CRAWFORD, L; THOMPSON, NP; POUNDER, RE; WAKEFIELD, AJ				HAMILTON, MI; DICK, R; CRAWFORD, L; THOMPSON, NP; POUNDER, RE; WAKEFIELD, AJ			IS PROXIMAL DEMARCATION OF ULCERATIVE-COLITIS DETERMINED BY THE TERRITORY OF THE INFERIOR MESENTERIC-ARTERY	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; VASCULITIS	The sharp demarcation between diseased and normal mucosa often observed in ulcerative colitis remains unexplained by current hypotheses of disease pathogenesis. To investigate whether this demarcation occurs at the watershed of vascular territories, the colonic arterial anatomy of 10 patients with ulcerative colitis was studied by in-vitro angiography and macroscopic and histological examination of total colectomy specimens. Of the 10 perfusion-fixed colectomy specimens studied, 7 had pancolitis associated with a complete marginal artery (Arteria marginalis coli) that spanned the entire length of the large bowel. 3 specimens had sharply demarcated disease in which the marginal artery arose from the inferior mesenteric artery and ended abruptly at the point of mucosal demarcation. The colon proximal to this point was histologically normal. These findings suggest that the proximal extent of colitis is determined by the limit of the marginal artery. We suggest that some characteristic of the mucosal microvasculature in the territory of the inferior mesenteric artery, possibly embryological in origin, predisposes the dependent colon to develop ulcerative colitis.	ROYAL FREE HOSP,SCH MED,INFLAMMATORY BOWEL DIS STUDY GRP,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT RADIOL,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								BACANER MB, 1966, GASTROENTEROLOGY, V51, P764; COLLINS WJ, 1979, GASTROENTEROLOGY, V77, P1091; DHILLON AP, 1992, HISTOPATHOLOGY, V21, P127, DOI 10.1111/j.1365-2559.1992.tb00360.x; GAFFNEY PR, 1993, GASTROENTEROLOGY, V104, pA703; HAMILTON WK, 1972, EMBRYOLOGY, P268; HOLLISHEAD WH, 1956, ANATOMY SURGEONS, P503; HULTEN L, 1977, GASTROENTEROLOGY, V72, P388; JEWELL DP, 1992, ULCERATIVE COLITIS C, P1; LUNDERQUIST A, 1967, AMER J ROENTGENOL RA, V99, P18, DOI 10.2214/ajr.99.1.18; MISIEWICZ JJ, 1987, ATLAS CLIN GASTROENT; NELSON J, 1986, NEUROLOGY, V36, P719, DOI 10.1212/WNL.36.5.719; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P202, DOI 10.1016/S0091-6749(05)80067-3; SHUBICH M G, 1976, Arkhiv Patologii, V38, P60; TALBOT RW, 1986, MAYO CLIN PROC, V61, P140, DOI 10.1016/S0025-6196(12)65200-8; THOMPSON NP, IN PRESS GASTROENTER; TSUCHIYA M, 1980, ANGIOLOGY, V31, P147, DOI 10.1177/000331978003100301; WAKEFIELD AJ, 1989, LANCET, V2, P1057	17	31	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					688	690		10.1016/S0140-6736(95)90867-6	http://dx.doi.org/10.1016/S0140-6736(95)90867-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885124				2022-12-01	WOS:A1995QM73200008
J	IMAI, K; NAKACHI, K				IMAI, K; NAKACHI, K			CROSS-SECTIONAL STUDY OF EFFECTS OF DRINKING GREEN TEA ON CARDIOVASCULAR AND LIVER-DISEASES	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BODY IRON STORES; (-)-EPIGALLOCATECHIN GALLATE; ULTRAVIOLET-LIGHT; FREE-RADICALS; CANCER; CHOLESTEROL; CONSUMPTION; RISK; FLAVONOIDS	Objective-To investigate the association between consumption of green tea and various serum markers in a Japanese population, with special reference to preventive effects of green tea against cardiovascular disease and disorders of the liver. Design-Cross sectional study. Setting-Yoshimi, Japan. Subjects-1371 men aged over 40 years resident in Yoshimi and surveyed on their living habits including daily consumption of green tea. Their peripheral blood samples were subjected to several biochemical assays. Results-Increased consumption of green tea was associated with decreased serum concentrations of total cholesterol (P for trend <0.001) and triglyceride (P for trend=0 . 02) and an increased proportion of high density lipoprotein cholesterol together with a decreased proportion of low and very low lipoprotein cholesterols (P for trend=0 . 02), which resulted in a decreased atherogenic index (P for trend=0.02). Moreover, increased consumption of green tea, especially more than 10 cups a day, was related to decreased concentrations of hepatological markers in serum, aspartate aminotransferase (P for trend=0 . 06), alanine transferase (P for trend=0 . 07), and ferritin (P for trend=0 . 02). Conclusion-The inverse association between consumption of green tea and various serum markers shows that green tea may act protectively against cardiovascular disease and disorders of the liver.			IMAI, K (corresponding author), SAITAMA CANC CTR,RES INST,DEPT EPIDEMIOL,KOMURO 818,INA,SAITAMA 362,JAPAN.							BROWN CA, 1993, J EPIDEMIOL COMMUN H, V47, P171, DOI 10.1136/jech.47.3.171; CHISAKA T, 1988, CHEM PHARM BULL, V36, P227; CONNEY AH, 1992, PREV MED, V21, P361, DOI 10.1016/0091-7435(92)90043-H; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FUJIKI H, 1992, PREV MED, V21, P503, DOI 10.1016/0091-7435(92)90057-O; GREEN MS, 1992, PREV MED, V21, P532, DOI 10.1016/0091-7435(92)90061-L; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HUSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489, DOI 10.1016/s0031-9422(00)83860-1; IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2; KONO S, 1992, PREV MED, V21, P526, DOI 10.1016/0091-7435(92)90060-U; MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613; NAKACHI K, 1992, JPN J CANCER RES, V83, P798, DOI 10.1111/j.1349-7006.1992.tb01983.x; NAKACHI K, 1991, CANCER RES, V51, P5177; NAKACHI K, 1993, CANCER RES, V53, P2994; NAKAYAMA T, 1994, CANCER RES S, V54; OSAWA T, 1990, BASIC LIFE SCI, V52, P139; SANO M, 1986, CHEM PHARM BULL, V34, P221; SELBY JV, 1988, INT J CANCER, V41, P677, DOI 10.1002/ijc.2910410507; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STENSVOLD I, 1992, PREV MED, V21, P546, DOI 10.1016/0091-7435(92)90062-M; STEVENS RG, 1986, J NATL CANCER I, V76, P605, DOI 10.1093/jnci/76.4.605; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; WANG ZY, 1992, CANCER RES, V52, P1162; WANG ZY, 1989, MUTAT RES, V223, P273, DOI 10.1016/0165-1218(89)90120-1; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yoshizawa S., 1987, PHYTOTHER RES, V1, P44, DOI [10.1002/ptr.2650010110, DOI 10.1002/PTR.2650010110]; YOUNG W, 1967, NATURE, V216, P1015, DOI 10.1038/2161015a0; ZHAO BL, 1989, CELL BIOPHYS, V14, P175, DOI 10.1007/BF02797132	30	340	343	4	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					693	696		10.1136/bmj.310.6981.693	http://dx.doi.org/10.1136/bmj.310.6981.693			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711535	Green Published			2022-12-01	WOS:A1995QN46100017
J	ORRELL, MW; ODWYER, AM				ORRELL, MW; ODWYER, AM			DEMENTIA, AGING, AND THE STRESS-CONTROL SYSTEM	LANCET			English	Editorial Material							ALZHEIMERS		UNIV CAMBRIDGE, DEPT PSYCHIAT, CAMBRIDGE, ENGLAND	University of Cambridge	ORRELL, MW (corresponding author), UCL, SCH MED, DEPT PSYCHIAT, LONDON W1N 8AA, ENGLAND.			Orrell, Martin/0000-0002-1169-3530				AMADUCCI L, 1992, INT J GERIATR PSYCH, V7, P383, DOI 10.1002/gps.930070602; BRAYNE C, 1988, LANCET, V1, P1265; BROE GA, 1990, NEUROLOGY, V40, P1699; DODT C, 1991, J CLIN ENDOCR METAB, V72, P272, DOI 10.1210/jcem-72-2-272; ELLIOTT EM, 1993, BRAIN RES, V602, P84, DOI 10.1016/0006-8993(93)90245-I; FRENCH SL, 1992, AM J COMMUN PSYCHOL, V20, P243, DOI 10.1007/BF00940838; JORM AF, 1991, INT J EPIDEMIOL S2, V20, P43; MILLER AH, 1994, AM J PSYCHIAT, V151, P267; Mullan Michael J., 1993, International Review of Psychiatry, V5, P351, DOI 10.3109/09540269309037798; OBRIEN JT, 1993, INT J GERIATR PSYCH, V8, P887, DOI 10.1002/gps.930081103; SAPOLSKY RM, 1990, BIOL PSYCHIAT, V27, P937, DOI 10.1016/0006-3223(90)90032-W; SAPOLSKY RM, 1986, ENDOCR REV, V7, P285	12	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 18	1995	345	8951					666	667		10.1016/S0140-6736(95)90862-5	http://dx.doi.org/10.1016/S0140-6736(95)90862-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM732	7885120				2022-12-01	WOS:A1995QM73200003
J	RIAD, H; NICHOLLS, A				RIAD, H; NICHOLLS, A			AN ETHICAL DEBATE - ELECTIVE VENTILATION OF POTENTIAL ORGAN DONORS	BRITISH MEDICAL JOURNAL			English	Article							DONATION	Elective ventilation describes the procedure of transferring selected patients dying from rapidly progressive intracranial haemorrhage from general medical wards to intensive care units for a brief period of ventilation before confirmation of brain stem death and harvesting of organs. This approach in Exeter has led to a rate of kidney retrieval and transplant higher than has been achieved elsewhere in the United Kingdom, with a stabilisation of numbers on patients on dialysis. Recently doubt has been cast on the legality of our practice of elective ventilation on the grounds that relatives are not permitted to consent to treatment of an incompetent person when that treatment is not in the patient's best interests. We are thus faced with the dilemma of a protocol that is ethical, practical, and operates for the greater good but which may be illegal. This article explores various objections to the protocol and calls for public, medical, and legal debate on the issues.	UNIV BRISTOL,BRISTOL ROYAL INFIRM,INTENS THERAPY UNIT,BRISTOL BS2 8HW,AVON,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,RENAL TRANSPLANT UNIT,LIVERPOOL,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,FAC LAW,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; THREE SERJEANTS INN,LONDON EC4Y 1BQ,ENGLAND	Bristol Royal Infirmary; University of Bristol; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Liverpool	RIAD, H (corresponding author), ROYAL DEVON & EXETER HOSP,EXETER EX2 5DW,DEVON,ENGLAND.		Sano, Michael/E-1715-2011					COLLINS CH, 1992, CARE CRITICALLY ILL, V8, P57; Conference of Medical Royal Colleges and their Faculties in the UK, 1979, LANCET, Vi, P261; FEEST TG, 1990, LANCET, V335, P1133, DOI 10.1016/0140-6736(90)91134-V; NEW B, 1994, 18 KINGS FUND I RES; NICHOLLS A, 1994, BRIT J HOSP MED, V51, P555; NICHOLLS A, 1993, BRIT MED J, V306, P517, DOI 10.1136/bmj.306.6876.517-d; NIELSEN MS, 1994, J ROY COLL PHYS LOND, V28, P85; RIAD H, 1994, BRIT J HOSP MED, V51, P555; RIAD H, 1993, BRIT J HOSP MED, V50, P438; ROBSON JG, 1981, LANCET, V2, P365; ROBSON JG, 1981, BMJ-BRIT MED J, V283, P505, DOI 10.1136/bmj.283.6289.505-a; Routh G, 1992, CARE CRIT ILL, V8, P60; SOMMERVILLE A, 1993, MED ETHICS TODAY ITS; WILLATTS SM, 1994, BRIT J HOSP MED, V51, P554; WILLIAMS R, 1993, J ROY COLL PHYS LOND, V27, P214; 1983, CADAVERIC ORGANS TRA; 1979, BRIT MED J, V1, P332; 1993, ISSUES NURSING SOC, V19	18	38	38	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					714	715		10.1136/bmj.310.6981.714	http://dx.doi.org/10.1136/bmj.310.6981.714			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711541	Green Published			2022-12-01	WOS:A1995QN46100024
J	CABELLI, RJ; HOHN, A; SHATZ, CJ				CABELLI, RJ; HOHN, A; SHATZ, CJ			INHIBITION OF OCULAR DOMINANCE COLUMN FORMATION BY INFUSION OF NT-4/5 OR BDNF	SCIENCE			English	Article							NERVE GROWTH-FACTOR; CATS VISUAL-CORTEX; NEUROTROPHIC FACTOR; MESSENGER-RNA; FACTOR FAMILY; MONOCULAR DEPRIVATION; MOLECULAR-CLONING; LIMBIC SEIZURES; STRIATE CORTEX; NGF	During the development of the visual system of higher mammals, axons from the lateral geniculate nucleus (LGN) become segregated into eye-specific patches (the ocular dominance columns) within their target, layer 4 of the primary visual cortex. This occurs as a consequence of activity-dependent synaptic competition between axons representing the two eyes, The possibility that this competition could be mediated through neurotrophin-receptor interactions was tested. Infusion of neurotrophin-4/5 (NT-4/5) or brain-derived neurotrophic factor (BDNF) into cat primary visual cortex inhibited column formation within the immediate vicinity of the infusion site but not elsewhere in the visual cortex. Infusion of nerve growth factor, neurotrophin 3 (NT-3), or vehicle solution did not affect column formation. These observations implicate TrkB, the common receptor for BDNF and NT-4/5, in the segregation of LGN axons into ocular dominance columns in layer 4. Moreover, they suggest that in addition to their better known roles in the prevention of cell death, neurotrophins may also mediate the activity-dependent control of axonal branching during development of the central nervous system.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	CABELLI, RJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.				NATIONAL EYE INSTITUTE [R01EY002858, R37EY002858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NEI NIH HHS [EY06327, EY02858] Funding Source: Medline; NIMH NIH HHS [MH 48108] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLENDOERFER KL, 1994, J NEUROSCI, V14, P1795; ANTONINI A, 1993, J NEUROSCI, V13, P3549; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CABELLI RJ, 1993, 23RD ANN M SOC NEUR; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHUN JJM, 1989, J COMP NEUROL, V282, P555, DOI 10.1002/cne.902820407; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COHENCORY S, 1991, J NEUROSCI, V11, P462; DIAMOND J, 1992, J NEUROSCI, V12, P1454; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; ERNFORS P, 1991, NEURON, V7, P164; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GHOSH A, 1994, J NEUROSCI, V14, P3862; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GU Q, 1994, P NATL ACAD SCI USA, V91, P8408, DOI 10.1073/pnas.91.18.8408; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HAYASHI M, 1990, NEUROSCIENCE, V36, P683, DOI 10.1016/0306-4522(90)90011-R; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOHN A, 1994, 24TH ANN M SOC NEUR; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; ISAACSON LG, 1992, J COMP NEUROL, V326, P327, DOI 10.1002/cne.903260302; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVAY S, 1975, J COMP NEUROL, V159, P559, DOI 10.1002/cne.901590408; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LOHOF AM, 1993, NATURE, V363; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PURVES D, 1988, NATURE, V336, P123, DOI 10.1038/336123a0; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; VAZQUEZ ME, 1991, NEUROREPORT, V2, P593, DOI 10.1097/00001756-199110000-00010; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	44	525	532	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1662	1666		10.1126/science.7886458	http://dx.doi.org/10.1126/science.7886458			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886458				2022-12-01	WOS:A1995QM39700042
J	DESSEN, A; QUEMARD, A; BLANCHARD, JS; JACOBS, WR; SACCHETTINI, JC				DESSEN, A; QUEMARD, A; BLANCHARD, JS; JACOBS, WR; SACCHETTINI, JC			CRYSTAL-STRUCTURE AND FUNCTION OF THE ISONIAZID TARGET OF MYCOBACTERIUM-TUBERCULOSIS	SCIENCE			English	Article							CATALASE-PEROXIDASE GENE; MYCOLIC ACID SYNTHESIS; RESISTANT STRAINS; SEQUENCES	Resistance to isoniazid in Mycobacterium tuberculosis can be mediated by substitution of alanine for serine 94 in the InhA protein, the drug's primary target. InhA was shown to catalyze the beta-nicotinamide adenine dinucleotide (NADH)-specific reduction of 2-trans-enoyl-acyl carrier protein, an essential step in fatty acid elongation. Kinetic analyses suggested that isoniazid resistance is due to a decreased affinity of the mutant protein for NADH. The three-dimensional structures of wild-type and mutant InhA, refined to 2.2 and 2.7 angstroms, respectively, revealed that drug resistance is directly related to a perturbation in the hydrogen-bonding network that stabilizes NADH binding.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine				Dessen, Andrea/0000-0001-6487-4020; Jacobs, William/0000-0003-3321-3080; Quemard, Annaik/0000-0002-5545-3424	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030189, R01AI033696, U01AI036849] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30189, AI33696, AI36849] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; HOWARD AJ, 1986, GUIDE DATA REDUCTION; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MCREE DE, 1993, PRACTICAL PROTEIN CR, P303; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; QUEMARD A, UNPUB; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SLABAS AR, 1986, BIOCHIM BIOPHYS ACTA, V877, P271, DOI 10.1016/0005-2760(86)90304-8; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TRONRUD DE, 1988, ACTA CRYSTALLOGR A, V43, P489; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Winder F, 1982, BIOL MYCOBACTERIA, V1, P354; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	27	380	397	2	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1638	1641		10.1126/science.7886450	http://dx.doi.org/10.1126/science.7886450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886450				2022-12-01	WOS:A1995QM39700034
J	HALANYCH, KM; BACHELLER, JD; AGUINALDO, AMA; LIVA, SM; HILLIS, DM; LAKE, JA				HALANYCH, KM; BACHELLER, JD; AGUINALDO, AMA; LIVA, SM; HILLIS, DM; LAKE, JA			EVIDENCE FROM 18S RIBOSOMAL DNA THAT THE LOPHOPHORATES ARE PROTOSTOME ANIMALS	SCIENCE			English	Article							SEQUENCES; ORIGIN; PHYLOGENY; RNA	The suspension-feeding metazoan subkingdom Lophophorata exhibits characteristics of both deuterostomes and protostomes. Because the morphology and embryology of lophophorates are phylogenetically ambiguous, their origin is a major unsolved problem of metazoan phylogenetics. The complete 18S ribosomal DNA sequences of all three lophophorate phyla were obtained and analyzed to clarify the phylogenetic relationships of this subkingdom. Sequence analyses show that lophophorates are protostomes closely related to mollusks and annelids, This conclusion deviates from the commonly held view of deuterostome affinity.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	HALANYCH, KM (corresponding author), UNIV TEXAS, DEPT ZOOL, AUSTIN, TX 78712 USA.		Halanych, Ken M/A-9480-2009; Hillis, David M/B-4278-2008; Hillis, David/L-5421-2019	Halanych, Ken M/0000-0002-8658-9674; 				BACKELJAU T, 1993, CLADISTICS, V9, P167, DOI 10.1111/j.1096-0031.1993.tb00216.x; BALLARD JWO, 1992, SCIENCE, V258, P1345, DOI 10.1126/science.1455227; CHRISTEN R, 1991, EMBO J, V10, P499, DOI 10.1002/j.1460-2075.1991.tb07975.x; DEQUEIROZ K, 1990, SYST ZOOL, V39, P307, DOI 10.2307/2992353; EERNISE DJ, 1993, SYST BIOL, V41, P305; EMIG C C, 1976, Zeitschrift fuer Zoologische Systematik und Evolutionsforschung, V14, P10; Emig C.C., 1982, P741; EMIG CC, 1982, ADV MAR BIOL, V19, P1, DOI 10.1016/S0065-2881(08)60086-3; FAITH DP, 1991, SYST ZOOL, V40, P366, DOI 10.2307/2992329; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Ghiselin M.T., 1988, Oxford Surveys in Evolutionary Biology, V5, P66; GUSTUS RM, 1972, ACTA ZOOL-STOCKHOLM, V53, P299; HALANYCH KM, 1993, BIOL BULL, V185, P417, DOI 10.2307/1542482; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; Hyman L. H., 1940, INVERTEBRATES PROTOZ, V1; Hyman L. H., 1959, INVERTEBRATES SMALLE, VV; HYMAN LH, 1958, BIOL BULL, V114, P106, DOI 10.2307/1538968; Jagersten G, 1972, EVOLUTION METAZOAN L; LAKE JA, 1989, INT CONGR SER, V824, P273; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; LAKE JA, UNPUB; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; MASLOV DA, 1994, NATURE, V368, P345, DOI 10.1038/368345a0; Nielsen C, 1977, BIOL BRYOZOANS, P519; OLSEN GJ, 1994, P NATL ACAD SCI USA, V91, P1455; PATTERSON C, 1989, INT CONGR SER, V824, P471; ROWELL AJ, 1982, LETHAIA, V15, P299, DOI 10.1111/j.1502-3931.1982.tb01695.x; Rudall K. M., 1973, BIOL REV, V40, P597; Schram F.R., 1991, P35; SWOFFORDS DL, 1993, PHYLOGENETIC ANAL US; TELFORD MJ, 1993, MOL BIOL EVOL, V10, P660; VALENTINE JW, 1973, SYST ZOOL, V22, P97, DOI 10.2307/2412093; VALENTINE JW, 1975, AM ZOOL, V15, P391; WADA H, 1994, P NATL ACAD SCI USA, V91, P1801, DOI 10.1073/pnas.91.5.1801; WILLIAMS A, 1977, PATTERNS EVOLUTION I, P79; Willmer P, 1990, INVERTEBRATE RELATIO; Zimmer R.L., 1973, P593; [No title captured]	41	465	481	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	1995	267	5204					1641	1643		10.1126/science.7886451	http://dx.doi.org/10.1126/science.7886451			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886451				2022-12-01	WOS:A1995QM39700035
J	KANG, HJ; SCHUMAN, EM				KANG, HJ; SCHUMAN, EM			LONG-LASTING NEUROTROPHIN-INDUCED ENHANCEMENT OF SYNAPTIC TRANSMISSION IN THE ADULT HIPPOCAMPUS	SCIENCE			English	Article							TERM POTENTIATION; KINASE-ACTIVITY; MESSENGER-RNAS; TRK FAMILY; CA1 REGION; BDNF; INHIBITOR; EXPRESSION; RECEPTORS; NT-3	The neurotrophins are signaling factors important for the differentiation and survival of distinct neuronal populations during development, To test whether the neurotrophins also function in the mature nervous system, the effects of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophic factor 3 (NT-3) on the strength of synaptic transmission in hippocampal slices were determined. Application of BDNF or NT-3 produced a dramatic and sustained (2 to 3 hours) enhancement of synaptic strength at the Schaffer collateral-CA1 synapses; NGF was without significant effect. The enhancement was blocked by K252a, an inhibitor of receptor tyrosine kinases, BDNF and NT-3 decreased paired-pulse facilitation, which is consistent with a possible presynaptic modification. Long-term potentiation could still be elicited in slices previously potentiated by exposure to the neurotrophic factors, which implies that these two forms of plasticity may use at least partially independent cellular mechanisms.	CALTECH,DIV BIOL 21676,PASADENA,CA 91125	California Institute of Technology			Schuman, Erin M/D-6204-2011					BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BERG MM, 1992, J BIOL CHEM, V267, P13; ENFORS P, 1992, EUR J NEUROSCI, V4, P1140; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KANG H, UNPUB; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KNUSEL B, 1991, J NEUROCHEM, V57, P955, DOI 10.1111/j.1471-4159.1991.tb08243.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LU B, 1991, P NATL ACAD SCI USA, V88, P937; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; TAPLEY P, 1992, ONCOGENE, V7, P371; VASQUEZ ME, 1991, NEUROREPORT, V2, P593; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	19	1162	1173	2	45	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1658	1662		10.1126/science.7886457	http://dx.doi.org/10.1126/science.7886457			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886457				2022-12-01	WOS:A1995QM39700041
J	KIKUYAMA, S; TOYODA, F; OHMIYA, Y; MATSUDA, K; TANAKA, S; HAYASHI, H				KIKUYAMA, S; TOYODA, F; OHMIYA, Y; MATSUDA, K; TANAKA, S; HAYASHI, H			SODEFRIN - A FEMALE-ATTRACTING PEPTIDE PHEROMONE IN NEWT CLOACAL GLANDS	SCIENCE			English	Article							CRESTED NEWT; GOLDFISH	A decapeptide called sodefrin was isolated from the abdominal gland of the cloaca of the male red-bellied newt, Cynops pyrrhogaster. The native peptide, as well as the synthetic one, had a female-attracting activity. Sodefrin was found in the apical portion of the epithelial cells of the abdominal gland. Sodefrin is apparently species specific because it did not attract females of Cynops ensicauda. This is the first amphibian pheromone to be identified and the first peptide pheromone identified in a vertebrate.	NARA MED UNIV,DEPT PHYSIOL,KASHIHARA,NARA 634,JAPAN; RIKEN,RES DEV CORP,WAKO,SAITAMA 35101,JAPAN; NIPPON MED COLL,DEPT PHARMACOL,TOKYO 113,JAPAN; GUNMA UNIV,INST ENDOCRINOL,MAEBASHI,GUMMA 371,JAPAN; GUNMA PREFECTURAL COLL HLTH SCI,MAEBASHI,GUMMA 371,JAPAN	Nara Medical University; RIKEN; Nippon Medical School; Gunma University	KIKUYAMA, S (corresponding author), WASEDA UNIV,SCH EDUC,DEPT BIOL,NISHIWASEDA,TOKYO 16950,JAPAN.		Ohmiya, Yoshihiro/J-7143-2013	Ohmiya, Yoshihiro/0000-0002-4944-509X				CEDRINI L, 1971, Monitore Zoologico Italiano, V5, P223; COLOMBO L, 1980, Bollettino di Zoologia, V47, P355; Houck L.D., 1986, CHEM SIGNALS VERTEBR, P173; Lebedeva N.Y., 1975, J ICHTHYOL, V15, P472; MALACARNE G, 1984, MONIT ZOOL ITAL, V18, P33; MALACARNE G, 1982, BEHAV PROCESS, V7, P307, DOI 10.1016/0376-6357(82)90003-1; MASON RT, 1989, SCIENCE, V245, P290, DOI 10.1126/science.2749261; NOVOTNY M, 1990, CHEM SIGNAL, V5, P1; OKADA H, 1979, SCI REP HOKKAIDO FIS, V33, P89; PFEIFFER W, 1978, J CHEM ECOL, V4, P665, DOI 10.1007/BF00990277; PFUDERER P, 1974, J EXP ZOOL, V187, P375, DOI 10.1002/jez.1401870306; RODRIGUEZ H, 1989, TECHNIQUES PROTEIN C, P186; Salthe S.N., 1974, P309; SORENSEN PW, 1988, BIOL REPROD, V39, P1039, DOI 10.1095/biolreprod39.5.1039; STACEY NE, 1986, CAN J ZOOL, V64, P2412, DOI 10.1139/z86-360; TAKATA K, 1991, J HISTOCHEM CYTOCHEM, V39, P287, DOI 10.1177/39.3.1993828; TOYODA F, 1994, PHYSIOL BEHAV, V55, P569, DOI 10.1016/0031-9384(94)90118-X; Tucker D., 1972, OLFACTION TASTE, VIV, P121	18	188	191	1	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1643	1645		10.1126/science.7886452	http://dx.doi.org/10.1126/science.7886452			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886452				2022-12-01	WOS:A1995QM39700036
J	MARCHETTI, M; ARICO, B; BURRONI, D; FIGURA, N; RAPPUOLI, R; GHIARA, P				MARCHETTI, M; ARICO, B; BURRONI, D; FIGURA, N; RAPPUOLI, R; GHIARA, P			DEVELOPMENT OF A MOUSE MODEL OF HELICOBACTER-PYLORI INFECTION THAT MIMICS HUMAN-DISEASE	SCIENCE			English	Article							PEPTIC-ULCERATION; CHRONIC GASTRITIS; IMMUNE-RESPONSE; PROTEIN	The human pathogen Helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer. The pathogenesis of H. pylori infection in vivo was studied by adapting fresh clinical isolates of bacteria to colonize the stomachs of mice. A gastric pathology resembling human disease was observed in infections With cytotoxin-producing strains but not with noncytotoxic strains. Oral immunization with purified H. pylori antigens protected mice from bacterial infection. This mouse model will allow the development of therapeutic agents and vaccines against H. pylori infection in humans.	BIOCINE SPA,IMMUNOBIOL RES INST SIENA,I-53100 SIENA,ITALY; UNIV SIENA,IST PATOL SPECIALE MED,I-53100 SIENA,ITALY	University of Siena				Figura, Natale/0000-0003-0318-4565				CANTORNA MT, 1990, CAN J MICROBIOL, V36, P237, DOI 10.1139/m90-041; CHEN M, 1994, INT J MED MICROBIOL, V280, P155; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; DUNN BE, 1990, J BIOL CHEM, V265, P2659; EULER AR, 1990, J CLIN MICROBIOL, V28, P2285, DOI 10.1128/JCM.28.10.2285-2290.1990; FERRERO RL, 1994, INFECT IMMUN, V62, P4981, DOI 10.1128/IAI.62.11.4981-4989.1994; FIOCCA R, 1989, ACTA GASTRO-ENT BELG, V52, P324; FOX JG, 1991, REV INFECT DIS, V13, pS671; GHIARA P, UNPUB; KARITA M, 1994, AM J GASTROENTEROL, V89, P208; KRAKOWKA S, 1987, INFECT IMMUN, V55, P2789, DOI 10.1128/IAI.55.11.2789-2796.1987; LEE A, 1993, LANCET, V341, P280, DOI 10.1016/0140-6736(93)92624-3; LEE A, 1990, GASTROENTEROLOGY, V99, P1315, DOI 10.1016/0016-5085(90)91156-Z; MACCHIA G, 1993, MOL MICROBIOL, V9, P645, DOI 10.1111/j.1365-2958.1993.tb01724.x; MEGRAUD F, 1993, GASTROENTEROL CLIN N, V22, P73; MICHETTI P, 1994, GASTROENTEROLOGY, V107, P1002, DOI 10.1016/0016-5085(94)90224-0; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; TSUDA M, 1994, INFECT IMMUN, V62, P3586, DOI 10.1128/IAI.62.8.3586-3589.1994; WARREN JR, 1983, LANCET, V2, P1273; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995; 1994, JAMA-J AM MED ASSOC, V272, P65	25	513	545	2	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1655	1658		10.1126/science.7886456	http://dx.doi.org/10.1126/science.7886456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886456				2022-12-01	WOS:A1995QM39700040
J	MENDEL, JE; KORSWAGEN, HC; LIU, KS; HAJDUCRONIN, YM; SIMON, MI; PLASTERK, RHA; STERNBERG, PW				MENDEL, JE; KORSWAGEN, HC; LIU, KS; HAJDUCRONIN, YM; SIMON, MI; PLASTERK, RHA; STERNBERG, PW			PARTICIPATION OF THE PROTEIN G(O) IN MULTIPLE ASPECTS OF BEHAVIOR IN C-ELEGANS	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NUCLEOTIDE-BINDING PROTEIN; ESCHERICHIA-COLI; ALPHA-SUBUNITS; GS-ALPHA; EXPRESSION; MUTANTS; G0; GO; RECEPTORS	The goa-1 gene encoding the alpha subunit of the heterotrimeric guanosine triphosphate-binding protein (G protein) G(o) from Caenorhabditis elegans is expressed in most neurons, and in the muscles involved in egg laying and male mating, Reduction-of-function mutations in goa-1 caused a variety of behavioral defects including hyperactive movement, premature egg laying, and male impotence, Expression of the activated G(o) alpha subunit (G alpha(o)) in transgenic nematodes resulted in lethargic movement, delayed egg laying, and reduced mating efficiency, Induced expression of activated G alpha(o) in adults was sufficient to cause these phenotypes, indicating that G alpha(o) mediates behavior through its role in neuronal function and the functioning of specialized muscles.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL,PASADENA,CA 91125; NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; Netherlands Cancer Institute			Korswagen, Hendrik/I-8782-2012	Sternberg, Paul/0000-0002-7699-0173				BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1983, GENETICS, V103, P43; HUFF RM, 1985, J BIOL CHEM, V260, P864; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1995, IN PRESS METHODS CEL; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; SCHMIDT CJ, 1989, CELL REGUL, V1, P125, DOI 10.1091/mbc.1.1.125; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; STRETTON AOW, 1985, TRENDS NEUROSCI, V8, P294, DOI 10.1016/0166-2236(85)90105-5; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TRENT C, 1983, GENETICS, V104, P619; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4561, DOI 10.1073/pnas.83.12.4561; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	33	204	210	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1652	1655		10.1126/science.7886455	http://dx.doi.org/10.1126/science.7886455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886455				2022-12-01	WOS:A1995QM39700039
J	MUSTARD, JF; SUNSHINE, JM				MUSTARD, JF; SUNSHINE, JM			SEEING THROUGH THE DUST - MARTIAN CRUSTAL HETEROGENEITY AND LINKS TO THE SNC METEORITES	SCIENCE			English	Article							REFLECTANCE SPECTRA; SURFACE	Through the application of new analytical techniques to high spatial resolution imaging spectrometer data, the ferrous mineralogy of major volcanic terrains on Mars is shown to consist of significant fractions of both low- and high-calcium pyroxene. Changes in the relative abundances of these pyroxenes are observed for units of different age and morphology, even in regions with higher degrees of alteration and contamination from dust. Volcanic rocks with these characteristics are uncommon on Earth but are typical of the basaltic SNC meteorites (shergottites, nakhlites, and chassignites) thought to be from Mars, Thus, it is possible to infer, even through the veil of dust, that the SNC meteorites have mineralogic affinities to major volcanic provinces on Mars and are therefore truly representative of the heterogeneity observed on the surface of the ''red planet.''	SETS TECHNOL,MILILANI,HI 96789		MUSTARD, JF (corresponding author), BROWN UNIV,DEPT GEOL SCI,BOX 1846,PROVIDENCE,RI 02912, USA.			Sunshine, Jessica/0000-0002-9413-8785				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; BIBRING JP, 1989, NATURE, V341, P591, DOI 10.1038/341591a0; BURNS RG, 1993, MINERALOGICAL APPLIC; CLARK BC, 1982, J GEOPHYS RES, V87, P59, DOI 10.1029/JB087iB12p10059; CLOUTIS EA, 1991, J GEOPHYS RES, V96, P18819; ERARD S, 1991, P LUNAR PLANET C, V21, P461; LONGHI J, 1991, P LUNAR PLANET SCI C, V19, P451; LONGHI J, 1992, MARS, pCH6; MCGETCHIN TR, 1978, ICARUS, V34, P512, DOI 10.1016/0019-1035(78)90042-8; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MCSWEEN HY, 1983, GEOCHIM COSMOCHIM AC, V47, P1501, DOI 10.1016/0016-7037(83)90309-5; MOUGINISMARK PJ, 1992, MARS, pCH13; MUSTARD JF, 1993, J GEOPHYS RES-PLANET, V98, P3387, DOI 10.1029/92JE02682; MUSTARD JF, 1993, LUNAR PLANET SCI, V24, P1039; MUSTARD JF, 1992, AM MINERAL, P345; PINET, 1994, GEOPHYS RES LETT, V21, P887; PINET P, 1990, J GEOPHYS RES-SOLID, V95, P14435, DOI 10.1029/JB095iB09p14435; Roush T.L., 1993, REMOTE GEOCHEMICAL A, P367; SCHUBERG G, 1992, MARS, pCH5; SINGER RB, 1993, RESOURCES NEAR EARTH, P709; SODERBLOM LA, 1992, MARS, pCH17; SUNSHINE JM, 1993, J GEOPHYS RES-PLANET, V98, P9075, DOI 10.1029/93JE00677; SUNSHINE JM, 1990, J GEOPHYS RES-SOLID, V95, P6955, DOI 10.1029/JB095iB05p06955; SUNSHINE JM, 1993, ICARUS, V105, P79, DOI 10.1006/icar.1993.1112; SUNSHINE JM, 1993, LUNAR PLANET SCI, V24, P1379; TARANTOLA A, 1982, REV GEOPHYS, V20, P219, DOI 10.1029/RG020i002p00219	26	96	96	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1623	1626		10.1126/science.7886449	http://dx.doi.org/10.1126/science.7886449			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886449				2022-12-01	WOS:A1995QM39700029
J	SCHONWETTER, BS; STOLZENBERG, ED; ZASLOFF, MA				SCHONWETTER, BS; STOLZENBERG, ED; ZASLOFF, MA			EPITHELIAL ANTIBIOTICS INDUCED AT SITES OF INFLAMMATION	SCIENCE			English	Article							ANTIMICROBIAL PEPTIDES; INSECT IMMUNITY; MESSENGER-RNA; DEFENSINS; CELLS; PURIFICATION; PRECURSOR; CDNA	The role of antimicrobial peptides in epithelial defense is not fully understood. An epithelial beta-defensin, lingual antimicrobial peptide (LAP), was isolated from bovine tongue and the corresponding complementary DNA cloned. LAP showed a broad spectrum of antibacterial and antifungal activities. LAP messenger RNA abundance was markedly increased in the epithelium surrounding naturally occurring tongue lesions. This increase coincided with the cellular hallmarks of acute and chronic inflammation in the underlying lamina propria, supporting a role for epithelial antimicrobial peptides as integral components of the inflammatory response.			SCHONWETTER, BS (corresponding author), MAGAININ PHARMACEUT INC,MAGAININ RES INST,5110 CAMPUS DR,PLYMOUTH MEETING,PA 19462, USA.							BEVINS CL, COMMUNICATION; BLAND PW, 1991, GASTROENTEROL CLIN N, V20, P577; BREY PT, 1993, P NATL ACAD SCI USA, V90, P6275, DOI 10.1073/pnas.90.13.6275; CHIRGWIN JJ, 1979, BIOCHEMISTRY-US, V13, P5294; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; DIAMOND G, 1994, CHEST, V105, pS51, DOI 10.1378/chest.105.3_Supplement.51S; GALLIN JI, 1988, INFLAMMATION; GANZ T, 1990, EUR J HAEMATOL, V44, P1; JACOB L, 1994, CIBA F SYMP, V186, P197; JONES DE, 1992, J BIOL CHEM, V267, P23216; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; MOORE KS, 1991, J BIOL CHEM, V266, P19851; NAKASHIMA H, 1993, AIDS, V7, P1129, DOI 10.1097/00002030-199308000-00019; NALLY F, 1991, PRACTITIONER, V235, P65; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SUN SC, 1992, COMP BIOCHEM PHYS B, V103, P225, DOI 10.1016/0305-0491(92)90436-U; WERSHIL BK, 1992, GASTROENTEROL CLIN N, V21, P387; YOUNG WS, 1986, NEUROSCI LETT, V70, P198; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZEGARELLI DJ, 1993, OTOLARYNG CLIN N AM, V26, P1069	24	359	399	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1645	1648		10.1126/science.7886453	http://dx.doi.org/10.1126/science.7886453			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886453				2022-12-01	WOS:A1995QM39700037
J	SEGALAT, L; ELKES, DA; KAPLAN, JM				SEGALAT, L; ELKES, DA; KAPLAN, JM			MODULATION OF SEROTONIN-CONTROLLED BEHAVIORS BY G(O) IN CAENORHABDITIS-ELEGANS	SCIENCE			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEIN; NERVOUS-SYSTEM; ALPHA-SUBUNIT; NEMATODE; MYRISTOYLATION; STIMULATION; GENES	Seven transmembrane receptors and their associated heterotrimeric guanine nucleotide-binding proteins (G proteins) have been proposed to play a key role in modulating the activities of neurons and muscles. The physiological function of the Caenorhabditis elegans G protein G(o) has been genetically characterized. Mutations in the goa-l gene, which encodes an a subunit of G(o) (G alpha(o)), cause behavioral defects similar to those observed in mutants that lack the neurotransmitter serotonin (5-HT), and goa-1 mutants are partially resistant to exogenous 5-HT. Mutant animals that lack G alpha(o) and transgenic animals that overexpress G alpha(o) [goa-l(xs) animals] have reciprocal defects in locomotion, feeding, and egg laying behaviors. In normal animals, all of these behaviors are regulated by 5-HT. These results demonstrate that the level of G(o) activity is a critical determinant of several C. elegans behaviors and suggest that G(o) mediates many of the behavioral effects of 5-HT.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NINDS NIH HHS [NS32196] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032196] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FINNEY M, 1987, THESIS MIT; HAGA K, 1992, J BIOL CHEM, V267, P2222; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JORGENSEN E, COMMUNICATION; JORGENSEN EO, UNPUB; KAPLAN J, UNPUB; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; LOGETHETIS DE, 1987, NATURE, V325, P321; MARDER E, 1989, SEMIN NEUROSCI, V1, P1; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SEGALAT L, UNPUB; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THOMAS JH, 1990, GENETICS, V124, P855; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; TRENT C, 1983, GENETICS, V104, P619; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	37	253	258	1	18	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1648	1651		10.1126/science.7886454	http://dx.doi.org/10.1126/science.7886454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886454				2022-12-01	WOS:A1995QM39700038
J	BOND, RA; LEFF, P; JOHNSON, TD; MILANO, CA; ROCKMAN, HA; MCMINN, TR; APPARSUNDARAM, S; HYEK, MF; KENAKIN, TP; ALLEN, LF; LEFKOWITZ, RJ				BOND, RA; LEFF, P; JOHNSON, TD; MILANO, CA; ROCKMAN, HA; MCMINN, TR; APPARSUNDARAM, S; HYEK, MF; KENAKIN, TP; ALLEN, LF; LEFKOWITZ, RJ			PHYSIOLOGICAL-EFFECTS OF INVERSE AGONISTS IN TRANSGENIC MICE WITH MYOCARDIAL OVEREXPRESSION OF THE BETA(2)-ADRENOCEPTOR	NATURE			English	Article							NUCLEOTIDE BINDING-PROTEIN; TERNARY COMPLEX MODEL; REGULATORY PROTEINS; INTRINSIC ACTIVITY; BETA-ADRENOCEPTOR; OPIOID RECEPTORS; ANTAGONISTS; MUTATION	G-PROTEIN-COUPLED receptors are thought to have an inactive conformation (R), requiring an agonist-induced conformational change for receptor/G-protein coupling(1-3). But new evidence suggests a two-state model(4-19) in which receptors are in equilibrium between the inactive conformation (R), and a spontaneously active conformation (R*) that can couple to G protein in the absence of ligand (Fig, 1). Classic agonists have a high affinity for R* and increase the concentration of R*, whereas inverse agonists have a high affinity for R and decrease the concentration of R*. Neutral competitive antagonists have equal affinity for R and R* and do not displace the equilibrium, but can competitively antagonize the effects both of agonists and of inverse agonists. The lack of suitable in vivo model systems has restricted the evidence for the existence of inverse agonists to computer simulations(7,8) and in vitro systems(5,9-12,20-23). We have used a transgenic mouse model in which there is such marked myocardial overexpression of beta(2)-adrenoceptors that a significant population of spontaneously activated receptor (R*) is present, inducing a maximal response without agonist(24). We show that the beta(2)-adrenoceptor ligand ICI-118,551 functions as an inverse agonist, providing evidence supporting the existence of inverse agonists and validating the two-state model of G-protein-coupled receptor activation.	FISONS PLC,DEPT PHARMACOL,LOUGHBOROUGH LE11 0RH,LEICS,ENGLAND; BAYLOR COLL MED,DEPT ANESTHESIOL,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CARDIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093; GLAXO INC,RES,RES TRIANGLE PK,NC 27709	Baylor College of Medicine; Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute; University of California System; University of California San Diego; GlaxoSmithKline	BOND, RA (corresponding author), UNIV HOUSTON,DEPT PHARMACOL & PHARMACEUT SCI,HOUSTON,TX 77204, USA.		Lefkowitz, Robert/AAW-2649-2021					AHRIENS EJ, 1954, ARCH INT PHARMACOD T, V99, P32; ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; BARKER EL, 1994, J BIOL CHEM, V269, P11687; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Clark Alfred Joseph., 1933, MODE ACTION DRUGS CE; Colquhoun D., 1973, DRUG RECEPTORS, P149, DOI [10.1007/978-1-349-00910-7_11, DOI 10.1007/978-1-349-00910-7_11]; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1992, MOL PHARMACOL, V41, P549; COSTA T, 1990, MOL PHARMACOL, V37, P383; DELEAN A, 1980, J BIOL CHEM, V255, P7108; EHLERT FJ, 1986, TRENDS PHARMACOL SCI, V7, P28, DOI 10.1016/0165-6147(86)90237-3; GOTZE K, 1964, EUR J PHARMACOL, V268, P151; LEFF P, IN PRESS TRENDS PHAR; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MEWES T, 1993, CIRCULATION, V88, P2916, DOI 10.1161/01.CIR.88.6.2916; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; ONARAN HO, 1992, MOL PHARMACOL, V43, P245; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; SCHWARTZ DD, 1988, J PHARMACOL EXP THER, V244, P11; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SENOGLES SE, 1987, J BIOL CHEM, V262, P4860; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; TIAN WN, 1994, MOL PHARMACOL, V45, P524	29	410	436	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					272	276		10.1038/374272a0	http://dx.doi.org/10.1038/374272a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885448	Green Submitted			2022-12-01	WOS:A1995QM38700053
J	BRENNAN, JA; BOYLE, JO; KOCH, WM; GOODMAN, SN; HRUBAN, RH; EBY, YJ; COUCH, MJ; FORASTIERE, AA; SIDRANSKY, D				BRENNAN, JA; BOYLE, JO; KOCH, WM; GOODMAN, SN; HRUBAN, RH; EBY, YJ; COUCH, MJ; FORASTIERE, AA; SIDRANSKY, D			ASSOCIATION BETWEEN CIGARETTE-SMOKING AND MUTATION OF THE P53 GENE IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL CAVITY; COLORECTAL TUMORIGENESIS; ALCOHOL-DRINKING; TOBACCO SMOKING; POINT MUTATIONS; HUMAN CANCERS; LUNG-CANCER; EXPRESSION; PROTEIN; LARYNX	Background. Although epidemiologic studies have long associated tobacco and alcohol use with the development of squamous-cell carcinoma of the head and neck, the molecular targets of these carcinogens have yet to be identified. We performed a molecular analysis to determine the pattern of mutations in the p53 gene in neoplasms from patients with squamous-cell carcinoma of the head and neck and a history of tobacco or alcohol use. Methods. Sequence analysis of the conserved regions of the p53 gene was performed in tumor samples from 129 patients with primary squamous-cell carcinoma of the head and neck. We then used statistical analysis to identify any patient characteristics associated with mutation of the p53 gene. Results. We found p53 mutations in 42 percent of the patients (54 of 129). Fifty-eight percent of the patients who smoked cigarettes and used alcohol (37 of 64; 95 percent confidence interval, 45 to 70 percent), 33 percent of the patients who smoked but abstained from alcohol (13 of 39; 95 percent confidence interval, 19 to 50 percent), and 17 percent of the patients who neither smoked nor drank alcohol (4 of 24, 95 percent confidence interval, 5 to 37 percent) had p53 mutations (P = 0.001). (Two patients used alcohol but did not smoke, and neither had a p53 mutation.) Furthermore, 100 percent of the mutations in the patients who neither drank nor smoked occurred at sites containing cytidine phosphate guanosine dinucleotides (potentially representing endogenous mutations) within the p53 gene (5 of 5 mutations; 95 percent confidence interval, 48 to 100 percent), whereas only 23 percent of those in cigarette smokers consisted of such changes (12 of 53 mutations; 95 percent confidence interval, 12 to 36 percent; P = 0.001). Conclusions. In our study, a history of tobacco and alcohol use was associated with a high frequency of p53 mutations in patients with squamous-cell carcinoma of the head and neck. Preliminary evidence linked cigarette smoking to p53 mutations at nonendogenous mutation sites. Our findings suggest a role for tobacco in the molecular progression of squamous-cell carcinoma of the head and neck and support the epidemiologic evidence that abstinence from smoking is important to prevent head and neck cancer.	JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, DIV HEAD & NECK CANC RES, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV BIOSTAT, BALTIMORE, MD USA; JOHNS HOPKINS UNIV HOSP, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine				Goodman, Steven/0000-0002-3872-5723	NCI NIH HHS [CA-58184-01, CA-54672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054672, P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; BAKER SJ, 1990, CANCER RES, V50, P7717; Beahrs OH, 1988, MANUAL STAGING CANCE, P27; BOFFETTA P, 1992, INT J CANCER, V52, P530, DOI 10.1002/ijc.2910520405; BONGIORNO PF, 1994, J THORAC CARDIOV SUR, V107, P590, DOI 10.1016/S0022-5223(94)70107-5; BOREK C, 1993, ENVIRON HEALTH PERSP, V101, P237, DOI 10.2307/3431732; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1991, CANCER RES, V51, P6393; BREIMER LH, 1988, BRIT J CANCER, V57, P6, DOI 10.1038/bjc.1988.2; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BUCHMAN GW, 1992, FOCUS, V14, P41; CARBONE D, 1992, AM J MED, V93, pS13, DOI 10.1016/0002-9343(92)90621-H; CHOI SY, 1991, INT J EPIDEMIOL, V20, P878, DOI 10.1093/ije/20.4.878; CHRISTEN AG, 1992, AM J MED, V93, pS25, DOI 10.1016/0002-9343(92)90624-K; CULLEN J, 1986, HDB PREVENTION, P308; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DUFFY MJ, 1993, CLIN BIOCHEM, V26, P439, DOI 10.1016/0009-9120(93)80007-H; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4; GOSNEY JR, 1993, INT J ONCOL, V2, P1071; HABUCHI T, 1993, CANCER RES, V53, P3795; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HONG WK, 1993, CANCER RES, V53, P5113; LESMES GR, 1992, AM J MED, V93, pS55, DOI 10.1016/0002-9343(92)90629-P; MAESTRO R, 1992, ONCOGENE, V7, P1159; MASHBERG A, 1993, CANCER-AM CANCER SOC, V72, P1369, DOI 10.1002/1097-0142(19930815)72:4<1369::AID-CNCR2820720436>3.0.CO;2-L; PUISIEUX A, 1991, CANCER RES, V51, P6185; RENAN MJ, 1992, RADIAT RES, V131, P227, DOI 10.2307/3578445; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SPRUCK CH, 1993, CANCER RES, V53, P2427; SPRUCK CH, 1993, CANCER RES, V53, P1162; STRAUSS BS, 1992, CANCER RES, V52, P249; SUZUKI H, 1992, CANCER RES, V52, P734; THOMAS S, 1994, CANCER RES, V54, P3588; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; VOGELSTEIN B, 1992, NATURE, V355, P209, DOI 10.1038/355209a0; WAGATA T, 1993, CANCER RES, V53, P846; WOGAN GN, 1992, ENVIRON HEALTH PERSP, V98, P167, DOI 10.2307/3431264; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; ZHANG ZF, 1994, CANCER EPIDEM BIOMAR, V3, P19; 1989, DHHS CDC898411 PUBL	47	505	512	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					712	717		10.1056/NEJM199503163321104	http://dx.doi.org/10.1056/NEJM199503163321104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854378				2022-12-01	WOS:A1995QL78800004
J	DERMOTT, SF; SAGAN, C				DERMOTT, SF; SAGAN, C			TIDAL EFFECTS OF DISCONNECTED HYDROCARBON SEAS ON TITAN	NATURE			English	Article							SURFACE; DISSIPATION; OCEAN	THERMODYNAMIC and photochemical arguments(1-4) suggest that Titan, the largest satellite of Saturn, has a deep ocean of liquid hydrocarbons. At visible wavelengths, Titan's surface is obscured by a thick stratospheric haze, but radar observations(5-7) have revealed large regions of high surface reflectivity that are inconsistent with a global hydrocarbon ocean. Titan's surface has also been imaged at infrared wavelengths(8-10), and the highest-resolution data (obtained by the Hubble Space Telescope) show clear variations in surface albedo and/or topography(10). The natural interpretation of these observations is that Titan, like the Earth, has continents and oceans. But Titan's high orbital eccentricity poses a problem for this interpretation, as the effects of oceanic tidal friction would have circularized Titan's orbit for most configurations of oceans and continents(1,11). Here we argue that a more realistic topography, in which liquid hydrocarbons are confined to a number of disconnected seas or crater lakes, may satisfy both the dynamical and observational constraints.	CORNELL UNIV,PLANETARY STUDIES LAB,ITHACA,NY 14853	Cornell University	DERMOTT, SF (corresponding author), UNIV FLORIDA,DEPT ASTRON,POB 112055,GAINESVILLE,FL 32611, USA.							BURNS JA, 1986, SATELLITES, P117; Butler B. J, 1992, B AM ASTRON SOC, V24, P954; CHAPMAN CR, 1986, SATELLITES, P492; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; ENGEL S, 1994, B AM ASTRON SOC, V26, P1183; FLASAR FM, 1983, SCIENCE, V221, P55, DOI 10.1126/science.221.4605.55; GRIFFITH CA, 1993, NATURE, V364, P511, DOI 10.1038/364511a0; GROSSMAN AW, 1992, B AM ASTRON SOC, V24, P954; LAMBECK K, 1980, EARTHS VARIABLE ROTA, P295; LEMMON MT, 1993, ICARUS, V103, P329, DOI 10.1006/icar.1993.1074; LUNINE JI, 1993, REV GEOPHYS, V31, P133, DOI 10.1029/92RG02794; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; Merian J. R., 1828, BEWEGUNG TROPFBARER; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; PEALE SJ, 1980, ICARUS, V43, P65, DOI 10.1016/0019-1035(80)90088-3; SAGAN C, 1982, NATURE, V300, P731, DOI 10.1038/300731a0; SAGAN C, 1994, B AM ASTRON SOC, V26, P1183; SEARS WD, IN PRESS ICARUS; SEARS WD, 1994, B AM ASTRON SOC, V26, P1184; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; SMITH PH, 1994, B AM ASTRON SOC, V26, P1181; Turcotte D.L., 1982, GEODYNAMICS; WEBB DJ, 1982, CONTEMP PHYS, V23, P419, DOI 10.1080/00107518208237094	23	34	34	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					238	240		10.1038/374238a0	http://dx.doi.org/10.1038/374238a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885443				2022-12-01	WOS:A1995QM38700042
J	DORN, A; STOFFEL, R; MATILE, H; BUBENDORF, A; RIDLEY, RG				DORN, A; STOFFEL, R; MATILE, H; BUBENDORF, A; RIDLEY, RG			MALARIAL HAEMOZOIN BETA-HEMATIN SUPPORTS HEME POLYMERIZATION IN THE ABSENCE OF PROTEIN	NATURE			English	Article							PLASMODIUM-FALCIPARUM; HEMOGLOBIN DEGRADATION; FERRIPROTOPORPHYRIN-IX; CHLOROQUINE; PARASITES; PIGMENT; CULTURE	MALARIAL parasites growing inside erythrocytes digest up to 80% of the host cell's haemoglobin within a lysosomal organelle, the digestive vacuole(1,2). They sequester the potentially toxic haem (Fe (II) protohaematoporphyrin) that is released during this process into an insoluble pigment called haemozoin, which consists of polymerized Fe(III) protohaematoporphyrin subunits(3). We have studied this process of haem polymerization, which was previously reported to be enzyme-mediated and the target of the quinoline antimalarial drugs chloroquine and quinine(4). Here we show that, rather than being enzyme-mediated, haem polymerization is actually a chemical process, dependent only on the presence of haem-derived material associated with haemozoin and not on protein. This discovery does not invalidate haem polymerization as a target for drug intervention and the mechanism by which haemozoin formation is initiated is still not understood, but our view of this process and of the action of chloroquine must be reconsidered.	F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES SPECT,CH-4002 BASEL,SWITZERLAND	Roche Holding	DORN, A (corresponding author), F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES INFECT DIS,CH-4002 BASEL,SWITZERLAND.							ASHONG JO, 1989, T ROY SOC TROP MED H, V83, P167, DOI 10.1016/0035-9203(89)90631-7; COHEN P, 1971, J CLIN INVEST, V50, P762, DOI 10.1172/JCI106547; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FITCH CD, 1987, J BIOL CHEM, V262, P15552; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1992, PARASITOL TODAY, V8, P280, DOI 10.1016/0169-4758(92)90146-S; GOMAN M, 1982, MOL BIOCHEM PARASIT, V25, P391; GUSHIMANA Y, 1993, BIOPHYS CHEM, V47, P153, DOI 10.1016/0301-4622(93)85033-E; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; SLATER AFG, 1993, Patent No. 9211279; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840	15	347	351	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					269	271		10.1038/374269a0	http://dx.doi.org/10.1038/374269a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885447	Green Published			2022-12-01	WOS:A1995QM38700052
J	LINDPAINTNER, K; PFEFFER, MA; KREUTZ, R; STAMPFER, MJ; GRODSTEIN, F; LAMOTTE, F; BURING, J; HENNEKENS, CH				LINDPAINTNER, K; PFEFFER, MA; KREUTZ, R; STAMPFER, MJ; GRODSTEIN, F; LAMOTTE, F; BURING, J; HENNEKENS, CH			A PROSPECTIVE EVALUATION OF AN ANGIOTENSIN-CONVERTING-ENZYME GENE POLYMORPHISM AND THE RISK OF ISCHEMIC-HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSERTION DELETION POLYMORPHISM; MYOCARDIAL-INFARCTION; CARDIOMYOPATHY; CHOLESTEROL; EXPRESSION	Background. In a previous study, men with a history of myocardial infarction were found to have an increased prevalence of homozygosity for the deletional allele (D) of the angiotensin-converting-enzyme (ACE) gene, The D allele is associated with higher levels of ACE, which may predispose a person to ischemic heart disease. We investigated the association between the ACE genotype and the incidence of myocardial infarction, as well as other manifestations of ischemic heart disease, in a large, prospective cohort of U.S. male physicians, Methods. In the Physicians' Health Study, ischemic heart disease as defined by angina, coronary revascularization, or myocardial infarction developed in 1250 men by 1992, They were matched with 2340 controls according to age and smoking history. Zygosity for the deletion-insertion (D-I) polymorphism of the ACE gene was determined by an assay based on the polymerase chain reaction, Data were analyzed for both matched pairs and unmatched samples, with adjustment for the effects of known or suspected risk factors by conditional and non-conditional logistic regression, respectively. Results. The ACE genotype was not associated with the occurrence of either ischemic heart disease or myocardial infarction, The adjusted relative risk associated with the D allele was 1.07 (95 percent confidence interval, 0.96 to 1.19; P = 0.24) for ischemic heart disease and 1.05 (95 percent confidence interval, 0.89 to 1.25; P = 0.56) for myocardial infarction, if an additive mode of inheritance is assumed, Additional analyses assuming dominant and recessive effects of the D allele also failed to show any association, as did the examination of low-risk subgroups, Conclusions. In a large, prospectively followed population of U.S. male physicians, the presence of the D allele of the ACE gene conferred no appreciable increase in the risk of ischemic heart disease or myocardial infarction.	BRIGHAM & WOMENS HOSP,DIV CARDIOVASC DIS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health			Kreutz, Reinhold/AEV-0507-2022	Kreutz, Reinhold/0000-0002-4818-211X	NATIONAL CANCER INSTITUTE [R01CA040360, R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003138] Funding Source: NIH RePORTER; NCI NIH HHS [CA40360, CA42182] Funding Source: Medline; NHLBI NIH HHS [K04-HL03138-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, NEW ENGL J MED; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BOHN M, 1993, CLIN GENET, V44, P298; BOHN M, 1993, CLIN GENET, V44, P292; BRITTON S, 1973, AM J PHYSIOL, V225, P1226, DOI 10.1152/ajplegacy.1973.225.5.1226; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; EVANS AE, 1994, Q J MED, V87, P211; FABRIS B, 1990, CLIN EXP PHARMACOL P, V17, P309, DOI 10.1111/j.1440-1681.1990.tb01326.x; HERBERT PN, 1985, J CLIN INVEST, V76, P403, DOI 10.1172/JCI111986; HERMAN B, 1983, AM J EPIDEMIOL, V118, P514, DOI 10.1093/oxfordjournals.aje.a113657; HIRSCH AT, 1991, CIRC RES, V59, P475; HOIT BD, 1986, CIRCULATION, V74, P712, DOI 10.1161/01.CIR.74.4.712; HUBERT C, 1991, J BIOL CHEM, V266, P15377; JORDE LB, 1988, AM J CARDIOL, V62, P708, DOI 10.1016/0002-9149(88)91207-6; LINDPAINTNER K, 1993, J MOL CELL CARDIOL, V25, P133, DOI 10.1006/jmcc.1993.1017; LINDPAINTNER K, 1993, CLIN RES, V41, pA216; Magrini F, 1988, Am J Med, V84, P55, DOI 10.1016/0002-9343(88)90205-7; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; MOCHIZUKI T, 1992, J CLIN INVEST, V89, P490, DOI 10.1172/JCI115611; OHISHI M, 1993, NAT GENET, V5, P324, DOI 10.1038/ng1293-324; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIDKER PM, 1993, CIRCULATION, V87, P1969, DOI 10.1161/01.CIR.87.6.1969; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; ROSNER B, 1978, INT J EPIDEMIOL, V7, P367, DOI 10.1093/ije/7.4.367; RUIZ J, 1994, P NATL ACAD SCI USA, V91, P3662, DOI 10.1073/pnas.91.9.3662; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SHANMUGAM V, 1993, PCR METH APPL, V3, P120; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TIRET L, 1992, AM J HUM GENET, V51, P197; TIRET L, 1993, LANCET, V341, P991, DOI 10.1016/0140-6736(93)91075-W; UNDERWOOD DA, 1985, AM J CARDIOL, V55, P631, DOI 10.1016/0002-9149(85)90126-2; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N	39	861	893	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					706	711		10.1056/NEJM199503163321103	http://dx.doi.org/10.1056/NEJM199503163321103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854377				2022-12-01	WOS:A1995QL78800003
J	LUCCHINI, R; SOGO, JM				LUCCHINI, R; SOGO, JM			REPLICATION OF TRANSCRIPTIONALLY ACTIVE CHROMATIN	NATURE			English	Article							RIBOSOMAL-RNA GENES; PSORALEN-CROSSLINKING; RDNA ENHANCER; DNA; FORK	IN eukaryotic cells, active genes and their regulatory sequences are organized into open chromatin conformations in which nucleosomes can be modified, disrupted or totally absent(1-3). It has been proposed that these characteristic chromatin structures and their associated factors might be directly inherited by the newly synthesized daughter strands during chromosome duplication(4-6). Here we show that in the yeast Saccharomyces cerevisiae, replication machinery entering upstream of a transcriptionally active ribosomal RNA gene generates two newly replicated coding regions regularly packaged into nucleosomes, indicating that the active chromatin structure cannot be directly inherited at the replication fork. Whereas the establishment of an exposed chromatin conformation at some newly replicated rRNA gene promoters can occur shortly after the passage of the replication fork, regeneration of the active chromatin structure along the coding region is always a post-replicative process involving disruption of preformed nucleosomes.			LUCCHINI, R (corresponding author), ETH HONGGERBERG,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND.							ALBERTS B, 1977, P INT S EUKARYOTIC G, P165; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; CHASMAN DI, 1990, GENE DEV, V4, P403; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; CONCONI A, 1984, J MOL BIOL, V178, P920, DOI 10.1016/0022-2836(84)90319-X; DAMMANN R, 1993, NUCLEIC ACIDS RES, V10, P2331; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KULKENS T, 1989, CURR GENET, V16, P351, DOI 10.1007/BF00340714; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LUCCHINI R, 1992, MOL CELL BIOL, V12, P4288, DOI 10.1128/MCB.12.10.4288; LUCCHINI R, 1994, MOL CELL BIOL, V14, P318, DOI 10.1128/MCB.14.1.318; MORROW BE, 1989, J BIOL CHEM, V264, P9061; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE AP, 1991, J CELL SCI, V99, P201	20	86	87	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					276	280		10.1038/374276a0	http://dx.doi.org/10.1038/374276a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885449				2022-12-01	WOS:A1995QM38700054
J	MCDOWALL, KJ; KABERDIN, VR; WU, SW; COHEN, SN; LINCHAO, S				MCDOWALL, KJ; KABERDIN, VR; WU, SW; COHEN, SN; LINCHAO, S			SITE-SPECIFIC RNASE-E CLEAVAGE OF OLIGONUCLEOTIDES AND INHIBITION BY STEM-LOOPS	NATURE			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; RIBOSOMAL-RNA; DEGRADATION; REPLICATION	THE enzyme RNase E (ref. 1) cuts RNA at specific sites within single-stranded segments(2-6). The role of adjacent regions of secondary structure in such cleavages is controversial(7-10). Here we report that 10-13-nucleotide oligomers lacking any stem-loop but containing the RNase E-cleaved sequence of RNA I11-13, the antisense repressor of replication of ColE1-type plasmids, are cut at the same phosphodiester bond as, and 20 times more efficiently than, RNA I. These findings indicate that, contrary to previous proposals(8,9), stem-loops do not serve as entry sites for RNase E, but instead limit cleavage at potentially susceptible sites. Cleavage was reduced further by mutations in a non-adjacent stem-loop, suggesting that distant conformational changes can also affect enzyme access. Modulation of RNase E cleavages by stem-loop regions and to a lesser extent by higher-order structure may explain why this enzyme, which does not have stringent sequence specificity(6,12,13), cleaves complex RNAs at a limited number of sites.	ACAD SINICA, INST MOL BIOL, TAIPEI, 94305, TAIWAN; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA USA	Academia Sinica - Taiwan; Stanford University			Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022; Kaberdin, Vladimir/C-3870-2017	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; Kaberdin, Vladimir/0000-0002-7166-5136				APIRION D, 1978, J BIOL CHEM, V253, P1738; APIRION D, 1992, MOL BIOL LIFE SCI AD, V11, P221; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; GOLDBLUM K, 1981, CELL, V15, P1055; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; MISRA TK, 1978, J BIOL CHEM, V253, P5594; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; TAKAHASHI K, 1961, J BIOCHEM-TOKYO, V49, P1; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TUCKER WT, 1984, CELL, V38, P191, DOI 10.1016/0092-8674(84)90540-3	24	124	126	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	1995	374	6519					287	290		10.1038/374287a0	http://dx.doi.org/10.1038/374287a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7533896				2022-12-01	WOS:A1995QM38700057
J	MRAK, RE				MRAK, RE			TRIPOLAR MITOTIC FIGURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MRAK, RE (corresponding author), VET AFFAIRS MED CTR,LITTLE ROCK,AR 72205, USA.								0	2	2	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					718	718		10.1056/NEJM199503163321105	http://dx.doi.org/10.1056/NEJM199503163321105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854379				2022-12-01	WOS:A1995QL78800005
J	NOAKES, PG; GAUTAM, M; MUDD, J; SANES, JR; MERLIE, JP				NOAKES, PG; GAUTAM, M; MUDD, J; SANES, JR; MERLIE, JP			ABERRANT DIFFERENTIATION OF NEUROMUSCULAR-JUNCTIONS IN MICE LACKING S-LAMININ LAMININ BETA-2	NATURE			English	Article							ORIGINAL SYNAPTIC SITES; ACETYLCHOLINE-RECEPTOR; SKELETAL-MUSCLE; BASAL LAMINA; PROTEIN; IDENTIFICATION; INNERVATION; SYNAPSIN; REGIONS; CELLS	SYNAPSE formation requires a complex interchange of information between the pre- and postsynaptic partners. At the skeletal neuromuscular junction, some of this information is contained in the basal lamina (BL), which runs through the synaptic cleft between the motor nerve terminal and the muscle fibre. During regeneration following injury, components of synaptic BL can trigger several features of postsynaptic differentiation in the absence of the nerve terminal, and of presynaptic differentiation in the absence of the muscle fibre(1-3). One nerve-derived component of synaptic BL, agrin, is known to affect postsynaptic differentiation3, but no muscle-derived components have yet been shown to influence motor nerve terminals. A candidate for such a role is s-laminin (also called laminin beta 2), a homologue of the B1 (beta 1) chain of the widely distributed BL glycoprotein, laminin(30). s-laminin is synthesized by muscle cells(5) and concentrated in synaptic BL(4). In vitro, recombinant s-laminin fragments are selectively adhesive for motor neuron-like cells, inhibit neurite outgrowth promoted by other matrix molecules, and act as a 'stop signal' for growing neurites(6,7). By generating and characterizing mice with a targeted mutation of the s-laminin gene, we show here that s-laminin regulates formation of motor nerve terminals.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Noakes, Peter/X-9825-2019	Noakes, Peter/0000-0001-9821-8478; Gautam, Medha/0000-0002-5418-4322				BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; COVAULT J, 1986, J CELL BIOL, V102, P716, DOI 10.1083/jcb.102.3.716; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; GREEN TL, 1992, J BIOL CHEM, V267, P2014; GREENGARD P, 1993, SCIENCE, V259, P708; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUTCHINSON DO, 1993, BRAIN, V116, P633, DOI 10.1093/brain/116.3.633; INOUE A, 1992, J BIOL CHEM, V267, P10613; JIRMANOVA I, 1975, J NEUROCYTOL, V4, P141, DOI 10.1007/BF01098779; KARNOVSKY MJ, 1964, J CELL BIOL, V23, P217, DOI 10.1083/jcb.23.2.217; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PORTER BE, IN PRESS NEURON; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; SCOTT LJC, 1988, J NEUROSCI, V8, P932; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313	30	400	406	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					258	262		10.1038/374258a0	http://dx.doi.org/10.1038/374258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885444				2022-12-01	WOS:A1995QM38700049
J	SCHOTLAND, J; SHUPLIAKOV, O; WIKSTROM, M; BRODIN, L; SRINIVASAN, M; YOU, ZB; HERRERAMARSCHITZ, M; ZHANG, WQ; HOKFELT, T; GRILLNER, S				SCHOTLAND, J; SHUPLIAKOV, O; WIKSTROM, M; BRODIN, L; SRINIVASAN, M; YOU, ZB; HERRERAMARSCHITZ, M; ZHANG, WQ; HOKFELT, T; GRILLNER, S			CONTROL OF LAMPREY LOCOMOTOR NEURONS BY COLOCALIZED MONOAMINE TRANSMITTERS	NATURE			English	Article							SPINAL-CORD; RAT STRIATUM; 5-HYDROXYTRYPTAMINE; SEROTONIN; DOPAMINE; AFTERHYPERPOLARIZATION; INVIVO	NEURONS in the central nervous system (CNS) often store more than one neurotransmitter(1,2), but as yet the functional significance of this type of coexistence is poorly understood. 5-Hydroxytryptamine (5-HT) modulates calcium-dependent K+ channels (K-Ca) responsible for the postspike afterhyperpolarization in different regions of the CNS3,4. In lamprey, 5-HT neurons control apamine-sensitive K-Ca channels in spinal locomotor network interneurons(4-6), thereby in addition regulating the duration of locomotor bursts(7,8). We report here that these spinal 5-HT neurons also contain dopamine. Like 5-HT, dopamine causes a reduction of the afterhyperpolarization, but in this case it is due to a reduction of calcium entry during the action potential, which results in a reduced activation of Kc,. 5-HT and dopamine are both released from these midline neurons, and both reduce the afterhyperpolarization through two distinctly different, but complementary cellular mechanisms. The net effect of dopamine (10-100 mu M) on the locomotor network is similar to that of 5-HT, and the effects of dopamine and 5-HT are additive at the network level.	KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,DEPT NEUROPHYSIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,DEPT PHARMACOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet			Shupliakov, Oleg/R-9148-2016	Shupliakov, Oleg/0000-0001-5352-6848				BRODIN L, 1990, BRAIN RES, V508, P172, DOI 10.1016/0006-8993(90)91134-3; BRODIN L, 1986, NEUROSCI LETT, V67, P53, DOI 10.1016/0304-3940(86)90207-7; CHRISTENSON J, 1989, NEUROSCI LETT, V100, P188, DOI 10.1016/0304-3940(89)90682-4; CHURCH PJ, 1993, J NEUROSCI, V13, P2790; Cuello A. C., 1982, COTRANSMISSION; CUMMING P, 1992, J NEUROCHEM, V59, P1905, DOI 10.1111/j.1471-4159.1992.tb11026.x; DEDEK J, 1979, J NEUROCHEM, V33, P687, DOI 10.1111/j.1471-4159.1979.tb05213.x; HARRISWARRICK RM, 1985, J EXP BIOL, V116, P27; HARRISWARRICK RM, 1985, NEUROSCIENCE, V14, P1127, DOI 10.1016/0306-4522(85)90282-9; HERRERAMARSCHIT.M, 1992, AMINO ACIDS, V2, P157; HILL RH, 1985, BRAIN RES, V358, P40, DOI 10.1016/0006-8993(85)90946-1; HOKFELT T, 1987, SYNAPTIC FUNCTION, P179; MATSUSHIMA T, 1992, J NEUROPHYSIOL, V67, P1683, DOI 10.1152/jn.1992.67.6.1683; NOMIKOS GG, 1992, NEUROPSYCHOPHARMACOL, V7, P7; SCHOTLAND JL, 1993, EXP BRAIN RES, V93, P391; SCHWINDT PC, 1992, J NEUROPHYSIOL, V67, P216, DOI 10.1152/jn.1992.67.1.216; SHARP T, 1986, J NEUROCHEM, V47, P113; STEINBUSCH HWM, 1991, NATO ASI SERIES, V58; VANDONGEN PAM, 1986, BRAIN RES, V366, P320; VANDONGEN PAM, 1985, J COMP NEUROL, V234, P501, DOI 10.1002/cne.902340408; VERHOFSTAD AAJ, 1983, CYTOCHEMISTRY PRACTI; VIGH B, 1983, CELL TISSUE RES, V231, P615, DOI 10.1007/BF00218119; WALLEN P, 1989, J NEUROPHYSIOL, V61, P759, DOI 10.1152/jn.1989.61.4.759	23	87	89	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					266	268		10.1038/374266a0	http://dx.doi.org/10.1038/374266a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885446				2022-12-01	WOS:A1995QM38700051
J	SERIZAWA, H; MAKELA, TP; CONAWAY, JW; CONAWAY, RC; WEINBERG, RA; YOUNG, RA				SERIZAWA, H; MAKELA, TP; CONAWAY, JW; CONAWAY, RC; WEINBERG, RA; YOUNG, RA			ASSOCIATION OF CDK-ACTIVATING KINASE SUBUNITS WITH TRANSCRIPTION FACTOR TFIIH	NATURE			English	Article							RNA POLYMERASE-II; C-TERMINAL DOMAIN; FACTOR-DELTA; RAT-LIVER; INITIATION; PHOSPHORYLATION; PROMOTERS; HELICASE; ATPASE; YEAST	THE RNA polymerase II large subunit contains an essential carboxy-terminal domain (CTD) believed to be involved in the response to regulators during transcription initiation(1-10). The CTD is phosphorylated on a portion of RNA polymerase II molecules in vivo(11,12) and it can be phosphorylated by the general transcription factor TFIIH in vitro(13-15). A highly purified TFIIH from rat liver has been described(16); this, like human and yeast TFIIH, contains associated CTD kinase and helicase activities(13-18). We report here that two polypeptides of the purified mammalian TFIIH are the MO15/Cdk7 kinase and cyclin H subunits of the Cdk-activating kinase Cak(19-21), previously identified as a positive regulator of Cdc2 and Cdk2. TFIIH and Cak preparations are each capable of phosphorylating recombinant CTD and recombinant Cdk2 proteins. The presence of Cak in TFIIH indicates that Cak may have roles in transcriptional regulation and in cell-cycle control.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	Massachusetts Institute of Technology (MIT); Oklahoma Medical Research Foundation	SERIZAWA, H (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		makela, tomi/B-3734-2009; Young, Richard A/F-6495-2012	makela, tomi/0000-0002-4869-8044; Young, Richard A/0000-0001-8855-8647; Conaway, Joan/0000-0002-2786-0663				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARLOW E, 1989, ANTIBODIES LABORATOR; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	32	327	342	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					280	282		10.1038/374280a0	http://dx.doi.org/10.1038/374280a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885450				2022-12-01	WOS:A1995QM38700055
J	SHIEKHATTAR, R; MERMELSTEIN, F; FISHER, RP; DRAPKIN, R; DYNLACHT, B; WESSLING, HC; MORGAN, DO; REINBERG, D				SHIEKHATTAR, R; MERMELSTEIN, F; FISHER, RP; DRAPKIN, R; DYNLACHT, B; WESSLING, HC; MORGAN, DO; REINBERG, D			CDK-ACTIVATING KINASE COMPLEX IS A COMPONENT OF HUMAN TRANSCRIPTION FACTOR TFIIH	NATURE			English	Article							RNA POLYMERASE-II; CARBOXYL-TERMINAL-DOMAIN; INITIATION	TRANSCRIPTION factor IIH (TFIIH) contains a kinase capable of phosphorylating the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II (RNAPII)1-3. Here we report the identification of the Cdk-activating kinase (Cak) complex (Cdk7 and cyclin H) as a component of TFIIH after extensive purification of TFIIH by chromatography. We find that affinity-purified antibodies directed against cyclin H inhibit TFIIH-dependent transcription and that both cyclin H and Cdk7 antibodies inhibit phosphorylation of the CTD of the largest subunit of the RNAPII in the preinitiation complex. Cak is present in at least two distinct complexes, TFIIH and a smaller complex that is unable to phosphorylate RNAPII in the preinitiation complex. Both Cak complexes, as well as recombinant Cak, phosphorylate a CTD peptide. Finally, TFIIH was shown to phosphorylate both Cdc2 and Cdk2, suggesting that there could be a link between transcription and the cell cycle machinery.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, HOWARD HUGHES MED INST, PISCATAWAY, NJ 08854 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; MASSACHUSETTS GEN HOSP, CTR CANC, MOLEC ONCOL LAB, BOSTON, MA 02129 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital			Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Morgan, David/0000-0001-8753-4416; Reinberg, Danny/0000-0003-4288-2016				CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FLORES O, 1992, J BIOL CHEM, V267, P2786; HARLOW E, 1988, ANTIBODIES LABORATOR; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; ZAWEL L, 1993, COLD SPRING HARB SYM, V58, P187, DOI 10.1101/SQB.1993.058.01.023	17	364	385	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	1995	374	6519					283	287		10.1038/374283a0	http://dx.doi.org/10.1038/374283a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7533895				2022-12-01	WOS:A1995QM38700056
J	SZATHMARY, E; SMITH, JM				SZATHMARY, E; SMITH, JM			THE MAJOR EVOLUTIONARY TRANSITIONS	NATURE			English	Review							NATURAL-SELECTION; ORIGIN; CHROMOSOMES; MECHANISMS; TEMPLATES; MODELS; GROWTH; CELLS; LIFE	There is no theoretical reason to expect evolutionary lineages to increase in complexity with time, and no empirical evidence that they do so. Nevertheless, eukaryotic cells are more complex than prokaryotic ones, animals and plants are more complex than protists, and so on. This increase in complexity may have been achieved as a result of a series of major evolutionary transitions. These involved changes in the way information is stored and transmitted.	EOTVOS LORAND UNIV, DEPT PLANT TAXON & ECOL, ECOL MODELLING RES GRP, H-1083 BUDAPEST, HUNGARY; UNIV SUSSEX, SCH BIOL SCI, BRIGHTON BN1 9QG, E SUSSEX, ENGLAND	Eotvos Lorand University; University of Sussex	SZATHMARY, E (corresponding author), COLLEGIUM BUDAPEST, INST ADV STUDY, SZENTHAROMSAG U2, H-1014 BUDAPEST, HUNGARY.		Szathmáry, Eörs/A-5007-2011; Szathmary, Eors/AAS-1202-2021	Szathmary, Eors/0000-0001-5227-2997				BACHMANN PA, 1992, NATURE, V357, P57, DOI 10.1038/357057a0; Bell G., 1985, ORIGIN EVOLUTION SEX, P221; BENNER SA, 1987, COLD SPRING HARB SYM, V52, P53, DOI 10.1101/SQB.1987.052.01.009; Bickerton Derek., 1990, LANGUAGE SPECIES; Bonner JT., 1988, EVOLUTION COMPLEXITY; Buss L. W., 1987, EVOLUTION INDIVIDUAL; CAIRNS-SMITH A G, 1974, Biosystems, V5, P173, DOI 10.1016/0303-2647(74)90030-6; Cavalier-Smith T, 1985, EVOLUTION GENOME SIZ; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CHAMOV E, 1976, NATURE, V263, P125; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Chomsky N., 1965, ASPECTS THEORY SYNTA; CROW JF, 1991, BIOESSAYS, V13, P305, DOI 10.1002/bies.950130609; Dawkins R., 1976, SELFISH GENE; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; FAMULOK M, IN PRESS J AM CHEM S; Ganti T., 1979, THEORY BIOCH SUPERSY; Ganti T, 1975, BIOSYSTEMS, V7, P189, DOI [10.1016/0303-2647(75)90057-X, DOI 10.1016/0303-2647(75)90057-X]; Ganti T., 1987, PRINCIPLE LIFE; GOPNIK M, 1990, NATURE, V344, P715, DOI 10.1038/344715a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hinton G. E., 1987, Complex Systems, V1, P495; HURST LD, 1992, P ROY SOC B-BIOL SCI, V247, P189, DOI 10.1098/rspb.1992.0027; HURST LD, 1992, P ROY SOC B-BIOL SCI, V248, P135, DOI 10.1098/rspb.1992.0053; HUTSON V, 1993, P ROY SOC LOND B BIO, V283, P43; JABLONKA E, 1994, J THEOR BIOL, V170, P301, DOI 10.1006/jtbi.1994.1191; JABLONKA ELM, 1995, EPIGENETIC INHERITAN; JEON KW, 1991, SYMBIOSIS SOURCE EVO, P118; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; KACSER H, 1984, J MOL EVOL, V20, P38, DOI 10.1007/BF02101984; KING GAM, 1980, BIOSYSTEMS, V13, P23, DOI 10.1016/0303-2647(80)90003-9; KIRK DL, 1988, TRENDS GENET, V4, P32, DOI 10.1016/0168-9525(88)90063-7; KOCH AL, 1985, J MOL EVOL, V21, P270, DOI 10.1007/BF02102359; KOUFOPANOU V, 1994, AM NAT, V143, P907, DOI 10.1086/285639; LAZCANO A, 1988, J MOL EVOL, V27, P283, DOI 10.1007/BF02101189; LEIGH EG, 1991, TRENDS ECOL EVOL, V6, P257, DOI 10.1016/0169-5347(91)90073-7; Leigh EG., 1971, ADAPTATION DIVERSITY; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Margulis L., 1993, SYMBIOSIS CELL EVOLU; Maynard Smith J., 1995, MAJOR TRANSITIONS EV; Maynard-Smith J., 1978, MODELS ECOLOGY; MOLNAR I, 1993, ABSTR BOT, V17, P207; PINKER S, 1990, BEHAV BRAIN SCI, V13, P707, DOI 10.1017/S0140525X00081061; Pinker S, 1994, LANGUAGE INSTINCT NE; PRUDENT JR, 1994, SCIENCE, V264, P1924; Rasbach H., 1979, BER BAYER BOT GES, V50, P23; RENSCH B, 1966, EVOLUTION SPECIES LE; SMITH A, 1777, WEALTH NATIONS; SMITH JM, 1983, PROC R SOC SER B-BIO, V219, P315, DOI 10.1098/rspb.1983.0076; SMITH JM, 1993, J THEOR BIOL, V164, P437, DOI 10.1006/jtbi.1993.1165; SZATHMARY E, 1989, J THEOR BIOL, V138, P55, DOI 10.1016/S0022-5193(89)80177-8; SZATHMARY E, 1990, NATURE, V344, P115, DOI 10.1038/344115a0; SZATHMARY E, 1993, P NATL ACAD SCI USA, V90, P9916, DOI 10.1073/pnas.90.21.9916; SZATHMARY E, 1987, J THEOR BIOL, V128, P463, DOI 10.1016/S0022-5193(87)80191-1; SZATHMARY E, 1991, TRENDS ECOL EVOL, V6, P366, DOI 10.1016/0169-5347(91)90228-P; SZATHMARY E, 1989, TRENDS ECOL EVOL, V4, P200, DOI 10.1016/0169-5347(89)90073-6; SZATHMARY E, 1993, J THEOR BIOL, V164, P447, DOI 10.1006/jtbi.1993.1166; Szathmary E., 1989, Oxford Surveys in Evolutionary Biology, V6, P169; SZATHMARY E, 1994, J THEOR BIOL, V169, P125, DOI 10.1006/jtbi.1994.1134; TARUMI K, 1987, B MATH BIOL, V49, P307, DOI 10.1016/S0092-8240(87)80026-5; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113; VONKLEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P923; WACHTERSHAUSER G, 1994, P NATL ACAD SCI USA, V91, P4283, DOI 10.1073/pnas.91.10.4283; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Williams G. C., 1966, P307; WILSON DS, 1989, J THEOR BIOL, V136, P337, DOI 10.1016/S0022-5193(89)80169-9; Wilson E.O., 1975, P1; WOLPERT L, 1990, BIOL J LINN SOC, V39, P109, DOI 10.1111/j.1095-8312.1990.tb00506.x; YCAS M, 1955, P NATL ACAD SCI USA, V41, P714, DOI 10.1073/pnas.41.10.714	72	638	651	3	209	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	1995	374	6519					227	232		10.1038/374227a0	http://dx.doi.org/10.1038/374227a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885442				2022-12-01	WOS:A1995QM38700040
J	WANG, T; XIE, ZP; LU, B				WANG, T; XIE, ZP; LU, B			NITRIC-OXIDE MEDIATES ACTIVITY-DEPENDENT SYNAPTIC SUPPRESSION AT DEVELOPING NEUROMUSCULAR SYNAPSES	NATURE			English	Article							LONG-TERM POTENTIATION; GLYCERYL TRINITRATE; METHYLENE-BLUE; MESSENGER; MUSCLE; RELAXATION	TEMPORAL correlation between pre- and postsynaptic activities is an important mechanism that regulates synaptic connectivity during development and synaptic plasticity in the adult(1-3). In developing neuromuscular junctions, postsynaptic activity is critical in functional suppression and, ultimately, elimination of the synapses(4-6). Although repetitive postsynaptic firing asynchronous to the presynaptic activity results in a persistent synaptic suppression(7-10), the underlying molecular mechanism remains unknown. Here we provide evidence that nitric oxide (NO), a free radical implicated in several forms of synaptic plasticity(11-15), may serve as a retrograde signal for activity-dependent suppression in the neuromuscular synapse. NO donors and activators of the cyclic GMP pathway suppressed spontaneous and evoked synaptic currents. Moreover, the synaptic suppression induced by repetitive postsynaptic depolarization was prevented by the NO-binding protein haemoglobin and by inhibitors of NO synthase. Thus, synaptic suppression may be triggered by NO released from a postsynaptic myocyte that fires asynchronously to the presynaptic terminal.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110				Lu, Bai/A-4018-2012	Lu, Bai/0000-0001-5418-9759				BETZ WJ, 1987, VERTEBRATE NEUROMUSC; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CONSTAINTINEPAT.M, 1990, A REV NEUROSCI, V13, P129; Crepel F, 1990, Neuroreport, V1, P133, DOI 10.1097/00001756-199010000-00013; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; GHEZ C, 1991, PRINCIPLE NEURAL SCI; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KIDOKORO Y, 1984, Neuroscience Research, V1, P157, DOI 10.1016/S0168-0102(84)80013-9; LO YJ, 1994, J NEUROSCI, V14, P4684; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LO YJ, 1994, J NEUROSCI, V14, P4694; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; SRIHARI T, 1978, J NEUROCYTOL, V7, P529, DOI 10.1007/BF01260887; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WOLIN MS, 1982, J BIOL CHEM, V257, P13312	28	169	172	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					262	266		10.1038/374262a0	http://dx.doi.org/10.1038/374262a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885445				2022-12-01	WOS:A1995QM38700050
J	ALLMAN, RM; GOODE, PS; PATRICK, MM; BURST, N; BARTOLUCCI, AA				ALLMAN, RM; GOODE, PS; PATRICK, MM; BURST, N; BARTOLUCCI, AA			PRESSURE ULCER RISK-FACTORS AMONG HOSPITALIZED-PATIENTS WITH ACTIVITY LIMITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SORES; SUPPORT; COHORT	Objective.-To identify specific demographic, medical, functional status, and nutritional characteristics that predict the development of stage 2 or greater pressure ulcers among patients whose activity is limited to bed or chair. Design.-Prospective inception cohort study. Setting.-Tertiary care, urban, university teaching hospital. Patients.-A total of 286 patients fulfilling the following criteria: admitted to the hospital within the previous 3 days, age 55 years or more, expected to be confined to bed or chair for at least 5 days or had a hip fracture, and without a stage 2 or greater pressure ulcer. Main Outcome Measure.-Time to in-hospital development of a stage 2 or greater pressure ulcer. Results.-Total cumulative incidence of pressure ulcers was 12.9% (n=37) after a median time of 9 days from admission to final skin examination. Age of 75 years or more, dry skin, nonblanchable erythema (a stage 1 pressure ulcer), previous pressure ulcer history, immobility, fecal incontinence, depleted triceps skinfold, lymphopenia (lymphocyte count <1.50x10(9)/L), and decreased body weight (<58 kg) were significantly associated with pressure ulcer development by univariate Kaplan-Meier survival analyses (P<.05 by log-rank test). Risk ratios (and 95% confidence intervals) for predictors (P less than or equal to.05) of pressure ulcer development after multivariable Cox regression analysis included the following: nonblanchable erythema, 7.52 (1.00 to 59.12); lymphopenia, 4.86 (1.70 to 13.89); immobility, 2.36 (1.14 to 4.85); dry skin, 2.31 (1.02 to 5.21); and decreased body weight, 2.18 (1.05 to 4.52). The 3-week cumulative incidence of pressure ulcers with none, one, two, or three or more of these characteristics was 0%, 11.4%, 39.6%, and 67.9%, respectively (P<.001 by log-rank test). Conclusions.-These results suggest that nonblanchable erythema, lymphopenia, immobility, dry skin, and decreased body weight are independent and significant risk factors for pressure ulcers in hospitalized patients whose activity is limited to bed or chair.	UNIV ALABAMA, DEPT MED, DIV GERONTOL & GERIATR MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOSTAT, BIRMINGHAM, AL 35294 USA; DEPT VET AFFAIRS MED CTR, BIRMINGHAM, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	ALLMAN, RM (corresponding author), UNIV ALABAMA, CTR AGING, 933 S 19TH ST, 201 CH-19, BIRMINGHAM, AL 35294 USA.		Allman, Richard M/D-5964-2011; Allman, Richard M./O-1693-2019	Allman, Richard M./0000-0002-1850-6515	NIA NIH HHS [5-R01-AG07178-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007178] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allman R M, 1989, Decubitus, V2, P30; ALLMAN RM, 1987, ANN INTERN MED, V107, P641, DOI 10.7326/0003-4819-107-5-641; ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; ANDERSEN KE, 1982, BMJ-BRIT MED J, V284, P1370, DOI 10.1136/bmj.284.6326.1370; [Anonymous], 1989, Decubitus, V2, P24; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; Braden B J, 1989, Decubitus, V2, P44; Braden BJ, 1989, DECUB J SKIN ULCERS, V2, P50; BRANDEIS GH, 1994, J AM GERIATR SOC, V42, P388, DOI 10.1111/j.1532-5415.1994.tb07486.x; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; EXTONSMITH A, 1961, LANCET, V2, P1124; Gilchrest BA., 1984, SKIN AGING PROCESSES; Gosnell D J, 1989, Decubitus, V2, P32; GOSNELL DJ, 1973, NURS RES, V22, P55; GURALNIK JM, 1988, J AM GERIATR SOC, V36, P807, DOI 10.1111/j.1532-5415.1988.tb04264.x; KEMP MG, 1993, RES NURS HEALTH, V16, P89, DOI 10.1002/nur.4770160203; KNAUS WA, 1981, JAMA-J AM MED ASSOC, V246, P2711, DOI 10.1001/jama.246.23.2711; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LOWTHIAN PT, 1976, BEDSORE BIOMECHANICS, P141; Norton D, 1975, INVESTIGATION GERIAT, P193; OKAMOTO GA, 1983, ARCH PHYS MED REHAB, V64, P20; Pennington JAT, 1985, FOOD VALUES PORTIONS; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; SHURAN M, 1986, GERIATRICS, V41, P48; SMITH DM, 1991, J GEN INTERN MED, V6, P81, DOI 10.1007/BF02599399; Stotts N A, 1988, Decubitus, V1, P24; WEINSIER R, 1989, HDB CLIN NUTRITION; 1992, PHS920047 US DEP HLT; 1985, 5TH PATIENT TYPE CLA	32	223	239	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					865	870		10.1001/jama.273.11.865	http://dx.doi.org/10.1001/jama.273.11.865			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869557				2022-12-01	WOS:A1995QL40200024
J	ASHTON, CM; KUYKENDALL, DH; JOHNSON, ML; WRAY, NP; WU, L				ASHTON, CM; KUYKENDALL, DH; JOHNSON, ML; WRAY, NP; WU, L			THE ASSOCIATION BETWEEN THE QUALITY OF INPATIENT CARE AND EARLY READMISSION	ANNALS OF INTERNAL MEDICINE			English	Article						PATIENT READMISSION; QUALITY OF HEALTH CARE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); HOSPITALIZATION	DISEASE	Objective: To determine whether the quality of care during a hospital stay is associated with unplanned readmission within 14 days. Design: Case-control study. Setting: 12 Veterans Affairs hospitals. Patients: Men discharged after a hospitalization for diabetes (n = 593), chronic obstructive lung disease (n = 1172), or heart failure (n = 748). The ratio of controls (men without an unplanned readmission within 14 days to any Veterans Affairs hospital) to cases (men with such a readmission) was 3:1. Main Outcome Measures: Unplanned readmission to any of the 159 Veterans Affairs hospitals within 14 days of discharge. Quality of care during the index stay was assessed by chart review using disease-specific explicit criteria for the process of inpatient care, which were developed by panels composed of expert physicians. Adherence scores (the percentage of applicable criteria that were met) were calculated for the admission workup, evaluation and treatment, and readiness for discharge. Results: After adjustment was made for demographic characteristics, severity of illness, and need for care, adherence scores correlated with early unplanned readmission (P < 0.05). For patients with diabetes and heart failure, decreased readiness-for-discharge adherence scores correlated with increased risk for readmission (P = 0.001 and P = 0.016, respectively). In patients with obstructive lung disease, decreased admission-workup scores correlated with increased risk for readmission (P = 0.013). One of 7 readmissions in patients with diabetes, 1 of 5 readmissions in patients with heart failure, and 1 of 12 readmissions in patients with obstructive lung disease were attributable to substandard care. Conclusions: Lower quality of inpatient care increases the risk for unplanned early readmission in patients with heart failure, diabetes, or obstructive lung disease. Under certain circumstances, readmission is associated with remediable deficiencies in the process of inpatient care.	BAYLOR COLL MED, HOUSTON, TX 77030 USA	Baylor College of Medicine	ASHTON, CM (corresponding author), VET AFFAIRS MED CTR, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; ASHTON CM, 1994, J GEN INTERN MED, V9, P208, DOI 10.1007/BF02600126; ASHTON CM, 1994, MED CARE, V32, P755, DOI 10.1097/00005650-199408000-00001; ASHTON CM, 1987, MED CARE, V25, P1184, DOI 10.1097/00005650-198712000-00008; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; FEINGLASS J, 1991, HEALTH SERV RES, V26, P183; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, P211, DOI DOI 10.2307/2530193; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; HAYWARD RA, 1993, MED CARE, V31, P394, DOI 10.1097/00005650-199305000-00002; Hosmer D, 2013, APPL LOGISTIC REGRES; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P162; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUDKE RL, 1993, INQUIRY-J HEALTH CAR, V30, P95; MANHEIM LM, 1990, MED CARE, V28, P29, DOI 10.1097/00005650-199001000-00005; REED RL, 1991, J GEN INTERN MED, V6, P223, DOI 10.1007/BF02598964; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; SIMMER TL, 1991, MED CARE, V29, pJS31; THOMAS JW, 1991, MED CARE, V29, P377, DOI 10.1097/00005650-199104000-00006; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; WILLIAMS EI, 1988, BRIT MED J, V297, P784, DOI 10.1136/bmj.297.6651.784; WRAY NP, 1995, MED CARE, V33, P75, DOI 10.1097/00005650-199501000-00007; 1989, ANAL READMISSIONS US; 1989, SAS UNIX 607	23	280	289	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					415	421		10.7326/0003-4819-122-6-199503150-00003	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM266	7856989				2022-12-01	WOS:A1995QM26600003
J	BURGE, MR; BOYLE, PJ				BURGE, MR; BOYLE, PJ			DIETARY THERAPY IN TYPE-II DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BURGE, MR (corresponding author), UNIV NEW MEXICO,SCH MED,ALBUQUERQUE,NM 87131, USA.							BANTLE JP, 1993, DIABETES CARE, V16, P1301, DOI 10.2337/diacare.16.9.1301; CRAPO PA, 1994, JOSLINS DIABETES MEL, P415; FREEMAN WL, 1988, PRIMARY CARE, V15, P327; HANSEN BC, 1988, DIABETES CARE, V11, P183, DOI 10.2337/diacare.11.2.183; HUGHES TA, 1984, AM J MED, V77, P7, DOI 10.1016/0002-9343(84)90429-7; REAVEN GM, 1980, DIABETOLOGIA, V19, P409, DOI 10.1007/BF00281817; 1994, DIABETES CARE, V17, P519; 1987, DIABETES CARE, V10, P639	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					898	898		10.1001/jama.273.11.898	http://dx.doi.org/10.1001/jama.273.11.898			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869567				2022-12-01	WOS:A1995QL40200035
J	HELM, TN				HELM, TN			EVALUATION OF ALOPECIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HELM, TN (corresponding author), SUNY BUFFALO,BUFFALO,NY, USA.							BERGFELD WF, 1994, CONSULTANT, V34, P1390; HELM TN, 1992, INT J DERMATOL, V31, P437, DOI 10.1111/j.1365-4362.1992.tb02680.x; STECK WD, 1978, CUTIS, V21, P543; WHITING DA, 1993, J AM ACAD DERMATOL, V28, P755, DOI 10.1016/0190-9622(93)70106-4	4	1	1	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					897	898						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869566				2022-12-01	WOS:A1995QL40200034
J	RUMBYRT, JS; BORISH, LC				RUMBYRT, JS; BORISH, LC			HOME ADMINISTRATION OF ALLERGEN EXTRACTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											RUMBYRT, JS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206, USA.							REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; TURKELTAUB PC, 1994, FDA MED B, V24, P7; 1990, J ALLERGY CLIN IMMUN, V85, P526	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					897	897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869565				2022-12-01	WOS:A1995QL40200033
J	SANCHEZGUERRERO, J; LIANG, MH; KARLSON, EW; HUNTER, DJ; COLDITZ, GA				SANCHEZGUERRERO, J; LIANG, MH; KARLSON, EW; HUNTER, DJ; COLDITZ, GA			POSTMENOPAUSAL ESTROGEN THERAPY AND THE RISK FOR DEVELOPING SYSTEMIC LUPUS-ERYTHEMATOSUS	ANNALS OF INTERNAL MEDICINE			English	Note							LOW PLASMA ANDROGENS; PROSPECTIVE COHORT; WOMEN; GLOMERULONEPHRITIS; PATHOGENESIS; SURVIVAL; MICE	Objective: To examine the relation between postmenopausal hormone use and development of systemic lupus erythematosus. Design: Prospective cohort study. Setting: Nurses' Health Study. Patients: 69 435 women aged 30 to 55 years in 1976 who reported that they had completed menopause and did not have systemic lupus erythematosus or any connective tissue disease were followed every 2 years from 1976 to 1990. These women were classified as never- or ever-(current and past) users of postmenopausal hormones. Measurements: Incidence rates of systemic lupus erythematosus and classification criteria from the American College of Rheumatology that were confirmed by chart review. Results: With never-users of postmenopausal hormones as the reference group, age-adjusted relative risks for systemic lupus erythematosus (n = 45 women) were 2.1 (95% CI, 1.1 to 4.0) for ever-users, 2.5 (CI, 1.2 to 5.0) for current users, and 1.8 (CI, 0.8 to 4.1) for past users. A proportional increase in the risk for systemic lupus erythematosus was observed that was related to the duration of use of postmenopausal hormones (test for trend, P = 0.011). Conclusions: Postmenopausal hormone therapy is associated with an increased risk for developing systemic lupus erythematosus.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	FOGARTY INTERNATIONAL CENTER [F05TW004573] Funding Source: NIH RePORTER; FIC NIH HHS [5F05 TW04573-02] Funding Source: Medline; NCI NIH HHS [CA 40396] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALARCONSEGOVIA D, 1984, J RHEUMATOL, V11, P588; COHEN JHM, 1983, J IMMUNOL, V131, P2767; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JUNGERS P, 1982, ARTHRITIS RHEUM, V25, P454, DOI 10.1002/art.1780250415; KARLSON EW, 1995, IN PRESS ANN EPIDEMI; KELLEY VE, 1980, CLIN IMMUNOL IMMUNOP, V16, P142, DOI 10.1016/0090-1229(80)90198-1; LAHITA RG, 1981, J CLIN ENDOCR METAB, V53, P174, DOI 10.1210/jcem-53-1-174; LAHITA RG, 1987, ARTHRITIS RHEUM, V30, P241, DOI 10.1002/art.1780300301; MASI AT, 1978, ARTHRITIS RHEUM-US, V21, P480, DOI 10.1002/art.1780210413; ROTHMAN KJ, 1979, PHS NIH791649 PUBL; ROUBINIAN JR, 1979, J CLIN INVEST, V63, P902, DOI 10.1172/JCI109390; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; Silman AJ, 1993, EPIDEMIOLOGY RHEUMAT, P163; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tosteson Anna N. A., 1994, P405	18	164	176	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					430	433		10.7326/0003-4819-122-6-199503150-00005	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856991				2022-12-01	WOS:A1995QM26600005
J	TAKALA, AK; JERO, J; KELA, E; RONNBERG, PR; KOSKENNIEMI, E; ESKOLA, J				TAKALA, AK; JERO, J; KELA, E; RONNBERG, PR; KOSKENNIEMI, E; ESKOLA, J			RISK-FACTORS FOR PRIMARY INVASIVE PNEUMOCOCCAL DISEASE AMONG CHILDREN IN FINLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLUENZAE TYPE-B; STREPTOCOCCUS-PNEUMONIAE; HEMOPHILUS-INFLUENZAE; HAEMOPHILUS-INFLUENZAE; OTITIS-MEDIA; EPIDEMIOLOGY; INFECTIONS; POPULATION; INFANTS; COUNTY	Objective.-To study risk factors for invasive pneumococcal disease among children. Design.-A population-based, case-control study of 149 cases and 284 controls matched for age, sex, and place of residence. Setting.-Finland, November 1986 through November 1989. Patients and Controls.-Patients were identified from a prospective nationwide surveillance for invasive bacterial diseases among children (0 to 15 years of age) through a network of bacteriologic laboratories. Two matched controls were selected for 135 of the cases and one matched control for 14 of the cases from the respective cases' child health center or school. Questionnaires evaluating potential risk factors were mailed to families of cases and controls. Results.-An increased risk for invasive pneumococcal disease among children younger than 2 years was associated with day care center attendance (odds ratio [OR]=36; 95% confidence interval [CI], 5.7 to 233), family day care (OR=4.4; 95% CI, 1.7 to 12), and history of frequent otitis media (OR=8.8; 95% CI, 2.5 to 31). For those at least 2 years of age, existence of siblings younger than school-age indicated increased risk for invasive pneumococcal disease (OR=2.2; 95% CI, 1.1 to 4.4). Conclusions.-Day care center attendance is a major risk factor for invasive pneumococcal disease for children younger than 2 years, with significantly higher risk than the risk associated with family day care.			TAKALA, AK (corresponding author), NATL PUBL HLTH INST,DEPT INFECT DIS & EPIDEMIOL,MANNERHEIMINTIE 170A,SF-00300 HELSINKI,FINLAND.							ANDERSSON B, 1986, J INFECT DIS, V153, P232, DOI 10.1093/infdis/153.2.232; ANIANSSON G, 1990, MICROB PATHOGENESIS, V8, P315, DOI 10.1016/0882-4010(90)90090-D; BLACK S, 1994, 34TH INT C ANT AG CH; BLUESTONE CD, 1992, PEDIATR INFECT DIS J, V11, pS7, DOI 10.1097/00006454-199208001-00002; BROOME CV, 1981, REV INFECT DIS, V3, P277; BURMAN LA, 1985, REV INFECT DIS, V7, P133; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; COCHI SL, 1986, J PEDIATR-US, V108, P887, DOI 10.1016/S0022-3476(86)80922-2; CORTESE MM, 1992, ARCH INTERN MED, V152, P2277, DOI 10.1001/archinte.152.11.2277; DAGAN R, 1992, JAMA-J AM MED ASSOC, V268, P3328, DOI 10.1001/jama.268.23.3328; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; ESKOLA J, 1992, JAMA-J AM MED ASSOC, V268, P3323, DOI 10.1001/jama.268.23.3323; FADEN H, 1991, ANN OTO RHINOL LARYN, V100, P612, DOI 10.1177/000348949110000802; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GRAY BM, 1982, AM J EPIDEMIOL, V116, P692, DOI 10.1093/oxfordjournals.aje.a113452; HALL PG, 1988, REPORT COMMITTEE INF, P328; HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55; ISTRE GR, 1985, J PEDIATR-US, V106, P190, DOI 10.1016/S0022-3476(85)80285-7; JACOBS NM, 1979, PEDIATRICS, V64, P296; KARMA P, 1987, ANN OTO RHINOL LARYN, V96, pS1; KLEIN JO, 1981, REV INFECT DIS, V3, P246; LEHMANN D, 1992, J INFECT DIS, V165, pS20, DOI 10.1093/infdis/165-Supplement_1-S20; LUOTONEN J, 1981, SCAND J INFECT DIS, V13, P177, DOI 10.3109/inf.1981.13.issue-3.04; MCGOWAN JE, 1973, NEW ENGL J MED, V288, P1309, DOI 10.1056/NEJM197306212882501; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MICHAELS RH, 1976, J CLIN MICROBIOL, V4, P413; NOHYNEK H, 1991, AM J DIS CHILD, V145, P618, DOI 10.1001/archpedi.1991.02160060036016; PETERSEN GM, 1991, AM J EPIDEMIOL, V134, P1212, DOI 10.1093/oxfordjournals.aje.a116024; REICHLER M, 1991, 31ST INT C ANT AG CH; SABHARWAL H, 1992, OCT EUR RES C RES C; SHAPIRO ED, 1994, J INFECT DIS, V169, P212, DOI 10.1093/infdis/169.1.212; SIPILA M, 1988, ACTA OTO-LARYNGOL, V106, P94, DOI 10.3109/00016488809107375; SNIADAK D, 1993, 33RD INT C ANT AG CH; TAKALA AK, 1992, J INFECT DIS, V165, pS11, DOI 10.1093/infdis/165-Supplement_1-S11; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P189, DOI 10.1097/00006454-199303000-00003; TAKALA AK, 1989, J PEDIATR-US, V115, P694, DOI 10.1016/S0022-3476(89)80644-4; TAKALA AK, 1994, DEV CLIN USES HAEMOP; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; TODD JK, 1984, PEDIATR INFECT DIS J, V3, P159, DOI 10.1097/00006454-198403000-00021; VADHEIM CM, 1992, AM J EPIDEMIOL, V136, P221, DOI 10.1093/oxfordjournals.aje.a116488; VINTHER S, 1992, CLIN INFECT DIS, V15, P794; 1989, MMWR-MORBID MORTAL W, V38, P733	43	75	75	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					859	864		10.1001/jama.273.11.859	http://dx.doi.org/10.1001/jama.273.11.859			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869556				2022-12-01	WOS:A1995QL40200023
J	VANDAELE, PLA; STOLK, RP; BURGER, H; ALGRA, D; GROBBEE, DE; HOFMAN, A; BIRKENHAGER, JC; POLS, HAP				VANDAELE, PLA; STOLK, RP; BURGER, H; ALGRA, D; GROBBEE, DE; HOFMAN, A; BIRKENHAGER, JC; POLS, HAP			BONE-DENSITY IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS - THE ROTTERDAM STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, NON-INSULIN-DEPENDENT; BONE DENSITY; FRACTURES; DIABETES MELLITUS, INSULIN-DEPENDENT; SEX FACTORS	HORMONE-BINDING GLOBULIN; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; ELDERLY WOMEN; MASS; FRACTURES; ESTROGENS; MEN; OSTEOPOROSIS	Objective: To investigate the relation between noninsulin-dependent diabetes mellitus and bone mineral density at the lumbar spine and hip. Design: Population-based study with a cross-sectional survey, Setting: A district of Rotterdam, the Netherlands. Participants: 5931 residents (2481 men, 3450 women) of the district aged 55 years or more. Measurements: Participants were classified as having non-insulin-dependent diabetes mellitus if they were receiving antidiabetic medication or if they had a serum glucose level of 11.1 mmol/L or more after a nonfasting oral glucose tolerance test. Bone mineral density, measured at the lumbar spine and proximal femur using dual-energy x-ray absorptiometry and the frequency of nonvertebral fractures during the preceding 5 years were compared between persons with and without non-insulin-dependent diabetes mellitus. Results: 243 men and 335 women had non-insulin-dependent diabetes mellitus. Both men and women with this condition had substantially higher mean bone mineral density values at all four sites measured than those with normal glucose tolerance. The increase could not be explained by age; obesity; use of estrogens, thiazides, or loop diuretics; impairment in abilities of daily living; smoking; or osteoarthritis. Women with non-insulin-dependent diabetes mellitus reported having had fewer fractures in the 5 preceding years than women without this condition (adjusted odds ratio, 0.63; 95% CI, 0.44 to 0.90). The frequency of fractures in men was similar for those with and without noninsulin-dependent diabetes mellitus (adjusted odds ratio, 0.96; CI, 0.60 to 1.52). Conclusions: Men and women with non-insulin-dependent diabetes mellitus have increased bone mineral density. Non-insulin-dependent diabetes mellitus in women is associated with a lower frequency of nonvertebral fractures.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			Stolk, Ronald P/B-2341-2013; Grobbee, Diederick/C-7651-2014	Stolk, Ronald P/0000-0002-0518-1205; Grobbee, Diederick/0000-0003-4472-4468				[Anonymous], 1985, DIABETES MELLITUS RE; BARRETTCONNOR E, 1992, JAMA-J AM MED ASSOC, V268, P3333; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; BIRKELAND KI, 1993, J CLIN ENDOCR METAB, V76, P275, DOI 10.1210/jc.76.2.275; CLEGHORN DB, 1992, J EPIDEMIOL COMMUN H, V46, P133, DOI 10.1136/jech.46.2.133; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DELEEUW I, 1977, DIABETES, V26, P1130, DOI 10.2337/diabetes.26.12.1130; ERNST M, 1987, CALCIFIED TISSUE INT, V40, P27, DOI 10.1007/BF02555725; GIACCA A, 1988, BONE, V9, P29, DOI 10.1016/8756-3282(88)90024-5; HAFFNER SM, 1993, METABOLISM, V42, P735, DOI 10.1016/0026-0495(93)90241-F; HEATH H, 1980, NEW ENGL J MED, V303, P567, DOI 10.1056/NEJM198009043031008; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; ISAIA G, 1987, ACTA DIABETOL LAT, V24, P305, DOI 10.1007/BF02742962; ISHIDA H, 1985, METABOLISM, V34, P797, DOI 10.1016/0026-0495(85)90101-5; JOHNSTON CC, 1985, METABOLISM, V34, P544, DOI 10.1016/0026-0495(85)90192-1; Kellgren, 1963, EPIDEMIOLOGY CHRONIC, V2; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502; LINDSAY R, 1991, BAILLIERE CLIN OB GY, V5, P837, DOI 10.1016/S0950-3552(05)80291-3; MCNAIR P, 1988, DAN MED BULL, V35, P109; MEEMA HE, 1967, CAN MED ASSOC J, V96, P132; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MURPHY S, 1993, BONE MINER, V20, P133, DOI 10.1016/S0169-6009(08)80022-0; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; PEIRIS AN, 1993, J CLIN ENDOCR METAB, V76, P279, DOI 10.1210/jc.76.2.279; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PLYMATE SR, 1988, J CLIN ENDOCR METAB, V67, P460, DOI 10.1210/jcem-67-3-460; PREZIOSI P, 1993, J CLIN ENDOCR METAB, V76, P283, DOI 10.1210/jc.76.2.283; REID IR, 1993, AM J PHYSIOL, V265, P655; RUWAARD D, 1993, VOLKSGEZONDHEID TOEK, P303; SAMBROOK PN, 1988, J RHEUMATOL, V15, P1415; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SMYTHE HA, 1987, J RHEUMATOL, V14, P91; VANHEMERT AM, 1989, CLIN ENDOCRINOL, V31, P499; WAKASUGI M, 1993, BONE, V14, P29, DOI 10.1016/8756-3282(93)90252-6; WEINSTOCK RS, 1989, J BONE MINER RES, V4, P97; YKIJARVINEN H, 1994, LANCET, V343, P91, DOI 10.1016/S0140-6736(94)90821-4; 1987, MEASURING OBESITY CL	38	251	255	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					409	414		10.7326/0003-4819-122-6-199503150-00002	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856988				2022-12-01	WOS:A1995QM26600002
J	ACKAH, AN; COULIBALY, D; DIGBEU, H; DIALLO, K; VETTER, KM; COULIBALY, IM; GREENBERG, AE; DECOCK, KM				ACKAH, AN; COULIBALY, D; DIGBEU, H; DIALLO, K; VETTER, KM; COULIBALY, IM; GREENBERG, AE; DECOCK, KM			RESPONSE TO TREATMENT, MORTALITY, AND CD4 LYMPHOCYTE COUNTS IN HIV-INFECTED PERSONS WITH TUBERCULOSIS IN ABIDJAN, COTE-DIVOIRE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; HIV-1-INFECTED PATIENTS; PULMONARY TUBERCULOSIS; ZAIRE; KENYA; MORBIDITY; KINSHASA; NAIROBI; CITY	We examined the severity of immune deficiency in patients with HIV-associated tuberculosis in Cote d'Ivoire and assessed its effect on mortality and response to treatment. Consecutive patients attending a tuberculosis treatment in Abidjan with smear-positive pulmonary or diagnosed extrapulmonary tuberculosis were tested for HIV-1 and HIV-2 infections and had CD4 lymphocyte counts measured. Patients received standard short-course chemotherapy. Analysis of outcome (restricted to smear-positive tuberculosis patients) was done at 6 months. The 247 HIV-positive patients were significantly more likely than the 312 HIV-negative patients to have CD4 lymphocyte counts of less than 200/mu L (43% vs 1%; odds ratio 56.9; [95% CI 19.7-185.3]) and 200-499/mu L (39% vs 14%, odds ratio 3.8; [2.5-5.9]). HIV-positive patients, median CD4 lymphocyte in those with extrapulmonary tuberculosis (198/mu L; n=67) was lower, but not significantly so, than among those with pulmonary tuberculosis (257/mu L; n=180). Among 460 patients with pulmonary tuberculosis, the overall mortality rate was significantly higher in HIV-positive than HIV-negative persons (6% vs 0.4%; relative risk 17.1 [2.2-131.4]), and increased with the severity of immune deficiency; mortality rates in HIV-positive patients with CD4 counts of <200/mu L and 200-499/mu L were 10% and 4%, relative risk 27.6 (3.5-220.8); and 11.5 (1.2-109), respectively, compared to HIV-negatives. Among patients completing treatment, cure rates were similar in HIV-positive patients (93%) and HIV-negative patients (92%), and were not related to CD4 counts. Severity of immune deficiency was the major determinant of mortality in HIV-associated tuberculosis. Among people completing treatment, microbiological response was satisfactory irrespective of serological or immune status.	PROJET RETRO CI,ABIDJAN,COTE IVOIRE; CTR ANTITUBERCULEUX,ABIDJAN,COTE IVOIRE; EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	Emory University; Centers for Disease Control & Prevention - USA								BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1993, LANCET, V342, P437, DOI 10.1016/0140-6736(93)92853-L; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DJOMAND G, 1994, AIDS, V8, P843, DOI 10.1097/00002030-199406000-00019; DJOMAND G, 1993, 8TH INT C AIDS AFR 8; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; KASSIM S, 1993, 8TH INT C AIDS AFR 8; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LOUIE E, 1986, CHEST, V256, P362; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; POZNIAK A, 1992, 8 INT C AIDS 3 STD W; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; 1986, WHO WKLY EPIDEMIOL R, V61, P72	20	190	194	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					607	610		10.1016/S0140-6736(95)90519-7	http://dx.doi.org/10.1016/S0140-6736(95)90519-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898177				2022-12-01	WOS:A1995QM07500007
J	ALLANDER, T; GRUBER, A; NAGHAVI, M; BEYENE, A; SODERSTROM, T; BJORKHOLM, M; GRILLNER, L; PERSSON, MAA				ALLANDER, T; GRUBER, A; NAGHAVI, M; BEYENE, A; SODERSTROM, T; BJORKHOLM, M; GRILLNER, L; PERSSON, MAA			FREQUENT PATIENT-TO-PATIENT TRANSMISSION OF HEPATITIS-C VIRUS IN A HEMATOLOGY WARD	LANCET			English	Article							POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; NON-A; REGION; INFECTION; ANTIBODY; GENOME; RNA	Blood transfusion is a well-documented route of transmission of hepatitis C virus (HCV). However, a persisting high frequency of HCV infections was recorded in our haematology ward even after screening of blood donors had been introduced. We investigated the viral strains in 37 patients with haematological malignant diseases who had developed hepatitis C when treated in the ward during 1990-93. 17 of the patients acquired hepatitis C despite being transfused only with blood components screened by second-generation anti-HCV tests. The viral strains were characterised by PCR genotyping and nucleotide sequencing of the hypervariable region of the E2 gene. Five clusters of closely related or identical viruses were found involving 2, 3, 4, 6, and 15 patients, respectively. Blood components could be ruled out as the common source of infection because no donor had given blood to all patients sharing a specific strain, and even donors whose blood had been given to several patients were negative for HCV RNA. All patients in each cluster had been treated in the ward during overlapping periods. These findings suggest that despite strict hygienic control, HCV transmission occurred between patients treated in the same hospital setting, as has previously been reported in a smaller group of haemodialysis patients.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT MED,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT LAB MED,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital				Persson, Mats/0000-0002-5118-6584				ALLANDER T, 1994, J MED VIROL, V43, P415, DOI 10.1002/jmv.1890430417; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ARICO M, 1994, BLOOD, V84, P2919; CHANT K, 1994, NEW S WALES PUBLIC H, V5, P47; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FEUCHT HH, 1994, MICROBIOL IMMUNOL, V38, P157, DOI 10.1111/j.1348-0421.1994.tb01758.x; GRUBER A, 1993, ANN ONCOL, V4, P229, DOI 10.1093/oxfordjournals.annonc.a058462; HIGASHI Y, 1993, VIROLOGY, V197, P659, DOI 10.1006/viro.1993.1641; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; TAKAMATSU K, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93229-I; WIDELL A, 1994, J MED VIROL, V44, P272, DOI 10.1002/jmv.1890440311; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409	17	188	189	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					603	607		10.1016/S0140-6736(95)90518-9	http://dx.doi.org/10.1016/S0140-6736(95)90518-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898176				2022-12-01	WOS:A1995QM07500006
J	BARTON, JS; TRIPP, JH; MCNINCH, AW				BARTON, JS; TRIPP, JH; MCNINCH, AW			NEONATAL VITAMIN-K PROPHYLAXIS IN THE BRITISH-ISLES - CURRENT PRACTICE AND TRENDS	BRITISH MEDICAL JOURNAL			English	Article							HEMORRHAGIC-DISEASE; NEWBORN				BARTON, JS (corresponding author), ROYAL DEVON & EXETER HOSP,DEPT CHILD HLTH,EXETER EX2 5DW,DEVON,ENGLAND.							CHAMBERLAIN R, 1975, BRIT BIRTHS 1970, V1; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; 1992, VITAMIN K PROPHYLAXI	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					632	633		10.1136/bmj.310.6980.632	http://dx.doi.org/10.1136/bmj.310.6980.632			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703751	Green Published			2022-12-01	WOS:A1995QL98400017
J	BERN, C; NATHANAIL, L				BERN, C; NATHANAIL, L			IS MID-UPPER-ARM CIRCUMFERENCE A USEFUL TOOL FOR SCREENING IN EMERGENCY SETTINGS	LANCET			English	Article							CHILDREN	In refugee emergencies, rapid collection of nutritional data provides important information for public-health planning. In Rwandan refugee camps in eastern Zaire in August, 1994, a two-step procedure of screening for referral to supplementary feeding programmes was used-mid-upper-arm circumference (MUAC) followed by weight-for-height for children with MUAC of less than 12 cm. To assess the usefulness of this procedure, we analysed data from complete screening of 3681 children in three camps. The performance of MUAC varied with the cut-off chosen; a high cut-off of 14 cm allowed detection of 88% of children with low weight-for-height but at the cost of measuring more than 40% of children in the second step. MUAC preferentially selects younger children as malnourished, and misses older children with low weight-for-height. The groups of children chosen by low MUAC and by low weight-for-height have poor overlap, varying from 20% to 391 overlap depending on age. Thus two-step screening does not save as much time as might be expected and low MUAC cannot be used as a substitute for low weight-for-height. For decision-making in refugee settings, weight-for-height surveys or screening are probably more efficient strategies for data collection.	SAVE CHILDREN FUND,POLICY DEPT UNIT,LONDON,ENGLAND	Save the Children	BERN, C (corresponding author), CTR DIS CONTROL & PREVENT,DIV NUTR,MATERNAL & CHILD HLTH BRANCH,ATLANTA,GA 30341, USA.							[Anonymous], 1986, WEIGH MEASURE CHILDR; BRIEND A, 1986, BRIT MED J, V293, P373, DOI 10.1136/bmj.293.6543.373; DEONIS M, 1993, B WORLD HEALTH ORGAN, V71, P703; GAYLE HD, 1988, J TROP PEDIATRICS, V34, P213, DOI 10.1093/tropej/34.5.213; GOLAZ A, 1994, 43RD EP INT SERV ANN; HALL G, 1993, LANCET, V341, P1481, DOI 10.1016/0140-6736(93)90927-9; JELIFFE DB, 1969, J TROP PEDIATRICS, V15, P177; LINDTJORN B, 1985, LANCET, V2, P1229; REES DG, 1987, LANCET, V1, P87; YOUNG H, 1992, FOOD SCARCITY FAMINE; 1986, B WORLD HEALTH ORGAN, V64, P929; 1993, GUIDELINES SUPPLEMEN; IN PRESS REPORT EXPE; 1992, MMWR-MORBID MORTAL W, V41, P1	14	24	24	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					631	633		10.1016/S0140-6736(95)90527-8	http://dx.doi.org/10.1016/S0140-6736(95)90527-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898183				2022-12-01	WOS:A1995QM07500015
J	FRANCIS, CM; CARUANA, L; KEARNEY, P; LOVE, M; SUTHERLAND, GR; STARKEY, IR; SHAW, TRD; MCMURRAY, JJV				FRANCIS, CM; CARUANA, L; KEARNEY, P; LOVE, M; SUTHERLAND, GR; STARKEY, IR; SHAW, TRD; MCMURRAY, JJV			OPEN ACCESS ECHOCARDIOGRAPHY IN MANAGEMENT OF HEART-FAILURE IN THE COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article							GASTROSCOPY	Objective-To assess the value of an open access echocardiography service. Design-Study of new open access service for general practitioners, who were invited to refer who patients taking diuretics for suspected heart failure, untreated patients with symptoms of possible heart failure, and asymptomatic patients with risk factors for left ventricular systolic dysfunction. Setting-Regional cardiology centre. Subjects-259 consecutive patients. Main outcome measure-Presence or absence of left ventricular systolic dysfunction and consequent changes in clinical management. Results-119 treated patients, 99 untreated patients, and nine asymptomatic patients were referred over five months. 32 were considered to be inappropriately referred. Among the treated patients, 31 had impaired left ventricular systolic function and five had valvular disease; angiotensin converting enzyme inhibitors were recommended for 34 of these patients, In addition, 53 were thought not to need diuretics. Eight untreated patients had impaired systolic function and six valvular disease. Conclusions-The service was well used by general practitioners and led to advice to change management in more than two thirds of patients.	WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				ALBIN G, 1990, AM J CARDIOL, V65, P1031, DOI 10.1016/0002-9149(90)91009-U; BRAMBLE MG, 1993, GUT, V34, P422, DOI 10.1136/gut.34.3.422; CHOY AMJ, 1994, BRIT HEART J, V72, P16; CLARKE KW, 1994, BRIT HEART J, V71, P584; DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; DEJONGE JW, 1994, BMJ-BRIT MED J, V308, P511, DOI 10.1136/bmj.308.6927.511; GASSCH WH, 1994, JAMA-J AM MED ASSOC, V271, P1276; Hart W, 1993, BR J MED EC, V6, P91; KERRIGAN DD, 1990, BRIT MED J, V300, P374, DOI 10.1136/bmj.300.6721.374; MCCLEMENTS BM, 1994, BRIT HEART J, V71, P531; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; SUTTON MS, 1994, CIRCULATION, V89, P68, DOI 10.1161/01.CIR.89.1.68; THOMAS JD, 1991, CIRCULATION, V84, P977, DOI 10.1161/01.CIR.84.3.977; Vuille C., 1994, PRINCIPLES PRACTICE, P575; WHEELDON NM, 1993, Q J MED, V86, P17; ZERMANSKY A, 1993, BRIT MED J, V306, P1750, DOI 10.1136/bmj.306.6894.1750-b; 1991, NEW ENGL J MED, V325, P293; 1994, BRIT HEART J, V72, P303; 1992, NEW ENGL J MED, V327, P685	20	136	136	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					634	636		10.1136/bmj.310.6980.634	http://dx.doi.org/10.1136/bmj.310.6980.634			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7503841	Green Published			2022-12-01	WOS:A1995QL98400019
J	GILMAN, EA; CHENG, KK; WINTER, HR; SCRAGG, R				GILMAN, EA; CHENG, KK; WINTER, HR; SCRAGG, R			TRENDS IN RATES AND SEASONAL DISTRIBUTION OF SUDDEN INFANT DEATHS IN ENGLAND AND WALES, 1988-92	BRITISH MEDICAL JOURNAL			English	Article									UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland	GILMAN, EA (corresponding author), UNIV BIRMINGHAM,SCH MED,INST PUBL & ENVIRONM HLTH,DEPT EPIDEMIOL & PUBL HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Cheng, Kar/AAL-8899-2021	Cheng, Kar/0000-0002-1516-1857; Scragg, Robert/0000-0003-0013-2620				LITTLE RE, 1990, EPIDEMIOL REV, V12, P241, DOI 10.1093/oxfordjournals.epirev.a036057; MITCHELL EA, 1994, ARCH DIS CHILD, V76, P291; 1993, REPORT CHIEF MED OFF; 1993, DH3932 OPCS MON SER	4	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					631	632		10.1136/bmj.310.6980.631	http://dx.doi.org/10.1136/bmj.310.6980.631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703750	Green Published			2022-12-01	WOS:A1995QL98400016
J	KAUFMANN, M; HEIDER, KH; SINN, HP; VONMINCKWITZ, G; PONTA, H; HERRLICH, P				KAUFMANN, M; HEIDER, KH; SINN, HP; VONMINCKWITZ, G; PONTA, H; HERRLICH, P			CD44 VARIANT EXON EPITOPES IN PRIMARY BREAST-CANCER AND LENGTH OF SURVIVAL	LANCET			English	Article							METASTASIS-ASSOCIATED VARIANT; EXPRESSION; CARCINOMAS; AMPLIFICATION; ONCOGENE; HOMOLOG; RELAPSE	CD44 designates a group of closely related cell-surface proteins generated by alternative splicing. We have previously shown that splice variants carrying sequences encoded by exon v6 are preferentially expressed in metastatic animal cancer cell lines and that they confer metastatic behaviour on non-metastatic animal tumour cell lines. In this study we set out to assess the expression of CD44 epitopes specific for variant exon sequences in human breast cancer and their potential for determining prognosis. We used affinity-purified polyclonal sera and four monoclonal antibodies raised against the human homologues of CD44 variant exon sequences to investigate the presence of CD44 on 100 primary invasive breast tumours, 12 local recurrences, 18 lymph node metastases, and normal tissue controls. Whereas normal mammary ductal epithelial cells and cells derived from hyperplastic lesions do not express CD44 variant exons, expression of v3, v5, and v6 epitopes was found in most tumour samples. The Dill (exon v6) epitope was present in 84% of the primary tumours and in 100% of axillary lymph node metastases and local recurrences. The presence of these CD44 epitopes is correlated with poor overall survival. 15 patients with exon-v6-negative tumours had good survival compared with 76 patients with exon-v6-positive tumours (p=0.005; log rank test). Multivariate analysis showed that the CD44 epitope encoded by exon v6 was a good marker for prognosis independent of progesterone receptor, lymph node status, tumour size, and grade.	FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,KARLSRUHE,GERMANY; UNIV HEIDELBERG,DEPT PATHOL,D-69115 HEIDELBERG,GERMANY	Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg	KAUFMANN, M (corresponding author), UNIV HEIDELBERG,DEPT OBSTET & GYNAECOL,D-69115 HEIDELBERG,GERMANY.		Sinn, Hans-Peter/C-5661-2008	Sinn, Hans-Peter/0000-0003-2836-6699				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BERGER MS, 1988, CANCER RES, V48, P1238; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COX DR, 1972, J R STAT SOC B, V34, P187; DALL P, 1994, CANCER RES, V54, P3337; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HEIDER KH, 1993, CANCER RES, V53, P4197; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; Hermanek P, 1987, TNM CLASSIFICATION M; JOENSUU H, 1993, AM J PATHOL, V143, P867; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SAINSBURY JRC, 1987, LANCET, V1, P1398; SINN HP, IN PRESS BREAST CANC; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; VONMINCKWITZ G, 1994, BREAST, V2, P229; WIELENGA VJM, 1993, CANCER RES, V53, P4754	21	358	374	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					615	619		10.1016/S0140-6736(95)90521-9	http://dx.doi.org/10.1016/S0140-6736(95)90521-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7534855				2022-12-01	WOS:A1995QM07500009
J	MAGRATH, I				MAGRATH, I			BONE-MARROW TRANSPLANTATION FOR LEUKEMIA - A LAME STALKING HORSE FOR USE OF HIGH-TECHNOLOGY MEDICAL-CARE	LANCET			English	Editorial Material											MAGRATH, I (corresponding author), NIH, LYMPHOMA BIOL SECT, BETHESDA, MD 20892 USA.							DICKE KA, 1993, ANN ONCOL, V4, pS81, DOI 10.1093/annonc/4.suppl_1.S81; GORIN NC, 1993, ANN ONCOL, V4, pS59, DOI 10.1093/annonc/4.suppl_1.S59; HAIOUN C, 1994, J CLIN ONCOL, V12, P2543, DOI 10.1200/JCO.1994.12.12.2543; KANTARJIAN HM, 1993, BLOOD, V82, P691; SEBBAN C, 1994, J CLIN ONCOL, V12, P2580, DOI 10.1200/JCO.1994.12.12.2580; 1994, GAOPEMD9410 US GEN A	6	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 11	1995	345	8950					601	602		10.1016/S0140-6736(95)90516-2	http://dx.doi.org/10.1016/S0140-6736(95)90516-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898174				2022-12-01	WOS:A1995QM07500004
J	PEREZTRALLERO, E; MONTES, M; ALCORTA, M; ZUBILLAGA, P; TELLERIA, E				PEREZTRALLERO, E; MONTES, M; ALCORTA, M; ZUBILLAGA, P; TELLERIA, E			NON-ENDOSCOPIC METHOD TO OBTAIN HELICOBACTER-PYLORI FOR CULTURE	LANCET			English	Note								A sampling method to collect samples for Helicobacter pylori culture that is easier than endoscopy would be useful. We used a capsule attached to a highly absorbent nylon string, which is swallowed to obtain gastric secretions. Antral biopsy and string specimens, sequentially obtained from 36 adults with clinically suspected ulcer or gastric disease were cultured. 9 (25%) patients were negative in both tests; 18 (50%) were positive by both methods; 6 (17%) were biopsy positive and string-test negative; and 3 (8%) were biopsy negative and string-test positive. The new test is useful, simple, and causes little discomfort.	HOSP NS ARANZAZU,FAC MED,UNIDAD EPIDEMIOL INFECCIOSA,E-20080 SAN SEBASTIAN,SPAIN		PEREZTRALLERO, E (corresponding author), HOSP NS ARANZAZU,FAC MED,MICROBIOL SERV,E-20080 SAN SEBASTIAN,SPAIN.								0	43	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					622	623		10.1016/S0140-6736(95)90524-3	http://dx.doi.org/10.1016/S0140-6736(95)90524-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898181				2022-12-01	WOS:A1995QM07500012
J	PEYRAT, JP; BONNETERRE, J; LUBIN, R; VANLEMMENS, L; FOURNIER, J; SOUSSI, T				PEYRAT, JP; BONNETERRE, J; LUBIN, R; VANLEMMENS, L; FOURNIER, J; SOUSSI, T			PROGNOSTIC-SIGNIFICANCE OF CIRCULATING P53 ANTIBODIES IN PATIENTS UNDERGOING SURGERY FOR LOCOREGIONAL BREAST-CANCER	LANCET			English	Note							PROTEIN; EPITOPES	P53 mutations can lead to the production of P53 antibodies in serum of cancer patients. Here we studied the prognostic value of P53 antibodies in 353 primary breast cancer patients. P53 antibodies were detected in 42 cases (12%) and were negatively related to oestradiol and progesterone receptors. The median duration of follow-up for live patients was 5.3 years. In actuarial analyses, overall survival was worse in patients with P53 antibody (p<0.0005); in Cox's multivariate analysis, P53 antibody was an independent prognostic variable. Thus plasma assay of P53 antibody would be useful to select rapidly and easily a population of patients with poor prognosis.	CTR OSCAR LAMBRET,DEPT MED ONCOL,F-59020 LILLE,FRANCE; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE	UNICANCER; Centre Oscar Lambret; Institut National de la Sante et de la Recherche Medicale (Inserm)	PEYRAT, JP (corresponding author), CTR OSCAR LAMBRET,ONCOL MOLEC HUMAINE LAB,BP 307,F-59020 LILLE,FRANCE.			VANLEMMENS, LAURENCE/0000-0001-7799-1648; soussi, thierry/0000-0001-8184-3293				BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BONNETERRE J, 1990, CANCER RES, V50, P6931; CALLAHAN R, 1992, J NATL CANCER I, V84, P826, DOI 10.1093/jnci/84.11.826; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; LUBIN R, 1993, CANCER RES, V53, P5872; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845	9	141	142	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					621	622		10.1016/S0140-6736(95)90523-5	http://dx.doi.org/10.1016/S0140-6736(95)90523-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898180				2022-12-01	WOS:A1995QM07500011
J	ROWE, PC; BOUHOLAIGAH, I; KAN, JS; CALKINS, H				ROWE, PC; BOUHOLAIGAH, I; KAN, JS; CALKINS, H			NEURALLY-MEDIATED HYPOTENSION AN UNRECOGNIZED CAUSE OF CHRONIC FATIGUE	LANCET			English	Note							HEAD-UP TILT; UNEXPLAINED SYNCOPE	Neurally mediated hypotension is now recognised as a common cause of otherwise unexplained recurrent syncope, but has not been reported in association with chronic fatigue. We describe seven consecutive non-syncopal adolescents with chronic post-exertional fatigue, four of whom satisfied strict criteria for chronic fatigue syndrome. Upright tilt-table testing induced significant hypotension in all seven (median systolic blood pressure 65 mm Hg, range 37-75), consistent with the physiology of neurally mediated hypotension. Four had prompt improvement. in their chronic fatigue when treated with atenolol or disopyramide. These observations suggest an overlap in the symptoms of chronic fatigue syndrome and neurally mediated hypotension.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21287 USA	Johns Hopkins University	ROWE, PC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21287 USA.							ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; CALKINS H, IN PRESS AM J MED; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KAPOOR WN, 1994, AM J MED, V97, P78, DOI 10.1016/0002-9343(94)90051-5; KENNY RA, 1986, LANCET, V1, P1352; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; MANU P, 1993, CIBA F SYMP, V173, P23; ROSS BA, 1991, AM HEART J, V122, P748, DOI 10.1016/0002-8703(91)90521-I; RUBIN AM, 1993, AM HEART J, V125, P476, DOI 10.1016/0002-8703(93)90029-9; SCHONDORF R, 1993, NEUROLOGY, V43, P132, DOI 10.1212/WNL.43.1_Part_1.132	10	186	198	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 11	1995	345	8950					623	624		10.1016/S0140-6736(95)90525-1	http://dx.doi.org/10.1016/S0140-6736(95)90525-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898182	hybrid			2022-12-01	WOS:A1995QM07500013
J	RYAN, M				RYAN, M			RUSSIAN REPORT - ALCOHOLISM AND RISING MORTALITY IN THE RUSSIAN-FEDERATION	BRITISH MEDICAL JOURNAL			English	Article								In the Russian Federation today the high incidence of alcoholism and drunkenness helps to account for rising death rates, more particularly among the male population. During the mid-1980s a significant reduction in deaths from alcohol related diseases was achieved by state action in curtailing the supply of alcohol. However, official data disclose a pattern of sharply increased consumption per head since 1987, with high proof drinks-especially vodka-now forming a larger share in the total. In current economic conditions the effects of a traditional macho drinking culture are exacerbated by a reduction of state control over the quality of alcohol available for purchase. A substantial increase has occurred in deaths from most principal causes, with a disproportionate increase in deaths from non-natural causes, including deaths caused predominantly by alcohol. Average expectation of life at birth has fallen especially sharply for men; by 1993 it had slumped to 59.0 years-that is, to below the age at which a pension starts to be paid.			RYAN, M (corresponding author), UNIV COLL SWANSEA,CTR RUSSIAN & E EUROPEAN STUDIES,SWANSEA SA2 8PP,W GLAM,WALES.							NEMTSOV A, 1994, IZVESZIYA, P19; RYAN M, 1990, CONT SOVIET SOC STAT, P253; 1993, ROSSIISKIE VESTI, V255, P4; 1994, ZDRAVOOKHRANENIE ROS, V3, P3	4	63	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					646	648						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QL984	7703754				2022-12-01	WOS:A1995QL98400023
J	SMITH, CD; AIN, KB				SMITH, CD; AIN, KB			BRAIN METABOLISM IN HYPOTHYROIDISM STUDIED WITH P-31 MAGNETIC-RESONANCE SPECTROSCOPY	LANCET			English	Note							SKELETAL-MUSCLE	Metabolic consequences of hypothyroidism in adult human brain, despite neuropsychological symptoms, have not been reported. We used P-31 nuclear magnetic-resonance spectroscopy of the frontal lobe to examine the effect of acute hypothyroidism on cerebral metabolism. Paired analysis showed that the phosphocreatine/inorganic-phosphate (PCr/Pi) ratio increased from a median of 2.04 (interquartile range 0.15) to 2.22 (0.25) after treatment with levothyroxine (p=0.01). These reversible alterations in adult cerebral phosphate metabolism during acute hypothyroidism parallel PCr/Pi ratio changes described in skeletal muscle. This is the first direct evidence of cerebral metabolic effects of hypothyroidism on adult brain.	UNIV KENTUCKY,MED CTR,DEPT MAGNET RESONANCE IMAGING,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,CTR SPECT,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,DEPT INTERNAL MED,DIV ENDOCRINOL DIABET & METAB,LEXINGTON,KY 40536; VET ADM MED CTR,MED SERV,LEXINGTON,KY 40511	University of Kentucky; University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	SMITH, CD (corresponding author), UNIV KENTUCKY,MED CTR,DEPT NEUROL,LEXINGTON,KY 40536, USA.		Ain, Kenneth/A-5179-2012	Ain, Kenneth/0000-0002-2668-934X	NCI NIH HHS [1-R29-CA58935-01A1] Funding Source: Medline; NINDS NIH HHS [NSO1421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARGOV Z, 1988, J CLIN INVEST, V81, P1695, DOI 10.1172/JCI113508; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; KAMINSKY P, 1992, J CLIN ENDOCR METAB, V74, P124, DOI 10.1210/jc.74.1.124; OBRIEN MD, 1968, LANCET, V1, P1170; RADDA G, 1984, BIOCHEM SOC T, V14, P517; SCHEINBERG P, 1950, J CLIN INVEST, V29, P1139, DOI 10.1172/JCI102351; SENSENBACH W, 1954, J CLIN INVEST, V33, P1434, DOI 10.1172/JCI103021; TAYLOR DJ, 1992, EUR J CLIN INVEST, V22, P358, DOI 10.1111/j.1365-2362.1992.tb01474.x	8	35	35	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					619	620		10.1016/S0140-6736(95)90522-7	http://dx.doi.org/10.1016/S0140-6736(95)90522-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898179				2022-12-01	WOS:A1995QM07500010
J	VANDUIJN, CM; HAVEKES, LM; VAN BROECKHOVEN, C; DEKNIJFF, P; HOFMAN, A				VANDUIJN, CM; HAVEKES, LM; VAN BROECKHOVEN, C; DEKNIJFF, P; HOFMAN, A			APOLIPOPROTEIN-E GENOTYPE AND ASSOCIATION BETWEEN SMOKING AND EARLY-ONSET ALZHEIMERS-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARKINSONS-DISEASE; BINDING; DEMENTIA; ALLELE	Objective-To investigate the hypothesis that differential survival between smokers and nonsmokers leading to a decrease in the frequency of the e4 allele of the apolipoprotein E gene may explain the inverse relation between smoking history and early onset Alzheimer's disease. Design-A population based case-control study. Setting-The four northern provinces of the Netherlands and metropolitan Rotterdam. Subjects-175 patients with early onset Alzheimer's disease and two independent control groups of 159 and 457 subjects. Main outcome measures-Frequencies of the apolipoprotein e4 allele and relative risk of early onset Alzheimer's disease, Results-The inverse association between smoking history and early onset Alzheimer's disease could not be explained by a decrease in the frequency the apolipoprotein e4 allele, Among of this allele with a family history of dementia subjects with a history of smoking had a strongly reduced risk of early onset Alzheimer's disease (odds ratio 0.10 (95% confidence interval 0.01 to 0.87)). Conclusions-The results suggest that the inverse relation between smoking history and early onset Alzheimer's disease cannot be explained by an increased mortality in carriers of the apolipoprotein e4 allele who smoke, The association is strongly modified by the presence of the apolipoprotein e4 allele as well as by a family history of dementia.	TNO, INST PREVENT & HLTH RES, GAUBIUS LAB, LEIDEN, NETHERLANDS; UNIV ANTWERP, DEPT BIOCHEM, BORN BUNGE FDN, NEUROGENET LAB, B-2020 ANTWERP, BELGIUM	Netherlands Organization Applied Science Research; University of Antwerp	VANDUIJN, CM (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		de Knijff, Peter/Y-2519-2018; Van Broeckhoven, Christine/G-8362-2017; Van Broeckhoven, Christine/M-7853-2019	de Knijff, Peter/0000-0002-0899-771X; Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665				BENSHLOMO Y, 1993, LANCET, V342, P1239; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; BRESLOW NE, 1987, INT AGENCY RES CANCE, V82; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Elston RC, 1987, ESSENTIALS BIOSTATIS; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HAVEKES LM, 1987, J LIPID RES, V28, P455; HOFMAN A, 1989, NEUROLOGY, V39, P1589, DOI 10.1212/WNL.39.12.1589; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; LARRICK JW, 1993, LANCET, V342, P1238, DOI 10.1016/0140-6736(93)92219-J; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORENS DM, 1994, LANCET, V343, P356, DOI 10.1016/S0140-6736(94)91194-0; POIRIER I, 1994, P SPRINGF M ALZH DIS, P72; RIGGS JE, 1993, LANCET, V342, P793, DOI 10.1016/0140-6736(93)91547-Y; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	25	75	76	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	1995	310	6980					627	631		10.1136/bmj.310.6980.627	http://dx.doi.org/10.1136/bmj.310.6980.627			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703749	Green Published, Green Submitted			2022-12-01	WOS:A1995QL98400015
J	AYER, DE; LAWRENCE, QA; EISENMAN, RN				AYER, DE; LAWRENCE, QA; EISENMAN, RN			MAD-MAX TRANSCRIPTIONAL REPRESSION IS MEDIATED BY TERNARY COMPLEX-FORMATION WITH MAMMALIAN HOMOLOGS OF YEAST REPRESSOR SIN3	CELL			English	Article							THYROID-HORMONE RECEPTOR; SACCHAROMYCES-CEREVISIAE; C-MYC; GENE-PRODUCT; PROTEIN; ACTIVATION; INTERACTS; HO; DIMERIZATION; EXPRESSION	The bHLH-ZIP protein Mad heterodimerizes with Max as a sequence-specific transcriptional repressor. Mad is rapidly induced upon differentiation, and the associated switch from Myc-Max to Mad-Max heterocomplexes seem to repress genes normally activated by Myc-Max. We have identified two related mammalian cDNAs that encode Mad-binding proteins. Both possess sequence homology with the yeast transcription repressor Sin3, including four conserved paired amphipathic helix (PAH) domains. mSin3A and mSin3B bind specifically to Mad and the related protein Mxi1. Mad-Max and mSin3 form ternary complexes in solution that specifically recognize the Mad-Max E box-binding site. Mad-mSin3 association requires PAHS of mSin3A/mSin3B and the first 25 residues of Mad, which contains a putative amphipathic alpha-helical region. Point mutations in this region eliminate interaction with mSin3 proteins and block Mad transcriptional repression. We suggest that Mad-Max represses transcription by tethering mSin3 to DNA as corepressors and that a transcriptional repression mechanism is conserved from yeast to mammals.			AYER, DE (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,ROOM A2-025,SEATTLE,WA 98104, USA.			Ayer, Donald/0000-0002-5595-3269	NCI NIH HHS [R01 CA57138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AUBLE DT, 1994, IN PRESS GENES DEV, V8; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENIKOFF S, 1987, GENETICS, V117, P711; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUDAK KA, 1994, GENETICS, V136, P475; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRICH R, 1989, P NATL ACAD SCI USA, V88, P10018; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VIDAL M, 1990, GENETICS, V125, P313; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HM, 1994, MOL GEN GENET, V245, P675, DOI 10.1007/BF00297274; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WANG HM, 1990, P NATL ACAD SCI USA, V87, P9761, DOI 10.1073/pnas.87.24.9761; WEINBERG RA, 1992, SCIENCE, V254, P1138; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YOSHIMOTO H, 1992, MOL GEN GENET, V233, P327, DOI 10.1007/BF00587597; ZAWEL L, 1992, CURR OPIN CELL BIOL, V4, P448; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, CELL, V79	61	530	538	1	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					767	776		10.1016/0092-8674(95)90355-0	http://dx.doi.org/10.1016/0092-8674(95)90355-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889570	Bronze			2022-12-01	WOS:A1995QM39900013
J	BLUNT, T; FINNIE, NJ; TACCIOLI, GE; SMITH, GCM; DEMENGEOT, J; GOTTLIEB, TM; MIZUTA, R; VARGHESE, AJ; ALT, FW; JEGGO, PA; JACKSON, SP				BLUNT, T; FINNIE, NJ; TACCIOLI, GE; SMITH, GCM; DEMENGEOT, J; GOTTLIEB, TM; MIZUTA, R; VARGHESE, AJ; ALT, FW; JEGGO, PA; JACKSON, SP			DEFECTIVE DNA-DEPENDENT PROTEIN-KINASE ACTIVITY IS LINKED TO V(D)J RECOMBINATION AND DNA-REPAIR DEFECTS ASSOCIATED WITH THE MURINE SCID MUTATION	CELL			English	Article							STRAND BREAK REPAIR; COMBINED IMMUNE-DEFICIENCY; RAY SENSITIVE MUTANTS; HAMSTER OVARY CELLS; RNA POLYMERASE-II; TRANSCRIPTION FACTORS; JUNCTIONAL SEQUENCES; IONIZING-RADIATION; HUMAN CHROMOSOME-8; RECEPTOR GAMMA	Murine cells homozygous for the severe combined immune deficiency mutation (scid) and V3 mutant hamster cells fall into the same complementation group and show similar defects in V(D)J recombination and DNA double-stranded break repair. Here we show that both cell types lack DNA-dependent protein kinase (DNA-PK) activity owing to defects in DNA-PKcs, the catalytic subunit of this enzyme. Furthermore, we demonstrate that yeast artificial chromosomes containing the DNA-PKcs, gene complement both the DNA repair and recombination deficiencies of V3 cells, and we conclude that DNA-PKcs, is encoded by the XRCC7 gene. As DNA-PK binds to DNA ends and is activated by these structures, our findings provide novel insights into V(D)J recombination and DNA repair processes.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND; HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT GENET,BOSTON,MA 02115; ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	University of Cambridge; University of Sussex; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto	BLUNT, T (corresponding author), UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Dry, Kate/I-2328-2014; demengeot, jocelyne/K-8072-2014; Jackson, Stephen Philip/R-4548-2019	demengeot, jocelyne/0000-0002-4761-614X; Jackson, Stephen Philip/0000-0001-9317-7937	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, R01AI020047, P01AI035714] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20047, AI-35714-01] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ANAND R, 1990, NUCLEIC ACIDS RES, V8, P1951; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BANGA SS, 1994, MUTAT RES-DNA REPAIR, V315, P239, DOI 10.1016/0921-8777(94)90035-3; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL KT, 1988, ANNU REV GENET, V23, P630; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GOTLIEB TM, 1994, TRENDS BIOCHEM SCI, V19, P500; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; ITOH M, 1993, RADIAT RES, V134, P364, DOI 10.2307/3578198; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1985, MUTAT RES, V145, P171, DOI 10.1016/0167-8817(85)90024-0; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KOMATSU K, 1993, HUM MOL GENET, V7, P1031; KUHN A, 1995, GENE DEV, V9, P198; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; MOMBAERT P, 1992, CELL, V68, P867; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TACCIOLI GE, 1994, J BIOL CHEM, V269, P4739; WEIBEZAHN KF, 1985, MUTAT RES, V145, P177, DOI 10.1016/0167-8817(85)90025-2; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881	54	758	770	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					813	823		10.1016/0092-8674(95)90360-7	http://dx.doi.org/10.1016/0092-8674(95)90360-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889575	Bronze			2022-12-01	WOS:A1995QM39900018
J	BROWN, K; GERSTBERGER, S; CARLSON, L; FRANZOSO, G; SIEBENLIST, U				BROWN, K; GERSTBERGER, S; CARLSON, L; FRANZOSO, G; SIEBENLIST, U			CENTRAL OF I-KAPPA-B-ALPHA PROTEOLYSIS BY SITE-SPECIFIC, SIGNAL-INDUCED PHOSPHORYLATION	SCIENCE			English	Article							ONCOPROTEIN BCL-3; INHIBITION; PROTEINS; COMMON	I kappa B-alpha inhibits transcription factor NF-kappa B by retaining it in the cytoplasm. Various stimuli, typically those associated with stress or pathogens, rapidly inactivate I kappa B-alpha. This liberates NF-kappa B to translocate to the nucleus and initiate transcription of genes important for the defense of the organism. Activation of NF-kappa B correlates with phosphorylation of I kappa B-alpha and requires the proteolysis of this inhibitor. When either serine-32 or serine-36 of I kappa B-alpha was mutated, the protein did not undergo signal-induced phosphorylation or degradation, and NF-kappa B could not be activated. These results suggest that phosphorylation at one or both of these residues is critical for activation of NF-kappa B.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Franzoso, Guido/GRR-8628-2022	Franzoso, Guido/0000-0002-0778-988X				BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWN KS, UNPUB; DEMARTIN R, 1994, EMBO J, V12, P2773; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x	19	1323	1364	1	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1485	1488		10.1126/science.7878466	http://dx.doi.org/10.1126/science.7878466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878466				2022-12-01	WOS:A1995QL49700034
J	CHAN, MK; MUKUND, S; KLETZIN, A; ADAMS, MWW; REES, DC				CHAN, MK; MUKUND, S; KLETZIN, A; ADAMS, MWW; REES, DC			STRUCTURE OF A HYPERTHERMOPHILIC TUNGSTOPTERIN ENZYME, ALDEHYDE FERREDOXIN OXIDOREDUCTASE	SCIENCE			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; ARCHAEBACTERIUM PYROCOCCUS-FURIOSUS; IRON-SULFUR PROTEIN; MOLYBDENUM COFACTOR; MACROMOLECULAR CRYSTALLOGRAPHY; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HEAT-STABILITY; ALPHA-HELICES; TUNGSTEN; CRYSTAL	The crystal structure of the tungsten-containing aldehyde ferredoxin oxidoreductase (AOR) from Pyrococcus furiosus, a hyperthermophilic archaeon (formerly archaebacterium) that grows optimally at 100 degrees C, has been determined at 2.3 angstrom resolution by means of multiple isomorphous replacement and multiple crystal form averaging. AOR consists of two identical subunits, each containing an Fe4S4 cluster and a molybdopterin-based tungsten cofactor that is analogous to the molybdenum cofactor found in a large class of oxotransferases. Whereas the general features of the tungsten coordination in this cofactor were consistent with a previously proposed structure, each AOR subunit unexpectedly contained two molybdopterin molecules that coordinate a tungsten by a total of four sulfur ligands, and the pterin system was modified by an intramolecular cyclization that generated a three-ringed structure. In comparison to other proteins, the hyperthermophilic enzyme AOR has a relatively small solvent-exposed surface area, and a relatively large number of both ion pairs and buried atoms. These properties may contribute to the extreme thermostability of this enzyme.	CALTECH, DIV CHEM & CHEM ENGN 14775CH, PASADENA, CA 91125 USA; UNIV GEORGIA, CTR METALLOENZYME STUDIES, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA	California Institute of Technology; University System of Georgia; University of Georgia			Kletzin, Arnulf/AAO-7366-2020	Kletzin, Arnulf/0000-0002-4500-2232; Adams, Michael/0000-0002-9796-5014	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050775, F32GM015006] Funding Source: NIH RePORTER; NIGMS NIH HHS [1F32 GM15006, GM50775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams M.W.W., 1994, ENCY INORGANIC CHEM, P4284; ADAMS MWW, 1992, ACS SYM SER, V498, P1; ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1016/0168-6445(94)90117-1; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BEGUM NS, 1992, POLYHEDRON, V11, P2823; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; CONN JF, 1974, J AM CHEM SOC, V96, P7152, DOI 10.1021/ja00829a081; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DAVIES GJ, 1993, PROTEINS, V15, P283, DOI 10.1002/prot.340150306; DAY MW, 1992, PROTEIN SCI, V1, P1494, DOI 10.1002/pro.5560011111; ENERNARK JH, 1994, ADV INORG CHEM, V40, P1; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; HOLM RH, 1990, COORDIN CHEM REV, V100, P183, DOI 10.1016/0010-8545(90)85010-P; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JOHNSON JL, 1993, J BIOL CHEM, V268, P4848; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1991, FEMS MICROBIOL LETT, V77, P213; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARRASCH M, 1990, FEBS LETT, V274, P48, DOI 10.1016/0014-5793(90)81326-J; KENDRICK MJ, 1992, METALS BIOL SYSTEMS; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KLETZIN A, UNPUB; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1994, P NATL ACAD SCI USA, V91, P423, DOI 10.1073/pnas.91.1.423; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; MUKUND S, 1993, J BIOL CHEM, V268, P13592; MUKUND S, UNPUB; PERUTZ MF, 1975, NATURE, V255, P256, DOI 10.1038/255256a0; PERUTZ MF, 1978, SCIENCE, V201, P1187, DOI 10.1126/science.694508; Pilato R. S., 1993, BIOINORGANIC CATALYS, P131; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; REES DC, UNPUB; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; SOYKA R, 1990, HELV CHIM ACTA, V73, P808, DOI 10.1002/hlca.19900730407; STEIFEL EI, 1993, ACS SYM SER, V535, P1; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1016/0378-1097(90)90526-V; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALKER JE, 1980, EUR J BIOCHEM, V108, P581, DOI 10.1111/j.1432-1033.1980.tb04753.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007	72	529	547	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1463	1469		10.1126/science.7878465	http://dx.doi.org/10.1126/science.7878465			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878465				2022-12-01	WOS:A1995QL49700027
J	CHENG, GH; CLEARY, AM; YE, ZS; HONG, DI; LEDERMAN, S; BALTIMORE, D				CHENG, GH; CLEARY, AM; YE, ZS; HONG, DI; LEDERMAN, S; BALTIMORE, D			INVOLVEMENT OF CRAF1, A RELATIVE OF TRAF, IN CD40 SIGNALING	SCIENCE			English	Article							FOLLICULAR DENDRITIC CELLS; X-LINKED IMMUNODEFICIENCY; HYPER-IGM SYNDROME; B-CELLS; T-CELLS; ACTIVATION MOLECULE; LYMPHOCYTES-B; LIGAND; ANTIGEN; EXPRESSION	CD40 is a receptor on the surface of B lymphocytes, the activation of which leads to B cell survival, growth, and differentiation. A yeast two-hybrid screen identified a gene, CRAF1, encoding a protein that interacts directly with the CD40 cytoplasmic tail through a region of similarity to the tumor necrosis factor-alpha (TNF-alpha) receptor-associated factors. Overexpression of a truncated CRAF1 gene inhibited CD40-mediated up-regulation of CD23. A region of CRAF1 was similar to the TNF-alpha receptor-associated factors TRAF1 and TRAF2 and so defined a shared TRAF-C domain that was necessary and sufficient for CD40 binding and homodimerization. The CRAF1 sequence also predicted a long amphipathic helix, a pattern of five zinc fingers, and a zinc ring finger. It is likely that other members of the TNF receptor superfamily use CRAF-related proteins in their signal transduction processes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Columbia University; Rockefeller University				Lederman, Seth/0000-0003-2781-1455	NATIONAL CANCER INSTITUTE [R01CA055713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA55713] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07367] Funding Source: Medline; PHS HHS [A122346] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BERBERICH I, 1994, J IMMUNOL, V15, P4357; CALLARD RE, 1994, J IMMUNOL, V153, P3295; CHENG G, UNPUB; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1992, J IMMUNOL, V148, P3327; CLEARY AM, UNPUB; CRAWFORD DH, 1993, IMMUNOLOGY, V80, P40; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURIE FH, 1994, IMMUNOL TODAY, V15, P406, DOI 10.1016/0167-5699(94)90269-0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FREMONT PS, 1991, CELL, V64, P483; GALY AHM, 1992, J IMMUNOL, V149, P775; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GORDON J, 1988, J IMMUNOL, V140, P1425; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRILLI M, 1991, INT REV CYTOL, V143, P1; GRUBER MF, 1989, J IMMUNOL, V142, P4144; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HU HM, 1994, J BIOL CHEM, V269, P30069; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; Miller JH., 1972, EXPT MOL GENETICS; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PARRY SL, 1994, J IMMUNOL, V152, P2821; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; RAMESH N, 1993, INT IMMUNOL, V5, P769, DOI 10.1093/intimm/5.7.769; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; SIEGEL JP, 1990, J IMMUNOL METHODS, V132, P287, DOI 10.1016/0022-1759(90)90040-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TARAGLIS LA, 1993, CELL, V74, P845; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YELLIN MJ, 1994, J IMMUNOL, V153, P666	51	432	457	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1494	1498		10.1126/science.7533327	http://dx.doi.org/10.1126/science.7533327			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7533327				2022-12-01	WOS:A1995QL49700037
J	COHN, MJ; IZPISUABELMONTE, JC; ABUD, H; HEATH, JK; TICKLE, C				COHN, MJ; IZPISUABELMONTE, JC; ABUD, H; HEATH, JK; TICKLE, C			FIBROBLAST GROWTH-FACTORS INDUCE ADDITIONAL LIMB DEVELOPMENT FROM THE FLANK OF CHICK-EMBRYOS	CELL			English	Article							APICAL ECTODERMAL RIDGE; POLARIZING ACTIVITY; EXPRESSION; RECEPTOR; BUD; MOUSE; CELLS; LOCALIZATION; GENES; FGF-4	Fibroblast growth factors (FGFs) act as signals in the developing limb and can maintain proliferation of limb bud mesenchyme cells. Remarkably, beads soaked in FGF-1, FGF-2, or FGF-4 and placed in the presumptive flank of chick embryos induce formation of ectopic limb buds, which can develop into complete limbs. The entire flank can produce additional limbs, but generally wings are formed anteriorly and legs posteriorly. FGF application activates Sonic hedgehog in cells with polarizing potential to make a discrete polarizing region. Hoxd-13 is also expressed in the ectopic bud, and an apical ectodermal ridge forms. A limb bud is thus established that can generate the appropriate signals to develop into a complete limb. The additional limbs have reversed polarity. This can be explained by the distribution of cells in the flank with potential polarizing activity. The results suggest that local production of an FGF may initiate limb development.	SALK INST BIOL STUDIES,GENE EXPRESS LABS,LA JOLLA,CA 92037; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	Salk Institute; University of Oxford; University of Birmingham	COHN, MJ (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DB,ENGLAND.			Abud, Helen/0000-0003-3792-4023	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; Balinsky B. I., 1933, ROUXS ARCH, V130, P704; BALINSKY BI, 1925, ROUX ARCH DEV BIOL, V143, P718; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CROSSLEY PH, 1995, IN PRESS DEVELOPMENT; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; IZPISUABELMONTE JC, 1992, DEVELOPMENT, V115, P553; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIORTSIS VASSILI, 1953, REV SUISSE ZOOL, V60, P301; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LOCATELLI P, 1924, B SOC MED CHIR PA, P36; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MESCHER AL, 1979, J EXP ZOOL, V207, P497, DOI 10.1002/jez.1402070318; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOLVEN A, 1990, DEVELOPMENT, V109, P279; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; OLIVER G, 1988, CELL, V55, P1017, DOI 10.1016/0092-8674(88)90246-2; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PETERS KG, 1992, DEVELOPMENT, V114, P233; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; SEARLS RL, 1964, DEV BIOL, V9, P35; SUMMERBELL D, 1973, NATURE, V224, P492; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; THOMAS KA, 1993, NEUROTROPHIC FACTORS, P285; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	48	484	491	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					739	746		10.1016/0092-8674(95)90352-6	http://dx.doi.org/10.1016/0092-8674(95)90352-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889567	Bronze			2022-12-01	WOS:A1995QM39900010
J	CURRAN, ME; SPLAWSKI, I; TIMOTHY, KW; VINCENT, GM; GREEN, ED; KEATING, MT				CURRAN, ME; SPLAWSKI, I; TIMOTHY, KW; VINCENT, GM; GREEN, ED; KEATING, MT			A MOLECULAR-BASIS FOR CARDIAC-ARRHYTHMIA - HERG MUTATIONS CAUSE LONG QT SYNDROME	CELL			English	Article							EARLY AFTERDEPOLARIZATIONS; GENE; DNA; LINKAGE; IDENTIFICATION; HETEROGENEITY; FRAGMENTS; CHANNEL; LOCUS; DEATH	To identify genes involved in cardiac arrhythmia, we investigated patients with long QT syndrome (LQT), an inherited disorder causing sudden death from a ventricular tachyarrhythmia, torsade de pointes. We previously mapped LQT loci on chromosomes 11 (LQT1), 7(LQT2), and 3(LQT3). Here, linkage and physical mapping place LQT2 and a putative potassium channel gene, HERG, on chromosome 7q35-36. Single strand conformation polymorphism and DNA sequence analyses reveal HERG mutations in six LQT families, including two intragenic deletions, one splice-donor mutation, and three missense mutations. In one kindred, the mutation arose de novo. Northern blot analyses show that HERG is strongly expressed in the heart. These data indicate that HERG is LQT2 and suggest a likely cellular mechanism for torsade de pointes.	UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DIV CARDIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; LATTER DAY ST HOSP,DEPT MED,SALT LAKE CITY,UT 84037; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	CURRAN, ME (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.				NCRR NIH HHS [MO1-RR00064] Funding Source: Medline; NHLBI NIH HHS [R01-HL 48074] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BENHORIN J, 1993, SCIENCE, V260, P1960, DOI 10.1126/science.8316839; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; CURRAN M, 1993, J CLIN INVEST, V92, P799, DOI 10.1172/JCI116653; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; GREEN ED, 1995, IN PRESS GENOMICS; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; JANUARY CT, 1989, CIRC RES, V64, P977, DOI 10.1161/01.RES.64.5.977; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MARCHUK D, 1990, NUCLEIC ACIDS RES, V19, P1154; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PTACEK LJ, 1991, CELL, V67, P1021; ROMANO C, 1965, LANCET, V1, P658; ROY N, 1994, NAT GENET, V8, P113, DOI 10.1038/ng1094-113; Schwartz PJ, 1995, CARDIAC ELECTROPHYSI, P788; SCHWARTZ PJ, 1975, AM HEART J, V109, P378; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; SURAWICZ B, 1989, J AM COLL CARDIOL, V14, P172, DOI 10.1016/0735-1097(89)90069-7; TOWBIN JA, 1994, CIRCULATION, V90, P2635, DOI 10.1161/01.CIR.90.6.2635; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WARD O C, 1964, J Ir Med Assoc, V54, P103; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7	38	1815	1888	0	86	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					795	803		10.1016/0092-8674(95)90358-5	http://dx.doi.org/10.1016/0092-8674(95)90358-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889573	Bronze			2022-12-01	WOS:A1995QM39900016
J	HIOM, K; WEST, SC				HIOM, K; WEST, SC			BRANCH MIGRATION DURING HOMOLOGOUS RECOMBINATION - ASSEMBLY OF A RUVAB-HOLLIDAY JUNCTION COMPLEX IN-VITRO	CELL			English	Article							ESCHERICHIA-COLI RUVA; DNA-REPAIR; PHYSICAL-PROPERTIES; PROTEINS; PURIFICATION; GENES	The RuvA and RuvB proteins of E. coli promote the branch migration or movement of Holliday junctions during genetic recombination and DNA repair. Using small synthetic Holliday junctions in which the crossover point is confined near one end of the DNA molecule, we show that RuvAB-mediated branch migration occurs with a defined polarity. The assembly of RuvA and RuvB on the Holliday junction has been investigated by sedimentation analysis and by DNase I footprinting. We find that RuvA protein binds and protects all four strands of DNA at the crossover point, whereas RuvB protein binds the DNA asymmetrically. The polarity of branch migration is defined by the asymmetric assembly of the RuvAB branch migration complex relative to the junction and is consistent with a model in which RuvAB drives branch migration by passing the DNA through the hexameric rings of RuvB.			HIOM, K (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			West, Stephen/0000-0001-8848-9418				BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; MURCHIE AIH, 1990, NUCLEIC ACIDS RES, V18, P2599, DOI 10.1093/nar/18.9.2599; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SAMBROOK E, 1989, MOL CLONING LABORATO; SARGENTINI NJ, 1989, MUTAT RES, V215, P115, DOI 10.1016/0027-5107(89)90224-8; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1994, J BIOL CHEM, V269, P26552; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315	26	68	69	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					787	793		10.1016/0092-8674(95)90357-7	http://dx.doi.org/10.1016/0092-8674(95)90357-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889572	Bronze			2022-12-01	WOS:A1995QM39900015
J	JEFFREY, PD; GORINA, S; PAVLETICH, NP				JEFFREY, PD; GORINA, S; PAVLETICH, NP			CRYSTAL-STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE P53 TUMOR-SUPPRESSOR AT 1.7 ANGSTROMS	SCIENCE			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; DNA-BINDING; MUTANT P53; GENE AMPLIFICATION; PROTEIN; TRANSCRIPTION; SEQUENCE; IDENTIFICATION; REFINEMENT	The p53 protein is a tetrameric transcription factor that plays a central role in the prevention of neoplastic transformation. Oligomerization appears to be essential for the tumor suppressing activity of p53 because oligomerization-deficient p53 mutants cannot suppress the growth of carcinoma cell lines. The crystal structure of the tetramerization domain of p53 (residues 325 to 356) was determined at 1.7 angstrom resolution and refined to a crystallographic R factor of 19.2 percent. The monomer, which consists of a beta strand and an alpha helix, associates with a second monomer across an antiparallel beta sheet and an antiparallel helix-helix interface to form a dimer. Two of these dimers associate across a second and distinct parallel helix-helix interface to form the tetramer.			JEFFREY, PD (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021, USA.			Jeffrey, Philip/0000-0002-4351-5341	NCI NIH HHS [CA08748-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR V3 1 MANUAL; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P273; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREENBLATT MS, 1994, DATABASE P53 MUTATIO; HALVEY O, 1990, SCIENCE, V250, P113; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	51	433	454	0	24	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1498	1502		10.1126/science.7878469	http://dx.doi.org/10.1126/science.7878469			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878469				2022-12-01	WOS:A1995QL49700038
J	KIRCHNER, J; CONNOLLY, CM; SANDMEYER, SB				KIRCHNER, J; CONNOLLY, CM; SANDMEYER, SB			REQUIREMENT OF RNA-POLYMERASE-III TRANSCRIPTION FACTORS FOR IN-VITRO POSITION-SPECIFIC INTEGRATION OF A RETROVIRUS-LIKE ELEMENT	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TY1 TRANSPOSITION; DNA; INVITRO; GENES; SEQUENCE; REGION; ENDONUCLEASE; NONRANDOM; HOTSPOTS	The yeast retroviruslike element Ty3 inserts at the transcription initiation sites of genes transcribed by RNA polymerase III (Pol III). An in vitro integration assay was developed with the use of Ty3 viruslike particles and a modified SUP2 tyrosine transfer RNA (tRNA(Tyr)) gene target. Integration was position-specific and required Ty3 integrase, Pol III transcription extract, and a transcriptionally competent tRNA gene. Use of individual transcription factor (TF) IIIB-, TFIIIC-, and Pol III-containing fractions showed that TFIIIB and TFIIIC, together, were sufficient for position-specific Ty3 integration, but not for transcription. This report demonstrates that in vitro integration of a retroelement can be targeted by cellular proteins.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					PHS HHS [33281] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLISON DS, 1983, CELL, V34, P655, DOI 10.1016/0092-8674(83)90398-7; BAKER RE, 1986, J BIOL CHEM, V261, P5275; CANNON PM, 1994, J VIROL, V68, P4768, DOI 10.1128/JVI.68.8.4768-4775.1994; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHALKER DL, 1990, GENETICS, V126, P837; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; EIBEL H, 1984, NATURE, V307, P386, DOI 10.1038/307386a0; ENGLEMAN A, 1992, J VIROL, V66, P6361; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1994, RNA POLYM, V3, pCH5; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; JI H, 1993, CELL, V73, P1007, DOI 10.1016/0092-8674(93)90278-X; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KIRCHNER J, 1993, J VIROL, V67, P19, DOI 10.1128/JVI.67.1.19-28.1993; Kirchner J., UNPUB; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LIEBMAN SW, 1993, GENETICS, V133, P499; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; MILOT E, 1994, VIROLOGY, V201, P408, DOI 10.1006/viro.1994.1310; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; NATSOULIS G, 1989, GENETICS, V123, P269; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SHIN CG, 1994, J VIROL, V68, P1633, DOI 10.1128/JVI.68.3.1633-1642.1994; TADDEO B, 1994, J VIROL, V68, P8401, DOI 10.1128/JVI.68.12.8401-8405.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; WIKERCHEN M, 1995, J VIROL, V69, P376; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473	37	182	188	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1488	1491		10.1126/science.7878467	http://dx.doi.org/10.1126/science.7878467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878467	Green Submitted			2022-12-01	WOS:A1995QL49700035
J	KLINGMULLER, U; LORENZ, U; CANTLEY, LC; NEEL, BG; LODISH, HF				KLINGMULLER, U; LORENZ, U; CANTLEY, LC; NEEL, BG; LODISH, HF			SPECIFIC RECRUITMENT OF SH-PTP1 TO THE ERYTHROPOIETIN RECEPTOR CAUSES INACTIVATION OF JAK2 AND TERMINATION OF PROLIFERATIVE SIGNALS	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MOTH-EATEN; KINASE; PHOSPHORYLATION; DOMAIN; CELLS; SH2; DIFFERENTIATION; TRANSDUCTION; SUPERFAMILY	The binding of erythropoietin (EPO) to its receptor (EPO-R) activates the protein tyrosine kinase JAK2. The mechanism of JAK2 inactivation has been unclear. We show that the hematopoietic protein tyrosine phosphatase SH-PTP1 (also called HCP and PTP1C) associates via its SH2 domains with the tyrosine-phosphorylated EPO-R. In vitro binding studies suggest that Y429 in the cytoplasmic domain of the EPO-R is the binding site for SH-PTP1. Mutant EPO-Rs lacking Y429 are unable to bind SH-PTP1; cells expressing such mutants are hypersensitive to EPO and display prolonged EPO-induced autophosphorylation of JAK2. Our results suggest that activation of SH-PTP1 by binding to the EPO-R plays a major role in terminating proliferative signals.	BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02215 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	KLINGMULLER, U (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Klingmüller, Ursula/G-8477-2013; Cantley, Lewis C/D-1800-2014	Klingmüller, Ursula/0000-0001-9845-3099; Cantley, Lewis C/0000-0002-1298-7653; Lorenz, Ulrike/0000-0002-7933-6855	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASE RD, 1994, J BIOL CHEM, V269, P10467; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.iy.10.040192.001455; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANZANT G, 1989, EXP HEMATOL, V17, P81; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	842	870	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					729	738		10.1016/0092-8674(95)90351-8	http://dx.doi.org/10.1016/0092-8674(95)90351-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889566	Bronze			2022-12-01	WOS:A1995QM39900009
J	KUCHROO, VK; DAS, MP; BROWN, JA; RANGER, AM; ZAMVIL, SS; SOBEL, RA; WEINER, HL; NABAVI, N; GLIMCHER, LH				KUCHROO, VK; DAS, MP; BROWN, JA; RANGER, AM; ZAMVIL, SS; SOBEL, RA; WEINER, HL; NABAVI, N; GLIMCHER, LH			B7-1 AND B7-2 COSTIMULATORY MOLECULES ACTIVATE DIFFERENTIALLY THE TH1/TH2 DEVELOPMENTAL PATHWAYS - APPLICATION TO AUTOIMMUNE-DISEASE THERAPY	CELL			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN PROTEOLIPID PROTEIN; CTLA-4 COUNTER-RECEPTOR; CELL ACTIVATION; BASIC-PROTEIN; LYMPHOCYTE-T; EXPRESSION; CD28; MICE; IDENTIFICATION	CD4 T helper precursor cells mature along two alternative pathways, Th1 and Th2. Here we show that these pathways are differentially activated by two costimulatory molecules, B7-1 and B7-2. Using anti-B7 antibodies, this developmental step was manipulated both in vitro and in vivo in experimental allergic encephalomyelitis (EAE). Anti-B7-1 reduced the incidence of disease while anti-B7-2 increased disease severity. Neither antibody affected overall T cell induction but rather altered cytokine profile. Administration of anti-B7-1 at immunization resulted in predominant generation of Th2 clones whose transfer both prevented induction of EAE and abrogated established disease. Since cotreatment with anti-IL-4 antibody prevented disease amelioration, costimulatory molecules may directly affect initial cytokine secretion. Thus, interaction of B7-1 and B7-2 with shared counterreceptors CD28 and CTLA-4 results in very different outcomes in clinical disease by influencing commitment of precursors to a Th1 or Th2 lineage.	BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; STANFORD UNIV,SCH MED,DEPT PATHOL,PALO ALTO,CA 94304; VET AFFAIRS MED CTR,LAB SERV,PALO ALTO,CA 94304; HOFFMANN LA ROCHE INC,RES CTR,DEPT INFLAMMAT & AUTOIMMUNE DIS,NUTLEY,NJ 07110	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Roche Holding	KUCHROO, VK (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.			Sobel, Raymond/0000-0002-0477-9002	NIAID NIH HHS [AI-21569] Funding Source: Medline; NINDS NIH HHS [NS-26773, NS-30843] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021569, R37AI021569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS030843, R01NS026773, R29NS030843, R01NS030843] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BASKAR S, 1995, IN PRESS J EXP MED; CHEN CY, 1994, IMMUNITY, V1, P147, DOI 10.1016/1074-7613(94)90108-2; CHEN CY, 1994, J IMMUNOL, V152, P2105; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COHEN J, 1993, SCIENCE, V262, P175, DOI 10.1126/science.8211135; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GUERDER S, 1994, IMMUNITY, V1, P155; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KUCHROO VK, 1993, J IMMUNOL, V151, P4371; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; LAURSEN RA, 1984, P NATL ACAD SCI-BIOL, V81, P2912, DOI 10.1073/pnas.81.9.2912; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NEWMAN S, 1987, P NATL ACAD SCI USA, V84, P886, DOI 10.1073/pnas.84.3.886; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; SOBEL RA, 1989, J NEUROPATHOL EXP NE, V49, P468; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; TUOHY VK, 1989, J IMMUNOL, V142, P1523; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	45	1618	1703	1	26	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					707	718		10.1016/0092-8674(95)90349-6	http://dx.doi.org/10.1016/0092-8674(95)90349-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7534215	Bronze			2022-12-01	WOS:A1995QM39900007
J	LISMAN, JE; IDIART, MAP				LISMAN, JE; IDIART, MAP			STORAGE OF 7+/-2 SHORT-TERM MEMORIES IN OSCILLATORY SUBCYCLES	SCIENCE			English	Article							RAT-ASSOCIATION CORTEX; PYRAMIDAL CELLS; RESPONSES; MONKEY	Psychophysical measurements indicate that human subjects can store approximately seven short-term memories. Physiological studies suggest that short-term memories are stored by patterns of neuronal activity. Here it is shown that activity patterns associated with multiple memories can be stored in a single neural network that exhibits nested oscillations similar to those recorded from the brain. Each memory is stored in a different high-frequency (''40 hertz'') subcycle of a low-frequency oscillation. Memory patterns repeat on each low-frequency (5 to 12 hertz) oscillation, a repetition that relies on activity-dependent changes in membrane excitability rather than reverberatory circuits. This work suggests that brain oscillations are a timing mechanism for controlling the serial processing of short-term memories.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT PHYS,WALTHAM,MA 02254	Brandeis University; Brandeis University	LISMAN, JE (corresponding author), BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254, USA.		idiart, marco/F-7389-2015	idiart, marco/0000-0002-7129-3520	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027337] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27337] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIT DJ, 1994, J NEUROSCI, V14, P6435; Amit DJ, 1989, MODELING BRAIN FUNCT, DOI 10.1017/CBO9780511623257; ANDRADE R, 1991, BRAIN RES, V548, P81, DOI 10.1016/0006-8993(91)91109-E; ARANEDA R, 1991, NEUROSCIENCE, V40, P399, DOI 10.1016/0306-4522(91)90128-B; Atkinson RC., 1968, PSYCHOL LEARNING MOT, V2, P89, DOI DOI 10.1016/S0079-7421(08)60422-3; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BRAGIN A, 1995, J NEUROSCI, V15, P47; CAESER M, 1993, EUR J NEUROSCI, V5, P560, DOI 10.1111/j.1460-9568.1993.tb00521.x; CHANG HT, 1950, J NEUROPHYSIOL, V13, P235, DOI 10.1152/jn.1950.13.3.235; Fahle M., 1994, Society for Neuroscience Abstracts, V20, P319; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1982, J NEUROSCI, V2, P361; HEBB DO, 1949, ORG BEHAVIOR; Horn D, 1991, NEURAL COMPUT, V3, P31, DOI 10.1162/neco.1991.3.1.31; HORN D, 1994, ADV NEURAL INFORMATI, V4, P125; JOLIOT M, 1994, P NATL ACAD SCI USA, V91, P11748, DOI 10.1073/pnas.91.24.11748; KAUFMAN L, 1992, ELECTROENCEPHALOGR C, V82, P226; Koch C., 1994, SOME FURTHER IDEAS R, P93; KREITER AK, 1992, EUR J NEUROSCI, V4, P369, DOI 10.1111/j.1460-9568.1992.tb00884.x; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/0033-295X.101.2.343; NAKAMURA K, 1992, NEUROREPORT, V3, P117, DOI 10.1097/00001756-199201000-00031; Oberly HS, 1928, AM J PSYCHOL, V40, P295, DOI 10.2307/1414490; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.ph.55.030193.002025; Skaggs W. E., 1993, Society for Neuroscience Abstracts, V19, P795; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; STERIADE M, 1991, P NATL ACAD SCI USA, V88, P4396, DOI 10.1073/pnas.88.10.4396; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; WINGFIELD A, 1972, SCIENCE, V176, P690, DOI 10.1126/science.176.4035.690; ZIPSER D, 1993, J NEUROSCI, V13, P3406	33	975	985	0	81	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1512	1515		10.1126/science.7878473	http://dx.doi.org/10.1126/science.7878473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878473				2022-12-01	WOS:A1995QL49700042
J	MASU, M; IWAKABE, H; TAGAWA, Y; MIYOSHI, T; YAMASHITA, M; FUKUDA, Y; SASAKI, H; HIROI, K; NAKAMURA, Y; SHIGEMOTO, R; TAKADA, M; NAKAMURA, K; NAKAO, K; KATSUKI, M; NAKANISHI, S				MASU, M; IWAKABE, H; TAGAWA, Y; MIYOSHI, T; YAMASHITA, M; FUKUDA, Y; SASAKI, H; HIROI, K; NAKAMURA, Y; SHIGEMOTO, R; TAKADA, M; NAKAMURA, K; NAKAO, K; KATSUKI, M; NAKANISHI, S			SPECIFIC DEFICIT OF THE ON RESPONSE IN VISUAL TRANSMISSION BY TARGETED DISRUPTION OF THE MGLUR6 GENE	CELL			English	Article							ROD BIPOLAR CELLS; METABOTROPIC GLUTAMATE-RECEPTOR; LATERAL GENICULATE-NUCLEUS; C-LIKE IMMUNOREACTIVITY; MAMMALIAN RETINA; FIELD PROPERTIES; OLFACTORY-BULB; CONDUCTANCE; PROTEIN; ELECTRORETINOGRAM	Taking advantage of the restricted expression of metabotropic glutamate receptor subtype 6 (mGluR6) in retinal ON bipolar cells, we generated knockout mice lacking mGluRG6expression. The homozygous mutant mice showed a loss of ON responses but unchanged OFF responses to light. The mutant mice displayed no obvious changes in retinal cell organization nor in the projection of optic fibers to the brain. Furthermore, the mGluR6-deficient mice showed visual behavioral responses to light stimulation as examined by shuttle box avoidance behavior experiments using light exposure as a conditioned stimulus. The results demonstrate that mGluR6 is essential in synaptic transmission to the ON bipolar cell and that the OFF response provides an important means for transmitting visual information.	KYOTO UNIV,FAC MED,DEPT OPHTHALMOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL,OSAKA 565,JAPAN; HYOGO MED UNIV,DEPT PHYSIOL,NISHINOMIYA,HYOGO 663,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT ANAT,TOKYO 113,JAPAN; KYUSHU UNIV,MED INST BIOREGULAT,FUKUOKA 812,JAPAN	Kyoto University; Kyoto University; Osaka University; Hyogo College of Medicine; University of Hyogo; Tokyo Medical & Dental University (TMDU); Kyushu University	MASU, M (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.		Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				AKAZAWA C, 1994, NEUROSCI LETT, V171, P52, DOI 10.1016/0304-3940(94)90602-5; ASHMORE JF, 1980, J PHYSIOL-LONDON, V300, P115, DOI 10.1113/jphysiol.1980.sp013155; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BURESOVA O, 1976, TECHNIQUES BASIC EXP, P91; DAW NW, 1990, TRENDS NEUROSCI, V13, P110, DOI 10.1016/0166-2236(90)90187-F; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; DEVRIES SH, 1993, NEURON S, V10, P139; DODT E, 1951, NATURE, V168, P738, DOI 10.1038/168738a0; FUKUDA Y, 1978, JPN J PHYSIOL, V28, P385; GREFERATH U, 1990, J COMP NEUROL, V301, P433, DOI 10.1002/cne.903010308; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; HAYHOW WR, 1962, J COMP NEUROL, V118, P295, DOI 10.1002/cne.901180303; HORTON JC, 1984, J NEUROSCI, V4, P374; INOUE A, 1992, J BIOL CHEM, V267, P10613; KNAPP AG, 1983, J NEUROPHYSIOL, V50, P1236, DOI 10.1152/jn.1983.50.5.1236; KNAPP AG, 1984, VISION RES, V24, P1841, DOI 10.1016/0042-6989(84)90016-6; KOLB H, 1994, OPHTHALMOL VIS SCI, V35, P2385; MESULAM MM, 1978, J HISTOCHEM CYTOCHEM, V26, P106, DOI 10.1177/26.2.24068; MILLER RF, 1986, TRENDS NEUROSCI, V9, P211, DOI 10.1016/0166-2236(86)90061-5; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NEGISHI K, 1988, NEUROSCI LETT, V94, P247, DOI 10.1016/0304-3940(88)90025-0; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SASAKI H, 1993, PROG BRAIN RES, V95, P103, DOI 10.1016/S0079-6123(08)60361-1; SCHILLER PH, 1982, NATURE, V297, P580, DOI 10.1038/297580a0; SCHILLER PH, 1986, NATURE, V322, P824, DOI 10.1038/322824a0; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; Schiller PH, 1984, HDB PHYSL, VIII, P457; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SHERK H, 1984, J NEUROSCI, V4, P381; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; Steinberg RH., 1991, PROGR RETINAL RES, V10, P121, DOI 10.1016/0278-4327(91)90011-P; STOCKTON RA, 1989, J GEN PHYSIOL, V93, P101, DOI 10.1085/jgp.93.1.101; TESSIERLAVIGNE M, 1991, PRINCIPLES NEURAL SC, P400; WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; Wurst W., 1993, Gene targeting: a practical approach., P33	43	391	401	1	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					757	765		10.1016/0092-8674(95)90354-2	http://dx.doi.org/10.1016/0092-8674(95)90354-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889569	Bronze			2022-12-01	WOS:A1995QM39900012
J	MAX, M; MCKINNON, PJ; SEIDENMAN, KJ; BARRETT, RK; APPLEBURY, ML; TAKAHASHI, JS; MARGOLSKEE, RF				MAX, M; MCKINNON, PJ; SEIDENMAN, KJ; BARRETT, RK; APPLEBURY, ML; TAKAHASHI, JS; MARGOLSKEE, RF			PINEAL OPSIN - A NONVISUAL OPSIN EXPRESSED IN CHICK PINEAL	SCIENCE			English	Article							VISUAL PIGMENT; RHODOPSIN; PROTEIN; SEQUENCE; GENES; CELL; ROD; PHYLOGENIES; RELEASE; CULTURE	Pineal opsin (P-opsin), an opsin from chick that is highly expressed in pineal but is not detectable in retina, was cloned by the polymerase chain reaction. It is likely that the P-opsin lineage diverged from the retinal opsins early in opsin evolution. The amino acid sequence of P-opsin is 42 to 46 percent identical to that of the retinal opsins. P-opsin is a seven-membrane spanning, G protein-linked receptor with a Schiff-base lysine in the seventh membrane span and a Schiff-base counterion in the third membrane span. The primary sequence of P-opsin suggests that it will be maximally sensitive to similar to 500-nanometer tight and produce a slow and prolonged phototransduction response consistent with the nonvisual function of pineal photoreception.	NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, NATL SCI FDN, CTR BIOL TIMING, EVANSTON, IL 60208 USA; HARVARD UNIV, SCH MED, HOWE LABS, BOSTON, MA 02114 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University; Harvard University; Harvard Medical School	MAX, M (corresponding author), HOFFMANN LA ROCHE INC, ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA.		Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878; Margolskee, Robert/0000-0002-9572-2887	NATIONAL EYE INSTITUTE [R01EY008467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039592, F31MH010287, R37MH039592] Funding Source: NIH RePORTER; NEI NIH HHS [EYO8467] Funding Source: Medline; NIMH NIH HHS [MH10287, MH39592] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APPLEBURY ML, 1994, MOL EVOLUTION PHYSL, P235; ARAKI M, 1992, DEV BRAIN RES, V65, P85, DOI 10.1016/0165-3806(92)90011-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Dayhoff M., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DEGUCHI T, 1988, J NEUROSCI, V8, P22; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; IBBOTSON RE, 1992, P ROY SOC B-BIOL SCI, V247, P145, DOI 10.1098/rspb.1992.0021; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T, 1989, MOL CLONING; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MCLAUGHLIN SK, 1993, BIOTECHNIQUES, V15, P506; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; VIGH B, 1982, Z MIKROSK ANAT FORSC, V96, P113; WANG SZ, 1992, BIOCHEMISTRY-US, V31, P3309, DOI 10.1021/bi00128a002; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; YOKOYAMA R, 1990, P NATL ACAD SCI USA, V87, P9315, DOI 10.1073/pnas.87.23.9315; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1994, J NEUROCHEM, V62, P2001	39	139	142	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1502	1506		10.1126/science.7878470	http://dx.doi.org/10.1126/science.7878470			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878470				2022-12-01	WOS:A1995QL49700039
J	MOTOYAMA, N; WANG, FP; ROTH, KA; SAWA, H; NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; SENJU, S; ZHANG, Q; FUJII, S; LOH, DY				MOTOYAMA, N; WANG, FP; ROTH, KA; SAWA, H; NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; SENJU, S; ZHANG, Q; FUJII, S; LOH, DY			MASSIVE CELL-DEATH OF IMMATURE HEMATOPOIETIC-CELLS AND NEURONS IN BCL-X-DEFICIENT MICE	SCIENCE			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; MUTANT CHIMERIC MICE; B-CELL; GENE; APOPTOSIS; PROTOONCOGENE; MECHANISMS; EXPRESSION; MUTATION; SYSTEM	bcl-x is a member of the bcl-2 gene family, which may regulate programmed cell death. Mice were generated that lacked Bcl-x. The Bcl-x-deficient mice died around embryonic day 13. Extensive apoptotic cell death was evident in postmitotic immature neurons of the developing brain, spinal cord, and dorsal root ganglia. Hematopoietic cells in the liver were also apoptotic. Analyses of bcl-x double-knockout chimeric mice showed that the maturation of Bcl-x-deficient lymphocytes was diminished. The life-span of immature lymphocytes, but not mature lymphocytes, was shortened. Thus, Bcl-x functions to support the viability of immature cells during the development oi the nervous and hematopoietic systems.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOL MOLEC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV CARDIOVASC MED,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Sawa, Hirofumi/AAW-8816-2021; wang, fang/GYD-4295-2022; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755; Roth, Kevin/0000-0002-0643-995X				ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FANG W, 1994, J IMMUNOL, V153, P4388; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HERMISTON ML, 1992, J HISTOCHEM CYTOCHEM, V40, P1283, DOI 10.1177/40.9.1506665; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; Kaufman MH, 1992, ATLAS MOUSE DEV, P128; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LEBRUN DP, 1993, AM J PATHOL, V142, P743; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LIN EY, 1993, J IMMUNOL, V151, P1979; MERRY DE, 1994, DEVELOPMENT, V120, P301; MOTOYAMA N, UNPUB; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NAKAYAMA K, UNPUB; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SAWYERS CL, 1994, CELL, V177, P121; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TUCKER RP, 1988, J COMP NEUROL, V271, P44, DOI 10.1002/cne.902710106; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VEISNOVACK D, 1994, AM J PATHOL, V145, P61; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	40	988	1013	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1506	1510		10.1126/science.7878471	http://dx.doi.org/10.1126/science.7878471			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878471				2022-12-01	WOS:A1995QL49700040
J	MURATA, Y; WHARTON, RP				MURATA, Y; WHARTON, RP			BINDING OF PUMILIO TO MATERNAL HUNCHBACK MESSENGER-RNA IS REQUIRED FOR POSTERIOR PATTERNING IN DROSOPHILA EMBRYOS	CELL			English	Article							3' UNTRANSLATED REGION; POLE CELL-FORMATION; C-ELEGANS; DETERMINANT NANOS; HEAD DEVELOPMENT; BICOID PROTEIN; BODY PATTERN; GENE NANOS; RNA; SEGMENTATION	Posterior patterning in Drosophila embryos is governed by nanos (nos), which acts by repressing the translation of maternal transcripts of the hunchback (hb) gene. Sites in hb mRNA that mediate this repression, named nanos response elements (NREs), have been identified. However, we know of no evidence of a direct interaction between nos, or any other protein, and the NRE. Here, we show that two proteins present in embryonic extracts, neither one nos, bind specifically to the NRE in vitro. Furthermore, we show that binding in vitro correlates with NRE function in vivo. One of the NRE-binding factors is encoded by pumilio (pum), a gene that, like nos, is essential for abdominal segmentation. These and other observations suggest that pum acts by recognizing the NRE and then recruiting nos. Presumably, the resulting complex inhibits some component of the translation machinery.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT MICROBIOL, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute	MURATA, Y (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT GENET, DURHAM, NC 27710 USA.							AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ARMEIN H, 1994, CELL, V76, P735; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEN WN, 1991, YEAST, V7, P309, DOI 10.1002/yea.320070314; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; HARLOW E, 1988, ANTIBODIES LABORATOR; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	47	335	342	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					747	756		10.1016/0092-8674(95)90353-4	http://dx.doi.org/10.1016/0092-8674(95)90353-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889568	Bronze			2022-12-01	WOS:A1995QM39900011
J	RUETER, SM; BURNS, CM; COODE, SA; MOOKHERJEE, P; EMESON, RB				RUETER, SM; BURNS, CM; COODE, SA; MOOKHERJEE, P; EMESON, RB			GLUTAMATE-RECEPTOR RNA EDITING IN-VITRO BY ENZYMATIC CONVERSION OF ADENOSINE TO INOSINE	SCIENCE			English	Article							B MESSENGER-RNA; CA2+ PERMEABILITY; STRUCTURAL DETERMINANTS; ION FLOW; CHANNELS; KAINATE; EXPRESSION	RNA encoding the B subunit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptor (GluR-B) undergoes a posttranscriptional modification in which a genomically encoded adenosine is represented as a guanosine in the GluR-B complementary DNA. In vitro editing of GluR-B RNA transcripts with HeLa cell nuclear extracts was found to result from an activity that converts adenosine to inosine in regions of double-stranded RNA by enzymatic base modification. This activity is consistent with that of a double-stranded RNA-specific adenosine deaminase previously described in Xenopus oocytes and widely distributed in mammalian tissues.	VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University				Emeson, Ronald/0000-0002-4585-1648	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BASS B, 1993, RNA WORLD, pCH15; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BOULTER J, 1989, NEURON, V3, P589; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; EGEBJERG J, 1993, P NATL ACAD SCI USA, V90, P755, DOI 10.1073/pnas.90.2.755; EGEBJERG J, 1994, P NATL ACAD SCI USA, V91, P10270, DOI 10.1073/pnas.91.22.10270; ELLIOTT MS, 1984, J BIOL CHEM, V259, P2407; GARCIA GA, 1993, J MOL BIOL, V231, P489, DOI 10.1006/jmbi.1993.1296; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; NAKANISHI N, 1990, TOXICON, V28, P1333; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SHULDINER AR, 1993, PCR PROTOCOLS CURREN, P169; Silberklang M, 1979, Methods Enzymol, V59, P58; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WU JH, 1990, J BIOL CHEM, V265, P12312	26	117	125	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1491	1494		10.1126/science.7878468	http://dx.doi.org/10.1126/science.7878468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878468				2022-12-01	WOS:A1995QL49700036
J	SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; RAO, G; GUIDA, P; SKOULTCHI, AI; DEPINHO, RA				SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; RAO, G; GUIDA, P; SKOULTCHI, AI; DEPINHO, RA			AN AMINO-TERMINAL DOMAIN OF MXI1 MEDIATES ANTI-MYC ONCOGENIC ACTIVITY AND INTERACTS WITH A HOMOLOG OF THE YEAST TRANSCRIPTIONAL REPRESSOR SIN3	CELL			English	Article							C-MYC; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MAX; PROTEIN; EXPRESSION; GENE; RECOGNITION; ACTIVATION; HELIX	Documented interactions among members of the Myc superfamily support a yin-yang model for the regulation of Myc-responsive genes in which transactivation-competent Myc-Max heterodimers are opposed by repressive Mxi1-Max or Mad-Max complexes. Analysis of mouse mxi1 has led to the identification of two mxi1 transcript forms possessing open reading frames that differ in their capacity to encode a short aminoterminal alpha-helical domain. The presence of this segment dramatically augments the suppressive potential of Mxi1 and allows for association with a mammalian protein that is structurally homologous to the yeast transcriptional repressor SIN3, These findings provide a mechanistic basis for the antagonistic actions of Mxi1 on Myc activity that appears to be mediated in part through the recruitment of a putative transcriptional repressor.	ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DIV DERMATOL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	SCHREIBERAGUS, N (corresponding author), ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461, USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [RT32CA-09173] Funding Source: Medline; NIA NIH HHS [2T32AG00194] Funding Source: Medline; NIGMS NIH HHS [T32GM07128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDELHOFF S, 1994, ONCOGENE, V9, P665; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO GJ, 1992, FASEB J, V6, P30565; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; Maxam A M, 1980, Methods Enzymol, V65, P499; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J., 1989, MOL CLONING LAB MANU; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRICH R, 1989, P NATL ACAD SCI USA, V86, P10018, DOI 10.1073/pnas.86.24.10018; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V83, P5455; YOSHIMOTO H, 1992, MOL GEN GENET, V233, P327, DOI 10.1007/BF00587597; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, CELL, V79; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	55	343	350	1	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					777	786		10.1016/0092-8674(95)90356-9	http://dx.doi.org/10.1016/0092-8674(95)90356-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889571	Bronze			2022-12-01	WOS:A1995QM39900014
J	TONG, G; SHEPHERD, D; JAHR, CE				TONG, G; SHEPHERD, D; JAHR, CE			SYNAPTIC DESENSITIZATION OF NMDA RECEPTORS BY CALCINEURIN	SCIENCE			English	Article							ISOLATED HIPPOCAMPAL-NEURONS; PROTEIN PHOSPHATASE-ACTIVITY; D-ASPARTATE RECEPTOR; CONDUCTANCES; PROBABILITY; RESPONSES; CULTURE; RELEASE; ACTIN; RAT	Desensitization is a phenomenon that is common to many ligand-gated ion channels but has been demonstrated only rarely with physiological stimulation. Numerous studies describe desensitization of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor by exogenous agonists, but whether synaptic stimulation causes desensitization has been unknown. Synaptic stimulation of NMDA receptors on rat hippocampal neurons resulted in desensitization that was prevented by intracellular 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), adenosine-5'-O-(3-thiotriphosphate) (ATP-gamma-S), or inhibitors of phosphatase 2B (calcineurin), but not by inhibitors of phosphatases 1 and 2A or of tyrosine phosphatases. Synaptic NMDA receptors may fluctuate between phosphorylated and dephosphorylated forms, depending on the rate of synaptic stimulation and the magnitude of the associated influx of calcium through NMDA receptors.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			Tong, Gary/AAC-9426-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021419] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21419] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; CHIZHMAKOV IV, 1992, J PHYSIOL-LONDON, V448, P453, DOI 10.1113/jphysiol.1992.sp019051; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAHR CE, 1990, J NEUROSCI, V10, P3178; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; MAYER ML, 1987, J NEUROSCI, V7, P3230; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; PETHIG R, 1989, CELL CALCIUM, V10, P491, DOI 10.1016/0143-4160(89)90026-2; ROSENMUND C, 1995, J NEUROPHYSIOL, V73, P427, DOI 10.1152/jn.1995.73.1.427; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0	26	339	345	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1510	1512		10.1126/science.7878472	http://dx.doi.org/10.1126/science.7878472			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878472				2022-12-01	WOS:A1995QL49700041
J	VONCKEN, JW; VANSCHAICK, H; KAARTINEN, V; DEEMER, K; COATES, T; LANDING, B; PATTENGALE, P; DORSEUIL, O; BOKOCH, GM; GROFFEN, J; HEISTERKAMP, N				VONCKEN, JW; VANSCHAICK, H; KAARTINEN, V; DEEMER, K; COATES, T; LANDING, B; PATTENGALE, P; DORSEUIL, O; BOKOCH, GM; GROFFEN, J; HEISTERKAMP, N			INCREASED NEUTROPHIL RESPIRATORY BURST IN BCR-NULL MUTANTS	CELL			English	Article							CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; NADPH OXIDASE; C-ABL; SUPEROXIDE PRODUCTION; NUCLEOTIDE EXCHANGE; B-CELL; PROTEIN; ONCOGENE; ACTIVATION	Philadelphia (Ph)-positive leukemias invariably contain a chromosomal translocation fusing BCR to ABL. The BCR-ABL protein is responsible for leukemogenesis. Here we show that exposure of bcr-null mutant mice to gram-negative endotoxin led to severe septic shock and increased tissue injury by neutrophils. Neutrophils of bcr (-/-) mice showed a pronounced increase in reactive oxygen metabolite production upon activation and were more sensitive to priming stimuli. Activated (-/-) neutrophils displayed a 3-fold increased p21(rac2) membrane translocation compared with (+/+) neutrophils. These results connect Bcr in vivo with the regulation of Rac-mediated superoxide production by the NADPH-oxidase system of leukocytes and suggest a link between Bcr function and the cell type affected in Ph-positive leukemia.	CHILDRENS HOSP LOS ANGELES, DEPT HEMATOL, LOS ANGELES, CA 90027 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Children's Hospital Los Angeles; Scripps Research Institute; Scripps Research Institute	VONCKEN, JW (corresponding author), CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, LOS ANGELES, CA 90027 USA.		Kaartinen, Vesa/AAU-5396-2021; Coates, Thomas/AAN-3556-2020; Heisterkamp, Nora/C-1698-2012	Coates, Thomas/0000-0001-9878-6029; Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NATIONAL CANCER INSTITUTE [R01CA050248] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NCI NIH HHS [CA50248] Funding Source: Medline; NHLBI NIH HHS [HL 48008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHMED S, 1994, J BIOL CHEM, V269, P17642; BEDI A, 1993, BLOOD, V81, P2898; BENNA JE, 1994, J BIOL CHEM, V269, P6729; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; DEFORGE LE, 1994, AM J PATHOL, V144, P599; DEMLING RH, 1990, CIRC SHOCK, V30, P297; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; EDWARDS SW, 1994, BIOCH PHYSL NEUTROPH, P235; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FIORETOS T, 1994, BLOOD, V83, P3441; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAAS OA, 1992, NATURE, V359, P414, DOI 10.1038/359414a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P473; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; HEWETT JA, 1992, LAB INVEST, V66, P347; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HIMMELFARB J, 1992, CYTOMETRY, V13, P83, DOI 10.1002/cyto.990130113; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LIU JX, 1993, ONCOGENE, V8, P101; LOFGREN R, 1993, J CELL BIOL, V123, P1597, DOI 10.1083/jcb.123.6.1597; LU D, 1993, BLOOD, V82, P1257; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MELO JV, 1993, BLOOD, V81, P158; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHAAFI RI, 1988, J LEUKOCYTE BIOL, V43, P18, DOI 10.1002/jlb.43.1.18; SHASBY DM, 1982, AM REV RESPIR DIS, V125, P443; SHIRATORI Y, 1990, HEPATOLOGY, V11, P83; SIMPSON R, 1993, ANN SURG, V218, P444, DOI 10.1097/00000658-199310000-00005; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1993, ADV RES TREATMENT, P295; WAKIYAMA H, 1993, CLIN EXP IMMUNOL, V92, P218; WATT SM, 1979, J CELL PHYSIOL, V100, P1, DOI 10.1002/jcp.1041000102; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; YOSHIKAWA T, 1994, CIRC SHOCK, V42, P53	52	152	156	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					719	728		10.1016/0092-8674(95)90350-X	http://dx.doi.org/10.1016/0092-8674(95)90350-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889565	Bronze			2022-12-01	WOS:A1995QM39900008
J	WANG, Q; SHEN, JX; SPLAWSKI, I; ATKINSON, D; LI, ZZ; ROBINSON, JL; MOSS, AJ; TOWBIN, JA; KEATING, MT				WANG, Q; SHEN, JX; SPLAWSKI, I; ATKINSON, D; LI, ZZ; ROBINSON, JL; MOSS, AJ; TOWBIN, JA; KEATING, MT			SCN5A MUTATIONS ASSOCIATED WITH AN INHERITED CARDIAC-ARRHYTHMIA, LONG QT SYNDROME	CELL			English	Article							HYPERKALEMIC PERIODIC PARALYSIS; MUSCLE SODIUM-CHANNEL; ALPHA-SUBUNIT; PARAMYOTONIA-CONGENITA; HUMAN CHROMOSOME-3; GENE; INACTIVATION; LINKAGE; FAMILIES; CLONING	Long QT syndrome (LQT) is an inherited disorder that causes sudden death from cardiac arrhythmias, specifically torsade de pointes and ventricular fibrillation. We previously mapped three LQT loci: LQT1 on chromosome 11p15.5, LQT2 on 7q35-36, and LQT3 on 3p21-24. Here we report genetic linkage between LQT3 and polymorphisms within SCN5A, the cardiac sodium channel gene. Single strand conformation polymorphism and DNA sequence analyses reveal identical intragenic deletions of SCN5A in affected members of two unrelated LQT families. The deleted sequences reside in a region that is important for channel inactivation. These data suggest that mutations in SCN5A cause chromosome 3-linked LQT and indicate a likely cellular mechanism for this disorder.	UNIV UTAH, HLTH SCI CTR, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, ECCLES PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, DIV CARDIOL, SALT LAKE CITY, UT 84112 USA; UNIV ROCHESTER, MED CTR, DEPT COMMUNITY & PREVENT MED, ROCHESTER, NY 14627 USA; UNIV ROCHESTER, MED CTR, DEPT MED, ROCHESTER, NY 14627 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Rochester; University of Rochester; Baylor College of Medicine; Baylor College of Medicine	WANG, Q (corresponding author), UNIV UTAH, HLTH SCI CTR, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA.		Towbin, Jeffrey A./J-5595-2019	Towbin, Jeffrey A./0000-0002-6585-714X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033843, R01HL051618] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL33843, R01-HL51618, R01-HL48074] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; ATTWELL D, 1979, PFLUG ARCH EUR J PHY, V379, P137, DOI 10.1007/BF00586939; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; CHIN H, 1991, GENOMICS, V11, P914, DOI 10.1016/0888-7543(91)90014-6; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; EBERS GC, 1991, ANN NEUROL, V30, P810, DOI 10.1002/ana.410300610; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1995, CYTOGENET CELL GENET, V68, P67; HONERJAGER P, 1981, REV PHYSIOL BIOCH P, V92, P1; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LERCHE H, 1993, J PHYSIOL-LONDON, V470, P13, DOI 10.1113/jphysiol.1993.sp019843; MAGOVCEVIC I, 1992, GENOMICS, V12, P125, DOI 10.1016/0888-7543(92)90414-N; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MCCLATCHEY AI, 1992, NAT GENET, V2, P148, DOI 10.1038/ng1092-148; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; ROMANO C, 1965, LANCET, V1, P658; RUDOLPH JA, 1992, NAT GENET, V2, P144, DOI 10.1038/ng1092-144; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SEINO S, 1992, GENOMICS, V13, P1375, DOI 10.1016/0888-7543(92)90078-7; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WANG Q, 1994, BIOTECHNIQUES, V17, P282; WARD O C, 1964, J Ir Med Assoc, V54, P103; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; YANG NB, 1994, P NATL ACAD SCI USA, V91, P12785, DOI 10.1073/pnas.91.26.12785; ZIPES DP, 1987, AM J CARDIOL, V59, pE26, DOI 10.1016/0002-9149(87)90198-6	42	1312	1366	1	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					805	811		10.1016/0092-8674(95)90359-3	http://dx.doi.org/10.1016/0092-8674(95)90359-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889574	Bronze			2022-12-01	WOS:A1995QM39900017
J	WUCHERPFENNIG, KW; STROMINGER, JL				WUCHERPFENNIG, KW; STROMINGER, JL			MOLECULAR MIMICRY IN T-CELL-MEDIATED AUTOIMMUNITY - VIRAL PEPTIDES ACTIVATE HUMAN T-CELL CLONES SPECIFIC FOR MYELIN BASIC-PROTEIN	CELL			English	Article							GLUTAMIC-ACID DECARBOXYLASE; MULTIPLE-SCLEROSIS PATIENTS; EPSTEIN-BARR VIRUS; LYMPHOCYTE-T; SUPERANTIGEN MAM; RECOGNITION; ENCEPHALOMYELITIS; ARTHRITIS; LINES; HEMAGGLUTININ	Structural similarity between viral T cell epitopes and self-peptides could lead to the induction of an autoaggressive T cell response. Based on the structural requirements for both MHC class II binding and TCR recognition of an immunodominant myelin basic protein (MBP) peptide, criteria for a data base search were developed in which the degeneracy of amino acid side chains required for MHC class II binding and the conservation of those required for T cell activation were considered. A panel of 129 peptides that matched the molecular mimicry motif was tested on seven MBP-specific T cell clones from multiple sclerosis patients. Seven viral and one bacterial peptide efficiently activated three of these clones. Only one peptide could have been identified as a molecular mimic by sequence alignment. The observation that a single T cell receptor can recognize quite distinct but structurally related peptides from multiple pathogens has important implications for understanding the pathogenesis of autoimmunity.			WUCHERPFENNIG, KW (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.				NCI NIH HHS [CA47554] Funding Source: Medline; NIAID NIH HHS [N01 AI 45198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; BAIG S, 1989, CLIN EXP IMMUNOL, V78, P390; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BROWN LR, 1991, J IMMUNOL, V147, P2677; BURNS J, 1983, CELL IMMUNOL, V81, P435, DOI 10.1016/0008-8749(83)90250-2; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; BUSCH R, 1991, J IMMUNOL, V147, P1292; CHAMBERS TM, 1989, VIROLOGY, V172, P180, DOI 10.1016/0042-6822(89)90119-0; COLE BC, 1993, ARTHRITIS RHEUM-US, V36, P994, DOI 10.1002/art.1780360717; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; DATTA AK, 1980, J BIOL CHEM, V255, P5120; EPSTEIN MA, 1977, LANCET, V2, P1270; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; JOHNSON RT, 1984, NEW ENGL J MED, V310, P137, DOI 10.1056/NEJM198401193100301; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; Koetssier, 1985, HDB CLIN NEUROLOGY, V3, P259; KURTZKE JF, 1979, ANN NEUROL, V5, P6, DOI 10.1002/ana.410050104; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARTIN R, 1990, J IMMUNOL, V145, P540; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; RAY CG, 1980, CLIN ENDOCRINOL, V12, P375, DOI 10.1111/j.1365-2265.1980.tb02723.x; REAY PA, 1994, J IMMUNOL, V152, P3946; ROSE NR, 1986, ANN NY ACAD SCI, V475, P146, DOI 10.1111/j.1749-6632.1986.tb20864.x; SCHLUESENER HJ, 1985, J IMMUNOL, V135, P3128; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SPIELMAN RS, 1982, EPIDEMIOL REV, V4, P45, DOI 10.1093/oxfordjournals.epirev.a036251; SPRUANCE S, 1945, J CLIN MICROBIOL, V22, P366; STADT D, 1990, EUR NEUROL, V30, P305, DOI 10.1159/000117361; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TOVEY MG, 1978, NATURE, V276, P270, DOI 10.1038/276270a0; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; VOGT AB, 1994, J IMMUNOL, V153, P1665; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581; WUCHERPFENNIG KW, 1991, IMMUNOL TODAY, V12, P277, DOI 10.1016/0167-5699(91)90126-E; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZHANG JW, 1994, J EXP MED, V179, P973, DOI 10.1084/jem.179.3.973	49	1213	1238	1	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					695	705		10.1016/0092-8674(95)90348-8	http://dx.doi.org/10.1016/0092-8674(95)90348-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7534214	Bronze, Green Published			2022-12-01	WOS:A1995QM39900006
J	CAVANAUGH, AH; HEMPEL, WM; TAYLOR, LJ; ROGALSKY, V; TODOROV, G; ROTHBLUM, LI				CAVANAUGH, AH; HEMPEL, WM; TAYLOR, LJ; ROGALSKY, V; TODOROV, G; ROTHBLUM, LI			ACTIVITY OF RNA-POLYMERASE-I TRANSCRIPTION FACTOR UBF BLOCKED BY RB GENE-PRODUCT	NATURE			English	Article							CELL DIFFERENTIATION; PROTEIN; PHOSPHORYLATION; TRANSACTIVATION; BINDING; GROWTH	THE protein encoded by the retinoblastoma susceptibility gene (Rb) functions as a tumour suppressor and negative growth regulator(1). As actively growing cells require the ongoing synthesis of ribosomal RNA, we considered that Rb might interact with the ribosomal DNA transcription apparatus, Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket(2); and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro. This last observation was confirmed by affinity chromatography and immunoprecipitation, which demonstrated an interaction between Rb and UBF. These results indicate that there is an additional mechanism by which Rb suppresses cell growth, namely that Rb directly represses transcription of the rRNA genes.	GEISINGER MED CLIN,SIGFRIED & JANET WEIS CTR RES,DANVILLE,PA 17822; MT SINAI MED CTR,DIV NEOPLAST DIS,NEW YORK,NY 10029	Geisinger Medical Center; Icahn School of Medicine at Mount Sinai								Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; NEVINS JR, 1992, SCIENCE, V258, P424; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; ROGALSKY V, 1993, BIOCHEM BIOPH RES CO, V192, P1139, DOI 10.1006/bbrc.1993.1535; ROGALSKY V, 1991, ANN NY ACAD SCI, V628, P323, DOI 10.1111/j.1749-6632.1991.tb17264.x; SCHNAPP G, 1994, EMBO J, V23, P190; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WAND CY, 1993, SCIENCE, V280, P1330	17	297	299	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					177	180		10.1038/374177a0	http://dx.doi.org/10.1038/374177a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877691				2022-12-01	WOS:A1995QL39700063
J	CHIBA, A; SNOW, P; KESHISHIAN, H; HOTTA, Y				CHIBA, A; SNOW, P; KESHISHIAN, H; HOTTA, Y			FASCICLIN-III AS A SYNAPTIC TARGET RECOGNITION MOLECULE IN DROSOPHILA	NATURE			English	Article							CELL-ADHESION MOLECULE; GROWTH CONE GUIDANCE; NEURONAL RECOGNITION; GENETIC-ANALYSIS; MOTONEURONS; MUSCLES; MELANOGASTER; MUTATIONS; COLLAPSE; PROTEIN	FASCICLIN III, a cell adhesion molecule of the immunoglobulin superfamily(1-3), is expressed by motor neuron RP3 and its synaptic targets (muscle cells 6 and 7) during embryonic neuromuscular development of Drosophila(4). We report here that RP3 often incorrectly innervates neighbouring non-target muscle cells when these cells misexpress fasciclin In, but still innervates normal targets in the fasciclin III null mutant, Fasciclin III manipulations do not influence target selections by other motor neurons, including fasciclin III-expressing RP1, We propose that fasciclin III acts as a synaptic target recognition molecule for motor neuron RP3, and also that its absence can be compensated for by other molecule(s).	UNIV TOKYO,GRAD SCH SCI,DEPT PHYS,TOKYO 113,JAPAN; NATL INST BASIC BIOL,CELLULAR COMMUN LAB,OKAZAKI,AICHI 444,JAPAN; SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); State University of New York (SUNY) System; State University of New York (SUNY) Albany; Yale University								BROADIE K, 1993, NATURE, V361, P350, DOI 10.1038/361350a0; CASH S, 1992, J NEUROSCI, V12, P2051; CHIBA A, 1993, J NEUROSCI, V13, P714; CRIPPS RM, 1994, J CELL BIOL, V126, P689, DOI 10.1083/jcb.126.3.689; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; KANIA A, 1993, NEURON, V11, P673, DOI 10.1016/0896-6273(93)90078-6; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, TRENDS NEUROSCI, V16, P278, DOI 10.1016/0166-2236(93)90182-L; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCALLISTER L, 1992, DEVELOPMENT, V115, P267; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RUBIN GM, 1982, SCIENCE, V218, P341; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WASSENBERG DR, 1987, J BIOL CHEM, V262, P10741; WHITLOCK KE, 1993, DEVELOPMENT, V117, P1251; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	29	110	110	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					166	168		10.1038/374166a0	http://dx.doi.org/10.1038/374166a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877688				2022-12-01	WOS:A1995QL39700060
J	GREENBERG, AS; AVILA, D; HUGHES, M; HUGHES, A; MCKINNEY, EC; FLAJNIK, MF				GREENBERG, AS; AVILA, D; HUGHES, M; HUGHES, A; MCKINNEY, EC; FLAJNIK, MF			A NEW ANTIGEN RECEPTOR GENE FAMILY THAT UNDERGOES REARRANGEMENT AND EXTENSIVE SOMATIC DIVERSIFICATION IN SHARKS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; CELL; IMMUNOGLOBULINS; RECOGNITION; EVOLUTION; PROTEINS; XENOPUS; TREES	IMMUNOGLOBULIN and T-cell receptor (TCR) molecules are central to the adaptive immune system, Sequence conservation, similarities in domain structure, and usage of similar recombination signal sequences and recombination machinery indicate that there was probably a time during evolution when an ancestral receptor diverged to the modern-day immunoglobulin and TCR(1-3). Other molecules that undergo rearrangement have not been described in vertebrates, nor have intermediates been identified that have features of both these gene families, We report here the isolation of a new member of the immunoglobulin superfamily from the nurse shark, Ginglymostoma cirratum, which contains one variable and five constant domains and is found as a dimer in serum. Analyses of complementary DNA clones show extensive sequence diversity within variable domains, which is generated by both rearrangement and somatic diversification mechanisms, Our results suggest that rearranging loci distinct from immunoglobulin and TCR have arisen during evolution.	BASEL INST IMMUNOL,CH-4058 BASEL,SWITZERLAND; PENN STATE UNIV,DEPT BIOL,ERWIN W MUELLER LAB 208,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	GREENBERG, AS (corresponding author), UNIV MIAMI,SCH MED,DEPT MICROBIOL & IMMUNOL,POB 016960,R-138,MIAMI,FL 33101, USA.			Flajnik, Martin Francis/0000-0002-2792-5084				CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLEM LW, 1971, P NATL ACAD SCI USA, V68, P139, DOI 10.1073/pnas.68.1.139; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Du Pasquier Louis, 1993, P199; FLAJNIK MF, 1991, AM ZOOL, V31, P580; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P10603, DOI 10.1073/pnas.90.22.10603; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HSU E, 1984, MOL IMMUNOL, V21, P257, DOI 10.1016/0161-5890(84)90096-8; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKELA O, 1980, NATURE, V287, P639, DOI 10.1038/287639a0; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; RZHETSKY A, 1992, MOL BIOL EVOL, V9, P945; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SMITH LC, 1994, ANN NY ACAD SCI, V712, P213, DOI 10.1111/j.1749-6632.1994.tb33575.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	23	484	583	7	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					168	173		10.1038/374168a0	http://dx.doi.org/10.1038/374168a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877689				2022-12-01	WOS:A1995QL39700061
J	HAY, JC; FISETTE, PL; JENKINS, GH; FUKAMI, K; TAKENAWA, T; ANDERSON, RA; MARTIN, TFJ				HAY, JC; FISETTE, PL; JENKINS, GH; FUKAMI, K; TAKENAWA, T; ANDERSON, RA; MARTIN, TFJ			ATP-DEPENDENT INOSITIDE PHOSPHORYLATION REQUIRED FOR CA2+-ACTIVATED SECRETION	NATURE			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; CYTOSOLIC PROTEINS; CHROMAFFIN CELLS; PHOSPHOLIPASE-C; EXOCYTOSIS; MEMBRANES; ANTIBODY; FUSION	REGULATED fusion of secretory granules with the plasma membrane in secretory cells requires ATP, Ca2+ and cytosolic(1-3) as well as membrane(4) proteins. ATP-dependent steps in Ca2+-activated secretion from PC12 cells require three cytosolic PEP proteins (priming in exocytosis proteins, PEP1-3)(5,6), the identity of which will provide insights into the required ATP-using reactions. PEP3 was recently identified as phosphatidylinositol transfer protein (PtdInsTP)(6), and here we report that PEP1 consists of the type I phosphatidylinositol-4-phosphate 5-kinase (PtdInsP5K), The roles of PEP3/PtdInsTP and PEP1/PtdInsP5K in sequential phosphoinositide recruitment and phosphorylation explains their synergistic activity in ATP-dependent priming, Moreover, inhibition of Ca2+-activated secretion by PtdIns(4,5)P-2-specific antibodies and phospholipase C implies that 5-phosphorylated inositides play a novel, necessary role in the regulated secretory pathway. The results indicate that lipid kinase-mediated phosphorylation is an important basis for ATP use in the exocytotic pathway.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT PHARMACOL,MADISON,WI 53706; UNIV WISCONSIN,CELL & MOLEC BIOL PROGRAM,MADISON,WI 53706; UNIV TOKYO,DEPT MOLEC ONCOL,TOKYO 108,JAPAN	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Tokyo				Anderson, Richard/0000-0001-6265-8359				ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BITTNER MA, 1993, CELL MOL NEUROBIOL, V13, P649, DOI 10.1007/BF00711564; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; LISCOVITCH M, 1993, J BIOL CHEM, V269, P21403; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; SCHOLZ G, 1992, EUR J BIOCHEM, V210, P461, DOI 10.1111/j.1432-1033.1992.tb17443.x; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; WU YN, 1992, BIOCHEM J, V285, P697, DOI 10.1042/bj2850697	30	444	451	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					173	177		10.1038/374173a0	http://dx.doi.org/10.1038/374173a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877690				2022-12-01	WOS:A1995QL39700062
J	HINSHAW, JE; SCHMID, SL				HINSHAW, JE; SCHMID, SL			DYNAMIN SELF-ASSEMBLES INTO RINGS SUGGESTING A MECHANISM FOR COATED VESICLE BUDDING	NATURE			English	Article							GTP-BINDING PROTEINS; MECHANOCHEMICAL ENZYME; DROSOPHILA; MICROTUBULES; ENDOCYTOSIS; SHIBIRE; DOMAIN	DYNAMIN, a 100K member of the GTPase superfamily(1), is the mammalian homologue of the Drosophila shihire gene product(2,3). Mutations in shibire cause a defect in endocytosis Leading to accumulation of coated pits and deep invaginations at the plasma membrane of all tissues examined(4,5). Similarly, invaginated coated pits accumulate in mammalian cells overexpressing dominant-negative mutants of dynamin, establishing that dynamin is required for the formation of 'constricted' coated pits and for coated vesicle budding(6). Whether dynamin functions in the classic GTPase mode as a molecular switch to regulate events leading to coated vesicle budding or instead actively participates as a mechanochemical enzyme driving coated vesicle formation is unclear(7). Here we show that dynamin spontaneously self-assembles into rings and stacks of interconnected rings, comparable in dimension to the 'collars' observed at the necks of invaginated coated pits that accumulate at synaptic terminals in shibire flies(4). We propose that invaginated coated pits become constricted by the assembly of dynamin into rings around their necks. A concerted conformational change would then close the rings and pinch off the budding coated vesicles.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Schmid, Sandra/0000-0002-1690-7024				CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TSURUHARA T, 1990, CELL TISSUE RES, V259, P199, DOI 10.1007/BF00318441; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WARNOCK DE, IN PRESS EMBO J	17	647	660	5	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					190	192		10.1038/374190a0	http://dx.doi.org/10.1038/374190a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877694				2022-12-01	WOS:A1995QL39700067
J	KOBE, B; DEISENHOFER, J				KOBE, B; DEISENHOFER, J			A STRUCTURAL BASIS OF THE INTERACTIONS BETWEEN LEUCINE-RICH REPEATS AND PROTEIN LIGANDS	NATURE			English	Article							PORCINE RIBONUCLEASE INHIBITOR; CRYSTAL-STRUCTURE; MOTIF	THE leucine-rich repeat is a recently characterized structural motif(1) used in molecular recognition processes as diverse as signal transduction, cell adhesion, cell development, DNA repair and RNA processing(2). We present here the crystal structure at 2.5 Angstrom resolution of the complex between ribonuclease A and ribonculease inhibitor, a protein built entirely of leucine-rich repeats, The unusual non-globular structure of ribonuclease inhibitor, its solvent-exposed parallel beta-sheet and the conformational flexibility of the structure are used in the interaction; they appear to be the principal reasons for the effectiveness of leucine-rich repeats as protein-binding motifs, The structure can serve as a model for the interactions of other proteins containing leucine-rich repeats with their ligands.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Kobe, Bostjan/D-1292-2009	Kobe, Bostjan/0000-0001-9413-9166				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AVEY HP, 1967, NATURE, V11, P557; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BIRDSALL DL, 1992, J BIOL CHEM, V267, P22230; BORKAKOTI N, 1983, EUR J BIOCHEM, V132, P89, DOI 10.1111/j.1432-1033.1983.tb07329.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DAVIES D R, 1992, Current Biology, V2, P254, DOI 10.1016/0960-9822(92)90369-L; FOMINAYA JM, 1992, J BIOL CHEM, V267, P24655; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KARTHA G, 1967, NATURE, V213, P862, DOI 10.1038/213862a0; KOBE B, 1994, J MOL BIOL, V241, P288, DOI 10.1006/jmbi.1994.1502; KOBE B, 1993, J MOL BIOL, V231, P137, DOI 10.1006/jmbi.1993.1263; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NACHMAN J, 1990, BIOCHEMISTRY-US, V29, P928, DOI 10.1021/bi00456a012; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROTH JS, 1956, BIOCHIM BIOPHYS ACTA, V21, P34, DOI 10.1016/0006-3002(56)90091-9; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; VOCENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	30	564	603	1	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					183	186		10.1038/374183a0	http://dx.doi.org/10.1038/374183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877692				2022-12-01	WOS:A1995QL39700065
J	KRAPIVINSKY, G; GORDON, EA; WICKMAN, K; VELIMIROVIC, B; KRAPIVINSKY, L; CLAPHAM, DE				KRAPIVINSKY, G; GORDON, EA; WICKMAN, K; VELIMIROVIC, B; KRAPIVINSKY, L; CLAPHAM, DE			THE G-PROTEIN-GATED ATRIAL K+ CHANNEL I-KACH IS A HETEROMULTIMER OF 2 INWARDLY RECTIFYING K+-CHANNEL PROTEINS	NATURE			English	Article							SUBUNIT; HEART	Heart rate is slowed in part by acetylcholine-dependent activation of a cardiac potassium (K+) channel, I-KACh. Activated muscarinic receptors stimulate I-KACh via the G-protein beta gamma-subunits. It has been assumed that the inwardly rectifying K+-channel gene, GIRK1, alone encodes I-KACh. It is now shown that I-KACh is a heteromultimer of two distinct inwardly rectifying K+-channel subunits, GIRK1 and a newly cloned member of the family, CIR.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; Wickman, Kevin/0000-0002-5179-9540				AGULLARBRYAN L, 1995, BIOPHYS J, V68, pA234; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; KUBO Y, 1993, NATURE, V384, P802; LIM N, 1995, J GEN PHYSIOL, V105, P1; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; TUNG R T, 1992, Journal of the American College of Cardiology, V19, p245A; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	15	741	770	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					135	141		10.1038/374135a0	http://dx.doi.org/10.1038/374135a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877685				2022-12-01	WOS:A1995QL39700050
J	LIAO, SM; ZHANG, JH; JEFFREY, DA; KOLESKE, AJ; THOMPSON, CM; CHAO, DM; VILJOEN, M; VANVUUREN, HJJ; YOUNG, RA				LIAO, SM; ZHANG, JH; JEFFREY, DA; KOLESKE, AJ; THOMPSON, CM; CHAO, DM; VILJOEN, M; VANVUUREN, HJJ; YOUNG, RA			A KINASE-CYCLIN PAIR IN THE RNA-POLYMERASE-II HOLOENZYME	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL DOMAIN; YEAST; PROTEIN; BINDING; CTD; PURIFICATION; ACTIVATION; SYSTEM; RESCUE	THE RNA polymerase II holoenzyme consists of RNA polymerase II, a subset of general transcription factors, and regulatory proteins known as SRB proteins(1,2). The genes encoding SRB proteins were isolated as suppressors of mutations in the RNA polymerase II carboxy-terminal domain (CTD3,4). The CTD and SRB proteins have been implicated in the response to transcriptional regulators(1-11). We report here the isolation of two new SRB genes, SRB10 and SRB11, which encode kinase- and cyclin-like proteins, respectively, Genetic and biochemical evidence indicates that the SRB10 and SRB11 proteins form a kinase-cyclin pair in the holoenzyme, The SRB10/11 kinase is essential for a normal transcriptional response to galactose induction in vivo. Holoenzymes lacking SRB10/11 kinase function are strikingly deficient in CTD phosphorylation, Although defects in the kinase substantially affect transcription in vivo, purified holoenzymes lacking SRB10/11 kinase function do not show defects in defined in vitro transcription systems, suggesting that the factors necessary to elicit the regulatory role of the SRB10/11 kinase are missing in these systems, These results indicate that the SRB10/11 kinase is involved in CTD phosphorylation and suggest that this modification has a role in the response to transcriptional regulators in vivo.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; UNIV STELLENBOSCH, DEPT MICROBIOL, STELLENBOSCH 7600, SOUTH AFRICA	Massachusetts Institute of Technology (MIT); Stellenbosch University	LIAO, SM (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		zhang, jianhua/D-3404-2009; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Viljoen-Bloom, Marinda/0000-0002-4825-2392; Zhang, Jianhua/0000-0002-2128-9574; Chao, David/0000-0001-9198-337X				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEES JM, 1991, GENE EXPRESSION, V1, P149; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUROSKY RT, 1994, MOL CELL BIOL, V14, P3446, DOI 10.1128/MCB.14.5.3446; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	30	369	376	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	1995	374	6518					193	196		10.1038/374193a0	http://dx.doi.org/10.1038/374193a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877695				2022-12-01	WOS:A1995QL39700068
J	LINDPAINTNER, K				LINDPAINTNER, K			FINDING AN OBESITY GENE - A TALE OF MICE AND MAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											LINDPAINTNER, K (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.							ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	1	35	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					679	680		10.1056/NEJM199503093321012	http://dx.doi.org/10.1056/NEJM199503093321012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7845436				2022-12-01	WOS:A1995QK06600012
J	ROTHSTEIN, TL; WANG, JKM; PANKA, DJ; FOOTE, LC; WANG, ZH; STANGER, B; CUI, H; JU, ST; MARSHAKROTHSTEIN, A				ROTHSTEIN, TL; WANG, JKM; PANKA, DJ; FOOTE, LC; WANG, ZH; STANGER, B; CUI, H; JU, ST; MARSHAKROTHSTEIN, A			PROTECTION AGAINST FAS-DEPENDENT TH1-MEDIATED APOPTOSIS BY ANTIGEN RECEPTOR ENGAGEMENT IN B-CELLS	NATURE			English	Article							CD40 LIGAND; LYMPHOCYTES; ANTIBODY; SIGNAL; MICE	CYTOTOXIC CD4(+) Th1-cells induce cell death by triggering a Fas-dependent apoptotic pathway(1-6). Potential targets include activated B cells(3,7), but it is not known whether the mode of B-cell stimulation influences susceptibility to Th1-mediated cytotoxicity. Here we report that CD40-ligand-stimulated B cells were extremely sensitive, whereas anti-IgM-stimulated B cells were resistant, to Fas-mediated apoptosis, B cells stimulated by both CD4DL and anti-IgM were not susceptible to cytolysis, demonstrating that anti-IgM-mediated protection is an active, dominant process. Resistance to Th1-mediated cytotoxicity was similarly observed in CD40L-stimulated 3-83 (anti-H-2K(k,b))(8) transgenic B cells co-cultured with H-2K(k) or H-2K(b) (but not H-2K(d)) splenocytes, These results indicate that B cells can participate in regulating their own destruction. Protection against Fas-dependent apoptosis afforded by immunoglobulin-receptor engagement may constitute a fail-safe mechanism that eliminates bystander B cells activated by CD40L-expressing T cells, but ensures survival of antigen-specific B cells.	BOSTON UNIV,MED CTR,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,MED CTR,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,MED CTR,EVANS MEM DEPT CLIN RES,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Boston University; Boston University; Boston University; Harvard University; Harvard Medical School	ROTHSTEIN, TL (corresponding author), BOSTON UNIV,MED CTR,DEPT MED,88 E NEWTON ST,BOSTON,MA 02118, USA.							BALK SP, 1981, J IMMUNOL, V126, P2177; DANIEL PT, 1994, J IMMUNOL, V152, P5624; ERB P, 1990, J IMMUNOL, V144, P790; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; JU ST, 1990, J IMMUNOL, V144, P23; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PARRY SL, 1994, J IMMUNOL, V152, P2821; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SANTOSARGUMEDO L, 1994, CELL IMMUNOL, V156, P272, DOI 10.1006/cimm.1994.1174; STALDER T, 1994, J IMMUNOL, V152, P1127; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	28	416	417	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					163	165		10.1038/374163a0	http://dx.doi.org/10.1038/374163a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7533263				2022-12-01	WOS:A1995QL39700059
J	SAITOU, M; SUGAI, S; TANAKA, T; SHIMOUCHI, K; FUCHS, E; NARUMIYA, S; KAKIZUKA, A				SAITOU, M; SUGAI, S; TANAKA, T; SHIMOUCHI, K; FUCHS, E; NARUMIYA, S; KAKIZUKA, A			INHIBITION OF SKIN DEVELOPMENT BY TARGETED EXPRESSION OF A DOMINANT-NEGATIVE RETINOLE ACID RECEPTOR	NATURE			English	Article							KERATIN EXPRESSION; EPIDERMAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; TRANSGENIC MICE; GENE; MOUSE; ALPHA; TRANSCRIPTION; TISSUE	ALTHOUGH pharmacological doses of retinoic acid (RA) have a wide variety of actions in vivo(1), experimental difficulties have prevented a definitive assignment of its physiological functions, We recently made a dominant-negative retinoic acid receptor (RAR) by a single amino-acid substitution(2) which creates a dominant-negative thyroid hormone receptor(3). The mutated RAR efficiently inhibited the endogenous activities of RARs (alpha, beta, gamma)(2). Thus, targeted expression of the mutated receptor should reveal RA functions during organogenesis by blocking RA signalling in the tissues concerned. To address this possibility, we expressed the dominant-negative RAR in the epidermis, a potential target organ of RA(4). We report here that the resultant transgenic mice exhibited dramatic suppression of epidermal maturation, demonstrating the requirement of RA in normal skin development.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT DERMATOL,KYOTO 60601,JAPAN; ONO PHARMACEUT,FUKUI INST SAFETY RES,FUKUI 913,JAPAN; UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	Kyoto University; Kyoto University; Ono Pharmaceutical Co Ltd; Howard Hughes Medical Institute; University of Chicago			Fuchs, Elaine/G-1565-2016					Armstrong Robert B., 1994, P545; BYRNE C, 1994, DEVELOPMENT, V120, P2369; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; DAVIDSON P, 1952, J ANAT, V86, P342; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GORDON JW, 1993, GUIDE TECHNIQUES MOU, P174; Gruneberg H, 1943, J HERED, V34, P89, DOI 10.1093/oxfordjournals.jhered.a105255; HANSON J, 1947, J ANAT, V81, P174; HARDISON RC, 1979, CELL, V18, P1285, DOI 10.1016/0092-8674(79)90239-3; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Peck Gary L., 1994, P631; SAITOU M, 1994, J BIOL CHEM, V269, P19101; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; STEINERT PM, 1975, BIOCHEM J, V149, P39, DOI 10.1042/bj1490039; STOLER A, 1989, J INVEST DERMATOL, V93, P728, DOI 10.1111/1523-1747.ep12284397; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	29	158	160	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					159	162		10.1038/374159a0	http://dx.doi.org/10.1038/374159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7533262				2022-12-01	WOS:A1995QL39700058
J	SHABAT, D; ITZHAKY, H; REYMOND, JL; KEINAN, E				SHABAT, D; ITZHAKY, H; REYMOND, JL; KEINAN, E			ANTIBODY CATALYSIS OF A REACTION OTHERWISE STRONGLY DISFAVOURED IN WATER	NATURE			English	Article							HYDROLYSIS; ETHERS	SEVERAL examples have been reported recently(1) of antibody catalysis(2) of reactions that are strongly disfavoured because of the high free energy of the transition state, Here we shaw that catalytic antibodies can be used to promote a particularly useful kind of reaction from a synthetic point of view: one involving an intermediate that is highly unstable in water, We show that an antibody elicited against the quaternary ammonium ion 4a (Fig, 1) catalyses the protonation of the enol ether 1 to form, with complete enantioselectivity, an oxocarbonium intermediate. This species is highly reactive in water, and would normally react with a water molecule to give the corresponding ketone 2, But the antibody provides a hydrophobic environment that allows the oxocarbonium ion instead to undergo an intramolecular reaction to form an enantiomerically pure ketal 3, This result shows that catalytic antibodies can exclude solvent molecules entirely from crucial steps on the reaction pathway.	TECHNION ISRAEL INST TECHNOL, DEPT CHEM, IL-32000 HAIFA, ISRAEL; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Technion Israel Institute of Technology; Scripps Research Institute				Reymond, Jean-Louis/0000-0003-2724-2942				BANAIT NS, 1991, J AM CHEM SOC, V113, P7951, DOI 10.1021/ja00021a021; EVANS DA, 1982, J AM CHEM SOC, V104, P1737, DOI 10.1021/ja00370a050; JAHANGIRI GK, 1994, J AM CHEM SOC, V116, P11264, DOI 10.1021/ja00104a008; JENKS WP, 1987, CATALYSIS CHEM ENZYM, P52; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LEWIS C, 1993, J AM CHEM SOC, V115, P1410, DOI 10.1021/ja00057a025; POTHIER N, 1992, HELV CHIM ACTA, V75, P604, DOI 10.1002/hlca.19920750217; REYMOND JL, 1994, ANGEW CHEM INT EDIT, V33, P475, DOI 10.1002/anie.199404751; REYMOND JL, 1993, J AM CHEM SOC, V115, P3909, DOI 10.1021/ja00063a009; REYMOND JL, 1991, ANGEW CHEM INT EDIT, V30, P1711, DOI 10.1002/anie.199117111; SCHMIR GL, 1965, J AM CHEM SOC, V87, P5692, DOI 10.1021/ja00952a030; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SCHUSTER M, 1994, J AM CHEM SOC, V116, P1135, DOI 10.1021/ja00082a047; SINHA SC, 1993, J AM CHEM SOC, V115, P4893, DOI 10.1021/ja00064a061; SINHA SC, 1993, P NATL ACAD SCI USA, V90, P11910, DOI 10.1073/pnas.90.24.11910	15	39	39	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					143	146		10.1038/374143a0	http://dx.doi.org/10.1038/374143a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	QL397	7877686				2022-12-01	WOS:A1995QL39700052
J	TAKEI, K; MCPHERSON, PS; SCHMID, SL; DECAMILLI, P				TAKEI, K; MCPHERSON, PS; SCHMID, SL; DECAMILLI, P			TUBULAR MEMBRANE INVAGINATIONS COATED BY DYNAMIN RINGS ARE INDUCED BY GTP-GAMMA-S IN NERVE-TERMINALS	NATURE			English	Article							FROG NEUROMUSCULAR JUNCTION; SYNAPTIC VESICLE MEMBRANE; I PROTEIN-I; BINDING PROTEINS; MECHANOCHEMICAL ENZYME; TRANSMITTER RELEASE; ENDOCYTOSIS; DROSOPHILA; PHOSPHOPROTEIN; MICROTUBULES	THE mechanisms through which synaptic vesicle membranes are reinternalized after exocytosis remain a matter of debate(1-5). Because several vesicular transport steps require GTP hydrolysis(6-9), GTP-gamma S may help identify intermediates in synaptic vesicle recycling. In GTP-gamma S-treated nerve terminals, we observed tubular invaginations of the plasmalemma that were often, but not always, capped by a clathrin-coated bud, Strikingly, the walls of these tubules were decorated by transverse electron-dense rings that were morphologically similar to structures formed by dynamin around tubular templates(10,11). Dynamin is a GTPase implicated in synaptic vesicle endocytosis(12-14) and here we show that the wails of these membranous tubules, but not their distal ends, were positive for dynamin immunoreactivity, These findings demonstrate that dynamin and clathrin act at different sites in the formation of endocytic vesicles, They strongly support a role for dynamin in the fission reaction and suggest that stabilization of the GTP-bound conformation of dynamin leads to tubule formation by progressive elongation of the vesicle stalk.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED RES INST, NEW HAVEN, CT 06510 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Yale University; Yale University; Scripps Research Institute				Schmid, Sandra/0000-0002-1690-7024; Takei, Kohji/0000-0002-6555-9425				CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NUOFFER C, 1994, REV BIOCH, V63, P949; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TAKEI K, 1992, J NEUROSCI, V12, P489; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617	35	643	652	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					186	190		10.1038/374186a0	http://dx.doi.org/10.1038/374186a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877693				2022-12-01	WOS:A1995QL39700066
J	WILCOCKSON, RW; CREAN, CS; DAY, TH				WILCOCKSON, RW; CREAN, CS; DAY, TH			HERITABILITY OF A SEXUALLY SELECTED CHARACTER EXPRESSED IN BOTH SEXES	NATURE			English	Article							TAIL ORNAMENT SIZE; COELOPA-FRIGIDA; SEAWEED FLY; MATING PREFERENCE; MATE CHOICE; EVOLUTION; DIMORPHISM; PARASITES; TRAITS	SEXUAL selection is thought to be responsible for the evolution of exaggerated male characters and of female mate preferences(1-7). Evolutionary mechanisms driven by an advantage to the progeny are only effective if the preferred character has a large genetic component of variance; in most systems in which sexual selection operates, little is known of the relevant genetics(8), We have measured parent-offspring correlations, and report here that the preferred character (adult size) in seaweed flies has large additive genetic variance in males, but not in females, Virtually all the variance in male size is attributable to a chromosomal inversion system and, consequently, because this system is also a major determinant of larval viability(9,10), male size could be used by females as a reliable indicator of offspring survival.	UNIV NOTTINGHAM, QUEENS MED CTR, DEPT GENET, NOTTINGHAM NG7 2UH, ENGLAND	University of Nottingham								ALATALO RV, 1988, BIOL J LINN SOC, V34, P363, DOI 10.1111/j.1095-8312.1988.tb01969.x; ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; Andersson Malte, 1994; AZIZ JB, 1975, THESIS U NEWCASTLE T; BORGIA G, 1990, AM ZOOL, V30, P279; BUTLIN RK, 1985, HEREDITY, V54, P107, DOI 10.1038/hdy.1985.14; BUTLIN RK, 1984, HEREDITY, V52, P415, DOI 10.1038/hdy.1984.49; BUTLIN RK, 1982, HEREDITY, V48, P45, DOI 10.1038/hdy.1982.5; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; DAY TH, 1982, HEREDITY, V48, P35, DOI 10.1038/hdy.1982.4; Falconer D. S., 1989, Introduction to quantitative genetics.; GILBURN AS, 1994, GENET RES, V64, P19, DOI 10.1017/S001667230003250X; GILBURN AS, 1992, HEREDITY, V69, P209, DOI 10.1038/hdy.1992.118; HOULE D, 1992, GENETICS, V130, P195; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LANDE R, 1980, EVOLUTION, V34, P292, DOI [10.2307/2407393, 10.1111/j.1558-5646.1980.tb04817.x]; LANDE R, 1985, J THEOR BIOL, V117, P651, DOI 10.1016/S0022-5193(85)80245-9; MILINSKI M, 1990, NATURE, V344, P330, DOI 10.1038/344330a0; MOLLER AP, 1991, EVOLUTION, V45, P1823, DOI 10.1111/j.1558-5646.1991.tb02690.x; POMIANKOWSKI A, 1991, EVOLUTION, V45, P1422, DOI 10.1111/j.1558-5646.1991.tb02645.x; POMIANKOWSKI A, IN PRESS P R SOC B; RITCHIE MG, 1992, TRENDS ECOL EVOL, V7, P328, DOI 10.1016/0169-5347(92)90123-S; SIMMONS LW, 1991, J EVOLUTION BIOL, V4, P593, DOI 10.1046/j.1420-9101.1991.4040593.x; SMITH JM, 1991, TRENDS ECOL EVOL, V6, P146, DOI 10.1016/0169-5347(91)90055-3; ZUK M, 1990, AM ZOOL, V30, P235; [No title captured]	26	43	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	1995	374	6518					158	159		10.1038/374158a0	http://dx.doi.org/10.1038/374158a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877687				2022-12-01	WOS:A1995QL39700057
J	XU, FF; COHEN, SN				XU, FF; COHEN, SN			RNA DEGRADATION IN ESCHERICHIA-COLI REGULATED BY 3' ADENYLATION AND 5' PHOSPHORYLATIAN	NATURE			English	Article							ANTISENSE RNAI; COPY NUMBER; GENE; STABILITY; PLASMIDS; PCNB; REPLICATION; TRANSCRIPT; EXPRESSION; INVIVO	ALTHOUGH polyadenylation has commonly been regarded as a special feature of eukaryotic messenger RNA(1,2), there are many reports of polyA tails on bacterial RNA (for example, refs 3-8). In Escherichia coli, adenylation mediated by the pcnB gene greatly accelerates decay of RNA I-8, an antisense repressor of replication of ColE1 type plasmids that resembles highly structured transfer RNA but shows the rapid turnover characteristic: of mRNA, Here we report that both 3' adenylation and 5' phosphorylation affect the rate of digestion of RNA I by the 3' exonuclease, polynucleotide phosphorylase(9); conversely, mutation of the polynucleotide phosphorylase-encoding pnp gene affects ribonuclease acting at the 5' end. Together these findings indicate that enzymes attacking RNA I at its separate termini can interact functionally, Additionally, our discovery that adenylation-mediated degradation by polynucleotide phosphorylase imparts an mRNA-like half-life to RNA I suggests a possible mechanism to account for the rapid decay of mRNA(10) in E. coli.	STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Stanford University								Baker EJ, 1993, CONTROL MESSENGER RN, P367; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BELTCHEV B, 1971, EUR J BIOCHEM, V19, P194, DOI 10.1111/j.1432-1033.1971.tb01304.x; BROWN JW, 1985, J BACTERIOL, V162, P909, DOI 10.1128/JB.162.3.909-917.1985; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P7546, DOI 10.1073/pnas.89.16.7546; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; GOPALAKRISHNA Y, 1981, BIOCHEM BIOPH RES CO, V103, P454, DOI 10.1016/0006-291X(81)90474-5; HAJNSDORF E, IN PRESS P NATN ACAD; HE L, 1993, MOL MICROBIOL, V9, P1131, DOI 10.1111/j.1365-2958.1993.tb01243.x; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; KELLY KO, 1992, J BIOL CHEM, V267, P16015; KING TC, 1987, CELLULAR MOL BIOL, P703; KLUG G, 1987, EMBO J, V6, P3515, DOI 10.1002/j.1460-2075.1987.tb02677.x; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LITTAUER UZ, 1982, ENZYMES, P518; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)80206-A; NAKAZATO H, 1975, NATURE, V256, P144, DOI 10.1038/256144a0; NEWBURY SF, 1987, CELL, V51, P1131, DOI 10.1016/0092-8674(87)90599-X; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; SACHS A, 1993, J BIOL CHEM, V268, P22955; SHEN V, 1982, ENZYMES, P518; SIPPEL AE, 1973, EUR J BIOCHEM, V37, P31, DOI 10.1111/j.1432-1033.1973.tb02953.x; THANG MN, 1971, EUR J BIOCHEM, V19, P184, DOI 10.1111/j.1432-1033.1971.tb01303.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; YU PL, 1982, FEMS MICROBIOL LETT, V14, P233	29	177	179	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					180	183		10.1038/374180a0	http://dx.doi.org/10.1038/374180a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7533264				2022-12-01	WOS:A1995QL39700064
J	DWYER, T; PONSONBY, AL; BLIZZARD, L; NEWMAN, NM; COCHRANE, JA				DWYER, T; PONSONBY, AL; BLIZZARD, L; NEWMAN, NM; COCHRANE, JA			THE CONTRIBUTION OF CHANGES IN THE PREVALENCE OF PRONE SLEEPING POSITION TO THE DECLINE IN SUDDEN-INFANT-DEATH-SYNDROME IN TASMANIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COT DEATHS; RISK; AUSTRALIA	Objective.-To determine the independent contribution of changes in infant sleep position to the recent decline in sudden infant death syndrome (SIDS) rate in Tasmania. Design.-(1) A comparison of the whole population incidence of SIDS before and after an intervention to reduce the prevalence of prone sleeping position. (2) A within-cohort analysis of the contribution of sleep position and other exposures to the decline in SIDS after the intervention. Setting.-Tasmania, Australia. Participants.-(1) All SIDS cases from 1975 through 1992. (2) A sample of one in five infants born in Tasmania who at perinatal assessment were scored to be at higher risk for SIDS since January 1988. Of 5534 infants included in the study, 39 later died of SIDS. Interventions.-Multiple public health activities to reduce the prevalence of the prone infant sleeping position in Tasmania and verbal information on the association between prone position and SIDS to cohort participants from May 1, 1991. Main Outcome Measure.-Sudden infant death syndrome incidence. Results.-The Tasmanian SIDS rate decreased (P<.01) from 3.8 (95% confidence interval [CI], 3.5 to 4.2) deaths per 1000 live births from 1975 through 1990 to a rate of 1.5 (95% CI, 0.9 to 2.2) deaths per 1000 live births in 1991 through 1992. The SIDS mortality rate in the cohort by period of birth was 7.6 (95% CI, 4.9 to 10.3) deaths per 1000 live births for those born from May 1, 1988, through April 30, 1991, and 4.1 (95% CI, 1.3 to 7.0) deaths per 1000 infants for those born from May 1, 1998, through October 31, 1992. The prevalence of usual prone sleeping position at 1 month of age was 29.9% and 4.3% in these two cohorts, respectively (adjusted odds ratio, 0.11; 95% CI, 0.08 to 0.13). Logistic regression demonstrated that 70% of the SIDS rate reduction in the cohort could be accounted for by the decreased prevalence of the prone sleeping position. Other factors examined individually contributed to less than 10% of the SIDS rate reduction. Conclusions.-The major contributing factor to the recent SIDS rate decline in Tasmania has been the reduction in the proportion of infants usually sleeping prone.			DWYER, T (corresponding author), UNIV TASMANIA,MENZIES CRR POPULAT HLTH RES,GPO BOX 252C,HOBART,TAS 7000,AUSTRALIA.		Ponsonby, Anne-Louise/AAE-4351-2019	Ponsonby, Anne-Louise/0000-0002-6581-3657	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028979] Funding Source: NIH RePORTER; NICHD NIH HHS [001 HD28979-01A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAL S, 1991, MED J AUSTRALIA, V155, P507, DOI 10.5694/j.1326-5377.1991.tb93882.x; BEAL SM, 1991, J PAEDIATR CHILD H, V27, P334, DOI 10.1111/j.1440-1754.1991.tb00414.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BRESLOW NE, 1993, STATISTICAL METHODS, V2, P109; d'Espaignet E T, 1990, Paediatr Perinat Epidemiol, V4, P422, DOI 10.1111/j.1365-3016.1990.tb00670.x; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; EMERY JL, 1986, MED J AUSTRALIA, V144, P469, DOI 10.5694/j.1326-5377.1986.tb101052.x; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; HOFFMAN HJ, 1992, CLIN PERINATOL, V19, P717, DOI 10.1016/S0095-5108(18)30427-5; HOLBOROW P, 1991, NEW ZEAL MED J, V104, P296; JONES ME, 1994, EPIDEMIOLOGY, V5, P332, DOI 10.1097/00001648-199405000-00012; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; LEWIS J, 1993, LANCET, V341, P51, DOI 10.1016/0140-6736(93)92525-X; MITCHELL EA, 1991, J PAEDIATR CHILD H, V27, P319, DOI 10.1111/j.1440-1754.1991.tb00409.x; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS9, DOI 10.1111/j.1440-1754.1992.tb02732.x; MITCHELL EA, 1992, J PAEDIATR CHILD H S; PONSONBY AL, 1994, PREV MED, V23, P402, DOI 10.1006/pmed.1994.1055; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PONSONBY AL, 1994, NEW ENGL J MED, V330, P64; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P146; SALONEN JT, 1989, INT J EPIDEMIOL, V18, P595, DOI 10.1093/ije/18.3.595; SPIERS PS, 1994, ARCH PEDIAT ADOL MED, V148, P141, DOI 10.1001/archpedi.1994.02170020027004; WILLIAMS AL, 1990, AUST NZ J OBSTET GYN, V30, P98, DOI 10.1111/j.1479-828X.1990.tb03235.x; 1993, STATISTICAL METHODS, V2, P131; 1992, SURVEY INFANT SLEEPI; 1993, BIRTHS 1988 1992 AUS; 1993, FETAL INFANT DEATHS; 1993, DEATHS 1988 1992 AUS; 1991, 112TH SESS NHMRC COU; [No title captured]; 1990, SAS STAT USERS GUIDE, V2; 1994, FETAL INFANT DEATHS; 1991, J PAEDIATR CHILD HLT, V27, P323; 1990, SAS STAT USERS GUIDE, V1	38	129	130	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					783	789		10.1001/jama.273.10.783	http://dx.doi.org/10.1001/jama.273.10.783			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861572				2022-12-01	WOS:A1995QJ75000029
J	KLONOFFCOHEN, HS; EDELSTEIN, SL				KLONOFFCOHEN, HS; EDELSTEIN, SL			A CASE-CONTROL STUDY OF ROUTINE AND DEATH SCENE SLEEP POSITION AND SUDDEN-INFANT-DEATH-SYNDROME IN SOUTHERN CALIFORNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COT DEATH; PRONE; RISK; EPIDEMIOLOGY	Objective.-To investigate whether infants who died of sudden infant death syndrome (SIDS) were routinely placed in different sleep positions compared with healthy infants in a multiethnic diverse population in the United States. Design.-A population-based case-control study. Setting.-Five counties in Southern California including Los Angeles, Orange, San Bernardino, Riverside, and San Diego. Participants.-Parents of 200 white, African-American, Hispanic, and Asian infants who died of SIDS between January 1989 and December 1992 and parents of 200 healthy, living infants matched on the basis of birth hospital, birth date, race, and gender. Information was obtained from detailed telephone interviews with the parents and validated with obstetric and pediatric records. Main Outcome Measures.-Routine sleep position, type of bedding, and objects in bed were determined for both case and control infants, while the last-placed and found sleep and face positions at death were reported for SIDS infants. Results.-Approximately 66% of SIDS infants and 64% of comparison infants routinely slept on their abdomens (P=.91). At the time of death, 80% of cases were found sleeping on their abdomens. There was no difference in routine sleep position for SIDS infants and comparison infants (odds ratio=0.76; 95% confidence interval, 0.42 to 1.38), while simultaneously adjusting for birth weight (in grams), medical conditions at birth, breast-feeding, passive smoking, maternal recreational drug use, prenatal care, and infant vomiting. Hispanic parents routinely placed their infants on their abdomens less frequently than white parents (P<.01). However, the prone sleep position (face down) was the most commonly found sleep position at death in both Hispanic and non-Hispanic infants. Conclusions.-Routine prone sleep position was not associated with an increased risk of SIDS in this study population. The results need to be confirmed with other parents of SIDS infants interviewed before the height of publicity regarding prone sleep position in the United States.			KLONOFFCOHEN, HS (corresponding author), UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, DIV EPIDEMIOL, 9500 GILMAN DR, 0607, LA JOLLA, CA 92037 USA.							BEAL S, 1991, MED J AUSTRALIA, V155, P507, DOI 10.5694/j.1326-5377.1991.tb93882.x; BEAL SM, 1991, J PAEDIATR CHILD H, V27, P334, DOI 10.1111/j.1440-1754.1991.tb00414.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BECKWITH J, 1988, SUDDEN INFANT DEATH; CAMERON MH, 1986, AUST PAEDIATR J, V22, P37; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; DREWS CD, 1990, INT J EPIDEMIOL, V19, P405, DOI 10.1093/ije/19.2.405; DWYER T, 1992, J EPIDEMIOL COMMUN H, V46, P98, DOI 10.1136/jech.46.2.98; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; GOULD JB, 1988, ANN NY ACAD SCI, V533, P62, DOI 10.1111/j.1749-6632.1988.tb37234.x; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; HOFFMAN HJ, 1992, CLIN PERINATOL, V19, P717, DOI 10.1016/S0095-5108(18)30427-5; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; KLEINBAUM D, 1982, OBSERVATIONAL RES; KROUS H F, 1988, Pediatrician, V15, P231; MCGLASHAN ND, 1988, LANCET, V2, P106; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS9, DOI 10.1111/j.1440-1754.1992.tb02732.x; NELSON EAS, 1989, AUST PAEDIATR J, V25, P202; NICHOLL JP, 1989, J EPIDEMIOL COMMUN H, V43, P133, DOI 10.1136/jech.43.2.133; PETERSON D R, 1988, Pediatrician, V15, P198; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; SENECAL J, 1987, ARCH FR PEDIATR, V44, P131; STEELE R, 1966, CAN MED ASSOC J, V94, P1165; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; 1991, CALIFORNIA MORBIDITY	32	35	35	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					790	794		10.1001/jama.273.10.790	http://dx.doi.org/10.1001/jama.273.10.790			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861573				2022-12-01	WOS:A1995QJ75000030
J	KLONOFFCOHEN, HS; EDELSTEIN, SL; LEFKOWITZ, ES; SRINIVASAN, IP; KAEGI, D; CHANG, JC; WILEY, KJ				KLONOFFCOHEN, HS; EDELSTEIN, SL; LEFKOWITZ, ES; SRINIVASAN, IP; KAEGI, D; CHANG, JC; WILEY, KJ			THE EFFECT OF PASSIVE SMOKING AND TOBACCO EXPOSURE THROUGH BREAST-MILK ON SUDDEN-INFANT-DEATH-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MATERNAL SMOKING; CIGARETTE-SMOKING; BIRTH-WEIGHT; RISK-FACTORS; PREGNANCY; HYPOXIA	Objective.-To examine the relationship between sudden infant death syndrome (SIDS) and smoking during pregnancy; postnatal tobacco smoke exposure from the mother, father, live-in adults, and day care providers; and postnatal smoke exposure from breast-feeding. Design.-Case-control study. Setting.-Five counties in Southern California. Participants.-A total of 200 white, African-American, Hispanic, and Asian parents of infants who died of SIDS between 1989 and 1992 were compared with 200 control parents who delivered healthy infants. Case infants were matched to control infants on the basis of birth hospital, birth date, gender, and race. All information was obtained from a detailed telephone interview and validated with medical records. Main Outcome Measures.-Risk of SIDS associated with passive smoking by the mother, father, live-in adults, and day care providers; smoking in the same room as the infant; total number of cigarettes smoked by all adults; and maternal smoking during the time period of breast-feeding. Results.-Conditional logistic regression resulted in overall adjusted odds ratios (ORs) for SIDS associated with passive smoke from the mother of 2.28, the father of 3.46, other live-in adults of 2.18, and all sources of 3.50 (95% confidence interval, 1.81 to 6.75), while simultaneously adjusting for birth weight, sleep position, prenatal care, medical conditions at birth, breast-feeding, and maternal smoking during pregnancy. A dose-response effect was noted for SIDS associated with increasing numbers of cigarettes, as well as total number of smokers. Breast-feeding was protective for SIDS among nonsmokers (OR=0.37) but not smokers (OR=1.38), when adjusting for potential confounders. Conclusions.-Passive smoking in the same room as the infant increases the risk for SIDS. Physicians should educate new and prospective parents about the risks of tobacco smoke exposure during pregnancy and the first year of the infant's life.			KLONOFFCOHEN, HS (corresponding author), UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, DIV EPIDEMIOL, 9500 GILMAN DR, 0607, LA JOLLA, CA 92093 USA.							AVERY ME, 1983, NEW ENGL J MED, V309, P107, DOI 10.1056/NEJM198307143090211; BERGMAN AB, 1976, PEDIATRICS, V58, P665; BULTERYS MG, 1990, PEDIATRICS, V86, P535; CARPENTE.RG, 1965, BRIT J PREV SOC MED, V19, P1; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; Golding J., 1985, SUDDEN INFANT DEATH; HAGLUND B, 1990, AM J PUBLIC HEALTH, V80, P29, DOI 10.2105/AJPH.80.1.29; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; KLONOFFCOHEN HS, 1995, JAMA-J AM MED ASSOC, V273, P790, DOI 10.1001/jama.273.10.790; KRAUS JF, 1989, INT J EPIDEMIOL, V18, P113, DOI 10.1093/ije/18.1.113; KROUS H F, 1988, Pediatrician, V15, P231; LI DK, 1991, AM J EPIDEMIOL, V134, P958, DOI 10.1093/oxfordjournals.aje.a116180; MALLOY MH, 1992, AM J PUBLIC HEALTH, V82, P1380, DOI 10.2105/AJPH.82.10.1380; MALLOY MH, 1988, AM J EPIDEMIOL, V128, P46, DOI 10.1093/oxfordjournals.aje.a114957; MCGLASHAN ND, 1989, SOC SCI MED, V29, P1015, DOI 10.1016/0277-9536(89)90059-2; MITCHELL E, 1991, NZ MED J, V106, P71; MITCHELL EA, 1987, NEW ZEAL MED J, V100, P269; MITCHELL EA, 1993, PEDIATRICS, V91, P893; MURPHY JF, 1982, J EPIDEMIOL COMMUN H, V36, P17, DOI 10.1136/jech.36.1.17; NAEYE RL, 1976, AM J DIS CHILD, V130, P1207, DOI 10.1001/archpedi.1976.02120120041005; PETERSON DR, 1981, AM J EPIDEMIOL, V113, P583, DOI 10.1093/oxfordjournals.aje.a113135; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PROTESTOS CD, 1973, ARCH DIS CHILD, V48, P835, DOI 10.1136/adc.48.11.835; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; STEELE R, 1966, CAN MED ASSOC J, V94, P1165; VANDENBERG M, 1985, NEW ZEAL MED J, V98, P1075; 1993, STATISTICS EPIDEMIOL; 1985, SAS USERS GUIDE VERS; 1988, MMWR-MORBID MORTAL W, V37, P644; 1986, HLTH CONSEQUENCES IN, P38	31	171	177	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					795	798		10.1001/jama.273.10.795	http://dx.doi.org/10.1001/jama.273.10.795			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861574				2022-12-01	WOS:A1995QJ75000031
J	SIMINOSKI, K				SIMINOSKI, K			DOES THIS PATIENT HAVE A GOITER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THYROID SIZE; CLINICAL-ASSESSMENT; ULTRASOUND; FREQUENCY; IODINE; VOLUME; ACCURACY; DISEASE; GLAND				SIMINOSKI, K (corresponding author), UNIV ALBERTA, DEPT MED, DIV ENDOCRINOL & METAB, 362 HMRC, EDMONTON, AB T6G 2S2, CANADA.							BERGHOUT A, 1988, CLIN ENDOCRINOL, V28, P409, DOI 10.1111/j.1365-2265.1988.tb03672.x; BERGHOUT A, 1987, CLIN ENDOCRINOL, V26, P273, DOI 10.1111/j.1365-2265.1987.tb00784.x; BRANDER A, 1992, J CLIN ULTRASOUND, V20, P37, DOI 10.1002/jcu.1870200107; BROWN MC, 1978, ACTA RADIOL ONCOL, V17, P337, DOI 10.3109/02841867809127937; BURCH WM, 1987, CASE STUDIES ENDOCRI, P52; CLAIN A, 1986, HAMILTON BAILLEYS DE, P155; COOK IJ, 1989, AM J PHYSIOL, V257, pG748, DOI 10.1152/ajpgi.1989.257.5.G748; CROOKS J, 1967, LANCET, V2, P625; Daniels G, 1991, WERNER INGBARS THYRO, P572; Dingle P R, 1966, Clin Exp Immunol, V1, P277; EASTHAM RD, 1985, POCKET GUIDE DIFFERE, P220; EDWARDS CRW, 1990, MACLEODS CLIN EXAMIN, P66; GREENSPAN FS, 1991, BASIC CLIN ENDOCRINO, P213; GURNEY C, 1970, LANCET, V2, P1275; GUTEKUNST R, 1986, ACTA ENDOCRINOL-COP, V112, P494, DOI 10.1530/acta.0.1120494; GWINUP G, 1975, J CLIN ENDOCR METAB, V40, P37, DOI 10.1210/jcem-40-1-37; HEGEDUS L, 1990, DAN MED BULL, V37, P249; HEGEDUS L, 1985, CLIN ENDOCRINOL, V22, P287, DOI 10.1111/j.1365-2265.1985.tb03242.x; HEGEDUS L, 1985, CLIN ENDOCRINOL, V23, P423, DOI 10.1111/j.1365-2265.1985.tb01100.x; HEGEDUS L, 1987, DAN MED BULL, V34, P121; HENNESSY W B, 1964, Med J Aust, V1, P505; HINTZE G, 1991, ACTA ENDOCRINOL-COP, V124, P12, DOI 10.1530/acta.0.1240012; HOLLINGSWORTH DR, 1963, MEDICINE, V42, P47, DOI 10.1097/00005792-196301000-00003; HULL OH, 1955, ARCH PATHOL, V59, P291; Jaffe RH, 1930, ARCH PATHOL, V10, P887; JARLOV AE, 1991, J INTERN MED, V229, P159, DOI 10.1111/j.1365-2796.1991.tb00324.x; JARLOV AE, 1991, DAN MED BULL, V38, P87; KATLIC MR, 1985, ANN THORAC SURG, V39, P391, DOI 10.1016/S0003-4975(10)62645-8; KEARNS JE, 1967, TREATMENT HYPERTHYRO, P16; KILPATRICK R, 1963, BMJ-BRIT MED J, P29; LADENSON PW, 1991, WERNER INGBARS THYRO, P901; MACLENNAN R, 1969, ENDEMIC GOITER, P67; MALAMOS B, 1970, ENDOKRINOLOGIE, V56, P232; MANDART G, 1975, INT J NUCL MED BIOL, V2, P185, DOI 10.1016/S0047-0740(75)80009-X; MERCER R D, 1975, Cleveland Clinic Quarterly, V42, P319; PEREZ C, 1958, Bull World Health Organ, V18, P217; PERRILD H, 1990, AM J PSYCHIAT, V147, P1518; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SHAPIRA JD, 1990, ART SCI BEDSIDE DIAG, P236; Silink K, 1966, ENDEMIC GOITRE ALLIE, P33; SIMINOSKI K, 1994, HEAD NECK-J SCI SPEC, V16, P21, DOI 10.1002/hed.2880160106; SMITH RN, 1967, BRIT MED J, V1, P129, DOI 10.1136/bmj.1.5533.129; TAMAYO SG, 1993, J GEN INTERN MED, V8, P69, DOI 10.1007/BF02599986; TANNAHILL AJ, 1978, CLIN ENDOCRINOL, V8, P483, DOI 10.1111/j.1365-2265.1978.tb02185.x; TROTTER WR, 1962, BRIT J PREV SOC MED, V16, P16; TROWBRIDGE FL, 1975, PEDIATRICS, V56, P82; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILLIAMS RH, 1949, AM J MED, V7, P702, DOI 10.1016/0002-9343(49)90409-X; WINSA B, 1990, ACTA ENDOCRINOL-COP, V122, P722, DOI 10.1530/acta.0.1220722	50	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					813	817		10.1001/jama.273.10.813	http://dx.doi.org/10.1001/jama.273.10.813			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861577				2022-12-01	WOS:A1995QJ75000035
J	BRACKBILL, RM; SIEGEL, PZ; ACKERMANN, SP				BRACKBILL, RM; SIEGEL, PZ; ACKERMANN, SP			SELF-REPORTED HYPERTENSION AMONG UNEMPLOYED PEOPLE IN THE UNITED-STATES	BRITISH MEDICAL JOURNAL			English	Article											BRACKBILL, RM (corresponding author), CTR DIS CONTROL & PREVENT,MAILSTOP E-44,ATLANTA,GA 30333, USA.							FRANCO LJ, 1985, AM J EPIDEMIOL, V21, P684; LEEFLANG RLI, 1992, SOC SCI MED, V34, P351, DOI 10.1016/0277-9536(92)90295-2; SMITH R, 1991, BRIT MED J, V305, P972; THEORELL T, 1975, INT J EPIDEMIOL, V4, P281, DOI 10.1093/ije/4.4.281; 1989, SURVEY DATA ANAL SUD	5	9	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					568	568		10.1136/bmj.310.6979.568	http://dx.doi.org/10.1136/bmj.310.6979.568			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QK700	7888932	Green Published			2022-12-01	WOS:A1995QK70000020
J	CHESTER, MR; BARNETT, DB				CHESTER, MR; BARNETT, DB			CARDIAC CHAMBER-SPECIFIC BETA-ADRENOCEPTOR REGULATION AND SYMPATHETIC INNERVATION	LANCET			English	Note							HEART-FAILURE; DOWN-REGULATION; BETA-1-ADRENOCEPTOR; BETA-2-ADRENOCEPTOR; CARDIOMYOPATHY	We assessed by radioligand binding techniques the effect of cardiac failure on beta-adrenoceptor density in 5 hearts from patients undergoing repeat transplantation and 5 normal (unused donor) hearts. Right ventricular total and subtype beta-adrenoceptors in the denervated repeat-transplant hearts were down-regulated compared with the normally innervated controls. Within the denervated hearts, beta(1)-adrenoceptors were selectively down-regulated in the right ventricle compared with the left ventricle. Tissue noradrenaline content confirmed sympathetic denervation in the transplantd hearts. Thus, regional sympathetic innervation is not necessary for chamber-specific beta-adrenoceptor down-regulation; other mechanisms for this process should be sought.	NATL HEART & LUNG INST, LONDON, ENGLAND; LEICESTER ROYAL INFIRM, DEPT PHARMACOL, LEICESTER LE2 7LX, LEICS, ENGLAND	Imperial College London; University of Leicester								BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1989, J AM COLL CARDIOL, V14, P323, DOI 10.1016/0735-1097(89)90181-2; CHESTER MR, 1992, BRIT J CLIN PHARMACO, V33, P417, DOI 10.1111/j.1365-2125.1992.tb04061.x; GILBERT EM, 1989, CIRCULATION, V79, P344, DOI 10.1161/01.CIR.79.2.344; KAWAI C, 1983, J AM COLL CARDIOL, V2, P834, DOI 10.1016/S0735-1097(83)80229-0; LIANG CS, 1989, J CLIN INVEST, V84, P1267, DOI 10.1172/JCI114294; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; WAAGSTEIN F, 1989, CIRCULATION, V80, P551, DOI 10.1161/01.CIR.80.3.551; YOSHIKAWA T, 1994, J AM COLL CARDIOL, V24, P210, DOI 10.1016/0735-1097(94)90565-7	10	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	1995	345	8949					553	555		10.1016/S0140-6736(95)90467-0	http://dx.doi.org/10.1016/S0140-6736(95)90467-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776776				2022-12-01	WOS:A1995QK44400012
J	DICKERSON, JEC; BROWN, MJ				DICKERSON, JEC; BROWN, MJ			INFLUENCE OF AGE ON GENERAL-PRACTITIONERS DEFINITION AND TREATMENT OF HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT		UNIV CAMBRIDGE,ADDENBROOKES HOSP,CLIN PHARMACOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge								BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; HART JT, 1993, BRIT MED J, V306, P437, DOI 10.1136/bmj.306.6875.437; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; 1985, BRIT MED J, V291, P97; 1992, BRIT MED J, V304, P405	5	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					574	574		10.1136/bmj.310.6979.574	http://dx.doi.org/10.1136/bmj.310.6979.574			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888934	Green Published, Green Submitted			2022-12-01	WOS:A1995QK70000022
J	FARRINGTON, P; PUGH, S; COLVILLE, A; FLOWER, A; NASH, J; MORGANCAPNER, P; RUSH, M; MILLER, E				FARRINGTON, P; PUGH, S; COLVILLE, A; FLOWER, A; NASH, J; MORGANCAPNER, P; RUSH, M; MILLER, E			A NEW METHOD FOR ACTIVE SURVEILLANCE OF ADVERSE EVENTS FROM DIPHTHERIA-TETANUS-PERTUSSIS AND MEASLES MUMPS RUBELLA VACCINES	LANCET			English	Article							IMMUNIZATION; RISK; VACCINATION; CHILDREN; SEIZURES	We describe a new method for active post-marketing surveillance of vaccine safety based on patient records. We studied the association between diphtheria/tetanus/pertussis (DTP) vaccination and febrile convulsion, and between measles/mumps/rubella (MMR) vaccination and febrile convulsion and idiopathic thrombocytopenic purpura (ITP) in five district health authorities in England by linking vaccination records with computerised hospital admission records. We found an increased relative incidence for convulsions 0-3 days after DTP vaccination. The effect was limited to the third dose of vaccine for which the attributable risk (all ages) was 1 in 12 500 doses. Completion of vaccination by 4 months instead of 10 months after the change in the UK to an accelerated immunisation schedule may have resulted in a 4-fold decrease in febrile convulsions attributable to DTP vaccine. 67% of admissions for a convulsion 6-11 days after MMR vaccination were attributable to the measles component of the vaccine (risk 1 in 3000 doses). An excess of admissions for a convulsion 15-35 days after MMR vaccination was found only for vaccines containing the Urabe mumps strain (1 in 2600 Urabe doses). There was a causal association between MMR vaccination and ITP resulting in admission 15-35 days subsequently; there was no evidence of a mumps strain-specific effect. The estimated absolute risk of 1 in 24 000 doses was 5 times that calculated from cases passively reported by clinicians. This finding emphasises the need for active surveillance of adverse events. The record linkage method that we used is an effective way to identify vaccine-attributable adverse events.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,STAT UNIT,LONDON NW9 5EQ,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,PUBL HLTH LAB,NOTTINGHAM NG7 2UH,ENGLAND; LEICESTER ROYAL INFIRM,PUBL HLTH LAB,LEICESTER,LEICS,ENGLAND; WILLIAM HARVEY HOSP,PUBL HLTH LAB,ASHFORD,KENT,ENGLAND; ROYAL PRESTON HOSP,PUBL HLTH LAB,PRESTON,LANCS,ENGLAND	Public Health England; Public Health England; University of Nottingham; University of Leicester; Royal Preston Hospital				Farrington, Conor Patrick/0000-0002-7148-2612				BEGG NT, 1989, PUBLIC HEALTH, V103, P81, DOI 10.1016/S0033-3506(89)80021-6; FARRINGTON CP, IN PRESS BIOMETRICS; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GRIFFIN MR, 1990, JAMA-J AM MED ASSOC, V263, P1641, DOI 10.1001/jama.263.12.1641; GRIFFIN MR, 1991, PEDIATRICS, V88, P881; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; MILLER E, 1993, LANCET, V341, P979, DOI 10.1016/0140-6736(93)91069-X; NEIMINEN U, 1993, ACTA PAEDIATR, V82, P267; POLLOCK TM, 1983, LANCET, V1, P753; SCHMITT HJ, 1993, EUR J PEDIATR, V152, P387, DOI 10.1007/BF01955892; WEIRSBITZKY S, 1993, LANCET, V341, P379	11	239	242	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					567	569		10.1016/S0140-6736(95)90471-9	http://dx.doi.org/10.1016/S0140-6736(95)90471-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7619183	Bronze			2022-12-01	WOS:A1995QK44400016
J	HORNE, JA; REYNER, LA				HORNE, JA; REYNER, LA			SLEEP-RELATED VEHICLE ACCIDENTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To assess the incidence, time of day, and driver morbidity associated with vehicle accidents where the most likely cause was the driver falling asleep at the wheel. Design-Two surveys were undertaken, in southwest England and the midlands, by using police databases or on the spot interviews. Subjects-Drivers involved in 679 sleep related vehicle accidents. Results-Of all vehicle accidents to which the police were summoned, sleep related vehicle accidents comprised 16% on major roads in southwest England, and over 20% on midland motorways. During the 24 hour period there were three major peaks: at around 0200, 0600, and 1600. About half these drivers were men under 30 years; few such accidents involved women. Conclusions-Sleep related vehicle accidents are largely dependent on the time of day and account for a considerable proportion of vehicle accidents, especially those on motorways and other monotonous roads. As there are no norms for the United Kingdom on road use by age and sex for time of day with which to compare these data, we cannot determine what the hourly exposure upsilon risk factors are for these subgroups. The findings are in close agreement with those from other countries.			HORNE, JA (corresponding author), LOUGHBOROUGH UNIV TECHNOL,DEPT HUMAN SCI,SLEEP RES LAB,LOUGHBOROUGH LE11 3TU,LEICS,ENGLAND.			Albery, Ian/0000-0002-5626-8677				AKERSTEDT T, 1994, J SLEEP RES, V3, P194; BRENDEL DH, 1990, PSYCHOPHYSIOLOGY, V27, P677, DOI 10.1111/j.1469-8986.1990.tb03193.x; HORNE JA, 1988, WHY WE SLEEP; LANGLOIS PH, 1986, CHRONOBIOL INT, V2, P131; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; MONK TH, 1991, SLEEPINESS SLEEP PER, P325; PACK AM, 1994, SLEEP RES, V23, P141; ZOMER J, 1990, SLEEP 90, P448; ZULLEY J, 1994, 248 KAR I STRESS RES, P104; 1994, ROAD ACCIDENTS GB 19	11	559	575	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					565	567		10.1136/bmj.310.6979.565	http://dx.doi.org/10.1136/bmj.310.6979.565			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888930	Green Published			2022-12-01	WOS:A1995QK70000018
J	HORTON, R				HORTON, R			WOMEN AS WOMEN WITH HIV	LANCET			English	Editorial Material																		CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; MILNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915; 1994, LANCET, V344, P207; 1995, MMWR-MORBID MORTAL W, V44, P81	4	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					531	532		10.1016/S0140-6736(95)90458-1	http://dx.doi.org/10.1016/S0140-6736(95)90458-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776767	Bronze			2022-12-01	WOS:A1995QK44400003
J	LIVINGSTON, MG				LIVINGSTON, MG			INTERACTIONS WITH SELECTIVE MAOIS	LANCET			English	Editorial Material							OXIDASE; PSEUDOPHAEOCHROMOCYTOMA; MOCLOBEMIDE; INHIBITORS; SELEGILINE				LIVINGSTON, MG (corresponding author), UNIV GLASGOW,GARTNAVEL ROYAL HOSP,DEPT PSYCHOL MED,GLASGOW,LANARK,SCOTLAND.							BASS C, 1989, BRIT MED J, V298, P345, DOI 10.1136/bmj.298.6670.345; FREEMAN H, 1993, LANCET, V342, P1528, DOI 10.1016/S0140-6736(05)80090-X; KNOLL J, 1978, BIOCHEM PHARMACOL, V27, P1739, DOI 10.1016/0006-2952(78)90550-6; LEFEBVRE H, 1995, CLIN ENDOCRINOL, V42, P95, DOI 10.1111/j.1365-2265.1995.tb02604.x; LEFEBVRE H, 1993, LANCET, V341, P555, DOI 10.1016/0140-6736(93)90314-7; MANN JJ, 1989, ARCH GEN PSYCHIAT, V46, P45; MCGRATH PJ, 1989, J CLIN PSYCHOPHARM, V9, P310; MONTASTRUC JL, 1993, LANCET, V341, P555, DOI 10.1016/0140-6736(93)90313-6; NEUVONEN PJ, 1993, LANCET, V342, P1419, DOI 10.1016/0140-6736(93)92774-N; ZORNBERG GL, 1991, LANCET, V337, P246, DOI 10.1016/0140-6736(91)92219-R; 1989, DRUG THER B, V27, P63	11	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					533	534		10.1016/S0140-6736(95)90460-3	http://dx.doi.org/10.1016/S0140-6736(95)90460-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776769				2022-12-01	WOS:A1995QK44400005
J	PERRY, IJ; WANNAMETHEE, SG; WALKER, MK; THOMSON, AG; WHINCUP, PH; SHAPER, AG				PERRY, IJ; WANNAMETHEE, SG; WALKER, MK; THOMSON, AG; WHINCUP, PH; SHAPER, AG			PROSPECTIVE-STUDY OF RISK-FACTORS FOR DEVELOPMENT OF NON-INSULIN-DEPENDENT DIABETES IN MIDDLE-AGED BRITISH MEN	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; PHYSICAL-ACTIVITY; MELLITUS; RESISTANCE; POPULATION	Objective-To determine the risk factors for noninsulin dependent diabetes in a cohort representative of middle aged British men. Design-Prospective study. Subjects and setting-7735 men aged 40-59, drawn from one group practice in each of 24 towns in Britain. Known and probable cases of diabetes at screening (n=158) were excluded. Main outcome measures-Non-insulin dependent diabetes (doctor diagnosed) over a mean follow up period of 12 . 8 years. Results-There were 194 new cases of non-insulin dependent diabetes. Body mass index was the dominant risk factor for diabetes, with an age adjusted relative risk (upper fifth to lower fifth) of 11 . 6; 95% confidence interval 5 . 4 to 16 . 8. Men engaged in moderate levels of physical activity had a substantially reduced risk of diabetes, relative to the physically inactive men, after adjustment for age and body mass index (0 . 4; 0 . 2 to 0 . 7), an association which persisted in full multivariate analysis. A nonlinear relation between alcohol intake and diabetes was observed, with the lowest risk among moderate drinkers (16-42 units/week) relative to the baseline group of occasional drinkers (0 . 6; 0 . 4 to 1 . 0). Additional significant predictors of diabetes in multivariate analysis included serum triglyceride concentration, high density lipoprotein cholesterol concentration (inverse association), heart rate, uric acid concentration, and prevalent coronary heart disease. Conclusion-These finding emphasise the interrelations between risk factors for non-insulin dependent diabetes and coronary heart disease and the potential value of an integrated approach to the prevention of these conditions based on the prevention of obesity and the promotion of physical activity.			PERRY, IJ (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Perry, Ivan/0000-0002-4965-9792; Wannamethee, Sasiwarang/0000-0001-9484-9977; Whincup, Peter/0000-0002-5589-4107	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHATURVEDI N, 1994, DIABETOLOGIA, V37, P765, DOI 10.1007/BF00404333; COOK DG, 1986, POSTGRAD MED J, V62, P1001, DOI 10.1136/pgmj.62.733.1001; COX DR, 1972, J R STAT SOC B, V34, P187; EVERHART J, 1985, DIABETES AM DIABETES; FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; LAWS A, 1993, BAILLIERE CLIN ENDOC, V7, P1063, DOI 10.1016/S0950-351X(05)80245-9; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; OHLSON LO, 1988, DIABETOLOGIA, V31, P798; PHILLIPS AN, 1986, THESIS U LONDON LOND; POCOCK SJ, 1989, J CLIN PATHOL, V42, P172, DOI 10.1136/jcp.42.2.172; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAVAGE PJ, 1993, BRIT HEART J, V69, P473; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; SHAPER AG, 1988, LANCET, V2, P1268; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; WALKER M, 1984, J R COLL GEN PRACT, V34, P197; WILLIAMS R, 1994, HLTH CARE NEEDS ASSE, V1, P31; 1992, CM1986 SECR STAT HLT	28	407	458	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					560	564		10.1136/bmj.310.6979.560	http://dx.doi.org/10.1136/bmj.310.6979.560			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888929	Green Published			2022-12-01	WOS:A1995QK70000017
J	PETO, J; HODGSON, JT; MATTHEWS, FE; JONES, JR				PETO, J; HODGSON, JT; MATTHEWS, FE; JONES, JR			CONTINUING INCREASE IN MESOTHELIOMA MORTALITY IN BRITAIN	LANCET			English	Article							ASBESTOS WORKERS	Mesothelioma is closely related to exposure to asbestos, and mesothelioma mortality can be taken as an index of past exposure to asbestos in the population. We analysed mesothelioma mortality since 1968 to assess the current state of the mesothelioma epidemic, and to predict its future course. We found that rates of mesothelioma in men formed a clear pattern defined by age and date of birth. Rates rose steeply with age showing a very similar pattern in all five-year birth cohorts. By date of birth, rates increased from mid-1893 to mid-1948, and then fell. Relative to the 1943-48 cohort, the risk for the 1948-53 cohort is 0.79 and for the 1953-58 cohort 0.48. Despite these falls, if the age profile of rates for these cohorts follows the pattern of past cohorts, their predicted lifetime mesothelioma risks will be 1.3%, 1.0%, and 0.6%. Combining projections for all cohorts results in a peak of annual male mesothelioma deaths in about the year 2020 of between 2700 and 3300 deaths. If diagnostic trend is responsible for a 20% growth in recorded cases every 5 years-an extreme but arguable case-and if this trend has now ceased, the peak of annual male deaths will be reduced to 1300, reached around the year 2010. Analysis of occupations recorded on death certificates indicate that building workers, especially plumbers and gas fitters, carpenters and electricians are the largest high-risk group. These data indicate that mesothelioma deaths will continue to increase for at least 15 and more likely 25 years. For the worst affected cohorts-men born in the 1940s-mesothelioma may account for around 1% of all deaths. Asbestos exposure at work in construction and building maintenance will account for a large proportion of these deaths, and it is important that such workers should be aware of the risks and take appropriate precautions.	HLTH & SAFETY EXECUT,EPIDEMIOL & MED STAT UNIT,BOOTLE,MERSEYSIDE,ENGLAND		PETO, J (corresponding author), INST CANC RES,EPIDEMIOL SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Matthews, Fiona/O-6932-2015	Matthews, Fiona/0000-0002-1728-2388				BERRY G, 1991, BRIT J IND MED, V48, P793; Burdett GJ, 1989, IARC SCI PUBL, V90, P277; CARBONE M, 1994, ONCOGENE, V9, P781; DINI S, 1992, AM J IND MED, V21, P569, DOI 10.1002/ajim.4700210412; HODGSON JT, 1986, BRIT J IND MED, V43, P158; JONES RD, 1988, SCAND J WORK ENV HEA, V14, P145, DOI 10.5271/sjweh.1938; NEWHOUSE ML, 1985, BRIT J IND MED, V42, P4; PETO J, 1982, BRIT J CANCER, V45, P124, DOI 10.1038/bjc.1982.15; PETO J, 1981, BANBURY REPORT, V9; Selikoff I J, 1979, Ann N Y Acad Sci, V330, P91, DOI 10.1111/j.1749-6632.1979.tb18711.x; Wagner JC, 1960, BR J IND MED, V17, P266; [No title captured]; 1995, IN PRESS OCCUPATIO S; 1968, ANN OCCUP HYG, V11, P47	14	457	463	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					535	539		10.1016/S0140-6736(95)90462-X	http://dx.doi.org/10.1016/S0140-6736(95)90462-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776771				2022-12-01	WOS:A1995QK44400007
J	QUAGLIARELLO, VJ; VISCOLI, C; HORWITZ, RI				QUAGLIARELLO, VJ; VISCOLI, C; HORWITZ, RI			PRIMARY PREVENTION OF CRYPTOCOCCAL MENINGITIS BY FLUCONAZOLE IN HIV-INFECTED PATIENTS	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PRIMARY PROPHYLAXIS; AMPHOTERICIN-B; AIDS	To evaluate whether oral fluconazole reduces the risk of a first episode of cryptococcal meningitis in HIV-infected patients, we conducted a case-control study of patients cared for in a university teaching hospital and two urban HIV-outpatient clinics. Cases consisted of HIV-infected patients with CD4 cell counts less than 250/mu L who developed a first episode of cryptococcal meningitis between July 1, 1990, and June 30, 1993. For each case (n=18), 4 control subjects were chosen from HIV-infected patients (CD4 count < 250/mu L) whose cerebrospinal fluid was negative for cryptococcal antigen and culture, and who were matched by age, sex, and time of lumbar puncture. There were no significant differences between cases and controls in age, sex, insurance status, mean CD4 count, history of oral candidosis, presence of a previous AIDS-defining illness, the number of visits to the HIV-outpatient clinic, or use of antiretroviral therapy. In the 6 months before lumbar puncture, 2 of 18 cases (11%) and 26 of 72 controls (36%) were exposed to fluconazole, a finding that gives a matched odds ratio (adjusted for race, route of HIV infection, and CD4 count) of 0.08 (95% CI 0.01-0.84; p=0.035) and indicates a 92% protective efficacy. We conclude that fluconazole reduces the risk of a first episode of cryptococcal meningitis in HIV-infected patients with a CD4 count less than 250/mu L. Although the optimum dose and duration of fluconazole could not be determined, our results suggest that less than daily use was effective in the prevention of cryptococcal meningitis.			QUAGLIARELLO, VJ (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510, USA.							Breslow N, 1980, STAT METHODS CANC RE, P248; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; Cotton D., 1992, AIDS Clinical Care, V4, P85; FEINSTEIN AR, 1988, J CLIN INVEST, V81, P1, DOI 10.1172/JCI113279; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P118; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; HAYDEN GF, 1982, JAMA-J AM MED ASSOC, V247, P326, DOI 10.1001/jama.247.3.326; IMPERIALE TF, 1990, AM J MED, V88, P131, DOI 10.1016/0002-9343(90)90461-L; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NIGHTINGALE SD, 1992, AIDS, V6, P191, DOI 10.1097/00002030-199202000-00008; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; POWDERLY WG, 1993, CLIN INFECT DIS, V17, P837, DOI 10.1093/clinids/17.5.837; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; Wheat L. J., 1994, AIDS Clinical Care, V6, P27; 1992, MMWR-MORBID MORTAL W, V41, P1	18	42	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					548	552		10.1016/S0140-6736(95)90465-4	http://dx.doi.org/10.1016/S0140-6736(95)90465-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776774	hybrid			2022-12-01	WOS:A1995QK44400010
J	RIMM, EB; CHAN, J; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC				RIMM, EB; CHAN, J; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC			PROSPECTIVE-STUDY OF CIGARETTE-SMOKING, ALCOHOL-USE, AND THE RISK OF DIABETES IN MEN	BRITISH MEDICAL JOURNAL			English	Article							BODY-FAT DISTRIBUTION; MIDDLE-AGED MEN; GLUCOSE-TOLERANCE; INSULIN RESISTANCE; PHYSICAL-ACTIVITY; FOLLOW-UP; MELLITUS; WOMEN; CONSUMPTION; POPULATION	Objective-To examine the association between smoking, alcohol consumption, and the incidence of non-insulin dependent diabetes mellitus in men of middle years and older. Design-Cohort questionnaire study of men followed up for six years from 1986. Setting-The health professionals' follow up study being conducted across the United States. Subjects-41 810 male health professionals aged 40-75 years and free of diabetes, cardiovascular disease, and cancer in 1986 and followed up for six years. Main outcome meausre-Incidence of non-insulin dependent diabetes mellitus diagnosed in the six years. Results-During 230 769 person years of follow up 509 men were newly diagnosed with diabetes. After controlling for known risk factors men who smoked 25 or more cigarettes daily had a relative risk of diabetes of 1 . 94 (95% confidence interval 1 . 25 to 3 . 03) compared with non-smokers. Men who consumed higher amounts of alcohol had a reduced risk of diabetes (P for trend <0 . 001). Compared with abstainers men who drank 30 . 0-49 . 9 g of alcohol daily had a relative risk of diabetes of 0 . 61 (95% confidence interval 0 . 44 to 0 . 91). Conclusions-Cigarette smoking may be an independent, modifiable risk factor for non-insulin dependent diabetes mellitus. Moderate alcohol consumption among healthy people may be associated with increased insulin sensitivity and a reduced risk of diabetes.			RIMM, EB (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; Chan, June/0000-0002-7620-569X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANES D, 1987, AM J PUBLIC HEALTH, V77, P439, DOI 10.2105/AJPH.77.4.439; ALDOORI WH, IN PRESS GUT; ARKY RA, 1989, ENDOCRIN METAB CLIN, V18, P75, DOI 10.1016/S0889-8529(18)30389-X; BALKAU B, 1991, J CLIN EPIDEMIOL, V44, P465, DOI 10.1016/0895-4356(91)90209-R; BALKAU B, 1991, AM J EPIDEMIOL, V134, P1469, DOI 10.1093/oxfordjournals.aje.a116056; BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BUTLER WJ, 1982, AM J EPIDEMIOL, V116, P971, DOI 10.1093/oxfordjournals.aje.a113499; CHAN JM, 1994, DIABETES CARE, V17, P1; CHRISTIANSEN C, 1994, BRIT J NUTR, V71, P449, DOI 10.1079/BJN19940151; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; EISEN SA, 1993, ARCH INTERN MED, V153, P2457, DOI 10.1001/archinte.153.21.2457; FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115; FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GIN H, 1992, DIABETES CARE, V15, P546, DOI 10.2337/diacare.15.4.546; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; HARRIS MI, 1985, DIABETES AM DIABETES, V6; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HODGE AM, 1993, AM J EPIDEMIOL, V137, P178, DOI 10.1093/oxfordjournals.aje.a116658; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; JANZON L, 1983, DIABETOLOGIA, V25, P86; JARRETT RJ, 1989, EPIDEMIOL REV, V11, P151, DOI 10.1093/oxfordjournals.epirev.a036034; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; MACMAHON B, 1982, CANCER-AM CANCER SOC, V50, P2676; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; MEDALIE JH, 1975, ARCH INTERN MED, V135, P811, DOI 10.1001/archinte.135.6.811; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; PYORALA K, 1985, ACTA MED SCAND S, V701, P38; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SEIDELL JC, 1991, AM J EPIDEMIOL, V133, P257, DOI 10.1093/oxfordjournals.aje.a115870; SHAPER AG, 1988, LANCET, V2, P1267; SHIMOKATA H, 1989, JAMA-J AM MED ASSOC, V261, P1169, DOI 10.1001/jama.261.8.1169; SPARROW D, 1986, DIABETES, V35, P411, DOI 10.2337/diabetes.35.4.411; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; WHITTEMORE AS, 1983, J CHRON DIS, V36, P251, DOI 10.1016/0021-9681(83)90059-0; WILSON PWF, 1986, AM J MED, V80, P3, DOI 10.1016/0002-9343(86)90532-2; 1989, USDA AGR HDB, V8; 1994, MONTHLY VITAL STATIS, V43	48	434	456	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					555	559		10.1136/bmj.310.6979.555	http://dx.doi.org/10.1136/bmj.310.6979.555			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888928	Green Submitted, Green Published			2022-12-01	WOS:A1995QK70000016
J	CLARKE, JT; PRANGE, R; BALLESTER, GE; TRAUGER, J; EVANS, R; REGO, D; STAPELFELDT, K; IP, W; GERARD, JC; HAMMEL, H; BALLAV, M; BENJAFFEL, L; BERTAUX, JL; CRISP, D; EMERICH, C; HARRIS, W; HORANYI, M; MILLER, S; STORRS, A; WEAVER, H				CLARKE, JT; PRANGE, R; BALLESTER, GE; TRAUGER, J; EVANS, R; REGO, D; STAPELFELDT, K; IP, W; GERARD, JC; HAMMEL, H; BALLAV, M; BENJAFFEL, L; BERTAUX, JL; CRISP, D; EMERICH, C; HARRIS, W; HORANYI, M; MILLER, S; STORRS, A; WEAVER, H			HST FAR-ULTRAVIOLET IMAGING OF JUPITER DURING THE IMPACTS OF COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article							HUBBLE-SPACE-TELESCOPE; POLAR AURORA	Hubble Space Telescope far-ultraviolet images of Jupiter during the Shoemaker-Levy 9 impacts show the impact regions darkening over the 2 to 3 hours after the impact, becoming darker and more extended than at longer wavelengths, which indicates that ultraviolet-absorbing gases or aerosols are more extended, more absorbing, and at higher altitudes than the absorbers of visible light, Transient auroral emissions were observed near the magnetic conjugate point of the K impact site just after that impact. The global auroral activity was fainter than average during the impacts, and a variable auroral emission feature was observed inside the southern auroral oval preceding the impacts of fragments Q1 and Q2.	UNIV PARIS 11, CNRS, INST ASTROPHYS SPATIALE, F-91405 ORSAY, FRANCE; CNRS, INST ASTROPHYS SPATIALE, F-75014 PARIS, FRANCE; JET PROPULS LAB, PASADENA, CA 91109 USA; MAX PLANCK INST AERON, D-37191 KATLENBURG DUHM, GERMANY; UNIV LIEGE, INST ASTROPHYS, B-4000 LIEGE, BELGIUM; MIT, CAMBRIDGE, MA 02139 USA; CNRS, SERV AERON, F-91371 VERRIERES LE BUISSON, FRANCE; UNIV COLORADO, ATMOSPHER & SPACE PHYS LAB, BOULDER, CO 80309 USA; UCL, DEPT PHYS & ASTRON, LONDON, ENGLAND; SPACE TELESCOPE SCI INST, BALTIMORE, MD 21218 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Universite Paris Saclay; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Max Planck Society; University of Liege; Massachusetts Institute of Technology (MIT); Centre National de la Recherche Scientifique (CNRS); University of Colorado System; University of Colorado Boulder; University of London; University College London; Space Telescope Science Institute	CLARKE, JT (corresponding author), UNIV MICHIGAN, SPACE PHYS RES LAB, ANN ARBOR, MI 48109 USA.		Weaver, Harold A/D-9188-2016; Crisp, David/F-6642-2017; Clarke, John/C-8644-2013; Stapelfeldt, Karl R/D-2721-2012	Weaver, Harold A/0000-0003-0951-7762; Crisp, David/0000-0002-4573-9998; Miller, Steven/0000-0002-7159-6871; GERARD, Jean-Claude/0000-0002-8565-8746; Horanyi, Mihaly/0000-0002-5920-9226				BALLESTER G, UNPUB; BOLIN O, 1994, GEOPHYS RES LETT, V21, P1063, DOI 10.1029/94GL00890; BOSLOUGH MB, 1994, GEOPHYS RES LETT, V21, P1555, DOI 10.1029/94GL01582; CALDWELL J, 1992, SCIENCE, V257, P1512, DOI 10.1126/science.257.5076.1512; CLARKE JS, UNPUB; CLARKE JT, 1980, ASTROPHYS J, V241, pL179, DOI 10.1086/183386; CONNERNEY JEP, 1992, PLANETARY RADIO EMIS, V3, P13; CONNERNEY JEP, COMMUNICATION; CRAVENS TE, 1994, GEOPHYS RES LETT, V21, P1075, DOI 10.1029/94GL01070; DEPATER I, UNPUB; DESSLER AJ, 1994, B AM ASTRON SOC, V26, P1593; DOLS V, 1992, GEOPHYS RES LETT, V19, P1803, DOI 10.1029/92GL02104; FARRELL WM, 1994, GEOPHYS RES LETT, V21, P1067, DOI 10.1029/94GL01066; GERARD JC, 1993, J GEOPHYS RES-PLANET, V98, P18793, DOI 10.1029/93JE01334; GOMBOSI TI, 1989, J GEOPHYS RES, V94, P359, DOI 10.1029/JA094iA01p00359; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; HARRIS W, 6040 INT ASTR UN CIR; HARRIS WM, 1994, 6040 INT ASTR UN CIR; HARRIS WM, 1990, J GEOPHYS RES, V95, P10375; HERBERT F, 1994, GEOPHYS RES LETT, V21, P1047, DOI 10.1029/94GL00884; HOLTZMAN J, IN PRESS PUBL ASTRON; IP WH, 1994, GEOPHYS RES LETT, V21, P1051, DOI 10.1029/94GL01063; KELLOGG PJ, 1994, GEOPHYS RES LETT, V21, P1055, DOI 10.1029/94GL01293; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; PRANGE R, 1995, SCIENCE, V267, P1317, DOI 10.1126/science.7871430; PRYOR WR, 1991, ICARUS, V91, P161, DOI 10.1016/0019-1035(91)90135-G; SCOTTI JV, 1993, NATURE, V365, P733, DOI 10.1038/365733a0; SHOEMAKER CS, 1993, 5725 INT ASTR UN CIR; SOMMERIA J, UNPUB; TAUGER JT, 1994, ASTROPHYS J, V435, pL3; WAGENER R, 1985, ICARUS, V63, P222, DOI 10.1016/0019-1035(85)90007-7; WAGENER R, 1988, ICARUS, V74, P141, DOI 10.1016/0019-1035(88)90036-X; WAITE JH, 1994, J GEOPHYS RES-SPACE, V99, P14799, DOI 10.1029/94JA01005; WAITE JH, UNPUB; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; YEOMANS DK, 1993, 22197 MIN PLAN CIRC	37	59	59	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1302	1307		10.1126/science.7871427	http://dx.doi.org/10.1126/science.7871427			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871427				2022-12-01	WOS:A1995QK06800032
J	CROSS, SM; SANCHEZ, CA; MORGAN, CA; SCHIMKE, MK; RAMEL, S; IDZERDA, RL; RASKIND, WH; REID, BJ				CROSS, SM; SANCHEZ, CA; MORGAN, CA; SCHIMKE, MK; RAMEL, S; IDZERDA, RL; RASKIND, WH; REID, BJ			A P53-DEPENDENT MOUSE SPINDLE CHECKPOINT	SCIENCE			English	Article							WILD-TYPE P53; MITOTIC CHROMOSOME TRANSMISSION; CELL-CYCLE EVENTS; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; SV40-TRANSFORMED CELLS; GENE AMPLIFICATION; DNA CONTENT; CARCINOMA; MITOSIS	Cell cycle checkpoints enhance genetic fidelity by causing arrest at specific stages of the cell cycle when previous events have not been completed. The tumor suppressor p53 has been implicated in a G(1) checkpoint. To investigate whether p53 also participates in a mitotic checkpoint, cultured fibroblasts from p53-deficient mouse embryos were exposed to spindle inhibitors. The fibroblasts underwent multiple rounds of DNA synthesis without completing chromosome segregation, thus forming tetraploid acid octaploid cells. Deficiency of p53 was also associated with the development of tetraploidy in vivo. These results suggest that murine p53 is a component of a spindle checkpoint that ensures the maintenance of diploidy.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; ERSTA HOSP,DEPT SURG,S-11635 STOCKHOLM,SWEDEN; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Ersta Sjukhus; University of Washington; University of Washington Seattle			Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X	NATIONAL CANCER INSTITUTE [R01CA055814] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA55814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNDTJOVIN DJ, 1977, J HISTOCHEM CYTOCHEM, V25, P585, DOI 10.1177/25.7.70450; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARBER HN, 1942, P ROY SOC LOND B BIO, V131, P258; BLOUNT PL, 1994, CANCER RES, V54, P2292; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BROWN M, 1991, COLD SH Q B, V56, P359; BUNN PA, 1982, BLOOD, V59, P528; BURHOLT DR, 1989, CANCER RES, V49, P3355; CARDER P, 1993, ONCOGENE, V8, P1397; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; GONG J, 1994, CANCER RES, V54, P428; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1985, GENETICS, V110, P381; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAKOBSEN A, 1983, CYTOMETRY, V4, P170, DOI 10.1002/cyto.990040211; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIRKLAND JA, 1967, CANCER, V20, P1934, DOI 10.1002/1097-0142(196711)20:11<1934::AID-CNCR2820201122>3.0.CO;2-4; KNOEFEL W T, 1987, Cancer Research, V47, P221; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUHAR SG, 1991, ONCOGENE, V6, P1499; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVAN A, 1956, ANN NY ACAD SCI, V63, P774, DOI 10.1111/j.1749-6632.1956.tb50892.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LIEBMANN J, 1994, CANCER CHEMOTH PHARM, V33, P331; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOPES NM, 1993, CANCER CHEMOTH PHARM, V32, P235, DOI 10.1007/BF00685842; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MURRAY AW, 1991, COLD SPRING HARB SYM, V56, P399; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; RAMEL S, IN PRESS PANCREAS; RASKIND WH, 1992, CANCER RES, V52, P2946; REIDER CL, 1989, MECHANISMS CHROMOSOM, P185; ROBERTS JR, 1990, CANCER RES, V50, P710; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; SHACKNEY SE, 1989, CANCER RES, V49, P3344; SHAPIRO JR, 1985, CANCER METAST REV, V4, P107, DOI 10.1007/BF00050691; WANG RJ, 1976, EXP CELL RES, V101, P331, DOI 10.1016/0014-4827(76)90385-2; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WIJKSTROM H, 1984, CANCER, V53, P1718, DOI 10.1002/1097-0142(19840415)53:8<1718::AID-CNCR2820530817>3.0.CO;2-E; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	53	690	696	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1353	1356		10.1126/science.7871434	http://dx.doi.org/10.1126/science.7871434			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871434				2022-12-01	WOS:A1995QK06800047
J	GIBBONS, A				GIBBONS, A			OUT OF AFRICA - AT LAST	SCIENCE			English	Editorial Material																		HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532	1	4	4	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1272	1273		10.1126/science.7871421	http://dx.doi.org/10.1126/science.7871421			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871421				2022-12-01	WOS:A1995QK06800024
J	GIBBONS, A				GIBBONS, A			LANGUAGES LAST STANDS	SCIENCE			English	Editorial Material																			0	4	4	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1272	1272		10.1126/science.7871421	http://dx.doi.org/10.1126/science.7871421			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871421				2022-12-01	WOS:A1995QK06800023
J	GRAHAM, JR; DEPATER, I; JERNIGAN, JG; LIU, MC; BROWN, ME				GRAHAM, JR; DEPATER, I; JERNIGAN, JG; LIU, MC; BROWN, ME			THE FRAGMENT-R COLLISION - WM-KEEK-TELESCOPE OBSERVATIONS OF SL9	SCIENCE			English	Article								The W. M. Keck telescope was used to observe the impact of comet Shoemaker-Levy 9 (SL9) fragment R at a wavelength of 2.3 micrometers on 21 July 1994. The data showed three outbursts. The first flash lasted about 40 seconds and was followed 1 minute after its peak by a second flash that lasted about 3 minutes. A third, longer lasting flare began 6 minutes after the first flash and lasted for 10 minutes. At its maximum brightness, the flare outshone Jupiter. The two short flashes are probably associated with the initial meteor trail and the subsequent fireball, respectively. The bright flare occurred when the impact site rotated into view. These data show that the explosion ejected material at least 1300 kilometers above the visible cloud tops. The luminosity of the impact site during the long bright flare was probably maintained by the release of gravitational potential energy, as this material fell back onto the lower atmosphere.	UNIV CALIF BERKELEY, SPACE SCI LAB, BERKELEY, CA USA	University of California System; University of California Berkeley	GRAHAM, JR (corresponding author), UNIV CALIF BERKELEY, DEPT ASTRON, 601 CAMPBELL HALL, BERKELEY, CA 94720 USA.			Brown, Michael E./0000-0002-8255-0545; Liu, Michael C/0000-0003-2232-7664				AHRENS TJ, 1994, GEOPHYS RES LETT, V21, P1087, DOI 10.1029/94GL01325; ASPHAUG E, 1994, NATURE, V370, P120, DOI 10.1038/370120a0; BOSLOUGH MB, 1994, GEOPHYS RES LETT, V21, P1555, DOI 10.1029/94GL01582; CHEVALIER RA, 1994, ASTROPHYS J, V429, P863, DOI 10.1086/174371; FROGEL JA, 1978, ASTROPHYS J, V220, P75, DOI 10.1086/155883; JEWITT D, 1993, B AM ASTRON SOC, V25, P1042; MACLOW MM, 1994, ASTROPHYS J, V434, pL33, DOI 10.1086/187565; MATTHEWS K, 1994, INFRARED ARRAYS ASTR; TAKATA T, 1994, ICARUS, V109, P3, DOI 10.1006/icar.1994.1074; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; ZAHNLE K, 1994, ICARUS, V108, P1, DOI 10.1006/icar.1994.1038; Zahnle Kevin, COMMUNICATION; ZELDOVICH YB, 1967, PHYSICS SHOCK WAVES	13	33	33	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1320	1323						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871431				2022-12-01	WOS:A1995QK06800036
J	HAMMEL, HB; BEEBE, RF; INGERSOLL, AP; ORTON, GS; MILLS, JR; SIMON, AA; CHODAS, P; CLARKE, JT; DEJONG, E; DOWLING, TE; HARRINGTON, J; HUBER, LF; KARKOSCHKA, E; SANTORI, CM; TOIGO, A; YEOMANS, D; WEST, RA				HAMMEL, HB; BEEBE, RF; INGERSOLL, AP; ORTON, GS; MILLS, JR; SIMON, AA; CHODAS, P; CLARKE, JT; DEJONG, E; DOWLING, TE; HARRINGTON, J; HUBER, LF; KARKOSCHKA, E; SANTORI, CM; TOIGO, A; YEOMANS, D; WEST, RA			HST IMAGING OF ATMOSPHERIC PHENOMENA CREATED BY THE IMPACT OF COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article							GREAT RED SPOT; JUPITERS	Hubble Space Telescope (HST) images reveal major atmospheric changes created by the collision of comet Shoemaker-Levy 9 with Jupiter. Plumes rose to 3000 kilometers with ejection velocities on the order of 10 kilometers second(-1); some plumes were visible in the shadow of Jupiter before rising into sunlight. During some impacts, the incoming bolide may have been detected. Impact times were on average about 8 minutes later than predicted. Atmospheric waves were seen with a wave front speed of 454 +/- 20 meters second(-1). The HST images reveal impact site evolution and record the overall change in Jupiter's appearance as a result of the bombardment.	MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA; CALTECH, DIV GEOL & PLANETARY SCI, PASADENA, CA 91125 USA; CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; UNIV MICHIGAN, DEPT ATMOSPHER & OCEAN SCI, ANN ARBOR, MI 48109 USA; UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; NEW MEXICO STATE UNIV, DEPT ASTRON, LAS CRUCES, NM 88003 USA	Massachusetts Institute of Technology (MIT); California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Michigan System; University of Michigan; University of Arizona; New Mexico State University	HAMMEL, HB (corresponding author), MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA.		Clarke, John/C-8644-2013; Dowling, Timothy E/J-4537-2013; Simon, Amy/C-8020-2012; Harrington, Joseph/E-6250-2011; Santori, Charles/A-7314-2009; Orton, Glenn/AAD-9862-2020	Dowling, Timothy E/0000-0002-7400-2274; Simon, Amy/0000-0003-4641-6186; Harrington, Joseph/0000-0002-8955-8531				AHRENS TJ, 1994, GEOPHYS RES LETT, V21, P1087, DOI 10.1029/94GL01325; [Anonymous], COMMUNICATION; Atreya S. K., 1986, ATMOSPHERES IONOSPHE; BELTON MJS, 1992, SPACE SCI REV, V60, P413, DOI 10.1007/BF00216864; BOSLOUGH MB, 1994, GEOPHYS RES LETT, V21, P1555, DOI 10.1029/94GL01582; BRONSHTEN VA, 1983, PHYSICS METEORIC PHE; BURROWS CJ, 1994, WIDE FIELD PLANETARY; CHODAS PW, COMMUNICATION; CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; DOWLING T, 1980, CLASSICAL MECHANICS, P40; DOWLING TE, 1989, J ATMOS SCI, V46, P3256, DOI 10.1175/1520-0469(1989)046<3256:JGRSAA>2.0.CO;2; GIERASCH PJ, 1986, ICARUS, V67, P456, DOI 10.1016/0019-1035(86)90125-9; HARRINGTON J, 1994, NATURE, V368, P525, DOI 10.1038/368525a0; HERBST T, UNPUB; HOLTZMAN JA, IN PRESS PUBL ASTRON; INGERSOLL AP, 1994, GEOPHYS RES LETT, V21, P1083, DOI 10.1029/94GL01057; INGERSOLL AP, 1981, J GEOPHYS RES-SPACE, V86, P8733, DOI 10.1029/JA086iA10p08733; INGERSOLL AP, UNPUB; LOW MMM, 1986, ICARUS, V65, P353, DOI 10.1016/0019-1035(86)90143-0; MACLOW MM, 1994, B AM ASTRON SOC, V26, P926; MARCUS PS, 1988, NATURE, V331, P693, DOI 10.1038/331693a0; Martin T, COMMUNICATION; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; SCOTTI J, 1994, 26TH ANN DIV PLAN SC; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEISSMAN P, 1994, NATURE, V370, P94, DOI 10.1038/370094a0; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; WILLIAMS GP, 1988, J ATMOS SCI, V45, P207, DOI 10.1175/1520-0469(1988)045<0207:TSAGOR>2.0.CO;2; ZAHNLE K, 1994, ICARUS, V108, P1, DOI 10.1006/icar.1994.1038; [No title captured]	31	177	181	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	1995	267	5202					1288	1296		10.1126/science.7871425	http://dx.doi.org/10.1126/science.7871425			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871425				2022-12-01	WOS:A1995QK06800030
J	HEIM, MH; KERR, IM; STARK, GR; DARNELL, JE				HEIM, MH; KERR, IM; STARK, GR; DARNELL, JE			CONTRIBUTION OF STAT SH2 GROUPS TO SPECIFIC INTERFERON SIGNALING BY THE JAK-STAT PATHWAY	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; MUTANT-CELL LINE; TRANSCRIPTION FACTOR; TRANSDUCTION; GAMMA; ALPHA; COMPLEMENTATION; PHOSPHORYLATION; POLYPEPTIDE; ACTIVATION	In response to specific ligands, various STAT proteins (signal transducers and activators of transcription) are phosphorylated on tyrosine by Jak protein kinases and translocated to the nucleus to direct gene transcription. Selection of a STAT at the interferon gamma receptor as well as specific STAT dimer formation depended on the presence of particular SH2 groups (phosphotyrosine-binding domains), whereas the amino acid sequence Surrounding the phosphorylated tyrosine on the STAT could vary. Thus, SH2 groups in STAT proteins may play crucial roles in specificity at the receptor kinase complex and in subsequent dimerization, whereas the kinases are relatively nonspecific.	ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; CLEVELAND CLIN FDN,RES INST,CLEVELAND,OH 44195	Rockefeller University; Cancer Research UK; Cleveland Clinic Foundation			Heim, Markus/A-7526-2008	Heim, Markus/0000-0002-7523-4894	NIAID NIH HHS [AI32489, AI34420] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489, R01AI034420, R37AI034420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTGETSINGER LS, 1993, CELL, V74, P237; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HEIM MH, UNPUB; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; LEUNG S, IN PRESS MOL CELL BI; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, UNPUB; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1994, NATURE, V366, P580; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG ZP, UNPUB	25	312	318	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1347	1349		10.1126/science.7871432	http://dx.doi.org/10.1126/science.7871432			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871432				2022-12-01	WOS:A1995QK06800045
J	MCGRATH, MA; HALL, DT; MATHESON, PL; WEAVER, HA; TRAUGER, JT; SMITH, TE; THOMAS, N; GLADSTONE, R; SCHNEIDER, NM; HARRIS, WM; LIVENGOOD, TA; PRANGE, R; FESTOU, MC				MCGRATH, MA; HALL, DT; MATHESON, PL; WEAVER, HA; TRAUGER, JT; SMITH, TE; THOMAS, N; GLADSTONE, R; SCHNEIDER, NM; HARRIS, WM; LIVENGOOD, TA; PRANGE, R; FESTOU, MC			RESPONSE OF THE IO-PLASMA TORUS TO COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article								Spectroscopic and imaging observations of the lo plasma torus were made in June and July 1994 in conjunction with the encounter of periodic comet Shoemaker-Levy 9 with Jupiter, Characteristic emissions from sulfur and oxygen ions showed a decline of about 30 percent in the extreme ultraviolet and an increase of about 40 percent in the far ultraviolet relative to preimpact observations. Changes in the extreme ultraviolet may be indicative of small changes in the torus electron temperature as a result of quenching of electrons by dust associated with the comet passage. However, no new emission features indicative of fragment dust within the torus were detected. The characteristic torus morphology seen in ground-based imaging was typical of that observed in the past.	JOHNS HOPKINS UNIV,DEPT PHYS & ASTRON,BALTIMORE,MD 21218; UNIV SO CALIF,DEPT AEROSP ENGN,LOS ANGELES,CA 90089; JET PROPULS LAB,PASADENA,CA 91109; MAX PLANCK INST AERON,W-3411 KATLENBURG DUHM,GERMANY; SW RES INST,SAN ANTONIO,TX 78238; UNIV COLORADO,ASTRON & SPACE PHYS LAB,BOULDER,CO 80309; UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771; INST ASTROPHYS SPATIALE,ORSAY,FRANCE; OBSERV MIDI PYRENEES,NATL CTR SCI RES,F-31400 TOULOUSE,FRANCE	Johns Hopkins University; University of Southern California; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Max Planck Society; Southwest Research Institute; University of Colorado System; University of Colorado Boulder; University of Michigan System; University of Michigan; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	MCGRATH, MA (corresponding author), SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218, USA.		Weaver, Harold A/D-9188-2016; Livengood, Timothy A/C-8512-2012	Weaver, Harold A/0000-0003-0951-7762; SCHNEIDER, NICHOLAS/0000-0001-6720-5519				CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; DEPATER I, 1994, B AM ASTRON SOC, V26, P4; DESSLER AJ, 1994, GEOPHYS RES LETT, V21, P1043, DOI 10.1029/94GL01294; GRUN E, 1994, GEOPHYS RES LETT, V21, P1035, DOI 10.1029/94GL00701; Grun E., 1984, PLANETARY RINGS; HALL DT, 1994, ASTROPHYS J, V426, pL51, DOI 10.1086/187337; HERBERT F, 1994, GEOPHYS RES LETT, V21, P1047, DOI 10.1029/94GL00884; HORANYI M, 1994, GEOPHYS RES LETT, V21, P1039, DOI 10.1029/94GL01326; MCGRATH MA, 1993, ASTROPHYS J, V415, pL55, DOI 10.1086/187031; MOOS HW, 1985, ASTROPHYS J, V294, P369, DOI 10.1086/163304; MORFILL GE, 1993, J GEOPHYS RES-SPACE, V98, P1435, DOI 10.1029/92JA01951; SCHNEIDER NM, 1991, SCIENCE, V253, P1394, DOI 10.1126/science.253.5026.1394; SCHNEIDER NM, UNPUB; SEKANINA Z, 1994, ASTRON ASTROPHYS, V289, P607; THOMAS N, 1993, J GEOPHYS RES-PLANET, V98, P18737, DOI 10.1029/93JE01461; TRAUGER JT, 1984, SCIENCE, V226, P337, DOI 10.1126/science.226.4672.337; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424	17	10	10	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1313	1317		10.1126/science.7871429	http://dx.doi.org/10.1126/science.7871429			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871429				2022-12-01	WOS:A1995QK06800034
J	NOLL, KS; MCGRATH, MA; TRAFTON, LM; ATREYA, SK; CALDWELL, JJ; WEAVER, HA; YELLE, RV; BARNET, C; EDGINGTON, S				NOLL, KS; MCGRATH, MA; TRAFTON, LM; ATREYA, SK; CALDWELL, JJ; WEAVER, HA; YELLE, RV; BARNET, C; EDGINGTON, S			HST SPECTROSCOPIC OBSERVATIONS OF JUPITER AFTER THE COLLISION OF COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article							CROSS-SECTION MEASUREMENTS; CARBON-MONOXIDE; NM; REGION; SO2; S2	Ultraviolet spectra obtained with the Hubble Space Telescope identified at least 10 molecules and atoms in the perturbed stratosphere near the G impact site, most never before observed in Jupiter. The large mass of sulfur-containing material, more than 10(14) grams in S-2 alone, indicates that many of the sulfur-containing molecules S-2, CS2, CS, H2S, and S+ may be derived from a sulfur-bearing parent molecule native to Jupiter. If so, the fragment must have penetrated at least as deep as the predicted NH4SH cloud at a pressure of approximately 1 to 2 bars, Stratospheric NH3 was also observed, which is consistent with fragment penetration below the cloud tops. Approximately 10(7) grams of neutral and ionized metals were observed in emission, including Mg II, Mg I, Si I, Fe I, and Fe II. Oxygen-containing molecules were conspicuous by their absence; upper limits for SO2, SO, CO, SiO, and H2O are derived,	UNIV TEXAS,DEPT ASTRON,AUSTIN,TX 78712; UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; INST SPACE & TERR SCI,SPACE ASTROPHYS LAB,N YORK,ON M3J 3K1,CANADA; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	University of Texas System; University of Texas Austin; University of Michigan System; University of Michigan; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	NOLL, KS (corresponding author), SPACE TELESCOPE SCI INST,3700 SAN MARTIN DR,BALTIMORE,MD 21218, USA.		Barnet, Christopher/F-5573-2010; Noll, Keith/C-8447-2012; Weaver, Harold A/D-9188-2016	Weaver, Harold A/0000-0003-0951-7762				AHEARN MF, 1983, ASTROPHYS J, V274, pL99, DOI 10.1086/184158; AHEARN MF, 1983, TR AP83044 U MAR TEC; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ANDERSON WR, 1979, J CHEM PHYS, V71, P821, DOI 10.1063/1.438372; Atreya S. K., 1987, ATMOSPHERES IONOSPHE; ATREYA SK, 1977, ICARUS, V31, P348, DOI 10.1016/0019-1035(77)90027-6; ATREYA SK, 1985, PLANETARY METEOROLOG, P17; BARROW RF, 1965, ELEMENTAL SULFUR; BEEBE R, COMMUNICATION; Chen F., UNPUB; CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; FELDMAN PD, 1993, ASTROPHYS J, V406, P279, DOI 10.1086/172439; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; JESSBURGER EK, 1989, COMPOSITION CORNETS; LANGHOFF S, COMMUNICATION; LARSON HP, 1984, ICARUS, V60, P621, DOI 10.1016/0019-1035(84)90169-6; LELLOUCH E, B AM ASTRON SOC; LEWIS JS, 1970, SCIENCE, V169, P472, DOI 10.1126/science.169.3944.472; MARTINEZ RD, 1992, GEOPHYS RES LETT, V19, P277, DOI 10.1029/91GL03165; MCGRATH MA, 1995, SCIENCE, V267, P1313, DOI 10.1126/science.7871429; MEYER KA, 1973, J CHEM PHYS, V59, P1933, DOI 10.1063/1.1680279; MOSES JI, UNPUB; NOLL KS, 1988, ASTROPHYS J, V324, P1210, DOI 10.1086/165975; ORTON G, 1995, SCIENCE, V267, P1277, DOI 10.1126/science.7871423; PRATHER MJ, 1978, ASTROPHYS J, V223, P1072, DOI 10.1086/156340; QUICK CR, 1981, J CHEM PHYS, V74, P4951, DOI 10.1063/1.441748; SMITH WH, 1969, J QUANT SPECTROSC RA, V9, P1191, DOI 10.1016/0022-4073(69)90106-X; TOZZI GP, UNPUB; TRAFTON LM, 1994, ASTROPHYS J, V421, P816, DOI 10.1086/173694; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; WIESE WL, 1969, NSRDSNBS22, V2; WU CYR, 1981, GEOPHYS RES LETT, V8, P769, DOI 10.1029/GL008i007p00769; XU H, 1993, GEOPHYS RES LETT, V20, P1035, DOI 10.1029/93GL00809; YEOMANS DK, COMMUNICATION; ZAHNLE K, 1994, ICARUS, V108, P1, DOI 10.1006/icar.1994.1038	36	109	109	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1307	1313		10.1126/science.7871428	http://dx.doi.org/10.1126/science.7871428			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871428				2022-12-01	WOS:A1995QK06800033
J	ORTON, G; AHEARN, M; BAINES, K; DEMING, D; DOWLING, T; GOGUEN, J; GRIFFITH, C; HAMMEL, H; HOFFMANN, W; HUNTEN, D; JEWITT, D; KOSTIUK, T; MILLER, S; NOLL, K; ZAHNLE, K; ACHILLEOS, N; DAYAL, A; DEUTSCH, L; ESPENAK, F; ESTERLE, P; FRIEDSON, J; FAST, K; HARRINGTON, J; HORA, J; JOSEPH, R; KELLY, D; KNACKE, R; LACY, J; LISSE, C; RAYNER, J; SPRAGUE, A; SHURE, M; WELLS, K; YANAMANDRAFISHER, P; ZIPOY, D; BJORAKER, G; BUHL, D; GOLISCH, W; GRIEP, D; KAMINSKI, C; ARDEN, C; CHAIKIN, A; GOLDSTEIN, J; GILMORE, D; FAZIO, G; KANAMORI, T; LAM, H; LIVENGOOD, T; MACLOW, MM; MARLEY, M; MOMARY, T; ROBERTSON, D; ROMANI, P; SPITALE, J; SYKES, M; TENNYSON, J; WELLNITZ, D; YING, SW				ORTON, G; AHEARN, M; BAINES, K; DEMING, D; DOWLING, T; GOGUEN, J; GRIFFITH, C; HAMMEL, H; HOFFMANN, W; HUNTEN, D; JEWITT, D; KOSTIUK, T; MILLER, S; NOLL, K; ZAHNLE, K; ACHILLEOS, N; DAYAL, A; DEUTSCH, L; ESPENAK, F; ESTERLE, P; FRIEDSON, J; FAST, K; HARRINGTON, J; HORA, J; JOSEPH, R; KELLY, D; KNACKE, R; LACY, J; LISSE, C; RAYNER, J; SPRAGUE, A; SHURE, M; WELLS, K; YANAMANDRAFISHER, P; ZIPOY, D; BJORAKER, G; BUHL, D; GOLISCH, W; GRIEP, D; KAMINSKI, C; ARDEN, C; CHAIKIN, A; GOLDSTEIN, J; GILMORE, D; FAZIO, G; KANAMORI, T; LAM, H; LIVENGOOD, T; MACLOW, MM; MARLEY, M; MOMARY, T; ROBERTSON, D; ROMANI, P; SPITALE, J; SYKES, M; TENNYSON, J; WELLNITZ, D; YING, SW			COLLISION OF COMET SHOEMAKER-LEVY-9 WITH JUPITER OBSERVED BY THE NASA INFRARED TELESCOPE FACILITY	SCIENCE			English	Article							ETHANE	The National Aeronautics and Space Administration (NASA) Infrared Telescope Facility was used to investigate the collision of comet Shoemaker-Levy 9 with Jupiter from 12 July to 7 August 1994. Strong thermal infrared emission lasting several minutes was observed after the impacts of fragments C, G, and R. All impacts warmed the stratosphere and some the troposphere up to several degrees. The abundance of stratospheric ammonia increased by more than 50 times. Impact-related particles extended up to a level where the atmospheric pressure measured several millibars. The north polar near-infrared aurora brightened by nearly a factor of 5 a week after the impacts.	UNIV MARYLAND, DEPT ASTRON, COLLEGE PK, MD 20742 USA; NASA, GODDARD SPACE FLIGHT CTR, GREENBELT, MD 20771 USA; MIT, CAMBRIDGE, MA 02139 USA; NO ARIZONA UNIV, DEPT PHYS & ASTRON, FLAGSTAFF, AZ 86011 USA; UNIV ARIZONA, STEWARD OBSERV, TUCSON, AZ 85721 USA; UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; UCL, DEPT PHYS & ASTRON, LONDON WC1E 6BT, ENGLAND; SPACE TELESCOPE SCI INST, BALTIMORE, MD 21218 USA; NASA, AMES RES CTR, MOFFETT FIELD, CA 94053 USA; UNIV MASSACHUSETTS, FIVE COLL ASTRON DEPT, AMHERST, MA 01003 USA; UNIV TEXAS, DEPT ASTRON, AUSTIN, TX 78712 USA; PENN STATE UNIV, ERIE, PA 16563 USA; UNIV ST ANDREWS, DEPT PHYS, ST ANDREWS, FIFE, SCOTLAND; SMITHSONIAN INST, NATL AIR & SPACE MUSEUM, WASHINGTON, DC 20560 USA; SMITHSONIAN ASTROPHYS OBSERV, CAMBRIDGE, MA 02138 USA; STANFORD UNIV, DEPT MECH ENGN & DESIGN, STANFORD, CA 94305 USA; UNIV CHICAGO, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA; NEW MEXICO STATE UNIV, DEPT ASTRON, LAS CRUCES, NM 88003 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA; UNIV LEICESTER, DEPT PHYS & ASTRON, LEICESTER LE1 7RH, LEICS, ENGLAND; CALTECH, PASADENA, CA 91126 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2BZ, ENGLAND	University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Northern Arizona University; University of Arizona; University of Arizona; University of Hawaii System; University of London; University College London; Space Telescope Science Institute; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Massachusetts System; University of Massachusetts Amherst; University of Texas System; University of Texas Austin; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of St Andrews; Smithsonian Institution; Harvard University; Smithsonian Institution; Stanford University; University of Chicago; New Mexico State University; University of California System; University of California Los Angeles; University of Leicester; California Institute of Technology; Imperial College London	ORTON, G (corresponding author), CALTECH, JET PROP LAB, 4800 OAK GROVE DR, PASADENA, CA 91109 USA.		Noll, Keith/C-8447-2012; Low, Mordecai-Mark Mac/AAN-1967-2021; Romani, Paul N/D-2729-2012; Lisse, Carey M/B-7772-2016; Goguen, Jay/E-5389-2018; Kostiuk, Theodor/A-3077-2014; Dowling, Timothy E/J-4537-2013; Tennyson, Jonathan/I-2222-2012; Marley, Mark S/I-4704-2013; Achilleos, Nicholas/C-1647-2008; Orton, Glenn/AAD-9862-2020; Livengood, Timothy A/C-8512-2012; Wellnitz, Dennis/B-4080-2012; Harrington, Joseph/E-6250-2011; Bjoraker, Gordon L/D-5032-2012	Low, Mordecai-Mark Mac/0000-0003-0064-4060; Lisse, Carey M/0000-0002-9548-1526; Dowling, Timothy E/0000-0002-7400-2274; Tennyson, Jonathan/0000-0002-4994-5238; Achilleos, Nicholas/0000-0002-5886-3509; Rayner, John/0000-0002-3165-159X; Hora, Joseph/0000-0002-5599-4650; Miller, Steven/0000-0002-7159-6871; Harrington, Joseph/0000-0002-8955-8531				ATREYA SK, 1981, ASTROPHYS J, V147, pL43; CALDWELL J, 1983, ICARUS, V53, P133, DOI 10.1016/0019-1035(83)90026-X; DROSSART P, 1989, NATURE, V340, P539, DOI 10.1038/340539a0; FESTOU MC, 1981, J GEOPHYS RES-SPACE, V86, P5715, DOI 10.1029/JA086iA07p05715; FLASAR M, 1986, NASA SPEC PUBL, V494, P324; GIERASCH PJ, 1986, ICARUS, V67, P456, DOI 10.1016/0019-1035(86)90125-9; GRAHAM JR, 1995, SCIENCE, V167, P1320; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P313, DOI 10.1117/12.158684; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; HARRINGTON J, 1994, NATURE, V368, P525, DOI 10.1038/368525a0; HOFFMANN WF, 1993, P SOC PHOTO-OPT INS, V1946, P449, DOI 10.1117/12.158697; HOFFMANN WF, 1994, INFRARED PHYS TECHN, V35, P175, DOI 10.1016/1350-4495(94)90079-5; HUNTEN DH, 1994, GEOPHYS RES LETT, V1, P1094; JEWITT D, 1994, COMMUNICATION   0719; KIM SJ, 1988, ICARUS, V75, P399, DOI 10.1016/0019-1035(88)90153-4; KOSTIUK T, 1987, ICARUS, V72, P394, DOI 10.1016/0019-1035(87)90182-5; KOSTIUK T, 1983, APPL OPTICS, V22, P2644, DOI 10.1364/AO.22.002644; KOSTIUK T, 1994, INFRARED PHYS TECHN, V35, P243, DOI 10.1016/1350-4495(94)90084-1; LACY JH, 1989, PUBL ASTRON SOC PAC, V101, P1166, DOI 10.1086/132593; LIVENGOOD TA, 1993, J GEOPHYS RES-PLANET, V98, P18813, DOI 10.1029/93JE01043; MARLEY MS, 1994, ASTROPHYS J, V427, pL63, DOI 10.1086/187365; MILLER S, 1995, GEOPHYS RES LETT, V22, P1629, DOI 10.1029/95GL00700; NICHOLSON PD, IN PRESS GEOPHYS RES; ORTON G, 1992, B AM ASTRON SOC, V24, P1041; ORTON GS, 1991, SCIENCE, V252, P537, DOI 10.1126/science.252.5005.537; ORTON GS, 1994, SCIENCE, V265, P625, DOI 10.1126/science.265.5172.625; RAYNER J, 1993, P SOC PHOTO-OPT INS, V1946, P490, DOI 10.1117/12.158701; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426	28	64	64	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1277	1282		10.1126/science.7871423	http://dx.doi.org/10.1126/science.7871423			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871423				2022-12-01	WOS:A1995QK06800028
J	PRANGE, R; ENGLE, IM; CLARKE, JT; DUNLOP, M; BALLESTER, GE; IP, WH; MAURICE, S; TRAUGER, J				PRANGE, R; ENGLE, IM; CLARKE, JT; DUNLOP, M; BALLESTER, GE; IP, WH; MAURICE, S; TRAUGER, J			AURORAL SIGNATURE OF COMET SHOEMAKER-LEVY-9 IN THE JOVIAN MAGNETOSPHERE	SCIENCE			English	Article								The electrodynamic interaction of the dust and gas comae of comet Shoemaker-Levy 9 with the jovian magnetosphere was unique and different from the atmospheric effects. Early theoretical predictions of auroral-type processes on the comet magnetic field line and advanced modeling of the time-varying morphology of these lines allowed dedicated observations with the Hubble Space Telescope Wide Field Planetary Camera 2 and resulted in the detection of a bright auroral spot, In that respect, this observation of the surface signature of an externally triggered auroral process can be considered as a ''magnetospheric active experiment'' on Jupiter.	INST ASTROPHYS,PARIS,FRANCE; USN ACAD,DEPT PHYS,ANNAPOLIS,MD 21402; UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SPACE & ATMOSPHER PHYS GRP,LONDON SW7 2BZ,ENGLAND; MAX PLANCK INST AERON,D-37191 KATLENBURG DUHM,GERMANY; EUROPEAN SPACE AGCY,ESTEC,DEPT SPACE SCI,SO,2200 AG NOORDWIJK,NETHERLANDS; JET PROPULS LAB,PASADENA,CA 91109	UDICE-French Research Universities; Sorbonne Universite; United States Department of Defense; United States Navy; United States Naval Academy; University of Michigan System; University of Michigan; Imperial College London; Max Planck Society; European Space Agency; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	PRANGE, R (corresponding author), UNIV PARIS 11,CNRS,INST ASTROPHYS SPATIALE,F-91405 ORSAY,FRANCE.		Clarke, John/C-8644-2013; dunlop, malcolm w/F-1347-2010	dunlop, malcolm w/0000-0002-8195-5137				BOLIN O, 1994, GEOPHYS RES LETT, V21, P1063, DOI 10.1029/94GL00890; CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; CONNERNEY JEP, 1981, J GEOPHYS RES-SPACE, V86, P8370, DOI 10.1029/JA086iA10p08370; CONNERNEY JEP, 1992, PLANETARY RADIO EM 3, V13; DOUGHERTY MK, COMMUNICATION; ENGLE I, UNPUB; ENGLE IM, 1992, J GEOPHYS RES-SPACE, V97, P17169, DOI 10.1029/92JA02036; ENGLE IM, 1991, J GEOPHYS RES-SPACE, V96, P7793, DOI 10.1029/90JA02391; FARRELL WM, 1994, GEOPHYS RES LETT, V21, P1067, DOI 10.1029/94GL01066; FELDMAN PD, 1994, 6027 INT ASTR UN CIR; GERARD JC, 1993, J GEOPHYS RES-PLANET, V98, P18793, DOI 10.1029/93JE01334; GERARD JC, IN PRESS PLANET SPAC; HERBERT F, 1994, GEOPHYS RES LETT, V21, P1047, DOI 10.1029/94GL00884; IP WH, 1994, GEOPHYS RES LETT, V21, P1051, DOI 10.1029/94GL01063; KELLOGG PJ, 1994, GEOPHYS RES LETT, V21, P1055, DOI 10.1029/94GL01293; LIPATOV AS, 1994, GEOPHYS RES LETT, V21, P1059, DOI 10.1029/94GL01295; MOURENAS D, 1993, PLANET SPACE SCI, V41, P347, DOI 10.1016/0032-0633(93)90068-D; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424	18	14	14	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1317	1320		10.1126/science.7871430	http://dx.doi.org/10.1126/science.7871430			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871430				2022-12-01	WOS:A1995QK06800035
J	SCHOENHERR, CJ; ANDERSON, DJ				SCHOENHERR, CJ; ANDERSON, DJ			THE NEURON-RESTRICTIVE SILENCER FACTOR (NRSF) - A COORDINATE REPRESSOR OF MULTIPLE NEURON-SPECIFIC GENES	SCIENCE			English	Article							SODIUM-CHANNEL GENE; NERVE GROWTH-FACTOR; BINDING-PROTEIN; SCG10 GENE; CELL LINE; EXPRESSION; DIFFERENTIATION; SEQUENCE; FAMILY; DNA	The neuron-restrictive silencer factor (NRSF) binds a DNA sequence element, called the neuron-restrictive silencer element (NRSE), that represses neuronal gene transcription in nonneuronal cells. Consensus NRSEs have been identified in 18 neuron-specific genes, Complementary DNA clones encoding a functional fragment of NRSF were isolated and found to encode a novel protein containing eight noncanonical zinc fingers. Expression of NRSF mRNA was detected in most nonneuronal tissues at several developmental stages, In the nervous system, NRSF mRNA was detected in undifferentiated neuronal progenitors, but not in differentiated neurons, NRSF represents the first example of a vertebrate silencer protein that potentially regulates a large battery of cell type-specific genes, and therefore may function as a master negative regulator of neurogenesis.	CALTECH,HOWARD HUGHES MED INST,DIV BIOL 21676,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23476] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BLAV HM, 1991, ANN REV BIOCH, V61, P1213; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEBER SM, 1990, J NEUROSCI, V10, P2451; LI L, P NATL ACAD SCI USA, V90, P1460; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MORITA H, 1992, ZOOL SCI, V9, P1; OU SKH, 1993, J IMMUNOL METHODS, V165, P75, DOI 10.1016/0022-1759(93)90108-J; PATHAK BG, 1984, NUCLEIC ACIDS RES, V22, P4748; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PFEIFFER SE, 1978, GLIAL CELL LINES, P287; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SCHOENHERR CS, UNPUB; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	35	904	929	1	59	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1360	1363		10.1126/science.7871435	http://dx.doi.org/10.1126/science.7871435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871435				2022-12-01	WOS:A1995QK06800049
J	STAHL, N; FARRUGGELLA, TJ; BOULTON, TG; ZHONG, Z; DARNELL, JE; YANCOPOULOS, GD				STAHL, N; FARRUGGELLA, TJ; BOULTON, TG; ZHONG, Z; DARNELL, JE; YANCOPOULOS, GD			CHOICE OF STATS AND OTHER SUBSTRATES SPECIFIED BY MODULAR TYROSINE-BASED MOTIFS IN CYTOKINE RECEPTORS	SCIENCE			English	Article							GAMMA SIGNAL-TRANSDUCTION; INTERFERON-ALPHA/BETA; KINASE; PATHWAY; GP-130; FAMILY; JAK2	Many members of the cytokine receptor superfamily initiate intracellular signaling by activating members of the Jak family of tyrosine kinases. Activation of the same Jaks by multiple cytokines raises the question of how these cytokines activate distinct intracellular signaling pathways. Selection of particular substrates-the transcriptional activator Stat3 and protein tyrosine phosphatase PTP1D-that characterize responses to the ciliary neurotrophic factor-interleukin-6 cytokine family depended not on which Jak was activated, but was instead determined by specific tyrosine-based motifs in the receptor components-gp130 and LIFR-shared by these cytokines. Further, these tyrosine-based motifs were modular, because addition of a Stat3-specifying motif to another cytokine receptor, that for erythropoietin, caused it to activate Stat3 in a ligand-dependent fashion.	ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University	STAHL, N (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CASE RD, 1994, J BIOL CHEM, V269, P10467; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, UNPUB; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	876	890	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	1995	267	5202					1349	1353		10.1126/science.7871433	http://dx.doi.org/10.1126/science.7871433			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871433				2022-12-01	WOS:A1995QK06800046
J	WEAVER, HA; AHEARN, MF; ARPIGNY, C; BOICE, DC; FELDMAN, PD; LARSON, SM; LAMY, P; LEVY, DH; MARSDEN, BG; MEECH, KJ; NOLL, KS; SCOTTI, JV; SEKANINA, Z; SHOEMAKER, CS; SHOEMAKER, EM; SMITH, TE; STERN, SA; STORRS, AD; TRAUGER, JT; YEOMANS, DK; ZELLNER, B				WEAVER, HA; AHEARN, MF; ARPIGNY, C; BOICE, DC; FELDMAN, PD; LARSON, SM; LAMY, P; LEVY, DH; MARSDEN, BG; MEECH, KJ; NOLL, KS; SCOTTI, JV; SEKANINA, Z; SHOEMAKER, CS; SHOEMAKER, EM; SMITH, TE; STERN, SA; STORRS, AD; TRAUGER, JT; YEOMANS, DK; ZELLNER, B			THE HUBBLE-SPACE-TELESCOPE (HST) OBSERVING CAMPAIGN ON COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article								The Hubble Space Telescope made systematic observations of the split comet P/Shoemaker-Levy 9 (SL9) (P designates a periodic comet) starting in July 1993 and continuing through mid-July 1994 when the fragments plunged into Jupiter's atmosphere. Deconvolutions of Wide Field Planetary Camera images indicate that the diameters of some fragments may have been as large as similar to 2 to 4 kilometers, assuming a geometric albedo of 4 percent, but significantly smaller values (that is, <1 kilometer) cannot be ruled out. Most of the fragments (or nuclei) were embedded in circularly symmetric inner comae from July 1993 until late June 1994, implying that there was continuous, but weak, cometary activity. At least a few nuclei fragmented into separate, condensed objects well after the breakup of the SL9 parent body, which argues against the hypothesis that the SL9 fragments were swarms of debris with no dominant, central bodies. Spectroscopic observations taken on 14 July 1994 showed an outburst in magnesium ion emission that was followed closely by a threefold increase in continuum emission, which may have been caused by the electrostatic charging and subsequent explosion of dust as the comet passed from interplanetary space into the jovian magnetosphere. No OH emission was detected, but the derived upper limit on the H2O production rate of similar to 10(27) molecules per second does not necessarily imply that the object was water-poor.	UNIV MARYLAND,DEPT ASTRON,COLLEGE PK,MD 20742; UNIV LIEGE,INST ASTROPHYS,B-4000 LIEGE,BELGIUM; SW RES INST,DIV 15,SAN ANTONIO,TX 78228; JOHNS HOPKINS UNIV,DEPT PHYS & ASTRON,BALTIMORE,MD 21218; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; LAB ASTRON SPATIALE TRAVERSE SIPHON,F-13376 MARSEILLE 12,FRANCE; HARVARD SMITHSONIAN CTR ASTROPHYS,CAMBRIDGE,MA 02138; UNIV HAWAII,INST ASTRON,HONOLULU,HI 96822; JET PROPULS LAB,PASADENA,CA 91109; NO ARIZONA UNIV,DEPT PHYS & ASTRON,FLAGSTAFF,AZ 86011; US GEOL SURVEY,FLAGSTAFF,AZ 86001; SW RES INST,DIV 15,BOULDER EXTENS OFF,BOULDER,CO 80302; GEORGIA SO UNIV,DEPT PHYS,STATESBORO,GA 30460	University System of Maryland; University of Maryland College Park; University of Liege; Southwest Research Institute; Johns Hopkins University; University of Arizona; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of Hawaii System; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Northern Arizona University; United States Department of the Interior; United States Geological Survey; University System of Georgia; Georgia Southern University	WEAVER, HA (corresponding author), SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218, USA.		Weaver, Harold A/D-9188-2016; Levy, David/GPS-4945-2022; Meech, Karen/CAH-1412-2022; Noll, Keith/C-8447-2012; Boice, Daniel/C-4831-2018	Weaver, Harold A/0000-0003-0951-7762; Boice, Daniel/0000-0001-6423-3768				Acuna M. H., 1983, PHYSICS JOVIAN MAGNE, P1, DOI [10. 1017/cbo9780511564574. 003, DOI 10.1017/CBO9780511564574.003]; ALLEN CW, 1976, ASTROPHYSICAL QUANTI, P162; Bobrovnikoff N. T., 1954, ASTRON J, V59, P357; BROWN WL, 1982, SCIENCE, V218, P525, DOI 10.1126/science.218.4572.525; COCHRAN AL, IN PRESS ICARUS; DEISEMME AH, 1982, COMETS, P85; DESSLER AJ, 1994, GEOPHYS RES LETT, V21, P1043, DOI 10.1029/94GL01294; FULLE M, 1990, NATURE, V359, P42; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; JEWITT D, 1986, ASTROPHYS J, V310, P937, DOI 10.1086/164745; JEWITT D, 1994, 5999 INT STR UN CIRC; LANDOLT AU, 1983, ASTRON J, V88, P439, DOI 10.1086/113329; MEECH KJ, 1993, ASTRON J, V106, P1222, DOI 10.1086/116721; SEKANINA Z, 1994, ASTRON ASTROPHYS, V289, P607; SEKANINA Z, 1994, HYPERVELOCITY IMPACT; SEKANINA Z, 1994, 6020 INT ASTR UN CIR; WALLACE LV, 1958, ASTRON J, V63, P213, DOI 10.1086/107729; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEISSMAN P, COMMUNICATION; WYCKOFF S, 1985, NATURE, V316, P241, DOI 10.1038/316241a0	20	75	75	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1282	1288		10.1126/science.7871424	http://dx.doi.org/10.1126/science.7871424			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871424				2022-12-01	WOS:A1995QK06800029
J	WEST, RA; KARKOSCHKA, E; FRIEDSON, AJ; SEYMOUR, M; BAINES, KH; HAMMEL, HB				WEST, RA; KARKOSCHKA, E; FRIEDSON, AJ; SEYMOUR, M; BAINES, KH; HAMMEL, HB			IMPACT DEBRIS PARTICLES IN JUPITER STRATOSPHERE	SCIENCE			English	Article							OPTICAL-PROPERTIES; ICE; CIRCULATION; ULTRAVIOLET; CONSTANTS	The aftermath of the impacts of periodic comet Shoemaker-Levy 9 on Jupiter was studied With the Wide Field Planetary Camera 2 on the Hubble Space Telescope. The impact debris particles may owe their dark brown color to organic material rich in sulfur and nitrogen. The total volume of aerosol 1 day after the last impact is equal to the volume of a sphere of radius 0.5 kilometer. In the optically thick core regions, the particle mean radius is between 0.15 and 0.3 micrometer, and the aerosol is spread over many scale heights, from approximately 1 millibar to 200 millibars of pressure or more. Particle coagulation can account for the evolution of particle radius and total optical depth during the month following the impacts.	UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; UCL, LONDON, ENGLAND; MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA	University of Arizona; University of London; University College London; Massachusetts Institute of Technology (MIT)	WEST, RA (corresponding author), CALTECH, JET PROP LAB, DIV EARTH & SPACE SCI, PASADENA, CA 91109 USA.							BAINES KH, 1994, 26TH ANN M AM ASTR S; BJORAKER GL, 1994, 26TH ANN M AM ASTR S; CONRATH BJ, 1990, ICARUS, V83, P255, DOI 10.1016/0019-1035(90)90068-K; DRAINE BT, 1985, ASTROPHYS J SUPPL S, V57, P587, DOI 10.1086/191016; FIELD GB, IN PRESS ASTRON ASTR; GUSTAVSEN RL, 1989, THESIS WASHINGTON ST; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; KARKOSCHKA E, 1994, ICARUS, V111, P174, DOI 10.1006/icar.1994.1139; KHARE BN, 1994, CAN J CHEM, V72, P678, DOI 10.1139/v94-093; LANDRY B, 1991, ICARUS, V89, P377, DOI 10.1016/0019-1035(91)90184-U; LATTIMER JM, 1982, 1980 P C FORM PLAN S, P190; MARTONCHIK JV, 1984, APPL OPTICS, V23, P541, DOI 10.1364/AO.23.000541; MORENO F, IN PRESS GEOPHYS RES; NICHOLSON PD, UNPUB; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; ORTON G, 1995, SCIENCE, V267, P1277, DOI 10.1126/science.7871423; OWEN T, 1994, 26TH ANN M AM ASTR S; PRUPPACHER HR, 1978, MICROPHYSICS CLOUDS, P358; SASSON R, 1985, ICARUS, V64, P368, DOI 10.1016/0019-1035(85)90061-2; TINGLE TN, 1992, ORIGINS LIFE EVOL B, V21, P385; TREPTE CR, 1992, NATURE, V355, P626, DOI 10.1038/355626a0; WALLACE L, 1986, ASTROPHYS J, V172, P755; WARREN SG, 1986, APPL OPTICS, V25, P2650, DOI 10.1364/AO.25.002650; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WEST RA, 1992, ICARUS, V100, P245, DOI 10.1016/0019-1035(92)90033-4; ZHANLE K, COMMUNICATION	26	83	83	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1296	1301		10.1126/science.7871426	http://dx.doi.org/10.1126/science.7871426			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871426				2022-12-01	WOS:A1995QK06800031
J	ARANY, Z; NEWSOME, D; OLDREAD, E; LIVINGSTON, DM; ECKNER, R				ARANY, Z; NEWSOME, D; OLDREAD, E; LIVINGSTON, DM; ECKNER, R			A FAMILY OF TRANSCRIPTIONAL ADAPTER PROTEINS TARGETED BY THE E1A ONCOPROTEIN	NATURE			English	Article							TISSUE-SPECIFIC EXTINGUISHER; REGULATORY SUBUNIT; TSE1 ENCODES; CYCLIC-AMP; ACTIVATION; KINASE; GENE	THE cellular protein p300 is a target of the adenoviral E1A oncoprotein and is thought to participate in preventing the G0/G1 transition in the cell cycle, activating certain enhancers and stimulating differentiation pathways(1). CBP is a protein that is associated with and coactivates the transcription factor CREB, mediating the induction by cyclic AMP of certain responsive promoters(2-4). The sequences of p300 and CBP are highly related(4,5). We show here that p300, like CBP2, can stimulate transcription, This activity is directly aml specifically inhibited by E1A. We also find that CBP exists in a DNA-bound complex containing a member of the CREB family and that E1A and CBP interact with one another in vivo. In keeping with the idea that E1A functionally targets CBP, cAMP-dependent transcription is repressed by E1A. Thus, p300 and CBP define a family of transcriptional adaptor proteins that are specifically targeted by the E1A oncoprotein.			ARANY, Z (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.							ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V30, P226; BARBEAU D, 1994, ONCOGENE, V9, P359; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KATO J, 1994, J CELL SCI, V79, P487; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; VAIRO G, 1990, J BIOL CHEM, V265, P2692; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	16	507	513	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					81	84		10.1038/374081a0	http://dx.doi.org/10.1038/374081a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870178				2022-12-01	WOS:A1995QK07900058
J	ELLING, CE; NIELSEN, SM; SCHWARTZ, TW				ELLING, CE; NIELSEN, SM; SCHWARTZ, TW			CONVERSION OF ANTAGONIST-BINDING SITE TO METAL-ION SITE IN THE TACHYKININ NK-1 RECEPTOR	NATURE			English	Article							NEUROKININ-1 RECEPTOR; PROTEIN; NK1; IDENTIFICATION; EPITOPES; DOMAINS; DESIGN	MUTATIONAL analysis of the tachykinin NK-1 (refs 1-7), NK-2 (ref. 8) and angiotensin AT-1 (refs 9, 10) receptors indicates that non-peptide antagonists act through residues located between the seven transmembrane segments, whereas natural peptide agonists bind to residues scattered in the exterior part of the receptor(1-4,11-13). The presumed contact points for the prototype NK-1 antagonist CP96,345 cluster on opposing faces of the outer portions of transmembrane helices V and VI (refs 1-5). Here we show that systematic introduction of histidyl residues at this antagonist-binding site in the human NK-1 receptor gradually converts it into a high-affinity metal-ion-binding site without affecting agonist binding. In a double mutant with histidine residues substituted at the top of transmembrane segments V and VI, respectively, Zn2+ inhibits binding of radiolabelled agonist peptide and efficiently blocks phosphoinositol turnover induced by substance P. We propose that Zn2+ and CP96,345 act as 'allosteric competitive' antagonists by stabilizing inactive conformations of the mutant and the wild-type receptor respectively. Introduction of metal-ion-binding sites could be used as a general tool in the structural and functional characterization of helix-helix interactions in G-protein-coupled receptors, as well as in other membrane proteins.	RIGSHOSP,DEPT CLIN BIOCHEM,MOLEC ENDOCRINOL LAB,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen				Schwartz, Thue W./0000-0002-0261-6904				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; CASCIERI MA, 1994, J BIOL CHEM, V269, P6587; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P57, DOI 10.1093/protein/4.1.57; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GETHER U, 1994, J BIOL CHEM, V269, P23959; GETHER U, 1994, MOL PHARMACOL, V45, P500; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P3; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; JERIGAN R, 1994, CURR OPIN STRUCT BIO, V4, P256; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; SAMAMA P, 1993, MOL PHARMACOL, V45, P390; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	30	160	164	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					74	77		10.1038/374074a0	http://dx.doi.org/10.1038/374074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7532789				2022-12-01	WOS:A1995QK07900056
J	GIBSON, F; WALSH, J; MBURU, P; VARELA, A; BROWN, KA; ANTONIO, M; BEISEL, KW; STEEL, KP; BROWN, SDM				GIBSON, F; WALSH, J; MBURU, P; VARELA, A; BROWN, KA; ANTONIO, M; BEISEL, KW; STEEL, KP; BROWN, SDM			A TYPE-VII MYOSIN ENCODED BY THE MOUSE DEAFNESS GENE SHAKER-1	NATURE			English	Article							SYNDROME TYPE-I; ARTIFICIAL CHROMOSOME LIBRARY; YEAST; RECOMBINATION; CONSTRUCTION; LINKAGE; MAPS	GENETIC deafness is common, affecting about 1 in 2,000 births(1). Many of these show primary abnormalities of the sensory neuroepithelia of the inner ear, as do several hearing-impaired mouse mutants, suggesting that genes involved in sensory transduction could be affected. Here we report the identification of one such gene, the mouse shaker-1 (sh1) gene. Shaker-1 homozygotes show hyperactivity, head-tossing and circling due to vestibular dysfunction, together with typical neuroepithelial-type cochlear defects involving dysfunction and progressive degeneration of the organ of Corti(2-7). The sh1 gene encodes an unconventional myosin molecule of the type VII family. Three mutations are described, two missense mutations and a splice acceptor site mutation, all in the region encoding the myosin head. The myosin type VII molecule encoded by sh1 is the first molecule to be identified that is known, by virtue of its mutations, to be involved in auditory transduction.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT BIOCHEM & MOLEC GENET, LONDON W2 1PG, ENGLAND; BOYS TOWN NATL RES HOSP, OMAHA, NE 68131 USA; MRC, INST HEARING RES, NOTTINGHAM NG7 2RD, ENGLAND	Imperial College London; Boys Town National Research Hospital								BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BROWN KA, 1992, GENOMICS, V13, P189, DOI 10.1016/0888-7543(92)90219-I; BURKE DT, 1991, MAMM GENOME, V1, P65, DOI 10.1007/BF00350849; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; DEOL MS, 1956, PROC R SOC SER B-BIO, V145, P206, DOI 10.1098/rspb.1956.0028; DIBB NJ, 1985, J MOL BIOL, V183, P543, DOI 10.1016/0022-2836(85)90170-6; EVANS KL, 1993, HUM MOL GENET, V2, P115, DOI 10.1093/hmg/2.2.115; Fraser G. R, 1976, BIG 4 CAUSES POVERTY; GIBSON F, 1994, BIOTECHNIQUES, V16, P453; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GREENFIELD A J, 1987, Genomics, V1, P153, DOI 10.1016/0888-7543(87)90007-3; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KIKUCHI K, 1965, ACTA OTOLARYNG STOCK, V60, P287; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LETTS VA, 1994, MOUSE GENOME, V92, P116; Lord EM, 1929, AM NAT, V63, P435, DOI 10.1086/280276; MIKAELIAN DO, 1964, ARCHIV OTOLARYNGOL, V80, P418; MOOSEKER M, 1993, CURR BIOL, V3, P245, DOI 10.1016/0960-9822(93)90346-P; RINCHIK EM, 1990, P NATL ACAD SCI USA, V87, P896, DOI 10.1073/pnas.87.3.896; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SOLC CF, IN PRESS AUD NEUROSC; STEEL KP, 1983, ARCH OTOLARYNGOL, V109, P22; STEEL KP, 1992, DEV AUDITORY VESTIBU, V2, P221; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	28	520	528	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	1995	374	6517					62	64		10.1038/374062a0	http://dx.doi.org/10.1038/374062a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870172				2022-12-01	WOS:A1995QK07900052
J	JERMANN, TM; OPITZ, JG; STACKHOUSE, J; BENNER, SA				JERMANN, TM; OPITZ, JG; STACKHOUSE, J; BENNER, SA			RECONSTRUCTING THE EVOLUTIONARY HISTORY OF THE ARTIODACTYL RIBONUCLEASE SUPERFAMILY	NATURE			English	Article							AMINO-ACID-SEQUENCE; PANCREATIC RIBONUCLEASE; ESCHERICHIA-COLI; LYSOZYMES; PROTEIN; TUMOR	THE sequences of proteins from ancient organisms can be reconstructed from the sequences of their descendants by a procedure that assumes that the descendant proteins arose from the extinct ancestor by the smallest number of independent evolutionary events ('parsimony')(1,2). Tbe reconstructed sequences can then be prepared in the laboratory and studied(3,4). Thirteen ancient ribonucleases (RNases) have been reconstructed as intermediates in the evolution of the RNase protein family in artiodactyls (the mammal order that includes pig, camel, deer, sheep and ox)(5). The properties of the reconstructed proteins suggest that parsimony yields plausible ancient sequences. Going back in time, a significant change in behaviour, namely a fivefold increase in catalytic activity against double-stranded RNA, appears in the RNase reconstructed for the founding ancestor of the artiodactyl lineage, which lived about 40 million years ago(6). This corresponds to the period when ruminant digestion arose in the artiodactyls, suggests that contemporary artiodactyl digestive RNases arose from a non-digestive ancestor, and illustrates how evolutionary reconstructions can help in tbe understanding of physiological function within a protein family(7-9).			JERMANN, TM (corresponding author), ETH ZURICH,DEPT CHEM,CH-8092 ZURICH,SWITZERLAND.							ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; ARDELT W, 1991, J BIOL CHEM, V266, P245; BARNARD EA, 1969, NATURE, V221, P340, DOI 10.1038/221340a0; BELNTEMA JJ, 1986, MOL BIOL EVOL, V3, P262; Blackburn P, 1982, ENZYMES, VXV, P317; BREUKELMAN HJ, 1993, J MOL EVOL, V37, P29; Carroll RL., 1988, VERTEBRATE PALEONTOL; CIGLIC M, 1994, THESIS ETH ZURICH; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; GRAUR D, 1993, FEBS LETT, V325, P152, DOI 10.1016/0014-5793(93)81432-Y; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; Ipata P L., 1968, FEBS Lett, V1, P29, DOI 10.1016/0014-5793(68)80010-9; JOLLES J, 1989, J MOL EVOL, V28, P528, DOI 10.1007/BF02602933; LANG K, 1986, EUR J BIOCHEM, V159, P275, DOI 10.1111/j.1432-1033.1986.tb09864.x; LIBONATI M, 1969, EUR J BIOCHEM, V8, P81, DOI 10.1111/j.1432-1033.1969.tb00498.x; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; MATOUSEK J, 1973, EXPERIENTIA, V29, P858, DOI 10.1007/BF01946329; MCGEEHAN GM, 1989, FEBS LETT, V247, P55, DOI 10.1016/0014-5793(89)81239-6; NAMBIAR KP, 1984, SCIENCE, V223, P1299, DOI 10.1126/science.6322300; NAMBIAR KP, 1987, EUR J BIOCHEM, V163, P67, DOI 10.1111/j.1432-1033.1987.tb10737.x; OKABE Y, 1991, J BIOCHEM-TOKYO, V109, P786, DOI 10.1093/oxfordjournals.jbchem.a123457; PAULING I, 1963, ACTA CHEM SCAND S1, V17, pS9; ROSE KD, 1982, SCIENCE, V216, P621, DOI 10.1126/science.216.4546.621; SORRENTINO S, 1980, BIOCHIM BIOPHYS ACTA, V609, P40, DOI 10.1016/0005-2787(80)90199-9; SOUCEK J, 1986, NAT IMMUN CELL GROW, V5, P250; STACKHOUSE J, 1990, FEBS LETT, V262, P104, DOI 10.1016/0014-5793(90)80164-E; Stevens C.E., 1988, COMP PHYSL VERTEBRAT; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; TRAUTWEIN K, 1991, SITE-DIRECTED MUTAGENESIS AND PROTEIN ENGINEERING, P53; WATANABE H, 1988, J BIOCHEM-TOKYO, V104, P939, DOI 10.1093/oxfordjournals.jbchem.a122587	30	184	190	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					57	59		10.1038/374057a0	http://dx.doi.org/10.1038/374057a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7532788				2022-12-01	WOS:A1995QK07900050
J	KAWAI, K; OHASHI, PS				KAWAI, K; OHASHI, PS			IMMUNOLOGICAL FUNCTION OF A DEFINED T-CELL POPULATION TOLERIZED TO LOW-AFFINITY SELF-ANTIGENS	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; CLONAL DELETION; POSITIVE SELECTION; TRANSGENIC MICE; RECEPTOR; TOLERANCE; ANERGY; INDUCTION; ANTIBODY	IN the thymus there are two major mechanisms of T-lymphocyte tolerance: clonal deletion and clonal inactivation(1-3). One important problem underlying the mechanism of clonal inactivation is why unresponsive cells are maintained in the mature peripheral T-cell repertoire. Here we report that transgenic alpha beta T-cells may be tolerized to a self antigen Mls-1(a), but still retain proliferative responses for alternative peptide antigens and superantigens. These self-tolerant T cells can also provide immunopathological and memory cytotoxic function in vivo. We propose that high-affinity/avidity self-reactive T cells are deleted in the thymus, whereas lower-affinity/avidity interactions lead to unresponsiveness and define the 'resting threshold' for a given T cell. These low-affinity self-tolerant T cells remain functionally competent for high-affinity foreign antigens, and efficiently eliminate natural pathogens in vivo.	UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Kawai, Kazuhiro/D-4998-2011	Kawai, Kazuhiro/0000-0001-9375-0713; Ohashi, Pamela S./0000-0003-2915-9317				BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; RAMSDELL F, 1992, SCIENCE, V257, P1130, DOI 10.1126/science.257.5073.1130; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROCHA B, 1993, J EXP MED, V177, P1517, DOI 10.1084/jem.177.5.1517; ROCKEN M, 1992, NATURE, V359, P79, DOI 10.1038/359079a0; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1991, J EXP MED, V174, P1001, DOI 10.1084/jem.174.5.1001; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAN XJ, 1993, J IMMUNOL, V150, P3873; YUI K, 1990, P NATL ACAD SCI USA, V87, P7135, DOI 10.1073/pnas.87.18.7135	22	77	78	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					68	69		10.1038/374068a0	http://dx.doi.org/10.1038/374068a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870174				2022-12-01	WOS:A1995QK07900054
J	LEE, JW; RYAN, F; SWAFFIELD, JC; JOHNSTON, SA; MOORE, DD				LEE, JW; RYAN, F; SWAFFIELD, JC; JOHNSTON, SA; MOORE, DD			INTERACTION OF THYROID-HORMONE RECEPTOR WITH A CONSERVED TRANSCRIPTIONAL MEDIATOR	NATURE			English	Article							26-S PROTEASE; TRANSACTIVATION; ACTIVATION; MODULATOR; DOMAIN; YEAST	THE thyroid-hormone receptors are hormone-dependent transcription factors that control expression of many target genes(1,2). This regulation is presumably a consequence of hormone-dependent contacts between the receptors and the basal transcription machinery(3). We used the yeast two-hybrid system(4,5) to identify a candidate human transcriptional mediator that interacts with both the thyroid-hormone receptor and the retinoid-X receptor in a ligand-dependent fashion. This protein, Trip1 (for thyroid-hormone-receptor Interacting protein), shares striking sequence conservation with the yeast transcriptional mediator Sug1 (refs 6, 7). Here we show that Trip1 can functionally substitute for Sug1 in yeast, and that both proteins interact in vitro with the thyroid-hormone receptor, acid with the transcriptional activation domains of yeast GAL4 and of herpes virus VP16.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LEE, JW (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,WELLMAN 9,BOSTON,MA 02114, USA.							Ausubel F.M., 1995, CURRENT PROTOCOLS MO; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BRENT GA, 1991, REV PHYSL, V53, P17; CARTER ME, 1994, MOL CELL BIOL, V14, P360; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; LEE JW, IN PRESS MOL ENDOCR; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0	20	392	404	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					91	94		10.1038/374091a0	http://dx.doi.org/10.1038/374091a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870181				2022-12-01	WOS:A1995QK07900061
J	LUNDBLAD, JR; KWOK, RPS; LAURANCE, ME; HARTER, ML; GOODMAN, RH				LUNDBLAD, JR; KWOK, RPS; LAURANCE, ME; HARTER, ML; GOODMAN, RH			ADENOVIRAL E1A-ASSOCIATED PROTEIN P300 AS A FUNCTIONAL HOMOLOG OF THE TRANSCRIPTIONAL COACTIVATOR CBP	NATURE			English	Article							REGION 1A PROTEINS; ESCHERICHIA-COLI; PROMOTER; IDENTIFICATION; ASSOCIATION; BINDS; GENE	THE 265K nuclear protein CBP was initially identified as a coactivator for the protein kinase A (PKA)-phosphorylated form of the transcription factor CREB(1). The domains in CBP that are involved in CREB binding and transcriptional activation are highly related to the adenoviral E1A-associated cellular protein p300 (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, R10E11.1 and K03H1.10 (refs 4 and 5, respectively), whose functions are unknown. Here, we show that CBP and p300 have similar binding affinity for the PKA-phosphorylated form of CREB, and that p300 can substitute for CBP in potentiating CREB-activated gene expression. We find that E1A binds to CBP through a domain conserved with p300 acid represses the CREB-dependent co-activator functions of both CBP and p300. Our results indicate that the gene repression and cell immortalization functions associated with E1A involve the inactivation of a family of related proteins that normally participate in second-messenger-regulated gene expression.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; CLEVELAND CLIN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Oregon Health & Science University; Cleveland Clinic Foundation								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARANY Z, 1994, CELL, V77, P7799; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANERJEE AC, 1994, ONCOGENE, V5, P1733; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KWOK RPS, 1994, NATURE, V378, P223; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH M, 1994, Z29560 GENB ACC; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	21	530	541	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					85	88		10.1038/374085a0	http://dx.doi.org/10.1038/374085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870179				2022-12-01	WOS:A1995QK07900059
J	PICCIOTTO, MR; ZOLL, M; LENA, C; BESSIS, A; LALLEMAND, Y; LENOVERE, N; VINCENT, P; PICH, EM; BRULET, P; CHANGEUX, JP				PICCIOTTO, MR; ZOLL, M; LENA, C; BESSIS, A; LALLEMAND, Y; LENOVERE, N; VINCENT, P; PICH, EM; BRULET, P; CHANGEUX, JP			ABNORMAL AVOIDANCE-LEARNING IN MICE LACKING FUNCTIONAL HIGH-AFFINITY NICOTINE RECEPTOR IN THE BRAIN	NATURE			English	Article							RAT-BRAIN; ACETYLCHOLINE-RECEPTORS; ALPHA-BUNGAROTOXIN; GENE; BETA-2-SUBUNIT; LOCALIZATION; BEHAVIOR; BINDING; SYSTEM	NICOTINE affects many aspects of behaviour including learning and memory(1,2) through its interaction with neuronal nicotinic acetylcholine receptors (nAChR). Functional nAChRs are pentameric proteins containing at least one type of alpha-subunit and one type of beta-subunit(3-5). The involvement of a particular neuronal nicotinic subunit in pharmacology and behaviour was examined using gene targeting to mutate beta 2, the most widely expressed nAChR subunit in the central nervous system(6-8). We report here that high-affinity binding sites for nicotine are absent from the brains of mice homozygous for the beta 2-subunit mutation. Further, electrophysiological recording from brain slices reveals that thalamic neurons from these mice do not respond to nicotine application. Finally, bebavioural tests demonstrate that nicotine no longer augments the performance of beta 2(-/-) mice on passive avoidance, a test of associative memory. Paradoxically, mutant mice are able to perform better than their non-mutant siblings on this task.	INST PASTEUR,UNITE EMBRYOL MOLEC,ERS 67,PARIS,FRANCE; GLAXO INST MOLEC BIOL SA,DEPT NEUROBIOL,CH-1211 GENEVA,SWITZERLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GlaxoSmithKline	PICCIOTTO, MR (corresponding author), INST PASTEUR,CNRS,UNITE NEUROBIOL MOLEC D1284,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Vincent, Pierre/A-1055-2012; Léna, Clément/T-8458-2018; Léna, Clément/ABE-4862-2021; Léna, Clément/P-6929-2019; Picciotto, Marina R./F-8747-2012; Beldar, Sagar V/C-8542-2011; , clement/ADN-8076-2022; Zoli, Michele/C-8899-2016; Le Novère, Nicolas/F-9973-2010	Vincent, Pierre/0000-0002-8479-1908; Léna, Clément/0000-0002-1431-7717; Léna, Clément/0000-0002-1431-7717; Léna, Clément/0000-0002-1431-7717; Picciotto, Marina R./0000-0002-4404-1280; Zoli, Michele/0000-0002-8034-2849; Le Novère, Nicolas/0000-0002-6309-7327; Bessis, Alain/0000-0001-8362-6874				ANAND R, 1991, J BIOL CHEM, V266, P11192; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; CRAWLEY JN, 1985, NEUROSCI BIOBEHAV R, V9, P37, DOI 10.1016/0149-7634(85)90030-2; DECKER MW, 1994, J PHARMACOL EXP THER, V2270, P319; FAIMAN CP, 1991, BEHAV NEURAL BIOL, V56, P1183; FLICKER C, 1983, PHARMACOL BIOCHEM BE, V18, P973, DOI 10.1016/S0091-3057(83)80023-9; FLORES CM, 1992, MOL PHARMACOL, V41, P31; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; HILL JA, 1993, J NEUROSCI, V13, P1551; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVIN ED, 1992, PSYCHOPHARMACOLOGY, V108, P417, DOI 10.1007/BF02247415; LUETJE CW, 1991, J NEUROSCI, V11, P837; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MARKS MJ, 1982, MOL PHARMACOL, V22, P554; MMARKS MJ, 1982, J NEUROSCI, V12, P2765; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; NORDBERG A, 1985, ACTA PHARMACOL TOX, V56, P337; OLIVERIO A, 1966, J PHARMACOL EXP THER, V154, P350; PICH EM, 1989, PHARMACOL RES, V21, P595; ROMANO C, 1980, SCIENCE, V210, P647, DOI 10.1126/science.7433991; Sambrook J., 1989, MOL CLONING LAB MANU; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SWANSON LW, 1983, P NATL ACAD SCI-BIOL, V80, P4532, DOI 10.1073/pnas.80.14.4532; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; ZOLI M, IN PRESS J NEUROSCI	28	540	556	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					65	67		10.1038/374065a0	http://dx.doi.org/10.1038/374065a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870173				2022-12-01	WOS:A1995QK07900053
J	PIETTE, JC; FRANCES, C				PIETTE, JC; FRANCES, C			IMAGES IN CLINICAL MEDICINE - RELAPSING POLYCHONDRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PIETTE, JC (corresponding author), HOP LA PITIE SALPETRIERE,F-75651 PARIS 13,FRANCE.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					580	580		10.1056/NEJM199503023320906	http://dx.doi.org/10.1056/NEJM199503023320906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838192				2022-12-01	WOS:A1995QJ09000006
J	SWAFFIELD, JC; MELCHER, K; JOHNSTON, SA				SWAFFIELD, JC; MELCHER, K; JOHNSTON, SA			A HIGHLY CONSERVED ATPASE PROTEIN AS A MEDIATOR BETWEEN ACIDIC ACTIVATION DOMAINS AND THE TATA-BINDING PROTEIN	NATURE			English	Article							MOLECULAR-WEIGHT PROTEASES; SACCHAROMYCES-CEREVISIAE; MULTICATALYTIC PROTEINASE; 26-S PROTEASE; YEAST; GENE; GAL4; MEMBER; FAMILY; PURIFICATION	BIOCHEMICAL and genetic studies suggest the existence of mediators that work between the activation domains (ADs) of regulatory proteins and the basic transcriptional machinery. We have previously shown genetically that Sug1 interacts with the AD of the yeast activator Ga14(1). Here we provide evidence that the Sug1 protein of yeast binds directly to the ADs of Ga14 and the viral activator, VP16. Sug1 protein is associated with the TATA-binding protein in vivo and binds to it in vitro, consistent with a mediator function. We also demonstrate that Sug1 is not a component of the 26S proteasome, contrary to previous reports(2-5). Sug1 is a member of a large, highly conserved family of ATPases, implying a role for ATP hydrolysis in the activation of transcription.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75325; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75325	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Melcher, Karsten/AAZ-3861-2020	Melcher, Karsten/0000-0002-9125-4027				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA CP, 1992, J BIOL CHEM, V267, P10515; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TOMAYAZU T, 1993, J BACTERIOL, V176, P1344; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WAXMAN L, 1987, J BIOL CHEM, V262, P2451	30	133	136	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					88	91		10.1038/374088a0	http://dx.doi.org/10.1038/374088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870180				2022-12-01	WOS:A1995QK07900060
J	VERBEEK, S; IZON, D; HOFHUIS, F; ROBANUSMAANDAG, E; TERIELE, H; VANDEWETERING, M; OOSTERWEGEL, M; WILSON, A; MACDONALD, HR; CLEVERS, H				VERBEEK, S; IZON, D; HOFHUIS, F; ROBANUSMAANDAG, E; TERIELE, H; VANDEWETERING, M; OOSTERWEGEL, M; WILSON, A; MACDONALD, HR; CLEVERS, H			AN HMG-BOX-CONTAINING T-CELL FACTOR REQUIRED FOR THYMOCYTE DIFFERENTIATION	NATURE			English	Article							TRANSCRIPTION FACTOR; RECEPTOR GENES; MICE; LYMPHOCYTES; PROTEIN; DOMAIN; TCF-1; LEF-1; BLOCK	Two candidate genes for controlling thymocyte differentiation, T-cell factor-1 (Tcf-1) and lymphoid enhancer-binding factor (Lef-1), encode closely related DNA-binding HMG-box proteins(1,2). Their expression pattern is complex and largely overlapping during embryogenesis, yet restricted to lymphocytes postnatally(3). Here we generate two independent germline mutations in Tcf-1 and find that thymocyte development is (otherwise normal) mutant mice is blocked at the transition from the CD8(+), immature single-positive to the CD4(+)/CD8(+) double-positive stage. Is contrast to wild-type mice, most of the immature single-positive cells in the mutants are not in the cell cycle and the number of immunocompetent T cells in peripheral lymphoid organs is reduced. We conclude that Tcf-1 controls an essential step in thymocyte differentiation.	UNIV UTRECHT HOSP,DEPT IMMUNOL,3508 GA UTRECHT,NETHERLANDS; NETHERLANDS CANC INST,DIV IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; UNIV LAUSANNE,LUDWIG INST CANC RES,CH-1066 EPALINGES,SWITZERLAND	Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; Netherlands Cancer Institute; Ludwig Institute for Cancer Research; University of Lausanne			Wilson, Anne/A-7131-2011					CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; OOSTERWEGEL M, 1992, J EXP MED, V173, P1133; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, J BIOL CHEM, V267, P8530; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; WILSON A, 1994, J EXP MED, V179, P1355, DOI 10.1084/jem.179.4.1355	20	423	426	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					70	74		10.1038/374070a0	http://dx.doi.org/10.1038/374070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870176	Green Submitted			2022-12-01	WOS:A1995QK07900055
J	WELL, D; BLANCHARD, S; KAPLAN, J; GUILFORD, P; GIBSON, F; WALSH, J; MBURU, P; VARELA, A; LEVILLERS, J; WESTON, MD; KELLEY, PM; KIMBERLING, WJ; WAGENAAR, M; LEVIACOBAS, F; LARGETPIET, D; MUNNICH, A; STEEL, KP; BROWN, SDM; PETIT, C				WELL, D; BLANCHARD, S; KAPLAN, J; GUILFORD, P; GIBSON, F; WALSH, J; MBURU, P; VARELA, A; LEVILLERS, J; WESTON, MD; KELLEY, PM; KIMBERLING, WJ; WAGENAAR, M; LEVIACOBAS, F; LARGETPIET, D; MUNNICH, A; STEEL, KP; BROWN, SDM; PETIT, C			DEFECTIVE MYOSIN VIIA GENE RESPONSIBLE FOR USHER SYNDROME TYPE 1B	NATURE			English	Article							SYNDROME TYPE-I; NASAL CILIA; HAIR-CELLS; CHROMOSOME-11; LINKAGE; MOTOR; MAPS	USHER syndrome represents the association of a hearing impairment with retinitis pigmentosa(1) and is the most frequent cause of deaf-blindness in humans. it is inherited as an autosomal recessive trait which is clinically and genetically heterogeneous(2,3). Some patients show abnormal organization of microtubules in the axoneme of their photoreceptors cells (connecting cilium)(4-6), nasal ciliar cells(7) and sperm cells(5), as well as widespread degeneration of the organ of Corti(8). Usher syndrome type 1 (USH1) is characterized by a profound congenital sensorineural hearing loss, constant vestibular dysfunction and prepubertal onset of retinitis pigmentosa. Of three different genes responsible for USH1(9-11) USH1B maps to 11q13.5 (ref. 10) and accounts for about 75% of USH1 patients(2,3). The mouse deafness shaker-1 (sh1) mutation has been localized to the homologous murine region(12,13). Taking into account the cytoskeletal abnormalities in USH patients, the identification of a gene encoding an unconventional myosin as a candidate for shaker-1 (ref. 14) led us to consider the human homologue as a good candidate for the gene that is defective in USH1B. Here we present evidence that a gene encoding myosin VIIA is responsible for USH1B. Two different premature stop codons, a six-base-pair deletion and two different missense mutations were detected in five unrelated families. In one of these families, the mutations were identified in both alleles. These mutations, which are located at the amino-terminal end of the motor domain of the protein, are likely to result in the absence of a functional protein. Thus USH1B appears as a primary cytoskeletal protein defect. These results implicate the genes encoding other unconventional myosins and their interacting proteins as candidates for other genetic forms of Usher syndrome.	INST PASTEUR, CNRS, UNITE GENET MOLEC HUMAINE 1968, F-75724 PARIS 15, FRANCE; HOP NECKER ENFANTS MALAD, INSERM, U393, UNITE RECH HANDICAPS GENET ENFANT, F-75743 PARIS 15, FRANCE; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT BIOCHEM & MOLEC GENET, LONDON W2 1PG, ENGLAND; BOYS TOWN NATL RES HOSP, DEPT PATHOL, OMAHA, NE 68131 USA; CATHOLIC UNIV NIJMEGEN, ST RADBOUD HOSP, 6500 HB NIJMEGEN, NETHERLANDS; MRC, INST HEARING RES, NOTTINGHAM NG7 2RD, ENGLAND	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Boys Town National Research Hospital; Radboud University Nijmegen				Guilford, Parry/0000-0002-7256-9576				ADAMS RJ, 1989, CELL MOTIL CYTOSKEL, V14, P178, DOI 10.1002/cm.970140203; ARDEN GB, 1979, NATURE, V279, P534, DOI 10.1038/279534a0; ASSAD JA, 1992, J NEUROSCI, V12, P3291; BARRONG SD, 1992, ARCH OPHTHALMOL-CHIC, V110, P706, DOI 10.1001/archopht.1992.01080170128040; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BONNEAU D, 1993, J MED GENET, V30, P253, DOI 10.1136/jmg.30.3.253; BROWN KA, 1992, GENOMICS, V13, P189, DOI 10.1016/0888-7543(92)90219-I; BROWN SDM, 1994, HUM MOL GENET, V3, P1453, DOI 10.1093/hmg/3.suppl_1.1453; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; COLLUCIO LM, 1989, J CELL BIOL, V108, P495; EVANS KL, 1993, HUM MOL GENET, V2, P115, DOI 10.1093/hmg/2.2.115; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; HUNTER DG, 1986, ARCH OPHTHALMOL-CHIC, V104, P385; JAEGER RG, 1994, HEARING RES, V77, P207, DOI 10.1016/0378-5955(94)90268-2; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; LARGETPIET D, 1994, GENOMICS, V21, P138, DOI 10.1006/geno.1994.1235; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; METCALF AB, 1994, P NATL ACAD SCI USA, V91, P11821, DOI 10.1073/pnas.91.25.11821; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.physiol.53.1.653; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SHINKAWA H, 1986, ANN OTO RHINOL LARYN, V95, P313, DOI 10.1177/000348948609500321; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SMITH RJH, 1994, AM J MED GENET, V50, P32, DOI 10.1002/ajmg.1320500107; STEELKP, 1994, TRENDS GENET SCI, V10, P428; TILNEY LG, 1992, ANNU REV CELL BIOL, V8, P257, DOI 10.1146/annurev.cellbio.8.1.257; USHER CR, 1913, LOND OPHTHAL HOSDP R, V19, P130; WILLIAMS DS, 1992, J CELL SCI, V103, P183	31	831	849	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	1995	374	6517					60	61		10.1038/374060a0	http://dx.doi.org/10.1038/374060a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870171				2022-12-01	WOS:A1995QK07900051
J	YANG, JH; SKLAR, P; AXEL, R; MANIATIS, T				YANG, JH; SKLAR, P; AXEL, R; MANIATIS, T			EDITING OF GLUTAMATE-RECEPTOR SUBUNIT-B PRE-MESSENGER-RNA IN-VITRO BY SITE-SPECIFIC DEAMINATION OF ADENOSINE	NATURE			English	Article							UNWINDING ACTIVITY; CA2+ PERMEABILITY; ION FLOW; CHANNELS; RNA; DETERMINANTS	EDITING Of the glutamate receptor subunit B (GluR-B) pre-mRNA at a single adenosine residue results in an amino-acid change that profoundly alters the electrophysiological properties of the (1-7). Here we show that the GluR-B pre-mRNA is efficiently and accurately edited in vitro, and that base-pair interactions between the editing site and a sequence in the downstream introns are required for substrate recognition. In addition, we directly demonstrate that editing results from the conversion of adenosine to inosine by enzymatic deamination. The biochemical properties of this GluR-B editing activity are similar to those of a double-stranded-RNA-dependent adenosine deaminase(9-15), but RNA competition and column fractionation experiments indicate that the GluR-B editing and deaminase activities are distinct. Thus, the GluR-B editing enzyme may contain the adenosine deaminase, or a similar activity, and an RNA recognition subunit that specifically targets the enzyme to the editing site.	COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT BIOCHEM,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute; Columbia University	YANG, JH (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,7 DIVIN AVE,CAMBRIDGE,MA 01238, USA.			Axel, Richard/0000-0002-3141-4076				BAS BL, 1993, RNA WORLD, P383; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass Brenda L., 1992, Seminars in Developmental Biology, V3, P425; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; MOORE MJ, 1993, SCIENCE, V256, P992; PASCHEN W, 1994, J NEUROCHEM, V63, P1596, DOI 10.1046/j.1471-4159.1994.63051596.x; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647	21	115	118	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					77	81		10.1038/374077a0	http://dx.doi.org/10.1038/374077a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870177				2022-12-01	WOS:A1995QK07900057
J	COOK, DJ; GUYATT, GH; JAESCHKE, R; REEVE, J; SPANIER, A; KING, D; MOLLOY, DW; WILLAN, A; STREINER, DL				COOK, DJ; GUYATT, GH; JAESCHKE, R; REEVE, J; SPANIER, A; KING, D; MOLLOY, DW; WILLAN, A; STREINER, DL			DETERMINANTS IN CANADIAN HEALTH-CARE WORKERS OF THE DECISION TO WITHDRAW LIFE-SUPPORT FROM THE CRITICALLY ILL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; RESOURCE-ALLOCATION; RATIONING DECISIONS; RESUSCITATE ORDERS; MEDICAL-CARE; INEVITABILITY; VARIABILITY; TECHNOLOGY; DIRECTIVES; ATTITUDES	Objective.-To examine the attitudes of health care workers regarding the withdrawal or life support. Design.-Cross-sectional survey. Participants.-Attending staff, house staff, and intensive care unit (ICU) nurses in 37 Canadian university-affiliate hospitals. Main Outcome Measures.-Health care workers' ratings of the importance of 17 factors considered in the decision to withdraw life support, and their ratings of five levels of care ranging from comfort measures to intensive care in two of 12 different clinical scenarios. Results.-We surveyed 1361 respondents (149 of 167 potentially eligible ICU attending staff, 142 of 173 ICU house staff, and 1070 of 1455 ICU nurses, with response rates of 89%, 82% and 74%, respectively). The most important factors were likelihood of surviving the current episode, likelihood of long-term survival, premorbid cognitive function, and age of the patient. In choosing the level of care for the patient scenarios, the same option was chosen by more than 50% of respondents in only one of 12 scenarios; opposite extremes of care were chosen by more than 10% of the respondents in eight of 12 scenarios. Respondent characteristics affecting choices included the number of years since graduation, the city and province in which they worked, the number of beds in their ICU, and their assessment of the likelihood that they would withdraw life support in comparison with their colleagues (P<.001 for all comparisons). Conclusions.-While ICU health care workers consistently identify a number of patient factors as important in decisions to withdraw care, there is extreme variability, which may be explained in part by the values of individual health care providers.	MCMASTER UNIV, FAC HLTH SCI, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA; MCGILL UNIV, JEWISH GEN HOSP, DEPT SURG, MONTREAL, PQ H3T 1E2, CANADA	McMaster University; McMaster University; McGill University			Embrett, Mark G./H-4466-2014; Streiner, David/E-6563-2011	Embrett, Mark G./0000-0002-3969-0219; Streiner, David/0000-0003-0610-6271				ALEMAYEHU E, 1991, CAN MED ASSOC J, V144, P1133; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; BYTH PL, 1990, ETHICAL ATTITUDES ME; COOK DJ, 1992, CURRENT PULMONOLOGY; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2047; Feinstein A.R., 1987, CLINIMETRICS, V141, P166, DOI DOI 10.2307/J.CTT1XP3VBC.13; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT GH, 1986, CAN MED ASSOC J, V134, P889; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; LOEWY EH, 1987, NEW ENGL J MED, V317, P1465, DOI 10.1056/NEJM198712033172308; LUCE JM, 1988, CHEST, V94, P621, DOI 10.1378/chest.94.3.621; MCCRARY SV, 1989, JAMA-J AM MED ASSOC, V265, P2411; MOLLOY DW, 1993, HUM MED, V9, P70; MOLLOY DW, 1991, CAN MED ASSOC J, V145, P307; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; SCHROEDER SA, 1979, NEW ENGL J MED, V300, P1306, DOI 10.1056/NEJM197906073002304; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPRUNG CL, 1992, CRIT CARE MED, V20, P320; SPRUNG CL, 1990, JAMA-J AM MED ASSOC, V263, P2211, DOI 10.1001/jama.263.16.2211; VINCENT JL, 1990, INTENS CARE MED, V16, P256, DOI 10.1007/BF01705162; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	28	304	309	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					703	708		10.1001/jama.273.9.703	http://dx.doi.org/10.1001/jama.273.9.703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QH814	7853627				2022-12-01	WOS:A1995QH81400028
J	ECKMAN, MH; GREENFIELD, S; MACKEY, WC; WONG, JB; KAPLAN, S; SULLIVAN, L; DUKES, K; PAUKER, SG				ECKMAN, MH; GREENFIELD, S; MACKEY, WC; WONG, JB; KAPLAN, S; SULLIVAN, L; DUKES, K; PAUKER, SG			FOOT INFECTIONS IN DIABETIC-PATIENTS - DECISION AND COST-EFFECTIVENESS ANALYSES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY AMPUTATIONS; ORAL ANTIMICROBIAL THERAPY; PEDAL OSTEOMYELITIS; CONVENIENT APPROXIMATION; PERSONAL-COMPUTER; BONE-SCINTIGRAPHY; LIFE EXPECTANCY; SOFT-TISSUE; CIPROFLOXACIN; DIAGNOSIS	Objective.-To examine the cost-effectiveness of approaches to the diagnosis and treatment of patients with type II (non-insulin-dependent) diabetes mellitus (NIDDM) who have foot infections and suspected osteomyelitis. Design.-Decision and cost-effectiveness analyses were performed using a Markov model. We examined the prevalence of osteomyelitis, the major complications and efficacies of long-term antibiotic therapy and surgery, and the performance characteristics of four diagnostic tests (roentgenography, technetium Tc 99m bone scanning, indium In 111-labeled white blood cell scanning, and magnetic resonance imaging). Data were drawn from the English-language literature using MEDLINE searches and bibliographies from selected articles. Setting.-Primary care. Patients.-Patients with NIDDM who had foot infections and suspected osteomyelitis but no signs of systemic toxicity. Interventions.-following hospitalization for surgical debridement and intravenous antibiotic therapy: (1) treatment for presumed soft-tissue infection, (2) culture-guided empiric treatment for presumed osteomyelitis, (3) 71 combinations of diagnostic tests preceding antibiotic therapy for osteomyelitis, (4) 71 combinations of tests preceding amputation, and (5) immediate amputation. Main Outcome Measures.-Quality-adjusted life expectancy, average costs. Results.-Culture-guided empiric treatment for osteomyelitis with 10 weeks of oral antibiotic therapy has similar effectiveness to testing followed by a long course of antibiotic therapy if any test result is positive. However, empiric treatment is the least expensive strategy. Conclusions.-Noninvasive testing adds significant expense to the treatment of patients with NIDDM in whom pedal osteomyelitis is suspected, and such testing may result in little improvement in health outcomes. In patients without systemic toxicity, a 10-week course of culture-guided oral antibiotic therapy following surgical debridement may be as effective as and less costly than other approaches.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, PRIMARY CARE OUTCOMES RES INST, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT SURG, DIV VASC SURG, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts Medical Center; Tufts University	ECKMAN, MH (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CLIN DECIS MAKING, BOX 302, 750 WASHINGTON AVE, BOSTON, MA 02111 USA.			Eckman, Mark/0000-0001-8253-269X; Kaplan, Sherrie/0000-0002-8644-5849; Sullivan, Lisa/0000-0003-0726-7149; Greenfield, Sheldon/0000-0003-4628-1998; Wong, John/0000-0003-4203-9010	AHRQ HHS [HS-06665] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		APELQVIST J, 1989, DIABETIC MED, V6, P526, DOI 10.1111/j.1464-5491.1989.tb01221.x; BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BELTRAN J, 1990, SKELETAL RADIOL, V19, P37; BENTON GS, 1985, SURG GYNECOL OBSTET, V161, P523; BILD DE, 1989, DIABETES CARE, V12, P24, DOI 10.2337/diacare.12.1.24; BLACK J, 1987, J INFECT DIS, V155, P968, DOI 10.1093/infdis/155.5.968; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; CHRISTENSEN S, 1976, ACTA ORTHOP SCAND, V47, P329, DOI 10.3109/17453677608992001; CONNELL FA, 1991, MMWR-MORBID MORTAL W, V40, P737; DAVIS H, 1989, ANN INTERN MED, V111, P1041, DOI 10.7326/0003-4819-111-12-1041; De Frang R D, 1991, Ann Vasc Surg, V5, P202, DOI 10.1007/BF02016758; DESAI Y, 1986, BRIT J SURG, V73, P392, DOI 10.1002/bjs.1800730527; DURHAM JR, 1989, AM J SURG, V158, P127, DOI 10.1016/0002-9610(89)90360-7; EDMONDS ME, 1986, Q J MED, V60, P763; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Geiss Linda S., 1993, Morbidity and Mortality Weekly Report, V42, P1; Gentry L O, 1990, Infect Dis Clin North Am, V4, P485; GENTRY LO, 1991, ANN INTERN MED, V114, P986, DOI 10.7326/0003-4819-114-11-986; GENTRY LO, 1988, J ANTIMICROB CHEMOTH, V21, P115, DOI 10.1093/jac/21.suppl_C.115; GENTRY LO, 1990, ANTIMICROB AGENTS CH, V34, P40, DOI 10.1128/AAC.34.1.40; Geroulakos G, 1991, Eur J Vasc Surg, V5, P655, DOI 10.1016/S0950-821X(05)80901-6; GREENFIELD S, 1994, DIABETES CARE, V17, P32; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HARRIS MI, 1985, NIH851468 US DEP HLT; Hobson M I, 1990, J R Coll Surg Edinb, V35, P113; HUGHES C E, 1987, Clinical Therapeutics, V10, P36; JONES EW, 1987, DIABETIC MED, V4, P475, DOI 10.1111/j.1464-5491.1987.tb00912.x; KAHN KL, 1986, J CLIN GASTROENTEROL, V8, P346, DOI 10.1097/00004836-198606002-00005; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; LAU J, 1983, MED DECIS MAKING, V3, P39, DOI 10.1177/0272989X8300300110; LEVEY AS, 1987, ANN INTERN MED, V107, P697, DOI 10.7326/0003-4819-107-5-697; LIPSKY B, 1989, 29TH INT C ANT AG CH; Lipsky B A, 1990, Clin Geriatr Med, V6, P747; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; LIPSKY BA, 1990, ARCH INTERN MED, V150, P790, DOI 10.1001/archinte.150.4.790; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; LOUIE TJ, 1976, ANN INTERN MED, V85, P461, DOI 10.7326/0003-4819-85-4-461; LUSK RH, 1977, J INFECT DIS, V135, pS111, DOI 10.1093/infdis/135.Supplement.S111; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MALONE JM, 1981, ARCH SURG-CHICAGO, V116, P93; MAURER AH, 1986, RADIOLOGY, V161, P221, DOI 10.1148/radiology.161.1.3763871; MOSKOWITZ AJ, 1988, ANN INTERN MED, V108, P435, DOI 10.7326/0003-4819-108-3-435; MOSKOWITZ AJ, 1986, MED DECIS MAKING, V6, P267; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; MUSHLIN AI, 1994, J GEN INTERN MED, V9, P1, DOI 10.1007/BF02599133; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; NEWMAN LG, 1991, JAMA-J AM MED ASSOC, V266, P1246, DOI 10.1001/jama.266.9.1246; NIX DE, 1987, AM J MED, V82, P146; OCONNOR GT, 1993, MED DECIS MAKING, V13, P87, DOI 10.1177/0272989X9301300201; PARK HM, 1982, J NUCL MED, V23, P569; PAUKER SG, 1981, ARCH INTERN MED, V141, P1831, DOI 10.1001/archinte.141.13.1831; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; POTTS JR, 1979, AM J SURG, V138, P924, DOI 10.1016/0002-9610(79)90323-4; ROSENBERG JM, 1984, AM J SURG, V147, P486, DOI 10.1016/0002-9610(84)90010-2; SANFORD JP, 1994, ANTIMICROBIAL THERAP; SAPICO FL, 1980, J CLIN MICROBIOL, V12, P413, DOI 10.1128/JCM.12.3.413-420.1980; SCHAUWECKER DS, 1988, J NUCL MED, V29, P1651; SEGALL GM, 1989, CLIN NUCL MED, V14, P255, DOI 10.1097/00003072-198904000-00003; SELDIN DW, 1985, J NUCL MED, V26, P988; SINGER RB, 1976, MED RISKS, pCH9; STIEFELD SM, 1991, ORTHOP CLIN N AM, V22, P439; STIRNEMANN P, 1987, J CARDIOVASC SURG, V28, P152; TU JV, 1993, AM REV RESPIR DIS, V148, P370, DOI 10.1164/ajrccm/148.2.370; Wagner F W Jr, 1981, Foot Ankle, V2, P64; WAGNER FW, 1986, SURGERY FOOT, P423; WALKER RC, 1991, MAYO CLIN PROC, V66, P1249, DOI 10.1016/S0025-6196(12)62477-X; WANG A, 1990, MAGN RESON IMAGING, V8, P805, DOI 10.1016/0730-725X(90)90017-V; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WASSERMAN Y, 1993, PHYSICIANS FEE REFER, P62; WEINSTEIN D, 1993, FOOT ANKLE, V14, P18, DOI 10.1177/107110079301400104; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WHEAT J, 1985, AM J MED, V78, P218, DOI 10.1016/0002-9343(85)90388-2; WHEAT LJ, 1986, ARCH INTERN MED, V146, P1935, DOI 10.1001/archinte.146.10.1935; WILSON KH, 1985, SOUTHERN MED J, V78, P223, DOI 10.1097/00007611-198502000-00035; YAMAMOTO F, 1980, PROGNOSIS SURGICAL D, P88; YUH WTC, 1989, AM J ROENTGENOL, V152, P795, DOI 10.2214/ajr.152.4.795; ZIMMERMAN J, 1980, SCAND J INFECT DIS, V12, P79, DOI 10.3109/inf.1980.12.issue-1.15; ZLATKIN MB, 1987, RADIOL CLIN N AM, V25, P1095; [No title captured]; 1990, PHS901101 US DEP HLT, P10	82	188	191	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					712	720		10.1001/jama.273.9.712	http://dx.doi.org/10.1001/jama.273.9.712			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853629				2022-12-01	WOS:A1995QH81400030
J	GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC				GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC			PHYSICAL-ACTIVITY, OBESITY, AND RISK FOR COLON-CANCER AND ADENOMA IN MEN	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-FAT DISTRIBUTION; COLORECTAL-CANCER; OCCUPATIONAL EXERCISE; ALCOHOL-CONSUMPTION; COLLEGE ALUMNI; GROWTH-FACTOR; BOWEL HABIT; YOUNG MEN; CELL-LINE; INSULIN	Objective: To determine whether physical inactivity and obesity increase risk for colon cancer and adenomas, which are precursors of cancer, and whether the abdominal distribution of obesity is an independent risk factor for these events. Design: Prospective cohort study. Setting: United States. Patients: 47 723 male health professionals, 40 to 75 years of age, who responded to a questionnaire mailed in 1986. Measurements: Questionnaires in 1986 about physical activity level and body mass index, and questionnaires in 1987 (31 055 respondents) about waist and hip circumferences. Between 1986 and 1992, 203 new patients were diagnosed with colon cancer and 586 were diagnosed with adenomas. Results: Physical activity was inversely associated with risk for colon cancer (high compared with low quintiles of average energy expenditure from leisure time activities: relative risk, 0.53 [95% CI, 0.32 to 0.88], P for trend = 0.03) after adjustment for age; history of colorectal polyp; previous endoscopy; parental history of colorectal cancer; smoking; body mass; use of aspirin; and intake of red meat, dietary fiber, folate, and alcohol. Body mass index was directly associated with risk for colon cancer independently of physical activity level. Waist circumference and waist-to-hip ratio were strong risk factors for colon cancer (waist-to-hip ratio greater than or equal to 0.99 compared with waist-to-hip ratio < 0.90: multivariate relative risk, 3.41 [CI, 1.52 to 7.66], P for trend = 0.01; waist circumference greater than or equal to 43 inches compared with waist circumference < 35 inches: relative risk, 2.56 [CI, 1.33 to 4.96], P for trend < 0.001). These associations persisted even after adjustment for body mass and physical activity. Similar associations were seen between obesity and physical inactivity and adenomas of 1 cm or more, but no association was observed for smaller adenomas. Height was also associated with a higher risk for colon cancer (height greater than or equal to 73 inches compared with height less than or equal to 68 inches: multivariate relative risk, 1.76 [CI, 1.13 to 2.74], P for trend = 0.02). Conclusions: The results support an inverse association between physical activity and risk for colon cancer, whereas height and obesity, particularly abdominal adiposity, are associated with an elevated risk.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	GIOVANNUCCI, E (corresponding author), CHANNING LABS, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ALBANES D, 1989, AM J PUBLIC HEALTH, V79, P744, DOI 10.2105/AJPH.79.6.744; ALBANES D, 1988, CANCER RES, V48, P1658; ALBANES D, 1990, NUTR CANCER, V14, P69, DOI 10.1080/01635589009514078; Albanes D, 1990, Epidemiology, V1, P65, DOI 10.1097/00001648-199001000-00014; ALBANES D, 1988, JNCI-J NATL CANCER I, V80, P772, DOI 10.1093/jnci/80.10.772; BALLARDBARBASH R, 1990, CANCER RES, V50, P3610; BINGHAM SA, 1989, GASTROENTEROLOGY, V97, P1389, DOI 10.1016/0016-5085(89)90381-8; BJORK J, 1993, SCAND J GASTROENTERO, V28, P879, DOI 10.3109/00365529309103129; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; BOYLE P, 1985, INT J CANCER, V36, P9, DOI 10.1002/ijc.2910360103; BROWNSON RC, 1989, AM J EPIDEMIOL, V130, P675, DOI 10.1093/oxfordjournals.aje.a115389; CHUTE CG, 1991, CANCER CAUSE CONTROL, V2, P117, DOI 10.1007/BF00053131; COENEN C, 1992, AM J GASTROENTEROL, V87, P292; DEVERDIER MG, 1990, INT J CANCER, V46, P985, DOI 10.1002/ijc.2910460606; DONAHUE RP, 1987, LANCET, V1, P821; FRASER G, 1993, CANCER CAUSE CONTROL, V4, P45, DOI 10.1007/BF00051713; FREDRIKSSON M, 1989, CANCER, V63, P1838; GARABRANT DH, 1984, AM J EPIDEMIOL, V119, P1005, DOI 10.1093/oxfordjournals.aje.a113805; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; GERHARDSSON M, 1988, INT J EPIDEMIOL, V17, P743, DOI 10.1093/ije/17.4.743; GERHARDSSON M, 1986, AM J EPIDEMIOL, V123, P775, DOI 10.1093/oxfordjournals.aje.a114306; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; GIOVANNUCCI E, 1995, IN PRESS CANCER CAUS; GIOVANNUCCI E, 1994, JNCI-J NATL CANCER I, V54, P2390; GRAHAM S, 1988, AM J EPIDEMIOL, V128, P490, DOI 10.1093/oxfordjournals.aje.a114997; HILL M, 1978, PATHOGENESIS COLOREC, P158; HIRSCH J, 1956, GASTROENTEROLOGY, V31, P274; HOPKINS WG, 1991, AM J EPIDEMIOL, V133, P73, DOI 10.1093/oxfordjournals.aje.a115805; HYAMS DE, 1974, BRIT MED J, V1, P107, DOI 10.1136/bmj.1.5898.107; KATO I, 1990, JPN J CANCER RES, V81, P1101, DOI 10.1111/j.1349-7006.1990.tb02520.x; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KLATSKY AL, 1988, AM J EPIDEMIOL, V128, P1007; KOENUMA M, 1989, JPN J CANCER RES, V80, P51, DOI 10.1111/j.1349-7006.1989.tb02244.x; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LEE IM, 1992, J NATL CANCER I, V84, P1326, DOI 10.1093/jnci/84.17.1326; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LEMARCHAND L, 1992, CANCER CAUSE CONTROL, V3, P349, DOI 10.1007/BF00146888; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LITTLE J, 1993, BRIT J CANCER, V67, P177, DOI 10.1038/bjc.1993.31; MILNE JS, 1972, GERONTOL CLIN, V14, P56, DOI 10.1159/000245372; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; NEUGUT AI, 1991, J NATL CANCER I, V83, P359, DOI 10.1093/jnci/83.5.359; OETTLE GJ, 1991, GUT, V32, P941, DOI 10.1136/gut.32.8.941; PAFFENBARGER RS, 1987, AM J CLIN NUTR, V45, P312, DOI 10.1093/ajcn/45.1.312; PETERS RK, 1989, CANCER RES, V49, P5459; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; POLEDNAK AP, 1976, CANCER, V38, P382, DOI 10.1002/1097-0142(197607)38:1<382::AID-CNCR2820380155>3.0.CO;2-V; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; REGENSTEINER JG, 1991, DIABETES CARE, V14, P1066, DOI 10.2337/diacare.14.11.1066; RICCARDI G, 1991, DIABETES CARE, V14, P1115, DOI 10.2337/diacare.14.12.1115; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SEVERSON RK, 1989, AM J EPIDEMIOL, V130, P522, DOI 10.1093/oxfordjournals.aje.a115366; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; SLATTERY ML, 1988, AM J EPIDEMIOL, V128, P989; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; VENA JE, 1985, AM J EPIDEMIOL, V122, P357, DOI 10.1093/oxfordjournals.aje.a114116; VENA JE, 1987, AM J CLIN NUTR, V45, P318, DOI 10.1093/ajcn/45.1.318; WATKINS LF, 1990, INT J CANCER, V45, P372, DOI 10.1002/ijc.2910450227; WHITTEMORE AS, 1990, JNCI-J NATL CANCER I, V82, P915, DOI 10.1093/jnci/82.11.915; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WILLETT W, 1990, NUTR EPIDEMIOLOGY, P217; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140; 1992, CANCER FACTS FIGURES	74	751	765	0	59	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					327	334		10.7326/0003-4819-122-5-199503010-00002	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847643				2022-12-01	WOS:A1995QJ08500002
J	GRAYSON, ML; GIBBONS, GW; BALOGH, K; LEVIN, E; KARCHMER, AW				GRAYSON, ML; GIBBONS, GW; BALOGH, K; LEVIN, E; KARCHMER, AW			PROBING TO BONE IN INFECTED PEDAL ULCERS - A CLINICAL SIGN OF UNDERLYING OSTEOMYELITIS IN DIABETIC-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THERAPEUTIC CONSIDERATIONS; UNSUSPECTED OSTEOMYELITIS; DIAGNOSIS; FOOT; FEATURES; IN-111; SCINTIGRAPHY; DISEASE	Objective.-To assess a bedside technique for diagnosing osteomyelitis. Design.-We prospectively assessed infected pedal ulcers for detectable bone by probing with a sterile, blunt, stainless steel probe. We then examined the relationship between detection of bone and the presence or absence of osteomyelitis that was defined histopathologically and/or clinically. Setting.-A tertiary care center. Patients.-Seventy-five hospitalized diabetic patients with a total of 76 infected foot ulcers were studied. Results.-Osteomyelitis was diagnosed in 50 instances (66%) and was excluded in 26 instances. Bone was detected by probing in 33 of 50 ulcers with contiguous osteomyelitis; in contrast, bone was probed in only four of 26 ulcers without contiguous osteomyelitis (P<.001). Bone detected on probing was visible in only three instances. Palpating bone on probing the pedal ulcer had a sensitivity of 66% for osteomyelitis, a specificity of 85%, a positive predictive value of 89%, and a negative predictive value of 56%. Conclusions.-Palpation of bone in the depths of infected pedal ulcers in patients with diabetes is strongly correlated with the presence of underlying osteomyelitis. If bone is palpated on probing, specialized roentgenographic and radionuclide tests to diagnose osteomyelitis are unnecessary. Probing for bone should be included in the initial assessment of all diabetic patients with infected pedal ulcers.	NEW ENGLAND DEACONESS HOSP,DEPT MED,DIV INFECT DIS,BOSTON,MA 02215; NEW ENGLAND DEACONESS HOSP,DEPT SURG,DIV VASC SURG,BOSTON,MA 02215; NEW ENGLAND DEACONESS HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School								BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BELTRAN J, 1990, SKELETAL RADIOL, V19, P37; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; GIBBONS GW, 1984, MANAGEMENT DIABETIC, P97; GRAYSON ML, 1994, CLIN INFECT DIS, V18, P683, DOI 10.1093/clinids/18.5.683; Karchmer A W, 1994, Curr Clin Top Infect Dis, V14, P1; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; MAURER AH, 1986, RADIOLOGY, V161, P221, DOI 10.1148/radiology.161.1.3763871; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; NEWMAN LG, 1991, JAMA-J AM MED ASSOC, V266, P1246, DOI 10.1001/jama.266.9.1246; NEWMAN LG, 1992, DIABETES CARE, V15, P1527, DOI 10.2337/diacare.15.11.1527; PARK HM, 1982, J NUCL MED, V23, P569; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; ROSAI J, 1989, ACKERMANS SURGICAL P, P1463; SCHAUWECKER DS, 1988, J NUCL MED, V29, P1651; SELDIN DW, 1985, J NUCL MED, V26, P988; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P316, DOI 10.1056/NEJM197002052820606; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P260, DOI 10.1056/NEJM197001292820507; WILLIAMSON MR, 1991, MAGN RESON IMAGING, V9, P945, DOI 10.1016/0730-725X(91)90540-3; YUH WTC, 1989, AM J ROENTGENOL, V152, P795, DOI 10.2214/ajr.152.4.795	22	342	353	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					721	723		10.1001/jama.273.9.721	http://dx.doi.org/10.1001/jama.273.9.721			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853630				2022-12-01	WOS:A1995QH81400031
J	HANSEN, P				HANSEN, P			CRISTINA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					686	686						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853608				2022-12-01	WOS:A1995QH81400002
J	CRUMP, BJ; PANTON, R; DRUMMOND, MF; MARCHMENT, M; HAWKES, RA				CRUMP, BJ; PANTON, R; DRUMMOND, MF; MARCHMENT, M; HAWKES, RA			TRANSFERRING THE COSTS OF EXPENSIVE TREATMENTS FROM SECONDARY TO PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article								General practitioners, especially fundholders, are becoming increasingly concerned about being asked to prescribe treatments for their patients that are outside their therapeutic experience. They are concerned about the clinical responsibility for such prescribing and the effects on their budgets. In some specialties transferring the costs of expensive treatments from secondary to primary care (cost shifting) has become partly institutionalised because of the separate sources of funding for drugs prescribed in the two sectors. With increased efforts to control the rising costs of the drugs budget and the emergence of new expensive treatments, cost shifting will be a challenge to clinicians and purchasers as they strive for rational, cost effective prescribing. A review of the funding mechanisms for drugs prescribing and of the relation between the licensing process and the decision to support the use of a treatment in primary or secondary care is needed.	KEELE UNIV,NEWCASTLE LYME ST5 5BC,STAFFS,ENGLAND; UNIV YORK,YORK YO1 5DD,N YORKSHIRE,ENGLAND; PREMIER HLTH TRUST,BURTON TRENT DE14 2AU,STAFFS,ENGLAND	Keele University; University of York - UK	CRUMP, BJ (corresponding author), S BIRMINGHAM HLTH AUTHOR,BIRMINGHAM B15 3DP,W MIDLANDS,ENGLAND.							DRUMMOND M, 1993, PHARMACOECONOMICS, V4, P173, DOI 10.2165/00019053-199304030-00003; 1993, CRDC1 STAND GROUP HL	2	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					509	512		10.1136/bmj.310.6978.509	http://dx.doi.org/10.1136/bmj.310.6978.509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888896	Green Published			2022-12-01	WOS:A1995QJ59800030
J	DALESSANDRO, U; OLALEYE, BO; MCGUIRE, W; LANGEROCK, P; BENNETT, S; AIKINS, MK; THOMSON, MC; CHAM, MK; CHAM, BA; GREENWOOD, BM				DALESSANDRO, U; OLALEYE, BO; MCGUIRE, W; LANGEROCK, P; BENNETT, S; AIKINS, MK; THOMSON, MC; CHAM, MK; CHAM, BA; GREENWOOD, BM			MORTALITY AND MORBIDITY FROM MALARIA IN GAMBIAN CHILDREN AFTER INTRODUCTION OF AN IMPREGNATED BEDNET PROGRAM	LANCET			English	Article							AFRICA; NETS; STRATEGY; TRIAL	After the success of a controlled trial of insecticide-treated bednets in lowering child mortality, The Gambia initiated a National Insecticide Impregnated Bednet Programme (NlBP) in 1992 with the objective of introducing this form of malaria control into all large villages in The Gambia. Five areas (population 115 895) were chosen as sentinel sites for evaluation of the NlBP. During the first year of intervention a 25% reduction was achieved in ail-cause mortality in children 1-9 years old living in treated villages (rate ratio 0.75 [95% CI 0.57-0.98], p=0.04). If one area where the programme was ineffective was excluded, the was 38% (0.62 [0.46-0.83), p=0.001). A in rates of parasitaemia and high-density parasitaemia, an increase in mean packed-cell volume (rate ratio 0.75 [95% Cl 0.59-0.98], p=0.04) and an improvement in the nutritional status of children living in treated villages were also detected. In a country such as The Gambia, where nets were widely used and which has a good primary health care system, it is possible to achieve insecticide-treatment of bednets at a national level with a significant reduction in child mortality; but at a cost which the country cannot afford.	MRC LABS,BANJUL,GAMBIA; JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC INFECT DIS GRP,OXFORD,ENGLAND; LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON,ENGLAND; MINIST HLTH & SOCIAL WELF,BANJUL,GAMBIA	MRC Laboratory Molecular Biology; University of Oxford; University of London; London School of Hygiene & Tropical Medicine			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; McGuire, William/0000-0001-8572-3467				ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O; ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P31, DOI 10.1016/0035-9203(93)90173-N; ALONSO PL, 1987, ANN TROP PAEDIATR, V7, P187, DOI 10.1080/02724936.1987.11748504; Bryan J.H., 1987, Parassitologia (Rome), V29, P221; DALESSANDRO U, 1994, B WORLD HEALTH ORGAN, V72, P391; EWBANK DC, 1993, INT J EPIDEMIOL, V22, pS8, DOI 10.1093/ije/22.Supplement_1.S8; GIGLIOLI G, 1972, B WORLD HEALTH ORGAN, V46, P181; GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q; GREENWOOD BM, 1983, T R SOC TROP MED S2, V87, P3; MAURITSEN RH, 1984, THESIS U WASHINGTON; SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; THOMPSON BH, 1993, CIRCULATION, V88, P638; WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	17	326	330	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					479	483		10.1016/S0140-6736(95)90582-0	http://dx.doi.org/10.1016/S0140-6736(95)90582-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861874				2022-12-01	WOS:A1995QH92900009
J	DOWELL, JS; SNADDEN, D; DUNBAR, JA				DOWELL, JS; SNADDEN, D; DUNBAR, JA			CHANGING TO GENERIC FORMULARY - HOW ONE FUNDHOLDING PRACTICE REDUCED PRESCRIBING COSTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To observe one general practice's attempt to reduce prescribing costs on becoming third wave fundholders through the introduction of a generic formulary applied to all new and repeat prescribing. To assess the impact on patients and prescribing patterns. Design-An observational study using interviews with patients and practitioners; questionnaires for patients and prescribing data. Setting-One urban general practice with five partners in Scotland. It became fundholding in April 1993. Subjects-71 searches of the register of repeat prescriptions identified 1274 potential changes in drugs. Questionnaires were sent to a stratified random sample of 280 patients four months after the changes were made; 33 interviews were conducted with 17 patients selected by local pharmacists to represent a wide range of opinion. Main outcome measures-Changes in prescribing and response and satisfaction of patients. Results-Of intended changes, 129 (70%) were in place after four months. Thirty three (20%) of the 167 patients who returned questionnaires were ''very unhappy,'' though interviews suggested that this was primarily with the communication they received rather than the change itself. Generic prescribing rose from one in three (37%) to over a half (58%). The volume of treatment dispensed (as treatment days) fell by 67 674 (10.7%), and the average cost per day's treatment fell by 3.1p from 32.3p per day in 1992 (9.4%), producing a total absolute saving of 24% (pound 137 712) over the first year. Conclusion-This practice has achieved a large reduction in prescribing costs rapidly. These were tolerated by patients, none of whom is thought to have left the practice for this reason. Great care must be taken to inform patients appropriately.	DOWNFIELD SURG,DUNDEE DD3 8NE,SCOTLAND		DOWELL, JS (corresponding author), WESTGATE HLTH CTR,TAYSIDE CTR GEN PRACTICE,DUNDEE DD2 4AD,SCOTLAND.		Dowell, Jonathan/M-6077-2019; Snadden, David/ABF-1586-2020; Dunbar, James A/G-3034-2012	Snadden, David/0000-0002-4818-1184; 				BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; KEELEY D, 1994, BRIT MED J, V308, P206, DOI 10.1136/bmj.308.6922.206c; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; PANTON R, 1993, BRIT MED J, V306, P310, DOI 10.1136/bmj.306.6873.310; Patton M. Q., 1990, QUALITATIVE EVALUATI, P280; 1994, PRESCRIPTION IMPROVE	7	71	71	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					505	508		10.1136/bmj.310.6978.505	http://dx.doi.org/10.1136/bmj.310.6978.505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7677830	Green Published			2022-12-01	WOS:A1995QJ59800028
J	HUGHESJONES, NC				HUGHESJONES, NC			RISK ASSESSMENT AND FACTOR-VIII CONCENTRATES	LANCET			English	Editorial Material											HUGHESJONES, NC (corresponding author), MRC CTR,MOLEC IMMUNOPATHOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND.							ALLAN HP, 1993, SIDA HEMOPHILES MON; [Anonymous], 1992, RISK ANAL PERCEPTION; BLOOM AL, 1984, LANCET, V1, P1452; DESFORGES JF, 1983, NEW ENGL J MED, V308, P94, DOI 10.1056/NEJM198301133080209; FRASER L, 1984, GENERAL PRACTIT 1019, P3; HUGHESJONES NC, 1979, LECTURE NOTES HAEMAT; LAYFIELD F, 1987, SIZEWELL B PUBLIC EN; ROWE PM, 1994, LANCET, V344, P876, DOI 10.1016/S0140-6736(94)92838-X; 1984, LANCET, V2, P1433	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					502	503		10.1016/S0140-6736(95)90589-8	http://dx.doi.org/10.1016/S0140-6736(95)90589-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861880				2022-12-01	WOS:A1995QH92900016
J	JANSEN, A; VANHAGEN, M; DREXHAGE, HA				JANSEN, A; VANHAGEN, M; DREXHAGE, HA			DEFECTIVE MATURATION AND FUNCTION OF ANTIGEN-PRESENTING CELLS IN TYPE-1 DIABETES	LANCET			English	Note							MICE	Macrophages and dendritic cells are important as antigen-presenting cells in the islet autoimmune response. We report decreased maturation of dendritic cells from blood monocytes of 61 patients with type 1 diabetes compared with 31 healthy controls (medians 26 and 35%, respectively, p=0.0005). The dendritic cells also had reduced ability to cluster (96 and 124 clusters, respectively, p=0.0005), and to stimulate autologous and allogeneic T cells. Because optimum antigen presentation is primarily required for tolerance induction rather than for immunisation, the defective maturation and function of diabetic dendritic cells might be the basis for disturbed activation of regulatory (suppressor) T cells.	ERASMUS UNIV ROTTERDAM,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam								CLARESALZLER MJ, 1992, J CLIN INVEST, V90, P741, DOI 10.1172/JCI115946; FAUSTMAN D, 1991, SCIENCE, V254, P1756, DOI 10.1126/science.1763324; INABA K, 1986, J EXP MED, V163, P247, DOI 10.1084/jem.163.2.247; JANSEN A, 1994, DIABETES, V43, P667, DOI 10.2337/diabetes.43.5.667; KNIGHT SC, 1985, P NATL ACAD SCI USA, V82, P4495, DOI 10.1073/pnas.82.13.4495; LANGMUIR PB, 1993, INT IMMUNOL, V5, P169, DOI 10.1093/intimm/5.2.169; LETY MA, 1992, CLIN IMMUNOL IMMUNOP, V64, P188, DOI 10.1016/0090-1229(92)90199-X; MOOIJ P, 1993, J ENDOCRINOL, V140, P503; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SERREZE DV, 1993, J IMMUNOL, V150, P2534	10	119	119	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					491	492		10.1016/S0140-6736(95)90586-3	http://dx.doi.org/10.1016/S0140-6736(95)90586-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861877				2022-12-01	WOS:A1995QH92900013
J	NEWTON, JN; REDBURN, J				NEWTON, JN; REDBURN, J			INCIDENCE OF MELANOMA IN 4 ENGLISH COUNTIES, 1989-92	BRITISH MEDICAL JOURNAL			English	Article									ANGLIA & OXFORD REG HLTH AUTHOR,OXFORD CANC INTELLIGENCE UNIT,OXFORD OX3 7LF,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND	University of Oxford; University of Oxford				Newton, John/0000-0002-5641-6457				[Anonymous], 1992, IARC MONOGRAPHS EVAL, V55; ARMITRAGE P, 1987, STATISTICAL METHODS; GRAHAMBROWN RAC, 1990, BRIT J DERMATOL, V122, P53, DOI 10.1111/j.1365-2133.1990.tb08239.x; SHARP L, 1993, CANCER REGISTRATION; 1994, CANCER STATISTICS RE	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					502	503		10.1136/bmj.310.6978.502	http://dx.doi.org/10.1136/bmj.310.6978.502			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888890	Green Published			2022-12-01	WOS:A1995QJ59800023
J	RICHARDS, C; RICHARDS, H; PHEBY, D				RICHARDS, C; RICHARDS, H; PHEBY, D			SKIN-CANCER - HOW ACCURATE ARE LOCAL DATA	BRITISH MEDICAL JOURNAL			English	Article									BRISTOL & DIST HLTH AUTHOR,DEPT PUBL HLTH MED,BRISTOL BS2 8EE,AVON,ENGLAND; S WESTERN REG CANC REGISTRY,BRISTOL BS8 2PR,AVON,ENGLAND	University of Bristol								BENN RT, 1982, INT J EPIDEMIOL, V11, P362, DOI 10.1093/ije/11.4.362; Boyle P, 1991, CANC REGISTRATION PR, V95, P126; 1990, REV NATIONAL CANCER; 1992, HLTH NATION SPECIFIC; 1993, PUBLIC HLTH COMMON D	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					503	503		10.1136/bmj.310.6978.503	http://dx.doi.org/10.1136/bmj.310.6978.503			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888891	Green Published			2022-12-01	WOS:A1995QJ59800024
J	SANCHEZTAPIAS, JM; RODES, J				SANCHEZTAPIAS, JM; RODES, J			DILEMMAS OF ORGAN-TRANSPLANTATION FROM ANTI-HCV-POSITIVE DONORS	LANCET			English	Editorial Material							HEPATITIS-C VIRUS; RECIPIENTS				SANCHEZTAPIAS, JM (corresponding author), UNIV BARCELONA,HOSP CLIN,LIVER UNIT,BARCELONA,SPAIN.							FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; KROES ACM, 1994, J HEPATOL, V21, P1113, DOI 10.1016/S0168-8278(05)80627-0; LIM HL, 1994, GASTROENTEROLOGY, V106, P248, DOI 10.1016/S0016-5085(94)95829-7; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; MILFRED SK, 1994, TRANSPLANTATION, V57, P568; MORALES JM, 1995, KIDNEY INT, V47, P236, DOI 10.1038/ki.1995.29; PEREIRA BJG, 1992, NEW ENGL J MED, V327, P910, DOI 10.1056/NEJM199209243271302; RAMOS EL, 1994, TRANSPLANTATION, V57, P490; ROTH D, 1992, ANN INTERN MED, V117, P470, DOI 10.7326/0003-4819-117-6-470; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1002/hep.1840190538; TESI RJ, 1994, TRANSPLANTATION, V57, P826, DOI 10.1097/00007890-199403270-00010; VINCENTI F, 1993, TRANSPLANTATION, V55, P674; ZUCKER K, 1994, TRANSPLANTATION, V57, P832, DOI 10.1097/00007890-199403270-00011	14	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					469	470		10.1016/S0140-6736(95)90579-0	http://dx.doi.org/10.1016/S0140-6736(95)90579-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7532253				2022-12-01	WOS:A1995QH92900006
J	STEER, P; ALAM, MA; WADSWORTH, J; WELCH, A				STEER, P; ALAM, MA; WADSWORTH, J; WELCH, A			RELATION BETWEEN MATERNAL HEMOGLOBIN CONCENTRATION AND BIRTH-WEIGHT IN DIFFERENT ETHNIC-GROUPS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMOGLOBIN CONCENTRATION; FOLATE SUPPLEMENTS; GROWTH-RETARDATION; PREGNANCY; IRON; ANEMIA; 2ND-TRIMESTER; HEMATOCRIT	Objective-To assess the relation of the lowest haemoglobin concentration in pregnancy with birth weight and the rates of low birth weight and preterm delivery in different ethnic groups. Design-Retrospective analysis of 153 602 pregnancies with ethnic group and birth weight recorded on a regional pregnancy database during 1988-91. The haemoglobin measurement used was the lowest recorded during pregnancy. Setting-North West Thames region. Subjects-115 262 white women, 22 206 Indo-Pakistanis, 4570 Afro-Caribbeans, 2642 mediterraneans, 3905 black Africans, 2351 orientals, and 2666 others. Main outcome measures-Birth weight and rates of low birth weight (<2500 g) and preterm delivery (<37 completed weeks). Results-Maximum mean birth weight in white women was achieved with a lowest haemoglobin concentration in pregnancy of 85-95 g/l; the lowest incidence of low birth weight and preterm labour occurred with a lowest haemoglobin of 95-105 g/l. A similar pattern occurred in all ethnic groups. Conclusions-The magnitude of the fall in haemoglobin concentration in pregnancy is related to birth weight; failure of the haemoglobin concentration to fall below 105 g/l indicates an increased risk of low birth weight and preterm delivery. This phenomenon is seen in all ethnic groups. Some ethnic groups have higher rates of low birth weight and preterm delivery than white women, and they also have higher rates of low haemoglobin concentrations. This increased rate of ''anaemia,'' however, does not account for their higher rates of low birth weight, which occurs at all haemoglobin concentrations.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL, LONDON EC1A 7BE, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT PUBL HLTH, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT OBSTET & GYNAECOL, LONDON W2 1PG, ENGLAND	University of London; Queen Mary University London; Imperial College London; Imperial College London	STEER, P (corresponding author), CHELSEA & WESTMINSTER HOSP, CHARING CROSS & WESTMINSTER MED SCH, ACAD DEPT OBSTET & GYNAECOL, LONDON SW10 9NH, ENGLAND.							Dieckmann WJ, 1934, ARCH INTERN MED, V53, P71, DOI 10.1001/archinte.1934.00160070076007; DUNLOP W, 1978, BRIT J OBSTET GYNAEC, V85, P938, DOI 10.1111/j.1471-0528.1978.tb15857.x; FENTON V, 1977, BRIT J HAEMATOL, V37, P145, DOI 10.1111/j.1365-2141.1977.tb08819.x; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; GOODLIN RC, 1982, J REPROD MED, V27, P639; HIBBARD BM, 1988, BRIT MED J, V297, P1324, DOI 10.1136/bmj.297.6659.1324; HORN E, 1988, BRIT MED J, V297, P1325, DOI 10.1136/bmj.297.6659.1325; HUISMAN A, 1986, ACTA OBSTET GYN SCAN, V65, P605, DOI 10.3109/00016348609158396; HYTTEN FE, 1963, J OBSTET GYN BR COMM, V70, P402; KLEBANOFF MA, 1989, JAMA-J AM MED ASSOC, V262, P511, DOI 10.1001/jama.262.4.511; KLEBANOFF MA, 1991, AM J OBSTET GYNECOL, V164, P59, DOI 10.1016/0002-9378(91)90626-3; KOLLER O, 1979, ACTA OBSTET GYN SCAN, V58, P9, DOI 10.3109/00016347909154904; LETSKY EA, 1994, HIGH RISK PREGNANCY, P337; LU ZM, 1991, OBSTET GYNECOL, V77, P190; MAHOMED K, 1993, PREGNANCY CHILDBIRTH; MAU G, 1977, J PERINAT MED, V5, P172, DOI 10.1515/jpme.1977.5.4.172; MURPHY JF, 1986, LANCET, V1, P992; PAINTIN D. B., 1966, Journal of Obstetrics and Gynaecology of the British Commonwealth, V73, P181, DOI 10.1111/j.1471-0528.1966.tb05144.x; SAGEN N, 1984, ACTA OBSTET GYN SCAN, V63, P245, DOI 10.3109/00016348409155506; TAYLOR DJ, 1979, BRIT J OBSTET GYNAEC, V86, P364, DOI 10.1111/j.1471-0528.1979.tb10611.x; 1978, BRIT MED J, V2, P1317; 1965, WHO TECH REP SER, V302, P5	22	208	218	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	1995	310	6978					489	491		10.1136/bmj.310.6978.489	http://dx.doi.org/10.1136/bmj.310.6978.489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888886	Green Published			2022-12-01	WOS:A1995QJ59800018
J	TRUSWELL, AS				TRUSWELL, AS			CHOLESTEROL-LOWERING IN INFANCY	LANCET			English	Editorial Material											TRUSWELL, AS (corresponding author), UNIV SYDNEY,HUMAN NUTR UNIT,SYDNEY,NSW,AUSTRALIA.							FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; HANSEN D, 1992, ACTA PAEDIATR, V81, P1023, DOI 10.1111/j.1651-2227.1992.tb12167.x; JAMES WPT, 1988, EUROEPAN SERIES, V24; RASANEN L, 1992, ACTA PAEDIATR, V81, P7, DOI 10.1111/j.1651-2227.1992.tb12069.x; TRUSWELL AS, 1976, EARLY NUTRITION LATE, P229; WIDDOWSON EM, 1975, BRIT MED J, V1, P653, DOI 10.1136/bmj.1.5959.653; 1989, DIET HLTH; 1992, REPORT AGE LIMIT ADO; 1991, REPORT HLTH SOCIAL S, V41; 1992, PEDIATRICS, V90, P469; 1994, NUTRITIONAL ASPECTS, V46; 1991, NIH N4LB1 US DHEW NA	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					468	469		10.1016/S0140-6736(95)90577-4	http://dx.doi.org/10.1016/S0140-6736(95)90577-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861871				2022-12-01	WOS:A1995QH92900004
J	AKERLEY, BJ; COTTER, PA; MILLER, JF				AKERLEY, BJ; COTTER, PA; MILLER, JF			ECTOPIC EXPRESSION OF THE FLAGELLAR REGULON ALTERS DEVELOPMENT OF THE BORDETELLA HOST INTERACTION	CELL			English	Article							VIRULENCE FACTORS; SALMONELLA-TYPHIMURIUM; SENSORY TRANSDUCTION; REPRESSED GENE; BVG-LOCUS; PERTUSSIS; SEQUENCES; PROTEINS; BRONCHISEPTICA; IDENTIFICATION	Signal transduction molecules within the two-component family represent a conserved adaptation for the control of genes involved in pathogenesis. The Bordetella virulence control locus, bvgAS, activates and represses gene expression in response to environmental signals. While infection requires virulence gene activation, the role of gene repression during infection is not understood. By altering regulatory genes and reversing regulatory connections, we found evidence that the BvgAS-repressed genes responsible for motility are neither required nor expressed during colonization of the host. Expression of this Bvg(-) phase-specific phenotype in the Bvg(+) growth phase resulted in a defect in tracheal colonization. Therefore, BvgAS promotes virulence both by activating genes required for colonization and by repressing genes that inhibit the development of infection.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles			Akerley, Brian/ABH-6977-2020; Akerley, Brian/B-7343-2008; Akerley, Brian/AAD-6668-2020	Akerley, Brian/0000-0002-8142-7035; Akerley, Brian/0000-0002-8142-7035	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008747] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08747, AI07323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERLEY BJ, 1993, J BACTERIOL, V175, P3468, DOI 10.1128/jb.175.11.3468-3479.1993; AKERLEY BJ, 1992, J BACTERIOL, V174, P980, DOI 10.1128/jb.174.3.980-990.1992; ARICO B, 1989, P NATL ACAD SCI USA, V86, P6671, DOI 10.1073/pnas.86.17.6671; ARICO B, 1991, MOL MICROBIOL, V5, P2481, DOI 10.1111/j.1365-2958.1991.tb02093.x; BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BEATTIE DT, 1992, INFECT IMMUN, V60, P571, DOI 10.1128/IAI.60.2.571-577.1992; BEATTIE DT, 1990, J BACTERIOL, V172, P6997, DOI 10.1128/jb.172.12.6997-7004.1990; BEHLAU I, 1993, J BACTERIOL, V175, P4475, DOI 10.1128/JB.175.14.4475-4484.1993; BOUCHER PE, 1994, J MOL BIOL, V241, P363, DOI 10.1006/jmbi.1994.1513; COTTER PA, 1994, INFECT IMMUN, V62, P3381, DOI 10.1128/IAI.62.8.3381-3390.1994; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENG P, 1990, J GEN MICROBIOL, V136, P337, DOI 10.1099/00221287-136-2-337; GRAF J, 1994, J BACTERIOL, V176, P6986, DOI 10.1128/JB.176.22.6986-6991.1994; HARLOW E, 1988, ANTIBODIES LABORATOR; JONES BD, 1992, INFECT IMMUN, V60, P2475, DOI 10.1128/IAI.60.6.2475-2480.1992; KOMEDA Y, 1982, J BACTERIOL, V150, P16, DOI 10.1128/JB.150.1.16-26.1982; LACEY B. W., 1960, JOUR HYG, V58, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XY, 1994, J BACTERIOL, V176, P7345, DOI 10.1128/JB.176.23.7345-7351.1994; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MILLER JF, 1992, J BACTERIOL, V174, P970, DOI 10.1128/jb.174.3.970-979.1992; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MULLER M, 1993, NUCLEIC ACIDS RES, V21, P3320, DOI 10.1093/nar/21.14.3320; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; REID JL, 1987, GENE, V57, P239; ROY CR, 1991, J BACTERIOL, V173, P2385, DOI 10.1128/JB.173.7.2385-2392.1991; ROY CR, 1990, P NATL ACAD SCI USA, V87, P3763, DOI 10.1073/pnas.87.10.3763; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARLATO V, 1990, P NATL ACAD SCI USA, V87, P6753, DOI 10.1073/pnas.87.17.6753; SCHMITT CK, 1994, J BACTERIOL, V176, P368, DOI 10.1128/JB.176.2.368-377.1994; SILVERMAN M, 1977, J BACTERIOL, V120, P1196; STAINER DW, 1971, J GEN MICROBIOL, V63, P211; STIBITZ S, 1989, NATURE, V338, P266, DOI 10.1038/338266a0; STIBITZ S, 1991, J BACTERIOL, V173, P4288, DOI 10.1128/JB.173.14.4288-4296.1991; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; UHL MA, 1994, P NATL ACAD SCI USA, V91, P1163, DOI 10.1073/pnas.91.3.1163; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983	39	211	219	2	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					611	620		10.1016/0092-8674(95)90515-4	http://dx.doi.org/10.1016/0092-8674(95)90515-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867068	Bronze			2022-12-01	WOS:A1995QJ60200013
J	BABBITT, PC; MRACHKO, GT; HASSON, MS; HUISMAN, GW; KOLTER, R; RINGE, D; PETSKO, GA; KENYON, GL; GERLT, JA				BABBITT, PC; MRACHKO, GT; HASSON, MS; HUISMAN, GW; KOLTER, R; RINGE, D; PETSKO, GA; KENYON, GL; GERLT, JA			FUNCTIONALLY DIVERSE ENZYME SUPERFAMILY THAT ABSTRACTS THE ALPHA-PROTONS OF CARBOXYLIC-ACIDS	SCIENCE			English	Article							ESCHERICHIA-COLI; MANDELATE RACEMASE; CRYSTAL-STRUCTURE; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-PUTIDA; LACTONIZING ENZYME; D-GALACTONATE; CARBON ACIDS; DNA-SEQUENCE; CLONING	Mandelate racemase and muconate lactonizing enzyme are structurally homologous but catalyze different reactions, each initiated by proton abstraction from carbon. The structural similarity to mandelate racemase of a previously unidentified gene product was used to deduce its function as a galactonate dehydratase. in this enzyme superfamily that has evolved to catalyze proton abstraction from carbon, three variations of homologous active site architectures are now represented: lysine and histidine bases in the active site of mandelate racemase, only a lysine base in the active site of muconate lactonizing enzyme, and only a histidine base in the active site of galactonate dehydratase. This discovery supports the hypothesis that new enzymatic activities evolve by recruitment of a protein catalyzing the same type of chemical reaction.	UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	University of Illinois System; University of Illinois Urbana-Champaign; Brandeis University; Harvard University; Harvard Medical School	BABBITT, PC (corresponding author), UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA.		Petsko, Gregory/AAO-7962-2020	Huisman, Gjalt/0000-0003-1955-1120	NIGMS NIH HHS [GM-40570, GM-34572] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040570] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRICH TL, 1987, GENE, V52, P185, DOI 10.1016/0378-1119(87)90045-X; BABBITT PC, UNPUB; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; BURLINGAME RP, M69160 GENB ACC; COOPER RA, 1978, ARCH MICROBIOL, V118, P199, DOI 10.1007/BF00415730; DEACON J, 1977, FEBS LETT, V77, P201, DOI 10.1016/0014-5793(77)80234-2; DOLNICK BJ, 1993, NUCLEIC ACIDS RES, V21, P1747, DOI 10.1093/nar/21.8.1747; DOLNICK BJ, COMMUNICATION; DONALD A, 1979, J BIOL CHEM, V254, P2132; EGAN SE, 1992, J BACTERIOL, V174, P4638, DOI 10.1128/JB.174.14.4638-4646.1992; EIGLMEIER K, 1987, MOL MICROBIOL, V1, P251, DOI 10.1111/j.1365-2958.1987.tb01931.x; Gerlt J.A., 1992, CURR OPIN STRUC BIOL, V2, P736; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; GOLDMAN A, 1987, J MOL BIOL, V194, P143, DOI 10.1016/0022-2836(87)90723-6; HASSON M, UNPB; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1111/j.1574-6968.1991.tb04544.x; HUISMAN GW, 1994, SCIENCE, V265, P537, DOI 10.1126/science.7545940; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; JENSEN RA, 1987, COLD SPRING HARBOR S, V52; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LANDRO JA, 1994, BIOCHEMISTRY-US, V33, P635, DOI 10.1021/bi00169a003; LEBIODA L, 1988, NATURE, V333, P683, DOI 10.1038/333683a0; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; PETSKO GA, 1993, TRENDS BIOCHEM SCI, V18, P372, DOI 10.1016/0968-0004(93)90091-Z; RANSOM SC, 1988, BIOCHEMISTRY-US, V27, P540, DOI 10.1021/bi00402a006; SCHNEIDER D, 1993, J GEN MICROBIOL, V139, P2559, DOI 10.1099/00221287-139-11-2559; SHAFER SL, UNPUB; TAYLOR KT, 1991, THESIS U MARYLAND CO; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; WEDEKIND JH, IN PRESS BIOCHEMISTR	34	138	139	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	1995	267	5201					1159	1161		10.1126/science.7855594	http://dx.doi.org/10.1126/science.7855594			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855594				2022-12-01	WOS:A1995QJ23700034
J	BUSSIERE, DE; BASTIA, D; WHITE, SW				BUSSIERE, DE; BASTIA, D; WHITE, SW			CRYSTAL-STRUCTURE OF THE REPLICATION TERMINATOR PROTEIN FROM BACILLUS-SUBTILIS AT 2.6-ANGSTROM	CELL			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; NUCLEOTIDE-SEQUENCE; LAMBDA-REPRESSOR; DNA; BINDING; OPERATOR; INVITRO; FORK	The crystal structure of the replication terminator protein (RTP) of B. subtilis has been determined at 2.6 Angstrom resolution. As previously suggested by both biochemical and biophysical studies, the molecule exists as a symmetric dimer and is in the alpha+beta protein-folding class. The protein has several uncommon features, including an antiparallel coiled-coil, which serves as the dimerization domain, and both an alpha-helix and a beta-ribbon suitably positioned to interact with the major and minor grooves of B-DNA. A site has been identified on the surface of RTP that is biochemically and positionally suitable for interaction with the replication-specific helicase. Other features of the structure are consistent with the polar contrahelicase mechanism of the protein. A model of the interaction between RTP and its cognate DNA is presented.	DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL & MOLEC BIOL PROGRAM,DURHAM,NC 27710	Duke University; Duke University			White, Stephen W/N-8164-2018		NIGMS NIH HHS [GM49264] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1988, X PLOR SYSTEM XRAY C; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; HIASA H, 1992, J BIOL CHEM, V267, P11379; HOSHINO T, 1987, P NATL ACAD SCI USA, V84, P653, DOI 10.1073/pnas.84.3.653; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KRALICEK AV, 1993, BIOCHEMISTRY-US, V32, P10216, DOI 10.1021/bi00089a043; KRALICEK AV, 1991, BIOCHEM J, V275, P823, DOI 10.1042/bj2750823; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; LANGLEY DB, 1993, MOL MICROBIOL, V10, P771, DOI 10.1111/j.1365-2958.1993.tb00947.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LEWIS PJ, 1989, J BACTERIOL, V171, P3564, DOI 10.1128/jb.171.6.3564-3567.1989; LEWIS PJ, 1991, RES MICROBIOL, V142, P893, DOI 10.1016/0923-2508(91)90070-Q; LEWIS PJ, 1990, J MOL BIOL, V244, P73; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MACALLISTER T, 1990, P NATL ACAD SCI USA, V72, P2905; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEHTA PP, 1992, J BIOL CHEM, V267, P18885; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; NICHOLLS A, 1993, GRASP; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PABO CO, 1982, NATURE, V298, P441, DOI 10.1038/298441a0; Pathak D., 1992, CURR OPIN STRUC BIOL, V2, P116, DOI [10.1016/0959-440X(92)90186-B, DOI 10.1016/0959-440X(92)90186-B]; PODJARNY AD, 1987, ANNU REV BIOPHYS BIO, V16, P351; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SAHOO T, 1995, IN PRESS EMBO J, V14; SATO Y, 1991, J BACTERIOL, V173, P7732, DOI 10.1128/jb.173.23.7732-7735.1991; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHARP KA, 1994, CURR OPIN STRUC BIOL, V4, P234, DOI 10.1016/S0959-440X(94)90314-X; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUEOKA N, 1968, COLD SPRING HARB SYM, V33, P695, DOI 10.1101/SQB.1968.033.01.078; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS AS, 1984, CELL, V39, P683, DOI 10.1016/0092-8674(84)90475-6; WHITE SW, 1988, STRUCT FUNC GENET, V5, P281; WONACOTT AJ, 1977, ROTATION METHOD CRYS, P75; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	62	74	74	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					651	660						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867072				2022-12-01	WOS:A1995QJ60200017
J	CHENG, RH; KUHN, RJ; OLSON, NH; ROSSMANN, MG; CHOI, HK; SMITH, TJ; BAKER, TS				CHENG, RH; KUHN, RJ; OLSON, NH; ROSSMANN, MG; CHOI, HK; SMITH, TJ; BAKER, TS			NUCLEOCAPSID AND GLYCOPROTEIN ORGANIZATION IN AN ENVELOPED VIRUS	CELL			English	Article							SEMLIKI-FOREST VIRUS; ROSS RIVER VIRUS; SINDBIS VIRUS; CORE PROTEIN; NUCLEOTIDE-SEQUENCE; 3-DIMENSIONAL STRUCTURE; ELECTRON MICROGRAPHS; SERINE PROTEINASE; SPHERICAL VIRUSES; DEDUCED SEQUENCE	Alphaviruses are a group of icosahedral, positive-strand RNA, enveloped viruses. The membrane bilayer, which surrounds the similar to 400 Angstrom diameter nucleocapsid, is penetrated by 80 spikes arranged in a T = 4 lattice. Each spike is a trimer of heterodimers consisting of glycoproteins E1 and E2. Cryoelectron microscopy and image reconstruction of Ross River virus showed that the T = 4 quaternary structure of the nucleocapsid consists of pentamer and hexamer clusters of the capsid protein, but not dimers, as have been observed in several crystallographic studies. The E1-E2 heterodimers form one-to-one associations with the nucleocapsid monomers across the lipid bilayer. Knowledge of the atomic structure of the capsid protein and our reconstruction allows us to identify capsid-protein residues that interact with the RNA, the glycoproteins, and adjacent capsid-proteins.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus			Cheng, Holland/A-8973-2008; Smith, Thomas J/K-9086-2013; Kuhn, Richard/AAR-2722-2021	Smith, Thomas J/0000-0003-3528-6793; Kuhn, Richard/0000-0003-4148-1026; , Timothy/0000-0001-6543-8968	NIAID NIH HHS [AI33982, P01 AI035212, AI11217] Funding Source: Medline; NIGMS NIH HHS [GM33050, R37 GM033050, R01 GM033050] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035212, R01AI011217, R29AI033982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033050, R37GM033050] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDROUBI A, 1992, ULTRAMICROSCOPY, V46, P175, DOI 10.1016/0304-3991(92)90013-A; ALIPERTI G, 1978, VIROLOGY, V90, P366, DOI 10.1016/0042-6822(78)90321-5; ANTHONY RP, 1991, J VIROL, V65, P1187, DOI 10.1128/JVI.65.3.1187-1194.1991; BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BARTH BU, 1992, J VIROL, V66, P7560, DOI 10.1128/JVI.66.12.7560-7564.1992; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHENG RH, 1992, VIROLOGY, V186, P655, DOI 10.1016/0042-6822(92)90032-K; CHENG RH, 1994, STRUCTURE, V2, P271; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; COOMBS K, 1987, J MOL BIOL, V195, P359, DOI 10.1016/0022-2836(87)90657-7; COOMBS K, 1987, VIRUS RES, V7, P131, DOI 10.1016/0168-1702(87)90075-X; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DALGARNO L, 1983, VIROLOGY, V129, P170, DOI 10.1016/0042-6822(83)90404-X; DALRYMPLE JM, 1976, VIROLOGY, V69, P93, DOI 10.1016/0042-6822(76)90197-5; DOHERTY R. L., 1963, AUSTRALIAN J SCI, V26, P183; FARAGHER SG, 1988, VIROLOGY, V163, P509, DOI 10.1016/0042-6822(88)90292-9; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GAROFF H, 1974, VIROLOGY, V61, P493, DOI 10.1016/0042-6822(74)90285-2; GAROFF H, 1974, P NATL ACAD SCI USA, V71, P3988, DOI 10.1073/pnas.71.10.3988; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; GEIGENMULLERGNI.U, 1993, J VIROL, V7, P1620; HAHN CS, 1988, P NATL ACAD SCI USA, V85, P5997, DOI 10.1073/pnas.85.16.5997; HARRISON S C, 1974, Journal of Supramolecular Structure, V2, P486, DOI 10.1002/jss.400020233; HARRISON SC, 1992, J MOL BIOL, V226, P277, DOI 10.1016/0022-2836(92)90141-6; HARRISON SC, 1984, TRENDS BIOCHEM SCI, V9, P345, DOI 10.1016/0968-0004(84)90057-4; HARRISON SC, 1971, J MOL BIOL, V60, P523, DOI 10.1016/0022-2836(71)90186-0; HELENIUS A, 1980, EUR J BIOCHEM, V106, P613, DOI 10.1111/j.1432-1033.1980.tb04609.x; HOLMES KC, 1994, STRUCTURE, V2, P589, DOI 10.1016/S0969-2126(00)00061-7; HORZINEK M, 1969, J VIROL, V4, P514, DOI 10.1128/JVI.4.4.514-520.1969; JACROT B, 1987, ANIMAL VIRUS STRUCTU, P89; KAARIAINEN L, 1971, VIROLOGY, V43, P291, DOI 10.1016/0042-6822(71)90246-7; Kay B. H., 1989, The arboviruses: epidemiology and ecology. Volume IV., P93; KENNEY JM, 1994, STRUCTURE, V2, P823, DOI 10.1016/S0969-2126(94)00083-2; KUHN RJ, 1991, VIROLOGY, V182, P430, DOI 10.1016/0042-6822(91)90584-X; LEE HR, 1994, VIROLOGY, V202, P390, DOI 10.1006/viro.1994.1355; LOPEZ S, 1994, J VIROL, V68, P1316, DOI 10.1128/JVI.68.3.1316-1323.1994; MARSHALL ID, 1984, CURRENT TOPICS VECTO, P31; MAYNE JT, 1984, VIROLOGY, V134, P338, DOI 10.1016/0042-6822(84)90302-7; METSIKKO K, 1990, J VIROL, V64, P4678; OLSON NH, 1989, ULTRAMICROSCOPY, V30, P281, DOI 10.1016/0304-3991(89)90057-0; PAREDES AM, 1993, P NATL ACAD SCI USA, V90, P9095, DOI 10.1073/pnas.90.19.9095; PAREDES AM, 1993, VIROLOGY, V187, P329; RICE CM, 1982, J MOL BIOL, V154, P325, DOI 10.1016/0022-2836(82)90067-5; RICE CM, 1981, P NATL ACAD SCI-BIOL, V78, P2062, DOI 10.1073/pnas.78.4.2062; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SIMMONS DT, 1974, J MOL BIOL, V86, P397, DOI 10.1016/0022-2836(74)90027-8; STRAUSS EG, 1978, J VIROL, V28, P466, DOI 10.1128/JVI.28.2.466-474.1978; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; STUBBS MJ, 1991, J MOL BIOL, V221, P39, DOI 10.1016/0022-2836(91)80200-E; TONG L, 1992, ACTA CRYSTALLOGR A, V48, P430, DOI 10.1107/S0108767391014630; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; UBOL S, 1991, J VIROL, V65, P6913, DOI 10.1128/JVI.65.12.6913-6921.1991; VENIENBRYAN C, 1994, J MOL BIOL, V236, P572, DOI 10.1006/jmbi.1994.1166; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0; VRATI S, 1986, VIROLOGY, V151, P222, DOI 10.1016/0042-6822(86)90044-9; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WANG KS, 1991, VIROLOGY, V181, P694, DOI 10.1016/0042-6822(91)90903-O; WEISS B, 1994, NUCLEIC ACIDS RES, V22, P780, DOI 10.1093/nar/22.5.780; WENGLER G, 1992, VIROLOGY, V191, P880, DOI 10.1016/0042-6822(92)90263-O; ZIEMIECKI A, 1978, J MOL BIOL, V122, P259, DOI 10.1016/0022-2836(78)90189-4	64	276	279	1	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					621	630						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867069				2022-12-01	WOS:A1995QJ60200014
J	D'SOUZA-SCHOREY, C; LI, GP; COLOMBO, MI; STAHL, PD				D'SOUZA-SCHOREY, C; LI, GP; COLOMBO, MI; STAHL, PD			A REGULATORY ROLE FOR ARF6 IN RECEPTOR-MEDIATED ENDOCYTOSIS	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; GOLGI MEMBRANES; MUTAGENESIS; EXPRESSION; COATOMER; CELLS	Adenosine diphosphate-ribosylation factor 6 (ARF6), ARF6 mutants, and ARF1 were transiently expressed in Chinese hamster ovary cells, and the effects on receptor-mediated endocytosis were assessed. Overexpressed ARF6 localized to the cell periphery and led to a redistribution of transferrin receptors to the cell surface and a decrease in the rate of uptake of transferrin. Similar results were obtained when a mutant defective in guanosine triphosphate hydrolysis was expressed. Expression of a dominant negative mutant, ARF6(T27N), resulted in an intracellular distribution of transferrin receptors and an inhibition of transferrin recycling to the cell surface. In contrast, overexpression of ARF1 had little or no effect on these parameters of endocytosis.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Li, Guangpu/GRS-5397-2022; Stahl, Philip/D-6315-2012					BALCH WE, 1992, J BIOL CHEM, V267, P13053; BERON W, UNPUB; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DSOUZASCHOREY C, UNPUB; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LI GP, 1993, J BIOL CHEM, V268, P24475; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Sambrook J., 1989, MOL CLONING LAB MANU; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; Whitney J. A., 1993, Molecular Biology of the Cell, V4, p445A; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	25	365	369	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	1995	267	5201					1175	1178		10.1126/science.7855600	http://dx.doi.org/10.1126/science.7855600			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855600				2022-12-01	WOS:A1995QJ23700040
J	DAMMER, U; POPESCU, O; WAGNER, P; ANSELMETTI, D; GUNTHERODT, HJ; MISEVIC, GN				DAMMER, U; POPESCU, O; WAGNER, P; ANSELMETTI, D; GUNTHERODT, HJ; MISEVIC, GN			BINDING STRENGTH BETWEEN CELL-ADHESION PROTEOGLYCANS MEASURED BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article							SPONGE MICROCIONA-PROLIFERA; AGGREGATION FACTOR; MARINE SPONGE	Measurement of binding forces intrinsic to adhesion molecules is necessary to assess their contribution to the maintenance of the anatomical integrity of multicellular organisms. Atomic force microscopy was used to measure the binding strength between cell adhesion proteoglycans from a marine sponge. Under physiological conditions, the adhesive force between two cell adhesion molecules was found to be up to 400 piconewtons. Thus a single pair of molecules could hold the weight of 1600 cells. High intermolecular binding forces are likely to form the basis for the integrity of the multicellular sponge organism.	UNIV BASEL HOSP,DEPT RES,CH-4031 BASEL,SWITZERLAND; UNIV BASEL,INST PHYS,CH-4056 BASEL,SWITZERLAND; ETH ZURICH,INST BIOCHEM 2,CH-8092 ZURICH,SWITZERLAND	University of Basel; University of Basel; Swiss Federal Institutes of Technology Domain; ETH Zurich			Popescu, Octavian/C-4027-2011; Anselmetti, Dario/F-1664-2011; Popescu, Octavian/E-4942-2010; Misevic, Gradimir/D-8294-2016; Popescu, Octavian/O-2134-2019	Anselmetti, Dario/0000-0002-8720-4369; Popescu, Octavian/0000-0002-2597-7155; Misevic, Gradimir/0000-0001-5047-2936; Popescu, Octavian/0000-0002-2597-7155				ANSELMETTI D, 1994, EUROPHYS LETT, V27, P365, DOI 10.1209/0295-5075/27/5/006; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; CAUDWELL CB, 1973, BIOCHEMISTRY-US, V12, P3051; DAMMER U, 1994, IN PRESS MAR NATO AS; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; GUTIERREZ C, 1979, J IMMUNOL METHODS, V29, P57, DOI 10.1016/0022-1759(79)90125-X; HARMANSON GT, 1992, IMMOBILIZED AFFINITY; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HUMPHREYS S, 1977, J SUPRAMOL STR CELL, V7, P339, DOI 10.1002/jss.400070307; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; LECKBAND DE, 1992, SCIENCE, V255, P1419, DOI 10.1126/science.1542789; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; RICE DJ, 1983, J BIOL CHEM, V258, P6394; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; WAGNER P, UNPUB; WINTER WT, 1977, J MOL BIOL, V117, P761, DOI 10.1016/0022-2836(77)90068-7; [No title captured]	22	355	367	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1173	1175		10.1126/science.7855599	http://dx.doi.org/10.1126/science.7855599			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855599	Green Submitted			2022-12-01	WOS:A1995QJ23700039
J	FIROUZI, A; KUMAR, D; BULL, LM; BESIER, T; SIEGER, P; HUO, Q; WALKER, SA; ZASADZINSKI, JA; GLINKA, C; NICOL, J; MARGOLESE, D; STUCKY, GD; CHMELKA, BF				FIROUZI, A; KUMAR, D; BULL, LM; BESIER, T; SIEGER, P; HUO, Q; WALKER, SA; ZASADZINSKI, JA; GLINKA, C; NICOL, J; MARGOLESE, D; STUCKY, GD; CHMELKA, BF			COOPERATIVE ORGANIZATION OF INORGANIC-SURFACTANT AND BIOMIMETIC ASSEMBLIES	SCIENCE			English	Article							SILICATE SOLUTIONS; CETYLTRIMETHYLAMMONIUM BROMIDE; TETRAMETHYLAMMONIUM SILICATE; ORGANIC INTERFACES; MAGNETIC-RESONANCE; COUNTERION BINDING; AQUEOUS-SOLUTIONS; X-RAY; MICELLES; CHLORIDE	A model that makes use of the cooperative organization of inorganic and organic molecular species into three dimensionally structured arrays is generalized for the synthesis of nanocomposite materials. In this model, the properties and structure of a system are determined by dynamic interplay among ion-pair inorganic and organic species, so that different phases can be readily obtained through small variations of controllable synthesis parameters, including mixture composition and temperature. Nucleation, growth, and phase transitions may be directed by the charge density, coordination, and steric requirements of the inorganic and organic species at the interface and not necessarily by a preformed structure. A specific example is presented in which organic molecules in the presence of multiply charged silicate oligomers self-assemble into silicatropic liquid crystals. The organization of these silicate-surfactant mesophases is investigated with and without interfacial silicate condensation to separate the effects of self-assembly from the kinetics of silicate polymerization.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,MAT RES LAB,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106; NIST,GAITHERSBURG,MD 20899	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; National Institute of Standards & Technology (NIST) - USA			Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067	NIGMS NIH HHS [GM 47334] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFREDSSON V, 1994, J CHEM SOC CHEM COMM, P921, DOI 10.1039/c39940000921; ARCHIBALD DD, 1993, NATURE, V364, P430, DOI 10.1038/364430a0; AUVRAY X, 1989, J PHYS CHEM-US, V93, P7458, DOI 10.1021/j100358a040; BACKLUND S, 1982, ACTA CHEM SCAND A, V36, P698, DOI 10.3891/acta.chem.scand.36a-0698; BARAL S, 1993, CHEM MATER, V5, P145, DOI 10.1021/cm00026a001; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; BLACKMORE ES, 1990, LIQ CRYST, V8, P131, DOI 10.1080/02678299008047336; BUNKER BC, 1994, SCIENCE, V264, P48, DOI 10.1126/science.264.5155.48; CHEN CY, 1993, MICROPOROUS MATER, V2, P17, DOI 10.1016/0927-6513(93)80058-3; CHEN CY, 1993, MICROPOROUS MATER, V2, P27, DOI 10.1016/0927-6513(93)80059-4; DAVIS ME, IN PRESS MATER RES S; EKWALL P, 1971, J COLLOID INTERF SCI, V35, P519, DOI 10.1016/0021-9797(71)90210-4; ENGELHARDT G, 1984, J MOL LIQ, V27, P125; Engelhardt G., 1987, HIGH RESOLUTION SOLI; EVANS DF, 1989, WATER SCI REV, V4, P1; FEHR FJ, 1989, J AM CHEM SOC, V111, P1288; FIROUZI A, UNPUB; GAMBOA C, 1989, J PHYS CHEM-US, V93, P5540, DOI 10.1021/j100351a043; GROENEN EJJ, 1986, ZEOLITES, V6, P403, DOI 10.1016/0144-2449(86)90070-9; HARRIS RK, 1982, J MOL STRUCT, V78, P273, DOI 10.1016/0022-2860(82)80013-6; HENDRICKS WM, 1991, J PHYS CHEM-US, V95, P9519, DOI 10.1021/j100176a088; HERRINGTON KL, 1993, J PHYS CHEM-US, V97, P13792, DOI 10.1021/j100153a058; HEYWOOD BR, 1994, ADV MATER, V6, P9, DOI 10.1002/adma.19940060103; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016; IKEDA S, 1991, COLLOID POLYM SCI, V269, P49, DOI 10.1007/BF00654659; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; JACOBSON K, 1975, BIOCHEMISTRY-US, V14, P152, DOI 10.1021/bi00672a026; KALER EW, 1992, J PHYS CHEM-US, V96, P6698, DOI 10.1021/j100195a033; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; KNIGHT CTG, 1989, ZEOLITES, V9, P448, DOI 10.1016/0144-2449(89)90103-6; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kumar D., UNPUB; LANGEVIN D, 1992, ANNU REV PHYS CHEM, V43, P341, DOI 10.1146/annurev.pc.43.100192.002013; LINDEMUTH PM, 1993, J PHYS CHEM-US, V97, P7769, DOI 10.1021/j100131a055; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MANN S, 1993, SCIENCE, V261, P1286, DOI 10.1126/science.261.5126.1286; Mann S., 1989, BIOMINERALIZATION CH; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; MURTHY AK, 1991, J COLLOID INTERF SCI, V145, P598, DOI 10.1016/0021-9797(91)90391-K; OGAWA M, 1994, J AM CHEM SOC, V116, P7941, DOI 10.1021/ja00096a079; OZEKI S, 1981, B CHEM SOC JPN, V54, P552, DOI 10.1246/bcsj.54.552; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; QUIRION F, 1986, J PHYS CHEM-US, V90, P5435, DOI 10.1021/j100412a108; REISSHUSSON F, 1964, J PHYS CHEM-US, V68, P3504, DOI 10.1021/j100794a011; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; STEEL A, 1994, J CHEM SOC CHEM COMM, P1571, DOI 10.1039/c39940001571; STEIN A, UNPUB; STUCKY GD, 1994, MOL CRYST LIQ CRYS A, V240, P187, DOI 10.1080/10587259408029730; SZLEIFER I, 1990, J CHEM PHYS, V92, P6800, DOI 10.1063/1.458267; VERKLEIJ AJ, 1974, BIOCHIM BIOPHYS ACTA, V339, P432, DOI 10.1016/0005-2736(74)90171-0; VONHOEBBEL D, 1982, Z ANORG ALLG CHEM, V494, P31; WARNHEIM T, 1988, J COLLOID INTERF SCI, V125, P627, DOI 10.1016/0021-9797(88)90030-6; WEINER S, 1986, CRC CR REV BIOCH MOL, V20, P365, DOI 10.3109/10409238609081998; WEINER S, 1984, PHILOS T ROY SOC B, V304, P425, DOI 10.1098/rstb.1984.0036; WIEBCKE M, 1992, J CHEM SOC DA, V16, P2451; ZASADZINSKI JAN, 1989, J ELECTRON MICR TECH, V13, P309, DOI 10.1002/jemt.1060130406	57	707	739	6	310	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1138	1143		10.1126/science.7855591	http://dx.doi.org/10.1126/science.7855591			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855591				2022-12-01	WOS:A1995QJ23700028
J	HECHT, A; LAROCHE, T; STRAHLBOLSINGER, S; GASSER, SM; GRUNSTEIN, M				HECHT, A; LAROCHE, T; STRAHLBOLSINGER, S; GASSER, SM; GRUNSTEIN, M			HISTONE H3 AND H4 N-TERMINI INTERACT WITH SIR3 AND SIR4 PROTEINS - A MOLECULAR-MODEL FOR THE FORMATION OF HETEROCHROMATIN IN YEAST	CELL			English	Article							SILENT MATING LOCI; POSITION EFFECT VARIEGATION; SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; DNA; TELOMERES; TRANSCRIPTION; REPRESSION; DROSOPHILA; SEQUENCE	The silent mating loci and chromosomal regions adjacent to telomeres of S. cerevisiae have features similar to heterochromatin of more complex eukaryotes. Transcriptional repression at these sites depends on the silent information regulators SIR3 and SIR4 as well as histones H3 and H4. We show here that the SIR3 and SIR4 proteins interact with specific silencing domains of the H3 and H4 N-termini in vitro. Certain mutations in these factors, which affect their silencing functions in vivo, also disrupt their interactions in vitro. Immunofluorescence studies with antibodies against RAP1 and SIR3 demonstrate that the H3 and H4 N-termini are required for the association of SIR3 with telomeric chromatin and the perinuclear positioning of yeast telomeres. Based on these interactions, we propose a model for heterochromatin-mediated transcriptional silencing in yeast, which may serve as a paradigm for other eukaryotic organisms as well.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Swiss Institute Experimental Cancer Research				Hecht, Andreas/0000-0003-2262-2575; Gasser, Susan/0000-0003-3610-9123	NIGMS NIH HHS [GM42421] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042421] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHICOINE LG, 1987, J CELL BIOL, V105, P127, DOI 10.1083/jcb.105.1.127; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MOORE GD, 1983, GENETICS, V105, P327; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RIVIER DH, 1994, CELL, V76, P963, DOI 10.1016/0092-8674(94)90373-5; SCHUSTER T, 1986, CELL, V45, P445, DOI 10.1016/0092-8674(86)90330-2; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TARTOF KD, 1990, DEVELOPMENT S, V120, P35; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	43	691	707	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					583	592		10.1016/0092-8674(95)90512-X	http://dx.doi.org/10.1016/0092-8674(95)90512-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867066	Bronze			2022-12-01	WOS:A1995QJ60200010
J	HUANG, ZJ; CURTIN, KD; ROSBASH, M				HUANG, ZJ; CURTIN, KD; ROSBASH, M			PER PROTEIN INTERACTIONS AND TEMPERATURE COMPENSATION OF A CIRCADIAN CLOCK IN DROSOPHILA	SCIENCE			English	Article							MESSENGER-RNA LEVELS; PERIOD GENE-PRODUCT; B P50 PRECURSOR; NEUROSPORA-CRASSA; VISUAL-SYSTEM; DNA-BINDING; MELANOGASTER; RHYTHMS; MUTANTS; DIMERIZATION	The periods of circadian clocks are relatively temperature-insensitive. Indeed, the per(L) mutation in the Drosophila melanogaster period gene, a central component of the clock, affects temperature compensation as well as period length. The per protein (PER) contains a dimerization domain (PAS) within which the per(L) mutation is located. Amino acid substitutions at the per(L) position rendered PER dimerization temperature-sensitive. In addition, another region of PER interacted with PAS, and the per(L) mutation enhanced this putative intramolecular interaction, which may compete with PAS-PAS intermolecular interactions. Therefore, temperature compensation of circadian period in Drosophila may be due in part to temperature-independent PER activity, which is based on competition between inter- and intramolecular interactions with similar temperature coefficients.			HUANG, ZJ (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.			Huang, Z. Josh/0000-0003-0592-028X	NIGMS NIH HHS [GM-33205] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COTE GG, 1986, J THEOR BIOL, V121, P487, DOI 10.1016/S0022-5193(86)80104-7; CURTIN K, 1994, NEURON, V13, P1167; DELABROUSSE FC, 1993, TRENDS GENET, V9, P151, DOI 10.1016/0168-9525(93)90149-C; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; EWER J, 1990, J NEUROGENET, V7, P31, DOI 10.3109/01677069009084151; Feldman J.F., 1986, J BIOL RHYTHM, V1, P18767; GARDNER GF, 1981, PLANT PHYSIOL, V68, P1244, DOI 10.1104/pp.68.6.1244; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HASTINGS JW, 1957, P NATL ACAD SCI USA, V43, P804, DOI 10.1073/pnas.43.9.804; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG Z, UNPUB; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1989, J NEUROGENET, V6, P1, DOI 10.3109/01677068909107096; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAKINTHOMAS PL, 1990, CRIT REV MICROBIOL, V17, P365, DOI 10.3109/10408419009114762; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MATTERN DL, 1982, P NATL ACAD SCI-BIOL, V79, P825, DOI 10.1073/pnas.79.3.825; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PITTENDRIGH CS, 1954, P NATL ACAD SCI USA, V40, P1018, DOI 10.1073/pnas.40.10.1018; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SMITH RF, 1982, MOL GEN GENET, V189, P30; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Worden, 1974, NEUROSCIENCES 3RD ST, P437; YU Q, 1987, P NATL ACAD SCI USA, V84, P784, DOI 10.1073/pnas.84.3.784; ZERR DM, 1990, J NEUROSCI, V10, P2749	38	126	126	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1169	1172		10.1126/science.7855598	http://dx.doi.org/10.1126/science.7855598			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855598	Green Submitted			2022-12-01	WOS:A1995QJ23700038
J	JIANG, J; STRUHL, G				JIANG, J; STRUHL, G			PROTEIN KINASE-A AND HEDGEHOG SIGNALING IN DROSOPHILA LIMB DEVELOPMENT	CELL			English	Article							SEGMENT-POLARITY GENE; SITE-SPECIFIC RECOMBINATION; CELL-CELL COMMUNICATION; PATCHED GENE; EXPRESSION; WINGLESS; COMPARTMENT; MELANOGASTER; PRODUCT; ENCODES	The Drosophila hedgehog (hh) gene encodes a secreted protein involved in organizing growth and patterning in many developmental processes. Hh appears to act by inducing the localized expression of at least two other signaling molecules, decapentaplegic (dpp) and wingless (wg), which then govern cell proliferation and patterning in surrounding tissue. Here, we demonstrate that cyclic AMP (cAMP)-dependent protein kinase A (PKA) is essential during limb development to prevent inappropriate dpp and wg expression. We also show that a constitutively active form of PKA can prevent inappropriate dpp and wg expression, but does not interfere with their normal induction by hh. We propose that the basal activity of PKA imposes a block on the transcription of dpp and wg and that hh exerts its organizing influence by alleviating this block.			JIANG, J (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, HOWARD HUGHES MED INST, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL G, 1995, IN PRESS DEVELOPMENT; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHOU TB, 1992, GENETICS, V131, P643; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DUNINBORKOWSKI OM, 1995, IN PRESS DEV BIOL; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HIDALGO A, 1990, DEVELOPMENT, V110, P291; Hooper J.E., 1992, Results and Problems in Cell Differentiation, V18, P1; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; SEGAL D, 1985, GENETICS, V109, P119; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; XU T, 1993, DEVELOPMENT, V117, P1223	45	289	298	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	1995	80	4					563	572		10.1016/0092-8674(95)90510-3	http://dx.doi.org/10.1016/0092-8674(95)90510-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867064	Bronze			2022-12-01	WOS:A1995QJ60200008
J	KIRCHGESSNER, CU; PATIL, CK; EVANS, JW; CUOMO, CA; FRIED, LM; CARTER, T; OETTINGER, MA; BROWN, JM				KIRCHGESSNER, CU; PATIL, CK; EVANS, JW; CUOMO, CA; FRIED, LM; CARTER, T; OETTINGER, MA; BROWN, JM			DNA-DEPENDENT KINASE (P350) AS A CANDIDATE GENE FOR THE MURINE SCID DEFECT	SCIENCE			English	Article							STRAND BREAK-REPAIR; COMBINED IMMUNE-DEFICIENCY; PLASMINOGEN-ACTIVATOR GENE; PRE-B CELLS; V(D)J RECOMBINATION; PROTEIN-KINASE; HUMAN CHROMOSOME-8; INSITU HYBRIDIZATION; KU PROTEIN; POLYMERASE-BETA	Severe combined immunodeficient (SCID) mice are deficient in a recombination process utilized in both DNA double-strand break repair and in V(D)J recombination. The phenotype of these mice involves both cellular hypersensitivity to ionizing radiation and a lack of B and T cell immunity. The catalytic subunit of DNA-dependent protein kinase, p350, was identified as a strong candidate for the murine gene SCID. Both p350 and a gene complementing the SCID defect colocalize to human chromosome 8q11. Chromosomal fragments expressing p350 complement the SCID phenotype, and p350 protein levels are greatly reduced in cells derived from SCID mice compared to cells from wild-type mice.	STANFORD UNIV,SCH MED,DEPT RADIAT ONCOL,STANFORD,CA 94305; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; ST JOHNS UNIV,DEPT BIOL SCI,JAMAICA,NY 11439	Stanford University; Harvard University; Massachusetts General Hospital; Saint John's University			Cuomo, Christina/L-2222-2019	Cuomo, Christina/0000-0002-5778-960X	NATIONAL CANCER INSTITUTE [R01CA015201, R37CA015201, R01CA037761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048026] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37761, CA 15201] Funding Source: Medline; NIGMS NIH HHS [GM48026] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ATHWAL RS, 1994, MUTAT RES, V315, P239; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA GC, 1989, IMMUNOGENETICS, V29, P54, DOI 10.1007/BF02341614; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNIZZARO LA, 1988, CYTOGENET CELL GENET, V47, P121, DOI 10.1159/000132527; CARROLL AM, 1989, J IMMUNOL, V143, P1087; CARROLL AM, 1988, EUR J IMMUNOL, V18, P1965, DOI 10.1002/eji.1830181215; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHANG C, 1993, CANCER RES, V53, P1244; CHEN DJ, 1992, GENOMICS, V13, P1088, DOI 10.1016/0888-7543(92)90023-L; CLEUTJENS CBJM, 1993, GENOMICS, V16, P520, DOI 10.1006/geno.1993.1220; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COX DR, 1989, GENOMICS, V4, P397, DOI 10.1016/0888-7543(89)90347-9; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA AJ, 1990, GENE CHROMOSOME CANC, V2, P248, DOI 10.1002/gcc.2870020314; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; GLASER T, 1989, GENOMICS, V6, P48; GOSS SJ, 1975, NATURE, V255, P680, DOI 10.1038/255680a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HENDRICKSON EA, 1988, GENE DEV, V2, P817, DOI 10.1101/gad.2.7.817; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; ITOH M, 1993, RADIAT RES, V134, P362; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KIRCHGESSNER C, UNPUB; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KOMATSU K, 1993, HUM MOL GENET, V2, P1031, DOI 10.1093/hmg/2.7.1031; KURIMASA A, 1994, HUM GENET, V93, P21; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MCBRIDE OW, 1990, CYTOGENET CELL GENET, V53, P108, DOI 10.1159/000132906; MILLER RD, 1993, GENOMICS, V16, P740, DOI 10.1006/geno.1993.1256; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; MORRIS CM, 1989, HUM GENET, V81, P339, DOI 10.1007/BF00283687; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; PROPST F, 1989, GENOMICS, V5, P118, DOI 10.1016/0888-7543(89)90094-3; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROWE LW, COMMUNICATION; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SPARU M, 1994, GENOMICS, V21, P208; Spurr N. K., 1995, Cytogenetics and Cell Genetics, V68, P147, DOI 10.1159/000133908; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; TRIPPUTI P, 1986, CYTOGENET CELL GENET, V42, P24, DOI 10.1159/000132245; VERHEIJEN JH, 1986, HUM GENET, V72, P153; WEIER HUG, 1991, HUM GENET, V87, P489; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; Wood S, 1993, Cytogenet Cell Genet, V64, P134; WOOD S, IN PRESS CYTOGENET C	70	575	584	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1178	1183		10.1126/science.7855601	http://dx.doi.org/10.1126/science.7855601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855601				2022-12-01	WOS:A1995QJ23700041
J	LEESMILLER, SP; GODBOUT, R; CHAN, DW; WEINFELD, M; DAY, RS; BARRON, GM; ALLALUNISTURNER, J				LEESMILLER, SP; GODBOUT, R; CHAN, DW; WEINFELD, M; DAY, RS; BARRON, GM; ALLALUNISTURNER, J			ABSENCE OF P350 SUBUNIT OF DNA-ACTIVATED PROTEIN-KINASE FROM A RADIOSENSITIVE HUMAN CELL-LINE	SCIENCE			English	Article							TERMINAL TRANSACTIVATION DOMAIN; RNA POLYMERASE-II; KU-PROTEIN; HUMAN CHROMOSOME-8; BINDING PROTEIN; SCID MUTATION; BREAK REPAIR; MICE; PHOSPHORYLATES; RADIATION	The radiosensitive rodent mutant cell line xrs-5 is defective in DNA double-strand break repair and lacks the Ku component of the DNA-activated protein kinase, DNA-PK. Here radiosensitive human cell lines were analyzed for DNA-PK activity and for the presence of related proteins. The radiosensitive human malignant glioma M059J cell line was found to be defective in DNA double-strand break repair, but fails to express the p350 subunit of DNA-PK. These results suggest that DNA-PK kinase activity is involved in DNA double-strand break repair.	CROSS CANC INST,RADIOBIOL PROGRAM,EDMONTON,AB T6G 1Z2,CANADA; UNIV CALGARY,DEPT BIOL SCI,CALGARY,AB T2N 1N4,CANADA; CROSS CANC INST,MOLEC ONCOL PROGRAM,EDMONTON,AB T6G 1Z2,CANADA	University of Alberta; University of Calgary; University of Alberta			Chan, Doris/O-1227-2014; Godbout, Roseline/I-4639-2016	Chan, Doris/0000-0002-4990-986X; Godbout, Roseline/0000-0002-4779-9265; Lees-Miller, Susan/0000-0001-5809-2516				ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; ALLALUNISTURNER MJ, UNPUB; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CC, COMMUNICATION; ANDERSON CW, IN PRESS METHODS PRO; ANDERSON CW, 1994, TRENDS BIOCHEM SCI, V18, P433; BANGA SS, 1994, MUTAT RES-DNA REPAIR, V315, P239, DOI 10.1016/0921-8777(94)90035-3; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHAN D, UNPUB; CHEN YR, 1991, J VIROL, V10, P5131; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; ILIAKIS G, 1991, INT J RADIAT BIOL, V59, P927, DOI 10.1080/09553009114550821; ITOH M, 1993, RADIAT RES, V134, P364, DOI 10.2307/3578198; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KOMATSU K, 1993, HUM MOL GENET, V2, P1031, DOI 10.1093/hmg/2.7.1031; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KURIMASA A, 1994, HUM GENET, V93, P21; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, UNPUB; LIU SH, 1993, J BIOL CHEM, V268, P21147; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MITSIS PG, 1989, J BIOL CHEM, V264, P5195; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1422; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WANATABE F, 1994, BIOCHIM BIOPHYS ACTA, V1223, P255; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	52	497	504	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1183	1185		10.1126/science.7855602	http://dx.doi.org/10.1126/science.7855602			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855602				2022-12-01	WOS:A1995QJ23700042
J	LI, W; OHLMEYER, JT; LANE, ME; KALDERON, D				LI, W; OHLMEYER, JT; LANE, ME; KALDERON, D			FUNCTION OF PROTEIN KINASE-A IN HEDGEHOG SIGNAL-TRANSDUCTION AND DROSOPHILA IMAGINAL DISC DEVELOPMENT	CELL			English	Article							POLARITY GENE HEDGEHOG; SEGMENT-POLARITY; CATALYTIC SUBUNIT; PATCHED GENE; EXPRESSION; WINGLESS; TRANSCRIPTION; MUTATIONS; DIRECTS; EMBRYO	Reduced protein kinase A (PKA) activity in anterior imaginal disc cells leads to cell-autonomous induction of decapentaplegic (dpp), wingless (wg), and patched (ptc) transcription that is independent of hedgehog (hh) gene activity. The resulting nonautonomous adult wing and leg pattern duplications are largely due to induced dpp and wg expression and resemble phenotypes elicited by ectopic hh expression. Inhibition of PKA in anterior cells close to the posterior compartment can substitute for hh activity to promote growth of imaginal discs, whereas overexpression of PKA can counteract transcriptional induction of ptc by hh in these cells. PKA therefore appears to be an integral component of the mechanism by which hh regulates the expression of key patterning molecules in imaginal discs.			LI, W (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.		Li, Willis/ABC-5695-2020; Li, Willis X/AAL-7212-2020	Li, Willis/0000-0001-9041-7341; Li, Willis X/0000-0001-9041-7341	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041815] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41815] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER NE, 1988, DEVELOPMENT, V102, P489; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRYANT PJ, 1980, GENETICS BIOL DROS C, V2, P230; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COHEN B, 1993, DEVELOPMENT, V117, P597; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HANNAH-ALAVA ALOHA, 1958, J MORPH, V103, P281, DOI 10.1002/jmor.1051030205; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SAMPEDRO J, 1991, NATURE, V353, P187, DOI 10.1038/353187a0; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223	52	283	295	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					553	562		10.1016/0092-8674(95)90509-X	http://dx.doi.org/10.1016/0092-8674(95)90509-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867063	hybrid			2022-12-01	WOS:A1995QJ60200007
J	LIU, B; ALBERTS, BM				LIU, B; ALBERTS, BM			HEAD-ON COLLISION BETWEEN A DNA-REPLICATION APPARATUS AND RNA-POLYMERASE TRANSCRIPTION COMPLEX	SCIENCE			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; FORK; TERMINATION; ELONGATION; SEQUENCE; HELICASE; PROTEIN; GENES; CHROMOSOME	An in vitro system reconstituted from purified proteins has been used to examine what happens when the DNA replication apparatus of bacteriophage T4 collides with an Escherichia coli RNA polymerase ternary transcription complex that is poised to move in the direction opposite to that of the moving replication fork. In the absence of a DNA helicase, the replication fork stalls for many minutes after its encounter with the RNA polymerase. However, when the T4 gene 41 DNA helicase is present, the replication fork passes the RNA polymerase after a pause of a few seconds. This brief pause is longer than the pause observed for a codirectional collision between the same two polymerases, suggesting that there is an inherent disadvantage to having replication and transcription directions oriented head to head. As for a codirectional collision, the RNA polymerase remains competent to resume faithful RNA chain elongation after the DNA replication fork passes; most strikingly, the RNA polymerase has switched from its original template strand to use the newly synthesized daughter DNA strand as the template.			LIU, B (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM-24020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024020, R37GM024020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T R SOC B, V317, P385; BARRY J, 1994, J BIOL CHEM, V269, P33049; BAUTZ EKF, 1976, RNA POLYMERASE, P273; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CAMPBELL AM, 1993, CURR OPIN GENET DEV, V3, P837, DOI 10.1016/0959-437X(93)90002-7; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1991, NATURE, V340, P730; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; LEE EH, 1992, J BIOL CHEM, V267, P8778; LINSKENS MH, 1988, MOL CELL BIOL, V8, P492; LIU B, 1994, P NATL ACAD SCI USA, V91, P10660, DOI 10.1073/pnas.91.22.10660; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MEDIGUE C, 1990, MOL MICROBIOL, V4, P1443, DOI 10.1111/j.1365-2958.1990.tb02055.x; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SANDERSON KE, 1988, MICROBIOL REV, V52, P485, DOI 10.1128/MMBR.52.4.485-532.1988; SELICK HE, 1987, DNA REPLICATION RECO, P183; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZEIGLER DR, 1990, GENETICS, V125, P703	38	161	163	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1131	1137		10.1126/science.7855590	http://dx.doi.org/10.1126/science.7855590			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855590				2022-12-01	WOS:A1995QJ23700027
J	MILLAR, AJ; CARRE, IA; STRAYER, CA; CHUA, NH; KAY, SA				MILLAR, AJ; CARRE, IA; STRAYER, CA; CHUA, NH; KAY, SA			CIRCADIAN CLOCK MUTANTS IN ARABIDOPSIS IDENTIFIED BY LUCIFERASE IMAGING	SCIENCE			English	Article							THALIANA	The cycling bioluminescence of Arabidopsis plants carrying a firefly luciferase fusion construct was used to identify mutant individuals with aberrant cycling patterns. Both long- and short-period mutants were recovered. A semidominant short-period mutation, timing of CAB expression (toc1), was mapped to chromosome 5. The toc1 mutation shortens the period of two distinct circadian rhythms, the expression of chlorophyll a/b-binding protein (CAB) genes and the movements of primary leaves, although toc1 mutants do not show extensive pleiotropy for other phenotypes.	UNIV VIRGINIA, DEPT BIOL, NSF, CTR BIOL TIMING, CHARLOTTESVILLE, VA 22903 USA; ROCKEFELLER UNIV, PLANT MOLEC BIOL LAB, NEW YORK, NY 10021 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; Rockefeller University			CARRE, Isabelle A/D-8802-2011; Millar, Andrew J/G-2423-2012; Kay, Steve A/F-6025-2011	CARRE, Isabelle A/0000-0002-0548-7378; Millar, Andrew J/0000-0003-1756-3654; Kay, Steve A/0000-0002-0402-2878	NIGMS NIH HHS [GM44640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM044640, R01GM044640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DEITZER GF, 1984, LIGHT FLOWERING PROC, P51; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DUNLAP JC, 1983, ANNU REV PHYSIOL, V55, P683; ENGELMANN W, 1992, Z NATURFORSCH C, V47, P925; HALL JC, 1990, ANNU REV GENET, V24, P659; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KOOMEEF M, 1992, METHODS ARABIDOPSIS, P83; MCCLUNG CR, 1994, ARABIDOPSIS THALIANA, P615; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MILLAR AJ, UNPUB; MILLAR AJ, 1994, THESIS ROCKEFFELLER; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; REITER RS, 1992, P NATL ACAD SCI USA, V89, P1477, DOI 10.1073/pnas.89.4.1477; TEAKLE GR, UNPUB	19	446	467	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	1995	267	5201					1161	1163		10.1126/science.7855595	http://dx.doi.org/10.1126/science.7855595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855595				2022-12-01	WOS:A1995QJ23700035
J	MILLAR, AJ; STRAUME, M; CHORY, J; CHUA, NH; KAY, SA				MILLAR, AJ; STRAUME, M; CHORY, J; CHUA, NH; KAY, SA			THE REGULATION OF CIRCADIAN PERIOD BY PHOTOTRANSDUCTION PATHWAYS IN ARABIDOPSIS	SCIENCE			English	Article							PLANTS; PHYTOCHROME; EXPRESSION; MUTANTS; CLOCK	Transgenic Arabidopsis plants expressing a luciferase gene fused to a circadian-regulated promoter exhibited robust rhythms in bioluminescence. The cyclic luminescence has a 24.7-hour period in white light but 30- to 36-hour periods under constant darkness. Either red or blue light shortened the period of the wild type to 25 hours. A phytochrome-deficient mutation lengthened the period in continuous red light but had little effect in continuous blue fight, whereas seedlings carrying mutations that activate light-dependent pathways in darkness maintained shorter periods in constant darkness. These results suggest that both phytochrome- and blue light-responsive photoreceptor pathways control the period of the circadian clock.	UNIV VIRGINIA,DEPT BIOL,NSF,CTR BIOL TIMING,CHARLOTTESVILLE,VA 22903; SALK INST,PLANT BIOL LAB,SAN DIEGO,CA 92186; ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; Salk Institute; Rockefeller University			Kay, Steve A/F-6025-2011; Millar, Andrew J/G-2423-2012	Kay, Steve A/0000-0002-0402-2878; Millar, Andrew J/0000-0003-1756-3654	NIGMS NIH HHS [GM44640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044640, R56GM044640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNIER G, 1993, PLANT CELL, V5, P1147, DOI 10.1105/tpc.5.10.1147; Bevington PR, 1969, DATA REDUCTION ERROR, P73; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; Edmunds L.N., 1988, CELLULAR MOL BASES B; HARRIS PJC, 1976, PLANTA, V129, P253, DOI 10.1007/BF00398267; HORWITZ BA, 1978, PLANT SCI LETT, V13, P9, DOI 10.1016/0304-4211(78)90058-5; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; MCCLUNG CR, 1994, ARABIDOPSIS THALIANA; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1994, THESIS ROCKEFELLER U; MILLAR AJ, UNPUB; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; ROENNEBERG T, 1988, NATURWISSENSCHAFTEN, V75, P206, DOI 10.1007/BF00735584; SIMON E, 1976, PLANT PHYSIOL, V58, P421, DOI 10.1104/pp.58.3.421; Sweeney BM., 1987, RHYTHMIC PHENOMENA P	21	223	228	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1163	1166		10.1126/science.7855596	http://dx.doi.org/10.1126/science.7855596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855596				2022-12-01	WOS:A1995QJ23700036
J	PAN, DJ; RUBIN, GM				PAN, DJ; RUBIN, GM			CAMP-DEPENDENT PROTEIN-KINASE AND HEDGEHOG ACT ANTAGONISTICALLY IN REGULATING DECAPENTAPLEGIC TRANSCRIPTION IN DROSOPHILA IMAGINAL DISKS	CELL			English	Article							POLARITY GENE HEDGEHOG; EXPRESSION; WINGLESS; DISKS; COMPARTMENTS; DIRECTS; CELLS; EYE	Localized expression of decapentaplegic (dpp) is required for proper development of the Drosophila imaginal discs. Using genetic mosaics, we show that in the anterior compartment of appendage discs and anterior to the morphogenetic furrow in the eye disc, cells that lack cAMP-dependent protein kinase (PKA) activity ectopically express dpp. Pka(-) cells can influence the fate of neighboring cells to reorganize anterior patterns in appendages and trigger ectopic morphogenetic furrows in the developing retina. This organizing activity of Pka mutant cells depends on dpp activity. Our findings suggest that PKA is a component of a signaling pathway that represses dpp expression and that hh antagonizes this pathway to maintain dpp expression at the anterior-posterior compartment border and in the morphogenetic furrow.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BROWN NL, 1991, DEVELOPMENT, V113, P1245; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223	38	221	224	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					543	552		10.1016/0092-8674(95)90508-1	http://dx.doi.org/10.1016/0092-8674(95)90508-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867062	Bronze			2022-12-01	WOS:A1995QJ60200006
J	PARK, IS; HAUSINGER, RP				PARK, IS; HAUSINGER, RP			REQUIREMENT OF CARBON-DIOXIDE FOR IN-VITRO ASSEMBLY OF THE UREASE NICKEL METALLOCENTER	SCIENCE			English	Article							KLEBSIELLA-AEROGENES UREASE; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE OXIDASE; MOLECULAR CHARACTERIZATION; BINDING PROTEIN; PURIFICATION; ACTIVATION; GENE; UREE	Assembly of protein metallocenters is not well understood. Urease offers a tractable system for examination of this process. Formation of the urease metallocenter in vivo is known to require four accessory proteins: UreD, postulated to be a urease-specific molecular chaperone; UreE, a nickel(II)-binding protein; and UreF and UreG, of unknown function. Activation of purified Klebsiella aerogenes urease apoprotein was accomplished in vitro by providing carbon dioxide (half-maximal activation at similar to 0.2 percent carbon dioxide) in addition to nickel ion. Activation coincided with carbon dioxide incorporation into urease in a pH-dependent reaction (pK(a) greater than or equal to 9, where K-a is the acid constant). The concentration of carbon dioxide also affected the amount of activation of UreD-urease apoprotein complexes. These results suggest that carbon dioxide binding to urease apoprotein generates a ligand that facilitates productive nickel binding.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University; Michigan State University				Hausinger, Robert/0000-0002-3643-2054	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045686] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45686] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Butler J.N., 1982, CARBON DIOXIDE EQUIL, P87, DOI [10.1016/0146-6380(83)90006-2, DOI 10.1016/0146-6380(83)90006-2]; DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; DONG JG, 1992, P NATL ACAD SCI USA, V89, P9789, DOI 10.1073/pnas.89.20.9789; FERNANDEZMACULE.JC, 1993, BIOCHEM BIOPH RES CO, V193, P1168; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Hausinger R.P., 1993, BIOCH NICKEL, V12, P23; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; Sumner JB, 1926, J BIOL CHEM, V69, P435; TODD MJ, 1989, J BIOL CHEM, V264, P15835; WANG S, 1994, INORG CHEM, V33, P1589, DOI 10.1021/ic00086a006; WEATHERBURN MW, 1967, ANAL CHEM, V39, P971, DOI 10.1021/ac60252a045	18	140	148	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1156	1158		10.1126/science.7855593	http://dx.doi.org/10.1126/science.7855593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855593				2022-12-01	WOS:A1995QJ23700033
J	STITT, TN; CONN, G; GORE, M; LAI, C; BRUNO, J; RADZIEJEWSKI, C; MATTSSON, K; FISHER, J; GIES, DR; JONES, PF; MASIAKOWSKI, P; RYAN, TE; TOBKES, NJ; CHEN, DH; DISTEFANO, PS; LONG, GL; BASILICO, C; GOLDFARB, MP; LEMKE, G; GLASS, DJ; YANCOPOULOS, GD				STITT, TN; CONN, G; GORE, M; LAI, C; BRUNO, J; RADZIEJEWSKI, C; MATTSSON, K; FISHER, J; GIES, DR; JONES, PF; MASIAKOWSKI, P; RYAN, TE; TOBKES, NJ; CHEN, DH; DISTEFANO, PS; LONG, GL; BASILICO, C; GOLDFARB, MP; LEMKE, G; GLASS, DJ; YANCOPOULOS, GD			THE ANTICOAGULATION FACTOR PROTEIN-S AND ITS RELATIVE, GAS6, ARE LIGANDS FOR THE TYRO 3/AXL FAMILY OF RECEPTOR TYROSINE KINASES	CELL			English	Article							HEPATOCYTE GROWTH-FACTOR; K-DEPENDENT PROTEIN; C4B-BINDING PROTEIN; BLOOD-COAGULATION; NERVOUS-SYSTEM; MESSENGER-RNA; CELLS; COMPONENT; DEFICIENCY; CNTF	We report the identification of ligands for Tyro 3 (alternatively called Sky, rse, brt, or tif) and Axl (alternatively, Ark or UFO), members of a previously orphan family of receptor-like tyrosine kinases. These ligands correspond to protein S, a protease regulator that is a potent anticoagulant, and Gas6, a protein related to protein S but lacking any known function. Our results are reminiscent of recent findings that the procoagulant thrombin, a protease that drives clot formation by cleaving fibrinogen to form fibrin, also binds and activates intracellular signaling via a G protein-coupled cell surface receptor. Proteases and protease regulators that also activate specific cell surface receptors may serve to integrate coagulation with associated cellular responses required for tissue repair and growth, as well as to coordinate protease cascades and associated cellular responses in other systems, such as those involved in growth and remodeling of the nervous system.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA; NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	Salk Institute; University of California System; University of California San Diego; Scripps Research Institute; University of Vermont; New York University; New York University	STITT, TN (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Glass, David/AAI-3910-2021					BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAI W, 1994, ONCOGENE, V9, P975; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HESSING M, 1991, BIOCHEM J, V277, P581, DOI 10.1042/bj2770581; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Luckow VA, 1992, BACULOVIRUS EXPRESSI; MAHASANDANA C, 1990, J PEDIATR-US, V117, P750, DOI 10.1016/S0022-3476(05)83335-9; MAILLARD C, 1992, ENDOCRINOLOGY, V130, P1599, DOI 10.1210/en.130.3.1599; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1994, J BIOL CHEM, V269, P10720; Monard D, 1993, Perspect Dev Neurobiol, V1, P165; NELSON RM, 1992, J BIOL CHEM, V267, P8140; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PEGELOW CH, 1992, PEDIATRICS, V89, P674; PHILLIPS DJ, 1993, J NEUROCHEM, V61, P344, DOI 10.1111/j.1471-4159.1993.tb03574.x; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZHAN X, 1987, ONCOGENE, V1, P369	43	594	637	1	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					661	670		10.1016/0092-8674(95)90520-0	http://dx.doi.org/10.1016/0092-8674(95)90520-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867073	hybrid			2022-12-01	WOS:A1995QJ60200018
J	SZANKASI, P; SMITH, GR				SZANKASI, P; SMITH, GR			A ROLE FOR EXONUCLEASE-I FROM S-POMBE IN MUTATION AVOIDANCE AND MISMATCH CORRECTION	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; DNA; REPAIR; ENDONUCLEASE; EXCISION	Exonuclease I (Exo I) from Schizosaccharomyces pombe, a 5' --> 3' double-stranded DNA exonuclease, is induced during meiotic prophase I. The exo1 gene is a member of a family of related DNA repair genes, including RAD2/rad13/xpgc and YKL510/rad2, conserved from yeast to humans. An exo1 mutant displays a mutator phenotype and alters activity of the ade6-M387 marker effect. These results suggest that Exo I acts in a pathway that corrects mismatched base pairs.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center				Smith, Gerald/0000-0002-8747-1352	NCI NIH HHS [P30 CA15704-20] Funding Source: Medline; NIGMS NIH HHS [GM32194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P145; CLAVERYS JP, 1983, P NATL ACAD SCI-BIOL, V80, P5956, DOI 10.1073/pnas.80.19.5956; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DETLOFF P, 1992, GENETICS, V132, P113; DEVEAUX LC, 1992, GENETICS, V130, P251; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLECK O, IN PRESS NUCLEIC ACI; GRIMM C, 1994, GENETICS, V136, P41; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIEB M, 1986, GENETICS, V114, P1041; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MARYON E, 1989, MOL CELL BIOL, V9, P4862, DOI 10.1128/MCB.9.11.4862; MCGREADY SJ, 1989, CURR GENET, V15, P27; MOORE CW, 1988, GENETICS, V119, P21; MUNZ P, 1975, MUTAT RES, V29, P155, DOI 10.1016/0027-5107(75)90030-5; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Phipps J, 1985, Adv Genet, V23, P1, DOI 10.1016/S0065-2660(08)60511-8; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P963; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAR P, 1993, GENETICS, V133, P825; SCHAR P, 1993, GENETICS, V133, P815; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SMITH GR, 1988, MICROBIOL REV, V52, P1; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; SZANKASI P, UNPUB; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WHITE JH, 1985, NATURE, V315, P350, DOI 10.1038/315350a0; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; WILLIAMSON MS, 1985, GENETICS, V110, P609; [No title captured]	49	178	182	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1166	1169		10.1126/science.7855597	http://dx.doi.org/10.1126/science.7855597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855597				2022-12-01	WOS:A1995QJ23700037
J	WHITE, MA; NICOLETTE, C; MINDEN, A; POLVERINO, A; VANAELST, L; KARIN, M; WIGLER, MH				WHITE, MA; NICOLETTE, C; MINDEN, A; POLVERINO, A; VANAELST, L; KARIN, M; WIGLER, MH			MULTIPLE RAS FUNCTIONS CAN CONTRIBUTE TO MAMMALIAN-CELL TRANSFORMATION	CELL			English	Article							ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; MAP KINASE; GROWTH-FACTOR; HA-RAS; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; IN-VITRO; RAF-1; YEAST	We have developed a generalized approach, using two hybrid interactions, to isolate Ha-Ras effector loop mutations that separate the ability of Ha-Ras to interact with different downstream effecters. These mutations attenuate or eliminate Ha-ras(G12V) transformation of mammalian cells, but retain complementary activity, as demonstrated by synergistic induction of foci of growth-transformed cells, and by the ability to activate different downstream components. The transformation defect of Ha-ras(G12V, E37G) is rescued by a mutant, raf1, that restores interaction. These results indicate that multiple cellular components, including Raf1, are activated by Ha-Ras and contribute to Ha-Ras-induced mammalian cell transformation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego	WHITE, MA (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Wigler, Michael/0000-0003-4396-1971				BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEL PL, 1994, IN PRESS METH ENZYMO; BOLLAG G, 1994, ANN REV CELL BIOL, V7, P601; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUADRADO A, 1993, ONCOGENE, V8, P2443; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PORRAS A, 1994, J BIOL CHEM, V269, P12741; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; Sambrook J., 1989, MOL CLONING LAB MANU; Sherman F., 1986, METHODS YEAST GENETI; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOTTON D, 1993, J BIOL CHEM, V268, P17975; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	58	631	637	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					533	541		10.1016/0092-8674(95)90507-3	http://dx.doi.org/10.1016/0092-8674(95)90507-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867061	Bronze			2022-12-01	WOS:A1995QJ60200005
J	BERLINER, E; YOUNG, EC; ANDERSON, K; MAHTANI, HK; GELLES, J				BERLINER, E; YOUNG, EC; ANDERSON, K; MAHTANI, HK; GELLES, J			FAILURE OF A SINGLE-HEADED KINESIN TO TRACK PARALLEL TO MICROTUBULE PROTOFILAMENTS	NATURE			English	Article							LIGHT-MICROSCOPY; MOVEMENT; MOLECULES; DENSITIES; DOMAINS	KINESIS, a two-headed motor enzyme molecule, hydrolyses ATP to direct organelle transport along microtubules. As it moves along a microtubule, kinesin remains associated with, or (tracks', microtubule protofilaments(1,2). We have prepared truncated kinesin derivatives that contain either two mechanochemical head domains(3) or only a single head. Unlike intact kinesin and the two-headed derivatives, the one-headed enzyme frequently fails to track protofilaments, suggesting that it detaches from microtubules during movement. In this way, the one-headed kinesin derivative is similar to the motor enzyme myosin, which frequently detaches from the actin filament during movement(4). For myosin (which has two heads), the consequence of this detachment is that single molecules do not appear to drive continuous movement along the filament(5). Our observations suggest that the ability of single two-headed kinesin molecules to drive continuous movement(6,7) results from a 'hand-over-hand' mechanism(6-8) in which one head remains bound to the microtubule while the other detaches and moves forwards.	BRANDEIS UNIV, GRAD DEPT BIOCHEM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, BIOPHYS PROGRAM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA	Brandeis University; Brandeis University; Brandeis University				Gelles, Jeff/0000-0001-7910-3421; Young, Edgar C./0000-0002-8453-088X				BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, 1994, J BIOL CHEM, V269, P23382; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GELLES J, 1989, Journal of Cell Biology, V109, p157A; GELLES J, IN PRESS BIOPHYS J; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Summers MD, 1987, MANUAL METHODS BACUL; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; YOUNG EC, IN PRESS J BIOL CHEM	28	164	165	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	1995	373	6516					718	721		10.1038/373718a0	http://dx.doi.org/10.1038/373718a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854458				2022-12-01	WOS:A1995QH92800060
J	ECKHARDT, M; MUHLENHOFF, M; BETHE, A; KOOPMAN, J; FROSCH, M; GERARDYSCHAHN, R				ECKHARDT, M; MUHLENHOFF, M; BETHE, A; KOOPMAN, J; FROSCH, M; GERARDYSCHAHN, R			MOLECULAR CHARACTERIZATION OF EUKARYOTIC POLYSIALYLTRANSFERASE-1	NATURE			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; N-CAM; NERVE; NCAM; POLYSACCHARIDE; EXPRESSION; ANTIBODY; BINDING; CLONING	POLYSIALIC acid (PSA) is a dynamically regulated product of posttranslational modification of the neural cell adhesion molecule, NCAM(1,2). Presence of the large anionic carbohydrate modulates NCAM binding properties and, by increasing the intercellular space, influences interactions between other cell surface molecules(1-5). PSA expression underlies cell type- and developmental-specific alterations(6) and correlates with stages of cellular motility(6-8), In the adult, PSA becomes restricted to regions of permanent neural plasticity and regenerating neural and muscle tissues(6,9,10). Recent data implicate its important function in spatial learning and memory(11,12), and in tumour biology(13-16). Here we describe the molecular characterization of polysialyltransferase-1, the key enzyme of eukaryotic PSA synthesis. In reconstitution experiments, the newly cloned enzyme induces PSA synthesis in all NCAM-expressing cell lines. Our data therefore represent convincing evidence that the polycondensation of alpha-2,8-linked sialic acids in mammals is the result of a single enzymatic activity and provide a new basis for studying the functional role of PSA in neuro- and tumour biology.	HANNOVER MED SCH,INST MED MIKROBIOL,D-30625 HANNOVER,GERMANY; NETHERLANDS CANC INST,DEPT TUMOR BIOL,1006 CX AMSTERDAM,NETHERLANDS	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Netherlands Cancer Institute			Frosch, Matthias/H-2411-2013					ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; BLERHUIZEN MFA, 1993, GENE DEV, V7, P468; BLOCH RJ, 1992, J CELL BIOL, V116, P449, DOI 10.1083/jcb.116.2.449; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DANILOFF JK, 1986, J CELL BIOL, V103, P929, DOI 10.1083/jcb.103.3.929; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GERARDYSCHAHN R, 1994, INT J CANCER S, V8, P38; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; KERN WF, 1993, LEUKEMIA LYMPHOMA, V12, P1, DOI 10.3109/10428199309059565; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOMMINOTH P, 1991, AM J PATHOL, V139, P297; LANDMESSER L, 1992, J NEUROBIOL, V23, P1131, DOI 10.1002/neu.480230906; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MCCOY RD, 1984, J BIOL CHEM, V260, P12659; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TAKAMATSU K, 1994, CANCER RES, V54, P2598; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TOMLINSON S, 1985, J VIROL, V55, P374, DOI 10.1128/JVI.55.2.374-378.1985; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487	31	269	278	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					715	718		10.1038/373715a0	http://dx.doi.org/10.1038/373715a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854457				2022-12-01	WOS:A1995QH92800059
J	GILBERT, SP; WEBB, MR; BRUNE, M; JOHNSON, KA				GILBERT, SP; WEBB, MR; BRUNE, M; JOHNSON, KA			PATHWAY OF PROCESSIVE ATP HYDROLYSIS BY KINESIN	NATURE			English	Article							ADP RELEASE; MICROTUBULES; MOVEMENT; MYOSIN; MOTOR; IDENTIFICATION; SUBFRAGMENT-1; ACTOMYOSIN; MOLECULES; MOTILITY	Direct measurement of the kinetics of kinesin dissociation from microtubules, the release of phosphate and ADP from kinesin, and rebinding of kinesin to the microtubule have defined the mechanism for the kinesin ATPase cycle. The processivity of ATP hydrolysis is ten molecules per site at low salt concentration but is reduced to one ATP per site at higher salt concentration. Kinesin dissociates from the microtubule after ATP hydrolysis. This step is rate-limiting. The subsequent rebinding of kinesin ADP to the microtubule is fast, so kinesin spends only a small fraction of its duty cycle in the dissociated state. These results provide an explanation for the motility differences between skeletal myosin and kinesin.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; MRC National Institute for Medical Research				Webb, Martin/0000-0002-0134-9621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026726] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM026726] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GREENE LE, 1980, J BIOL CHEM, V255, P543; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SADHU A, 1992, J BIOL CHEM, V267, P11352; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TAYLOR EW, 1992, HEART CARDIOVASCULAR, P1281; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	24	255	256	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					671	676		10.1038/373671a0	http://dx.doi.org/10.1038/373671a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854446	Green Accepted			2022-12-01	WOS:A1995QH92800045
J	HALL, DT; STROBEL, DF; FELDMAN, PD; MCGRATH, MA; WEAVER, HA				HALL, DT; STROBEL, DF; FELDMAN, PD; MCGRATH, MA; WEAVER, HA			DETECTION OF AN OXYGEN ATMOSPHERE ON JUPITER MOON EUROPA	NATURE			English	Article							IO PLASMA TORUS; FREQUENCY REDISTRIBUTION; GALILEAN SATELLITES; ELECTRON-IMPACT; CROSS-SECTIONS; SPECTROSCOPY; EXCITATION; MOLECULES; UV	EUROPA, the second large satellite out from Jupiter, is roughly the size of Earth's Moon, but unlike the Moon, it has water ice on its surface(1), There have been Suggestions that an oxygen atmosphere should accumulate around such a body, through reactions which break up the water molecules and form molecular hydrogen and oxygen(2,3), The lighter H-2 molecules would escape from Europa relatively easily, leaving behind an atmosphere rich in oxygen, Here we report the detection of atomic oxygen emission from Europa, which we interpret as being produced by the simultaneous dissociation and excitation of atmospheric O-2 by electrons from Jupiter's magnetosphere, Europa's molecular oxygen atmosphere is very tenuous, with a surface pressure about 10(-11) that of the Earth's atmosphere at sea level.	SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218	Space Telescope Science Institute	HALL, DT (corresponding author), JOHNS HOPKINS UNIV,CTR ASTROPHYS SCI,34TH & CHARLES ST,BALTIMORE,MD 21218, USA.		Strobel, Darrell5/AAO-6643-2021; Weaver, Harold A/D-9188-2016	Strobel, Darrell5/0000-0002-0944-8675; Weaver, Harold A/0000-0003-0951-7762				BAGENAL F, 1994, J GEOPHYS RES-SPACE, V99, P11043, DOI 10.1029/93JA02908; Cheng A.F., 1986, SATELLITES, P403, DOI [10.2307/j.ctv1v3gr3r.13, DOI 10.2307/J.CTV1V3GR3R.13]; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; GLADSTONE GR, 1992, J GEOPHYS RES-SPACE, V97, P19519, DOI 10.1029/92JA00991; HAPKE B, 1981, ICARUS, V47, P361, DOI 10.1016/0019-1035(81)90184-6; ITIKAWA Y, 1989, J PHYS CHEM REF DATA, V18, P23, DOI 10.1063/1.555841; JOHNSON RE, 1983, GEOPHYS RES LETT, V10, P892, DOI 10.1029/GL010i009p00892; LAHER RR, 1990, J PHYS CHEM REF DATA, V19, P277, DOI 10.1063/1.555872; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LEE JS, 1980, ASTROPHYS J, V240, P185, DOI 10.1086/158222; MALIN MC, 1986, SATELLITES, P689; MEIER RR, 1991, SPACE SCI REV, V58, P1, DOI 10.1007/BF01206000; MEIER RR, 1982, PLANET SPACE SCI, V30, P439, DOI 10.1016/0032-0633(82)90053-8; NELSON RM, 1987, ICARUS, V72, P358, DOI 10.1016/0019-1035(87)90180-1; SHEMANSKY DE, 1988, J GEOPHYS RES, V93, P1773, DOI 10.1029/JA093iA03p01773; SITTLER EC, 1987, J GEOPHYS RES, V92, P5741, DOI 10.1029/JA092iA06p05741; VANHOOSIER ME, 1988, ASTROPHYS LETT COMM, V27, P163; YUNG YL, 1977, ICARUS, V20, P97; ZIPF EC, 1986, J PHYS B-AT MOL OPT, V19, P2199, DOI 10.1088/0022-3700/19/14/014; [No title captured]	20	278	280	0	55	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					677	679		10.1038/373677a0	http://dx.doi.org/10.1038/373677a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854447				2022-12-01	WOS:A1995QH92800046
J	HE, JL; FURMANSKI, P				HE, JL; FURMANSKI, P			SEQUENCE SPECIFICITY AND TRANSCRIPTIONAL ACTIVATION IN THE BINDING OF LACTOFERRIN TO DNA	NATURE			English	Article							NUCLEAR-LOCALIZATION; ENRICHED POPULATION; CELLS; PROTEIN; INFECTION; FRAGMENTS; AFFINITY; INVITRO; IRON	LACTOFERRIN, an iron-binding glycoprotein found in high concentrations in human milk and other epithelial secretions' and in the secondary (specific) granules of neutrophils(2), is thought to be responsible for primary defence against microbial infection, mainly as a result of lactoferrin sequestration of iron required for microbial growth(3). Many other functions have been attributed to lactoferrin, including immunomodulation and cell growth regulation (reviewed in ref. 4). Some of these functions appear to be at least in part independent of the iron-binding activity of lactoferrin, It also has been consistently observed that lactoferrin interacts avidly with nucleic acids(5-7). Lactoferrin enhancement of the activity of natural killer and lymphokine-activated killer cells in vitro is inhibited by RNA and DNA(8). Lactoferrin taken up by K562 human myelogenous leukaemia cells appears in the nucleus where it is bound to DNA(9) The report here that binding of lactoferrin to DNA occurs under stringent conditions with distinct sequence specificity, and that interaction between lactoferrin and these sequences intracellularly leads to transcriptional activation.	NYU,DEPT BIOL,NEW YORK,NY 10003	New York University								AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BENNETT RM, 1983, J CLIN INVEST, V71, P611, DOI 10.1172/JCI110807; BENNETT RM, 1981, J IMMUNOL, V127, P1211; BEZAULT J, 1994, CANCER RES, V54, P2310; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARRE C, 1992, J CELL PHYSIOL, V153, P477, DOI 10.1002/jcp.1041530306; GREEN I, 1971, P SOC EXP BIOL MED, V137, P1311; HASHIZUME S, 1983, BIOCHIM BIOPHYS ACTA, V763, P377, DOI 10.1016/0167-4889(83)90099-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUTCHENS TW, 1991, PEDIATR RES, V29, P243, DOI 10.1203/00006450-199103000-00005; LONNERDAL B, 1988, NUTR RES, V8, P853; Lyer S, 1993, EUR J CLIN NUTR, V47, P232; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MIYAUCHI J, 1987, CELL TISSUE RES, V247, P249; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; SLEBENLIST U, 1984, CELL, V37, P381; SPIK G, 1978, BRIT MED J, V5, P69; WALMER DK, 1992, ENDOCRINOLOGY, V131, P1458, DOI 10.1210/en.131.3.1458; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978; WEINBERG ED, 1992, LIFE SCI, V50, P1289, DOI 10.1016/0024-3205(92)90279-X; ZHANG XY, 1992, ANAL BIOCHEM, V201, P366, DOI 10.1016/0003-2697(92)90353-9; ZIERE GJ, 1993, J BIOL CHEM, V268, P27069; ZUCALI JR, 1987, BLOOD, V69, P33; ZUCALI JR, 1987, BLOOD, V70, pA191	27	314	333	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					721	724		10.1038/373721a0	http://dx.doi.org/10.1038/373721a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854459				2022-12-01	WOS:A1995QH92800061
J	HEBERLEIN, U; SINGH, CM; LUK, AY; DONOHOE, TJ				HEBERLEIN, U; SINGH, CM; LUK, AY; DONOHOE, TJ			GROWTH AND DIFFERENTIATION IN THE DROSOPHILA EYE COORDINATED BY HEDGEHOG	NATURE			English	Article							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; BETA FAMILY; HAIRY GENE; EXPRESSION; PROTEIN; HOMOLOG; DIRECTS; RETINA	DIFFERENTIATION Of the Drosophila retina is asynchronous: it starts at the posterior margin of the eye imaginal disc and progresses anteriorly over two days. During this time the disc continues to grow, increasing in size by approximately eightfold, An indentation in the epithelium, the morphogenetic furrow(1), marks the front edge of the differentiation wave. Anterior progression of the furrow is thought to be driven by signals emanating from differentiating photoreceptor cells in the posterior eye disc(2,3). A good candidate for such a signal is the product of the hedgehog (hh) gene(4-7); it is expressed, and presumably secreted, by differentiating photoreceptors and its function is required for continued furrow movement(2,3). Here we show that ectopic expression of hedgehog sets in motion ectopic furrows in the anterior eye disc, In addition to changes in cell shape, these ectopic furrows are associated with a tightly orchestrated series of events, including proliferation, cell cycle synchronization and pattern formation, that parallel normal furrow progression. We propose that the morphogenetic furrow coincides with a transient boundary that coordinates growth and differentiation of the eye disc, and that hedgehog is necessary and sufficient to propagate this boundary across the epithelium.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	HEBERLEIN, U (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT NEUROL,GALLO CTR BLDG 1,RM 101,SAN FRANCISCO,CA 94110, USA.							ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BROWN NL, 1991, DEVELOPMENT, V113, P1245; BROWN NL, IN PRESS CELL; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thomas Barbara J., 1994, Trends in Cell Biology, V4, P389, DOI 10.1016/0962-8924(94)90051-5; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5	30	176	182	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					709	711		10.1038/373709a0	http://dx.doi.org/10.1038/373709a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854455				2022-12-01	WOS:A1995QH92800057
J	KEEFE, AD; NEWTON, GL; MILLER, SL				KEEFE, AD; NEWTON, GL; MILLER, SL			A POSSIBLE PREBIOTIC SYNTHESIS OF PANTETHEINE, A PRECURSOR TO COENZYME-A	NATURE			English	Article							PURINE NUCLEOSIDES; ACIDS	THE involvement of coenzyme A in many enzyme reactions suggests that it acted in this capacity very early in the development of life on Earth. Particularly relevant in this regard is its role in the activation of amino acids and hydroxy acids in the biosynthesis of some peptide antibiotics(1,2)-a mechanism of peptide synthesis that forms the basis for the proposal that a thioester world(3) could have preceded the RNA world(4), The components of coenzyme A have been shown to be probable prebiotic compounds: beta-alanine, pantoyl lactone and cysteamine(5,6) and possibly adenosine(7,8). We show here that the pantetheine moiety of coenzyme A (which also occurs in a number of enzymes) can be synthesized in yields of several per cent by heating pantoyl lactone, beta-alanine and cysteamine at temperatures as low as 40 degrees C. These components are extremely soluble and so would have been preferentially concentrated in evaporating bodies of water, for example on beaches and at lagoon margins. Our results show that amide bonds can be formed at temperatures as low as 40 degrees C, and provide circumstantial support for the suggestion that pantetheine and coenzyme A were important in the earliest metabolic systems.			KEEFE, AD (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.							BISHOP MJ, 1972, NATURE, V237, P162, DOI 10.1038/237162a0; de Duve C, 1991, BLUEPRINT CELL NATUR; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; Fox SW, 1972, MOL EVOLUTION ORIGIN; FULLER WD, 1972, J MOL EVOL, V1, P249, DOI 10.1007/BF01660244; FULLER WD, 1972, J MOL BIOL, V67, P25, DOI 10.1016/0022-2836(72)90383-X; GESTELAND RF, 1993, RNA WORLD; GUNNING HE, 1966, ADV PHOTOCHEM, V4, P143; KVENVOLDEN KA, 1971, P NATL ACAD SCI USA, V68, P486, DOI 10.1073/pnas.68.2.486; LAKINTHOMAS PL, 1985, EUR J BIOCHEM, V146, P141, DOI 10.1111/j.1432-1033.1985.tb08630.x; LOHRMANN R, 1977, J MOL EVOL, V10, P137, DOI 10.1007/BF01751807; Miller S. L., 1974, ORIGINS LIFE EARTH; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; Peltzer E T, 1984, Adv Space Res, V4, P69, DOI 10.1016/0273-1177(84)90546-5; ROHLFING DL, 1976, SCIENCE, V193, P68, DOI 10.1126/science.935858; SCHLESINGER G, 1993, J MOL EVOL, V36, P308; SCHLESINGER G, 1993, J MOL EVOL, V36, P302; Smith ERB, 1940, J BIOL CHEM, V132, P47; Torchinsky Y, 1981, SULFUR PROTEINS	19	59	59	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					683	685		10.1038/373683a0	http://dx.doi.org/10.1038/373683a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854449				2022-12-01	WOS:A1995QH92800049
J	LEPAGE, T; COHEN, SM; DIAZBENJUMEA, FJ; PARKHURST, SM				LEPAGE, T; COHEN, SM; DIAZBENJUMEA, FJ; PARKHURST, SM			SIGNAL-TRANSDUCTION BY CAMP-DEPENDENT PROTEIN-KINASE-A IN DROSOPHILA LIMB PATTERNING	NATURE			English	Article							HEDGEHOG GENE; PATCHED GENE; POLARITY; TRANSCRIPTION; ORGANIZATION; EXPRESSION; DIRECTS; CELLS	INTERACTION between distinctly specified cells in adjacent compartments establishes organizing centres that control growth and specify cell fate in the developing limbs of Drosophila(1-5). Localized expression of the secreted Hedgehog protein (Hh) by cells in the posterior compartment(6-8) induces expression of the secreted signalling molecules decapentaplegic (dpp) or wingless (wg) in nearby anterior cells(2,3). wg and dpp in turn organize spatial pattern in the wing and leg imaginal discs(2,4,9). The Hh signal is thought to act by antagonizing the ability of the patched (ptc) gene product to repress log and dpp expression(10-14). Here we present evidence that removing activity of the gene encoding cyclic AMP-dependent protein kinase A (pka) is functionally equivalent to removing ptc activity or to providing cells with the Hh signal. These findings suggest that cyclic AMP-dependent protein kinase A is a component of the signal transduction pathway through which Hh and Ptc direct localized expression of dpp (or wg) and establish the compartment boundary organizer.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,A1-162,SEATTLE,WA 98104	European Molecular Biology Laboratory (EMBL); Fred Hutchinson Cancer Center			Cohen, Stephen M/G-9930-2011; Diaz-Benjumea, Fernando/K-7667-2014; Lepage, Thierry/V-4208-2019; Lepage, Thierry/AAF-8925-2019	Cohen, Stephen M/0000-0003-2858-9163; Diaz-Benjumea, Fernando/0000-0003-3007-2489; Lepage, Thierry/0000-0003-2889-5064; 				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FORBES AJ, 1993, DEVELOPMENT, P115; GRAU Y, 1987, DEV BIOL, V122, P186, DOI 10.1016/0012-1606(87)90344-7; HARTWELL L, 1994, NATURE, V371, P286, DOI 10.1038/371286a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; RAFERTY LA, 1991, DEVELOPMENT, V113, P27; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; STRADLER CD, 1994, REV BIOCH, V63, P101; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TOROK T, 1993, GENETICS, V35, P71; Watson S., 1994, G PROTEIN LINKED REC; XU T, 1993, DEVELOPMENT, V117, P1223	29	150	158	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					711	715		10.1038/373711a0	http://dx.doi.org/10.1038/373711a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854456				2022-12-01	WOS:A1995QH92800058
J	OTT, M; SCHAEFFEL, F				OTT, M; SCHAEFFEL, F			A NEGATIVELY POWERED LENS IN THE CHAMELEON	NATURE			English	Article							ACCOMMODATION	CHAMELEONS are arboral Lizards that spot their prey visually and catch it by highly precise shots with their long sticky tongue, They scan their environment by large-amplitude independent saccadic eye movements; once an insect is detected, the head axis is aligned towards the target ('head tracking'(1), both eyes come forward to fixate the insect and, in a phase called 'initial protrusion'(2), the sticky tongue is loaded with tension by a special hyoid apparatus(3) and subsequently shot out of the mouth with great precision, Lenses placed in front of the eyes produce predictable errors in distance estimation(4), suggesting that chameleons rely on accommodation cues when measuring the distance to their prey, but focusing has never been measured directly, Using a new technique to measure accommodation(5), we now show that accommodation is precise enough to serve as the major distance cue. Because accurate focusing requires large retinal images, we have tested image magnification and find that it is higher than in any other vertebrate eye scaled to the same size, This is a result of a unique optical design: unlike other vertebrate eyes, the crystalline lens of the chameleon has negative refractive power, Although there is a trend among vertebrates to increase corneal power and to decrease lens power with higher visual acuity, only in the chameleon eye has this tendency led to a reversal of the sign of the power of the lens.	UNIV TUBINGEN,HOSP EYE,DEPT EXPTL OPHTHALMOL,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen								ALTEVOGT R, 1954, Z VERGL PHYSIOL, V36, P66, DOI 10.1007/BF00297854; CITRON MC, 1973, VISION RES, V13, P873, DOI 10.1016/0042-6989(73)90050-3; FLANDERS M, 1985, VISION RES, V25, P935, DOI 10.1016/0042-6989(85)90204-4; GLICKSTEIN M, 1970, SCIENCE, V192, P605; HARKNESS L, 1977, NATURE, V267, P346, DOI 10.1038/267346a0; Hughes A., 1977, HDB SENSORY PHYSL, V5, P613, DOI [DOI 10.1007/978-3-642-66468-7, 10.1007/978-3-642-66468-7_11, DOI 10.1007/978-3-642-66468-7_11]; Martin G.R., 1994, P5; Miller W.H., 1979, HDB SENSORY PHYSL, V7 / 6 / 6 A, P69, DOI [10.1007/978-3-642-66999-6_3, DOI 10.1007/978-3-642-66999-6]; OKEEFE LP, 1988, OPHTHAL PHYSL OPT, V8, P97, DOI 10.1111/j.1475-1313.1988.tb01086.x; SCHAEFFEL F, 1987, J COMP PHYSIOL A, V160, P375, DOI 10.1007/BF00613027; SCHAEFFEL F, 1988, VISION RES, V28, P639, DOI 10.1016/0042-6989(88)90113-7; SCHAEFFEL F, 1994, J OPT SOC AM A, V11, P487, DOI 10.1364/JOSAA.11.000487; SCHAEFFEL F, 1988, CLIN VISION SCI, V3, P83; WAGNER H, 1992, J COMP PHYSIOL A, V169, P515; WAINWRIGHT PC, 1992, J EXP BIOL, V168, P1; YOUNG T, 1801, PHILOS T R SOC LONDO, V19, P23	16	58	59	2	44	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					692	694		10.1038/373692a0	http://dx.doi.org/10.1038/373692a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854450				2022-12-01	WOS:A1995QH92800052
J	PARVIN, JD; MCCORMICK, RJ; SHARP, PA; FISHER, DE				PARVIN, JD; MCCORMICK, RJ; SHARP, PA; FISHER, DE			PRE-BENDING OF A PROMOTER SEQUENCE ENHANCES AFFINITY FOR THE TATA-BINDING FACTOR	NATURE			English	Article							CRYSTAL-STRUCTURE; MINOR-GROOVE; BOX COMPLEX; TFIID BINDS; DNA; PROTEIN; ELEMENTS	TATA-binding protein (TBP) binds the minor groove of the TATA element with the DNA bent 80 degrees towards the major groove(1-4). A constrained minicircle strategy(5) has been used to test the effect of DNA topology on the affinity of TBP for the TATA element. We report here that TBP bound to DNA which was slightly pre-bent towards the major groove with 100-fold higher affinity than unbent (linear) DNA of identical sequence and 300-foId higher affinity than DNA pre-bent towards the minor groove, Similar discrimination was observed with the holo-TFIID transcription complex. DNA topology, particularly bending, is determined by many factors including chromatin in cells and may, through changes in the affinity of the TATA factor, be important in the control of transcription.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Parvin, Jeffrey D/C-8955-2009					BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM JL, 1994, NAT STRUCT BIOL, V1, P621; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KUDDUS R, 1993, NUCLEIC ACIDS RES, V21, P1789, DOI 10.1093/nar/21.8.1789; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E	19	163	165	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					724	727		10.1038/373724a0	http://dx.doi.org/10.1038/373724a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854460				2022-12-01	WOS:A1995QH92800062
J	SCHMIDT, C; BLADT, F; GOEDECKE, S; BRINKMANN, V; ZSCHIESCHE, W; SHARPE, M; GHERARDI, E; BIRCHMEIER, C				SCHMIDT, C; BLADT, F; GOEDECKE, S; BRINKMANN, V; ZSCHIESCHE, W; SHARPE, M; GHERARDI, E; BIRCHMEIER, C			SCATTER FACTOR/HEPATOCYTE GROWTH-FACTOR IS ESSENTIAL FOR LIVER DEVELOPMENT	NATURE			English	Article							MET RECEPTOR; EPITHELIAL INTERACTIONS; MOLECULAR-CLONING; TYROSINE KINASE; HEPATOCYTE; IDENTIFICATION; CELLS; MOTILITY; GENE	POLYPEPTIDE growth factors are important effecters of cell growth and differentiation in vitro and are thought to be critical for processes such as specification of cell fate, tissue growth and organogenesis in vivo, Scatter factor(1-3)/hepatocyte growth factor(4,5) (SF/HGF) is the prototype of an emerging family of growth factors that resemble in their domain structure and mechanism of activation the blood proteinase plasminogen(6,7). The cellular responses of SF/HGF are mediated by the c-Met tyrosine kinase receptor(8-10). Here we report that mice lacking SF/HGF fail to complete development and die in utero. The mutation affects the embryonic liver, which is reduced in size and shows extensive loss of parenchymal cells, In addition, development of the placenta, particularly of trophoblast cells, is impaired. Thus, SF/HGF is essential for the development of several epithelial organs.	MAX PLANCK GESELL,MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY; UNIV CAMBRIDGE,SCH MED,MRC CTR,ICRF,CELL INTERACT LAB,CAMBRIDGE CB2 2QH,ENGLAND	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; MRC Laboratory Molecular Biology; University of Cambridge			Gherardi, Ermanno/AAB-9608-2022; Brinkmann, Volker/A-6015-2009	GHERARDI, ERMANNO/0000-0002-0016-2945				BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; DENK H, 1985, EXP CELL RES, V161, P161, DOI 10.1016/0014-4827(85)90500-2; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HILBERG F, 1993, NATURE, V385, P179; KUEHN R, 1991, Science (Washington D C), V254, P707; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145	29	1177	1246	2	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					699	702		10.1038/373699a0	http://dx.doi.org/10.1038/373699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854452				2022-12-01	WOS:A1995QH92800054
J	STREBEL, PM; IONNEDELCU, N; BAUGHMAN, AL; SUTTER, RW; COCHI, SL				STREBEL, PM; IONNEDELCU, N; BAUGHMAN, AL; SUTTER, RW; COCHI, SL			INTRAMUSCULAR INJECTIONS WITHIN 30 DAYS OF IMMUNIZATION WITH ORAL POLIOVIRUS VACCINE - A RISK FACTOR FOR VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENGLAND; SYSTEM; WALES	Background. In Romania the rate of vaccine-associated paralytic poliomyelitis is for unexplained reasons 5 to 17 times higher than in other countries. Long ago it was noted that intramuscular injections administered during the incubation period of wild-type poliovirus infection increased the risk of paralytic disease (a phenomenon known as ''provocation'' poliomyelitis). We conducted a case-control study to explore the association between intramuscular injections and vaccine-associated poliomyelitis in Romania. Methods. The patients were 31 young children in whom vaccine-associated paralytic poliomyelitis developed from 1988 through 1992. Eighteen were vaccine recipients, and 13 had acquired the disease by contact with vaccine recipients. Each of these children was matched with up to five controls according to health center, age, and in the case of vaccine recipients, history of receipt of the live attenuated oral poliovirus vaccine. Data were abstracted from medical records that documented the injections administered in the 30 days before the onset of paralysis. Results. Of the 31 children with vaccine-associated disease, 27 (87 percent) had received one or more intramuscular injections within 30 days before the onset of paralysis, as compared with 77 of the 151 controls (51 percent) (matched odds ratio, 31.2; 95 percent confidence interval, 4.0 to 244.2). Nearly all the intramuscular injections were of antibiotics, and the association was strongest for the patients who received 10 or more injections (matched odds ratio for greater than or equal to 10 injections as compared with no injections, 182.1; 95 percent confidence interval, 15.2 to 2186.4). The risk of paralytic disease was strongly associated with injections given after the oral poliovirus vaccine, but not with injections given before or at the same time as the vaccine (matched odds ratio, 56.7; 95 percent confidence interval, 8.9 to infinity). The attributable risk in the population for intramuscular injections given in the 30 days before the onset of paralysis was 86 percent (95 percent confidence interval, 66 to 95 percent); that is, we estimate that 86 percent of the cases of vaccine-associated paralytic poliomyelitis in this population might have been prevented by the elimination of intramuscular injections within 30 days after exposure to Oral poliovirus vaccine. Conclusions. Provocation paralysis, previously described only for wild-type poliovirus infection, may rarely occur in a child who receives multiple intramuscular injections shortly after exposure to oral poliovirus vaccine, either as a vaccine recipient or through contact with a recent recipient. This phenomenon may explain the high rate of vaccine-associated paralytic poliomyelitis in Romania, where the use of intramuscular injections of antibiotics in infants with febrile illness is common.	CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,DIV DATA MANAGEMENT,ATLANTA,GA 30333; MINIST HLTH,EXPANDED PROGRAMME IMMUNIZAT,BUCHAREST,ROMANIA	Centers for Disease Control & Prevention - USA	STREBEL, PM (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,DIV EPIDEMIOL & SURVEILLANCE,MAILSTOP E-61,ATLANTA,GA 30333, USA.							ANDERSON GW, 1951, PEDIATRICS, V7, P741; ANDRUS JK, IN PRESS B WHO; BANKS HS, 1950, BRIT MED J, V2, P251, DOI 10.1136/bmj.2.4673.251; BODIAN D, 1954, AM J HYG, V60, P358, DOI 10.1093/oxfordjournals.aje.a119727; BRESLOW NE, 1980, IARC SCI PUBL, V32, P247; COCKBURN WC, 1988, B WORLD HEALTH ORGAN, V66, P143; COLLINGHAM KE, 1978, LANCET, V1, P976; CRAINIC R, 1983, INFECT IMMUN, V41, P1217, DOI 10.1128/IAI.41.3.1217-1225.1983; Deivanayagam N, 1993, Indian Pediatr, V30, P335; ESTEVES K, 1988, B WORLD HEALTH ORGAN, V66, P739; FLEISS JL, 1991, STATISTICAL METHODS; GREENBERG M, 1952, AM J PUBLIC HEALTH, V42, P142; GREENLAND S, 1987, STAT MED, V6, P701, DOI 10.1002/sim.4780060607; GUYER B, 1980, B WORLD HEALTH ORGAN, V58, P285; HERSH BS, 1993, AIDS, V7, P1617, DOI 10.1097/00002030-199312000-00012; HILL AB, 1950, BMJ-BRIT MED J, V2, P1; HIRJI KF, 1989, AM STAT, V43, P7, DOI 10.2307/2685158; HIRJI KF, 1988, BIOMETRICS, V44, P803, DOI 10.2307/2531592; Hollander M., 1973, NONPARAMETRIC STAT, P68; JOCE R, 1992, BRIT MED J, V305, P79, DOI 10.1136/bmj.305.6845.79; MCCLOSKEY BP, 1950, LANCET, V1, P659; NATHANSON N, 1961, B JOHNS HOPKINS HOSP, V108, P308; REN R, 1993, J INFECT DIS, V166, P747; ROSEN L, 1953, AM J HYG, V57, P237, DOI 10.1093/oxfordjournals.aje.a119571; SIMOES EAF, 1994, 34TH INT C ANT AG CH, P66; STREBEL PM, 1994, AM J EPIDEMIOL, V140, P1111, DOI 10.1093/oxfordjournals.aje.a117211; SUTTER RW, 1989, AM J PUBLIC HEALTH, V79, P495, DOI 10.2105/AJPH.79.4.495; SUTTER RW, 1992, J INFECT DIS, V165, P444, DOI 10.1093/infdis/165.3.444; TOWNSENDCOLES WF, 1953, T ROY SOC TROP MED H, V47, P77, DOI 10.1016/0035-9203(53)90027-3; Wyatt H V, 1986, Dev Biol Stand, V65, P123; WYATT HV, 1990, REV INFECT DIS, V12, P547; WYATT HV, 1984, SOC SCI MED, V19, P911, DOI 10.1016/0277-9536(84)90320-4; WYATT HV, 1985, T ROY SOC TROP MED H, V79, P355, DOI 10.1016/0035-9203(85)90379-7; YANG CF, 1991, VIRUS RES, V20, P159; 1981, INFECT DIS, P35; 1982, B WORLD HEALTH ORGAN, V60, P231; 1956, LANCET, V2, P1223; 1976, B WORLD HEALTH ORGAN, V53, P319; 1993, LOGXACT TURBO USER M; 1989, EXPANDED PROGRAMME I, P35	40	61	61	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					500	506		10.1056/NEJM199502233320804	http://dx.doi.org/10.1056/NEJM199502233320804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830731				2022-12-01	WOS:A1995QH28800004
J	STRUTT, DI; WIERSDORFF, V; MLODZIK, M				STRUTT, DI; WIERSDORFF, V; MLODZIK, M			REGULATION OF FURROW PROGRESSION IN THE DROSOPHILA EYE BY CAMP-DEPENDENT PROTEIN-KINASE-A	NATURE			English	Article							POLARITY GENE HEDGEHOG; DECAPENTAPLEGIC GENE; PATCHED GENE; BETA FAMILY; MELANOGASTER; EXPRESSION; RETINA	THE earliest physical sign of differentiation in the Drosophila retina is the passage of the morphogenetic furrow across the epithelium of the eye disc(1,2). Secreted factors encoded by hedgehog (hh)(3-7) and decapentaplegic (dpp)(8-10) have been implicated in propagation of the furrow(11,12) and the subsequent initiation of photoreceptor differentiation. The morphogenetic furrow initiates at the posterior edge of the third larval instar eye imaginal disc, Its continued progression towards the anterior is believed to depend upon secretion of Hh protein by the differentiating clusters of photoreceptors that emerge posterior to the moving furrow(11,12). This progression is marked by the initiation of expression of the transforming growth factor-beta homologue Dpp in cells entering the furrow anteriorly, and loss of dpp expression in cells emerging posteriorly(16,17). Although the transmembrane protein encoded by the patched gene has been genetically implicated as the Hh receptor(12,18-20), the intercellular signalling pathways involved in these inductive processes remain uncharacterized. Here we show that the catalytic subunit of cyclic AMP-dependent protein kinase A (Pka-C1)(13-15) is required for the correct spatial regulation of dpp expression during eye development. Loss of Pka-C1 function is sufficient to produce an ectopic morphogenetic wave marked by premature ectopic photoreceptor differentiation and non-autonomous propagation of dpp expression. Our results indicate that Pka-C1 lies in a signalling pathway that controls the orderly temporal progression of differentiation across the eye imaginal disc.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Strutt, David/E-6196-2010	Strutt, David/0000-0001-8185-4515; Wiersdorff, Volker/0000-0003-1460-334X				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; FOSTER JL, 1988, J BIOL CHEM, V263, P1676; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; LANE ME, 1993, GENESDEV, V7, P129; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOROK T, 1993, GENETICS, V135, P71; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; XU T, 1993, DEVELOPMENT, V117, P1223	28	116	118	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					705	709		10.1038/373705a0	http://dx.doi.org/10.1038/373705a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854454				2022-12-01	WOS:A1995QH92800056
J	UEHARA, Y; MINOWA, O; MORI, C; SHIOTA, K; KUNO, J; NODA, T; KITAMURA, N				UEHARA, Y; MINOWA, O; MORI, C; SHIOTA, K; KUNO, J; NODA, T; KITAMURA, N			PLACENTAL DEFECT AND EMBRYONIC LETHALITY IN MICE LACKING HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR	NATURE			English	Article							SCATTER FACTOR; MOUSE TROPHOBLAST; MOLECULAR-CLONING; MET PROTOONCOGENE; MESSENGER-RNA; EXPRESSION; RAT; DIFFERENTIATION; IDENTIFICATION; PURIFICATION	HEPATOCYTE growth factor/scatter factor (HGF/SF) functions as a mitogen, motogen and morphogen for a variety of cultured cells(1-7). The genes for HGF/SF and its receptor (the c-met protooncogene product(8)) are expressed in many tissues during the embryonic periods and in the adult(9-14). HGF/SF is thought to mediate a signal exchange between the mesenchyme and epithelia during mouse development(15). To examine the physiological role of HGF/SF, we generated mutant mice with a targeted disruption of the HGF/SF gene. Here we report that homozygous mutant embryos have severely impaired placentas with markedly reduced numbers of labyrinthine trophoblast cells, and die before birth. The growth of trophoblast cells was stimulated by HGF/SF in vitro, and the HCF/SF activity was released by allantois in primary culture of normal but not mutant embryos. These findings suggest that HGF/SF is an essential mediator of allantoic mesenchyme-trophoblastic epithelia interaction required for placental organogenesis.	KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN; CANC INST,DEPT CELL BIOL,TOKYO 170,JAPAN; KYOTO UNIV,SCH MED,DEPT ANAT,KYOTO 606,JAPAN	Kansai Medical University; Japanese Foundation for Cancer Research; Kyoto University			Noda, Tetsuo/B-1667-2016; Minowa, Osamu/AAM-1238-2020					BARLOW PW, 1972, J EMBRYOL EXP MORPH, V27, P447; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DERENZO MF, 1991, ONCOGENE, V6, P1997; GARBISBERKVENS JM, 1987, PHARMACOKINETICS TER, P13; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUNTENER M, 1977, ACTA ANAT, V98, P241; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P95555; PEEL S, 1977, J ANAT, V124, P675; ROSSANT J, 1981, J EMBRYOL EXP MORPH, V62, P217; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; ZARNEGAR R, 1989, CANCER RES, V49, P3314	30	904	936	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					702	705		10.1038/373702a0	http://dx.doi.org/10.1038/373702a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854453				2022-12-01	WOS:A1995QH92800055
J	WEBSTER, MA; MOLLON, JD				WEBSTER, MA; MOLLON, JD			COLOR CONSTANCY INFLUENCED BY CONTRAST ADAPTATION	NATURE			English	Article							MECHANISMS; ILLUMINANT	VISUAL sensitivity is controlled by at least two distinct types of adaptation: light adaptation adjusts sensitivity to the mean luminance and colour in the stimulus(1), and contrast adaptation adjusts sensitivity to the variations in luminance and colour(2-5). Light adaptation is thought to be important in maintaining the perceived colour of objects despite changes in illumination ('colour constancy'), compensating for the mean changes in the light reflected from scenes under different illuminants(6). But for naturalistic colour signals, we show here that changes in an illuminant can also alter colour contrasts in images (how colours are distributed around the mean) enough to alter the state of contrast adaptation. Thus perceived colour under different illuminants may also be noticeably influenced by contrast adaptation.	UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,CAMBRIDGE CB2 3EB,ENGLAND	University of Cambridge	WEBSTER, MA (corresponding author), UNIV NEVADA,DEPT PSYCHOL,RENO,NV 89557, USA.		Mollon, John/C-3520-2009; Mollon, John/U-2631-2019	Mollon, John/0000-0001-8533-033X; Mollon, John/0000-0001-8533-033X; Webster, Michael/0000-0001-8262-7525				AREND LE, 1993, J OPT SOC AM A, V10, P2134, DOI 10.1364/JOSAA.10.002134; ATICK JJ, 1993, VISION RES, V33, P123, DOI 10.1016/0042-6989(93)90065-5; BARLOW HB, 1989, VISION CODING EFFICI, P363; BRAINARD DH, 1992, J OPT SOC AM A, V9, P1433, DOI 10.1364/JOSAA.9.001433; BROWN RO, 1991, INVEST OPHTH VIS SCI, V32, P1214; COHEN J, 1964, PSYCHON SCI, V1, P369, DOI 10.3758/BF03342963; DZMURA M, 1986, J OPT SOC AM A, V3, P1662, DOI 10.1364/JOSAA.3.001662; FLANAGAN P, 1989, Investigative Ophthalmology and Visual Science, V30, P130; GEORGESON M A, 1985, Spatial Vision, V1, P103, DOI 10.1163/156856885X00125; JUDD DB, 1964, J OPT SOC AM, V54, P1031, DOI 10.1364/JOSA.54.001031; KRAUSKOPF J, 1986, VISION RES, V26, P23, DOI 10.1016/0042-6989(86)90068-4; KRAUSKOPF J, 1982, VISION RES, V22, P1123, DOI 10.1016/0042-6989(82)90077-3; MACLEOD DIA, 1979, J OPT SOC AM, V69, P1183, DOI 10.1364/JOSA.69.001183; MACLEOD DJA, 1985, CENTRAL PERIPHERAL M; STILES WS, 1959, P NATL ACAD SCI USA, V45, P100, DOI 10.1073/pnas.45.1.100; VONKRIES J, 1970, FESTSCHRIFT A LUDWIG; WEBSTER MA, 1991, NATURE, V349, P235, DOI 10.1038/349235a0; WEBSTER MA, 1993, J OPT SOC AM A, V10, P1332, DOI 10.1364/JOSAA.10.001332; WEBSTER MA, 1994, VISION RES, V34, P1993, DOI 10.1016/0042-6989(94)90028-0; WORTHEY JA, 1982, J OPT SOC AM, V72, P74, DOI 10.1364/JOSA.72.000074; WORTHEY JA, 1986, J OPT SOC AM A, V3, P1708, DOI 10.1364/JOSAA.3.001708; Yarbus A. L., 1967, EYE MOVEMENTS VISION; ZAIDI Q, 1993, BIOL CYBERN, V69, P415, DOI 10.1007/BF01185413; [No title captured]	24	97	97	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					694	698		10.1038/373694a0	http://dx.doi.org/10.1038/373694a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854451				2022-12-01	WOS:A1995QH92800053
J	XUE, QF; YEUNG, ES				XUE, QF; YEUNG, ES			DIFFERENCES IN THE CHEMICAL-REACTIVITY OF INDIVIDUAL MOLECULES OF AN ENZYME	NATURE			English	Article							CONFORMATIONAL CHANGES; DENATURED PROTEINS; KINETIC ASPECTS	MUCH attention has been focused recently on the detection and physical characterization of individual molecules(1-11). Using such methods to study the chemical properties, such as reactivity, of single molecules offers the potential to investigate how these might vary from molecule to molecule, and for individual molecules as a function of time, The complex structures of biomolecules such as enzymes make them particularly attractive targets for studying how subtle changes or differences at the molecular level might influence chemical reactivity. We have shown previously(12,13) that very small (zeptomole) amounts of enzymes can be studied using a fluorescence microassay; single enzyme molecules have also been detected in oil-dispersed droplets by fluorescence microscopy(14,15). Here we report the observation of reactions of individual molecules of lactate dehydrogenase (LDH-1), which produces NADH from lactate and nicotinamide adenine dinucleotide (NAD(+)), When they are present at very low concentrations in a narrow capillary, each enzyme molecule produces a discrete zone of NADH; these can be manipulated electrophoretically and monitored by fluorescence spectroscopy, We find that the activity of individual electrophoretically pure enzyme molecules can vary by up to a factor of four, and that these activities remain unchanged over a two-hour period. We suggest that the origin of the activity differences may lie in the presence of several stable forms of the enzyme.	IOWA STATE UNIV SCI & TECHNOL,US DOE,AMES LAB,AMES,IA 50011; IOWA STATE UNIV SCI & TECHNOL,DEPT CHEM,AMES,IA 50011	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University								AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; BARNES MD, 1993, ANAL CHEM, V65, P2360, DOI 10.1021/ac00065a032; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; EVERSE J, 1973, ADV ENZYMOL RAMB, V37, P61; HOLBROOK JJ, 1975, ENZYMES, P280; ISHIKAWA M, 1994, JPN J APPL PHYS 1, V33, P1571, DOI 10.1143/JJAP.33.1571; LEVI AS, 1971, J BIOL CHEM, V246, P6409; MILLER KJ, 1993, ANAL CHEM, V65, P3267, DOI 10.1021/ac00070a017; MOERNER WE, 1994, SCIENCE, V285, P46; ORITT M, 1993, J PHYS CHEM-US, V97, P10256; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; Rotman B., 1973, FLUORESCENCE TECHNIQ, P333; SMITH RD, 1994, NATURE, V369, P137, DOI 10.1038/369137a0; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; STRANFORD PE, 1962, JAMA-J AM MED ASSOC, V182, P123; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P798, DOI 10.1021/bi00781a012; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; XUE QF, 1994, ANAL CHEM, V66, P1175, DOI 10.1021/ac00079a036; ZUBAY G, 1993, BIOCHEMISTRY-US, P859	23	293	318	1	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					681	683		10.1038/373681a0	http://dx.doi.org/10.1038/373681a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854448				2022-12-01	WOS:A1995QH92800048
J	LEGALL, JR; LEMESHOW, S; LELEU, G; KLAR, J; HUILLARD, J; RUE, M; TERES, D; ARTIGAS, A				LEGALL, JR; LEMESHOW, S; LELEU, G; KLAR, J; HUILLARD, J; RUE, M; TERES, D; ARTIGAS, A			CUSTOMIZED PROBABILITY-MODELS FOR EARLY SEVERE SEPSIS IN ADULT INTENSIVE-CARE PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPTIC SHOCK; FAILURE; TRIAL	Objective.-To develop customized versions of the Simplified Acute Physiology Score II (SAPS II) and the 24-hour Mortality Probability Model II (MPM II24) to estimate the probability of mortality for intensive care unit patients with early severe sepsis. Design and Setting.-Logistic regression models developed for patients with severe sepsis in a database of adult medical and surgical intensive care units in 12 countries. Patients.-Of 11 458 patients in the intensive care unit for at least 24 hours, 1130 had severe sepsis based on criteria of the American College of Chest Physicians and the Society of Critical Care Medicine (systemic inflammatory response syndrome in response to infection, plus hypotension, hypoperfusion, or multiple organ dysfunction). Results.-In patients with severe sepsis, mortality was higher (48.0% vs 19.6% among other patients) and 28-day survival was lower. The customized SAPS II was well calibrated (P=.92 for the goodness-of-fit test) and discriminated well (area under the receiver operating characteristic [ROC] curve, 0.78). Performance in the validation sample was equally good (P=.85 for the goodness-of-fit test; area under the ROC curve, 0.79). The customized MPM II24 was well calibrated (P=.92 for the goodness-of-fit test) and discriminated well (area under the ROC curve, 0.79). Performance in the validation sample was equally good (P=.52 for the goodness-of-fit test; area under the ROC curve, 0.75). The models are independent of each other; either can be used alone to estimate the probability of mortality of patients with severe sepsis. Conclusions.-Customization provides a simple technique to apply existing models to a subgroup of patients. Accurately assessing the probability of hospital mortality is a useful adjunct for clinical trials.	FAC MED LARIBOISIERE,PARIS,FRANCE; UNIV MASSACHUSETTS,SCH PUBL HLTH,AMHERST,MA 01003; BAYSTATE MED CTR,SPRINGFIELD,MA 01107; HOSP SABADELL,SABADELL,SPAIN	UDICE-French Research Universities; Universite Paris Cite; University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center; Autonomous University of Barcelona; Parc Tauli Hospital Universitari			Rue, Montserrat/B-5663-2009	Rue, Montserrat/0000-0002-7862-9365				[Anonymous], 1992, CRIT CARE MED, V20, P864; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D, 2013, APPL LOGISTIC REGRES; HOSMER DW, 1994, REANIMATION URGENCES, V3, P173; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1987, NEW ENGL J MED, V317, P659	14	136	141	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					644	650		10.1001/jama.273.8.644	http://dx.doi.org/10.1001/jama.273.8.644			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844875				2022-12-01	WOS:A1995QG74800030
J	PUI, CH; BOYETT, JM; HANCOCK, ML; PRATT, CB; MEYER, WH; CRIST, WM				PUI, CH; BOYETT, JM; HANCOCK, ML; PRATT, CB; MEYER, WH; CRIST, WM			OUTCOME OF TREATMENT FOR CHILDHOOD-CANCER IN BLACK AS COMPARED WITH WHITE-CHILDREN - THE ST-JUDE-CHILDRENS-RESEARCH-HOSPITAL EXPERIENCE, 1962 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; BREAST-CANCER; RACIAL-DIFFERENCES; SOCIOECONOMIC-STATUS; SURVIVAL RATES; RACE; WOMEN; PLACE	Objective.-To determine whether there is a racial difference in prognosis among childhood cancers. Design.-An overall (30-year) survival analysis by race was followed by separate studies for ''early'' and ''recent'' treatment eras, defined by time points at which significantly improved outcome was demonstrated for specific tumor types, Stratified analyses were performed to adjust for recognized prognostic features. Setting.-Pediatric oncology research and treatment center. Patients.-The study included 798 black and 4507 white children with newly diagnosed malignancies treated from January 1962 through June 1992. These patients were accepted for treatment regardless of their financial status and were enrolled on disease-specific protocols. Results.-Across the 30-year study period, black children had a significantly poorer rate of survival than white children (P<.,001, log-rank test). In the early treatment era, a significant difference was seen for all forms of cancer combined (P<.001), with 10-year Kaplan-Meier estimates (+/-SE) of 37%+/-3% for black children and 50%+/-1% for white children. This difference largely reflected the poorer prognosis of black children with the most common childhood cancer, acute lymphoblastic leukemia. In the recent treatment era, there were no significant differences in treatment outcome by race for specific disease categories or for all forms of cancer combined, Ten-year survival rates were 67%+/-6% for black children and 66%+/-3% for white children, indicating a significantly greater improvement in the former group. Conclusion.-With equal access to effective contemporary treatment, black children with cancer fare as well as white children when treated with protocol-based therapy at a pediatric oncology research center.	ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, COLL MED, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	PUI, CH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NCI NIH HHS [P01 CA 20180, P30 CA 21765, P01 CA 23099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180, P01CA023099, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; AZIZ H, 1988, AM J CLIN ONCOL-CANC, V11, P166, DOI 10.1097/00000421-198804000-00015; BAIN RP, 1987, AM J OBSTET GYNECOL, V157, P914, DOI 10.1016/S0002-9378(87)80089-3; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; BIRCH JM, 1988, BRIT MED J, V296, P1372, DOI 10.1136/bmj.296.6633.1372; BLATT J, 1992, AM J MED, V93, P57, DOI 10.1016/0002-9343(92)90680-A; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BORING CC, 1992, CA-CANCER J CLIN, V42, P7, DOI 10.3322/canjclin.42.1.7; BRODER S, 1993, STEM CELLS, V1, P3; COX DR, 1968, STATISTICAL ANAL SER, P229; DANSEY RD, 1988, CANCER, V61, P1908, DOI 10.1002/1097-0142(19880501)61:9<1908::AID-CNCR2820610931>3.0.CO;2-N; DAYAL H, 1987, J CHRON DIS, V40, P857, DOI 10.1016/0021-9681(87)90185-8; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; EVANS WE, 1991, SEMIN HEMATOL, V28, P15; FALLETTA JM, 1984, PROG CANCER RES THER, V27, P191; HOWARD J, 1992, CANCER, V69, P2349, DOI 10.1002/1097-0142(19920501)69:9&lt;2349::AID-CNCR2820690925&gt;3.0.CO;2-7; KALWINSKY DK, 1985, LEUKEMIA RES, V9, P817, DOI 10.1016/0145-2126(85)90300-5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kitagawa EM, 1973, DIFFERENTIAL MORTALI, V80, P532; KLINGEMANN HG, 1986, BONE MARROW TRANSPL, V1, P87; KRAMER S, 1984, J CLIN ONCOL, V2, P917, DOI 10.1200/JCO.1984.2.8.917; LENNOX EL, 1979, BRIT MED J, V2, P567, DOI 10.1136/bmj.2.6190.567; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; MANTEL N, 1959, J NATL CANCER I, V22, P719; MEADOWS AT, 1983, CANCER INVEST, V1, P49, DOI 10.3109/07357908309040932; MILLER RW, 1989, PRINCIPLES PRACTICE, P3; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; OWNBY HE, 1985, J NATL CANCER I, V75, P55; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PUI CH, 1993, BLOOD, V82, P343; PUI CH, 1990, BLOOD, V76, P1449; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RAGLAND KE, 1991, AM J EPIDEMIOL, V133, P672; REAMAN GH, 1984, PROG CANCER RES THER, V27, P163; REINTGEN DS, 1982, JAMA-J AM MED ASSOC, V248, P1856, DOI 10.1001/jama.248.15.1856; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SATHER H, 1984, PROG CANCER RES THER, V27, P179; STEINHORN SC, 1986, AM J EPIDEMIOL, V124, P85, DOI 10.1093/oxfordjournals.aje.a114373; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; WALTERS TR, 1972, CANCER, V29, P210, DOI 10.1002/1097-0142(197201)29:1<210::AID-CNCR2820290131>3.0.CO;2-U; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; 1992, PEDIATRICS, V89, P597; 1990, TREATMENT EARLY BREA, P1	46	73	74	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					633	637		10.1001/jama.273.8.633	http://dx.doi.org/10.1001/jama.273.8.633			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844873				2022-12-01	WOS:A1995QG74800028
J	SALLER, DN; LESSER, KB; HARREL, U; ROGERS, BB; OYER, CE				SALLER, DN; LESSER, KB; HARREL, U; ROGERS, BB; OYER, CE			THE CLINICAL UTILITY OF THE PERINATAL AUTOPSY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To evaluate the clinical utility of the perinatal autopsy in determining the cause of a perinatal death. Design.-Retrospective observational survey. Setting.-University-affiliated, private, tertiary care hospital, limited to obstetrics, gynecology, and neonatology. Subjects.-All fetal deaths and neonatal deaths from 1990 and 1991 at Women and Infants Hospital, Providence, RI, were reviewed. Fetal deaths with a gestational age of less than 20 weeks and neonatal deaths occurring more than 48 hours after birth were excluded. Main Outcome Measures.-A clinical medical record review assessed the clinical diagnosis. Pathology records were reviewed independently. The clinical and autopsy diagnoses were compared and categorized as follows: (1) confirm (clinical and autopsy diagnoses concordant); (2) change (clinical and autopsy diagnoses discordant); (3) add (significant unexpected findings noted on the autopsy although the clinical diagnosis was not altered); (4) autopsy inconclusive; (5) autopsy not done or not available. Results.-Of 168 perinatal deaths, an autopsy was not obtained in 26.2% and was inconclusive in 24.2% of cases with an autopsy. Of 94 patients with conclusive autopsies, in 55.3%, the pathologic diagnosis confirmed the clinical diagnosis, and in 44.7%, it changed or significantly added to the clinical diagnosis. Conclusions.-These findings support the clinical relevance of the perinatal autopsy. As few published reports directly address the specific yield of the autopsy among fetal and neonatal deaths, these results may be useful in counseling patients who are considering a perinatal autopsy.	UNIV ROCHESTER,STRONG MEM HOSP,SCH MED,DEPT PEDIAT,ROCHESTER,NY 14642; BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,DEPT OBSTET & GYNECOL,PROVIDENCE,RI; BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,DEPT PATHOL,PROVIDENCE,RI; UNIV ARIZONA,DEPT OBSTET & GYNECOL,TUCSON,AZ; CHILDRENS MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Rochester; Brown University; Women & Infants Hospital Rhode Island; Brown University; Women & Infants Hospital Rhode Island; University of Arizona	SALLER, DN (corresponding author), UNIV ROCHESTER,STRONG MEM HOSP,SCH MED,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,BOX 8668,ROCHESTER,NY 14642, USA.							CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P5; FRETTS RC, 1992, OBSTET GYNECOL, V79, P35; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; LUNDBERG GD, 1994, JAMA-J AM MED ASSOC, V271, P317, DOI 10.1001/jama.1994.03510280079038; MCKUSICK VA, 1992, MENDELIAN INHERITANC, pR21; MEIER PR, 1986, OBSTET GYNECOL, V67, P349; RAO MG, 1990, AM J CLIN PATHOL, V93, P486, DOI 10.1093/ajcp/93.4.486; SHEN-SCHWARZ S, 1989, Pediatric Pathology, V9, P1	9	83	86	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					663	665		10.1001/jama.273.8.663	http://dx.doi.org/10.1001/jama.273.8.663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844878				2022-12-01	WOS:A1995QG74800033
J	TRANSUE, ER				TRANSUE, ER			SHREDS OF A FLOWERED SHIRT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					623	623		10.1001/jama.273.8.623	http://dx.doi.org/10.1001/jama.273.8.623			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844871				2022-12-01	WOS:A1995QG74800026
J	ANTO, JM; SUNYER, J				ANTO, JM; SUNYER, J			NITROGEN-DIOXIDE AND ALLERGIC-ASTHMA - STARTING TO CLARIFY AN OBSCURE ASSOCIATION	LANCET			English	Editorial Material							EXPOSURE				ANTO, JM (corresponding author), UNIV AUTONOMA BARCELONA,INST MUNICIPAL INVEST MED,IMAS,BARCELONA,SPAIN.		Anto, J M/H-2676-2014; Sunyer, Jordi/G-6909-2014	Anto, J M/0000-0002-4736-8529; Sunyer, Jordi/0000-0002-2602-4110				ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; BROUGHT GFJ, 1993, LR941 WARR SPRING LA; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; FOLINSBEE LJ, 1992, TOXICOL IND HEALTH, V8, P273; HARLOS DP, 1988, THESIS HARVARD SCH P; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258, DOI 10.1164/ajrccm/148.5.1258; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X	9	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					402	403		10.1016/S0140-6736(95)90395-X	http://dx.doi.org/10.1016/S0140-6736(95)90395-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853945				2022-12-01	WOS:A1995QG90400003
J	ASHBY, EC; ASHFORD, NS; CAMPBELL, MJ				ASHBY, EC; ASHFORD, NS; CAMPBELL, MJ			POSTURE, BLOOD VELOCITY IN COMMON FEMORAL VEIN, AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM	LANCET			English	Note							COMPRESSION; THROMBOSIS	Might leg elevation and avoidance of poor postures provide better prophylaxis against venous thromboembolism than heparin or mechanical methods? 12 supine subjects tilted in 3 degrees increments from 6 degrees leg-down to 12 degrees leg-up showed linear increase in mean peak blood velocity and reduction in calibre in the common femoral vein (colour-duplex ultrasound). Between horizontal and 6 degrees leg-up, velocity was increased by 17% and diameter reduced by 14%.: A ranking of mean peak velocities in six postures (sitting; standing; trunk raised 35 degrees to legs which were first horizontal and then tilted up 6 degrees; supine, first horizontal then 6 degrees leg-up) showed significant increases in velocity between consecutive positions.	CHICHESTER HOSP,CHICHESTER,W SUSSEX,ENGLAND; UNIV SOUTHAMPTON,DEPT MED STAT,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton								ANDREWS B, 1993, BRIT J SURG, V80, P198, DOI 10.1002/bjs.1800800221; ASHBY EC, 1993, LANCET, V142, P1562; CLAGETT PG, 1988, ANN SURG, V208, P227; COMEROTA AJ, 1992, AM J SURG, V164, P265, DOI 10.1016/S0002-9610(05)81083-9; COMEROTA AJ, 1989, SURGERY, V106, P301; FLANC C, 1969, LANCET, V1, P477; MATHEWS JNS, 1990, BRIT MED J, V300, P230; MONETA GL, 1988, J VASC SURG, V8, P285; NICOLAIDES AN, 1992, 1991 EUR CONS STAT W; 1992, BRIT MED J, V305, P567	10	27	29	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					419	421		10.1016/S0140-6736(95)90402-6	http://dx.doi.org/10.1016/S0140-6736(95)90402-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853951				2022-12-01	WOS:A1995QG90400010
J	DEBERKER, D; IBBOTSON, S; SIMPSON, NB; MATTHEWS, JNS; IDLE, JR; REES, JL				DEBERKER, D; IBBOTSON, S; SIMPSON, NB; MATTHEWS, JNS; IDLE, JR; REES, JL			REDUCED EXPERIMENTAL CONTACT SENSITIVITY IN SQUAMOUS-CELL BUT NOT BASAL-CELL CARCINOMAS OF SKIN	LANCET			English	Note							EXPOSURE; BIOLOGY	Basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) show clinical and epidemiological differences not accounted for by different ultraviolet radiation exposure. We have studied experimentally induced contact sensitivity to dinitrochlorobenzene by measuring increases in skin-fold thickness. Patients (n=37) with squamous tumours had impaired responses compared with controls (33) and patients with BCCs (31) (mean increase 4.5 vs 7.8 and 8.6 mm, respectively; p=0.002). This diminished immunological response may be causally related to the development of SCC. Because glutathione S-transferase (GST) metabolises dinitrochlorobenzene and polymorphisms of GST are associated with multiple skin tumours, variations in GST may underlie these differences.	UNIV NEWCASTLE UPON TYNE,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED STAT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Ibbotson, Sally H/H-7061-2019; Matthews, John N S/H-7502-2013	Ibbotson, Sally H/0000-0001-5685-752X; Matthews, John N S/0000-0003-2559-037X				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; FRIEDMANN PS, 1990, CLIN EXP IMMUNOL, V81, P507; GRANSTEIN RD, 1990, SEMIN DERMATOL, V9, P16; HEAGERTY AHM, 1994, LANCET, V343, P266, DOI 10.1016/S0140-6736(94)91115-0; JONES SM, 1988, CARCINOGENESIS, V9, P395, DOI 10.1093/carcin/9.3.395; KWA RE, 1992, J AM ACAD DERMATOL, V26, P1, DOI 10.1016/0190-9622(92)70001-V; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; REES JL, 1989, BRIT J DERMATOL, V120, P371, DOI 10.1111/j.1365-2133.1989.tb04162.x	9	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					425	426		10.1016/S0140-6736(95)90406-9	http://dx.doi.org/10.1016/S0140-6736(95)90406-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853955				2022-12-01	WOS:A1995QG90400014
J	DEMITRI, MS; POUSSIN, K; BACCARINI, P; PONTISSO, P; DERRICO, A; SIMON, N; GRIGIONI, W; ALBERTI, A; BEAUGRAND, M; PISI, E; BRECHOT, C; PATERLINI, P				DEMITRI, MS; POUSSIN, K; BACCARINI, P; PONTISSO, P; DERRICO, A; SIMON, N; GRIGIONI, W; ALBERTI, A; BEAUGRAND, M; PISI, E; BRECHOT, C; PATERLINI, P			HCV-ASSOCIATED LIVER-CANCER WITHOUT CIRRHOSIS	LANCET			English	Article							HEPATITIS-C VIRUS; POLYMERASE CHAIN-REACTION; B SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; DNA; INTEGRATION; SEQUENCES; GENOMES; DISEASE	Chronic infection with hepatitis C virus (HCV) is regarded as a risk factor for hepatocellular cancer, mostly in patients with liver cirrhosis. We looked for HCV genomes in the livers of patients with hepatocellular cancer who did not have cirrhosis to see whether HCV was directly oncogenic. Cancerous and non-cancerous liver tissue, and serum samples from 19 patients negative for hepatitis B surface antigen were analysed by polymerase chain reaction for the presence of HCV genome, HCV replication, HCV genotyping, and HBV genome. 13 of 19 patients were HCV RNA-positive in cancerous and non-cancerous liver tissue; 8 of 17 tested were anti-HCV positive. Among the 13 HCV RNA-positive patients, 11 had genotype 1b and 2 had genotype 2a. 7 of 13 serum samples were HCV RNA positive. 7 of 19 patients were HBV DNA positive in cancerous and non-cancerous liver tissue, 5 of them anti-HBc positive. 4 patients were both HCV RNA and HBV DNA positive and 3 were both HCV RNA and HBV DNA negative. Our results provide evidence for the association of HCV, mostly genotype 1b, with hepatocellular cancer without the intermediate. step of cirrhosis.	FAC MED NECKER ENFANTS MALAD,INSERM,U370,F-75015 PARIS,FRANCE; UNIV BOLOGNA,DEPT INTERNAL MED,BOLOGNA,ITALY; UNIV BOLOGNA,DEPT PATHOL,BOLOGNA,ITALY; UNIV PADUA,DEPT INTERNAL MED,PADUA,ITALY; AURA,PARIS,FRANCE; HOP VERDIER,DEPT GASTROENTEROL,BONDY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Bologna; University of Bologna; University of Padua; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP			; Foschini, Maria P./A-6306-2016; PONTISSO, PATRIZIA/K-3574-2018	ALBERTI, ALFREDO/0000-0001-9926-2382; Foschini, Maria P./0000-0001-7079-7260; PONTISSO, PATRIZIA/0000-0003-2077-9202				BLUM HE, 1994, HEPATOLOGY, V19, P251, DOI 10.1016/0270-9139(94)90078-7; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; Brouwer J. T., 1993, Journal of Hepatology, V18, pS10; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOMBO M, 1994, PRIMARY LIVER CANC E, P49; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; FERAY C, IN PRESS GASTROENTER; GERBER MA, 1992, AM J PATHOL, V141, P1271; HERR W, 1993, CLIN INVESTIGATOR, V71, P49, DOI 10.1007/BF00210964; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; KATO N, 1993, HEPATOLOGY, V18, P16, DOI 10.1016/0270-9139(93)90500-M; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; MELIA WM, 1984, Q J MED, V211, P391; MIYAMURA T, 1994, PRIMARY LIVER CANC E, P125; NOUSBAUM J, IN PRESS ANN INTERN; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; PATERLINI P, 1990, NEW ENGL J MED, V323, P80, DOI 10.1056/NEJM199007123230202; PATERLINI P, IN PRESS VIRAL HEPAT; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; POZZATO G, 1992, Journal of Hepatology, V16, pS3; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SBOLLI G, 1990, J MED VIROL, V30, P230, DOI 10.1002/jmv.1890300316; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	30	243	248	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					413	415		10.1016/S0140-6736(95)90400-X	http://dx.doi.org/10.1016/S0140-6736(95)90400-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7772123				2022-12-01	WOS:A1995QG90400008
J	FALL, CHD; OSMOND, C; BARKER, DJP; CLARK, PMS; HALES, CN; STIRLING, Y; MEADE, TW				FALL, CHD; OSMOND, C; BARKER, DJP; CLARK, PMS; HALES, CN; STIRLING, Y; MEADE, TW			FETAL AND INFANT GROWTH AND CARDIOVASCULAR RISK-FACTORS IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; ADULT LIFE; HEART-DISEASE; HYPERTENSION; MORTALITY; INUTERO; DEATH	Objective-To examine whether cardiovascular risk factors in women are related to fetal and infant growth. Design-Follow up study of women born 1923-30 whose birth weights and weights at one year were recorded. Setting-Hertfordshire. Subjects-297 women born and still living in East Hertfordshire. Main outcome measures-Plasma glucose and insulin concentrations during a standard oral glucose tolerance test; fasting plasma proinsulin and 32-33 split proinsulin concentrations; blood pressure; fasting serum total, low density lipoprotein and high density lipoprotein cholesterol, triglyceride, and apolipoprotein A I and B concentrations; and plasma fibrinogen and factor VII concentrations. Results-Fasting plasma concentrations of glucose, insulin, and 32-33 split proinsulin fell with increasing birth weight (P=0.04, P-0.002, and P=0.0002 respectively, when current body mass index was allowed for). Glucose and insulin concentrations 120 minutes after an oral glucose load showed similar trends (P=0.03 and P=0.02). Systolic blood pressure, waist:hip ratio, and serum triglyceride concentrations also fell with increasing birth weight (P=0.08, P=0.07, and P=0.07 respectively), while serum high density lipoprotein cholesterol concentrations rose (P=0.04). At each birth weight women who currently had a higher body mass index had higher levels of risk factors. Conclusion-In women, as in men, reduced fetal growth leads to insulin resistance and the associated disorders: raised blood pressure and high serum triglyceride and low serum high density lipoprotein cholesterol concentrations. The highest values of these coronary risk factors occur in people who were small at birth and become obese. In contrast with men, low rates of infant growth did not predict levels of risk factors in women.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; ST BARTHOLOMEWS HOSP,WOLFSON INST PREVENT MED,MRC,EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; Queen Mary University London	FALL, CHD (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				[Anonymous], 1980, CLASSIFICATION OCCUP; Barker D, 1994, MOTHER BABIES DISEAS; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LUCAS A, 1991, CIBA F S, V156; MARTYN CN, IN PRESS BR HEART J; MCKEIGUE PM, 1994, DIABETIC MED S2, V11, pA17; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PHILLIPS DIW, 1994, DIABETIC MED, V11, P286, DOI 10.1111/j.1464-5491.1994.tb00273.x; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/BF00403383	23	353	364	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					428	432		10.1136/bmj.310.6977.428	http://dx.doi.org/10.1136/bmj.310.6977.428			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873947	Green Published			2022-12-01	WOS:A1995QJ24200017
J	FERRARI, S; RIZZOLI, R; CHEVALLEY, T; SLOSMAN, D; EISMAN, JA; BONJOUR, JP				FERRARI, S; RIZZOLI, R; CHEVALLEY, T; SLOSMAN, D; EISMAN, JA; BONJOUR, JP			VITAMIN-D-RECEPTOR-GENE POLYMORPHISMS AND CHANGE IN LUMBAR-SPINE BONE-MINERAL DENSITY	LANCET			English	Note							WOMEN; MASS; DETERMINANTS; CALCIUM; TWIN	Common vitamin-D-receptor (VDR) gene allelic variants predict bone mineral density. We analysed VDR alleles and rate of change of lumbar-spine bone mineral density over 18 months in 72 elderly subjects. 9 BB homozygotes lost bone mineral density but 26 homozygotes for the alternative genotype (bb) did not (mean change -2.3 [SE 1.0] vs 0.9 [0.7]% per year, p<0.05), irrespective of calcium intake. Among 37 heterozygotes (Bb), however, change in bone mineral density correlated with calcium intake (r=035, p<0.03). This association between a marker and rate of bone loss in the elderly suggests that the effect of calcium intake on maintenance of bone mass could relate to VDR gene polymorphisms.	WHO,COLLABORATING CTR OSTEOPOROSIS & BONE DIS,DEPT MED,DIV CLIN PATHOPHYSIOL,GENEVA,SWITZERLAND; UNIV HOSP GENEVA,DEPT RADIOL,DIV NUCL MED,CH-1211 GENEVA,SWITZERLAND	World Health Organization; University of Geneva			Ferrari, Serge/ABD-2730-2020; Chevalley, Thierry/AAQ-1412-2021; Eisman, John A/C-2886-2014	Ferrari, Serge/0000-0002-1372-4417; Chevalley, Thierry/0000-0003-3338-1148; 				CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHEVALLEY T, 1994, OSTEOPOROSIS INT, V4, P245, DOI 10.1007/BF01623348; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DEQUEKER J, 1987, BONE, V8, P207, DOI 10.1016/8756-3282(87)90166-9; Kelly P J, 1990, Osteoporos Int, V1, P56, DOI 10.1007/BF01880417; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476	10	235	240	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					423	424		10.1016/S0140-6736(95)90404-2	http://dx.doi.org/10.1016/S0140-6736(95)90404-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853953				2022-12-01	WOS:A1995QG90400012
J	MADICO, G; GILMAN, RH; CHECKLEY, W; CABRERA, L; KOHLSTADT, I; KACENA, K; DIAZ, JF; BLACK, R				MADICO, G; GILMAN, RH; CHECKLEY, W; CABRERA, L; KOHLSTADT, I; KACENA, K; DIAZ, JF; BLACK, R			COMMUNITY INFECTION RATIO AS AN INDICATOR FOR TUBERCULOSIS-CONTROL	LANCET			English	Article								The epidemiology of tuberculosis remains poorly understood. We investigated the relative importance of within-household and community transmission of infection among children aged 6 months to 14 years living in a Peruvian shanty-town. The prevalence of Mycobacterium tuberculosis exposure among 175 contact children (sharing a household with a person who had confirmed pulmonary tuberculosis) and 382 control children (living in nearby households free of active tuberculosis) was defined as the proportion of children with a positive purified protein derivative (PPD) skin-test. 97 (55%) contact children and 129 (34%) controls were PPD positive. Living in a contact household (odds ratio 1.74, 95% CI 1.11-2.73) and age (1.11, 1.06-1.18) were significant risk factors for PPD positivity. We calculated the community infection ratio (CIR) as the odds ratio of PPD-positive controls to PPD-positive contacts: [GRAPHICS] A low CIR therefore suggests mainly household spread of infection, whereas a high value suggests frequent transmission outside the household. The adjusted odds ratio (for age, sex, within-household correlation, and household size) was 0.40 (95% CI 0.26-0.64), compared with values of 0.18-0.37 in studies elsewhere. Currently recommended tuberculosis control strategies are suitable for areas with low CIRs. Different strategies may be needed for areas, such as that we studied, with high values.	AB PRISMA,LIMA,PERU; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH & BIOSTAT,BALTIMORE,MD 21205	Johns Hopkins University				Madico, Guillermo/0000-0002-8323-8262; Black, Robert/0000-0001-9926-7984; Checkley, William/0000-0003-1106-8812				ASPIN J, 1953, Tubercle, V34, P20, DOI 10.1016/S0041-3879(53)80042-5; Brown K. H., 1981, Nutrition Research, V1, P33, DOI 10.1016/S0271-5317(81)80006-1; CAREY V, 1993, BIOMETRIKA, V80, P517, DOI 10.2307/2337173; COMSTOCK GW, 1967, AM REV RESPIR DIS, V95, P935; DESPREZ R, 1990, PRINCIPLES PRACTICE, P1880; FLEISS JL, 1991, STATISTICAL METHODS, P76; GETCHELL WS, 1992, AM J TROP MED HYG, V47, P721, DOI 10.4269/ajtmh.1992.47.721; GLASSROTH J, 1980, NEW ENGL J MED, V302, P1441, DOI 10.1056/NEJM198006263022603; GRYZBOWSKI S, 1975, B INT UNION TUBERC, V50, P90; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; MENZIES R, 1992, AM REV RESPIR DIS, V145, P621, DOI 10.1164/ajrccm/145.3.621; NARAIN SR, 1966, B WORLD HEALTH ORGAN, V34, P639; QAQISH BF, 1992, BIOMETRICS, V48, P939, DOI 10.2307/2532359; ROSE CE, 1979, AM REV RESPIR DIS, V119, P603; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; STYBLO K, 1989, REV INF DIS S2, V2, pS339; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489	18	44	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					416	419		10.1016/S0140-6736(95)90401-8	http://dx.doi.org/10.1016/S0140-6736(95)90401-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853950				2022-12-01	WOS:A1995QG90400009
J	PAPHASSARANG, C; TOMSON, G; CHOPRAPAWON, C; WEERASURIYA, K				PAPHASSARANG, C; TOMSON, G; CHOPRAPAWON, C; WEERASURIYA, K			THE LAO NATIONAL DRUG POLICY - LESSONS ALONG THE JOURNEY	LANCET			English	Article									KAROLINSKA INST,DEPT INT HLTH & SOCIAL MED,INT HLTH CARE RES UNIT,S-17177 STOCKHOLM,SWEDEN; THAILAND HLTH RES INST,BANGKOK,THAILAND; UNIV COLOMBO,FAC MED,DEPT PHARMACOL,COLOMBO,SRI LANKA; MINIST PUBL HLTH,DEPT FOOD & DRUG,VIANGCHAN,LAOS	Karolinska Institutet; University of Colombo								CHETLEY A, 1994, LANCET, V343, P967; DUMOULIN J, 1994, LAO DRUG DATA BASE; FUNCK B, 1993, CHALLENGE EC REFORMM, P123; Hall P, 1975, CHANGE CHOICE CONFLI; HOGERZEIL HV, 1993, LANCET, V343, P1408; KINTANAR QL, 1992, PRESCRIPTION CHANGE, P32; MANGLA B, 1993, LANCET, V342, P608, DOI 10.1016/0140-6736(93)91424-K; PAPHASSARANG C, 1992, NATIONAL DRUG POLICY; PONGPRADITH S, 1993, DIARRHOEAL DISEASE C; REICH MR, 1994, HLTH POLICY PLANN, V9, P1; ROBLES A, 1992, PRESCRIPTION CHANGE; TOMSON G, 1986, LANCET, V2, P620; TOMSON G, 1992, NAIONAL DRUG POLICY; 1988, GUIDELINES DEV NATIO; 1994, REPORT BIENNIUM 1992; 1993, INVESTING HLTH WORLD; 1993, NATIONAL DRUG POLICY; 1994, LAO SOCIAL INDICATOR; 1992, ETHICAL CRITERIA MED	19	23	23	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					433	435		10.1016/S0140-6736(95)90408-5	http://dx.doi.org/10.1016/S0140-6736(95)90408-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853957				2022-12-01	WOS:A1995QG90400016
J	PAVORD, ID; TATTERSFIELD, AE				PAVORD, ID; TATTERSFIELD, AE			BRONCHOPROTECTIVE ROLE FOR ENDOGENOUS PROSTAGLANDIN E(2)	LANCET			English	Note							INHALED PROSTAGLANDIN-E2; BRONCHIAL REACTIVITY; ASTHMATIC-PATIENTS; INDOMETHACIN; EXERCISE; ASPIRIN; TRANSMISSION; METHACHOLINE; INHIBITION; CHALLENGE	The possibility that impaired production of bronchoprotective factors contributes to the pathogenesis of asthma cannot be excluded. Prostaglandin E(2) (PGE(2)) could be such a factor. It is a dominant cyclo-oxygenase product of airway epithelium and smooth muscle; it has inhibitory effects on inflammatory cells and pathways involved in bronchoconstriction at concentrations known to occur in the airway; inhalation of PGE(2) has considerable bronchoprotective effects in patients with asthma; and manoeuvres that increase or decrease endogenous production of PGE(2) have beneficial and deleterious effects on airway function.			PAVORD, ID (corresponding author), UNIV NOTTINGHAM,CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND.			Pavord, Ian/0000-0002-4288-5973				ALAM R, 1993, AM REV RESPIR DIS, V148, P1066, DOI 10.1164/ajrccm/148.4_Pt_1.1066; BECKETT WS, 1992, CHEST, V102, P775, DOI 10.1378/chest.102.3.775; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822, DOI 10.1164/arrd.1987.135.4.822; CHOUAIB S, 1987, J CLIN INVEST, V80, P333, DOI 10.1172/JCI113077; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; CRAVEN PA, 1982, J PHARMACOL EXP THER, V222, P306; DELAMERE F, 1994, BRIT J PHARMACOL, V111, P983, DOI 10.1111/j.1476-5381.1994.tb14840.x; GARDINER PJ, 1980, PROSTAGLANDINS, V19, P819, DOI 10.1016/0090-6980(80)90116-1; HOLGATE S, 1993, THORAX, V48, P103, DOI 10.1136/thx.48.2.103; ITO I, 1990, PROSTAGLANDINS, V39, P639, DOI 10.1016/0090-6980(90)90024-P; ITO Y, 1981, J PHYSIOL-LONDON, V319, P379, DOI 10.1113/jphysiol.1981.sp013915; LEE TH, 1991, J ALLERGY CLIN IMMUN, V88, P827, DOI 10.1016/0091-6749(91)90237-I; MATHE AA, 1975, AM REV RESPIR DIS, V111, P313; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P678, DOI 10.1016/S0091-6749(87)80165-3; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; OCONNOR BJ, 1994, THORAX, V49, P307, DOI 10.1136/thx.49.4.307; OZAKI T, 1987, J APPL PHYSIOL, V62, P219, DOI 10.1152/jappl.1987.62.1.219; PASARGIKLIAN M, 1977, RESPIRATION, V34, P79, DOI 10.1159/000193780; PASARGIKLIAN M, 1976, ADV PROSTAG THROMB R, V1, P461; PAVORD I, 1994, THORAX, V49, P245, DOI 10.1136/thx.49.3.245; PAVORD I, 1992, THORAX, V47, P895; PAVORD ID, 1994, EUR RESPIR J, V7, P50, DOI 10.1183/09031936.94.07010050; PAVORD ID, 1991, THORAX, V46, P633, DOI 10.1136/thx.46.9.633; PAVORD ID, 1992, THORAX, V47, P797, DOI 10.1136/thx.47.10.797; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; POLOSA R, 1992, THORAX, V47, P853; SWEATMAN WJ, 1968, NATURE, V217, P69, DOI 10.1038/217069a0; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; VERLEDEN GM, 1994, THORAX, V49, P657, DOI 10.1136/thx.49.7.657; 1990, LANCET, V335, P944	33	188	192	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					436	438		10.1016/S0140-6736(95)90409-3	http://dx.doi.org/10.1016/S0140-6736(95)90409-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853958				2022-12-01	WOS:A1995QG90400017
J	PERRY, IJ; BEEVERS, DG; WHINCUP, PH; BAREFORD, D				PERRY, IJ; BEEVERS, DG; WHINCUP, PH; BAREFORD, D			PREDICTORS OF RATIO OF PLACENTAL WEIGHT TO FETAL WEIGHT IN MULTIETHNIC COMMUNITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IRON-DEFICIENCY; ADULT LIFE; HYPERTENSION; PREGNANCY	Objective-To determine whether placental ratio is influenced by maternal ethnic origin, obesity, hypertension, and haematological indices of iron deficiency anaemia. Design-Observational study. Setting-District general hospital in Birmingham. Subjects-692 healthy nulliparous pregnant women, of whom 367 were European, 213 Asian, 99 Afro-Caribbean, and 13 of other or undocumented ethnic origin. Main outcome measures-Placental ratio and maternal body mass index, blood pressure, and haematological indices. Results-Though birth weight and placental weight were lower in Asian women than in other groups, mean placental ratio was similar in Asian (19.5% (SD 3.3%)), European (20.0% (4.0%)), and Afro-Caribbean women (20.4% (5.3%)). Gestational age at birth was the main predictor of placental ratio in the univariate analysis (r=-0.34, P < 0.001) and multivariate analysis. The only other significant predictor of placental ratio in multivariate analysis was maternal body mass index, which was positively associated with placental ratio (r=0.1, P=0.01). Mean (SD) placental ratio was not significantly higher in women who developed gestational hypertension (20.4% (4.5%)) and pre-eclampsia (23.3% (7.3%)) than in normal women (19.8% (3.8%)). No evidence of a relation between placental ratio and first antenatal visit haemoglobin concentration or mean cell volume was detected, and placental ratio was not associated with change in mean cell volume during pregnancy or with third trimester serum ferritin concentration. Conclusions-These data do not support the proposed association between poor maternal nutrition and increased placental ratio. The association between high placental ratio and adult hypertension may be confounded by genetic and environmental factors associated with maternal obesity (and possibly maternal hypertension).	DUDLEY RD GEN HOSP, DEPT MED, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND; DUDLEY RD GEN HOSP, DEPT HAEMATOL, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND		PERRY, IJ (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH, LONDON NW3 2PF, ENGLAND.			Whincup, Peter/0000-0002-5589-4107; Perry, Ivan/0000-0002-4965-9792	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADDISON GM, 1972, J CLIN PATHOL, V25, P326, DOI 10.1136/jcp.25.4.326; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; CHAMBERLAIN G, 1978, BRIT BIRTHS 1970, V2; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; EATON PM, 1984, BR J NUTR, V52, P477; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; ESKENAZI B, 1991, JAMA-J AM MED ASSOC, V266, P237; Fox H, 1988, HDB HYPERTENSION, V10, P16; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; HIMMELMANN A, 1994, J INTERN MED, V235, P347, DOI 10.1111/j.1365-2796.1994.tb01085.x; PERRY IJ, 1993, BRIT MED J, V307, P420, DOI 10.1136/bmj.307.6901.420; PERRY IJ, 1994, BRIT J OBSTET GYNAEC, V101, P587, DOI 10.1111/j.1471-0528.1994.tb13648.x; WHARTON PA, 1984, BRIT J NUTR, V52, P469, DOI 10.1079/BJN19840114; WHINCUP P, 1994, J HUM HYPERTENS, V8, P337; 1989, MINITAG STATISTICAL	17	83	85	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	1995	310	6977					436	439		10.1136/bmj.310.6977.436	http://dx.doi.org/10.1136/bmj.310.6977.436			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873949	Green Published			2022-12-01	WOS:A1995QJ24200019
J	SHARP, D				SHARP, D			WORMS, SPIRALS, FLUKES AS CARCINOGENS	LANCET			English	Editorial Material																		SHARP DW, 1993, SCI WATCH, V4, P5; 1994, IARC MONGRAPHS EVALU, V61; 1994, IARC MONOGRAPHS EVAL, V59	3	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					403	404		10.1016/S0140-6736(95)90396-8	http://dx.doi.org/10.1016/S0140-6736(95)90396-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853946				2022-12-01	WOS:A1995QG90400004
J	STRACHAN, DP; LEON, DA; DODGEON, B				STRACHAN, DP; LEON, DA; DODGEON, B			MORTALITY FROM CARDIOVASCULAR-DISEASE AMONG INTERREGIONAL MIGRANTS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; GEOGRAPHIC VARIATIONS; DEATH RATES; ADULT LIFE; MIGRATION; INFANCY; BRITAIN; STROKE	Objective-To investigate the extent to which geographical variations in mortality from ischaemic heart disease and stroke in Britain are influenced by factors in early life or in adulthood. Design-Longitudinal study of migrants. Subjects-1% sample of residents in England and Wales born before October 1939 and enumerated at the 1971 census (the Office of Population Censuses and Surveys' longitudinal study). Main outcome measure-18221 deaths from ischaemic heart disease and 9899 deaths from stroke during 1971-88 were analysed by areas of residence in 1939 and 1971. These included 2928 deaths from ischaemic heart disease and 1608 deaths from stroke among individuals moving between 14 areas defined by the major conurbations and nine standard administrative regions of England and Wales. Results-The southeast to northwest gradient in mortality from ischaemic heart disease was related significantly to both the 1939 area (chi(2)=6.09, df=1) and area in 1971 (chi(2)=5.05, df=1). Geographical variations in mortality from stroke were related significantly to the 1939 area (chi(2)=4.09, df=1) but the effect of area in 1971 was greater (chi(2)=8.07, df=1). The effect of 1971 area on mortality from stroke was largely due to a lower risk of death from stroke among individuals moving into Greater London compared with migrants to the rest of the South East region (chi(2)=4.54, df=1). Conclusions-Geographical variations in mortality from cardiovascular disease in Britain may be partly determined by genetic factors, environmental exposures, or lifestyle acquired early in life, but the risk of fatal ischaemic heart disease and stroke changes on migration between areas with differing mortality. The low risk of death from stroke associated with residence in Greater London is acquired by individuals who move there.	LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON EC1V 0HB,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; City University London	STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762				BAKER RJ, 1978, GLIM SYSTEM; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARKER DJP, 1987, BMJ-BRIT MED J, V295, P83, DOI 10.1136/bmj.295.6590.83; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1992, BRIT MED J, V305, P1551, DOI 10.1136/bmj.305.6868.1551; Barker DJP, 1992, FETAL INFANT ORIGINS; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BRITTON M, 1990, SERIES DS, V9, P80; ELFORD J, 1989, LANCET, V1, P343; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; FOX AJ, 1982, SERIES LS, V1; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEON DA, 1993, ENVIRON PLANN A, V25, P1441, DOI 10.1068/a251441; MARMOT MG, 1984, LANCET, V1, P1003; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; OSMOND C, 1990, SERIES DS, V9, P96; WILLIAMS DRR, 1979, J EPIDEMIOL COMMUNIT, V39, P199; 1944, NATIONAL REGISTER UK; 1932, REGISTRAR GENERALS 1; 1937, REGISTRAR GENERALS 1; 1935, REGISTRAR GENERALS 1; 1933, REGISTRAR GENERALS 1; 1936, REGISTRAR GENERALS 1; 1934, REGISTRAR GENERALS 1; 1931, REGISTRAR GENERALS 1; 1938, REGISTRAR GENERALS 1; 1975, REORGANISATION LOCAL	29	54	56	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					423	427		10.1136/bmj.310.6977.423	http://dx.doi.org/10.1136/bmj.310.6977.423			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873946	Green Published			2022-12-01	WOS:A1995QJ24200015
J	WINDELER, J; LANGE, S				WINDELER, J; LANGE, S			EVENTS PER PERSON YEAR - A DUBIOUS CONCEPT	BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CLINICAL-TRIALS; FRACTURE RATE; CALCIUM; THERAPY; WOMEN	In 1982 a new measure was introduced in research into osteoporosis and is now used everywhere in the literature. The so called ''fracture rate'' relates the number of fractures (single in some patients, multiple in others) to the cumulative time of observation of all patients. This concept, however, has no sound basis. Counting events instead of patients usually violates basic statistical assumptions and invalidates the use of common statistical tests and estimators. Its clinical interpretation is rather dubious. The use of such a measure impedes the search for valid and clinically meaningful outcome criteria and should be abandoned.	RUHR UNIV BOCHUM,MED INFORMAT & BIOMATH ABT,BOCHUM,GERMANY	Ruhr University Bochum	WINDELER, J (corresponding author), UNIV HEIDELBERG,INST MED BIOMETRIE,NEUENHEIMER FELD 305,D-69120 HEIDELBERG,GERMANY.							ANDERSEN B, 1990, METHODOLOGICAL ERROR, P152; [Anonymous], 1982, EPIDEMIOLOGIC RES; ARMITAGE P, 1987, STATISTICAL METHODS; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; PAK C Y C, 1990, Journal of Bone and Mineral Research, V5, pS149; PALMIERI GMA, 1989, CALCIFIED TISSUE INT, V45, P137, DOI 10.1007/BF02556055; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802; RYAN PJ, 1992, ANN RHEUM DIS, V51, P1063, DOI 10.1136/ard.51.9.1063; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; STORM T, 1990, NEW ENGL J MED, V323, P1210; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	19	68	68	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					454	456		10.1136/bmj.310.6977.454	http://dx.doi.org/10.1136/bmj.310.6977.454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873955	Green Published			2022-12-01	WOS:A1995QJ24200027
J	BUONOMANO, DV; MERZENICH, MM				BUONOMANO, DV; MERZENICH, MM			TEMPORAL INFORMATION TRANSFORMED INTO A SPATIAL CODE BY A NEURAL-NETWORK WITH REALISTIC PROPERTIES	SCIENCE			English	Article							RAT HIPPOCAMPUS; PAIRED-PULSE; DISCRIMINATION; FACILITATION; COMPUTATION; INVITRO; CORTEX; TIME; CA1	Neurons exhibit a wide range of properties in addition to postsynaptic potential (PSP) summation and spike generation. Although other neuronal properties such as paired-pulse facilitation (PPF) and slow PSPs are well characterized, their role in information processing remains unclear. It is possible that these properties contribute to temporal processing in the range of hundreds of milliseconds, a range relevant to most complex sensory processing. A continuous-time neural network model based on integrate-and-fire elements that incorporate PPF and slow inhibitory postsynaptic potentials (IPSPs) was developed here. The time constants of the PPF and IPSPs were estimated from empirical data and were identical and constant for all elements in the circuit. When these elements were incorporated into a circuit inspired by neocortical connectivity, the network was able to discriminate different temporal patterns. Generalization emerged spontaneously. These results demonstrate that known time-dependent neuronal properties enable a network to transform temporal information into a spatial code in a self-organizing manner-that is, with no need to assume a spectrum of time delays or to custom-design the circuit.			BUONOMANO, DV (corresponding author), UNIV CALIF SAN FRANCISCO, KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA.				NIMH NIH HHS [F32 MH10431] Funding Source: Medline; NINDS NIH HHS [NS-10414] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH010431] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anderson J.A., 1988, NEUROCOMPUTING; ANDERSON JA, 1990, NEUROCOMPUTING, V2; ANTON PS, 1991, BIOL CYBERN, V65, P407, DOI 10.1007/BF00216975; Braitenberg V, 1967, Prog Brain Res, V25, P334; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUONOMANO DV, 1994, NEURAL COMPUT, V6, P38, DOI 10.1162/neco.1994.6.1.38; CARR CE, 1993, ANNU REV NEUROSCI, V16, P223, DOI 10.1146/annurev.ne.16.030193.001255; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; DOUGLAS RJ, 1990, J PHYSIOL-LONDON, V40, P735; GIBBON J, 1984, ANN NY ACAD SCI, V423, P52, DOI 10.1111/j.1749-6632.1984.tb23417.x; GROSSBERG S, 1989, NEURAL NETWORKS, V2, P79, DOI 10.1016/0893-6080(89)90026-9; Margoliash D., 1983, J NEUROSCI, V3, P133; MASON A, 1991, J NEUROSCI, V11, P72; MCCORMICK DA, 1989, J NEUROPHYSIOL, V62, P1018, DOI 10.1152/jn.1989.62.5.1018; MCCORMICK DA, 1990, SYNAPTIC ORG BRAIN, P33; MOORE JW, 1989, BIOL CYBERN, V62, P17, DOI 10.1007/BF00217657; NATHAN T, 1991, J NEUROPHYSIOL, V66, P1704, DOI 10.1152/jn.1991.66.5.1704; OGDEN G, 1978, PSYCHOL REV, V85, P172; Rumelhart D., 1986, PARALLEL DISTRIBUTED; SULLIVAN WE, 1982, J NEUROPHYSIOL, V48, P1033, DOI 10.1152/jn.1982.48.4.1033; Swadlow H. A., 1993, Society for Neuroscience Abstracts, V19, P1704; TALLAL P, 1993, ANN NY ACAD SCI, V682; TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896; WELKER E, 1993, EUR J NEUROSCI, V5, P691, DOI 10.1111/j.1460-9568.1993.tb00534.x; WOOD CC, 1976, J ACOUST SOC AM, V60, P1381, DOI 10.1121/1.381231; WORGOTTER F, 1991, J NEUROSCI, V11, P1959; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	27	320	322	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1028	1030		10.1126/science.7863330	http://dx.doi.org/10.1126/science.7863330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863330				2022-12-01	WOS:A1995QG99000040
J	DAVIS, JG; OBERHOLTZER, JC; BURNS, FR; GREENE, MI				DAVIS, JG; OBERHOLTZER, JC; BURNS, FR; GREENE, MI			MOLECULAR-CLONING AND CHARACTERIZATION OF AN INNER EAR-SPECIFIC STRUCTURAL PROTEIN	SCIENCE			English	Article							TRIPLE-HELICAL DOMAINS; X COLLAGEN GENE; TECTORIAL MEMBRANE; HAIR-CELLS; MONOCLONAL-ANTIBODIES; OTOLITHIC MEMBRANE; V COLLAGEN; LOCALIZATION; ORGANIZATION; COCHLEA	Molecular biological studies of the mammalian inner ear have been limited by the relatively small size of the sensory endorgans contained within. The saccular otolithic organ in teleostian fish is structurally similar to its mammalian counterpart but can contain an order of magnitude more sensory cells. The prospect of the evolutionary conservation of proteins utilized in the vertebrate inner ear and the relative abundance of teleostian saccular sensory tissue made this an attractive system for molecular biological studies. A complementary DNA obtained by differential screening of a saccular complementary DNA library was identified that encodes an inner ear-specific collagen molecule.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DIV NEUROPATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Burns, Frank/0000-0001-9528-4808	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000069] Funding Source: NIH RePORTER; NIDCD NIH HHS [K08-DC00069] Funding Source: Medline; NINDS NIH HHS [5 T32 NS07064-13] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIGES M, 1983, ACTA OTO-LARYNGOL, V95, P522, DOI 10.3109/00016488309139436; CORWIN JT, 1981, J COMP NEUROL, V201, P541, DOI 10.1002/cne.902010406; CORWIN JT, 1991, ANNU REV NEUROSCI, V14, P301, DOI 10.1146/annurev.neuro.14.1.301; DAVIS JG, 1994, THESIS U PENNSYLVANI; DOHLMAN GF, 1960, NEURAL MECHANISMS AU, P258; DRESCHER DG, 1989, BRAIN RES, V485, P225, DOI 10.1016/0006-8993(89)90565-9; GILLESPIE PG, 1991, J CELL BIOL, V112, P625, DOI 10.1083/jcb.112.4.625; GOODYEAR R, 1994, HEARING RES, V80, P93, DOI 10.1016/0378-5955(94)90013-2; HASKO JA, 1988, HEARING RES, V35, P21, DOI 10.1016/0378-5955(88)90037-8; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; KACHAR B, 1990, HEARING RES, V45, P179, DOI 10.1016/0378-5955(90)90119-A; KAWAMATA S, 1993, ACTA OTOLARYNGOL S S, V504, P30; KHAN KM, 1990, HEARING RES, V43, P149, DOI 10.1016/0378-5955(90)90224-D; KILLICK R, 1992, HEARING RES, V64, P21, DOI 10.1016/0378-5955(92)90165-J; KILLICK R, 1994, MAY MECH SENS REG C; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Lewis E. R., 1985, VERTEBRATE INNER EAR; Lim D J, 1973, Adv Otorhinolaryngol, V19, P35; Lim D J, 1973, Ann Otol Rhinol Laryngol, V82, P23; LIM DJ, 1990, ACTA OTO-LARYNGOL, V110, P224, DOI 10.3109/00016489009122541; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; OBERHOLTZER JC, 1986, HEARING RES, V23, P161, DOI 10.1016/0378-5955(86)90013-4; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; Platt C., 1981, HEARING SOUND COMMUN; POPPER AN, 1984, HEARING RES, V15, P133, DOI 10.1016/0378-5955(84)90044-3; POPPER AN, 1993, BRAIN BEHAV EVOLUT, V41, P14, DOI 10.1159/000113821; PRIETO JJ, 1991, HEARING RES, V54, P59, DOI 10.1016/0378-5955(91)90136-W; PRIETO JJ, 1990, HEARING RES, V45, P51, DOI 10.1016/0378-5955(90)90182-O; REID KBM, 1990, IMMUNOL TODAY, V11, P387, DOI 10.1016/0167-5699(90)90150-8; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; RICHARDSON GP, 1987, HEARING RES, V25, P45, DOI 10.1016/0378-5955(87)90078-5; SAWADA H, 1984, EUR J CELL BIOL, V35, P226; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SCHMID TM, 1984, J ULTRA MOL STRUCT R, V86, P186, DOI 10.1016/S0022-5320(84)80057-X; SHEPHERD GMG, 1989, P NATL ACAD SCI USA, V86, P4973, DOI 10.1073/pnas.86.13.4973; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SLEPECKY NB, 1992, ACTA OTO-LARYNGOL, V112, P611, DOI 10.3109/00016489209137449; SLEPECKY NB, 1992, CELL TISSUE RES, V267, P413, DOI 10.1007/BF00319363; SOKOLOWSKI BHA, 1986, SCANNING ELECTRON MI, V4, P1635; SPRINGER J, 1991, J HISTOCHEM CYTOCHEM, V39, P23; STEEL K, 1980, ACTA OTO-LARYNGOL, V89, P27, DOI 10.3109/00016488009127104; STEEL KP, 1983, HEARING RES, V9, P327, DOI 10.1016/0378-5955(83)90035-7; SUMMERS TA, 1988, J BIOL CHEM, V263, P581; TAKUMIDA M, 1992, ACTA OTO-LARYNGOL, V112, P643, DOI 10.3109/00016489209137454; THALMANN I, 1987, LARYNGOSCOPE, V97, P357; THALMANN I, 1980, ARCH OTO-RHINO-LARYN, V226, P123, DOI 10.1007/BF00455126; TILNEY MS, 1989, J CELL BIOL, V109, P1711, DOI 10.1083/jcb.109.4.1711; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P1602; ZAJIC G, 1991, HEARING RES, V52, P59, DOI 10.1016/0378-5955(91)90187-E	57	67	69	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1031	1034		10.1126/science.7863331	http://dx.doi.org/10.1126/science.7863331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863331				2022-12-01	WOS:A1995QG99000041
J	HALEVY, O; NOVITCH, BG; SPICER, DB; SKAPEK, SX; RHEE, J; HANNON, GJ; BEACH, D; LASSAR, AB				HALEVY, O; NOVITCH, BG; SPICER, DB; SKAPEK, SX; RHEE, J; HANNON, GJ; BEACH, D; LASSAR, AB			CORRELATION OF TERMINAL CELL-CYCLE ARREST OF SKELETAL-MUSCLE WITH INDUCTION OF P21 BY MYOD	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; MYOGENIC DIFFERENTIATION; DEPENDENT KINASES; PROTEIN; EXPRESSION; E2F; P53; SUPPRESSION; ASSOCIATION; INHIBITION	Skeletal muscle differentiation entails the coordination of muscle-specific gene expression and terminal withdrawal from the cell cycle. This cell cycle arrest in the G(0) phase requires the retinoblastoma tumor suppressor protein (Rb). The function of Rb is negatively regulated by cyclin-dependent kinases (Cdks), which are controlled by Cdk inhibitors. Expression of MyoD, a skeletal muscle-specific transcriptional regulator, activated the expression of the Cdk inhibitor p21 during differentiation of murine myocytes and in nonmyogenic cells. MyoD-mediated induction of p21 did not require the tumor suppressor protein p53 and correlated with cell cycle withdrawal. Thus, MyoD may induce terminal cell cycle arrest during skeletal muscle differentiation by increasing the expression of p21.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PEDIAT HEMATOL ONCOL,BOSTON,MA 02115; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute			Hannon, Gregory/AAB-3568-2019; Rhee, James/V-9973-2019	Novitch, Bennett/0000-0002-2696-3708	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008214] Funding Source: NIH RePORTER; NIAMS NIH HHS [F32ARO8214-01A1] Funding Source: Medline; NICHD NIH HHS [N01-HD-6-2915] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CLEGG CH, 1987, J CELL BIOL, V105, P937, DOI 10.1083/jcb.105.2.937; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COPPOLA JA, 1990, ONCOGENE, V5, P1731; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DOTTO P, COMMUNICATION; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; NEVINS JR, 1992, SCIENCE, V258, P424; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOVITCH BG, UNPUB; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VOGELSTEIN B, COMMUNICATION; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	49	1090	1102	0	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1018	1021		10.1126/science.7863327	http://dx.doi.org/10.1126/science.7863327			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863327				2022-12-01	WOS:A1995QG99000037
J	LINTON, MF; ATKINSON, JB; FAZIO, S				LINTON, MF; ATKINSON, JB; FAZIO, S			PREVENTION OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE BY BONE-MARROW TRANSPLANTATION	SCIENCE			English	Article							HERITABLE HYPERLIPIDEMIC RABBITS; III HYPERLIPOPROTEINEMIA; LIVER-TRANSPLANTATION; DENSITY-LIPOPROTEIN; PLASMA-LIPOPROTEINS; MOUSE MACROPHAGES; APOPROTEIN-E; CELLS; HYPERCHOLESTEROLEMIA; CHOLESTEROL	Apolipoprotein E (apoE) deficiency causes severe hyperlipidemia and atherosclerosis in humans and in gene-targeted mice. Although the majority of apoE in plasma is of hepatic origin, apoE is synthesized by a variety of cell types, including macrophages. Because macrophages derive from hematopoietic cells, bone marrow transplantation was used to examine the potential of apoE synthesized by bone marrow-derived cells to correct the hyperlipidemia and atherosclerosis caused by apoE deficiency. After transplantation of bone marrow from mice with the normal apoE gene into apoE-deficient mice, apoE was detected in serum and promoted clearance of lipoproteins and normalization of serum cholesterol levels. ApoE-deficient mice given transplants of normal bone marrow showed virtually complete protection from diet-induced atherosclerosis.	VANDERBILT UNIV,MED CTR N,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232	Vanderbilt University	LINTON, MF (corresponding author), VANDERBILT UNIV,MED CTR N,SCH MED,DEPT MED,DIV ENDOCRINOL,ROOM AA 4206,NASHVILLE,TN 37232, USA.				NHLBI NIH HHS [HL-02925] Funding Source: Medline; NIDDK NIH HHS [DK-26657-15] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BASU SK, 1982, J BIOL CHEM, V257, P9788; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BRUNSTETTER MA, 1971, ARCH INTERN MED, V127, P1064, DOI 10.1001/archinte.127.6.1064; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; FAZIO S, 1993, TRENDS CARDIOVAS MED, V3, P191, DOI 10.1016/1050-1738(93)90005-Q; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; KERR WJ, COMMUNICATION; KLEIN J, 1983, IMMUNOGENETICS, V17, P553, DOI 10.1007/BF00366126; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1994, CIRCULATION, V90, P133; LINTON MF, UNPUB; LONGO DL, 1980, J EXP MED, V151, P1452, DOI 10.1084/jem.151.6.1452; LONGO DL, 1983, J IMMUNOL, V130, P2525; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PARADIS K, 1990, J PEDIATR GASTR NUTR, V11, P525, DOI 10.1097/00005176-199011000-00014; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; THIELE DL, 1989, J CLIN INVEST, V84, P1947, DOI 10.1172/JCI114383; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; YAMADA N, 1992, J CLIN INVEST, V89, P706, DOI 10.1172/JCI115639; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	37	399	418	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1034	1037		10.1126/science.7863332	http://dx.doi.org/10.1126/science.7863332			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863332				2022-12-01	WOS:A1995QG99000042
J	MALNATI, MS; PERUZZI, M; PARKER, KC; BIDDISON, WE; CICCONE, E; MORETTA, A; LONG, EO				MALNATI, MS; PERUZZI, M; PARKER, KC; BIDDISON, WE; CICCONE, E; MORETTA, A; LONG, EO			PEPTIDE SPECIFICITY IN THE RECOGNITION OF MHC CLASS-I BY NATURAL-KILLER-CELL CLONES	SCIENCE			English	Article							VIRUS-INFECTED CELLS; COMPLEX CLASS-I; NK CLONES; HLA-C; MOLECULES; BINDING; HLA-B27; LYSIS; SELF; BETA-2-MICROGLOBULIN	Recognition by natural killer (NK) cells of major histocompatibility complex (MHC) class I molecules on target cells inhibits NK-mediated lysis. Here, inhibition of NK clones by HLA-B*2705 molecules mutated at single amino acids in the peptide binding site varied among HLA-B*2705-specific NK clones. In addition, a subset of such NK clones was inhibited by only one of several self peptides loaded onto HLA-B*2705 molecules expressed in peptide transporter-deficient cells, showing that recognition was peptide-specific. These data demonstrate that specific self peptides, complexed with MHC class I, provide protection from NK-mediated lysis.	NIAID,IMMUNOGENET LAB,ROCKVILLE,MD 20852; NIAID,MOLEC STRUCT LAB,ROCKVILLE,MD 20852; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV GENOA,IST ISTOL & EMBRIOL GEN,I-16132 GENOA,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Genoa; IRCCS AOU San Martino IST; University of Genoa			Long, Eric O/G-5475-2011; Malnati, Mauro/AAN-4207-2020	Long, Eric O/0000-0002-7793-3728; Parker, Kenneth/0000-0002-6282-2478; Malnati, mauro/0000-0001-5355-1680				ANDERSON KS, 1993, J IMMUNOL, V151, P3407; BELLONE G, 1993, J EXP MED, V177, P1117, DOI 10.1084/jem.177.4.1117; CARBONE E, 1993, EUR J IMMUNOL, V23, P1752, DOI 10.1002/eji.1830230803; CARRENO BM, 1992, MOL IMMUNOL, V29, P1131, DOI 10.1016/0161-5890(92)90046-Z; CARRENO BM, 1993, INT IMMUNOL, V5, P353, DOI 10.1093/intimm/5.4.353; CHADWICK BS, 1992, J IMMUNOL, V149, P3150; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; CICCONE E, 1994, EUR J IMMUNOL, V24, P1003, DOI 10.1002/eji.1830240434; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; DIBRINO M, 1994, J IMMUNOL, V152, P620; DIBRINO M, 1994, J BIOL CHEM, V269, P32426; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KAUFMAN DS, 1992, P NATL ACAD SCI USA, V89, P8337, DOI 10.1073/pnas.89.17.8337; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; LJUNGGREN HG, 1994, P NATL ACAD SCI USA, V91, P6520, DOI 10.1073/pnas.91.14.6520; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MALNATI MS, 1993, J EXP MED, V178, P961, DOI 10.1084/jem.178.3.961; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; PARKER KC, 1994, BIOCHEMISTRY-US, V33, P7736, DOI 10.1021/bi00190a029; PARKER KC, 1992, J IMMUNOL, V149, P1896; STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; STORKUS WJ, 1992, J IMMUNOL, V149, P1185; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	31	282	288	1	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1016	1018		10.1126/science.7863326	http://dx.doi.org/10.1126/science.7863326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863326				2022-12-01	WOS:A1995QG99000036
J	PARKER, SB; EICHELE, G; ZHANG, PM; RAWLS, A; SANDS, AT; BRADLEY, A; OLSON, EN; HARPER, JW; ELLEDGE, SJ				PARKER, SB; EICHELE, G; ZHANG, PM; RAWLS, A; SANDS, AT; BRADLEY, A; OLSON, EN; HARPER, JW; ELLEDGE, SJ			P53-INDEPENDENT EXPRESSION OF P21(CIP)1 IN MUSCLE AND OTHER TERMINALLY DIFFERENTIATING CELLS	SCIENCE			English	Article							CYCLIN-DEPENDENT KINASES; GENE MYF-5; PROTEIN; MYOD; MICE; FIBROBLASTS; P53; PROLIFERATION; NEUROGENESIS; INACTIVATION	Terminal differentiation is coupled to withdrawal from the cell cycle. The cyclin-dependent kinase inhibitor (CKI) p21(Cip1) is transcriptionally regulated by p53 and can induce growth arrest. CKIs are therefore potential mediators of developmental control of cell proliferation. The expression pattern of mouse p21 correlated with terminal differentiation of multiple cell lineages including skeletal muscle, cartilage, skin, and nasal epithelium in a p53-independent manner. Although the muscle-specific transcription factor MyoD is sufficient to activate p21 expression in 10T1/2 cells, p21 was expressed in myogenic cells of mice lacking the genes encoding MyoD and myogenin, demonstrating that p21 expression does not require these transcription factors. The p21 protein may function during development as an inducible growth inhibitor that contributes to cell cycle exit and differentiation.	BAYLOR COLL MED,HOWARD HUGHES MED INST,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT HUMAN & MOLEC GENET,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center				Harper, Jeffrey/0000-0002-6944-7236; Bradley, Allan/0000-0002-2349-8839	NIAMS NIH HHS [AR40339, AR39849] Funding Source: Medline; NIA NIH HHS [AG-11085] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039849, R01AR040339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRENNAN T, 1990, J CELL BIOL, V11, P929; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHRIST B, 1983, ANAT EMBRYOL, V166, P87, DOI 10.1007/BF00317946; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EDMONDSON D, 1989, GENE DEV, V3, P28; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDIERY WS, 1994, CANCER RES, V54, P1169; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P874; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; KAEHN K, 1988, ANAT EMBRYOL, V177, P191, DOI 10.1007/BF00321131; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LI Y, 1994, ONCOGENE, V9, P2261; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MICHIELI P, 1994, CANCER RES, V54, P3391; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAWLS A, UNPUB; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V344, P303; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang P. X., UNPUB	53	1052	1067	1	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1024	1027		10.1126/science.7863329	http://dx.doi.org/10.1126/science.7863329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863329				2022-12-01	WOS:A1995QG99000039
J	SKAPEK, SX; RHEE, J; SPICER, DB; LASSAR, AB				SKAPEK, SX; RHEE, J; SPICER, DB; LASSAR, AB			INHIBITION OF MYOGENIC DIFFERENTIATION IN PROLIFERATING MYOBLASTS BY CYCLIN D1-DEPENDENT KINASE	SCIENCE			English	Article							RETINOBLASTOMA PROTEIN; EXPRESSION; MUSCLE; P21	Although the myogenic regulator MyoD is expressed in proliferating myoblasts, differentiation of these cells is limited to the G(0) phase of the cell cycle. Forced expression of cyclin D1, but not cyclins A, B, or E, inhibited the ability of MyoD to transactivate muscle-specific genes and correlated with phosphorylation of MyoD. Transfection of myoblasts with cyclin-dependent kinase (Cdk) inhibitors p21 and p16 augmented muscle-specific gene expression in cells maintained in high concentrations of serum, suggesting that an active cyclin-Cdk complex suppresses MyoD function in proliferating cells.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PEDIAT HEMATOL ONCOL,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute			Rhee, James/V-9973-2019		NIAMS NIH HHS [1F32AR08214-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008214] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; KATO J, 1993, GENE DEV, V7, P331; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NODA A, 1994, EXP CELL RES, V211, P98; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SKAPEK SX, UNPUB; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	33	470	471	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1022	1024		10.1126/science.7863328	http://dx.doi.org/10.1126/science.7863328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863328				2022-12-01	WOS:A1995QG99000038
J	SPENCE, RA; KATI, WM; ANDERSON, KS; JOHNSON, KA				SPENCE, RA; KATI, WM; ANDERSON, KS; JOHNSON, KA			MECHANISM OF INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY NONNUCLEOSIDE INHIBITORS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PYRIDINONE DERIVATIVES; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; ZIDOVUDINE AZT; BINDING-SITE; AIDS VIRUS; TYPE-1; DNA	The mechanism of inhibition of HIV-1 reverse transcriptase by three nonnucleoside inhibitors is described. Nevirapine, O-TIBO, and Cl-TIBO each bind to a hydrophobic pocket in the enzyme-DNA complex close to the active site catalytic residues. Pre-steady-state kinetic analysis was used to establish the mechanism of inhibition by these noncompetitive inhibitors. Analysis of the pre-steady-state burst of DNA polymerization indicated that inhibitors blocked the chemical reaction, but did not interfere with nucleotide binding or the nucleotide-induced conformational change. Rather, in the presence of saturating concentrations of the inhibitors, the nucleoside triphosphate bound tightly (K-d, 100 nM), but nonproductively. The data suggest that an inhibitor combining the functionalities of a nonnucleoside inhibitor and a nucleotide analog could bind very lightly and specifically to reverse transcriptase and could be effective in the treatment of AIDS.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; ABBOTT LABS, DEPT ANTIINFECT RES, ABBOTT PK, IL 60064 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Abbott Laboratories; Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613, R01GM049551] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM084741, GM44613, GM49551] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119; ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; CARROLL SS, 1993, J BIOL CHEM, V268, P276; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P4110; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSTON L, 1992, INT J SOCIOL LAW, V20, P1; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MELLORS JW, 1993, MOL PHARMACOL, V43, P11; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MULLER B, 1989, J BIOL CHEM, V264, P13975; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; RITTINGER K, UNPUB; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TAYLOR PB, 1994, J BIOL CHEM, V269, P6325; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106	47	426	445	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	1995	267	5200					988	993		10.1126/science.7532321	http://dx.doi.org/10.1126/science.7532321			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7532321	Green Accepted			2022-12-01	WOS:A1995QG99000028
J	ALBEROLAILA, J; FORBUSH, KA; SEGER, R; KREBS, EG; PERLMUTTER, RM				ALBEROLAILA, J; FORBUSH, KA; SEGER, R; KREBS, EG; PERLMUTTER, RM			SELECTIVE REQUIREMENT FOR MAP KINASE ACTIVATION IN THYMOCYTE DIFFERENTIATION	NATURE			English	Article							T-CELL ACTIVATION; EXPRESSION; INVIVO; MICE	ENGAGEMENT of the T-cell receptor (TCR) with cognate ligands provokes different outcomes depending on the developmental stage of the T cell and on the properties of the ligand. In immature thymocytes TCR stimulation may result in maturation (positive selection) or death (negative selection), whereas in mature T cells it may induce proliferation, death or unresponsiveness(1-5). To investigate the different signals involved in these processes, we have analysed the role of the MAP kinase (MAPK) cascade, which is required for growth-factor-stimulated replication and for differentiation in other cell types(6-9), by expressing a catalytically inactive form of MAPK kinase (MEK-1) in thymocytes, thereby blocking MAPK activation, We find that positive selection of these cells is inhibited but that negative selection and TCR-induced proliferation are unaffected. Our results indicate that the intracellular signals regulating lineage commitment in T cells parallel those in photoreceptor cell specification in Drosophila(10) and vulval cell differentiation in Caenorhabditis elegans(11), suggesting that general rules for cell-type specification could apply among all metazoans.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	ALBEROLAILA, J (corresponding author), UNIV WASHINGTON,DEPT IMMUNOL,SL-15,SEATTLE,WA 98195, USA.			alberola-ila, Jose/0000-0003-2439-553X				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGERTON M, 1990, INT IMMUNOL, V2, P501, DOI 10.1093/intimm/2.6.501; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1992, J BIOL CHEM, V267, P25628; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; VONBOEHMER H, 1991, J EXP MED, V174, P1001, DOI 10.1084/jem.174.5.1001; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	29	360	362	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					620	623		10.1038/373620a0	http://dx.doi.org/10.1038/373620a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854419				2022-12-01	WOS:A1995QG99700056
J	BRADLEY, DC; QIAN, N; ANDERSEN, RA				BRADLEY, DC; QIAN, N; ANDERSEN, RA			INTEGRATION OF MOTION AND STEREOPSIS IN MIDDLE TEMPORAL CORTICAL AREA OF MACAQUES	NATURE			English	Article							VISUAL AREA; FUNCTIONAL-PROPERTIES; NEURONS; MONKEY; DIRECTION; SELECTIVITY; ORIENTATION; SENSITIVITY; PERCEPTION; DISPARITY	THE primate visual system incorporates a highly specialized subsystem for the analysis of motion in the visual field(1-6). A key element of this subsystem is the middle temporal (MT) cortical area, which contains a majority of direction-selective neurons(1-3). MT neurons are also selective for binocular disparity (depth), which is perplexing given that they are not sensitive to motion through depth(7). What is the role of disparity in MT? Our data suggest an important link between disparity and transparent motion detection. Motion signals in different directions tend to inhibit each other within a given MT receptive field(8). This inhibition has an averaging effect which minimizes MT responses to random motion signals created by light intensity changes and other non-motion stimuli (motion noise)9. But, in the absence of disparity cues, inhibition may also occur between surfaces moving in different directions through the same part of the visual field (transparent motion), thus impairing the detection of either surface. Here we show that inhibition in MT occurs mainly between motion signals with similar disparities. Transparent surface movements at different depths are thus represented independently in MT (that is, without inhibiting each other) whereas spurious motion signals from a given surface tend to cancel out. To our knowledge, these results provide the first evidence for a functional integration of motion and disparity in MT.			BRADLEY, DC (corresponding author), CALTECH,DIV BIOL 21676,PASADENA,CA 91125, USA.							ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ALLMAN JM, 1971, BRAIN RES, V31, P84; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; LINIDSEY DT, 1994, INVEST OPHTH VIS SCI, V35, P1389; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MATHER G, 1983, Q J EXP PSYCHOL-A, V35, P513, DOI 10.1080/14640748308402485; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1148, DOI 10.1152/jn.1983.49.5.1148; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; QIAN N, 1994, J NEUROSCI, V14, P7367; QIAN N, 1994, J NEUROSCI, V14, P7357; ROY JP, 1992, J NEUROSCI, V12, P2478; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; SNOWDEN RJ, 1989, J OPT SOC AM A, V6, P1096, DOI 10.1364/JOSAA.6.001096; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679	19	181	182	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					609	611		10.1038/373609a0	http://dx.doi.org/10.1038/373609a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854417				2022-12-01	WOS:A1995QG99700053
J	BRENNAN, JA; MAO, L; HRUBAN, RH; BOYLE, JO; EBY, YJ; KOCH, WM; GOODMAN, SN; SIDRANSKY, D				BRENNAN, JA; MAO, L; HRUBAN, RH; BOYLE, JO; EBY, YJ; KOCH, WM; GOODMAN, SN; SIDRANSKY, D			MOLECULAR ASSESSMENT OF HISTOPATHOLOGICAL STAGING IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPH-NODE INVOLVEMENT; PROGNOSTIC FACTORS; ORAL CAVITY; POSITIVE MARGINS; GENE-MUTATIONS; P53 MUTATIONS; CANCER; OROPHARYNX; DISSECTION; TUMORS	Background. Surgical oncologists rely heavily on the histopathological assessment of surgical margins to ensure total excision of the tumor in patients with head and neck cancer. However, current techniques may not detect small numbers of cancer cells at the margins of resection or in cervical lymph nodes. Methods. We used molecular techniques to determine whether clonal populations of infiltrating tumor cells harboring mutations of the p53 gene could be detected in histopathologically negative surgical margins and cervical lymph nodes of patients with squamous-cell carcinoma of the head and neck. Results. We identified 25 patients with primary squamous-cell carcinoma of the head and neck containing a p53 mutation who appeared to have had complete tumor resection on the basis of a negative histopathological assessment. In 13 of these 25 patients, molecular analysis was positive for a p53 mutation in at least one tumor margin. In 5 of 13 patients with positive margins by this method (38 percent), the carcinoma has recurred locally, as compared with none of 12 patients with negative margins (P=0.02 by the log-rank test). Furthermore, molecular analysis identified neoplastic cells in 6 of 28 lymph nodes (21 percent) that were initially negative by histopathological assessment. Conclusions. Among specimens initially believed to be negative on light microscopy, a substantial percentage of the surgical margins and lymph nodes from patients with squamous-cell carcinoma of the head and neck contained p53 mutations specific for the primary tumor. Patients with these positive margins appear to have a substantially increased risk of local recurrence. Molecular analysis of surgical margins and lymph nodes can augment standard histopathological assessment and may improve the prediction of local tumor recurrence.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,DIV HEAD & NECK CANC RES,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,DIV BIOSTAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358; Goodman, Steven/0000-0002-3872-5723	NCI NIH HHS [CA-58184-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARANY F, 1991, PCR METH APPL, V1, P5; Beahrs OH, 1988, MANUAL STAGING CANCE, P27; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN CT, 1991, LARYNGOSCOPE, V101, P1175; BUCHMAN GW, 1992, FOCUS, V14, P41; BYERS RM, 1978, AM J SURG, V136, P525, DOI 10.1016/0002-9610(78)90275-1; CHEN TY, 1987, INT J RADIAT ONCOL, V13, P833, DOI 10.1016/0360-3016(87)90095-2; CLOSE LG, 1989, ARCH OTOLARYNGOL, V115, P1304; DAVIDSON TM, 1981, OTOLARYNG HEAD NECK, V89, P244, DOI 10.1177/019459988108900219; DAVIDSON TM, 1984, ARCH OTOLARYNGOL, V110, P193; DAVIDSON TM, 1988, LARYNGOSCOPE, V98, P1078; EIBAND JD, 1989, AM J SURG, V158, P314, DOI 10.1016/0002-9610(89)90123-2; FARRAR WB, 1988, AM J SURG, V156, P173, DOI 10.1016/S0002-9610(88)80058-8; FEINMESSER R, 1992, HEAD NECK-J SCI SPEC, V14, P173, DOI 10.1002/hed.2880140302; FIELDING LP, 1992, CANCER, V70, P2367, DOI 10.1002/1097-0142(19921101)70:9<2367::AID-CNCR2820700927>3.0.CO;2-B; GANDOUREDWARDS RF, 1993, HEAD NECK-J SCI SPEC, V15, P373, DOI 10.1002/hed.2880150502; GHOURI AF, 1993, OTOLARYNG HEAD NECK, V108, P225, DOI 10.1177/019459989310800304; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JESSE RH, 1976, AM J SURG, V132, P435, DOI 10.1016/0002-9610(76)90314-7; JONES KR, 1992, ARCH OTOLARYNGOL, V118, P483; KALNINS IK, 1977, AM J SURG, V134, P450, DOI 10.1016/0002-9610(77)90376-2; KOWALSKI LP, 1993, ARCH OTOLARYNGOL, V119, P958; Lee JG, 1974, T AM ACAD OPHTHALMOL, V78, pORL49; LEEMANS CR, 1993, CANCER, V71, P452, DOI 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B; LOOSER KG, 1978, HEAD NECK SURG, V1, P107, DOI 10.1002/hed.2890010203; MAESTRO R, 1992, ONCOGENE, V7, P1159; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MAO L, 1994, CANCER RES, V54, P1634; NAWROZ H, 1994, CANCER RES, V54, P1152; NEES M, 1993, CANCER RES, V53, P4189; OBRIEN CJ, 1987, CANCER, V59, P994, DOI 10.1002/1097-0142(19870301)59:5<994::AID-CNCR2820590524>3.0.CO;2-E; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PRADIER R, 1993, CANCER, V71, P2472, DOI 10.1002/1097-0142(19930415)71:8<2472::AID-CNCR2820710808>3.0.CO;2-Y; SCHOLL P, 1986, AM J SURG, V152, P354, DOI 10.1016/0002-9610(86)90304-1; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SNOW GB, 1982, CLIN OTOLARYNGOL, V7, P185, DOI 10.1111/j.1365-2273.1982.tb01581.x; Snow GB, 1989, CANC HEAD NECK, P17; SNYDERMAN CH, 1992, AM J OTOLARYNG, V13, P373, DOI 10.1016/0196-0709(92)90079-9; SOO KC, 1988, AM J SURG, V156, P281, DOI 10.1016/S0002-9610(88)80292-7; SUAREZ C, 1993, OTOLARYNG HEAD NECK, V109, P3, DOI 10.1177/019459989310900102; TADA M, 1993, CANCER RES, V53, P2472; TOBI M, 1994, J NATL CANCER I, V86, P1007; YOO GH, 1994, CANCER RES, V54, P4603; ZATTERSTROM UK, 1991, HEAD NECK-J SCI SPEC, V13, P477, DOI 10.1002/hed.2880130603; ZIESKE LA, 1986, ARCH OTOLARYNGOL, V112, P863	47	594	621	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					429	435		10.1056/NEJM199502163320704	http://dx.doi.org/10.1056/NEJM199502163320704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7619114				2022-12-01	WOS:A1995QF77000004
J	DEBELLO, WM; OCONNOR, V; DRESBACH, T; WHITEHEART, SW; WANG, SSH; SCHWEIZER, FE; BETZ, H; ROTHMAN, JE; AUGUSTINE, GJ				DEBELLO, WM; OCONNOR, V; DRESBACH, T; WHITEHEART, SW; WANG, SSH; SCHWEIZER, FE; BETZ, H; ROTHMAN, JE; AUGUSTINE, GJ			SNAP-MEDIATED PROTEIN-PROTEIN INTERACTIONS ESSENTIAL FOR NEUROTRANSMITTER RELEASE	NATURE			English	Article							SQUID GIANT SYNAPSE; MEMBRANE-FUSION; CALCIUM; TRANSPORT; SYNAPTOTAGMIN; POTENTIATION; DOCKING; FAMILY; YEAST	The constitutive fusion of transport vesicles with intracellular membranes requires soluble proteins called SNAPs(1). Certain presynaptic proteins(2-4) implicated in synaptic vesicle exocytosis(5) also bind SNAPs, suggesting that SNAPs participate in the calcium-regulated membrane fusion events mediating neurotransmitter release(6,7). Here we show that injection of recombinant SNAPs into the giant synapse of squid enhances transmitter release. Conversely, injection of peptides designed to mimic the sites at which SNAP interacts with its binding partners inhibits transmitter release downstream of synaptic vesicle docking. A SNAP-dependent protein complex must therefore mediate transmitter release, showing that transmitter release shares a common molecular mechanism with constitutive membrane fusion.	MARINE BIOL LAB,WOODS HOLE,MA 02543; MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,D-60528 FRANKFURT,GERMANY; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Marine Biological Laboratory - Woods Hole; Max Planck Society; Memorial Sloan Kettering Cancer Center	DEBELLO, WM (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710, USA.		Augustine, George James/J-9228-2013	Whiteheart, Sidney/0000-0001-5577-0473				ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; Katz B., 1969, RELEASE NEURAL TRANS; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; OCONNOR V, 1994, CELL, V75, P785; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V363, P318; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; SUDHOF TC, 1993, CELL, V75, P1; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	30	142	146	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					626	630		10.1038/373626a0	http://dx.doi.org/10.1038/373626a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854421				2022-12-01	WOS:A1995QG99700058
J	FLYNN, JJ; WYSS, AR; CHARRIER, R; SWISHER, CC				FLYNN, JJ; WYSS, AR; CHARRIER, R; SWISHER, CC			AN EARLY MIOCENE ANTHROPOID SKULL FROM THE CHILEAN ANDES	NATURE			English	Article							OLIGOCENE; ARGENTINA; FOSSILS	PARTLY because of their poor fossil record, the relationships of neotropical platyrrhine monkeys to other groups of primates and to each other remain perhaps the most poorly known for any major primate clade(1). Here we report the discovery of a complete platyrrhine skull from the Andes of central Chile, by far the best preserved Tertiary primate cranium from South America. This find, coupled with recent phylogenetic analyses of higher groups of anthropoid primates(2-4), has the potential to revise substantially our understanding of platyrrhine interrelationships, indicating, among other points, significant modification to reconstruction of the ancestral platyrrhine morphotype and a likely African origin for New World monkeys. A 40Ar/39Ar radioisotopic date directly associated with the skull indicates an Early Miocene age(5), marking the first report of South American mammals of this age from outside Argentine Patagonia. Finally, this discovery demonstrates the enormous potential of vastly distributed, but virtually untapped, Andean volcaniclastic deposits to yield further insights into the origin and diversification of South American primates.	UNIV CALIF SANTA BARBARA, DEPT GEOL SCI, SANTA BARBARA, CA 93106 USA; UNIV CHILE, FAC CIENCIAS FIS & MATEMAT, DEPT GEOL, SANTIAGO, CHILE; INST HUMAN ORIGINS, CTR GEOCHRONOL, BERKELEY, CA 94709 USA	University of California System; University of California Santa Barbara; Universidad de Chile	FLYNN, JJ (corresponding author), FIELD MUSEUM NAT HIST, DEPT GEOL, ROOSEVELT RD & LAKE SHORE DR, CHICAGO, IL 60605 USA.							BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; DEQUEIROZ K, 1992, ANNU REV ECOL SYST, V23, P449, DOI 10.1146/annurev.ecolsys.23.1.449; FLEAGLE JG, 1990, J HUM EVOL, V19, P61, DOI 10.1016/0047-2484(90)90012-Z; FLEAGLE JG, 1987, J HUM EVOL, V16, P483, DOI 10.1016/0047-2484(87)90036-4; FLEAGLE JG, 1983, FOLIA PRIMATOL, V41, P240, DOI 10.1159/000156135; Fleagle JG, 1988, PRIMATE ADAPTATION E; FLEAGLE JG, 1990, J HUM EVOL, V19; FLYNN JJ, SEPM SPECIAL PUBLICA; Ford S.M., 1986, P73; GINGERICH PD, 1982, AM J PHYS ANTHROPOL, V58, P81, DOI 10.1002/ajpa.1330580110; HERSHKOVITZ P, 1974, FOLIA PRIMATOL, V21, P1, DOI 10.1159/000155594; Hershkovitz P., 1977, P1; HOFFSTETTER R, 1969, CR ACAD SCI D NAT, V269, P434; Hoffstetter R., 1980, P103; Jerison HJ., 1973, EVOLUTION BRAIN INTE, DOI 10.4324/9781315787107-3; Kay R.F., 1980, International Journal of Primatology, V1, P21, DOI 10.1007/BF02692256; Kay R.F., 1994, EVOL ANTHROPOL, V3, P32; KAY RF, 1990, J HUM EVOL, V19, P175, DOI 10.1016/0047-2484(90)90016-5; Martin R.D., 1990, PRIMATE ORIGINS EVOL; PASCUAL R, 1990, J HUM EVOL, V19, P23, DOI 10.1016/0047-2484(90)90011-Y; Rosenberger A.L., 1981, P9; ROSENBERGER AL, 1990, J HUM EVOL, V19, P209, DOI 10.1016/0047-2484(90)90017-6; Rusconi C., 1935, Revista Argentina de Paleontologia y Antropologia Ameghinia, V1, P39; RUSCONI C, 1935, REV ARGENTINA PALEON, V1, P103; RUSCONI C, 1935, REV ARGENTINA PALEON, V1, P71; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; SIMONS EL, 1986, J HUM EVOL, V15, P205, DOI 10.1016/S0047-2484(86)80046-X; STEIGER RH, 1977, EARTH PLANET SC LETT, V36, P359, DOI 10.1016/0012-821X(77)90060-7; SWISHER CC, 1992, SCIENCE, V257, P954, DOI 10.1126/science.257.5072.954; TAUBER A, 1991, ACAD NAC CIENCIAS MI, V82; Taylor J.R., 1982, INTRO ERROR ANAL; Wyss A.R., 1994, American Museum Novitates, V3098, P1	32	64	70	0	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 16	1995	373	6515					603	607		10.1038/373603a0	http://dx.doi.org/10.1038/373603a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG997	7854415				2022-12-01	WOS:A1995QG99700051
J	JOLIET, V; DEMMA, M; PRYWES, R				JOLIET, V; DEMMA, M; PRYWES, R			INTERACTION WITH RAP74 SUBUNIT OF TFIIF IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION BY SERUM RESPONSE FACTOR	NATURE			English	Article							RNA POLYMERASE-II; TERNARY COMPLEX-FORMATION; INITIATION-FACTOR; DOMAIN; CDNA; SRF; DNA	A FEW general transcription factors, in particular TFIID and TFIIB, have been found to bind transcriptional activators(1). Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter. Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding. Further, RAP74's central charged cluster domain is required for binding to SRF's activation domain. Deletion of this domain impairs RAP74's ability to support SRF-activated transcription in vitro but has Little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription. The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University								ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P195; CHANG CH, 1993, J BIOL CHEM, V268, P20482; DALTON S, 1992, CELL, V88, P597; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1989, J BIOL CHEM, V284, P8913; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V386, P466; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LIU SH, 1993, J BIOL CHEM, V268, P21147; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273; ZHU H, 1994, J BIOL CHEM, V269, P3489	23	73	75	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					632	635		10.1038/373632a0	http://dx.doi.org/10.1038/373632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854423				2022-12-01	WOS:A1995QG99700060
J	LELLOUCH, E; PAUBERT, G; MORENO, R; FESTOU, MC; BEZARD, B; BOCKELEEMORVAN, D; COLOM, P; CROVISIER, J; ENCRENAZ, T; GAUTIER, D; MARTEN, A; DESPOIS, D; STROBEL, DF; SIEVERS, A				LELLOUCH, E; PAUBERT, G; MORENO, R; FESTOU, MC; BEZARD, B; BOCKELEEMORVAN, D; COLOM, P; CROVISIER, J; ENCRENAZ, T; GAUTIER, D; MARTEN, A; DESPOIS, D; STROBEL, DF; SIEVERS, A			CHEMICAL AND THERMAL RESPONSE OF JUPITER ATMOSPHERE FOLLOWING THE IMPACT OF COMET SHOEMAKER-LEVY-9	NATURE			English	Article							MILLIMETER	July 1994, the collisions of the fragments of comet Shoemaker-Levy 9 with Jupiter resulted in dramatic changes in the planet's atmosphere. Observations of the events suggest that the composition and thermal properties of the atmosphere were considerably modified at the impact sites, with the changes persisting for times lasting from minutes to weeks (see, for example, refs 1-4). Here we report observations of the impact sites at millimetre wavelengths, which reveal strong emission lines associated with carbon monoxide, carbonyl sulphide and carbon monosulphide. The abundance of carbon monoxide in the jovian atmosphere is normally very low(5); carbonyl sulphide and carbon monosulphide, on the other hand, have not hitherto been detected, We find that the largest fragments (G and K) each produced approximately 10(14) g of carbon monoxide, 3 x 10(12) g of carbonyl sulphide and 3 x 10(11) g of carbon monosulphide, most probably by shock-induced chemical reactions(6). Our observations also place firm constraints on the thermal response of Jupiter's stratosphere to the impacts.	IRAM, E-18012 GRANADA, SPAIN; OBSERV MIDI PYRENEES, F-31400 TOULOUSE, FRANCE; OBSERV BORDEAUX, F-33270 FLOIRAC, FRANCE; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Johns Hopkins University	LELLOUCH, E (corresponding author), OBSERV PARIS, F-92195 MEUDON, FRANCE.		Strobel, Darrell5/AAO-6643-2021	Strobel, Darrell5/0000-0002-0944-8675; Bezard, Bruno/0000-0002-5433-5661; Gorski, Andrzej/0000-0002-0863-6041				ALLEN M, 1992, ICARUS, V100, P527, DOI 10.1016/0019-1035(92)90115-N; BJORAKER GL, IN PRESS B AM ASTR S; BOCKELEEMORVAN D, IN PRESS B AM ASTR S; BROOKE T, IN PRESS B AM ASTR S; BROSSMAN AW, IN PRESS B AM ASTR S; ENCRENAZ T, IN PRESS B AM ASTR S; GLADSTONE GR, 1987, SP494 NASA, P221; GRIFFIN MJ, 1986, ICARUS, V65, P244, DOI 10.1016/0019-1035(86)90137-5; GRIFFITH CA, IN PRESS B AM ASTR S; JESSBERGER EK, 1991, COMETS POST HALLEY E, V2, P1075; LELLOUCH E, 1984, ASTRON ASTROPHYS, V135, P365; MAILLARD JP, IN PRESS GEOPHYS RES; MARTIN TZ, IN PRESS B AM ASTR S; MEADOWS V, IN PRESS B AM ASTR S; MOSES JI, IN PRESS B AM ASTR S; NOLL KS, 1988, ASTROPHYS J, V324, P1210, DOI 10.1086/165975; NOLL KS, IN PRESS SCIENCE; ORTON GS, IN PRESS SCIENCE; WEST R, IN PRESS B AM ASTR S; ZAHNLE K, 1994, ICARUS, V108, P1, DOI 10.1006/icar.1994.1038; ZAHNLE K, IN PRESS B AM ASTR S	21	66	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	1995	373	6515					592	595		10.1038/373592a0	http://dx.doi.org/10.1038/373592a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854414				2022-12-01	WOS:A1995QG99700047
J	LI, XT; NICKLAS, RB				LI, XT; NICKLAS, RB			MITOTIC FORCES CONTROL A CELL-CYCLE CHECKPOINT	NATURE			English	Article							ANAPHASE	EVERY time a cell divides, the chromosomes must be distributed accurately to the daughter cells. Errors in distribution arise if chromosomes are improperly attached to the mitotic spindle. Improper attachment is detected by a cell-cycle checkpoint in many cells(1,2) and the completion of cell division is delayed, allowing time for error correction. How is an improperly attached chromosome detected? An absence of tension from mitotic forces is one possibility(3). Here we test this possibility directly by applying tension to an improperly attached chromosome with a micromanipulation needle, In the absence of tension, the entry into anaphase and the completion of mitosis was delayed by 5-6 hours. When the misattached chromosome was placed under tension, however, the cell entered anaphase in 56 minutes, on average. Tension from mitotic forces or from a micromanipulator's needle evidently signals to the checkpoint that all is in order and that cell division can proceed.			LI, XT (corresponding author), DUKE UNIV,DEPT ZOOL,BOX 91000,DURHAM,NC 27708, USA.							CALLAN H. G., 1957, JOUR GENETICS, V55, P200, DOI 10.1007/BF02981625; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Hughes-Schrader S, 1943, BIOL BULL-US, V85, P265, DOI 10.2307/1538227; LUCA FC, 1993, CURR BIOL, V3, P716, DOI 10.1016/0960-9822(93)90078-3; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; VANDRE DD, 1989, J CELL SCI, V94, P245; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	11	460	466	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					630	632		10.1038/373630a0	http://dx.doi.org/10.1038/373630a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854422				2022-12-01	WOS:A1995QG99700059
J	SHAYWITZ, BA; SHAYWITZ, SE; PUGH, KR; CONSTABLE, RT; SKUDLARSKI, P; FULBRIGHT, RK; BRONEN, RA; FLETCHER, JM; SHANKWEILER, DP; KATZ, L; GORE, JC				SHAYWITZ, BA; SHAYWITZ, SE; PUGH, KR; CONSTABLE, RT; SKUDLARSKI, P; FULBRIGHT, RK; BRONEN, RA; FLETCHER, JM; SHANKWEILER, DP; KATZ, L; GORE, JC			SEX-DIFFERENCES IN THE FUNCTIONAL-ORGANIZATION OF THE BRAIN FOR LANGUAGE	NATURE			English	Article							SENSORY STIMULATION; ASYMMETRY	A MUCH debated question is whether sex differences exist in the functional organization of the brain for language(1-4). A long-held hypothesis posits that language functions are more likely to be highly lateralized in males and to be represented in both cerebral hemispheres in females(5,6), but attempts to demonstrate this have been inconclusive(7-17). Here we use echo-planar functional magnetic resonance imaging(18-21) to study 38 right-handed subjects (19 males and 19 females) during orthographic (letter recognition), phonological (rhyme) and semantic (semantic category) tasks. During phonological tasks, brain activation in males is lateralized to the left inferior frontal gyrus regions; in females the pattern of activation is very different, engaging more diffuse neural systems that involve both the left and right inferior frontal gyrus. Our data provide clear evidence for a sex difference in the functional organization of the brain for language and indicate that these variations exist at the level of phonological processing.	YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; HASKINS LABS INC,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT DIAGNOST RADIOL,NEW HAVEN,CT 06510; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77030; YALE UNIV,BECTON ENGIN & APPL SCI CTR,DEPT APPL PHYS,NEW HAVEN,CT 06520	Yale University; Yale University; Haskins Laboratories; Yale University; University of Texas System; Yale University	SHAYWITZ, BA (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,POB 208064,NEW HAVEN,CT 06510, USA.		Constable, R. Todd/ABE-8038-2021; fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020	Constable, R. Todd/0000-0001-5661-9521; 				BRADSHAW JL, 1978, BRAIN LANG, V5, P166, DOI 10.1016/0093-934X(78)90016-0; Bryden M.P., 1988, HDB DICHOTIC LISTENI, P1, DOI DOI 10.1002/ACP.2350040307; Demonet J. F., 1993, Human Brain Mapping, V1, P39, DOI 10.1002/hbm.460010105; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; DEMONET JF, 1994, BRAIN, V117, P671, DOI 10.1093/brain/117.4.671; EFRON R, 1990, DECLINE FALL HEMISPH, P1; FRACKOWIAK RSJ, 1994, TRENDS NEUROSCI, V17, P109, DOI 10.1016/0166-2236(94)90119-8; FRISTON KJ, 1994, HUMAN BRAIN MAPPING, V1, P69; HALPERN D, 1992, SEX DIFFERENCES COGN, P1; HAMPSON E, 1992, P357; HARSHMAN R, 1983, LANGUAGE BRAIN, V3; HELLIGE JB, 1993, HEMISPHERIC ASYMMETR, P1; HINES M, 1990, HORMONES BRAIN BEHAV, V1, P51; INGLIS J, 1981, SCIENCE, V212, P693, DOI 10.1126/science.7221560; KULYNYCH JJ, 1994, CEREB CORTEX, V4, P107, DOI 10.1093/cercor/4.2.107; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LACCINO J, 1993, LEFT BRAIN RIGHT BRA, P1; LEVY J, 1972, BIOL BEHAVIOR; LUKATELA G, 1991, J EXP PSYCHOL HUMAN, V17, P951, DOI 10.1037/0096-1523.17.4.951; MCCARTHY G, 1993, P NATL ACAD SCI USA, V90, P4952, DOI 10.1073/pnas.90.11.4952; MCGLONE J, 1977, BRAIN, V100, P775, DOI 10.1093/brain/100.4.775; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PETERSEN SE, 1993, ANNU REV NEUROSCI, V1, P509; PUGH KR, 1994, J EXP PSYCHOL HUMAN, V20, P807, DOI 10.1037/0096-1523.20.4.807; SHAYWITZ BA, 1995, HUM BRAIN MAPP, V2, P21; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TENG EL, 1981, NEUROPSYCHOLOGIA, V19, P235, DOI 10.1016/0028-3932(81)90107-X; VOYER D, 1990, BRAIN COGNITION, V13, P18, DOI 10.1016/0278-2626(90)90037-O; WITELSON SF, 1992, J COMP NEUROL, V323, P326, DOI 10.1002/cne.903230303	30	973	997	0	81	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					607	609		10.1038/373607a0	http://dx.doi.org/10.1038/373607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG997	7854416				2022-12-01	WOS:A1995QG99700052
J	SPACH, DH; KANTER, AS; DOUGHERTY, MJ; LARSON, AM; COYLE, MB; BRENNER, DJ; SWAMINATHAN, B; MATAR, GM; WELCH, DF; ROOT, RK; STAMM, WE				SPACH, DH; KANTER, AS; DOUGHERTY, MJ; LARSON, AM; COYLE, MB; BRENNER, DJ; SWAMINATHAN, B; MATAR, GM; WELCH, DF; ROOT, RK; STAMM, WE			BARTONELLA (ROCHALIMAEA) QUINTANA BACTEREMIA IN INNER-CITY PATIENTS WITH CHRONIC-ALCOHOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CAT-SCRATCH DISEASE; HENSELAE SP-NOV; BACILLARY ANGIOMATOSIS; PELIOSIS HEPATIS; FEVER; AGENT	Background. Bartonella (Rochalimaea) quintana is a fastidious gram-negative bacterium known to cause trench fever, cutaneous bacillary angiomatosis, and endocarditis. Between January and June 1993 in Seattle, we isolated B. quintana from 34 blood cultures obtained from 10 patients not known to be infected with the human immunodeficiency virus (HIV). Methods. After identifying the isolates as B. quintana by direct immunofluorescence and DNA-hybridization studies, we determined strain hybridization with studies of restriction-fragment-length polymorphisms (RFLPs) of the intergenic spacer (noncoding) region of ribosomal DNA amplified by the polymerase chain reaction (PCR). To characterize the epidemiologic and clinical features of bartonella infections in these patients, we performed a retrospective case-control study using as controls 20 patients from whom blood was obtained for culture at approximately the same time as from the index patients. Results. B. quintana isolates from the 10 patients were indistinguishable by PCR-RFLP typing. All 10 patients had chronic alcoholism, and 8 were homeless (P=0.001 for both comparisons with controls). The six patients who underwent HIV testing were seronegative. At the time of their initial presentation, seven patients had temperatures of at least 38.5 degrees C. Six patients had three or more blood cultures that were positive for B. quintana, and in four of these patients B. quintana was isolated from blood cultures obtained 10 or more days apart. Subacute endocarditis developed in two patients and required surgical removal of the infected aortic valve in one of them. Nine patients recovered; one died of sepsis from Streptococcus pneumoniae infection. Conclusions. B. quintana is a cause of fever, bacteremia, and endocarditis in HIV-seronegative, homeless, inner-city patients with chronic alcoholism.	HARBORVIEW MED CTR,DIV INFECT DIS,SEATTLE,WA; HARBORVIEW MED CTR,DEPT MED,SEATTLE,WA; HARBORVIEW MED CTR,DEPT LAB MED,SEATTLE,WA; UNIV WASHINGTON,MED CTR,DEPT MED,SEATTLE,WA 98195; NATL CTR INFECTIOUS DIS,DIV BACTERIAL & MYCOT DIS,EMERGING BACTERIAL & MYCOT DIS BRANCH,ATLANTA,GA; NATL CTR INFECTIOUS DIS,DIV BACTERIAL & MYCOT DIS,FOODBORNE & DIARRHEAL DIS BRANCH,ATLANTA,GA; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PEDIAT,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,CLIN MICROBIOL LABS,OKLAHOMA CITY,OK 73190	Harborview Medical Center; Harborview Medical Center; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center				Kanter, Andrew/0000-0002-4019-7894				BRENNER DJ, 1993, INT J SYST BACTERIOL, V43, P777, DOI 10.1099/00207713-43-4-777; BRENNER DJ, 1982, J CLIN MICROBIOL, V15, P1133, DOI 10.1128/JCM.15.6.1133-1140.1982; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; HADFIELD TL, 1993, HUM PATHOL, V24, P1140, DOI 10.1016/0046-8177(93)90196-N; KOEHLER JE, 1993, CLIN INFECT DIS, V17, P612, DOI 10.1093/clinids/17.4.612; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; LARSON AM, 1994, J CLIN MICROBIOL, V32, P1492, DOI 10.1128/JCM.32.6.1492-1496.1994; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; MATAR GM, 1993, J CLIN MICROBIOL, V31, P1730, DOI 10.1128/JCM.31.7.1730-1734.1993; MAURIN M, 1994, J CLIN MICROBIOL, V32, P1166, DOI 10.1128/JCM.32.5.1166-1171.1994; MYERS WF, 1984, ANTIMICROB AGENTS CH, V25, P690, DOI 10.1128/AAC.25.6.690; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; RAOULT D, 1994, LANCET, V343, P977, DOI 10.1016/S0140-6736(94)90102-3; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1991, NEW ENGL J MED, V324, P1514; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SCHWARTZMAN WA, 1992, CLIN INFECT DIS, V15, P893, DOI 10.1093/clind/15.6.893; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SLATER LN, 1992, ARCH INTERN MED, V152, P602, DOI 10.1001/archinte.152.3.602; SLATER LN, 1992, J CLIN MICROBIOL, V30, P1722, DOI 10.1128/JCM.30.7.1722-1727.1992; SLATER LN, 1995, PRINCIPLES PRACTICE, P1741; SPACH DH, 1993, J CLIN MICROBIOL, V31, P692, DOI 10.1128/JCM.31.3.692-694.1993; SPACH DH, IN PRESS CLIN INFECT; TAPPERO JW, 1993, ANN INTERN MED, V118, P363, DOI 10.7326/0003-4819-118-5-199303010-00007; VINSON JW, 1969, AM J TROP MED HYG, V18, P713, DOI 10.4269/ajtmh.1969.18.713; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	28	196	204	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					424	428		10.1056/NEJM199502163320703	http://dx.doi.org/10.1056/NEJM199502163320703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7529895				2022-12-01	WOS:A1995QF77000003
J	STEBBINS, CE; BORUKHOV, S; ORLOVA, M; POLYAKOV, A; GOLDFARB, A; DARST, SA				STEBBINS, CE; BORUKHOV, S; ORLOVA, M; POLYAKOV, A; GOLDFARB, A; DARST, SA			CRYSTAL-STRUCTURE OF THE GREA TRANSCRIPT CLEAVAGE FACTOR FROM ESCHERICHIA-COLI	NATURE			English	Article							RNA-POLYMERASE; ELONGATION-FACTOR; PROTEIN; ERRORS; MAPS	TRANSCRIPTION elongation factors stimulate the activity of DNA-dependent RNA polymerases by increasing the overall elongation rate and the completion of RNA chains. One group of such factors, which includes Escherichia coli GreA, GreB and eukaryotic SII (TFIIS), acts by inducing hydrolytic cleavage of the transcript within the RNA polymerase, followed by relase of the 3'-terminal fragment(1-5). Here we report the crystal structure of GreA at 2.2 Angstrom resolution. The structure contains an amino-terminal domain consisting of an antiparallel alpha-helical coiled-coil dimer which extends into solution, reminiscent of the coiled coil in seryl-tRNA synthetases(6). A site near the tip of the coiled-coil 'finger' plays a direct role in the transcript cleavage reaction by contacting the 3'-end of the transcript. The structure exhibits an unusual asymmetric charge distribution which indicates the manner in which GreA interacts with the RNA polymerase elongation complex.	ROCKEFELLER UNIV,NEW YORK,NY 10021; PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016	Rockefeller University			Borukhov, Sergei/AAF-3195-2019; Stebbins, Erec/N-2565-2018	Borukhov, Sergei/0000-0002-3517-3003; Stebbins, Erec/0000-0001-6229-5308				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DARST SA, 1994, J MOL BIOL, V242, P582, DOI 10.1006/jmbi.1994.1603; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; MARKS GL, 1992, NUCLEIC ACIDS RES, V20, P3785, DOI 10.1093/nar/20.14.3785; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REIONES D, 1992, J BIOL CHEM, V26, P3795; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P359; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V16, P6443; WOODY AYM, 1984, BIOCHEMISTRY-US, V23, P2843, DOI 10.1021/bi00308a001; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	26	116	121	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					636	640		10.1038/373636a0	http://dx.doi.org/10.1038/373636a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854424				2022-12-01	WOS:A1995QG99700061
J	STEEGMAIER, M; LEVINOVITZ, A; ISENMANN, S; BORGES, E; LENTER, M; KOCHER, HP; KLEUSER, B; VESTWEBER, D				STEEGMAIER, M; LEVINOVITZ, A; ISENMANN, S; BORGES, E; LENTER, M; KOCHER, HP; KLEUSER, B; VESTWEBER, D			THE E-SELECTIN-LIGAND ESL-1 IS A VARIANT OF A RECEPTOR FOR FIBROBLAST GROWTH-FACTOR	NATURE			English	Article							LEUKOCYTE ADHESION MOLECULE-1; P-SELECTIN; GLYCOPROTEIN LIGAND; EXPRESSION; CELLS; ANTIGEN; IDENTIFICATION; SPECIFICITIES; DISTINCT; SURFACE	E-SELECTIN is an inducible cell-adhesion molecule on endothelial cells, which mediates the binding of neutrophils and functions as a Ca2+-dependent lectin(1-3). We have recently identified a 150K glycoprotein as the major ligand for E-selectin on myeloid cells, using a recombinant antibody-like form of mouse E-selectin as an affinity probe(4,5). Here we report the isolation of a mouse complementary DNA for this E-selectin ligand (ESL-1). The predicted amino-acid sequence of ESL-1 is 94% identical (over 1,078 amino acids) to the recently identified chicken cysteine-rich fibroblast growth-factor receptor(6), except for a unique 70-amino-acid amino-terminal domain of mature ESL-1. Fucosylation of ESL-1 is imperative for affinity isolation with E-selectin-IgG. A fucosylated, recombinant antibody-like form of ESL-1, but not for L-selectin, supports adhesion of E-selectin-transfected Chinese hamster ovary cells. Antibodies against ESL-1 block the binding of mouse myeloid cells to E-selectin. ESL-1, with a structure essentially identical to that of a receptor, thus functions as a cell adhesion ligand of E-selectin.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY; SANDOZ PHARMA LTD,CH-4002 BASEL,SWITZERLAND	Max Planck Society; Novartis; Sandoz			Isenmann, Stefan/AAJ-3788-2020					BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; KISHIMOTO TK, 1991, BLOOD, V78, P805; KOTOVUORI P, 1993, GLYCOBIOLOGY, V3, P131, DOI 10.1093/glycob/3.2.131; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; VESTWEBER D, 1994, RES IMMUNOL, V144, P704; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WELLER A, 1992, J BIOL CHEM, V267, P15176; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WILLIAMS RL, 1988, CELL, V52, P121	24	322	328	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					615	620		10.1038/373615a0	http://dx.doi.org/10.1038/373615a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7531823				2022-12-01	WOS:A1995QG99700055
J	VARNUM, BC; YOUNG, C; ELLIOTT, G; GARCIA, A; BARTLEY, TD; FRIDELL, YW; HUNT, RW; TRAIL, G; CLOGSTON, C; TOSO, RJ; YANAGIHARA, D; BENNETT, L; SYLBER, M; MEREWETHER, LA; TSENG, A; ESCOBAR, E; LIU, ET; YAMANE, HK				VARNUM, BC; YOUNG, C; ELLIOTT, G; GARCIA, A; BARTLEY, TD; FRIDELL, YW; HUNT, RW; TRAIL, G; CLOGSTON, C; TOSO, RJ; YANAGIHARA, D; BENNETT, L; SYLBER, M; MEREWETHER, LA; TSENG, A; ESCOBAR, E; LIU, ET; YAMANE, HK			AXL RECEPTOR TYROSINE KINASE STIMULATED BY THE VITAMIN-K-DEPENDENT PROTEIN ENCODED BY GROWTH-ARREST-SPECIFIC GENE-6	NATURE			English	Article							BLOOD-COAGULATION; SEQUENCE; CDNA	THE Axl receptor tyrosine kinase was identified as a protein encoded by a transforming gene from primary human myeloid leukaemia cells by DNA-mediated transformation of NIH 3T3 cells(1-3). Axl is the founding member of a family of related receptors that includes Eyk(4), encoded by a chicken proto-oncogene originally described as a retroviral transforming gene, and c-Mer(5), encoded by a human proto-oncogene expressed in neoplastic B- and T-cell lines. The transforming activity of Axl demonstrates that the receptor can drive cellular proliferation. The function of Axl in non-transformed cells and tissues is unknown, but may involve the stimulation of cell proliferation in response to an appropriate signal, namely a ligand that activates the receptor. We report here the purification of an Axl stimulatory factor, and its identification as the product of growth-arrest-specific gene 6 (ref. 6). This is, to our knowledge, the first description of a ligand for the Axl family of receptors.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	VARNUM, BC (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.		Liu, Edison/C-4141-2008					DECLERCK YA, 1991, J BIOL CHEM, V226, P3893; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FAUSSET PR, 1991, ELECTROPHORESIS, V12, P22, DOI 10.1002/elps.1150120106; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1990, MOL CELL BIOL, V11, P5016; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	15	401	429	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					623	626		10.1038/373623a0	http://dx.doi.org/10.1038/373623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854420				2022-12-01	WOS:A1995QG99700057
J	VOLBEDA, A; CHARON, MH; PIRAS, C; HATCHIKIAN, EC; FREY, M; FONTECILLACAMPS, JC				VOLBEDA, A; CHARON, MH; PIRAS, C; HATCHIKIAN, EC; FREY, M; FONTECILLACAMPS, JC			CRYSTAL-STRUCTURE OF THE NICKEL-IRON HYDROGENASE FROM DESULFOVIBRIO-GIGAS	NATURE			English	Article							SULFATE-REDUCING BACTERIA; ESR-DETECTABLE NICKEL; ACTIVE-SITE NICKEL; ELECTRON-TRANSFER; NIFE HYDROGENASE; METHANOCOCCUS-VOLTAE; CHROMATIUM-VINOSUM; REDOX PROPERTIES; SULFUR CENTERS; BACULATUS	The X-ray structure of the heterodimeric Ni-Fe hydrogenase from Desulfovibrio gigas, the enzyme responsible for the metabolism of molecular hydrogen, has been solved at 2.84 Angstrom resolution. The active site, which appears to contain, besides nickel, a second metal ion, is buried in the 60K subunit. The 28K subunit, which coordinates one [3Fe-4S] and two [4Fe-4S] clusters, contains an amino-terminal domain with similarities to the redox protein flavodoxin. The structure suggests plausible electron and proton transfer pathways.	INST BIOL STRUCT,CRISTALLOG & CRISTALLOGENESE PROT LAB,F-38027 GRENOBLE 1,FRANCE; CNRS,UNITE BIOENERGET & INGN PROT,F-13402 MARSEILLE 20,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite				Volbeda, Anne/0000-0002-6038-0979				ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ADAMS MWW, 1981, BIOCHIM BIOPHYS ACTA, V594, P105; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAGYINKA C, 1993, J AM CHEM SOC, V115, P3576, DOI 10.1021/ja00062a022; BARONDEAU DP, 1994, J AM CHEM SOC, V116, P3442, DOI 10.1021/ja00087a033; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOXER SG, 1994, STRUCT BIOL, V11, P749; BRICOGNE G, 1991, ISOMORPHOUS REPLACEM, P60; BRUNGER A, 1988, CRYSTALLOGRAPHIC COM, V4, P127; CAMMACK R, 1982, FEBS LETT, V142, P289, DOI 10.1016/0014-5793(82)80154-3; CAMMACK R, 1987, BIOCHIM BIOPHYS ACTA, V912, P98, DOI 10.1016/0167-4838(87)90252-4; CERIOTTI A, 1984, INORG CHEM, V23, P1363, DOI 10.1021/ic00178a013; CHAPMAN A, 1988, FEBS LETT, V242, P134, DOI 10.1016/0014-5793(88)81001-9; EIDSNESS MK, 1989, P NATL ACAD SCI USA, V86, P147, DOI 10.1073/pnas.86.1.147; FAN CL, 1991, J AM CHEM SOC, V113, P20, DOI 10.1021/ja00001a003; FAUQUE G, 1988, FEMS MICROBIOL LETT, V54, P299, DOI 10.1111/j.1574-6968.1988.tb02748.x; FERNANDEZ VM, 1986, BIOCHIM BIOPHYS ACTA, V883, P145, DOI 10.1016/0304-4165(86)90145-5; HATCHIKIAN EC, 1978, BIOCHEM BIOPH RES CO, V82, P451, DOI 10.1016/0006-291X(78)90896-3; HE SH, 1989, J BIOL CHEM, V264, P2678; Hendrickson W. A., 1980, COMPUTING CRYSTALLOG; HIGUCHI Y, 1994, ACTA CRYSTALLOGR D, V50, P781, DOI 10.1107/S0907444994002416; HUYNH BH, 1987, J BIOL CHEM, V262, P795; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1990, ACTA CRYSTALLOGR A, V47, P110; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOLODZIEJ AF, 1994, PROG INORG CHEM, V41, P493, DOI 10.1002/9780470166420.ch7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, ESFCCP4 NEWSL, V27, P30; MENON NK, 1993, FEBS LETT, V331, P91, DOI 10.1016/0014-5793(93)80303-C; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NIVIERE V, 1988, BIOCHIM BIOPHYS ACTA, V935, P34, DOI 10.1016/0005-2728(88)90105-3; ODOM JM, 1984, ANNU REV MICROBIOL, V38, P551, DOI 10.1146/annurev.mi.38.100184.003003; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; Otwinowski Z, 1991, ISOMORPHOUS REPLACEM, P60; PRZYBYLA AE, 1992, FEMS MICROBIOL LETT, V88, P109, DOI 10.1016/0378-1097(92)90687-J; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SMITH WW, 1977, J MOL BIOL, V117, P195, DOI 10.1016/0022-2836(77)90031-6; SORGENFREI O, 1993, FEBS LETT, V332, P291, DOI 10.1016/0014-5793(93)80652-B; SORGENFREI O, 1993, EUR J BIOCHEM, V213, P1355, DOI 10.1111/j.1432-1033.1993.tb17888.x; TEIXEIRA M, 1989, J BIOL CHEM, V264, P16435; VANDERZWAAN JW, 1985, FEBS LETT, V179, P271, DOI 10.1016/0014-5793(85)80533-0; VANDERZWAAN JW, 1986, BIOCHIM BIOPHYS ACTA, V872, P208, DOI 10.1016/0167-4838(86)90273-6; VELLIEUX FMD, IN PRESS J APPL CRYS; VOLBEDA A, 1993, ESF CCP4 NEWSLETTER, V28, P30; VOORDOUW G, 1992, ADV INORG CHEM, V38, P397, DOI 10.1016/S0898-8838(08)60069-0; VOORDOUW G, 1989, J BACTERIOL, V171, P2894, DOI 10.1128/jb.171.5.2894-2899.1989; WHITEHEAD JP, 1993, J AM CHEM SOC, V115, P5629, DOI 10.1021/ja00066a032; WU LF, 1993, FEMS MICROBIOL LETT, V104, P243	50	1342	1364	5	217	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					580	587		10.1038/373580a0	http://dx.doi.org/10.1038/373580a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854413				2022-12-01	WOS:A1995QG99700044
J	WHITTINGTON, MA; TRAUB, RD; JEFFERYS, JGR				WHITTINGTON, MA; TRAUB, RD; JEFFERYS, JGR			SYNCHRONIZED OSCILLATIONS IN INTERNEURON NETWORKS DRIVEN BY METABOTROPIC GLUTAMATE-RECEPTOR ACTIVATION	NATURE			English	Article							CAT VISUAL-CORTEX; RAT HIPPOCAMPUS; PYRAMIDAL NEURONS; INHIBITORY NEURONS; OLFACTORY SYSTEM; RESPONSES; FREQUENCY; INVITRO; HUMANS; EEG	PARTIALLY synchronous 40-Hz oscillations of cortical neurons have been implicated in cognitive function. Specifically, coherence of these oscillations between different parts of the cortex may provide conjunctive properties(1,2) to solve the 'binding problem': associating features detected by the cortex into unified perceived objects. Here we report an emergent 40-Hz oscillation in networks of inhibitory neurons connected by synapses using GABA(A) (gamma-aminobutyric acid) receptors in slices of rat hippocampus and neocortex. These network inhibitory postsynaptic potential oscillations occur in response to the activation of metabotropic glutamate receptors. The oscillations can entrain pyramidal cell discharges. The oscillation frequency is determined both by the net excitation of interneurons and by the kinetics of the inhibitory postsynaptic potentials between them. We propose that interneuron network oscillations, in conjunction with intrinsic membrane resonances and long-loop (such as thalamocortical) interactions, contribute to 40-Hz rhythms in vivo.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND; IBM CORP,DIV RES,TJ WATSON RES CTR,YORKTOWN HTS,NY 10598; COLUMBIA UNIV,DEPT NEUROL,NEW YORK,NY 10032	Imperial College London; International Business Machines (IBM); Columbia University			Jefferys, John G R/AAF-1164-2021; Jefferys, John/E-6132-2012	Jefferys, John G R/0000-0003-0106-4412; Jefferys, John/0000-0003-0106-4412; Whittington, Miles Adrian/0000-0002-0247-1362	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BRESSLER SL, 1980, ELECTROEN CLIN NEURO, V50, P19, DOI 10.1016/0013-4694(80)90319-3; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; EECKMAN FH, 1990, BRAIN RES, V528, P238, DOI 10.1016/0006-8993(90)91663-2; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; KATSUMARU H, 1988, EXP BRAIN RES, V72, P363; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; MILES R, 1993, J PHYSIOL-LONDON, V463, P461, DOI 10.1113/jphysiol.1993.sp019605; NUNEZ A, 1992, NEUROSCIENCE, V51, P7, DOI 10.1016/0306-4522(92)90464-D; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; ROPERT N, 1990, J PHYSIOL-LONDON, V428, P707, DOI 10.1113/jphysiol.1990.sp018236; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; STERIADE M, 1993, NEUROSCIENCE, V56, P1, DOI 10.1016/0306-4522(93)90556-U; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501	28	1219	1235	2	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					612	615		10.1038/373612a0	http://dx.doi.org/10.1038/373612a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854418				2022-12-01	WOS:A1995QG99700054
J	BRUNO, A; JONES, WL; AUSTIN, JK; CARTER, S; QUALLS, C				BRUNO, A; JONES, WL; AUSTIN, JK; CARTER, S; QUALLS, C			VASCULAR OUTCOME IN MEN WITH ASYMPTOMATIC RETINAL CHOLESTEROL EMBOLI - A COHORT STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						EMBOLISM, CHOLESTEROL; RETINA; CEREBROVASCULAR DISORDERS; MYOCARDIAL INFARCTION; CEREBRAL INFARCTION	CEREBRAL INFARCTION; RISK-FACTORS; ARTERY; CONCOMITANTS; STENOSIS	Objective: To determine whether asymptomatic retinal cholesterol embolism is a risk factor for vascular events. Design: Cohort study with retrospectively selected controls. Setting: A Veterans Affairs medical center. Patients: 70 consecutive patients with asymptomatic retinal cholesterol emboli on dilated ocular examination in an eye clinic and 70 controls without retinal emboli. Controls were matched to patients for sex; age; prevalence of hypertension, diabetes mellitus, and ischemic heart disease; serum cholesterol level; and smoking history. Measurements: Stroke, myocardial infarction, and death. Results: During a mean follow-up of 3.4 years, stroke occurred at an annual rate of 8.5% among patients and 0.8% among controls (adjusted relative risk, 9.9; 95% Cl, 2.3 to 43.1; P = 0.002). Nineteen strokes occurred, 17 in patients and 2 in controls; all were nonfatal cerebral infarctions. Twelve of the 17 that occurred in patients were in a carotid artery territory ipsilateral to the qualifying retinal cholesterol embolus and 5 were in another vascular territory. Ocular infarction or hemorrhagic stroke did not occur. Nonfatal myocardial infarction or vascular death occurred at an annual rate of 7.7% among patients and 4.9% among controls (adjusted relative risk, 1.4; 95% Cl, 0.7 to 2.9; P = 0.39). Conclusion: Asymptomatic retinal cholesterol embolism is an important risk factor for cerebral infarction independent of commonly recognized vascular risk factors.	VET AFFAIRS MED CTR, OPTOMETRY SECT 112A, ALBUQUERQUE, NM 87108 USA; VET AFFAIRS MED CTR, NEUROL SERV 127, ALBUQUERQUE, NM 87108 USA; UNIV NEW MEXICO, DEPT MATH & STAT, ALBUQUERQUE, NM 87131 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico					NCRR NIH HHS [MO1 RR00997] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000997] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BOGOUSSLAVSKY J, 1985, ARCH NEUROL-CHICAGO, V42, P864, DOI 10.1001/archneur.1985.04060080042014; BRUNO A, 1992, STROKE, V23, P900, DOI 10.1161/01.STR.23.6.900; BULL DA, 1992, J CARDIOVASC SURG, V33, P401; BUNT TJ, 1986, J VASC SURG, V4, P559; CROUSE JR, 1987, STROKE, V18, P990, DOI 10.1161/01.STR.18.6.990; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; EHRENFEL.WK, 1966, ARCH SURG-CHICAGO, V93, P787; FABRIS F, 1994, STROKE, V25, P1133, DOI 10.1161/01.STR.25.6.1133; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GARRAWAY WM, 1979, STROKE, V10, P657, DOI 10.1161/01.STR.10.6.657; MAURIZI CP, 1968, ARCH PATHOL, V86, P528; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; RICHARDS AM, 1965, AM J CARDIOL, V15, P696, DOI 10.1016/0002-9149(65)90359-0; RUSSELL RWR, 1968, LANCET, V2, P789; SAVINO PJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P1185, DOI 10.1001/archopht.1977.04450070083005; SAVINO PJ, 1988, AMAUROSIS FUGAX, P90; SAYRE GP, 1959, ARCH INTERN MED, V103, P799, DOI 10.1001/archinte.1959.00270050121019; THURLBECK WM, 1957, NEW ENGL J MED, V257, P442, DOI 10.1056/NEJM195709052571002; 1990, SAS STAT USERS GUIDE, P1027	20	62	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					249	253		10.7326/0003-4819-122-4-199502150-00002	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825759				2022-12-01	WOS:A1995QF76900002
J	HOSKINS, KF; STOPFER, JE; CALZONE, KA; MERAJVER, SD; REBBECK, TR; GARBER, JE; WEBER, BL				HOSKINS, KF; STOPFER, JE; CALZONE, KA; MERAJVER, SD; REBBECK, TR; GARBER, JE; WEBER, BL			ASSESSMENT AND COUNSELING FOR WOMEN WITH A FAMILY HISTORY OF BREAST-CANCER - A GUIDE FOR CLINICIAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINE P53 MUTATIONS; OVARIAN-CANCER; INDIVIDUALIZED PROBABILITIES; RISK; DISEASE; ONSET; PREVENTION; LINKAGE; AGE	More women in all risk categories are seeking information regarding their individual breast cancer risk, and there is a need for their primary care clinicians to be able to assess familial risk factors for breast cancer, provide individualized risk information, and offer surveillance recommendations. Estimates of the number of women with a family history of breast cancer range from approximately 5% to 20%, depending on the population surveyed. Many of these women will not have a family history that suggests the presence of a highly penetrant breast cancer susceptibility gene. However, it small subset of such women will come from families with a striking incidence of breast and other cancers often associated with inherited mutations. The development and refinement of risk prediction models provide an epidemiologic basis for counseling women with a family history that does not appear related to a dominant susceptibility gene. In contrast, the recent isolation of BRCA1, the localization of BRCA2, and the acknowledgment that additional breast cancer susceptibility genes must exist provide a molecular basis for counseling some high-risk women. We present a guide for primary care clinicians that may be helpful in defining families as moderate or high risk, in determining individual risk in women with a family history of breast cancer based on this distinction, and for counseling women in a setting where the data necessary to design surveillance and prevention strategies are lacking. We include criteria for selecting women who may be candidates for detection of inherited mutations in breast cancer susceptibility genes.	UNIV PENN, MED CTR, DEPT INTERNAL MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT EPIDEMIOL & BIOSTAT, PHILADELPHIA, PA USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI USA; DANA FARBER CANC INST, BOSTON, MA USA	University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan; Harvard University; Dana-Farber Cancer Institute			Rebbeck, Timothy/GLU-8348-2022	Rebbeck, Timothy/0000-0002-4799-1900; Calzone, Kathleen/0000-0002-2354-6810				ANDERSON DE, 1985, CANCER, V56, P383, DOI 10.1002/1097-0142(19850715)56:2<383::AID-CNCR2820560230>3.0.CO;2-0; ANDREWS LB, 1994, ASSESSING GENETIC RI, P1; Becker MH, 1974, HLTH BELIEF MODEL PE; BENICHOU J, 1993, COMPUT BIOMED RES, V26, P373, DOI 10.1006/cbmr.1993.1026; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620; BOWCOCK AM, 1994, AM J HUM GENET, V55, pR1; BROWNSTEIN MH, 1978, CANCER, V41, P2393, DOI 10.1002/1097-0142(197806)41:6<2393::AID-CNCR2820410644>3.0.CO;2-K; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Champion V L, 1991, Oncol Nurs Forum, V18, P733; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; EASTON DF, 1994, LANCET, V344, P761, DOI 10.1016/S0140-6736(94)92256-X; EASTON DF, 1993, AM J HUM GENET, V52, P678; EVANS DGR, 1993, BRIT J CANCER, V67, P612, DOI 10.1038/bjc.1993.112; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL NR, 1994, EUR J CANCER, V30A, P180, DOI 10.1016/0959-8049(94)90083-3; HARTLEY AL, 1986, BRIT J CANCER, V54, P819, DOI 10.1038/bjc.1986.245; HOLFORD TR, 1991, J CLIN EPIDEMIOL, V44, P29, DOI 10.1016/0895-4356(91)90198-I; HUGGINS M, 1990, AM J HUM GENET, V47, P4; KASH KM, 1992, J NATL CANCER I, V84, P24, DOI 10.1093/jnci/84.1.24; Kelly P T, 1992, Semin Oncol Nurs, V8, P288, DOI 10.1016/0749-2081(92)90042-2; KELSEY JL, 1991, CA-CANCER J CLIN, V41, P146, DOI 10.3322/canjclin.41.3.146; LERMAN C, 1990, PREV MED, V19, P279, DOI 10.1016/0091-7435(90)90028-I; LERMAN C, 1991, HEALTH PSYCHOL, V10, P259, DOI 10.1037/0278-6133.10.4.259; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LYNCH HT, 1994, P ASCO, V13, P56; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORRELL D, 1986, J NATL CANCER I, V77, P89; MUIR EG, 1967, BRIT J SURG, V54, P191, DOI 10.1002/bjs.1800540309; MULVIHILL JJ, 1989, CLIN GENET, V36, P313; MURRAY TH, 1991, FASEB J, V5, P55, DOI 10.1096/fasebj.5.1.1825074; NAROD SA, 1991, LANCET, V338, P82; OFFIT K, 1994, J CLIN ONCOL, V12, P1724, DOI 10.1200/JCO.1994.12.8.1724; POLEDNAK AP, 1991, CANCER DETECT PREV, V15, P257; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SHAPIRO DE, 1992, HEALTH PSYCHOL, V11, P61, DOI 10.1037/0278-6133.11.1.61; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SKINNER CS, 1994, AM J PUBLIC HEALTH, V84, P43, DOI 10.2105/AJPH.84.1.43; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; STARINK TM, 1984, J AM ACAD DERMATOL, V11, P1127, DOI 10.1016/S0190-9622(84)70270-2; STEFANEK ME, 1992, CANCER EPIDEM BIOMAR, V1, P591; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAPLIN S, 1989, AM J PUBLIC HEALTH, V79, P1494, DOI 10.2105/AJPH.79.11.1494; WELLISCH DK, 1992, PSYCHOSOMATICS, V33, P171, DOI 10.1016/S0033-3182(92)71993-8; WENDER RC, 1993, CANCER, V72, P1093, DOI 10.1002/1097-0142(19930801)72:3+<1093::AID-CNCR2820721326>3.0.CO;2-B; Wood DA, 1943, CANCER RES, V3, P509; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	63	263	268	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					577	585		10.1001/jama.273.7.577	http://dx.doi.org/10.1001/jama.273.7.577			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF686	7837392				2022-12-01	WOS:A1995QF68600029
J	HUNG, J; KISHIMOTO, Y; SUGIO, K; VIRMANI, A; MCINTIRE, DD; MINNA, JD; GAZDAR, AF				HUNG, J; KISHIMOTO, Y; SUGIO, K; VIRMANI, A; MCINTIRE, DD; MINNA, JD; GAZDAR, AF			ALLELE-SPECIFIC CHROMOSOME 3P DELETIONS OCCUR AT AN EARLY-STAGE IN THE PATHOGENESIS OF LUNG-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMALL-CELL; BRONCHIAL EPITHELIUM; SHORT ARM; CANCER; DNA; ABNORMALITIES; AMPLIFICATION; HYPERPLASIA; TUMORS; GENE	Background.-Deletions in the short arm of chromosome 3 (3p) are present in most lung carcinomas. Objective.-To investigate the role of these chromosome 3p deletions in the pathogenesis of non-small cell lung carcinomas. Design.-Seven archival, paraffin-embedded, surgically resected lung cancer specimens were studied. Fifty precisely identified malignant and preneoplastic lesions present in bronchi, bronchioles, and alveoli were microdissected from stained slides and analyzed for allele loss using polymerase chain reaction-based assays for dinucleotide repeat polymorphisms at three chromosome 3p loci (3p14, 3p21.3, and 3p25). Setting.-University-based medical center and affiliated hospitals. Subjects.-Samples were analyzed from seven patients who underwent surgical resection with curative intent for non-small cell lung cancer and whose specimens included extensive multifocal areas of preneoplastic lesions (hyperplasia, metaplasia, dysplasia, or noninvasive cancer). Results.-Lymphocytes from all seven cases were heterozygous (ie, informative) for all three microsatellites analyzed. Six (86%) of seven invasive cancers had loss of heterozygosity at one or more chromosome 3p sites. In the accompanying preneoplastic lesions, loss of heterozygosity was detected in none of two normal bronchioles, 13 (76%) of 17 hyperplasias, six (86%) of seven dysplasias, and four (100%) of four noninvasive cancers. Loss of heterozygosity was detected throughout the respiratory tract, in bronchi, bronchioles, and alveoli. In 18 (78%) of 23 preneoplastic lesions, the specific alleles lost were identical to those lost in the corresponding carcinomas. The probability of this happening by chance is 5.3x10(-3). Conclusions.-Deletions in the short arm of chromosome 3 occur at the earliest stage (hyperplasia) in the pathogenesis of lung cancer and involve all regions of the respiratory tract. Allele loss is highly specific, but its mechanism remains unknown. Our findings may be of considerable biologic, prognostic, and clinical significance.	UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX; UNIV TEXAS,SW MED CTR,ACAD COMP SERV,DALLAS,TX	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [P20 CA58220-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA058220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; CHENG JM, 1993, NAT GENET, V4, P191, DOI 10.1038/ng0693-191; DALY MC, 1993, ONCOGENE, V8, P1271; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; GAZDAR AF, 1994, BIOL GENETICS LUNG C; GREENBERG SD, 1987, LUNG CARCINOMAS, P287; HALL JG, 1992, NEW ENGL J MED, V326, P827, DOI 10.1056/NEJM199203193261210; HEGI ME, 1994, CANCER RES, V54, P6257; HIBI K, 1992, ONCOGENE, V7, P445; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LITT M, 1993, BIOTECHNIQUES, V15, P280; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; NAKANISHI K, 1990, ARCH PATHOL LAB MED, V114, P363; OCONNELL P, 1994, BREAST CANCER RES TR, V32, P5, DOI 10.1007/BF00666201; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; SACCOMANNO G, 1976, ANN NY ACAD SCI, V271, P377, DOI 10.1111/j.1749-6632.1976.tb23134.x; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SATO S, 1994, CANCER RES, V54, P5652; SEKIDO Y, 1994, ONCOGENE, V9, P853; SIEGEL S, 1956, NONPARAMETRIC STAT, P36; SLAUGHTER DP, 1954, CANCER, V6, P963; SOZZI G, 1991, CANCER RES, V51, P400; STRONG MS, 1984, J OTOLARYNGOL, V13, P1; SUGIO K, 1994, CANCER RES, V54, P5811; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; WENG S, 1990, HISTOPATHOLOGY, V16, P101, DOI 10.1111/j.1365-2559.1990.tb01073.x; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHETSELL L, 1992, ONCOGENE, V7, P2355; YAMAKAWA K, 1993, ONCOGENE, V8, P327; [No title captured]	38	288	307	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					558	563		10.1001/jama.273.7.558	http://dx.doi.org/10.1001/jama.273.7.558			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837389				2022-12-01	WOS:A1995QF68600026
J	KANTARJIAN, HM; SMITH, TL; OBRIEN, S; BERAN, M; PIERCE, S; TALPAZ, M; ROBERTSON, L; KOLLER, C; ESTEY, E; KEATING, MJ				KANTARJIAN, HM; SMITH, TL; OBRIEN, S; BERAN, M; PIERCE, S; TALPAZ, M; ROBERTSON, L; KOLLER, C; ESTEY, E; KEATING, MJ			PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						LEUKEMIA, MYELOID, CHRONIC; INTERFERON-ALPHA; CYTOGENETICS; BASOPHILS; SPLENOMEGALY	PHILADELPHIA-CHROMOSOME; CHRONIC-PHASE; REMISSION	Objective: To determine whether a cytogenetic response after interferon-alpha therapy in patients with chronic myelogenous leukemia is independently associated with improved survival. Design: Retrospective analysis. Patients: 274 patients with a diagnosis of Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase who were treated with interferon-alpha-based programs between 1982 and 1990. Intervention: Therapy with daily subcutaneous interferon-alpha given at 5 x 10(6) U/m(2) body surface area (highest dose schedule allowed on studies) or the maximally tolerated lower-dose schedule. Results: Overall, 219 (80%) patients achieved a complete hematologic response and 104 (38%) achieved a major cytogenetic response (<35% Philadelphia chromosome-positive cells). Estimated median survival was 89 months. Several pretreatment factors were associated with failure to achieve a major cytogenetic response and with worse survival. The existing prognostic models were generally predictive of which patients were likely to achieve a major cytogenetic response (P less than or equal to 0.01) and of survival outcomes (P less than or equal to 0.01). Multivariate analysis identified bone marrow basophilia (P < 0.01) and splenomegaly (P < 0.01) as independent poor prognostic factors for survival. Achievement of a major cytogenetic response, entered as a time-dependent variable while accounting for the other independent factors, was associated with improved survival (P < 0.001). Comparison of survival (dated from 12 months into therapy) with cytogenetic response at 12 months showed that a cytogenetic response was associated with longer survival (P < 0.001). Conclusion: Achieving a cytogenetic response with interferon-alpha therapy in patients with chronic myelogenous leukemia was independently associated with improved survival when tested as a time-dependent variable in a multivariate analysis, and this association was confirmed by landmark analysis at 12 months.			KANTARJIAN, HM (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, BOX 61, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.			Talpaz, Moshe/0000-0003-3361-3981	NCI NIH HHS [CA19639] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMENA G, 1988, BLOOD, V72, P642; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; COX DR, 1972, J R STAT SOC B, V34, P187; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1990, LEUKEMIA, V4, P163; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; KANTARJIAN HM, 1993, BLOOD, V82, P691; KANTARJIAN HM, 1990, AM J MED, V88, P1, DOI 10.1016/0002-9343(90)90119-X; KANTARJIAN HM, 1985, BLOOD, V66, P1326; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; OZER H, 1993, BLOOD, V82, P2975; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TURA S, 1994, NEW ENGL J MED, V330, P820; TURA S, 1994, NEW ENGL J MED, V331, P402; 1988, GUIDELINES REPORTING	21	422	428	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					254	261		10.7326/0003-4819-122-4-199502150-00003	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825760				2022-12-01	WOS:A1995QF76900003
J	KURZROCK, R; COHEN, PR				KURZROCK, R; COHEN, PR			ERYTHEMA-GYRATUM-REPENS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED SPECIALTIES,DERMATOL SECT,HOUSTON,TX; UNIV TEXAS,SCH MED,DEPT DERMATOL,HOUSTON,TX; UNIV TEXAS,SCH MED,DEPT PATHOL,HOUSTON,TX	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System	KURZROCK, R (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN INVEST,BOX 302,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Kurzrock, Razelle/AAU-9782-2020					BARBER PV, 1978, BRIT J DERMATOL, V98, P465; BARRIERE H, 1978, ANN DERMATOL VENER, V105, P319; BOYD AS, 1992, J AM ACAD DERMATOL, V26, P757, DOI 10.1016/0190-9622(92)70107-Q; CHEESBROUGH MJ, 1985, CLIN EXP DERMATOL, V10, P466, DOI 10.1111/j.1365-2230.1985.tb00606.x; GAMMEL JA, 1952, AMA ARCH DERM SYPH, V66, P494, DOI 10.1001/archderm.1952.01530290070010; HOLT PJA, 1977, BRIT J DERMATOL, V96, P343, DOI 10.1111/j.1365-2133.1977.tb07127.x; INGBER A, 1983, Z HAUTKRANKHEITEN, V58, P1298; OLSEN TG, 1984, CUTIS, V34, P351; TYRING SK, 1993, CLIN DERMATOL, V11, P135, DOI 10.1016/0738-081X(93)90110-X	9	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					594	594		10.1001/jama.273.7.594	http://dx.doi.org/10.1001/jama.273.7.594			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837395				2022-12-01	WOS:A1995QF68600032
J	LIFSON, AR; ALLEN, S; WOLF, W; SERUFILIRA, A; KANTARAMA, G; LINDAN, CP; HUDES, ES; NSENGUMUREMYI, F; TAELMAN, H; BATUNGWANAYO, J				LIFSON, AR; ALLEN, S; WOLF, W; SERUFILIRA, A; KANTARAMA, G; LINDAN, CP; HUDES, ES; NSENGUMUREMYI, F; TAELMAN, H; BATUNGWANAYO, J			CLASSIFICATION OF HIV-INFECTION AND DISEASE IN WOMEN FROM RWANDA - EVALUATION OF THE WORLD-HEALTH-ORGANIZATION HIV STAGING SYSTEM AND RECOMMENDED MODIFICATIONS	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REPRESENTATIVE SAMPLE; CHILDBEARING WOMEN; SEDIMENTATION-RATE; ORAL CANDIDIASIS; LYMPHOCYTE COUNT; HOMOSEXUAL MEN; AIDS; TUBERCULOSIS; PROGRESSION	Objective: To develop a human immunodeficiency virus (HIV) staging system for sub-Saharan Africa on the basis of an evaluation of the World Health Organization (WHO) system and predictors of mortality. Design: Prospective cohort study with 4 years of follow-up. Setting: Kigali, Rwanda. Patients: 412 HIV-infected women recruited from prenatal and pediatric clinics. Measurements: Clinical signs and symptoms of HIV disease, laboratory assays (including complete blood count and erythrocyte sedimentation rate), and cumulative mortality. Results: The WHO staging system includes a clinical and a laboratory axis. The clinical axis was revised by inclusion of oral candidiasis, chronic oral or genital ulcers, and pulmonary tuberculosis as ''severe'' disease (clinical stage IV); in addition, body mass index was substituted for weight loss in the definition for the wasting syndrome. The 36-month cumulative mortality was 7% for women in modified clinical stage I (''asymptomatic''), 15% for those in stage II, 19% for those in stage III, and 36% for those in stage IV (P < 0.001). The laboratory axis was revised by replacing lymphocyte count with hematocrit and erythrocyte sedimentation rate. The 36-month mortality was 10% for women in modified stage A (''normal'' laboratory results) and 33% for those in stage B (erythrocyte sedimentation rate >65 mm/h or hematocrit <0.38) (P < 0.001). A single staging system combining clinical and laboratory criteria is proposed, with a 36-month mortality of 7% for women in combined stage I, 10% for those in stage II, 29% for those in stage III, and 62% for those in stage IV (P < 0.001). Conclusions: On the basis of this analysis, a staging system relevant for sub-Saharan Africa is proposed that reflects the range of HIV-related outcomes, has strong prognostic significance, includes inexpensive and available laboratory tests, and can be used by both clinicians and researchers.	UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, SAN FRANCISCO, CA 94105 USA; CENT HOSP, KIGALI, RWANDA; MINIST HLTH, KIGALI, RWANDA	University of California System; University of California San Francisco					NIAID NIH HHS [AI23980] Funding Source: Medline; NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1994, Wkly Epidemiol Rec, V69, P273; [Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; AYLWARD RB, 1994, AIDS, V8, P1129, DOI 10.1097/00002030-199408000-00015; BATUNGWANAYO J, 1993, AIDS, V7, P73, DOI 10.1097/00002030-199301000-00011; BATUNGWANAYO J, 1994, AM J RESP CRIT CARE, V149, P1591, DOI 10.1164/ajrccm.149.6.8004318; BLATT SP, 1993, JAMA-J AM MED ASSOC, V269, P622, DOI 10.1001/jama.269.5.622; CAHN P, 1993, AIDS, V7, P711; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P186; FERROLUZZI A, 1992, EUR J CLIN NUTR, V46, P173; HAVERKOS HW, 1985, J INFECT DIS, V152, P1095, DOI 10.1093/infdis/152.5.1095; HOOVER DR, 1993, J ACQ IMMUN DEF SYND, V6, P537; KATZ MH, 1992, AIDS, V6, P95, DOI 10.1097/00002030-199201000-00013; KERLIKOWSKE KM, 1994, AIDS, V8, P963, DOI 10.1097/00002030-199407000-00014; LEDERMAN MM, 1994, J ACQ IMMUN DEF SYND, V7, P727; LEFRERE JJ, 1988, AIDS, V2, P63, DOI 10.1097/00002030-198802000-00013; LIMA LAA, 1993, AIDS, V7, P295, DOI 10.1097/00002030-199302000-00031; LIN RY, 1993, AM J MED SCI, V305, P345, DOI 10.1097/00000441-199306000-00001; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; Mann J, 1992, AIDS WORLD, P11; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; RABENECK L, 1993, J GEN INTERN MED, V8, P5, DOI 10.1007/BF02600284; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; REVICKI DA, 1986, AM J PUBLIC HEALTH, V76, P992, DOI 10.2105/AJPH.76.8.992; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; SCHECHTER M, 1994, J ACQ IMMUN DEF SYND, V7, P163; SCHWARTLANDER B, 1993, AIDS, V7, P813, DOI 10.1097/00002030-199306000-00009; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; VANDENBRUAENE M, 1993, AIDS, V7, P1613, DOI 10.1097/00002030-199312000-00011; VANDEPERRE P, 1988, SCAND J INFECT DIS, V20, P277, DOI 10.3109/00365548809032451; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WENIGER BG, 1992, J ACQ IMMUN DEF SYND, V5, P1212; 1986, MMWR-MORBID MORTAL W, V35, P334	42	58	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					262	270		10.7326/0003-4819-122-4-199502150-00004	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825761				2022-12-01	WOS:A1995QF76900004
J	POTOSKY, AL; MILLER, BA; ALBERTSEN, PC; KRAMER, BS				POTOSKY, AL; MILLER, BA; ALBERTSEN, PC; KRAMER, BS			THE ROLE OF INCREASING DETECTION IN THE RISING INCIDENCE OF PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GEOGRAPHIC-VARIATION; TRENDS	Objective.-To assess the reasons for the dramatic surge in prostate cancer incidence from 1986 to 1991. Design.-Population-based study of incidence rates and procedures used to detect and diagnose prostate cancer derived from Medicare claims data and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program from 1986 to 1991. Setting.-Four SEER areas (Connecticut; Atlanta, Ga; Detroit, Mich; and Seattle-Puget Sound, Wash) covering approximately 6% of the US population. Participants.-A 5% random sample of male fee-for-service Medicare beneficiaries aged 65 years and older without cancer, and all men with prostate cancer diagnosed at 65 years of age and older residing in the four areas. Main Outcome Measures.-The age-adjusted rates of prostate cancer incidence, prostate needle biopsy, transurethral resection of the prostate, serum prostate-specific antigen (PSA) testing, and transrectal ultrasound. Results.-The age-adjusted incidence rate of prostate cancer among men aged 65 years and older in the four SEER areas rose 82% from 1986 to 1991, with the largest annual increases occurring in 1990 (20%) and 1991 (19%). Prostate needle biopsy rates increased while the use of transurethral resection of the prostate declined from 1986 to 1991. The rising needle biopsy rate has been driven by an exponential increase in PSA testing in the general population from 1988 to 1991 and, to a much lesser extent, the increasing use of transrectal ultrasound since 1986. The use of PSA or transrectal ultrasound has increased across age and race groups and in different geographic areas. However, there remain wide geographic variations in the use of PSA screening. Conclusions.-The recent dramatic epidemic of prostate cancer is likely the result of the increasing detection of tumors resulting from increased PSA screening. The magnitude and rapidity of the incidence rise suggest that changes in the intensity of medical surveillance is the most plausible explanation for this trend. Implications.-The rapid diffusion of screening interventions that have the ability to detect latent asymptomatic disease leads to important concerns regarding costs and patient quality of life for men aged 65 years and older, Geographic variability in the adoption of PSA testing underscores uncertainty and disagreement about its value for reducing prostate cancer mortality. More research is required to determine the effectiveness of screening for prostate cancer.	NCI,CANC STAT BRANCH,SURVEILLANCE PROGRAM,BETHESDA,MD; NCI,DIV CANC PREVENT & CONTROL,EARLY DETECT & COMMUNITY ONCOL PROGRAM,BETHESDA,MD; UNIV CONNECTICUT,CTR HLTH,DIV UROL,FARMINGTON,CT	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Connecticut	POTOSKY, AL (corresponding author), NCI,APPL RES BRANCH,6130 EXECUT BLVD,EPN ROOM 313,BETHESDA,MD 20892, USA.							ALDER J, 1993, NEWSWEEK        1227, P40; AUSTIN DF, 1989, NEW ENGL J MED, V321, P1197; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOSLAND MC, 1988, ADV CANCER RES, V51, P1, DOI 10.1016/S0065-230X(08)60220-1; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; DEMERS RY, 1994, ARCH INTERN MED, V154, P1211, DOI 10.1001/archinte.154.11.1211; DEVESA SS, 1987, J NATL CANCER I, V79, P701; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; Fleming C, 1993, JAMA, V269, P2650; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; GILLILAND F, 1994, CANCER EPIDEM BIOMAR, V3, P105; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LEVY IG, 1993, CAN MED ASSOC J, V149, P617; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; NATTINGER AB, 1992, NEW ENGL J MED, V26, P1102; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; POTOSKY AL, 1993, MED CARE, V31, P732; PROROK PC, 1981, J CHRON DIS, V34, P159, DOI 10.1016/0021-9681(81)90026-6; RIES LA, 1994, NIH942789 NCI PUBL; ROOS NP, 1980, MED CARE, V20, P945; SERVAAS C, 1992, SATURDAY EVENING POS, V264, P58; SIWEK J, 1991, WASHINGTON POST 0709, pZ15; Stuart M E, 1992, HMO Pract, V6, P5; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WENNBERG JE, 1991, JAMA-J AM MED ASSOC, V265, P1306, DOI 10.1001/jama.265.10.1306; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676	33	520	534	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					548	552		10.1001/jama.273.7.548	http://dx.doi.org/10.1001/jama.273.7.548			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7530782				2022-12-01	WOS:A1995QF68600024
J	SATO, S; SUZUKI, K; AKAHANE, Y; AKAMATSU, K; AKIYAMA, K; YUNOMURA, K; TSUDA, F; TANAKA, T; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M				SATO, S; SUZUKI, K; AKAHANE, Y; AKAMATSU, K; AKIYAMA, K; YUNOMURA, K; TSUDA, F; TANAKA, T; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M			HEPATITIS-B VIRUS-STRAINS WITH MUTATIONS IN THE CORE PROMOTER IN PATIENTS WITH FULMINANT-HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B E ANTIGENS; GENETIC CODE	COMPLETE NUCLEOTIDE-SEQUENCE; PRECORE-REGION DEFECTS; E-ANTIGEN; PREGENOME ENCAPSIDATION; HBV-DNA; PROTEIN; EXPRESSION; ANTIBODY; MUTANTS; INFECTION	Objective: Fulminant hepatitis B can be induced by hepatitis B virus (HBV) strains with mutations in the precore region that cannot encode hepatitis B e antigen (HBeAg). Such mutations are rarely seen in HBV DNA clones from patients with fulminant hepatitis B in the United States and France. Thus, the other mutations in HBV strains causing fulminant hepatitis B need to be identified. Design: Retrospective clinical, serologic, and molecular biological studies of patients with fulminant hepatitis B. Setting: University and city hospitals in Japan. Patients: 43 patients with fulminant hepatitis B. Measurements: The precore region coding fora part of the HBeAg precursor and the core promoter regulating the transcription of precore messenger RNA were sequenced in HBV DNA clones. Results: A point mutation from G to A at nucleotide 1896 in the precore region was detected in 519 (98%) of 529 HBV DNA clones from 38 patients. Two point mutations in the core promoter, from A to T at nucleotide 1762 and from G to A at nucleotide 1764, were detected in all 130 clones from the remaining 5 patients, who did not have mutations in the precore region, and in 20 (63%) of 32 clones from a patient with chronic hepatitis B who had transmitted HBV to 1 of these other 5 patients. Mutations in the core promoter were also detected in clones from 26 (68%) of the 38 patients with the precore mutation at nucleotide 1896. Neither HBeAg nor antibody to HBeAg was detected in 37 (90%) of the 41 patients tested. Conclusions: In Japan, fulminant hepatitis B is closely associated with HBV strains that do not produce HBeAg because of mutations in the precore region, which affect translation of HBeAg, or because of mutations in the core promoter, which affect transcription of the HBeAg coding region.	JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; IWATE MED UNIV, SCH MED, DEPT INTERNAL MED 1, MORIOKA, IWATE 020, JAPAN; YAMANASHI MED UNIV, DEPT INTERNAL MED 1, TAMAHO, YAMANASHI 40938, JAPAN; EHIME UNIV, SCH MED, DEPT INTERNAL MED 3, SHIGENOBU, EHIME 79102, JAPAN; ASAHIKAWA MED COLL, DEPT INTERNAL MED 2, ASAHIKAWA, HOKKAIDO 078, JAPAN; DOKKYO UNIV, SCH MED, DEPT INTERNAL MED 2, MIBU, TOCHIGI 32102, JAPAN; TOSHIBA GEN HOSP, DEPT MED SCI, TOKYO 140, JAPAN; MITA INST, TOKYO 108, JAPAN; JAPANESE RED CROSS, SAITAMA BLOOD CTR, URAWA, SAITAMA 338, JAPAN	Jichi Medical University; Iwate Medical University; University of Yamanashi; Ehime University; Asahikawa Medical College; Dokkyo Medical University; Toshiba Corporation; Japanese Red Cross Medical Center			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964				BRUNETTO MR, 1991, P NATL ACAD SCI USA, V88, P4186, DOI 10.1073/pnas.88.10.4186; BRUSS V, 1988, VIROLOGY, V163, P268, DOI 10.1016/0042-6822(88)90266-8; CARMAN WF, 1989, LANCET, V2, P588; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; FERAY C, 1993, J HEPATOL, V18, P119, DOI 10.1016/S0168-8278(05)80019-4; GIMSON AES, 1983, GUT, V24, P615, DOI 10.1136/gut.24.7.615; IIZUKA H, 1992, VOX SANG, V63, P107, DOI 10.1111/j.1423-0410.1992.tb02495.x; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; KOJIMA M, 1991, VOX SANG, V60, P34, DOI 10.1111/j.1423-0410.1991.tb00868.x; KOSAKA Y, 1991, GASTROENTEROLOGY, V100, P1087, DOI 10.1016/0016-5085(91)90286-T; LASKUS T, 1993, GASTROENTEROLOGY, V105, P1173, DOI 10.1016/0016-5085(93)90964-E; LASKUS T, 1994, J HEPATOL, V20, P837, DOI 10.1016/S0168-8278(05)80158-8; LI JS, 1993, J VIROL, V67, P5402, DOI 10.1128/JVI.67.9.5402-5410.1993; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; MCLACHLAN A, 1987, J VIROL, V61, P683, DOI 10.1128/JVI.61.3.683-692.1987; MILICH DR, 1990, P NATL ACAD SCI USA, V87, P6599, DOI 10.1073/pnas.87.17.6599; MISKA S, 1993, J HEPATOL, V18, P53, DOI 10.1016/S0168-8278(05)80009-1; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; OGATA N, 1993, VIROLOGY, V194, P263, DOI 10.1006/viro.1993.1257; OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; PREISLERADAMS S, 1994, GASTROENTEROLOGY, V106, pA965; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903; TERAZAWA S, 1991, PEDIATR RES, V29, P5, DOI 10.1203/00006450-199101000-00002; TONG SP, 1993, J VIROL, V67, P5651, DOI 10.1128/JVI.67.9.5651-5655.1993; TREPO CG, 1976, GUT, V17, P10, DOI 10.1136/gut.17.1.10; TREY C, 1968, NEW ENGL J MED, V279, P798, DOI 10.1056/NEJM196810102791504; TSUDA F, 1984, GASTROENTEROLOGY, V87, P159; VAUDIN M, 1988, J GEN VIROL, V69, P1383, DOI 10.1099/0022-1317-69-6-1383; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WILL H, 1987, J VIROL, V61, P904, DOI 10.1128/JVI.61.3.904-911.1987; WOOLF IL, 1976, BMJ-BRIT MED J, V2, P669, DOI 10.1136/bmj.2.6037.669; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YOTSUMOTO S, 1992, HEPATOLOGY, V16, P31, DOI 10.1002/hep.1840160107; YUH CH, 1992, J VIROL, V66, P4073, DOI 10.1128/JVI.66.7.4073-4084.1992	38	257	279	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					241	248		10.7326/0003-4819-122-4-199502150-00001	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825758				2022-12-01	WOS:A1995QF76900001
J	HERRINTON, LJ; FRIEDMAN, GD				HERRINTON, LJ; FRIEDMAN, GD			SERUM-CHOLESTEROL CONCENTRATION AND RISK OF BRAIN CANCER	BRITISH MEDICAL JOURNAL			English	Article							TUMORS				HERRINTON, LJ (corresponding author), KAISER PERMANENTE MED CTR,DIV RES,3505 BROADWAY AVE,OAKLAND,CA 96411, USA.				NCI NIH HHS [R35 CA49761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; KNEKT P, 1991, BRIT MED J, V302, P90, DOI 10.1136/bmj.302.6768.90; NEUGUT AI, 1989, INT J EPIDEMIOL, V18, P798, DOI 10.1093/ije/18.4.798; SMITH GD, 1989, BMJ-BRIT MED J, V299, P26, DOI 10.1136/bmj.299.6690.26; SMITH GD, 1992, AM J EPIDEMIOL, V135, P259, DOI 10.1093/oxfordjournals.aje.a116279	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					367	368		10.1136/bmj.310.6976.367	http://dx.doi.org/10.1136/bmj.310.6976.367			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866214	Green Published			2022-12-01	WOS:A1995QG72100019
J	PAN, WH; LI, LA; TSAI, MJ				PAN, WH; LI, LA; TSAI, MJ			TEMPERATURE EXTREMES AND MORTALITY FROM CORONARY HEART-DISEASE AND CEREBRAL INFARCTION IN ELDERLY CHINESE	LANCET			English	Article							SEASONAL-VARIATION	We studied the relation between outdoor temperature and mortality rates from cardiovascular disease in Taiwan from 1981 to 1991. In 11 years, there were 30 085, 21 750, and 39 818 deaths from coronary artery disease, cerebral infarction, and cerebral haemorrhage, respectively, among 7.6 million residents aged 25 and over in selected areas where climate was recorded. A temperature-mortality relation was especially apparent in the elderly. A U-shaped relation was observed between temperature and mortality from coronary artery disease and cerebral infarction. The range corresponding to least deaths from coronary artery disease (26-29 degrees C) and cerebral infarction (27-29 degrees 0) was higher than that in countries with colder climates. In the elderly, the risk of cerebral infarction at 32 degrees C was 66% higher than that at 27-29 degrees C; the risk increased by 3.0% per 1 degrees C reduction from 27-29 degrees C. The risk of coronary artery disease at 32 degrees C was 22% higher than that at 26-29 degrees C; below 26-29 degrees C, the risk increased by 2.8% per 1 degrees C reduction. Mortality from cerebral haemorrhage decreased with increasing temperature at a rate of 3.3% per 1 degrees C. These results imply a pathophysiological difference between thromboembolic and haemorrhagic cardiovascular diseases. Poor thermoregulation in older people may precipitate cardiovascular disease events.	ACAD SINICA,INST STAT,TAIPEI 115,TAIWAN; NATL TAIWAN UNIV,COLL PUBL HLTH,INST EPIDEMIOL,TAIPEI 10764,TAIWAN	Academia Sinica - Taiwan; National Taiwan University	PAN, WH (corresponding author), ACAD SINICA,INST BIOMED SCI,DIV EPIDEMIOL & PUBL HLTH,TAIPEI 115,TAIWAN.		Pan, Wen-Harn/F-9972-2010	Pan, Wen-Harn/0000-0001-9136-0658				Clark R.P., 1985, MAN HIS THERMAL ENV; DOUGLAS AS, 1991, SCOT MED J, V36, P76, DOI 10.1177/003693309103600304; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; KEATINGE WR, 1986, AM J MED, V81, P795, DOI 10.1016/0002-9343(86)90348-7; KUNST AE, 1993, AM J EPIDEMIOL, V137, P331, DOI 10.1093/oxfordjournals.aje.a116680; NATSUME K, 1992, INT J BIOMETEOROL, V36, P1, DOI 10.1007/BF01208726; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; WOO J, 1991, NEUROEPIDEMIOLOGY, V10, P260, DOI 10.1159/000110282; WOODHOUSE PR, 1993, AGE AGEING, V22, P273, DOI 10.1093/ageing/22.4.273; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	10	203	218	1	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					353	355		10.1016/S0140-6736(95)90341-0	http://dx.doi.org/10.1016/S0140-6736(95)90341-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845116				2022-12-01	WOS:A1995QF72200009
J	RASENACK, JWF; SCHLAYER, HJ; HETTLER, F; PETERS, T; PREISLERADAMS, S; GEROK, W				RASENACK, JWF; SCHLAYER, HJ; HETTLER, F; PETERS, T; PREISLERADAMS, S; GEROK, W			HEPATITIS-B VIRUS-INFECTION WITHOUT IMMUNOLOGICAL MARKERS AFTER OPEN-HEART-SURGERY	LANCET			English	Note							CHRONIC LIVER-DISEASE; SURFACE-ANTIGEN; DNA; IDENTIFICATION; SEQUENCE	Post-transfusion hepatitis is still an important problem, despite the screening of blood donors for hepatitis B (HBV) and C virus infections. We assessed whether HBV DNA might be detected by PCR in prospectively collected serum samples of patients with unexplained post-transfusion hepatitis but no immunological HBV markers. We found HBV DNA in 4 (20%) of 20 patients with unexplained post transfusion hepatitis and in 5 patients with mildly increased aminotransferases. The clinical course of these HBV infections was usually mild and self-limiting. Thus we found that low-titre, immunologically negative HBV infections do exist and might represent a significant cause of post-transfusion hepatitis.			RASENACK, JWF (corresponding author), UNIV FREIBURG,DEPT GASTROENTEROL & HEPATOL,D-79106 FREIBURG,GERMANY.							AZAR N, 1993, J HEPATOL, V18, P24, DOI 10.1016/S0168-8278(05)80006-6; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; CHAZOUILLERES O, 1994, LANCET, V343, P142, DOI 10.1016/S0140-6736(94)90934-2; LAI MY, 1990, HEPATOLOGY, V12, P575, DOI 10.1002/hep.1840120321; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; PETERS T, 1994, J MED VIROL, V42, P420, DOI 10.1002/jmv.1890420416; PREISLERADAMS S, 1993, NUCLEIC ACIDS RES, V21, P2258, DOI 10.1093/nar/21.9.2258; PREISLERADAMS S, 1993, ARCH VIROL, V133, P385, DOI 10.1007/BF01313777; THIERS V, 1988, LANCET, V2, P1273; WANG JT, 1991, J INFECT DIS, V163, P397, DOI 10.1093/infdis/163.2.397	10	18	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					355	357		10.1016/S0140-6736(95)90342-9	http://dx.doi.org/10.1016/S0140-6736(95)90342-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845117				2022-12-01	WOS:A1995QF72200010
